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Fat fate and disease - from science to global policy
Peter Gluckman
Office of Chief Science Advsor to the Prime Minister
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1
Attempts to deal with the obesity epidemic based solely on adult be-
havioural change have been rather disappointing. Indeed the evidence
that biological, developmental and contextual factors are operating
from the earliest stages in development and indeed across generations
is compelling. The marked individual differences in the sensitivity to the
obesogenic environment need to be understood at both the individual
and population level. There is considerable evidence showing that the
fetus and neonate are affected by the environment created by its
mother and these have longer-term metabolic consequences including
obesity and the implications for non-communicable disease (NCD). But
while this evidence emerged over 30 years ago, it is only in the past 5
years it has gained traction in the policy domain. A number of barriers,
both scientific and societal, existed to the incorporation of this know-
ledge into public policy. These barriers included an over-simplistic un-
derstanding of the phenomenon, a failure to appreciate its normative
nature and multiple mechanisms that are best understood in a evolu-
tionary medicine context, a lack of compelling biological mechanistic
explanations and estimates of the size of the developmental compo-
nent. These issues have largely been addressed to the extent needed
for policy recommendations although there are areas of research that
need further promotion – in particular those related to the develop-
ment of eating behaviours and satiety control. However in part because
of the Millennium Development Goals that brought an emphasis to ma-
ternal and girls’ health and because of scientific progress as reflected in
the “ first 1000 days” movement, the first recognition of the develop-
mental and epigenetic component to obesity was noted in the political
declaration of the UN General Assembly in 2011. This led the WHO and
an increasing number of governments to start to formulate develop-
mental strategies to confront obesity. The World Health Assembly in
May 2016 adopted the report of the Commission on Ending Childhood
Obesity and this has major implications for national and global health
policy. I will discuss these developments from both a scientific and pub-
lic policy perspective.
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Bone Fragility in Children - Genes and Treatments
Frank Rauch
Shriners Hospitals for Children
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a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile
osteoporosis (JO). OI is usually caused by dominant mutations affect-
ing one of the two genes that code for two collagen type I, but a re-
cessive form of OI is present in 5-10% of individuals with a clinical
diagnosis of OI. Most of the involved genes code for proteins that
play a role in the processing of collagen type I protein (BMP1,
CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1,
SERPINH1, SEC24D, SPARC,
TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific
phenotypes are caused by mutations in SERPINF1 (recessive OI type
VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter
like’). Patients with heritable bone fragility who do not have extraske-
letal manifestations of OI are often diagnosed with JO. The JO
phenotype can be caused by mutations in LRP5 and PLS3, but also
by mutations in some of the genes that cause OI. For most of these
gene defects the mechanisms linking mutation to phenotype remain
to be elucidated. Regarding specific medical therapy of bone fragility
in children, bisphosphonates are currently the main treatment op-
tion. Recent data indicate that children with moderate to severe OI
have the ability to reshape most compressed vertebra, if treatment is
started early enough and is continued throughout the growing
period. However, bisphosphonate therapy does not have a major ef-
fect on the development of scoliosis and the incidence of long- bone
fractures remains elevated. Even though children with moderate OI
(OI type IV) typically achieve independent ambulation, this is rarely
the case for children with severe OI (OI type III). Newer medications
are being evaluated in an attempt to improve on the therapeutic effi-
cacy of bisphosphonates but the available information about their
action in OI is very limited at present.
PS3
Unique Newly Discovered Muse Cells May Lead to the Paradigm
Shift of Stem Cell Therapy
Mari Dezawa
Department of Stem Cell Biology and History & Department of Anatomy
and Anthropology, Tohoku University Graduate School of Medicine
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS3
Multilineage-differentiating stress enduring (Muse) cells are naturally
existing unique stem cells that are non- tumorigenic and are
pluripotent-like because they can generate cells representative of all
three germ layers from a single cell, express pluripotency markers,
and are able to self-renew and to spontaneously differentiate into
cells compatible to the tissue they homed in vivo after engraftment.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 2 of 144Whenever they are injected intravenously, they can escape from be-
ing trapped in the lung and spleen, unlike mesenchymal stem cells
(MSCs), and efficiently home into damaged tissue, suggesting that
robust repair can be delivered by intravenous injection of naïve Muse
cells. Such unique functions of Muse cells were demonstrated in ani-
mal models of stroke, partial hepatectomy, skin ulcer of diabetes
mellitus and muscle degeneration. They do not have to be “induced,”
or genetically manipulated, to be pluripotent or be purposive cells be-
fore transplantation as required with some other cell varieties - they
already display inherent pluripotent-like properties after isolation and,
with their acquired properties of purposive cells, Muse cells spontan-
eously repair damaged sites based on their unique mechanisms.
They can be collected as cells positive for SSEA-3, a surface marker
for pluripotent stem cells, from readily accessible sources such as the
bone marrow (~0.03% of the total mononucleated cell population),
and from cultured fibroblasts (several %), as well as from the dermis
and adipose tissue. Thus, they are expected to be practical cells for
clinical application. Recently, Muse cells are shown to circulate in per-
ipheral blood in healthy donors, and the number increases in stroke
patients in an acute phase, suggesting that endogenous Muse cells
are mobilized into peripheral blood to repair tissues while their num-
ber is not sufficient to recover, and that supply of exogenous Muse
cells is expected to deliver clinically relevant functional recovery.
Overall, results suggest that Muse cells are a feasible and promising
source for cell-based approaches.
PS4
RASopathy - from molecular mechanism to clinical practice
Yoichi Matsubara
National Center for Child Health and Development
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS4
Studies in the past decade revealed that a group of genetic disorders
results from dysregulation of the Ras/ MAPK (mitogen-activated pro-
tein kinase) signaling pathway. These syndromes are comprehen-
sively termed “Ras/ MAPK pathway syndromes” or “RASopathies”.
These disorders include Noonan syndrome, Noonan syndrome with
multiple lentigines (formerly called LEOPARD syndrome), Costello
syndrome, cardiofaciocutaneous (CFC) syndrome, Noonan-like
syndrome, neurofibromatosis type I, NF-llike syndrome, hereditary
gingival fibromatosis, Legius syndrome and capillary malformation-
arteriovenous malformation. Patients with these syndromes share
many clinical features such as distinct facial appearances, develop-
mental delays, cardiac defects, growth delays, and neurological dis-
turbances. Molecular analyses identified mutations in genes related
to the Ras/MAPK signaling pathway, namely PTPN11, SOS1, RAF1,
KRAS, BRAF, NRAS, HRAS, MAP2K1/2, SHOC2, CBL, NF1, SPRED1 and
RASA1.
More recently, novel gene variants, including RIT1, RRAS, RASA2,
A2ML1, SOS2 and LZTR1, have been shown to be associated with
RASopathies, further expanding the disease entity. Molecular
characterization of these syndromes help to better elucidate an un-
derstanding of the pathogenesis of these disorders and aid in the de-
velopment of potential therapeutic approaches. Model organisms,
such as zebrafish and mice, harboring disease-causing mutations
have been produced and they exhibit phenotypes resembling clinical
pictures of patients. A series of compounds acting on the Ras/MAPK
pathway seem to ameliorate various symptoms, holding promise for
treating patients with these syndromes.
SY1-1
Growth: New era of growth disorders
How to approach growth disorders: genetics for better clinical care
Andrew Dauber
Cincinnati Center for Growth Disorders, Division of Endocrinology,
Cincinnati Children fs Hospital Medical Center
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY1-1
Human growth is a complex process governed by a multitude of bio-
logical process. Traditionally, genetic analysis has played a limited
role in the pediatric endocrinologist’s evaluation of patients withgrowth disorders. Focused candidate gene testing is employed in
cases of distinct syndromes (i.e. Leri-Weill Dyschondrosteosis, Noonan
Syndrome, Russell Silver Syndrome) or clear defects in the growth
hormone/IGF-I axis. We will first explore the role of candidate gene
testing in the evaluation of short stature and growth hormone
deficiency. We will then turn to the use of genomic technologies
including whole exome sequencing and chromosomal microarrays
for the identification of rare genetic sequence and copy number vari-
ants underlying individual patient’s short stature. We will review a
proposed algorithm for the diagnosis of growth disorders.
SY1-2
Growth: New era of growth disorders
IGF2 mutation in Silver-Russell syndrome
Thomas Eggermann
Institute of Human Genetics, University Hospital, Aachen Technical
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY1-2
With the identification of 11p15.5 disturbances in Silver-Russell syn-
drome (SRS) ten years ago, the central role of at least the telomeric
imprinted region ICR1 in 11p15.5 for the etiology of the disease be-
came obvious. Two of the genes regulated by the ICR1 are IGF2 and
H19. Due to its physiological function and its imprinting status, IGF2
had been suggested as the causative gene for SRS, but the final clue
was still missing. We recently identified a paternally inherited IGF2
mutation in a family with growth retardation and SRS, we could con-
firm the hypothesis that IGF2 is the key factor for the growth retard-
ation and other features in SRS. However, molecular studies in
further SRS families as well as in sporadic patients did not identify
further cases, thus IGF2 mutations do not significantly contribute to
the mutation spectrum in this disorder. However, in the last decade
it has emerged that IGF2 and other imprinted genes belong to com-
mon functional networks, either because of their physiological func-
tion or because they belong to the imprinted genes network (IGN),
and molecular alterations of genes of IGF2 interaction partners also
contribute to growth retardation. Comprehensive studies in our pa-
tient cohort (n>500) referred for SRS diagnostic testing helped us to
identify further molecular alterations in the 11p15.5 region itself, but
also in other genes and chromosomes (e.g. GRB10 in 7p13, MEST in
7q31, IGF1R in 15q26). Our data and those from animal and cellular
models indicate that IGF2 and the coregulated H19 gene as well as
further imprinted and/or functionally related factors belong to the
IGN and the IGFII-IGF1R signaling cascade by cis and trans acting
mechanisms. These findings contribute to a better understanding of
human growth and its disturbances. The translational use of this
knowledge has significantly improved molecular diagnostics of SRS
and will have an impact on personalized patient management.
SY1-3
Growth: New era of growth disorders
Treatment Strategies for Short Stature in Achondroplasia
Hiroshi Kitoh
Department of Orthopaedic Surgery, Nagoya University Graduate School
of Medicine
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY1-3
Achodnroplasia (ACH) is one of the most common short-limbed skel-
etal dysplasias characterized by rhizomelic shortening of the extrem-
ities, frontal bossing with midface hypoplasia, and trident hands.
ACH is caused by gain- of-function mutations in the fibroblast
growth factor receptor 3 (FGFR3) gene, which is a negative regulator
of longitudinal bone growth. No effective treatments for short stature
in ACH are currently available. The limb lengthening is a therapeutic
option to gain bone length, but the treatment period for bone mat-
uration is very long which results in higher rates of complications.
We have established a novel cell therapy using culture-expanded
bone marrow cells (BMC) and platelet rich plasma (PRP) during the
limb lengthening to accelerate callus formation. We have performed
this cell therapy in more than 130 bones since 2002. The clinical out-
come of the limb lengthening in ACH was significantly improved by
BMC and PRP transplantation. The effectiveness of this cell therapy,
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limited osteoblastic differentiation of BMC.
For further improvement of our cell therapy, we tried to search clinic-
ally applicable drugs that promote the activity of Runx2, which plays
a pivotal role in the differentiation of mesenchymal cells to the
osteoblastic lineages. By drug repositioning (DR) strategy, we found
that a proton pump inhibitor, lansoprazole, enhanced nuclear accu-
mulation of Runx2, promoted expressions of various osteoblastic
genes, and induced osteoblastogenesis of human BMC. Systemic ad-
ministration of lansoprazole to a rat femoral fracture model increased
osteoblastogenesis. Lansoprazole could be applicable for ex vivo cul-
ture to obtain better quality of BMC.
We next tried to search drugs that suppress abnormally activated
FGFR3 signaling in ACH. We found that meclozine, an antihistamine
drug that has long been used for motion sickness, facilitated chon-
drocyte proliferation and mitigated loss of extracellular matrix in ACH
model cells. Meclozine also suppressed abnormally activated FGFR3
signaling in various chondrocytic cells that were infected with human
mutants. In bone explant culture, meclozine increased the longitu-
dinal growth of embryonic tibia from ACH model mice. After 3 weeks
administration of meclozine, the body and tail length, and the indi-
vidual bone length was significantly longer in meclozine-treated ACH
mice than in untreated ACH mice. The plasma concentration of
meclozine during treatment was within the range that has been used
in clinical settings for motion sickness. These results indicated poten-
tial clinical feasibility of meclozine for the improvement of short stat-
ure in ACH.
SY2-1
Puberty: Mechanisms and disorders of puberty
Neuroendocrine mechanism regulating puberty onset
Hiroko Tsukamura
Nagoya University
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY2-1
Puberty, which is associated with a maturation of the gonadal axis, is
timed by an increase in tonic gonadotropin release from the anterior
pituitary, where synthesis and release of gonadotropins are stimu-
lated by gonadotropin- releasing hormone (GnRH) released from the
hypothalamus. Kisspeptin, encoded by Kiss1, is a potent stimulator of
gonadotropin release via inducing GnRH release, and plays a critical
role in puberty onset, because inactivating mutation of Kiss1 or
GPR54, a kisspeptin receptor gene, causes pubertal failure in rodents
and humans. Accumulating evidence suggests that KNDy neurons,
which express kisspeptin, neurokinin B and dynorphin A, in the
hypothalamic arcuate nucleus (ARC) are a key regulator of tonic
GnRH/gonadotropin release, which governs gonadal activity, i.e.,
gametogenesis and steroidogenesis in both sexes. Most probably,
pubertal maturation of gonadal axis is triggered by an increase in
Kiss1/kisspeptin expression in the ARC KNDy neurons in rodents. It is
likely that estrogen derived from the immature ovary plays a critical
role in prepubertal restraint of ARC Kiss1/ kisspeptin expression, and
that a decrease in sensitivity to the estrogen negative feedback dur-
ing peripubertal period is a key event for pubertal maturation of the
hypothalamic mechanism regulating GnRH and then gonadal activity
in rodents.
SY2-2
Puberty: Mechanisms and disorders of puberty
Central precocious puberty caused by mutations in the imprinted gene
MKRN3
Ana Paula Abreu
Universidade de Sao Paulo/ Brigham and Women's Hospital
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY2-2
Puberty and reproduction are controlled by the hypothalamic-
pituitary-gonadal axis. This axis is active during the embryonic and
neonatal stages of human life but then suppressed during childhood,
then ultimately re-activated, first detected as an increase in ampli-
tude and frequency of gonadotropin-releasing hormone (GnRH)
pulses, to initiate puberty. The precise mechanisms that regulateGnRH secretion to constrain the HPG axis during infancy and
childhood and subsequently trigger the initiation of puberty remain
elusive. Complex interactions among genetic, nutritional, and
environmental factors influence pubertal initiation. Pubertal timing is as-
sociated with risks of subsequent disease. Early activation of the hypo-
thalamic–pituitary–gonadal axis results in gonadotropin- dependent or
central precocious puberty, which is clinically evidenced by pubertal ini-
tiation before 8 years old in girls and 9 years old in boys. The genetic
determinants of the timing of human pubertal development and in par-
ticular CPP are largely unknown. In 2013, we identified loss-of-function
mutations in a single gene, MKRN3, encoding makorin ring finger pro-
tein 3, in five of 15 families with central precocious puberty, using an ex-
ome sequencing approach. MKRN3 is located on chromosome 15q, in
the Prader-Willi Syndrome critical region, and is maternally imprinted,
expressed only from the paternally inherited allele. Following this inherit-
ance pattern, all MKRN3 mutations identified in patients with central pre-
cocious puberty were inherited from their fathers. To date, MKRN3 is the
most common genetic defect associated with central precocious pu-
berty in families from several different ethnic groups. MKRN3 belongs to
the Makorin family, a family of E3 ubiquitin ligases. Its protein structure
has a ubiquitin ligase domain. The mutations identified in patients with
central precocious puberty are expected to disrupt protein function.
MKRN3 expression in the arcuate nucleus of mice is high prepubertally
and decreases before puberty initiation, reaching very low levels in adult
life. Taken together, these findings suggest that the loss of function of
MKRN3 results in the release of a restraint mechanism on the GnRH
pulse generator, which in turn releases the brake on puberty. MKRN3 is
the first gene with an inhibitory role on GnRH secretion with mutations
identified in humans.
SY2-3
Puberty: Mechanisms and disorders of puberty
Mechanisms of pubertal growth spurt and growth plate closure
Kye Shik Shim
Kyung Hee University Hospital at Gangdong
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY2-3
Growth of height is increased in early or mid-puberty and is known as
pubertal growth spurt, but decreased and ceased after growth plate
closure in late puberty. Therefore, the pubertal growth spurt has a
growth-promoting effect and the growth plate closure reveals a limit-
ing effect on bone elongation. However, the mechanisms behind these
contrary phenomena during puberty are still not exactly known.
The elongation of long bones results from chondrocyte differenti-
ation, proliferation and hypertrophy, and extracellular matrix secre-
tion in proliferative and hypertrophic zone of epiphyseal plates.
The growth plate closure is thought as the result of epiphyseal sen-
escence due to the loss of differentiation potential of chondrocytes
in resting zone of epiphyseal plates.
The complex networks of genetic, nutritional, cellular, paracrine, and
endocrine factors are considered closely related with pubertal
growth spurt and growth plate closure.
The genetic factors include the genes linked with intracellular, extra-
cellular, paracrine and endocrine factors. The intracellular factors con-
tain chondrocyte transcription factors, Ras-MAPK signaling, and
centrosomal proteins, etc. The extracellular factors are the cartilage
extracellular matrixes that contain specific collagen, non-collagenous
proteins, and proteoglycans, etc.
The important paracrine factors that regulate the growth plate chondro-
cytes are parathyroid hormone-related protein/Indian hedgehog path-
way, fibroblast growth factor and C-type natriuretic peptide signaling.
The major endocrine systems that control pubertal growth are
GH-IGF-I and estrogen signaling.
Therefore, a lot of factors include the cellular factors involved with
chondrocyte differentiation, proliferation and hypertrophy, and mul-
tiple molecular pathways related with chondrocyte differentiation,
vascularization, and ossification in the growth plate are considered
influencing each other. However, the complex interactions of these
factors are still unclear. Elucidation of the detailed mechanisms of
the pubertal growth spurt and growth plate closure will allow a
better understanding of the molecular mechanisms responsible for
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 4 of 144idiopathic short stature, precocious puberty, and skeletal disorders. It
will also contribute to the development of new therapeutic modal-
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Iodine is a trace element that is essential for thyroid hormone syn-
thesis, and the adequate production of thyroid hormone is essential
for brain development, physical growth and control of metabolic pro-
cesses in the body throughout the lifespan. In pregnant women, thy-
roid hormone is essential for neurological development of the fetus.
During the infancy period, iodine is also essential for neurological de-
velopment, being involved in neuronal cell migration, myelination
and various other functions.
The major source of iodine is from exogenous or dietary intake. How-
ever, dietary sources provide only a small amount of iodine which is
usually insufficient to meet the daily requirement. Long duration of
iodine insufficiency leads to iodine deficiency disorder which is a sig-
nificant public health problem in many countries. Iodine deficiency-
related problems such as goiter, hypothyroidism, growth stunting,
and cognitive impairment are relatively common. Various national
policies have been enacted to eliminate conditions related to iodine
insufficiency. Iodine supplementation through salt iodization is an ef-
fective and sustainable strategy for preventing iodine deficiency. Bio-
markers used to monitor iodine status at the population level include
urinary iodine excretion (UIE), goiter rates, and serum thyroid stimu-
lating hormone (TSH) levels. In recent decades the more extreme man-
ifestations of iodine deficiency such as cretinism or multinodular goiter
have significantly decreased, however the various less severe manifes-
tations noted above are still prevalent. Hence, national surveillance
strategies towards establishing the iodine status in a country’s popula-
tion should be regularly carried out. In common clinical practice, spot
urinary iodine levels for measuring the median iodine excretion are
generally used to assess iodine status in population studies.
The most susceptible group for iodine deficiency disorder is women
of reproductive age, whose offspring, if iodine deficient in utero, are
at high risk of irreversible mental impairment. The other susceptible
group is women providing breast milk to their children, as this may
be the only source of iodine during the first 6 months of life. Low
concentrations of thyroid hormone during the fetal stage and early
infancy are associated with irreversible brain damage, including men-
tal retardation and neurological abnormalities. The main factors influ-
encing the extent and magnitude of neurological complications
arising from iodine deficiency are the timing and severity of the defi-
ciency and consequent thyroid hormone deficits. Subtle impairment
of cognitive function is likely to occur even in offspring of pregnant
women with mild or asymptomatic hypothyroidism.
SY3-2
Thyroid: Management of thyroid disorders
The long term outcome of subclinical congenital hypothyroidism
Sarah Mathai
Department of Pediatrics, Christian Medical College
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY3-2
The biochemical diagnosis of congenital primary hypothyroidism(CH)
is made when serum TSH level is elevated and Free T4(FT4) level is
low/low normal. Newborn babies have a physiological TSH surge
soon after birth (70- 100 mIU/ml) which declines by 72 hours of age.
TSH level remains rather stable (< 6 mIU/ml) between one month of
age and adult life. Elevated TSH level (>6mIU/ml) with normal FT4
levels beyond the neonatal period may be defined as subclinical con-
genital hypothyroidism(SCCH).
Hypothyroidism adversely affects growth & cause irreversible
developmental delay especially in young children, therefore urgent
initiation of levothyroxine(LT4) supplements is recommended in
CH. However overtreatment may cause hyperactivity, bone ageadvancement and craniosynostosis. In children with SCCH, decision to
treat or not during early infancy is very difficult. The American Academy
of Pediatrics recommend treatment if TSH is persistently > 10 mIU/ml
beyond 2 weeks of age irrespective of T4 levels. There are no definite
guidelines regarding initiation of treatment in infants with TSH
levels 6-10 mIU/ml.
Among the factors implicated in subclinical hypothyroidism, the most
important is maternal iodine deficiency. In fact maternal iodine status
rather than the maternal thyroid status has been reported to adversely
affect the cognitive development in children according to a recent
study and this group has demonstrated improvement in neurodevelop-
mental outcome with maternal iodine supplementation.
There is limited data on the long term outcome of SCCH in children.
The outcomes reported are ongoing subclinical hypothyroidism even
up to late adolescence, adverse neurodevelopmental outcome
especially verbal skills and development of overt hypothyroidism.
Children who had persistent TSH elevation have been reported to
have abnormal thyroid scintiscans. While better cognitive outcome
has been reported with initiation of low dose LT4 supplements dur-
ing infancy, some studies have also reported bone age advancement.
In our institution we have screened 150,000 newborns for CH over
the last 15 years. In our practice we often do not commence LT4
supplements for children with SCCH but periodic monitoring is done.
We have assessed their growth and development and the results
are awaited.
In conclusion, CH should be diagnosed based on S.TSH and T4/FT4
levels to prevent overdiagnosis and overtreatment. Demonstration of
abnormal thyroid scintiscan in children with SCCH may predict per-
sistence of TSH elevation. All children with SCCH whether treated or
not need long term monitoring. Optimising maternal iodine and thy-
roid status may be simple and effective in reducing SCCH prevalence
and its adverse long term impact on children.
SY3-3
Thyroid: Management of thyroid disorders
Management of autoimmune thyroiditis
Andrew Bauer
The Children's Hospital of Philadelphia; Perelman School of Medicine,
The University of Pennsylvania
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY3-3
Autoimmune thyroid disease (AITD) is comprised of two distinct but
related disorders, Graves’ disease (GD) and Hashimoto’s thyroiditis
(HT). In both disorders T-cells infiltrate the thyroid resulting in tissue
disruption as well as activating B-cells to produce anti-thyroid anti-
bodies. GD is associated with the production of a TSH-receptor anti-
body that stimulates dysregulated overproduction of thyroid
hormone. In contrast, HT is associated with thyrocyte apoptosis and
production of anti-thyroglobulin (TgAb) and anti-thyroid peroxidase
(TPOAb), with TPOAb further reducing thyroid hormone production
via decreased organification. Iodine excess may increase the risk for
developing AITD, in particular HT. Early identification and treatment
of autoimmune thyroid disease in children and adolescents is critical
to optimize growth and development. In addition, there is evidence
that both GD and HT may increase the risk for developing thyroid
nodules and thyroid cancer. We will review the evaluation and
management of these two entities with a focus on subclinical
hypothyroidism and the definitive treatment of GD.
SY4-1
New Strategy
Next-generation sequencing and array-based comparative genomic
hybridization for patients with pediatric endocrine disorders
Maki Fukami
National Research Institute for Child Health and Development
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY4-1
Recent advances in molecular technology including next-generation se-
quencing (NGS) and array-based comparative genomic hybridization
(aCGH) enabled researchers to perform high-throughput mutation
screening and genome-wide copy number analysis for multiple
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than 500 patients with pediatric endocrine disorders. Representative
results include the flowing. [1] Molecular diagnosis of patients with
hypogonadism or hypospadias: We performed NGS-based mutation
screening of all known causative genes and aCGH-based genome-wide
copy-number analysis. We analyzed 58 patients with hypogonadotropic
hypogonadism and identified pathogenic molecular defects in 14
patients. Oligogenicity was not evident in our patient group. As rare ab-
normalities, we identified a submicroscopic deletion involving FGFR1,
an SOX3 polyalanine deletion, and a WDR11 splice site mutation. Then,
we also analyzed 62 patients with non-syndromic hypospadias. We
found that monogenic and digenic mutations in known causative
genes and cryptic copy-number alterations account for more than 10%
of cases. [2] Identification of genomic rearrangements underlying aro-
matase excess syndrome: We performed aCGH for male patients with
hereditary gynecomastia. The results suggest that microdeletions,
microduplications, and complex rearrangements around CYP19A1 en-
coding aromatase lead to estrogen overproduction and resultant
gynecomastia. These data provides novel models of human disorders
caused by cryptic genomic rearrangements. [3] Whole exome sequen-
cing of patients with disorders of sex development (DSD): We per-
formed whole exome sequencing for individuals with various types of
disorders of sex development. As a result, we detected intragenic muta-
tions and upstream deletion of SOX9 in 46,XY DSD patients without
campomelic dysplasia. These data expand the phenotypic spectrum of
known monogenic disorders. Furthermore, we identified novel gene
mutations that may be associated with DSD.
This session aims to introduce the usefulness of NGS and aCGH in
the field of pediatric endocrinology.
SY4-2
New Strategy
Generating Functional Miniature Organs (Organoids) in a Dish
Hidenori Akutsu
Department of Reproductive Medicine, National Research Institute for
Child Health and Development
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY4-2
Pluripotent stem cells can generate virtually any cell type and, as
such, can be used to model development and disease and even hold
the promise of providing cell-replacement therapies. Structures re-
sembling whole organs, termed organoids, have been generated
from stem cells through the development of three dimensional cul-
ture systems. Organoids are derived from pluripotent stem cells that
differentiate to form an organlike tissue exhibiting multiple cell
types. However, no one reported that organoids in vitro possessed
similar functions of “real” organs. Intestines are generated through a
highly orchestrated, serial developmental process and are composed
of cell types from all three primary germ layers. Directed differenti-
ation of human pluripotent stem cells (hPSCs) can yield gut-specific
cell types; however, these structures do not replicate some of the
critical functional interactions between cell types of different germ
layers. Recently, we have developed a simple protocol based on a tis-
sue self- organization concept for generation of mature functional in-
testinal organoids from hPSCs under xenogeneic- free conditions.
The organoids showed the gut tube-like architecture consisted of
mucosa and submucosa by histological, immunofluorescence and
electron micrograph examinations. Stem cell-derived miniature guts
(mini-guts) were derived from all three germ layers and contained
distinct types of intestinal cells, including enterocytes, goblet cells,
Paneth cells, and enteroendocrine cells. They demonstrated intestinal
functions including peptide absorption and innervated bowel
movements responsive in response to stimulation with histamine
and anticholinergic drugs. Here, I present our recent achievements of
mini-guts and discuss about future applications with 3D organoids.SY4-3
New Strategy
Clinical steroid mass spectrometry and metabolomics
Cedric HL Shackleton
Institute of Metabolism and systems research (IMSR), University of
Birmingham / UCSF Benioff Children fs Hospital Oakland Research
Institute
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY4-3
This talk will summarise the 80 year history of steroid metabolomics
in diagnosis, ending with latest developments in tandem MS and
machine interpretation of GC/MS metabolomic data.
The characterization and measurement of steroids in health and dis-
ease has been fundamental to endocrinology since the 1930s. The
first example of a diagnostic steroid for an endocrine disorder was
the discovery of pregnanetriol in the urine of patients with the adre-
nogenital syndrome (CAH) by Guy Marrian in 1937. For decades,
paper and TLC dominated metabolomic (urinary steroid) approaches
to steroid analysis, while from the 1960s RIA of circulating hormones
and precursors was pre-eminent and remains useful.
Mass spectrometry now dominates the steroid analytical field but it
has taken a long time to reach this position. The breakthrough came
in the mid-1960s, when a Swedish company introduced the LKB
9000 GC/MS instrument combining the separation powers of gas
chromatography with the structural information of mass spectrom-
etry. In 1967 this presenter had the privilege to use the first British
LKB in Professor Charles Brooks’ lab in Glasgow to document the
structures of steroids excreted by the human newborn.
In the 50 years of steroid mass spectrometry there have been con-
tinuous advances, notably for GC/MS the introduction of capillary col-
umns, chemical derivatisation methods and advanced data systems.
A most important advance was combining HPLC and MS and the
introduction of MS/MS to provides high specificity and sensitivity.
Automated HPLC MS/MS systems now allow quick separations and
accurate measurement of vanishingly small amounts of hormonal
steroids. The high throughput has rendered HPLC/tandem MS the
desired method for routine clinical serum steroid measurements. In
contrast to serum steroids, HPLC/MS of urinary steroids was challen-
ging because of the metabolite structures involved but in the last
two years quality comprehensive urinary steroid profiles have been
produced and the method will be central to metabolomics.
In spite of being labour intensive GC/MS still holds its own for
metabolomic studies, although an ongoing drawback of complex
metabolomic data production is interpretation by the operator and
explaining diagnostic findings to the interested clinician. To that
end my colleagues in Birmingham (Prof Wiebke Arlt. Elizabeth
Baranowski, Angela Taylor, Tulay Gulan, Michael Biehl, Kerstin
Bunte, Peter Tino and others) have developed a novel interpretable
machine learning technique, Angle Learning Vector Quantisation ,
designed to distinguish multiple biosynthetic error conditions in
adults and children using the urinary steroid metabolome. Predic-
tions with close to 100% specificity and sensitivity. Interestingly,
pregnanetriol, the mother of steroid metabolites, remains a central
analyte with our metabolic profile studies almost 80 years after
Marrian’s painstaking identification.SY5-1
Obesity: Increasing risk of morbidity in children and adolescents
The role of MC4R in pediatric obesity: above and beyond the central
nervous system
Feihong Luo
Deparment of Pediatric Endocrinology and Inborn Metabolic Diseases,
Shanghai, China
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY5-1
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 6 of 144Obesity is a worldwide health problem. Approximately 21-24% chil-
dren and adolescents are overweight, and 16-18% of individuals
have abdominal obesity. Obese 10- to 13-year-old children are 6 to 7
times more likely to become obese adults, when compared with their
nonobese peers 50% to 65% of adults with severe obesity (>180% of
ideal weight) were obese as children. Obesity is a complex,
multifactorial condition with high heritability. Increasing evidence
that environmental and nutritional influences during infant and early
childhood’s development can have lasting effects on adult’s predis-
position to obesity and metabolic syndrome. We analyzed the suc-
cessive anthropometric data from birth to 24 months and found
parental pre-pregnant BMI played the most important role in their
offspring’s body size after 6 months age; the total gestational weight
gaining during pregnancy of the mother steadily explains nearly a
quarter (25 ± 5%) of the relative importance of children’s weight; the
weight of the parents is the major factor influencing the children’s
weight after 6 months of age, this complex feature of human early
growth highlights the underlying association with epigenetic and
genetic regulation. While, among the known obese-causing single
gene defects which result in human obesity, MC4R deficiency is
probably the most frequent. The prevalence of loss-of-function MC4R
mutations ranges from 0.5% to 5.8% in childhood onset obesity. A
generational effect was observed, with a penetrance of 40% in
MC4R-deficient adults aged>52 years, 60% in 18-52 year-old adults
and 79% in children. MC4R is expressed by distinct neurons in the
CNS that synapse with neurons that express the pomc gene, and
produce a α -MSH-related end-product. The role of MC4R as a regula-
tor of feeding behavior in mice was established not long after the
characterization of the mc4r gene. The binding of α -MSH to neurons
in the hypothalamus that express mc4r will decrease feeding behav-
ior. Conversely, point mutations of the mc4r gene that render the re-
ceptor nonfunctional result in the onset of obesity. The patients with
MC4R mutations were obese from an early age, but with increase in
both fat and lean masses, and were excessively hungry from 6–8
months of age with hyperphagia and persistent food-seeking behav-
ior. Besides of the well- established central MC4R pathways, recent
research revealed that MC4Rs expressed on intestinal enteroendo-
crine L cells regulate PYY and GLP-1 secretion, two gut hormones im-
plicated in the regulation of energy and glucose homeostasis.
Increasing evidences support the notion that MC4R may have a
variety of physiological roles in the pathogenesis of pediatric early
onset obesity.
SY5-2
Obesity: Increasing risk of morbidity in children and adolescents
Management of hypothalamic obesity
Mitchell Eugene Geffner
Keck School of Medicine of USC
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY5-2
Hypothalamic obesity is typically an intractable form of obesity that
was initially described in patients with craniopharyngiomas usually
following surgical treatment and unintentional damage to hypothal-
amic nuclei, which results in disruption of energy regulation. How-
ever, this definition has now expanded to include obesity developing
after a variety of hypothalamic insults, both acquired and congenital
(such as other hypothalamic tumors, pituitary macroadenomas with
suprasellar extension, gliomas, meningiomas, teratomas, and germ
cell tumors; radiotherapy, Prader-Willi syndrome, and mutations in
the leptin, leptin receptor, POMC , MC4R , and CART genes). The
pathogenic mechanisms underlying hypothalamic obesity are com-
plex and multifactorial, including damage to the ventromedial hypo-
thalamus, which leads to hyperphagia; a low-resting metabolic rate;
autonomic imbalance; hypomobility; and insomnia. Additional mech-
anisms by which the brain regulates adipose tissue and β -cells of
the pancreas include the sympathetic nervous system, vagally-
mediated hyperinsulinemia, and the endocrine system, namely the
growth hormone, thyroid, and hypothalamo-pituitary-adrenal axes.
Medical therapy to date (methamphetamine derivatives, somato-
statin analogs, GLP-1 and its analogs, oxytocin, and MetAP2 inhibitors
have been tried with varying degrees of success), with bariatricsurgery now coming under study. Understanding the central role of
the hypothalamus in the regulation of feeding and energy metabol-
ism may also be critical to help gain insight into the pathogenesis
and management of common obesity.
SY5-3
Obesity: Increasing risk of morbidity in children and adolescents
Determinants, consequences and prevention of childhood overweight
and obesity
Muhammad Yazid Jalaludin
Department of Paediatrics, Faculty of Medicine, University Malaya
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY5-3
Over the recent years, the prevalence of childhood obesity has in-
creased rapidly worldwide, likely as a result of complex interactions
between genes, dietary intake, physical activity, and the environ-
ment. The determinants of childhood obesity is multifactorial and in-
volves a complex relationship among various non-modifiable and
modifiable factors. Apart from genetic factors, maternal obesity, ges-
tational diabetes and adiposity rebound are some of the important
non-modifiable factors. Evaluating modifiable factors contributing to
obesity (weight gain during infancy, physical activity, diet, sleep, par-
ental feeding practices, screentime, parental obesity and families
from lower socioeconomic status) is an important step towards ef-
fective intervention.
Childhood obesity is associated with significant short and long-term
health and social consequences. Childhood obesity affects nearly
every organ of the body. Short term health impacts such as hyper-
tension, dyslipidaemia and insulin resistance (metabolic syndrome)
which were earlier considered markers of adult cardiovascular
disease, are now common among obese children. Long term health
impacts of childhood obesity although less commonly seen by
paediatrician, include premature cardiovascular diseases, type 2
diabetes, non-alcoholic fatty liver disease (NAFLD), obstructive sleep
apnoea syndrome (OSAS), infertility and orthopaedic pain.
Prevention is more effective than treatment in dealing with the rising
prevalence of childhood obesity. Roots of obesity can be traced to
very early in life and appropriate prenatal and postnatal nutrition can
help to reduce the risk of overweight/obesity in adulthood. Establish-
ing healthy dietary and lifestyle habits after birth and throughout the
childhood and adolescent period can help reduce the risk of child-
hood obesity. Child health clinics, school health screening pro-
grammes, as well as general paediatricians/family physicians are at
the first line of defense even before the BMI crosses the acceptable
range and hence play a crucial role in prevention and treatment of
childhood obesity. Routine anthropometric measurement are essen-
tial during clinic visits to detect overweight/ obesity at an early stage,
thus permitting necessary actions to be taken.
Once the child’s BMI crosses the overweight percentile, individualise
interventions are critical for successful weight management. The
Staged Approach recommended by the American Academy of
Paediatrics (AAP) involves multi- disciplinary team as early as Stage 2.
The need for multi-disciplinary team involvement increases as the
problem escalate.
SY6-1
Which is most dangerous for future cognition in young children
with diabetes: hypo- or hyperglycemia?
Diabetes dysglycaemia, cognition and the developing brain
Fergus Cameron
Royal Children fs Hospital
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY6-1
Glucose is the preferred metabolite of the brain with 25% of circulat-
ing blood glucose in adults destined for cerebral metabolism. It is
intuitive then that type 1 diabetes mellitus (T1DM), a disorder charac-
terised by perturbations in blood glucose (“dysglycaemia”), should
cause acute and chronic brain dysfunction. These cognitive and
affective impacts appear to be greatest in the developing brain of
children and adolescents with T1DM. Aspects of diabetic dys-
glycaemia that appear to be most significant are hypoglycaemia,
Fig. 1 (abstract SY6-3). See text for description
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 7 of 144hyperglycaemia and diabetic ketoacidosis (DKA). Some early in vitro
work suggest that glycaemic variability may also play a significant
role in neural cell injury. Prospective observational data from the
point of diagnosis to neuromaturation in the Royal Children’s Hos-
pital Diabetes Cohort Study revealed a rather lamentable “rule of
thirds”- one third of subjects developed a DSM IV threshold mental
health disorder, one third did not complete secondary schooling and
one third did not continue in adult care after transition. This was co-
incident with a 0.3 SD loss of full scale IQ and changes in regional
brain volumes. More recent functional imaging studies have provided
insight into some of the mechanistic aspects of dysglycaemia-
induced brain injury. DKA at the point of diagnosis is associated with
acute grey and white matter volume and spectroscopic changes that
are associated with neurocognitive outcome in the medium term.
Clamp studies combined with MRI have shown that hypo- and hyper-
glycaemia result in distinct regional changes in brain perfusion and
metabolic activity. Potential synergies of chronic and additive dysgly-
caemic insults are difficult to quantitate largely due to an inability to
fully record all aspects of glycaemic perturbation over a life course.
In addition to this, pre-conditioning and programming may also play
significant mediating roles. However, developmental age at the time
of diabetes onset appears to have a critical influence upon outcome.
A nascent understanding of mechanism of neural injury is providing
some insights as to potential non-glycaemic interventions that might
be used to protect the developing brain.
SY6-2
Which is most dangerous for future cognition in young children
with diabetes: hypo- or hyperglycemia?
Improving metabolic control without increasing severe hypoglycemia
Karin Åkesson
National Swedish Padiatric Diabetes Registry
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY6-2
Over the last years the metabolic control in children with type 1 dia-
betes in Sweden has improved and the mean HbA1c in year 2015 is
57.3 mmol/mol, IFCC (7.4 %, DCCT). Data on almost all (>97 %) chil-
dren, 0-18 years of age, with type 1 diabetes in Sweden is registered
in Swediabkids, the Swedish Pediatric Diabetes Quality Registry. Swe-
diabkids includes data on HbA1c, BMI, insulin dose and frequency of
insulin pumps as well as on acute and chronic complications. This al-
lows us to continuously follow changes in the frequency of severe
hypoglycemia when HbA1c is decreasing. The new technology, with
Continuous Glucose Monitoring and advanced insulin pumps, has
made it possible to have a tight control of the children’s glucose
level. The children are taught to correct their glucose level if it is
below 4 or above 8 mmol/mol and to always give dextrose to
normalize a low glucose level. These recommendations make the
children and their families highly involved in their own treatment.
The families as well as the personnel in schools and day care centers
are taught to count carbohydrates and to give insulin correction
doses during the days. Since July 2009 a new law is implemented in
Sweden to secure the rights of children with diabetes. The pediatric
diabetologist or nurse has to make a detailed agreement with the
parents or other caregivers to what extent the child needs help with
the diabetes self-care during school day. This agreement should be
written down in a national uniform action plan form. By giving the
child and its close environment the possibility to take command over
the treatment and by extra support from the pediatric diabetes team
when this is needed, it is possible to improve metabolic control with-
out increasing severe hypoglycemia.
SY6-3
Which is most dangerous for future cognition in young children
with diabetes: hypo- or hyperglycemia?
Closed loop systems to avoid extreme hypo- and hyperglycemia
Martin de Bock
Princess Margaret Hospital
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY6-3Closed loop insulin delivery systems aim to closely regulate blood
glucose levels by using algorithms that interpret real-time sensor glu-
cose values and adjust insulin delivery in real time, without increas-
ing the risk of hypoglycaemia. These systems have been extensively
tested in closely regulated scenarios including hotels and diabetes
camps – all of which have shown favourable glycaemic outcomes
compared to standard pump therapy. The first long term, unsuper-
vised outpatient trials have now been conducted, confirming that
these results can be translated into real life settings. Closed loop in-
sulin delivery systems are expected to be commercially available
within the next 2 years, heralding a new era for patients with type 1
diabetes, where tight glycaemic control can be achieved, without the
burden of hypoglycaemia or requirement for frequent patient initi-
ated management strategies.SY7-1
DSD: Variations in Sex Development and in Gender Identity
Initial approach to Disorders of Sexual Differentiation
Kah Yin Loke
National University of Singapore
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY7-1
The disorders of sexual differentiation (DSD) comprise many conditions
of diverse pathophysiology which present in the newborn with atypical
external genitalia or in the adolescent with atypical sexual develop-
ment during the pubertal years. These clinical situations are difficult to
manage and an initial comprehensive evaluation is necessary to (1) as-
sign the appropriate gender, (2) develop a logical, pragmatic plan for
investigation and (3) organize the necessary medical, surgical and psy-
chological intervention.
The initial diagnostic clinical evaluation requires a thorough prenatal and
family history. Dysmorphic features and midline facial defects may pro-
vide clues to the underlying cause. External genitalia should be examined
for the presence and symmetry of gonads in the labioscrotal folds, fusion
of the folds, phallic size and site of the urinary meatus on the phallus,
from which the external masculinization score can be derived.
For infants with ambiguous genitalia, investigations can be ordered
based on:
Bilateral non-palpable gonads: first line tests include sex chromosome
karyotyping, serum electrolytes, serum 17-hydroxyprogesterone
[17OHP], testosterone, LH, FSH, and a pelvic ultrasound for female in-
ternal organs.
The normal 46 XX chromosomal female with elevated 17OHP levels
and the presence of a uterus suggests congenital adrenal hyperplasia
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 8 of 144(CAH). (ii) For infants with chromosomal karyotype other than 46 XX,
the second line tests aimed to determine the presence of a testes
and the adequacy of androgen production include measuring the
anti-Mullerian hormone, HCG stimulation test, with further imaging
and laparoscopy. Confirmation of a specific diagnosis may require
genetic analysis.
Palpable gonads (likely to be testis / ovotestis): sex chromosomal
karyotyping should be performed, followed by second line tests indi-
cated above.
Adolescents with DSD may present as:
Girls with primary amenorrhoea, which may be caused by DSD with
46 XY sex reversal (gonadal dysgenesis, testosterone biosynthetic de-
fects, androgen insensitivity syndrome [AIS], LH receptor mutations).
Initial relevant investigations will include a chromosomal karyotype,
LH, FSH, androgen levels and pelvic ultrasound, followed by an HCG
stimulation test.
Girls who virilise at puberty, which can be caused by DSDs with un-
detectable Mullerian structures (17 β
-hydroxysteroid dehydrogenase deficiency, 5 α -reductase deficiency,
partial AIS), and DSDs with detectable Mullerian structures (partial
gonadal dysgenesis, ovotesticular DSD, CAH, androgen secreting tu-
mours). Relevant investigations include a pelvic ultrasound, LH, FSH,
dehydroepiandrosterone, serum androgen with their precursor levels
and 17OHP.
SY7-2
DSD: Variations in Sex Development and in Gender Identity
Long-term outcome of early surgical intervention for hypospadias; What
happens at Puberty?
Kimihiko Moriya
Department of Renal and Genitourinary Surgery, Hokkaido University
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY7-2
Hypospadias (HS) is one of the most common congenital anomalies
in male children. The goal of HS surgery is reconstructing the urethra
to the tip of the glans and straightening the penis. Successful HS sur-
gery ensures a cosmetic penile appearance, voiding in the standing
position and unhampered sexual function in adulthood. Despite
great surgical interest in short-term results, there are only a few stud-
ies regarding the long-term outcome. In this lecture, I will present a
long term outcome of HS surgery, focusing on the cosmetic and
endocrinological outcome at puberty from our long-term outcome
study.
As a first study, to clarify the cosmetic and sexual outcome, a ques-
tionnaire was mailed to HS patients and control subjects at 18 years
old or older. This study demonstrated that although their sexual be-
havior was not different from that in control subjects, HS patients
had a higher rate of dissatisfaction with smaller penile size. Following
the outcome of the questionnaire study, actual penile length of HS
patients was evaluated. As a result, while the severity of HS and
endocrinological abnormality at post-pubertal evaluation were fac-
tors affecting penile size, penile length in patients with severe HS
was shorter even in cases without endocrinological abnormality.
These results suggest that severe HS is not only a disorder of urethral
development, but also a disorder of penile development.
A multifactorial etiology is considered to be involved in the genesis
of HS. Among them, androgen actions have an important role for ur-
ethral development during fetal period. Several studies have shown
a prepubertal hormonal abnormality in patients with HS from the
endocrinological viewpoint. However, reports of hormonal status in
HS patients at puberty are scarce. Therefore, we retrospectively
reviewed endocrinological status at puberty. Endocrinological abnor-
mality was identified in patients with mild as well as severe HS. While
severity of HS did not affected the incidence of high serum FSH, his-
tory of the undescended testis was a risk factor for high serum FSH
at post-pubertal evaluation.
In conclusion, penile size, which is most dissatisfied issue from the
patients’ view point at puberty, is affected by severity of HS. In
addition, history of undescended testis is an important issue from
the endocrinological view point, especially on reproductive function.
Since both testicular descent and urethral formation are influencedby androgen action, coexistence of these pathology would be a se-
vere form in the spectrum of male genital anomaly form the repro-
ductive view point.
SY7-3
DSD: Variations in Sex Development and in Gender Identity
Transgender Youth: Current Concepts, Management, and Priorities for
Research
Stephen Rosenthal
Division of Pediatric Endocrinology, Child and Adolescent Gender
Center, University of California, San Francisco
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY7-3
An increasing number of preadolescents and adolescents identifying
as “gender nonconforming”, “gender expansive”, or “transgender”,
are seeking medical services to enable the development of physical
characteristics consistent with their experienced gender. The onset of
puberty in transgender youth is often accompanied by increased
gender dysphoria, the persistent distress associated with incongru-
ence between assigned sex at birth and experienced gender identity.
While recent reports from the Netherlands have shown that gender
dysphoria may be ameliorated by a gender-affirming model of care,
including puberty suppression, cross sex hormones, and gender con-
firming surgery, there are relatively limited outcomes data, and many
questions remain unanswered. This presentation will highlight
current concepts of the biology of gender identity development,
management of gender dysphoria, gaps in knowledge, and priorities
for research. It is hoped that such research will inform optimal care
of transgender youth and promote further understanding and ac-
ceptance of these individuals.
SY8-1
Workshop on Developing countries
A report on the first year of the APPES-CLAN Equity Working Group.
Where to from here? What can you do to help?
Kate Armstrong
President & Founder, CLAN (Caring & Living As Neighbours)
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY8-1
The APPES-CLAN Equity (ACE) Working Group was established in
2015 as a formal collaboration between the Asia Pacific Pediatric
Endocrinology Society (APPES) and CLAN (Caring & Living As Neigh-
bours) to drive long-term, sustainable change that redresses inequity
and improves quality of life for children living with endocrine condi-
tions in the Asia Pacific region.
The ACE Working Group agreed to adopt a rights-based, community
development approach to achieving equity for children living with
endocrine conditions, and committed to the principles of: participa-
tion; accountability; non- discrimination and equality; empowerment;
and legal, policy and ethical frameworks. CLAN’s strategic framework
for action and five pillars further informed the ACE Working Group
partnership as early priorities were considered:
Affordable access to medicines and equipment
Education, research and advocacy
Optimal medical management
Encouragement of family support groups and
Reducing financial burdens on families.
Deliverables for the first six months of the ACE Working Group
included: a mapping exercise to determine the most vulnerable
paediatric endocrine communities in the Asia Pacific region; develop-
ment of equity markers to track achievements and improvements in
health outcomes for children affected by endocrine conditions; -col-
laborative action with CAH communities and APPES members to ad-
dress barriers to accessing essential medicines and equipment
identification of existing educational resources for paediatric endo-
crine communities, with information made publicly available online;
development of a clear strategic plan to inform action improving ac-
cess to hydrocortisone and fludrocortisone for the CAH Community
in the region; support of fellows training, informed by community
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 9 of 144priorities; utilisation of communication platforms to promote activ-
ities of the partnership; advocacy and action relating to universal
access to newborn screening for congenital hypothyroidism in the
region; strengthening networks between paediatric endocrine com-
munities and associated professional societies clarification of barriers
to financial independence for paediatric endocrine communities,
with particular focus on school attendance and health insurance.
This presentation will report on the achievements of the ACE
Working Group in its first year, including practical examples of collab-
orative action already transforming the lives of children in the Asia
Pacific region. The session will be an opportunity for APPES members
and multisectoral partners to engage with ACE Working Group mem-
bers and collaboratively explore opportunities for involvement in
future activities.
SY8-2
Workshop on Developing countries
Challenges for Pediatric Endocrinology in a resource constrained
environment
Syed Jamal Raza
National Institute of Child Health
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY8-2
Development of Pediatric subspecialties is a relatively new frontier
for certain countries where overall healthcare scenario is still far be-
hind the developed world. Lack of adequate finances is a major but
not the only constraint that obstructs growth of specialties.
There are many other barriers and challenges in developing, estab-
lishing and flourishing of the subspecialty. Access to health care,
which is a general problem, also affects disorders of endocrinology
especially in situations where you need urgent care like Diabetic
Ketoacidosis, salt wasting adrenal crises etc.
However, the most pressing and difficult problem is the lack of
trained personal. In Pakistan, a country of population over 180 mil-
lion have only a handful of trained Pediatric Endocrinologist. Lack of
trained personal not only makes it difficult to establish the discipline
but also results in a dearth of training opportunities for local doctors.
This situation can be helped greatly by other countries by providing
funded training opportunities for doctors from resource-constrained
countries. Once enough trained personal become available, local
training programs can be developed, subsequently reducing the
need for people to go abroad from training.
Lack of availability of affordable endocrine investigations have also
been and will remain a barrier in developing services. With more so-
phisticated (and hence expensive) tests becoming available which on
one hand improve the diagnostic acumen but remain difficult to per-
form even in large towns and centers and even more in peripheral
or small towns with limited health facility. Molecular work in diagno-
sis has now become a norm, and most of the conditions can only be
diagnosed with certainty with molecular testing (especially DSD). This
not only has prognostic implications for patients but also imperative
for prenatal testing. Facilities for molecular testing are not only expen-
sive, but also require technical manpower which is difficult to obtain
and retain in public sectors which is only place the majority can access.
Drug availability has also unfortunately been a problem in many such
countries and simple, essential life saving drugs like hydrocortisone
and fludrocortisone are not registered and regularly available in coun-
try like Pakistan. This brings a disastrous situation for the patients when
despite the diagnosis they cannot be adequately treated.
So, in conclusion, there are many barriers and challenges still withhold-
ing development in resource poor countries. Most can be overcome
with advocacy, planning and some help from the developed world.
SY8-3
Workshop on Developing countries
Building Newborn Screening Systems
Dianne Webster
Newborn Metabolic Screening Programme / Antenatal Screening for
Down Syndrome & Other Conditions
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY8-3Newborn baby screening for congenital hypothyroidism (CH) is a
proven, well accepted public health initiative but implementation
generally is problematic in developing economies. The first consider-
ation is that of prioritisation of public health initiatives within the jur-
isdiction and newborn screening may be perceived as of lower
benefit and priority than eg immunisation or elimination of disease
carrying vectors or provision of clean water. Following a decision to
screen items for consideration include who (start with private payers?
With hospitals?); what condition/s? what cutoff/s? who will collect
samples, test, organise followup and treatment? Payment for treat-
ment? Audit and monitoring? Of high importance is definition of the
goals of screening in terms of health outcomes eg for CH growth
and intellectual development optimal for the individual. Achievement
of health outcomes requires definition of a newborn screening
system incorporating not only the sampling and laboratory testing
(relatively easy to establish) but also the maternity services and facil-
ities, diagnostic and treatment pathways including paediatrics, phar-
macy, followup monitoring testing, family information and support
that are essential to ensure that an infant with a high TSH level
achieves their full potential. Collection and transport of samples is
generally difficult especially outside urban areas and consideration
should be given in the initial stages of a programme of testing for
conditions where the baby will benefit from detection of the condi-
tion even if this is delayed beyond what many programmes would
consider optimal (receipt in laboratory by 4-5 days of age) such as
CH; and to starting in an urban setting, with families able to pay if
this is the only way to begin screening. Followup of positive tests
has been an issue in some programmes and an argument can be
made for setting the screening cutoffs at values which give high
positive predictive values until the followup system is established.
Conditions such as CAH where the testing and notification is time
critical can be added, the population screened broadened and
cutoffs lowered when the infrastructure is in place. The gradual
approach to implementation enables building of the multiple




Epigenetics as the mediator of gene:environment interactions and
programming of non-communicable disease
Richard Saffery
Murdoch Childrens Research Insitute and Department of Pediatrics,
University of Melbourne
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY9-1
The Developmental Origins of Health and Disease (DOHaD) hypoth-
esis is based largely on observational studies in humans and direct
experimentation in animal models. Several mechanisms have been
proposed to account for the latency between an “exposure” in utero
and ‘programming’ of later disease risk, including epigenetic vari-
ation induced early in development. Environmental sensitvity is a
hallmark of epigenetic variation and exogenous exposures have the
potential to influence epigenetic profile, modifying the developmen-
tal trajectory and risk of disease.
Animal studies have demonstrated conclusively that the in utero
environment can modify the epigenetic profile in progeny in
association with long term (even intergenerational) phenotypic con-
sequences, though replication in such models remains fragmented.
Equivalent data in humans are also beginning to emerge. However,
to establish epigenetics as the mediator of ‘programming’ in humans
several criteria must be met. First, interindividual differences in epi-
genetic profile must be present in early life. Second, environmental
exposures implicated in later life phenotypic outcomes, must be
linked to specific epigenetic variants. Third, such epigenetic variants
should be reproducibly associated with later life phenotypic out-
comes. Fourth, specific epigenetic variants must have demonstrated
functional consequences on gene activity or cellular function.
It is now clear that genetic variation ‘shapes’ the human epigenetic
profile throughout life and may play a role in mediating the effects
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 10 of 144of environmental exposures on epigenetic variation. Specific in utero
exposures (such as maternal smoking) induce defined epigenetic
changes in newborns, some of which persists into adulthood.
Mounting evidence also links early epigenetic variation to later onset phe-
notypes and non-communicable diseases. The field is advancing at a
rapid pace but remains in its infancy. The recent adoption of standardised
platforms for epigentic analysis, the advent of several very large prospect-
ive birth cohorts, and the formation of large consortia to build sample
sizes with sufficient power to detect small magnitude effects, represent
major advances. Ultimately, a complementary approach encompassing
(i), well controlled and reproducible animal studies, (ii) ongoing human
longitudinal observational cohorts, and (iii) well-informed interventional
studies, represents the best way forward to firmly establish epigentic vari-
ation as a mediator of DOHaD-related health outcomes in humans.
Author details: Professor Richard Saffery is National Health & Medical
Research Council (Australia) Senior Research Fellow with 20 years ex-
perience in Molecular and Cellular Biology, including 15 in the field
of Epigenetics. He heads a team investigating the determinants of
the human epigenetics profile in early life and its role in later health
outcomes. This involves state-of-the-art multidisciplinary approaches,
encompassing genetic, environmental and epigenetic analysis. Cen-
tral to our work has been the establishment of several longitudinal
birth cohorts with detailed environmental, anthropometric, clinical
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The Tübingen family study collects people with increased risk to de-
velop type 2 diabetes and comprises by now approx. 3.000 deeply
phenotyped individuals. We used wholebody MRI imaging to assess
bodyfat distribution patterns. We could identify subphenotypes of
bodyfat distribution, a metabolically healthy phenotype of obesity
(MHO) versus a metabolically unhealthy phenotype (MUHO) as well
as distinct patterns of perivascular adiopose tissue as well as neckfat.
In a subgroup of approx. 250 individuals we studied brain insulin ef-
fects by MEG and fMRI and observed brain insulin resistance in obese
people. We used nasal insulin as a tool to study brain effects in the
fMRI.
Stimulation of brain insulin signalling by nasal insulin caused brain
responses related to homeostatic regulation, eating behaviour but
also caused changes of peripheral insulin sensitivity as determined
by glucose clamp. Based on stable isotope techniques this brain de-
rived signals affect both glucose appearance from the liver as well as
glucose disappearance. Low hypothalamic insulin sensitivity corre-
lated with increased visceral fat and decreased subcutaneous fat. We
hypothesize that the brain insulin resistance causes unfavourable fat
distribution patterns as a consequence of impaired signalling from
the brain to the periphery favouring accumulation of visceral fat. This
mechanism might also favour the develoment of NAFLD.
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):SY9-3Most patients with primary adrenal insufficiency (PAI), such as 21-
hydroxylase deficiency, can be diagnosed biochemically by measur-
ing urine or serum steroid metabolites, while a minor subset of PAI
patients lacks diagnostic biochemical features. We analyzed known
causative genes in biochemically uncharacterized PAI patients and di-
agnosed genetically about 70% of them. Nonetheless, etiologies of
the remaining 30% were not elucidated. By exome sequencing and
follow-up genetic analyses in 24 early-onset PAI patients with bio-
chemically and genetically unknown etiologies, we identified hetero-
zygous SAMD9 mutations in 11 patients. According to the common
clinical features among these 11 patients, we named this disorder
‘MIRAGE’ syndrome. 1) Myelodysplasia; All patients showed transient
thrombocytopenia and/or anemia in early infancy. Two patients sub-
sequently developed myelodysplastic syndrome and died in early
childhood. 2) Infection; All patients experienced severe invasive infec-
tions, and six patients died before age two years. 3) Restriction of
growth; All patients were born preterm (gestational age, 25 to 35
weeks), small-for-gestational age (birth weight, -4.0 to -2.2 SD), and
also had severe growth restriction after birth. 4) Adrenal hypoplasia;
All seven evaluated patients showed adrenal hypoplasia by ultrason-
ography. Postmortem analysis of two female patients revealed that
their adrenal glands were extremely small and highly disorganized.
The adrenal medulla was only partially surrounded by the adrenal
cortex, and the cytoplasm of dysgenetic adrenocortical cells were
foamy in appearance. 5) Genital phenotypes; All seven patients with
46,XY karyotype had underdeveloped external genitalia. Postmortem
analysis of the two female patients revealed that their ovaries were
extremely small and had very few primordial cells. 6) Enteropathy; All
nine evaluated patients had chronic diarrhea with colonic dilation.
In this symposium, I will talk about identification of a new causative
gene for PAI, SAMD9 , clinical features of MIRAGE syndrome and
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Up to 50% of children fracture before age 18 years, with a peak inci-
dence during early adolescents. Of these who fracture, approximately
20% will sustain a second fracture. Although childhood fracture is
usually associated with trauma there are increasing data to indicate
that fracture incidence in children is related to reduced bone mineral
density and relative skeletal fragility.
It is impractical and unnecessary for the bone health to be assessed
in every child who presents with fracture. The ISCD 2013 Pediatric Of-
ficial Position on Fracture Prediction and the Definition of Osteopor-
osis in Children and Adolescents (1) has recommended:
Evaluation of bone health should identify children and adolescents
who may benefit from intervention to decrease their elevated risk of
a clinically significant fracture
A clinically significant fracture history is one or more of the following:
Two or more long bone fractures by age 10 yr
Three or more long bone fractures at any age up to 16 yr.
Vertebral compression fracture (loss of 20% height at any point).
One or more vertebral compression fractures are indicative of osteo-
porosis. In such children and adolescents, measuring BMD adds to
the overall assessment of bone health. Children who fulfil the above
criteria should undergo a bone health evaluation.
So, what investigations should be performed in a child with recurrent
fracture? This can be guided by the clinical features of the child but
there are ‘routine screening’ investigations that may be considered in
the majority of children. It is important to assess mineral homeostasis
and vitamin D levels. Coeliac and thyroid disease should be screened.
Dependent on the age of the child, gonadal status may be evaluated.
All children with recurrent fracture should have a lateral spine xray
to assess for vertebral compression fracture. This is especially the
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 11 of 144case in children with low trauma fracture, osteogenesis imperfecta or
if there is a history of glucocorticoid therapy. Duel energy xray ab-
sorptiometry (DXA) remains the gold standard for assessment of re-
duced bone density and bone mineral content for age. The caveats
of DXA in children will be discussed.
Management of recurrent fracture in children centres around reduc-
tion of risk factors and improvement in muscle and bone mass. Opti-
mising vitamin D, calcium and pubertal progression are also
important as is the judicious use of bisphosphonates and other bone
specific therapy.
Reference
Bishop et al. 2014 Journal of Clinical Densitometry: Assessment &
Management of Musculoskeletal Health Volume 17.
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The state-of-the-art applications of PET in endocrinology
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Growth & Genetics
Genetic Approaches to make a Diagnosis in Short Stature
Peter Clayton
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Over the last 30 years many monogenic causes of growth disorders,
including hormonal, primordial, skeletal and syndrome-associated,
have been identified by examining candidate genes or hunting for
the causative gene in regions of homozygosity or gene rearrange-
ment. For instance mutations in most of the components of the GH-
IGF axis have been identified, as have the causes of major skeletal
dysplasias.
In more recent years, genome wide association studies (GWAS) have
found variants in a number of these genes contribute to adult stat-
ure, and revealed that many other genes, as yet not implicated in
growth disorders, also contribute. In addition array studies have
shown that copy number variants (CNVs) are more commonly found
in short stature. Alongside these observations, advances in genetic
technologies have led to the increasing use of targeted gene panels
(e.g. for rasopathies) and whole exome (or genome) sequencing
(WES) in growth disorders. This is leading to diagnoses of a particular
condition that had not been anticipated based on phenotype.
We therefore have powerful tools to achieve a diagnosis, but how
should they be used in the approach to a child presenting with sig-
nificant short stature (height SDS <-2). Attention to defining auxology
(including limb to axial skeleton proportions) and growth pattern in
relation to stature and development in the family, obtaining a com-
prehensive history of potential risk factors and/or occult system dis-
ease, and carefully documenting overall phenotype remains the
cornerstone of initial assessment. This clinical evaluation is likely to
trigger a request for investigations that may include a screen for sys-
tem disease, a skeletal survey, hormonal evaluation and an array
study. In some cases, the clinical features may immediately point to
a specific genetic condition, and if so, then a traditional search for a
mutation in a single gene could be undertaken. If there are suggest-
ive features, a targeted gene panel would be appropriate. In those
whose short stature appears to be of undefined aetiology (so called
idiopathic short stature [ISS]), then WES can provide an opportunity
to make a diagnosis.
These testing strategies have led to the recognition that genes
known to cause short stature syndromes with well-defined clinical
features may be mutated in ISS children. This extends the phenotype,
and can lead to the recognition of more subtle features associated
with that condition. These strategies may also identify genes impli-
cated in growth physiology but not previously recognized to causehuman disease. The CNV and whole exome/genome approaches
may lead to genes never previously recognized as related to growth
being implicated as causes of short stature. In this situation it is im-
portant that defects in these genes are found in multiple families to
confirm causality.
The use of genetic technologies will vary considerably dependent on
the health-care resource setting. Studies evaluating large cohorts of
unselected ISS children are required to evaluate the cost-
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Background: Children born SGA have a higher risk to develop meta-
bolic diseases in adulthood. GH treatment increases adult height but
also causes insulin resistance, which have raised concerns about the
long-term consequences of GH treatment in children born SGA. Pub-
lished data of the SAGhE project suggested an increased cardiovas-
cular mortality in adults born SGA who were treated with GH during
childhood. The main limitation of the SAGhE project is that data of
ex-GH-treated adult patients are compared with national reference
values and not with an age-matched untreated adult patients. To
study the long-term effects of GH treatment on the risk of diabetes
mellitus type 2 and cardiovascular diseases, it is important to com-
pare data of previously GH-treated adults born SGA with those of un-
treated adults born SGA.
Outline: This session will give an overview of published GH safety
data and will present recently published data of the largest follow-up
study in 199 previously GH-treated SGA young adults who were lon-
gitudinally studied for five years after attainment of adult height, at
GH-cessation, six months, two and five years thereafter. Body com-
position, insulin sensitivity and β -cell function were determined and
data at five years after GH-cessation were compared with untreated
age-matched controls: 51 untreated short SGA adults, 92 SGA adults
with spontaneous catch-up growth, and 142 adults born appropriate
for gestational age.
Main findings: Data show a steady increase in fat mass during five
years after GH treatment, indicating the loss of pharmacologic effects
of GH. Reassuringly, the GH-induced reduction in insulin sensitivity
was fully reversed within six months after cessation of GH treatment
and remained similar thereafter, despite the increase in fat mass. At
5 years after GH-cessation, fat mass, insulin sensitivity and β -cell
function of previously GH-treated SGA adults were similar to un-
treated short SGA adults, indicating that long-term GH treatment in
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Maintenance of the tonicity of extracellular fluids within a very nar-
row range is crucial for proper cell function. Extracellular osmolality
regulates cell shape as well as intracellular concentrations of ions
and other osmolytes. Furthermore, proper extracellular ionic concen-
trations are necessary for the correct function of ion channels, action
potentials, and other modes of intercellular communication. Extracel-
lular fluid tonicity is regulated almost exclusively by the amount of
water intake and excretion, whereas extracellular volume is regulated
by the level of sodium chloride intake and excretion. Normal blood
tonicity is maintained over a 10-fold variation in water intake by a
coordinated interaction among thirst, arginine vasopressin (AVP)/
anti-diuretic hormone (ADH), and renal systems. Dysfunction in any




Definition Initial Post-operative Staging
Low Disease confined to the thyroid
with minimal level VI lymph
node metastasis
TSH suppressed Tg at 3 month
intervals with neck ultrasound
at 6 months
Intermediate Extrathyroidal extension with
extensive level VI or lateral neck
lymph node metastasis
TSH-stimulated Tg and
diagnostic 123I whole body
scan
High Regionally extensive disease with
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osmolality, which if not properly recognized and treated may cause
dysfunction in neuronal and other cellular activities. When the
relationships among water intake, vasopressin status, and renal
responsiveness are not understood, life-threatening hyponatremia or
hypernatremia may occur, whereas knowledge of these systems
almost always allows for proper management of sodium and water
balance without these complications.
Learning objectives: As a result of participating in this session,
learners should be able:
To understand how to treat a patient with diabetes insipidus or
SIADH with combinations of fluid and AVP or DDAVP, without
causing hyper- or hypo-natremia. When AVP/DDAVP is high
(anti-diuretic state), a patient can only tolerate 1/10th as much
fluid as when vasopressin/DDAVP is low (diuretic state).
To diagnose cause of polyuria: central diabetes insipidus versus
primary increased fluid intake
To use measurement of blood copeptin instead of AVP
To diagnose cause of hyponatremia: dehydration/reduced
intravascular volume versus SIAD




Diagnosis and Management of CAH
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Congenital adrenal hyperplasia (CAH) refers to a range of autosomal
recessive diseases resulting from deficiency of cortisol secretion. The
incidence is 1/10,000-20,000 globally and 21-OHD is the most fre-
quent disease among CAH cases. Many patients with 21-OHD have
pigmentation, virilization of the external genitalia in females, failure
to thrive and poor weight gain, but others have 21-OHD with only
very mild clinical symptoms. Elevated blood 17-hydroxyprogesterone
is the best biochemical diagnostic marker fro diagnosis. Furthermore,
tests for diagnosis and understanding of the pathological condition
include plasma ACTH, serum electrolytes, plasma glucose, plasma al-
dosterone, plasma renin activity or concentration, and blood gas. If
21-OHD is suspected due to clinical symptoms and abnormal test re-
sults, and a manifestation of adrenal insufficiency is found, treatment
must be the priority.
The principles of treatment of 21-OHD are to supplement insufficient
glucocorticoid and mineralocorticoid levels, inhibit enhanced adrenal
androgen production, and maintain growth and maturation similar
to those of healthy children. Treatment continues for life. Insufficient
treatment causes adrenal crisis (acute and severe adrenal
insufficiency) due to decreased tolerance to physical stress and short
stature due to bone age advancement. Excessive treatment causes
iatrogenic Cushing's syndrome, including short stature, obesity and
hypertension.
In the neonatal stage, since adrenal androgen production is markedly
enhanced, high dose of hydrocortisone (HC) (25-100 mg/m2) is
needed to suppress adrenal androgen. HC is also used as mainten-
ance therapy and the dose of glucocorticoids during maintenance
therapy must be carefully determined to prevent overdose and
underdose. Salt wasting 21-OHD is not sufficiently treated with HC
alone and requires fludrocortisone (FC). Sodium intake from breast
milk and bottle formula is insufficient for treatment in the infant
stage, and sodium chloride replacement is also necessary. A dose of
FC in maintenance therapy is 0.025 to 0.2 mg/day. The FC dose
should be adjusted based on the plasma renin activity or concentra-
tion, electrolyte levels; and body weight gain. Adverse reactions
including increased blood pressure and edema should be monitored.
It is also very important to avoid adrenal insufficiency. If a patient
has febrile illness, gastroenteritis with dehydration, surgery or
trauma, it is necessary to increase the dose of glucocorticoids transi-
ently. A child at an early age has a risk for hypoglycemia andelectrolyte imbalance; therefore, long-term fasting conditions should
be avoided, and intravenous administration of glucose and sodium
should be performed as required.MTE7
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Evaluation and management of nodular thyroid disease in the
pediatric population is different from the adult population. Thyroid
nodules and cancer in the pediatric population have distinct biology,
pathophysiology, clinical findings, and prognosis. For example, thy-
roid nodules are less frequent in childhood than in adulthood, but
are more often malignant. Previous guidelines for the management
of thyroid nodules and cancers were geared toward adults. Diagnos-
tic work up or treatment that may be recommended for an adult
may not be appropriate for a child. In 2015, the American Thyroid As-
sociation (ATA) formulated and published guidelines for evaluation
and management of children and adolescents with thyroid tumors.
The intent of the guideline was to provide recommendations to en-
sure stratification of care based on complete and accurate pre-
operative assessment with thyroid/neck ultrasound and fine needle
aspiration. Pediatric specific post-operative risk levels were also cre-
ated to identify patients at risk of persistent disease that would
benefit from radioiodine therapy. The evaluation and management
of patients with persistent and/or recurrent disease were also
reviewed with recommendations directed at reducing surgical com-
plications as well potential complications associated with repeat
radioiodine therapy.
We will address the initial work up, operative management and
postop care in the pediatric population. In addition to review of the
key points outlined in the ATA pediatric guidelines, we will also dis-
cuss additional strategies from our practice to reduce complications
of therapy as well as more recent data from the literature.LS9
New Genetic Causes of Short Stature: A Primer for
Endocrinologists
Andrew Dauber
Cincinnati Center for Growth Disorders, Division of Endocrinology,
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In this talk, we will review recent advances in the field of growth
genetics. These defects include mutations in genes within the growth
hormone/IGF-I axis, including the recently discovered mutations in
the PAPPA2 and IGF2 genes, as well as mutations in genes outside
this axis. We will review a few genes with direct effects at the growth
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 13 of 144plates (ACAN and NPR2). We will also briefly discuss new findings in
primordial dwarfism including a network of DNA damage repair genes
in which mutations cause severe short stature. Finally, there will be a
brief overview of the lessons learned from genomewide association
studies about the genetics of height in the general population.LS10
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Peter Clayton
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Pituitary-derived growth hormone (GH) was first used in the 1950s
and withdrawn in the mid-1980s because of its link with Creutzfeld-
Jacob disease, with recombinant human GH (r-hGH) now being in
use for >30 years. Over that time its safety and efficacy in children
and adults has been subject to considerable scrutiny. R-hGH is used
under licence in a wide range of disorders, including growth failure
associated with a number of diverse aetiologies in children, GH
deficiency in adults with onset in childhood or adulthood, and HIV/
AIDS-wasting in adults. It has also been used in clinical trials to assess
its impact in skeletal dysplasias, steroid-induced growth failure, poor
growth associated with inflammatory disorders and fracture healing,
as well as off-label use.
There are therefore significant challenges in evaluating safety in all
these contexts. These include: lack of an untreated comparator popu-
lation, relatively small sample sizes, inadequate long-term data on
GH exposure, in particular dosages, inconsistent definitions of diag-
noses and outcomes, and reporting bias of adverse events. Neverthe-
less there is a large literature primarily from observational studies
while on r-hGH that indicates an overall good safety record, with no
increase in de-novo cancer or tumour recurrence in children. There
are a number of well recognised but infrequent side-effects (intracra-
nial hypertension, musculoskeletal symptoms, obstructive sleep
apnoea, bone problems [usually related to the underlying condition
e.g. scoliosis], and alterations in thyroid and cortisol metabolism).
Despite r-hGH’s safety record, there have been underlying concerns
related to the potential impact of the physiological actions of r-hGH
on cell growth and metabolism, that could associate with cancer risk
and cardiometabolic effects, and hence an overall effect on mortality.
To address these concerns, large cohorts of patients with well-
characterised diagnoses and treatment exposures need to be assem-
bled and followed long-term, both while on r-hGH and in the years
after treatment is completed. The ‘Safety and Appropriateness of GH
treatments in Europe’ study was established to assemble a large
group of patients, who were at least 18 years of age and had been
treated in childhood only with r-hGH. This cohort was first assembled
in France, followed by 7 other European countries. This has resulted
in a metacohort of ~25,000 individuals, most commonly treated for
growth failure due to isolated GH deficiency, idiopathic short stature
or short stature in children born small for gestational age (53%),
Turner syndrome (13%) and growth hormone deficiency linked to
neoplasia (12%), with >400,000 person years of follow-up and an
average duration of 17 years per patient.
To date results on cancer incidence, mortality and vascular complica-
tions have been reported from the French cohort (n=6298), and mor-
tality has been reported from a combined Swedish, Belgium and
Dutch (S/B/D) cohort (n=2543). In the French cohort, there was an in-
creased standardised mortality ratio (SMR) for ‘ill-defined conditions’
(SMR 3.35), bone neoplasms (SMR 5) and cerebrovascular disease
(SMR 5.29), while in S/B/D cohort there were no deaths from cancer
or vascular disease. In the French study, high GH doses (>50μg/kg/
day) were associated with an increased SMR (3.41). These different
results illustrate the importance of assembling very large datasets,
and this will be addressed in the full SAGhE cohort.
A recent position statement, generated by an international panel of
experts, which had evaluated published safety data and current
pharma databases, concluded that ‘GH continues to have a good
safety record when used for approved indications and at recom-
mended doses’. Importantly the group recommended that long-termpharmacovigilance of all exposed to r-hGH should occur over the
years after treatment.
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The most important reason for treating children with Prader-Willi
Syndrome (PWS) with growth hormone (GH) is to optimize their
body composition.
Setting Longitudinal study to evaluate efficacy and safety data during
8 years of GH treatment, in a Dutch cohort of 60 prepubertal children
with genetically proven Prader Willi syndrome, treated with 1 mg
GH/m2/day (0.035 mg GH/kg/day). Annual measurements of lean
body mass (LBM) and fat mass percentage (%) by the same dual-
energy x-ray absorptiometry (DXA) machine in all children.
Results: After a significant increase during the first year of GH treat-
ment (P < 0.0001), LBM remained stable for 7 years at a level above
baseline (P < 0.0001). After a significant decrease in the first year, fat
mass % SDS and body mass index (BMI) SDS remained stable at a
level not significantly higher than at baseline (P = 0.06, P = 0.14,
resp.). BMI SDS based on PWS references was, however, significantly
lower after 8 years of GH treatment than at baseline (P < 0.0001).
After 8 years of treatment, height SDS and head circumference SDS
had completely normalized. Mean IGF-I SDS increased to + 2.36 SDS
during the first year of treatment (P < 0.0001) and remained stable
since then. GH treatment did not adversely affect glucose homeosta-
sis, serum lipids, blood pressure and bone maturation.
Conclusion: This 8-year study demonstrates that long-term GH treat-
ment is able to change the Prader Willi phenotype, by counteracting
the natural course of increasing obesity and abnormal body compos-
ition in PWS.
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Introduction: Jintrolong® (PEG-rhGH) is a long-acting rhGH prepared
by conjugating a branched polyethylene glycol molecule to rhGH. A
phase-I pharmacokinetics study showed it to be suitable for weekly
dosing regimen in children with GHD. A phase-II study established the
efficacious dose of weekly PEG-rhGH to be 0.2-mg/kg/wk. Phase III and
IV studies were designed to evaluate short-term and long-term efficacy
and safety of PEG-rhGH in large scale of children with GHD.
Methods: A phase-III, multicenter, randomized, open-label, controlled
trial enrolled treatment-naïve, prepubertal GHD children >3 years.
108 patients were randomized in a 2:1 ratio to s.c. injection weekly
PEG-rhGH at a dose of 0.2-mg/ kg/wk or to daily rhGH at a dose of
0.25-mg/kg/wk for 25-weeks. The primary endpoint was height vel-
ocity (HV) increase at 25 weeks. The phase IV study included 4 sub-
studies, that enrolled prepubertal GHD children ≥3 years from 80
hospitals, that were treated for 26-weeks. The study design is
showed in figure-1. The primary endpoint was height standard devi-
ation score increase (ΔHtSDS) at 26 weeks. All patients were enrolled
to extension studies after 26-weeks with optimal PEG-rhGH dosage
until final height.
Results: Significantly greater HV increase was associated with PEG-
rhGH treatment vs. daily rhGH (P<0.05) at 25 weeks in the phase-III
study. Adverse events (AEs) were comparable between two groups.
In the phase-IV study, 944 patients from 4 sub-studies completed the
26-week treatment. TheΔHtSDS were comparable between the differ-
ent dosage PEG-rhGH groups in sub-study-1, and sub-study-2.
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weekly PEG-rhGH and daily rhGH in sub-study-3, a borderline
significance trend was observed after 39-weeks follow-up between
the bi-weekly and weekly PEG-rhGH. In the observational, open-label
sub-study-4, the most frequent treatment dosage was weekly PEG-
rhGH at 0.15-mg/kg/wk. AEs were comparable between PEG-rhGH
and daily rhGH in all 4 sub-studies.
Conclusions: PEG-rhGH showed excellent safety and efficacy in GHD
children treated with doses from 0.1 to 0.2-mg/kg/wk. Preliminary
results from phase IV studies need to be confirmed with additional
patients and long-term follow-up.Fig. 1 (abstract LS12). Phase IV study designLS13
Moving Towards an International Consensus on the Future of GH
therapy
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As growth hormone (GH) therapy completes its sixth decade, it has
become a staple of endocrine therapy for both children and adults.
Thirty years ago, recombinant daily GH replaced pituitary GH therapy
that was associated with risk of Jakob-Creutzfeldt Disease. However,
as daily rhGH treatment continued to be refined, concerns about its
safety (primarily related to cancer risk) lingered, even as large obser-
vational phase-IV studies did not demonstrate specific risks. Over the
last several years, preliminary results of a retrospective analysis of a
large cohort with long term outcomes of GH recipients in Europe
(SAGhE) raised serious concerns about the possibility of increased
mortality in a French sub-cohort that were related mainly to cardio-
vascular causes. Analysis of other sub-cohorts including Scandinavian
data did not confirm this finding. The international pediatric
endocrine community responded to this concern with serious
reconsideration of the issues that culminated in a consensus work-
shop co-sponsored by all of the major relevant societies that recog-
nized some inherent concerns related to GH use, particularly as they
relate to second malignancies among cancer survivors, but did not
find evidence for elevated cancer risk in other populations and con-
cluded that overall mortality did not appear to be increased when
the entire SAGhE population was taken into account (1). These im-
portant lessons will be critical in the clinical integration of a new
generation of long-acting growth hormone products, with over six
different distinct preparations currently being tested in phase-II and
–III studies. Another consensus workshop recently held and pub-
lished, examined the various issues involved in developing this new
product class (2). While challenges in optimizing safety and efficacy
of these new drugs clearly exist, early data, and a rationale clinicaldevelopment strategy, make it very likely that several long-acting
products will soon be available for the use of the endocrine commu-
nity, which will enhance physician-patient choices, improve conveni-
ence, and potentially overcome adherence and compliance issues,
without compromising the excellent safety record of GH.
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When one gene does it all: monogenic forms of autoimmune
diabetes
Elisa De Franco
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Neonatal diabetes is diagnosed before 6 months of age and is gener-
ally caused by a mutation in a single gene. Traditionally it has been
considered as a separate entity from the more common type 1 dia-
betes, which is generally diagnosed after 6 months and is caused by
a combination of genetic predisposition and environmental triggers.
Last generation genetic approaches have allowed great advances in
the knowledge of the genetic basis of both type 1 and neonatal dia-
betes, challenging the conventional view of neonatal diabetes and
type 1 diabetes as two completely distinct diseases.
Mutations in 23 genes have been identified to date to cause
neonatal diabetes, providing a genetic diagnosis for 82% of patients
diagnosed before 6 months of age. The majority of these genes are
involved in insulin sensing/ secretion and beta cell function/develop-
ment. A notable exception are mutations in three genes (FOXP3,
STAT3, and IL2RA) which cause neonatal diabetes with additional
autoimmune features. These three genes are not directly involved in
beta cell development or function, in fact they encode for proteins
that are important for regulation of the immune system and preven-
tion of autoimmunity. Patients with mutations in these genes have
diabetes soon after birth as a result of early autoimmune destruction
of their beta cells. Furthermore, these patients generally have low
birth weight, suggesting that the autoimmune reaction starts in
utero. These patients generally develop additional autoimmune
features early in infancy and allogenic stem cell transplantion is
currently the only therapeutic option. The Exeter team has been spe-
cifically looking for the genetic causes of early onset diabetes and
autoimmunity and has currently identified 2 further genes causing
neonatal diabetes through immune dysregulation.
But how accurate is the cut-off of 6 months for a differential diagnosis
of neonatal diabetes versus type 1 diabetes? We have assessed this
using a T1D genetic risk score generated from type 1 diabetes-
associated common genetic variants in patients diagnosed before 6
months of age in whom a genetic cause could not be identified. This
approach has identified patients who are likely to have early onset type
1 diabetes who were indeed diagnosed before the age of 6 months.
Uncovering the genetic basis of neonatal and type 1 diabetes
broadens our understanding of the mechanisms involved in the the
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 15 of 144pathogenesis of both diseases. Emerging evidence points towards a
continuum model for different diabetes subtypes: from monogenic
to more common forms of diabetes.
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African Efe Pygmies: From Anthropology to Endocrinology
Mitchell E. Geffner
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Pygmy populations occupy a vast territory extending west-to-east
along the central equatorial African belt from the Congo Basin to
Lake Victoria, but are also found in other parts of the world, e.g. ,
Papua, New Guinea. Their short stature is thought to be adaptive (as
opposed to a defect) in terms of ease of locomotion through dense
forest understory, minimization of food requirements during cyclical
periods of undernutrition, and selection for survival in hot, humid for-
est environment where greater surface area:body mass ratio is neces-
sary for sufficient thermoregulation. The evolutionary history of the
human pygmy phenotype (small body size), a characteristic of
African rainforest hunter-gatherers, is largely unknown. Certain gen-
omic regions are significantly associated with the pygmy phenotype
in some rainforest hunter-gatherer populations from east central
Africa and have multiple attributes that provide supporting evidence
of genuine association with the pygmy phenotype, including enrich-
ments for SNPs previously associated with stature variation in
Europeans and for genes with growth hormone receptor and regula-
tory functions consistent with early suggestions that the short stature
of pygmies results from GH resistance and an absent adolescent
growth spurt. Efe pygmies of northeast Zaire have the shortest mean
adult stature of any population on earth. We previously described
GH and IGF-I unresponsiveness in T-lymphoblast cell lines derived
from Efe pygmies. Using this model, we also found markedly de-
creased cell surface expression of type 1 IGF receptors (IGF-I recep-
tors) with normal ligand binding affinity. The pygmy IGF-I receptors
were not autophosphorylated and did not transmit a signal in re-
sponse to physiological concentrations of IGF-I. There was a substan-
tially decreased level of IGF-I receptor mRNA in the pygmy cells with
a normal mRNA half-life. No consistent mutation was found in the
exons encoding the IGF-I receptor. These results indicate decreased
IGF-I receptor gene transcription and IGF-I receptor signaling as the
primary variation in the pygmy cell lines, with GH resistance a sec-
ondary back-up phenomenon. Our findings point to the IGF-I recep-
tor as the locus governing short stature in the African Efe pygmy and
suggest that human stature may be genetically controlled by expres-
sion of the IGF-I receptor.
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Skeletal, Growth, and Functional Improvements in Children with
Hypophosphatasia Treated with Asfotase Alfa for 5 years
Jill H Simmons
Vanderbilt University School of Medicine
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):LS16
Hypophosphatasia (HPP) is an ultra-rare orphan disease caused by
mutation(s) in the ALPL gene resulting in deficiency of tissue-
nonspecific alkaline phosphatase (ALP). Disease presentation is vari-
able, ranging from frequently fatal in the perinatal or infantile forms
to primarily causing musculoskeletal abnormalities and pain in juve-
niles and adults. Infantile HPP features poor bone mineralization
leading to rickets and is sometimes complicated by seizures, respira-
tory compromise, poor growth, and delayed motor function. Juvenile
HPP features include delayed/ impaired motor function, generalized
muscle pain, poor bone mineralization, abnormal gait, and early
tooth loss. Historically, HPP patients were treated with surgical
management, dental hygiene, respiratory support, and dietary modi-
fications when necessary, but until recently, there was no disease-specific therapy available. Recombinant bone-targeted ALP is avail-
able for patients with HPP, and studies have demonstrated benefits
upon the perinatal, infantile, and juvenile forms. Asfotase Alfa (AA) is
given subcutaneously at a dose of 2 mg/ kg/ day 3 days per week or
1 mg/ kg/ day 6 days per week in Japan.
Five- year survival in perinatal/ infantile HPP patients treated with AA
was 84%(n=37) , which was higher than that observed in a historical
control group (27%). Changes in HPP-related skeletal disease have
been demonstrated, with the Radiographic Global Impression of
Change (RGI-C) scale (-3=severe worsening; +3=near/complete heal-
ing) improving to +2.7 (+1.3, +3.0) by year 1 (n=9) and continuing at
+2.0 (+2.0, +3.0) at year 5 (n=9) Infants treated with AA also have sig-
nificant improvement in respiratory status, growth and motor skills
development. Thirteen 6-12 year-old childhood-onset HPP patients
treated with AA for 5 years were compared with 16 untreated
pediatric historical controls with HPP. Improvements were seen in
RGI-C scale of treated patients by 6 weeks [+1 (0.0, +2.0), p=0.001]
and persisted through 5 years [+2.2 (+1.7, +2.7), p=0.0005]; no
change was seen in the RGI-C scale of historical controls. In the
treated group, improvements occurred in weight and height z-scores
and developmental, pain, and disability assessments.
In all patient populations studied, serious adverse events have been
rare but injection site reactions (ISR) are common and include ery-
thema, warmth, and lipohypertrophy at injection sites. ISRs and AES
have not led to medication discontinuation.
In conclusion, AA enzyme replacement therapy has been demon-
strated to improve survival, skeletal mineralization, growth, and
motor skills in children with HPP. Side effects have been minimal
and have not led to drug discontinuation. Follow-up for long-term ef-
fects needs to continue.ES1-1
Total management of Rickets: causes, prevention and treatment
Global Consensus Recommendations on Prevention and Management
of Nutritional Rickets: Definition and Diagnosis
Lorna Ramos-Abad
University of the Philippines College of Medicine, Philippine General
Hospital Metro Manila
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):ES1-1
Nutritional Rickets (NR), a disorder of defective chondrocyte differen-
tia- tion and mineralization of the growth plate and defective osteoid
mineralization, is caused by vitamin D deficiency and/or low calcium
intake in children. Osteo- malacia is abnormal matrix mineralization
in established bone, and although present in children with rickets, it
is used to describe bone mineralization defects after com- pletion of
growth.
Diagnosis of NR is made on the basis of history, physical examin-
ation, and biochemical testing and is confirmed by radiographs. Os-
seous signs and symptoms include: swelling wrists and ankles
Delayed fontanelle closure (normally closed by the age of 2 years)
Delayed tooth eruption (no incisors by the age of 10 months, no mo-
lars by 18 months), Leg deformity (genu varum, genu valgum, wind-
swept deformity) Rachitic rosary (enlarged costochondral joints – felt
anteriorly, lateral to the nipple line) Frontal bossing Craniotabes (soft-
ening of skull bones, usually evident on palpation of cranial sutures
in the first 3 months) Bone pain, restlessness, and irritability. Radio-
graphic features are: splaying, fraying, cupping, and coarse trabecular
pattern of metaphyses, widening of the growth plate, Osteopenia.
There could be nonosseous features such as Hypocalcemic seizure
and tetany, Hypocalcemic dilated cardiomyopathy (heart failure,
arrhythmia, cardiac arrest, death) Failure to thrive and poor linear
growth, delayed gross motor development with muscle weakness,
raised intracranial pressure.
Biochemical testing alone is not sufficient to diagnose NR and may
not differentiate whether the primary cause of NR is vitamin D or
dietary calcium deficiency because combined deficiencies are com-
mon. Vitamin D status is assessed by measuring blood levels of total
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 16 of 14425OHD. Classification of vitamin D status is based on serum 25-
hydroxyvitamin as: sufficiency, >50 nmol/l , Insufficiency, 30–50
nmol/l Deficiency, <30 nmol/l .
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Nutritional rickets (NR) has been increasingly reported in high and
low income countries. Resurgence of NR has been observed in the
high income countries due to increase in immigrants and refugee
groups. There is a considerable variation in the definition, diagnosis
and management of NR. European Society for Pediatric Endocrin-
ology decided to formulate evidence-based recommendations
together with the PES, JSPE, SLEP, APEG, ISPAE, ASPAE, CSPEM,
ESPGHAN. The consensus paper includes evidence up to the end
of 2014.
Nutritional rickets is defined as defective chondrocyte differentiation
and mineralization of growth plate due to vitamin D deficiency and
or low calcium intake. Defective mineralization results in growth
plate widening, metaphyseal cupping and fraying seen on the radi-
ography. Vitamin D status is assessed by measuring blood levels of
total 25 OH vitamin D. Dietary calcium deficiency is diagnosed by
obtaining a calcium intake history with the help of dietary calcium
intake questionnaire specific to their country/region. Vitamin D level
of >50 nmol/ l is considered sufficient, 30-50 nmol/l is considered as
insufficient and < 30 nmol/L is deficient and >250nmol/ l with hyper-
calciuria is considered as vitamin D toxicity. It is recommended to
provide 400IU of vitamin D daily for all infants from birth irrespective
of mode of feeding and 600IU is recommended for children and
adults through diet or supplementation. In countries where food for-
tification is not a routine practice, vitamin D supplementation is
needed for children with a history of vitamin D deficiency, children
and adult at risk of vitamin D deficiency and pregnant women. Min-
imal dose of vitamin D to treat rickets is 2000IU daily for 3 months.
Oral route of vitamin D is recommended. Calcium 500mg as dietary
intake or supplement is routinely needed together with vitamin D in
addition to vitamin D supplement. Complementary feeding rich in
calcium should be started no later than 26 weeks to prevent rickets.
Population based studies should determine the burden of rickets
and screening should be done based on clinical features. NR can
have a major impact on the health of infants, children, and adoles-
cents. It is important to recognize NR as a preventable global public
health problem and implement rickets preventing programs by ad-
hering recommended vitamin D and calcium intakes, monitoring for
adherence and promoting staple food fortification programs.
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Hypophosphatemic Rickets: Current Status and Future Perspectives
Toshimi Michigami
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Osaka Japan
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Phosphate is a component of hydroxyapatite and is indispensable for
skeletal mineralization. Prolonged deficiency of phosphate can be
caused by impaired intestinal absorption and/or renal phosphatewasting, resulting in rickets in children and osteomalacia in adults.
Although phosphate is abundant in food, patients with malnutrition
or malabsorption may have phosphate deficiency, leading to hypo-
phosphatemic rickets. Renal phosphate wasting can be observed in
the conditions with impaired function of renal proximal tubules, such
as Fanconi syndrome and some forms of renal tubular acidosis. Renal
reabsorption of phosphate is mostly mediated by type 2a and 2c
sodium-phosphate co-transporters (NPT2a and NPT2c) in the prox-
imal tubules. Loss-of-function mutations in SLC34A3 encoding NPT2c
cause hereditary hypophosphatemic rickets with hypercalciuria
(HHRH).
Several kinds of hypophosphatemic rickets and osteomalacia are
caused by excessive actions of fibroblast growth factor 23 (FGF23).
FGF23 is produced mainly by osteocytes in the bone and exerts its
effects on the distant organs. In the kidney, FGF23 increases renal
phosphate excretion by suppressing the expression of NPT2a and
NPT2c. In addition, FGF23 reduces the level of 1,25-dihydroxyvitamin
D. FGF23-related hypophosphatemic rickets/ osteomalacia is charac-
terized by renal phosphate wasting, hypophosphatemia, and in-
appropriately low level of serum 1,25(OH)2D. Mutations in FGF23
that make the protein resistant to proteolytic cleavage cause
autosomal dominant hypophosphatemic rickets (ADHR). X-linked
hypophosphatemic rickets (XLH), the most common form of FGF23-
related hereditary hypophosphatemic rickets, is caused by inactivat-
ing mutations in the phosphate- regulating gene homologous to
endopeptidase on X chromosome (PHEX). Genetic evidence has re-
vealed that loss- of-function mutations in dentin matrix protein 1
(DMP1), ectonucleotide pyrophosphatase phosphodiesterase-1
(ENPP1) , and family with sequence similarity 20, member C
(FAM20C) lead to FGF23-related hypophosphatemic rickets/osteomal-
acia of autosomal recessive inheritance. Other conditions such as
McCune-Albright syndrome, linear nevus sebaceous syndrome, and
tumor-induced osteomalacia, are also associated with FGF23-related
hypophosphatemia. Measurement of serum FGF23 levels is useful to
distinguish FGF23-related hypophosphatemia from rickets or osteo-
malacia of other causes, because they are rather low in vitamin D de-
ficiency and intrinsic defects in renal proximal tubules. Patients with
XLH are currently treated with active vitamin D and phosphorus.
However, the administration of active vitamin D and phosphorus fur-
ther increases the level of FGF23, which might worsen the disease. A
neutralizing antibody against FGF23 has been developed recently as
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Adrenarche is the initiation of dehydroepiandrosterone (DHEA) and
DHEA-sulfate (DHEAS) secretion from the zona reticularis of the ad-
renal gland during childhood. Adrenarche is a gradual process begin-
ning during the first five years of life, whereas pubarche, the
appearance of pubic hair and an end result of adrenarche, normally
occurs when children are eight or more years of age. Premature
adrenarche is among the most common pediatric endocrine disor-
ders, usually considered benign but occasionally the first sign of an
adrenal tumor or enzyme deficiency. In some children, premature
adrenarche may be a forerunner of the polycystic ovary syndrome or
the metabolic syndrome. The trigger for adrenarche remains un-
known, and initiating factors leading to production of adrenal andro-
gens are poorly defined.
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learners should be able:
To understand the changes that occur in 17, 20 lyase and 3 β
HSD2 enzyme activities during adrenarche
To understand changes in the zona reticularis during adrenarche
To understand how to identify true, genetic 3 β HSD2 deficiency
To understand whether mild, nonclassical 3 β HSD2 exists
To discuss the possible role of intracrine, intra-adrenal cortisol in
the onset of adrenarche
To speculate on why benign premature adrenarche is associated
with obesity
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1 Thymic deletion of ICA69 induces autoimmune diabetes and
other endocrine diseases
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Aim: Islet autoantigen 69 (ICA69), encoded by the Ica1 gene, is
one of the known autoantigens in type 1 diabetes (T1D). In
addition to pancreatic beta cells, ICA69 is also present in extra-
pancreatic endocrine and exocrine tissues, such as the thyroid
and salivary gland. Notably, ICA69 is ectopically expressed in the
thymus, and its level of expression is significantly decreased in
T1D prone NOD mice, compared to that of T1D resistant C57BL/6
mice. Immunization with ICA69 peptides in NOD mice not only
accelerates diabetes progression, but also induces autoimmune
response in the salivary glands. These results highlight the
antigenic role of ICA69 in the progression of these diseases and
suggest that thymic ICA69 expression is essential to establish
immune tolerance of ICA69-expressing organs. In this study we
attempted to elucidate the underlying mechanism of ICA69 and
its role in the induction of autoimmunity in the pancreas and
other endocrine tissues.
Materials and Methods: C57BL/6 mice with systemic Ica1 gene defi-
ciency (B6.ICAdel/wt for heterozygous and B6.ICAdel/del for homozy-
gous ICA69 deletion) were first generated to observe the
spontaneous effect of ICA69 in the endocrine tissues. Next, ICA69
was eliminated specifically in the thymus using the Cre-lox system
(Aire-ICA69). Endocrine functions were assessed by intraperitoneal
glucose tolerance tests and saliva flow rate. Flow cytometry, Enzyme-
Linked ImmunoSpot assay, and immunohistochemistry were per-
formed to investigate the potential link between the level of thymic
ICA69 expression and peripheral anti-ICA69 autoimmunity.
Results: Significant decrease of thymic ICA69 expression was ob-
served in B6.ICAdel/wt mice. When immunized with ICA69 peptides,
B6.ICAdel/wt mice develop both insulitis and thyroiditis. Consistently,
Aire-ICA69 mice displayed an impaired glucose tolerance as early as
12 weeks of age. In addition to insulitis, immunohistochemical ana-
lyses revealed the spontaneous development of autoimmunity in
multiple extrapancreatic organs, including sialadenitis, thyroiditis,
and gastritis.
Conclusion: Our findings establish a direct link between compro-
mised thymic ICA69 expression and autoimmunity against multiple
ICA69- expressing organs, and identify a potential mechanism for the
development of T1D-associated autoimmune disorders, as well as
other multi- organ diseases, such as autoimmune polyglandular syn-
dromes 2 and 3.Kaichi-Kida
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Background: DNA methylation defects at differentially methylated
regions (DMRs) of imprinted loci are one of the cause of intra-
uterine growth restriction (IUGR) and postnatal growth failure.
Among eight known imprinting disorders, Silver-Russell syn-
drome (SRS), Temple syndrome and Prader-Willi syndrome pa-
tients show pre- and postnatal growth retardation. Furthermore,
maternal uniparental disomy of chromosome 6 (UPD(6)mat) and
20 (UPD(20)mat) have also been associated with growth failure.
However, there is no single report of systematic methylation
analysis of a large cohort of patients with IUGR and postnatal
growth failure. In this study, we aimed to clarify the frequency
of methylation defects in short children born small for gesta-
tional age (SGA).
Participants: A total of 183 short children (height < -2.0 SD after
the age of 2 years or before growth hormone treatment) born
SGA were recruited in this study. Inclusion criteria of SGA were
defined as birth weight and birth length SDS less than 10th per-
centile for gestational age. Patients with apparent chromosomal
or monogenic abnormalities which induce IUGR were excluded.
28 patients were classified as ‘Likely-SRS’ according to the
Nechine-Haribison clinical scoring system.
Methods: We performed quantitative DNA methylation analysis at
DMRs of 9 imprinted loci (PLAGL1 , PEG1 , PEG10 , H19 , Kv,
DLK1-MEG3 intergenic (IG), MEG3 , SNRPN and GNAS A/B) by py-
rosequencing using genomic DNA isolated from peripheral blood
leukocytes. When we detected methylation defects, we carried
out further studies, such as comparative genomic hybridization,
multiplex-ligation dependent probe amplification and microsatel-
lite analysis, to determine the genetic causes of methylation ab-
normalities (microscopic chromosomal rearrangement, UPD or
epimutation).
Results: We identified loss of methylation (LOM) at H19 -DMR in
19 cases, UPD(7)mat in 6 cases, LOM at IG-DMR and MEG3 -DMR
in one case, UPD(14)mat in 5 cases, UPD(15)mat in one case,
UPD(6)mat in 3 cases and UPD(20)mat in 2 cases. In addition, we
detected one case with partial LOM at IG-DMR and MEG3 -DMR
due to trisomy 14 mosaicism with UPD(14)mat, and another case
with partial LOM at A/B DMR due to 20pter microdeletion and
20qter microduplication.
Conclusions: Methylation defects were detected in 39 of 183 (21%)
short children born SGA. Our results highlight the clinical importance
of methylation defects as genetic causes of short stature born SGA.
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Background: In recent years the gut microbiome has been shown to
influence the development of obesity and type 2 diabetes mellitus.
We hypothesize that adverse early life events in preterm children
may lead to alterations in the gut microbiome, which contribute to
later metabolic disease. Children born preterm are at increased risk
for insulin resistance, obesity, and cardiovascular disease.
Aim: To correlate the metabolic phenotype with the gut microbiome
composition and functional capacity in children born very preterm
compared to those born at term.
Results: Participants were healthy prepubertal children aged 5 to 11
years born very preterm (-4 · min-1(mU/l); p=0.0007). Stool metatran-
scriptomics identified Coriobacteriaceae and Collinsella species as
being associated with children who were born preterm (highly sig-
nificant with LDA score >4.0, LefSe). There were also functional
changes in the activity of the microbiome in children born preterm,
including glutamate and arginine metabolism, known to be involved
in glucose metabolism. Changes to the metabolites within the pre-
term fecal and plasma correlated with the observed phenotypes.
Conclusion: Children born very preterm are insulin resistant with dif-
ferences in gut microbiome species and activity. In preterm children
we speculate that (i) these changes in the gut microbiome were
established in early infancy, and (ii) the altered gut microbiome con-
tributes to insulin resistance.Kaichi-Kida
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Objectives: This study aimed to discover the genetic mutations and
identify the etiologies in a cohort of complete growth hormone
deficiency patients, and to establish a new genetic testing
method—targeted next-generation sequencing (NGS) in genetic
evaluation of complete growth hormone deficiency and verify its po-
tential utility.
Methods: A total of 90 complete growth hormone deficiency pa-
tients were included in the study. Twenty-three genes related to
growth hormone deficiency were sequenced parallel by the combin-
ation of NGS and targeted genomic enrichments. The clinical signifi-
cances of variants detected in patients were evaluated on the basis
of the extant clinical guideline.
Results: These patients were divided into two categories based on
clinical diagnosis, including 56 with idiopathic growth hormone defi-
ciency (IGHD) and 34 with multiple pituitary hormone deficiencies
(MPHD). We identified 20 gene variants as the possible geneticcauses for 18 (20%) of the 90 growth hormone deficiency patients,
which included 12(66.7%) of IGHD patients and 8 (33.3%) of MPHD
patients. Of the variants detected, 6 were previously reported and
the others were not reported. Of the 12 IGHD patients with possible
genetic causes, 4 were identified with CHD7 mutation, 2 with GHSR
mutation, 2 with VPS13B mutation, 1 with ALMS1 mutation, 1 with
SEMA3E mutation, 1 with a novel homozygous deletion in chromo-
some 17: 61994532- 61996228 of the whole GH1 gene and 1 with a
novel heterozygous duplication in chr3 F57231913-57234310 of the
whole HESX1 gene. Among the 6 MPHD patients with possible gen-
etic causes, 2 were identified with GLI2 mutation, 3 with SOX3 muta-
tion, 1 with LHX4 mutation and 1 with a novel homozygous deletion
in chromosome 17: 61994532- 61996228 of the whole GH1 gene.
Conclusions: The method of combination of NGS and targeted gen-
omic enrichments is able to explain 20% of the molecular etiologies
of the GHD patients. This study confirmed the high efficiency and
precise of such a comprehensive genetic evaluation in clinics. It pro-
vides a good way to a large-scale genetic study of GHD. Part of pa-
tients with pathogenic gene mutations may not show the
corresponding phenotypes. Different patients with the same genetic
mutation can lead to variable phenotypes.
Key words: growth hormone deficiency, multiple pituitary hormone
deficiency, genetic etiology, next-generation sequencing Ctargeted
genomic enrichments.vKaichi-Kida
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Identification of causative genes for skeletal dysplasia (SD) is important
to provide an exact diagnosis and decide treatment modalities and to
counsel the patients. Due to the genetic heterogeneity in SD, the high
throughput method can be adapted for the efficient diagnosis. To this
end, a new diagnostic pipeline were designed to screen 260 reported
candidate genes for SD. A total of 22 patients diagnosed with skeletal
dysplasia, or suspected to have it were recruited over one year. Their
clinical diagnosis were hypochondroplasia, osteogenesis imperfect type
I, Sticker syndrome, pseudohypoparathyroidism, osteopetrosis. pycno-
dysostosis, spondyloepiphyseal dysplasia strudwick type, and ischiosp-
inal dysostosis. We applied targeted exome sequencing (TES) on 260
genes in the 22 probands with SD. Potential causative variants deter-
mined using TES were confirmed by filtering steps. These variants were
then filtered out with clinical features, inheritance pattern and a co-
segregation study in the family and allele frequency in normal 197
control subjects. Finally, we detected 18 causative variants, and these
variants were in the FGFR3, GANS, COL1A1, COL1A2, COL2A1, LRP5,
CLCN7, CTSK, BMPER, and TNFSF11 genes bringing the total detection
rate in all the patients to be 68.2% (15/22). These variants were vali-
dated using Sanger sequencing. Despite the advent of whole genome
and whole exome sequencing, we propose TES as a screening and
diagnostic tool at least for SD to find mutations based upon its efficacy
and cost-effectiveness.
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Background: It has not been conclusively established whether intra-
uterine hyperglycemia affects prepubertal offspring obesity regard-
less of maternal obesity. This study evaluates the effect of maternal
obesity and hyperglycemia on the fat mass (FM) of prepubertal off-
spring of mothers with gestational diabetes mellitus (OGDM).
Methods: FM was determined by dual-energy X-ray absorptiometry
in 22 OGDM aged 5-6 years, and was compared with that of 49 age-
matched offspring of normoglycemic mothers. The relationship be-
tween FM and the results of a 100 g oral glucose tolerance test
(OGTT) during the second trimester was analyzed in OGDM.
Results: FM was higher (3,548 g vs. 2,245 g) and lean mass was lower
(15,609 g vs. 16,941 g) in OGDM compared with control subjects, re-
spectively, whereas body mass index (BMI) did not significantly differ
between the two groups. FM and truncal FM positively correlated
with glucose levels, especially 0 hour glucose level (r = 0.580 and P =
0.005, r = 0.655 and P = 0.001, respectively). After adjusting for ma-
ternal prepregnancy BMI, total FM (r = 0.535, P = 0.012) and truncal
FM (r = 0.535, P = 0.003) of OGDM correlated with maternal 0 h glu-
cose levels of the 100 g OGTT.
Conclusions: Increased FM of OGDM aged 5-6 years is associated
with intrauterine hyperglycemia regardless of maternal obesity.
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Relationship of lower heart rate variability with risk for metabolic
syndrome in patients with childhood-onset craniopharyngioma
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Jung-Eun Cheon5, In-One Kim5, Choong Ho Shin1, Sei Won Yang1
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Objective: Autonomic nervous system (ANS) dysfunction with hypo-
thalamic involvement (HI) is implicated in the development of obes-
ity and metabolic complications. In patients treated for childhood
onset craniopharyngioma, we investigated changes in ANS activity
according to the extent of HI and presence of obesity, using mea-
sures of heart rate variability (HRV). Risks for being metabolically un-
healthy were analyzed in relation to HRV changes.
Methods: From March 2014 to January 2016, HRV indices of overall
variability [standard deviation NN interval (SDNN) and total power
(TP)], parasympathetic modulation [root mean square of successive
RR interval differences (RMSSD) and high frequency (HF)], and sym-
pathetic or sympathovagal modulation [low frequency (LF) and LF/
HF ratio] were measured in 48 patients (28 males) aged 10-30 years
with HI after craniopharyngioma treatment at Seoul National University
Children’s Hospital. The extent of HI was graded on magneticresonance imaging. Anthropometric measurements, fasting glucose, in-
sulin, lipid panel, and blood pressure were obtained.
Results: Patients with extensive HI showed increased BMI z-scores
(P = 0.008), waist circumference (P = 0.037) and insulin resistance
(homeostasis model assessment of insulin resistance, HOMA-IR,
P = 0.043). HRV indices were decreased with extensive HI, but showed
no differences between obese and non-obese. SDNN, TP, RMSSD, and
LF were all decreased with extensive HI. Obese patients with concomi-
tantly reduced overall variability (by SDNN or TP) showed increased
HOMA-IR (P < 0.05, for both), triglycerides (P < 0.05, for both), blood pres-
sure (P < 0.05, for both), and decreased HDL cholesterol (P < 0.05, for
both). Risk of being metabolically unhealthy was increased in patients
with both obesity and reduced overall variability (P < 0.05, for both).
Conclusion: Extensive HI is associated with obesity as well as de-
creases in overall variability and parasympathetic modulation. Obese
patients with concomitant reduced HRV had higher risk of being
metabolically unhealthy.
O1-3
Relationship between Asymmetric dimethylarginine in Umbilical
Cord Plasma and Birth Weight Follows a U-shaped Curve
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1Department of Pediatrics, Kawachi General Hospital, Department of
Pediatrics; 2Kansai Medical University
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):O1-3
Objective: Placental transport of nutrients is dependent on vascular de-
velopment, which determines blood flow to the placenta. The ability of
the uterine artery to dilate during pregnancy may be specifically related
to upregulation of multiple pathways for production of nitric oxide
(NO). Asymmetric dimethylarginine (ADMA), an L-arginine analog and a
nonselective NO synthase inhibitor is associated with cardiovascular
and metabolic disorders. In addition, epidemiological studies confirm
that the relationships between human birth weight and adult obesity,
hypertension, or insulin resistance follow U-shaped curves. We hypoth-
esized that increased ADMA and decreased NO might underlie the
initial pathophysiologic events leading to insulin resistance. To test the
hypothesis, the relationship between birth weight and ADMA or nitric
oxide parameters was evaluated.
Methods: The study group consisted of 41 singleton subjects with ges-
tational ages ranging from 36-41 wk, and birth weights ranging from
1,798-3,822 g. The subjects were divided into 9 infants with small for
gestational age (SGA) and 32 with appropriate for gestational age
(AGA). Their cord plasma ADMA, insulin, insulin-like growth factor-
1(IGF-1), and adipocytokine levels were determined using enzyme-
linked immunosorbent assays. The plasma NOX [nitrite (NO2-)+nitrate
(NO3-)] levels were measured using the colorimetric assay.
Results: The relationship between birth weight and ADMA levels
followed a U-shaped curve rather than inverse linear associations ex-
pected over a full range of birth weight distribution. ADMA positively
correlated with birth weight in AGA group (p< 0.001, R=0.590),
and inversely correlated with birth weight in SGA group (p< 0.05,
R=-0.741). Plasma ADMA was inversely correlated with adiponec-
tin (p< 0.05, R=-0.289) and quantitative insulin sensitivity check index
(QUICKI) (p< 0.05, R=-0.294) in all subjects, while not correlated with
NOx. Plasma glucose, ADMA, NOx, and resistin concentrations did not
differ significantly between SGA and AGA group. However, plasma insu-
lin, IGF-1, leptin, adiponectin and QUICKI were lower in the SGA group
than in the AGA group.
Conclusions: Plasma ADMA levels in cord blood might be an early
marker of fetal growth and insulin resistance. High plasma ADMA
levels may represent prenatal programming of insulin resistance,
and may be used as a predictor of adult diseases. An analysis of
all of these reports would generate that the relationship between
birth weight and these metabolic abnormalities in adult life can
be described by a U-shaped curve. Our results indicate a possible
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sulin resistance.
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The aim was to evaluate the associations of Sfrp5 and Wnt5a with
blood pressure (BP), and to examine whether BP can be influenced by
changes in adipocytokines, such as Sfrp5, adiponectin, chemerin, and
hsCRP, in obese children after lifestyle intervention. A cross-sectional
study was conducted in 263 obese children. In addition, a 6-month life-
style intervention was performed in a subgroup of 89 obese children
with hypertension. Anthropometric parameters, clinical data, adiponec-
tin, chemerin, Sfrp5, and Wnt5a were measured at baseline and after
lifestyle intervention. Sfrp5 and adiponectin levels were significantly
lower in obese children with hypertension, but Wnt5a, hsCRP, and che-
merin levels were elevated in obese children with hypertension. In
multivariable linear regression analysis, Sfrp5, Wnt5a, adiponectin,
chemerin, and hsCRP were associated with both standard deviation
score-systolic blood pressure (SDS-SBP) and -diastolic blood pressure
(SDS-DBP). Lifestyle intervention resulted in a significant improvement
in BP and weight loss. These were accompanied by significant de-
creases in hsCRP and chemerin, and significant increases in Sfrp5 and
adiponectin, whereas Wnt5a was not changed. Furthermore, the
changes in Sfrp5, adiponectin, chemerin, and hsCRP act as partial medi-
ators of the relationship between weight loss and BP reduction.
Although Sfrp5 and Wnt5a levels correlated with BP at baseline, after
lifestyle intervention, Sfrp5 is more sensitive to reduction in BMI and BP
compared to Wnt5a, and the relationship between weight loss and BP
reduction were partially mediated by changes in Sfrp5. So we speculate
if Sfrp5 and Wnt5a each play a role in regulating BP, it must be
different roles.
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polymorphisms with a presence of thyroid antibody in Japanese
children with Type 1A diabetes
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Introduction: We have made it clear that among Japanese children
with Type 1A diabetes (T1AD), the thyroid autoantibody (T-Ab) posi-
tive rate is 26.6%, higher in females, and rises depending on age in
females. The aim of our study was to clear the genetic factors which
associate with a high risk of T-Ab possession in Japanese pediatric
T1AD.
Subjects and Methods: HLA-DRB1 and DQB1 were analyzed for the
registered 909 T1AD patients (the average age at the time of the
registration was 12 years and 5 months old and 217 cases had T-Ab)
in the Japanese Study Group of Insulin Therapy for Childhood and
Adolescent Diabetes, and the relation with the T-Ab (someone with
more than one of the anti-thyroid peroxidase antibody and the anti-
thyroglobulin antibody) was considered. CTLA4 rs231775 and
rs3087243 polymorphisms were analyzed for 905 T1AD patients and
compared with 455 healthy controls. Then, the influence on T-Ab
possession of CTLA4 SNPs for 905 T1AD patients was considered. The
contribution to the T-Ab possession was considered by using logistic
regression analysis, making these genotypes (HLA-DRB1, DQB1, and
CTLA4 SNPs), gender and age explanatory variables.
Results: The susceptible HLA-DRB1 and DQB1 alleles, haplotypes and
genotypes to T1AD didn’t associate with the risk of T-Ab possession.
In pediatric T1AD, CTLA4 rs231775 had a significantly high frequency
of G allele compared with controls regardless T-Ab presence (OR:1.56, p<0.001) and rs3087243 had a significantly high frequency of G
allele compared with controls only in T-Ab positive T1AD (OR: 1.87,
p<0.001). 2 SNPs of CTLA4 had a significantly high frequencies of G
allele compared with T-Ab negative T1AD in T-Ab positive T1AD. The
age (OR: 3.55~4.98), the sex (OR: 2.11) and CTLA4 rs3087243
(OR: 1.63) were statistically significant effects on the risk of the
T-Ab possession with logistic analysis.
Conclusions: This study newly demonstrated CTLA4 rs231775 con-
ferred susceptibility to T1AD regardless T-Ab presence, and females
with allele G of CTLA4 rs3087243 were at high risk to possess T-Ab in
the age dependence in Japanese pediatric T1AD.O1-6
The Protective Effects of Adenovirus-mediated IL-10 Gene and
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Mice in the Early Stage of Natural T1D Onset
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Objective: To investigate the protective effects of Adenovirus-
mediated IL-10 gene and anti-CD20 monoclonal antibody (mAbs) on
the pancreatic β cells in nonobese diabetes (NOD) mice with type 1
diabetes mellitus (T1D) at early stage.
Methods: 35 female NOD mice at onset of diabetes and aged 17–20
weeks old were randomly divided into 5 groups. Mouse 1,2,3,4 and 5
groups were intravenously injected 500ug of anti-CD20 mAbs, 500ug
of anti-CD20 mAbs combined with 100ul of Ad-IL-10, 100ul of
Ad- IL-10, 100ul of Ad-GFP, 100ul of normal saline respectively. All
mice were monitored for blood glycose everyday, and sacrificed 9
weeks after injection. Their serum levels of C-peptide were measured
and the degree of insulitis were observed. Apoptosis related gene and
protein were detected.
Results: (1) The blood glucose level of mice in group 2 was reduced.
(2) A majority of the insulitis was grade 0-1 in group 2, and grade 2-3
in group 5. (3) The apoptosis rate of pancreatic β cells was signifi-
cantly lower in group 2 than that in the group 3,4,5, p<0.05. (4) Im-
munohistochemistry indicated that IL-10 could be highly expressed
locally in the pancreatic islets. (5) The results of qPCR and western
blot showed that combined intervention exerted protective effects
on pancreatic β cells through activating Bcl-2 anti-apoptosis pathway,
inhibiting the expression of TNF- α and Fas, and blocking caspase-8–
caspase-3 as well as caspase-9–caspase-3 apoptosis pathways.
Conclusion: Combined intervention could reduce the apoptosis of
pancreatic β cells of NOD mice in the early stage of T1D, and had
certain protective effects on the residual pancreatic β cell function.O2-1
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Purpose: Congenital lipoid adrenal hyperplasia (CLAH) is caused by
mutations in the StAR gene and StAR protein plays a critical role for
transport of cholesterol to mitochondria. The aim of this study was
to investigate StAR mutation spectrum and associated clinical and
endocrinologic characteristics in patients with CLAH.
Methods: The study included 45 patients with CLAH from 42 unre-
lated families diagnosed by clinical features, endocrine profile, and
mutation analysis. Clinical features, endocrine data, and radiologic
finding were reviewed retrospectively. Seven exons and associated
intronic flanking regions of the StAR gene were amplified by PCR
and directly sequenced.
Fig. 1 (abstract O2-2). See text for description
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adrenal crisis in the neonatal period, while 3 late-onset patients with
skin hyperpigmentation after age 2 years. Among 45 patients, 19 were
genetic males with 46,XY karyotype, 21 had a 46,XX, whereas the other
5 patients’ karyotype was not available. Patients with non-classic type
CLAH presented with skin hyperpigmentation and chronic adrenal in-
sufficiency without salt-wasting crisis after age 12 months. Two genetic
females having compound heterozygous mutations showed late onset
adrenal insufficiency, while one genetic male with compound heterozy-
gous for p.Q258* and p.R272H was incompletely virilized and raised as
a boy. Three pubertal-aged genetic females exhibited spontaneous
breast development at age 10 to 13 years. One of them showed spon-
taneous menarche at age 13 years and experienced ovarian cyst torsion
at age 14 years. Mental retardation was found in two patients. One pa-
tient died of adrenal crisis at the age of 2 months due to poor adher-
ence to medication. The genotype of the StAR was clarified in all
patients, identifying 9 different mutations. Of these, p.Q258* was the
most common (86.9%, 73/84 alleles), suggesting founder effect.
Conclusion: CLAH has wide clinical spectrum from life-threatening
adrenal insufficiency in early infancy to chronic adrenal insufficiency
thatcan present much later in life. CLAH was known to be mainly
caused by p.Q258* mutation in Korea by founder effect. However,
this study indicate that mutations of the StAR gene have diverse
spectrum with various mutations.
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Background: 17 α -hydroxylase deficiency (17OHD) is one of congenital
adrenal hyperplasia due to CYP17A1 gene abnormality. Affected 46,XY
patients usually have female external genitalia. Corticosterone (B) me-
tabolites and cortisol (F) metabolites ratio, a theoretical biochemical
marker of 17a-hydroxylase activity, was reported to be increased in
17OHD. However, no data are available to distinguish 17OHD from
cytochrome P450 oxidoreductase deficiency (PORD) which is a disease
theoretically showing similar urinary steroid metabolites pattern.
Objective: The objective of this study was to establish differential diag-
nostic approach of 17OHD from PORD using urinary steroid profile.
Methods: We recruited genetically confirmed 5 Japanese children of
46,XY 17OHD, age between 6 months - 17 years, and 254 controls
(22 PORD, 25 disorders of sex development (DSD), and 207 non-
disease controls. We measured urinary steroid metabolites by gas
chromatography mass spectrometry (mg/g creatinine) including B
metabolites (B-group; 5a-, 5b-tetrahydrocorticosterone and 5a-, 5b-
tetrahydro-11-dehydrocorticosterone), F metabolites (F-group; 5a-,
5b-tetrahydrocortisol and 5a-, 5b-tetrahydrocortisone), and pregna-
netriolone (Ptl). We calculated B-group/F-group ratio.
Results: Twelve patients (all five 17OHD and 7 out of 22 PORD)
showed B-group/F-group ratio of more than 1 (upper figure). Among
12 patients, Ptl showed no overlap between 17OHD and PORD using
cutoff value of 0.3 mg/g creatinine (lower figure).
Discussion: These data indicated that biochemical differential diagnosis
of 17OHD from PORD in Japanese children was possible by urinary ster-
oid metabolites; B-group/F-group ratio and Ptl with cutoff values of 1
and 0.3 mg/ g creatinine, respectively. Future studies are needed to as-
sess these urinary biochemical markers can distinguish 17OHD from
isolated 17,20-lyase deficiency, another phenotype of CYP17A1 gene
abnormality and adrenal tumor, likely showing similar urinary steroid
metabolites pattern of 17OHD.O2-3
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Background: Congenital adrenal hyperplasia (CAH) due to steroid 21-
hydroxylase (21-OH) deficiency (21-OHD) is an autosomal recessive
disorder, in which CYP21A2 mutations or deletions result in under-
production of glucocorticoid and mineralocorticoid, and overproduc-
tion of androgens. Patients with CAH are treated with oral steroid
supplementation, but optimal control of blood steroid levels remains
difficult. Thus, new therapeutic approaches are still needed. Previ-
ously, adenovirus-mediated administration of human CYP21A2 to ad-
renal glands rescued the phenotype of a mouse model of 21-OHD.
To date, adeno-associated virus vectors became a good candidate
with its weak immunogenicity and are capability of delivering genes
to various tissues to maintain stable expression. In this study, we ex-
amined whether transduction of murine Cyp21a1 in extra-adrenal tis-
sues could rescue steroid metabolism in 21- OHD mice.
Methods: A naturally occurring mouse model of 21-OHD was obtained
by mating heterozygous pairs. Heterozygous pregnant mothers received
daily injections of dexamethasone from late pregnancy to the day of de-
livery, to prevent deaths of newborn pups. Homozygous newborn mice
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the first 3 weeks after birth. A serotype-2 AAV vector containing Cyp21a1
cDNA and a cytomegalovirus promoter was constructed and we injected
the AAV vector to the thigh muscles of the homozygote mice aged be-
tween 3 and 10 months (n = 4 for Cyp21a1- containing vector and n = 2
for control). Serum progesterone and DOC levels were measured before
and 4 weeks after injection. One AAV-injected mouse was subjected to
monthly blood sampling during 8 months after injection.Progesterone
and DOC in serum samples were measured by liquid chromatography
tandem mass spectrometry.
Results: Serum progesterone/DOC ratios were markedly reduced in
all four animals at 4 weeks after injection. The effect had been con-
tinued until 8 months after injection. (Figure)
Conclusion: These results indicate that extra-adrenal induction of
Cyp21a1 ameliorates steroid metabolism in 21-OHD mice for long
term. This study suggests a novel therapeutic strategy for congenital
adrenal hyperplasia, which warrants further investigations.Fig. 1 (abstract O2-3). See text for descriptionO2-4
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Background: Congenital Adrenal Hyperplasia (CAH) is a disorder
characterized by the impaired activity of one of the enzymes needed
for cortisol synthesis. The most common cause of CAH is the 21-
hydroxylase deficiency that leads to cortisol and aldosterone defi-
ciency in addition to androgen excess. Therapy in these cases is a
long-life treatment of glucocorticoid and often mineralocorticoid.
Many reports consider these patients were at risk of glucocorticoid
induces osteoporosis. However, bone tissue is significantly affected
by androgens and glucocorticoid. There were conflicting results re-
garding the effect of glucocorticoid treatment on bone mineral dens-
ity (BMD) in CAH patients. Objectives: The objectives of this present
study were to evaluate the effect of glucocorticoid treatment on
BMD in children with CAH compared to normal healthy children.
Search methods: We performed literature search of studies using
Cochrane Library, MEDLINE, EBSCO, PROQUEST, and another data-
base to identify studies of BMD and CAH through May 2015. We alsosearched the reference lists of articles and contacted researchers in
the field. We retrieved English language articles for review, and we
searched for both published and unpublished studies.
Selection criteria: Randomized controlled trial, cohort, case control
and cross sectional studies was considered. The type of participants
was CAH patient who has already on glucocorticoid treatment at
least two years. The comparison for these patients were normal
healthy children. The outcome measure in this review was Whole
BMD Z-score and Lumbar Spine BMD Z-score, which were measured
by dual-energy X-ray absorptiometry (DXA).
Data collection and analysis: Two authors reviewed (AU and JB) in-
dependently abstracts for inclusion and read full- text articles to ex-
tract data. The risk of bias was assessed regarding randomisation,
allocation sequence concealment, blinding, incomplete outcome
data, selective outcome reporting, and other biases.
Main Results: We included nine studies involving 222 patients for
systematic review; however only four studies involving 84 patients
could be included in the meta-analysis. There were no randomized
studies that met inclusion criteria. Thus we use non-randomised
study that fulfilled the inclusion criteria. The meta-analysis showed
that there was no significant mean difference between Whole BMD
Z-Score and Lumbar spine BMD Z-Score among children with CAH
who treated with glucocorticoid compared to normal healthy child
(p=0.57, 95% CI, -0.46-0.84 and p = 0,86; CI 95%, -2,3 – 1,94,
respectively).
Conclusions: Whole BMD and Lumbar spine BMD Z-Score in children
with CAH treated with the glucocorticoid is similar with normal
children.
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Background: An increasing number of preterm infants were treated
with glucocorticoids for late-onset circulatory instability (CI) thought
to be caused adrenal insufficiency. However, the presence of adrenal
insufficiency, which is presented with late-onset CI in preterm infants,
is not fully verified yet. We aimed to describe the incidence and clin-
ical features of late-onset CI which responded to glucocorticoid re-
placement, and to determine the frequency of low serum cortisol
values that meet criteria for relative adrenal insufficiency in these
preterm infants.
Methods: Among 1,840 preterm infants who were admitted to a sin-
gle neonatal intensive care unit between 2010 and August 2014, 47,
who showed clinical signs of CI after 7 days-old and were recovered
shortly after hydrocortisone replacement, were enrolled. Clinical signs
of CI included hypotension, hyponatremia, hyperkalemia and oliguria.
Infants with infection, hypovolemia, and cardiac problems were ex-
cluded. Medical records including serum cortisol levels during CI
were reviewed retrospectively.
Results: Median gestational age (GA) of 47 infants was 28+2 weeks
(range, 24+0 - 33+6 weeks), and median birth weight was 995 g
(range, 430 - 2,275 g). Median age of development of CI was 20 days
(range, 8 - 49 days). Incidence of CI was 2.6% (47/1,840) in all pre-
term infants; 8.65% (47/543) in infants of ≤ 34 weeks of GA; 18.2%
(22/110) in infants of ≤ 28 weeks of GA. Incidence of CI in infants
below 1,500g birth weight was 13% (40/302). Median serum cortisol
level during CI was 8.0 μ g/dL (range, 2.0 - 12.0 μ g/dL), which met
the criteria of vs. 129.3 mmol/L, P <0.001), and hourly urine output
(3.7 vs . 1.7 mL/kg/hour, P <0.001) were decreased, and serum potas-
sium levels (4.64 vs .5.99 mmol/L, P <0.001) were increased when
compared the levels before CI. The clinical signs of CI were improved
within 24 hours after hydrocortisone replacement in all 47 infants.
Conclusions: Our findings suggest that adrenal insufficiency is pre-
sented with late-onset glucocorticoid responsive CI, and is not rare in
preterm infants.
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Introduction: Optimal treatment of congenital adrenal hyperplasia
(CAH) due to 21-hydroxylase deficiency (21-OHD) requires monitoring
of clinical parameters and steroid markers such as 17-
hydroxyprogesterone (17-OHP), androstenedione, and testosterone.
However, an increase of 17-OHP levels is commonly observed during
pubertal period, due to gonadal co-secretion of 17-OHP. Since the
accumulated 17-OHP can be converted to 21-deoxycortisol (21-DOC)
via 11-hydroxylation in adrenals only. We hypothesize that 21-DOC
may serve as a better adrenal steroid marker for treatment monitor-
ing in CAH youth.
Objectives: We aim to evaluate the utility of comprehensive serum
adrenal steroids by liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) as markers of clinical control in CAH youth, and
compare two different 17-OHP and testosterone assays (LC-MS/MS
vs. commercial immunoassays).
Methods: A cross-sectional study of 37 patients (24 females) with
classic 21-OHD aged 1-26 years were enrolled. Single serum samples
were collected at 8 AM before the morning dose of glucocorticoid to
measure steroid panels by LC-MS/MS and immunoassays. Patients
were classified as being in “good control” or “poor control” based on
clinical criteria including signs of androgen excess, degree of hyper-
pigmentation, bone age advancement, and ACTH levels. Compari-
sons of serum steroid concentrations were performed between two
groups. The receiver operating characteristic (ROC) curves were used
to determine the cut-off values for diagnosing “poor control”.
Results: Serum 17-OHP, progesterone, androstenedione, testosterone,
and DHEA concentrations were higher in “poor control” group, but
21-DOC and DHEAS levels were not different. The ROC curves
showed that 17-OHP, androstenedione, progesterone, and testoster-
one concentrations were the best hormonal predictors of clinical
poor control with areas under the curves (95%CI) of 0.91 (0.79-1.0),
0.92 (0.82- 1.0), 0.88 (0.76-1.0), 0.87 (0.73-0,99), P 0.001, respectively.
By the Bland & Altman plot, the differences of 17-OHP and testoster-
one levels between LC-MS/MS and immunoassay were 9.2 ng/mL
(95%CI -82 to 101), and 0.6 ng/mL (95%CI -2.1 to 3.2), respectively.
The higher levels of 17-OHP or testosterone exhibited higher discrep-
ancy between two methods.
Conclusion: Serum 17-OHP, androstenedione, and testosterone con-
centrations are of significance in diagnosing clinical poor control. 21-
DOC is not useful for treatment monitoring in CAH. Despite decent
overall correlation, absolute 17-OHP and testosterone concentrations
differed substantially between two different assays. Frequent moni-
toring of clinical parameters and standardized methods of steroid as-
says are crucial to diminish the
O3-1
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Background: The survival rates for children and adolescents with ma-
lignant cancers have increased these days, along with the improve-
ment of treatments modality. Consequently, the childhood cancersurvivors (CCSs) with late treatment-related complications, especially
with endocrinopathy are increasing.
Objective: To assess the frequency and characteristics of endocrino-
pathy of CCSs in single institute in Japan.
Methods: 272 CCSs from 2002 to 2016 were involved in this study.
Patients with craniopharyngioma were excluded because of no
chemotherapy and radiotherapy. 71 patients with benign disorders,
complicated with other syndromes, or last cancer treatment within
one year were excluded from 272 CCSs. The number of original dis-
eases are: solid tumors 83 (neuroblastoma, langerhans cell histiocyto-
sis, retinoblastoma, rhabdomyosarcoma, hepatoblastoma, Wilms’
tumor), brain tumors 51 (medulloblastoma, germinoma, teratoma,
optic glioma, ependymoma), hematological malignancies 67 (Acute
lymphocytic leukemia, acute myeloid leukemia, lymphoma). The
medical history and the hormonal data of 201 patients (98 males,
103 females, aged 2 ~ 19 (average 12) years) at our endocrine
follow-up clinic for CCSs were obtained retrospectively.
Results: Over all, growth hormone deficiency were observed in 32
patients (20 in brain tumor (39.2% in brain tumor) and 12 in others
(8.0% in other tumor)), thyroid dysfunction in 22 (12 in brain tumor
(23.5%) and 10 in others (6.6%)), adrenal dysfunction in 18(8 in brain
tumor (15.7%) and 10 in others (6.6%)), respectively. Among those
with brain tumors, AVP replacement was performed in 9 (17.6%). In
146 patients with pubertal age (male>13 years and female>11years),
sex hormone replacement were necessary in 15 (10.3%). GnRH agon-
ist was prescribed for 21 (10.4%) in children below 12 years old, ex-
cept 1 case, because of central precocious puberty or early puberty
for height. Hormone replacement was more common in patients
with hypothalamic-pituitary tumors. Patients with neuroblastoma
(n=27) also showed higher frequency of hormone replacement ther-
apy. Adult height was obtained from 5 patients with neuroblastoma,
3 of them showed adult height less than -4SD without GHD.
Assessment: Patients with brain tumor was at higher risk of pituitary
dysfunction. Patients with neuroblastoma, when compared to those
with other peripheral solid tumor, tended to have growth failure and
hormone deficiency suggesting that intense chemotherapy and radi-
ation therapy may have disrupting effect on endocrine system and
resistance to growth hormone.
Conclusion: Endocrinopathy is common for CCSs. We need to
continue surveillance to know more to follow them up appropriately.
O3-2
Genome-wide analysis of differential DNA methylation in
Silver-Russell syndrome
Di Wu, Chunxiu Gong
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Background: Silver-Russell Syndrome (SRS) is clinically heteroge-
neous disorder characterized by low birth weight, postnatal growth
restriction and variable dysmorphic features. The aetiology of SRS is
complex and current evidence strongly implicates imprinted genes.
Although approximately half of all patients exhibit DNA hypomethy-
lation at the H19/IGF2 imprinted domain, and around 7%-10% have
maternal uniparental disomy of chromosome 7(UPD (7) mat), no
clear mechanism is apparent in the other patients. In this study, we
aim to look for further DNA methylation defects in SRS patients.
Methods: We measured DNA methylation in 7 SRS patients and 5
controls at >485,000 CpG sites using DNA methylation microarrays.
We analyzed methylation changes genome-wide as well as at known
imprinted regions to identify SRS-associated epimutations. Then we
used bisulfite sequencing and digital PCR to identify the differentially
methylated regions (DMRs) we found.
Results: Our analysis identifies epimutations at the previously charac-
terised domains of H19/ IGF2, providing proof of principle that our
methodology can detect DNA methylation changes at imprinted loci.
In addition we discovered a novel imprinted gene OSBPL5 associated
with SRS and located at chromosome 11p14with the probe
cg25963939 hypomethylated in 4/7 patients (P=0.023, β =-0.243). We
also report DMRs in other genes including TGF β 3 AHSF1 AGAP43
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way analysis.
Conclusions: We identified the probe cg25963939, located at the
5’UTR of imprinted gene OSBPL5, as a noval DMRs, which associated
with SRS. This findings provide a new mechanism of SRS etiology and
aid the further stratification of SRS patients by molecular phenotypes.
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Background: Hyperinsulinemic hypoglycemia (HH) is a consequence
of unregulated insulin secretion by pancreatic β -cells. Congenital HH
is caused by mutations in genes involved in regulation of insulin se-
cretion (ABCC8 , KCNJ11 , GLUD1 , CGK , HADH , SLC16A1, HNF4A
and UCP2 ). Severe forms of congenital HH are caused by inactivat-
ing mutations in ABCC8 and KCNJ11, which encode the two compo-
nents of the pancreatic β -cell ATP-sensitive potassium channel.
Objective and hypotheses: Our aim is to identify mutations in the
ABCC8 and KCNJ11, HNF4A and GLUD genes, and to describe geno-
type and phenotype correlations of Vietnamese children with con-
genital hyperinsulinism.
Method: A prospective study was conducted on 101 cases with con-
genital hyperinsulinism diagnosed and treated at Vietnam Children’s
Hospital from January 2007 to June 2016. Patients were selected by
using inclusion criteria of Hussain K (2008). All exons of ABCC8;
KCNJ11 , HNF4A and GLUD1 were amplified from genomic DNA and
directly sequenced.
Results: Mutations were identified in 52 cases (51.5%) including muta-
tions of ABCC8 gene (46 cases; 45.5%), Among these cases 26 with
homozygous/compound heterozygous of ABCC8 and 20 cases with one
paternal/maternal mutation of ABCC8 gene); KCNJ11 (5 cases; 5.0%),
HNF4A (1 case; 1.0%). 100% of cases with homozygous/compound het-
erozygous recessive mutations or one paternal dominant mutation of
ABCC8 gene did not respond to diazoxide treatment and required 95%
pancreatectomy or octreotide injection. Other cases without identified
mutations responded to diazoxide and/or glucose infusion.
Conclusion: children with congenital hyperinsulinism should be per-
formed mutation analysis which helps in making diagnosis and treat-
ment decision. Families of children with congenital hyperinsulinism
should be given genetic counseling. Prenatal diagnosis should be
performed as well as follow - up and treatment should be given to
children with congenital hyperinsulinism immediately after birth.
O3-5
Short and long-term outcome of patients with congenital
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1/50000 birth and frequently becomes the cause of persistent
hypoglycemia in neonates. Most of persistent hypoglycemia states
are caused by genetic defects. Some can be managed by medication,
some can be cured by surgical resection of focal pancreatic lesion,
but some are intractable and uncontrolled by any medication.
Objective: To evaluate the adequacy of treatment choice and long-
term prognosis for CHI patients in one institute.
Methods: We retrospectively investigated clinical course, laboratory
data, diagnosis, treatment modality, and short and long-term out-
come in patients with hyperinsulinemic hypoglycemia through their
medical records from 2002 to 2016.
Results: 41 patients from 3-month-old to 46-year-old (current age),
diagnosed as transient or persistent hyperinsulinemic hypoglycemia
were involved in this study. Observation periods are from 3 months
to 14 years. Most of the patients were diagnosed in their first to
second days after birth, while 9 patients were diagnosed at 3 to 9-
month-old. 12 cases (31.6%) were transient, and 10 out of these 12
were born preterm or LFD (Light for date). Among 41 patients, 12
(31.6%) were born HFD (Heavy for date), 9 of which had ATP-
sensitive potassium channel abnormalities. 19 patients (46%) were di-
agnosed as CHI. Genetic evaluations were performed in 21 patients;
particular gene mutations were found in 12 patients (57%) (ABCC8
gene mutation in 9, KCNJ11 gene mutation in 1, GLUD1 gene muta-
tion in 2 ). The long-term prognosis of 19 CHI patients, 1 case was
treated only by diet control, 8 cases continue diazoxide, 1 case was
controlled by octreotide, 1 case by diazoxide and octreotide combin-
ation, and 8 cases had partial pancreas resection or subtotal pancreas
resection. The decision of partial resection was decided upon the result
of 18F-DOPA PET-CT. Among those who had subtotal (>95%) resection,
4 patients became insulin-dependent diabetes mellitus, and 2 cases
continuing the treatment for hyperinsulinemic hypoglycemia. Consider-
able mental retardation is observed in only one grown-up case.
Conclusions: Genetic testing and imaging study using 18F-DOPA PET-
CT, in addition to clinical evaluation, are helpful for the decision of
treatment choice. Long-term neurological outcome with adequate
medical and surgical treatment seems to be better in recent cases
when compared to old case, however, further evaluation is necessary.O3-6
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Purpose: Combined pituitary hormone deficiency (CPHD) is caused
by mutations in pituitary transcription factors involved in the devel-
opment of the hypothalamic-pituitary axis. Minor allele frequencies
of genes involved in CPHD are so low and varies substantially be-
tween ethnicities. This study evaluated the frequency of mutations in
the most relevant transcription factor genes (POU1F1 , PROP1 , LHX3
, LHX4 , and HESX1 ) in patients with CPHD and isolated growth hor-
mone deficiency (IGHD).
Method: This study included 27 patients with IGHD and CPHD. The
following parameters were analyzed: age at diagnosis, height, weight,
birth history, combined anterior pituitary function tests, and sellar
magnetic resonance image (MRI) findings. Mutation analysis of the
POU1F1 , PROP1 , LHX3 , LHX4 and HESX1 genes were performed
using genomic DNA from peripheral blood leukocytes.
Results: IGHD was observed in 4 patients and CPHD in 23 patients.
Age at diagnosis was 8.28 ± 7.25 years (range, 0.2–16.9 years) in
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Serum IGF-1 and peak GH levels after GH provocation tests were signifi-
cantly low in patients with CPHD compared to those of IGHD (P <0.05).
The sellar MRI findings found structural abnormalities in 3 patients with
IGHD (75%) and 21 patients with CPHD (91.3%) (P = 0.62). Mutation
analysis identified homozygous c.326G>A (p.R109Q) mutations in
HESX1 in a patient with CPHD. No mutation was identified in POU1F1 ,
PROP1 , LHX3 , and LHX4 genes in the other patients.
Conclusion: Patients with CPHD had severe GHD than those with
IGHD. Patients with GHD should be evaluated for other systemic dis-
eases and endocrine functions by means of ophthalmologic examin-
ation, sellar MRI, and combined anterior pituitary function tests. As
the mutation frequency of pituitary transcription factors is rare in
patients with CPHD and IGHD, further research should be done to
investigate other causative genes or environmental factors.O4-1
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This randomised, open-label, active-controlled, dose-escalation trial
(NCT01973244) investigated single-dose exposure and insulin-like
growth factor (IGF)-I response to somapacitan in 32 children with GHD
after a 7–10-day GH-washout period. Pre-pubertal children (aged 6–13
years) were assigned equally to four cohorts: 0.02, 0.04, 0.08 and 0.16
mg/kg somapacitan, pending safety assessments performed at each
dose level increase. Within each cohort, six children were randomised
to a single dose of somapacitan and two were randomised to Norditro-
pin® SimpleXx® once daily at a fixed dose of 0.03 mg/kg/day for a week.
The once-weekly dose range of somapacitan was expected to cover
the clinically relevant dose range in GHD as guided by simulations of
the anticipated PK and IGF-I response in children with GHD. There were
dose-dependent increases in somapacitan serum concentrations and in
baseline-adjusted IGF-I AUC (0–168h) (area under the IGF-I concentra-
tion–time curve from 0–168h) and maximum concentration (Cmax).
Compared with once-daily GH, IGF-I responses were lower with 0.02
mg/kg somapacitan (estimate: 0.56 ng*h/mL [95%CI: 0.44; 0.71], p
<0.0001), but similar with 0.04 and 0.08 mg/kg (estimated ratios, ap-
proximately 1:1) and higher with 0.16 mg/kg (1.25 ng*h/mL [95%CI:
0.98; 1.59], p =0.0672). Only an initial peak in IGF-I response to 0.08 mg/
kg was outside the reference range (+2 to –2 SDS). A similar dose-
dependent response was observed for IGF-binding protein-3 (IGFBP-3)
with the initial peak being largest with 0.16 mg/kg somapacitan (2.3
mg/kg vs. 0.6–1.3 mg/kg for other doses) and subsequent stabilisation
within reference range. No serious adverse events with either treatment
and few local tolerability issues were observed (four transient injection
site reactions in three children all receiving 0.16 mg/kg somapacitan).
All somapacitan doses were well tolerated with no clinically relevant
safety or immunogenicity issues observed.
In a model-based analysis, steady-state PK and IGF-I responses were
simulated across dose levels and compared to daily GH treatment for
Cmax and average concentration (Cavg). In this model, an IGF-I dose
of 0.04 mg/kg is expected to provide Cmax IGF-I levels matching
average daily GH treatment; 0.08 mg/kg is expected to provide Cavg
IGF-I levels matching average daily GH treatment; 0.16 mg/kg is ex-
pected to provide higher IGF-I levels, with average concentrations
within +2 SDS after a single dose or at steady state.
In conclusion, the single-dose results indicate that doses of 0.04, 0.08
and 0.16 mg/kg may be suitable for once-weekly administration of
somapacitan and may be effective for the treatment of childhood GHD.O4-2
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Background: The diagnosis of Growth Hormone Deficiency (GHD) in-
volves the use of multiple GH stimulation tests which require day case
admission, multiple blood samples and the administration of pharma-
cological agents. Replacing these tests with a single blood sample
would be a major advance for patients being evaluated for GHD.
Aim: To assess the utility of gene expression (GE) profiling and candi-
date SNP analysis for the diagnosis and classification of GHD.
Method: Pre-pubertal treatment-naïve children with GHD (n=98)
were enrolled from the PREDICT study and controls (n=26) acquired
from online datasets. Whole blood gene expression (GE) was deter-
mined with Affymetrix HU133v2.0 microarrays. Genotyping was per-
formed on DNA extracted from whole blood using Illumina
GoldenGate for 1536 SNPs, located on 103 candidate genes. The cor-
relation between GE and peak GH was investigated using rank re-
gression and a Random Forest algorithm tested for prediction of the
presence of GHD and in classification of GHD into severe (peak GH>4
μg/L ). For GHD severity classification, data on age, gender, baseline
IGF-I and IGFBP-3 levels were added to the Random Forest model
along with SNP genotype. Performance was assessed using Area
under the Receiver Operating Characteristic Curve (AUC-ROC). A bio-
logical network of GE related to peak GH levels was generated and
cluster hierarchy assessed.
Results: Rank regression identified 347 probesets representing 271
genes where expression correlated with peak GH concentrations:
(R = + 0.28, p<0.01). These 347 probesets gave an AUC of 0.98 (sensi-
tivity 100%, specificity 96%) for predicting GHD status (GHD versus con-
trols). At the DNA level, 18 SNPs in 12 genes were associated with peak
GH concentrations; 16/18 were intronic and none were rare (defined as
Minor Allele Frequency <1%). The function of the genes associated with
the SNPs included pituitary transcription factor (POU1F1 ), generation
of oestrogen (CYP19A1 ), IGF binding (IGFBP1 ), apoptosis (BCL2), cell
cycle (CCND3 ) and signal transduction (PTPN1 , RARA ). Random Forest
analysis was also able to accurately predict GHD severity with an AUC
of 0.93 using transcriptomic data but not improved with addition of
demographic, biochemical or SNP genotype data.
Conclusion: GE profiling differentiates normal subjects from those
with GHD and, in a cohort of GHD subjects, accurately predicts GHD
severity. It may therefore be a useful tool in clinical practice to aid in
the diagnosis of GHD, potentially replacing two GH stimulation tests
with a single blood sample.
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Background: Human chromosome 14q32.2 carries paternally
expressed genes and maternally expressed genes together with the
germline- derived DLK1-MEG3 intergenic differentially methylated
Table 1 (abstract O4-4). See text for description
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sistent with this, maternal uniparental disomy 14 (UPD(14)mat), and
epimutations and microdeletions affecting the imprinted region of
paternal origin result in discernable and non-specific clinical features
such as pre- and postnatal growth failure, hypotonia, early onset pu-
berty, and small hands. Recently, this clinically recognizable disorder
has been named “Temple syndrome” (TS14) (OMIM 616222) and
identified in 58 patients. Clinical features of TS14 overlap with that of
Prader-Willi syndrome (PWS) and Silver-Russell syndrome (SRS). Here,
we performed comprehensive clinical studies in 30 patients molecu-
larly diagnosed with TS14.
Subjects and Methods: We performed methylation analysis for the
IG-DMR and the MEG3 -DMR in 186 patients with SRS-like phenotype
without 11p15 loss of methylation or UPD(7)mat,157 patients with
PWS-like phenotype with normal methylation pattern of the SNRPN -
DMR, 202 patients with SGA-short stature (SGA-SS), together with 33
patients with TS14 phenotype. For patients with hypomethylation of
these DMRs, we carried out structural analysis to detect paternal
microdeletion, and microsatellite analysis to detect UPD(14)mat. To
collect detailed clinical data of all patients, we used a comprehensive
questionnaire from attending physicians.
Results: Thirty Japanese patients with TS14, UPD(14)mat (n=21); epi-
mutations (n=5); microdeletions (n=3); and unknown (n=1), were
identified. Their clinical diagnoses were TS14 (n=5), PWS (n=13), SRS
(n=6), SGA-SS (n=2), and others (n=4). Fifteen patients had the score
of 4 or more in Netchine-Harbison SRS clinical scoring. The combin-
atory method of PNA-NGS can detect somaticedian SD of birth
weight, birth length, present height, and present weight are –2.1, –
2.7, –2.3 and –1.6, respectively. Early onset puberty was identified in
11 out of 15 patients older than 4 years. Motor development was de-
layed in early infancy due to muscular hypotonia. Median develop-
mental/intellectual quotient (DQ/IQ) was 83 (rage, 53–114), and two
out of 15 patients who reached school age needed special educa-
tion. Hyperlipidemia was identified in four out of 21 patients whose
laboratory data were obtained. The median BMI was 15.1 (range,
10.9–37.3)
Discussion: We show detailed clinical features and course of 30 Japa-
nese TS14 patients. Because of non-specific clinical features, clinical
diagnosis of TS14 was difficult. Methylation analyses for the DMRs on
chromosome 14 should be considered in patients with SRS- or PWS-
compatible phenotype but no abnormal methylation pattern of the
DMRs on chromosome 7, 11, and 15, as well as in patients with SGA-
SS and hypotonia.
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Background: Silver-Russell syndrome (SRS) is a rare disorder
associated with pre- and postnatal growth failure and characteristic
features. SRS is genetically heterogeneous. H19 -differentially methyl-
ated region (DMR) hypomethylation (H19 -hypo) and maternal unipa-
rental disomy chromosome 7 (upd(7)mat) can be detected in
approximately 50% of SRS patients, and the etiology of remaining
patients is unknown. Recently, some cases with Temple syndrome,
upd(16)mat, upd(20)mat, and submicroscopic chromosomal abnor-
mality were recognized in SRS patients without known etiology, but
sample size of these cohort was small.
Patients and Method: This study consisted of fifty SRS patients
diagnosed based on Netchine-Harbison SRS clinical scoring system
(NH- CSS). To clarify the exact frequency of patients with PCNV in
SRS patients without known etiology, we included only patients with
normal methylation pattern for nine DMRs (H19 , Kv, IG, MEG3 ,
PLAGL1 , PEG1 , PEG10 , SNRPN , and GNAS A/B). We extractedgenomic DNA from peripheral leucocytes. Oligoarray comparative
genomic hybridization was performed in all patients using 8 × 60K
catalog array (Agilent technology). To determine whether copy num-
ber variations identified in the patients were pathogenic or not, we
utilized the information from Database of Genomic Variants and
medical publications. The frequency of clinical features between pa-
tients with pathogenic copy number variants (PCNV) and those with
H19 -hypo or upd(7)mat (previously reported by us) was analyzed by
Fisher’s exact probability test.
Result: PCNV were detected in five patients in our cohort. The abnor-
malities included 4p microdeletion, 11p15 microduplication (two pa-
tients), 17p12 microduplication, and mosaic 18 trisomy. Clinical
features of patients with PCNV are shown in the Table. Of note,
among the patients with PCNV four patients presented congenital
heart diseases and three patients developed epilepsy. The frequency
of relative macrocephaly and body asymmetry was lower in the SRS
patients with PCNV than in H19 -hypo group.
Discussion: We identified five patients with PCNV in fifty SRS patients
satisfying N-H CSS. Our study revealed exact frequency of patients
with PCNV in SRS patients without known etiology. We suggest that
copy number analysis would improve genetic diagnosis of the SRS
patients without known etiology, especially those with atypical fea-
tures including congenital heart defect or epilepsy.O4-5
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Objective: To study the clinical characteristics of patients with short
stature related to bone and cartilage diseases (BCD), and evaluate
the efficacy and safety of the recombinant human growth hormone
(rhGH) treatment in BCD patients.
Methods: Clinical data of 33 cases of BCD patients were retrospect-
ively analyzed. Eleven of them had undergone genetic testing. Based
on receiving rhGH treatment or not, all BCD patients were divided
into the treated group (BCD-T) and the untreated group (BCD-C).
Twenty- one age/gender matched growth hormone deficiency (GHD)
patients were collected as the control (GHD-T) group. Clinical and la-
boratory parameters were analyzed between each follow-up and
group. The safety of rhGH treatment in BCD patients was also
evaluated.
Results: Thirty-three BCD patients with mean age of 7.74 years old
and mean initial height standard deviation score (Ht-SDS) of -4.50 in-
cluded 18 achondroplasia/hypochondroplasia (54.5%) patients, 5
spondyloepiphyseal dysplasia (15.2%) patients, 3 multiple epiphyseal
dysplasia patients, and 7 others. All patients underwent genetic test-
ing existed gene mutations. Each of FBN1, FGFR3 and COL2A1 muta-
tions revealed in 2 patients. The other mutations included COL9A1,
NPR2, TRAPPC2, RUNX2 and CENPJ . All 15 patients in the BCD-T
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Ht-SDS after 12-month treatment (P<0.05). While 18 patients in BCD-
C group had no change in GV and Ht-SDS before and after follow-
ups (p>0.05). All changes of GV and Ht-SDS in the BCD-T, BCD-C, and
GHD-T groups were shown in figure1 and figure2. The rhGH dosage
needed in the BCD-T group was significantly higher than that in
GHD-T group (p<0.05). Insulin-like growth factor-1 (IGF-1) levels were
both significantly increased in the BCD-T and GHD-T groups after
rhGH treatment (p<0.05). No serious adverse reaction occurred dur-
ing the follow-ups.
Conclusions: Though the effect of rhGH therapy is poorer in BCD patients
compared with that in GHD patients, an appropriate dose of rhGH ther-
apy is still helpful to improve the GV and Ht-SDS. The study of the long-
term safety of rhGH treatment in BCD patients is still required.
Key words: short stature; bone and cartilage diseases; recombinantFig. 1 (abstract O4-5). See text for descriptionhuman growth hormone
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GX-H9 is a hybrid Fc-based long-acting recombinant human growth
hormone (hGH). The safety, tolerability, and PK/PD were assessed in
a single ascending dose study in healthy volunteers and in multiple
sequential dose studies in patients with adult (AGHD) and pediatric
growth hormone deficiencies (PGHD). The efficacy of GX-H9 was
compared to that of a daily recombinant hGH.A double-blind, randomized, placebo-controlled, single ascending
dose Phase 1 study of GX-H9 was conducted in 4 groups of healthy
subjects (n=32) with four sequential dose levels (0.2, 0.4, 0.8 or 1.6
mg/kg). Currently, a Phase 2, randomized, active-controlled, open-
label, sequential dose study of GX-H9 (0.1 mg/kg/weekly, 0.2 and 0.3
mg/kg/semi-monthly) is being conducted in patients with AGHD
(n=45). In addition, a Phase 2, randomized, active-controlled, open-
label, multiple dose study of GX-H9 with weekly and semi-monthly
administrations is being conducted in patients with PGHD (n=48).
Single doses of GX-H9 were well tolerated at all dose levels in
healthy volunteers. No safety concerns were noted, including ab-
sence of any lipoatrophy or anti-drug antibodies. Geometric mean of
t1/2 ranged between 69.2 and 138.0 hours. IGF-1 serum concentra-
tions increased in a dose-dependent manner between 0.2 and 1.6
mg/kg. The interim Phase 2 results in AGHD have indicated that ad-
ministration of 0.1 mg/ kg/week and 0.3mg/kg/every other week
with GX-H9 for 12 weeks were safe and efficacious. The weekly treat-
ment of 0.1mg/kg in AGHD patients demonstrated the mean in-
crease in IGF-1 comparable with those receiving 6 μg/kg of
Genotropin® daily for 12 weeks (101.3 ± 31.2 ng/mL vs 109.1 ± 45.0
ng/mL, respectively). A limited interim analysis of PK and IGF-1 level
in PGHD study was performed for the first 12 subjects after complet-
ing a single dose period, demonstrating the safety of GX-H9 and
dose-dependent PK profile in pediatric patients. The administration
of higher doses showed a potential for semi-monthly treatment of
GX-H9 in both AGHD and PGHD. The data from ongoing Phase 2
studies will be presented.
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Background: NK2 homeobox 1 (NXK2-1) is a relatively common re-
sponsible gene in congenital hypothyroidism (CH). It plays a very import-
ant role in the development of thyroid, lung and central nervous system
(CNS). We identified a de novo heterozygous NKX2-1 mutation c.799G>T
(p.Val235Phe, NP_001073136.1) in a pair of twin boys who had primary
CH and ataxia. As the most common NKX2-1 gene mutation, the patho-
logic mechanisms of the c. 799G>T mutation is still undetermined.
Methods: We introduced the mutation c.799G>T in an NKX2-1 ex-
pression vector, and then analyzed the protein expression differences
in HEK293 cells between wildtype and mutant vectors through trans-
fection experiments and Western blot. After co-transfected the ex-
pression vectors and reporter vectors harboring TG/TPO /SP-B gene
promoters, we performed the dual-luciferase assay to evaluate the
function of NKX2-1 c.799G>T heterozygous mutation. Furthermore,
we also analyzed local structure variations of mutant NKX2-1 p.V235F
using bioinformatics software.
Results: Compared with wildtype NKX2-1, the expression of mutant
NKX2-1 p.V235F was significantly reduced in HEK293 cells. All TG,
TPO, and SP-B promoters could be activated by wildtype NXK2-1. TG
promoter was activated in a dose-dependent pattern, while TPO and
SP-B promoters were not. All TG, TPO or SP-B promoters were failed
to be efficiently activated by mutant NKX2-1 p.V235F. And dose
changes of mutant NKX2-1 p.V235F didn’t change the transcription
activity of TG, TPO or SP-B promoters induced by wildtype NKX2-1.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 28 of 144Local structure analysis of mutant Phe235 showed abnormal contacts
with nearby amino acids and Arg221. Surface charge distribution also
changed in this mutant model.
Conclusions: NKX2-1 haploinsufficiency in TG promoter activation
and decreased TG transcriptional activity induced by mutant NKX2-1
p.V235F may cause hypothyroidism in NXK2-1 c.799G>T patients. Our
study discovered part of the pathologic mechanisms of NXK2-1
c.799G>T mutation.
Keywords: NKX2-1 related disorder; Congenital hypothyroidism;
Thyroglobulin gene promoter; Thyroperoxidase gene promoter;
Surfactant protein-B gene promoterFig. 1 (abstract O5-1). See text for descriptionO5-2
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Background: Mutations in the thyroglobulin (TG) are important gen-
etic causes of congenital hypothyroidism, characterized by congenital
goiter and low serum TG. Importantly, these patients are at elevated
risk for developing thyroid cancer. Here, we report clinical features of
four cases with various TG gene mutations.
Case report: Case 1 was born with remarkable goiter and his TSH was
high (80 μ U/ml) at neonatal mass screening (MS). At 10 day-old, thy-
roid function tests confirmed overt hypothyroidism with low serum TG
(11.5ng/ml) and L-T4 replacement started. Ultrasonography showed
remarkable goiter. At re-evaluation in 3 year-old, TRH-test showed ele-
vated basal TSH and exaggerated response (13.34 → 97.02 IU/ ml). 123I
scintigraphy showed high uptake (68.89%) and negative perchlorate
discharge. Ultrasonography still exhibited thyroid enlargemant.
Case 2 and 3 are male siblings of 14 and 12 year-old at first visit to our
hospital. Their TSH levels were high at MS (Case 2: 110.1 μ U/ml,
Case 3: 64.3 μ U/ml). Thyroid function tests confirmed overt
hypothyroidism and L-T4 replacement started. Serum TG and thyroid
size were not evaluated at neonatal period. At 14 and 12 year-old, they
had no goiter and examinations revealed euthyroid status with un-
detectable serum TG.
Case 4 is 40 day-old at first visit to our hospital. His TSH level was high
(13.2 μ U/ml) at MS. Thyroid function tests confirmed overthypothyroidism and L-T4 replacement started. No data about serum TG
and thyroid size at neonatal period was available. At 40 day-old, he had
no goiter and examinations revealed euthyroid status with normal TG
level (47.2 ng/ml). At re-evaluation in 3 year-old, TRH-test showed ele-
vated basal TSH and exaggerated response (17.39 → 109.3 IU/ml). 123I
scintigraphy showed high uptake (54.86%) and negative perchlorate
discharge. His thyroid size was normal in ultrasonography.
Genetic analysis identified heterozygous mutations in the TG gene
(Case 1; c.4177A>T, pK1393X, c.3790T>C, pC1264R, Case 2 and 3;
c.4177A>T, p.K1393X, c.4235delT, p.L1412fs, Case 4; c.1006T>C,
p.C336A, c.7006C>T, p.R2317X).
Discussion: Cases with TG mutations have exhibited variability in
clinical presentation. Goiter was often not evaluated at neonatal
period and serum TG did not decrease in some cases. Careful diagno-
sis of goiter by ultrasonography should be performed. High uptake
in 123I scintigraphy and negative perchlorate discharge are import-
ant findings at re-evaluation. According to these findings, TG muta-
tions should be considerd even in cases with no goiter and normal
serum TG. Active detection of TG mutation is expected to decrease
future thyroid cancer risk.
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Introduction: Mental retardation is a severe complication of congeni-
tal hypothyroidism (CH) and preventable by early diagnosis and
therapeutic intervention. More than half of the cases with thyroid
dyshormonogenesis, which accounts for 15 % of CH, is caused by
the mutation of a single gene. Sibling cases of CH are occasionally
observed and clinical courses are sometimes different among them.
In the current study we performed imaging and genetic analysis in 7
patients from three familial cases of CH to understand the associ-
ation between pathogenesis of CH and their clinical courses.
Subjects and methods: Seven patients from three familial cases of
CH were recruited in the study. The type and cause of
hypothyroidism was determined based on radioisotope scanning
with the perchlorate discharge test and ultrasonograph. Genomic
DNA was extracted from peripheral blood and genetic analysis was
performed using targeted next-generation sequencing. The identified
mutation was confirmed using the Sanger sequencing method.
Results: Family 1: A 19-year-old man was positive for neonatal mass
screening (NMS) and diagnosed as having CH. His 15-year-old
brother was negative for NMS, but subsequently diagnosed as CH at
4-month old, and synthetic thyroxin was initiated. Iodine transport
defect was noted and a heterozygous mutation in the NIS gene was
identified in both patients.
Family 2: A 14-year-old boy was positive for NMS and diagnosed as
CH. His 11-year-old brother was also positive for NMS, but synthetic
thyroxin was not initiated as TSH levels declined and thyrotropin
levels were maintained within normal range. Thyroid iodine organifi-
cation defect was detected and homozygous mutation in DUOX2
gene was identified in the former case, whereas a heterozygous mu-
tation was present in the latter case.
Family 3: The proband is a 17-year-old girl. She was positive for NMS
and diagnosed as CH. Her 14- and 10-year old brothers were nega-
tive for NMS, but subsequently diagnosed as subclinical CH. Thyroid
hypoplasia was noted and no mutations were identified in the
proband.
Discussion and Conclusion: Early therapeutic intervention is critical
to improve the intellectual outcomes in CH patients; however, NMS
sometimes fails to detect CH especially when the hypothyroidism is
trivial. Here we present a sibling case of CH (Family 1) who followed
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 29 of 144different clinical courses despite the presence of identical mutation,
suggesting the importance to monitor the thyroid function in chil-
dren when there exists CH sibling(s) in the family even if the NMS
test was negative.
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Background: The Toll-like receptors (TLRs) are germline-encoded re-
ceptors that play an essential role in initiating the immune response
against pathogens. In this study, we assess the association of TLR
polymorphism with autoimmune thyroid disease (AITD) in Korean
children.
Methods: Seven Toll-like receptor genes (TLR-1, -2, -3, -4, -5, -6, -9) in-
cluding 15 single-nucleotide polymorphisms were analyzed on 104
Korean children with AITD [Hashimoto¢s disease (HD) = 40, Graves¢
disease (GD) = 60 (thyroid-associated ophthalmopathy (TAO) = 29,
non- TAO = 31)] and 192 healthy individuals.
Results: The allele frequencies of 15 SNPs in AITD patients and con-
trols are shown in Table 3. For overall AITD cases, the frequencies of
these alleles had no statistical difference with controls. When catego-
rized by disease subgroup, GD showed lower frequencies of the TLR4
rs1927911 T allele (cP <0.018) and HD showed an lower frequencies
of the TLR3 (-7) rs3775296 C allele (cP <0.044) than the control
group. Between GD and HD group, the frequencies of the TLR4
rs1927911 CC genotype in HD (cP < 0.048) was lower, whereas TLR4
rs1927911 T allele in HD (cP < 0.032) showed higher frequencies than
in GD. When categorized GD by sex, female-GD group showed
higher frequencies of the TLR4 rs1927911 CC genotype (cP < 0.026)
and lower frequency of the TLR4 rs1927911 T allele (cP < 0.017) than
control. Male-GD group showed lower frequency of the the TLR4
rs1927911 CT genotype (cP < 0.031) than control. Between female
and male group in GD, the frequencies of TLR4 rs10759932 CC geno-
type (cP <0.006) and TLR4 rs1927911 TT genotype (cP < 0.024) in
male were higher, whereas TLR4 rs10759932 T allele (cP < 0.004) and
TLR4 rs1927911 C allele (cP < 0.016) in male were lower than female-
GD.
Conclusions: Our results suggest that TLR- 3 and -4 gene polymor-
phisms may contribute to the pathogenesis of AITD and TAO. Sexual
dimorphism in polymorphisms of TLR 4 gene might influence female
predominance of AITD.
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Introduction: Childhood hyperthyroidism occurs less commonly in
children than hypothyroidism, yet far more symptomatic. Hyperthy-
roidism in children is mostly due to autoimmunity, predominantly as
a result of Graves’ disease. Non-autoimmune hyperthyroidism caused
by activating mutations in the Thyroid-stimulating Hormone Recep-
tor (TSHR) gene occurs to a much lesser extent.
Case report: We report a Malay family with three affected individuals
(a mother and her two daughters). The two sisters, aged 5 years and
1 month old and 2 years and 5 months old were under General Pae-
diatricians follow up since infancy for symptomatic hyperthyroidism.Despite high dose of anti-thyroid medication (carbimazole), their thy-
roid function tests continued to be deranged (high fT4, suppressed
TSH). They were then referred to our Paediatric Endocrinology clinic
for further management. The family history revealed that the mother
was presumed as having Graves’ disease since the age of 15 and had
radioactive iodine therapy at the age of 24 years due to failure of
medical treatment. She subsequently became hypothyroid and cur-
rently requiring daily L-thyroxine replacement. On examination, both
siblings have palpable goiters with mildly prominent eyes. Thyroid
antibodies screening were all negative. Thyroid ultrasound scan
showed diffuse thyroid disease with lymphadenopathies. Bone ages
were also advanced. In view of the findings, TSHR mutation analysis
was done for the two siblings and the parents. Direct DNA sequen-
cing of the TSHR gene revealed a heterozygous cytosine-to-adenine
transversion in exon 10 in the two siblings and the mother. This mis-
sense mutation was not found in the father. The mutation leads to
serine to arginine substitution, affecting TSHR codon 505 (S505R).
The S505R mutation had previously been characterized and was ob-
served to cause the activation of TSHR protein (gain- of-function
mutation).
Discussion: In conclusion, the evidence of non-autoimmune hyper-
thyroidism in several family generations warrants initiation of muta-
tion analysis to detect the possible mutation in the TSHR gene
leading to the clinical entity. Affected family members harbouring
the exact same mutation may exhibit variable phenotypes with
regards to the age of onset and severity of hyperthyroidism.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Backgroud: Allogeneic hematopoietic stem cell transplantation
(HSCT) is a potentially curative therapy for a variety of malignant and
non- malignant disorders. Improved outcome leads to increasing at-
tention to late complications in long-term survivors. Secondary can-
cer belongs to the most serious complications.
Aims: Occurrence of secondary solid tumors following allogeneic
HSCT was analyzed.
Methods: We have evaluated clinical and laboratory data (including
fT4, TSH, thyroid antibodies, thyroid function and ultrasound im-
aging) in 499 patients (315 M, 184 F) who underwent 545 allogeneic
HSCT at a median age 8.4 years since 1989 till 2014. Of them 60%
(300/499) patients are still alive and disease free.
Results: We have documented secondary malignancy in 29 patients
(5.8%). Of them 13 developed post-transplant lymphoproliferative
disorder at a median time 0.3 (0-1.8) years after HSCT. Secondary
solid tumor was diagnosed in further 16 patients (3.2%) at a median
time 11.4 (range 5.4-17.8) years after HSCT (thyroid carcinoma n=8,
carcinoma of oral cavity n=3, malignant schwannoma n=2, melan-
oma n=1, peritoneal mesothelioma n=1, breast cancer n=1). All pa-
tients with secondary solid tumor underwent surgery and/or chemo-
radiotherapy and are alive. 15/16 patients (93.8%) with secondary
solid tumor received total body irradiation (TBI) 12-14.4 Gy as a part
of conditioning regimen. Papillary carcinoma (in all 8 cases micro-
nodular form, T1 or T2 stage) was the most frequent secondary solid
tumor (5F, 3M; 50% of secondary solid tumors) diagnosed at a
median time 10.8 years (range 5.4-17.0) after HSCT. At the time of
diagnosis three patients were treated with thyroxine for auto-
immune thyroid disease, one for hypothyroidism and another one
for nodular goiter. All but one had HSCT for malignant disease and
7/8 received TBI.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 30 of 144Conclusions: The early diagnosis is one of the key tasks of long-life
multidisciplinary post-transplant care including regular ultrasound
evaluation of thyroid gland and neck especially more than 5 years
after HSCT and namely after irradiation. The incidence of complica-
tions following allogeneic HSCT in childhood namely after TBI is in-
creasing within time. Papillary thyroid carcinoma was the most
frequent secondary solid tumor detected. Supported by MHCZ for
conceptual development 00064203 University Hospital Motol.O6-1
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Background: Disorders of sex development (DSDs) include 46, XY go-
nadal dysgenesis (GD), where a specific genetic diagnosis is made in
only ~30% of patients. Improved understanding of the genetic
causes of 46, XY GD is therefore required to better inform clinical
diagnosis and management. Among the genes induced by upstream
SRY-SOX9 signalling to promote male sex determination is fibroblast
growth factor (FGF) 9. Expressed within the pre-Sertoli cell lineage,
FGF9 suppresses the female program of gonadal development via its
receptor FGFR2. In mouse both are critical for testis determination as
FGF9/FGFR2 knockout mice show XY sex reversal. Despite this, to
date no FGF9 gene mutations/deletions/insertions have been identi-
fied in human DSD patients.
Results: We identified an FGF9 variant, a maternally derived hetero-
zygous single nucleotide substitution c.583G>A (p.D195N), in a 46,XY
GD female presented with delayed puberty, primary amenorrhea, cli-
tromegaly, Müllerian duct remnants and raised gonadotrophin levels
using 1032 DSD gene targeted parallel sequencing. In silico analysis
predicted the D195N variant to be deleterious for FGF9 protein func-
tion, and in vitro studies indicated the D195 residue lies at the
homodimerisation interface. Purified recombinant FGF9-D195N pro-
tein showed a reduced affinity for heparin, a property necessary for
stable FGF-FGFR complexes, and reduced ability to induce Sertoli cell
proliferation in vitro . To model the D195N mutation in vivo ,
Fgf9D195N/+ knockin mice were generated via CRISPR/Cas9 gene-
editing. Pilot studies showed that E15.5 Fgf9D195N/D195N embry-
onic XY gonads exhibit a truncated male-specific coelomic blood ves-
sel, and immunofluorescence analysis revealed ectopic expression of
the female meiotic marker γ H2AX, indicative of sex reversal. We also
investigated gonadal development in Fgf9N143T/N143T mice which
also carry a mutation in the FGF9 homodimerisation domain. Like-
wise, E15.5 Fgf9N143T/ N143T embryonic XY gonads show a trun-
cated coelomic blood vessel and partial sex reversal.
Conclusion: These results suggest that FGF9 homodimerisation and
heparin binding are required for FGF9 function in testes determin-
ation. In addition, human FGF9 mutations may be the cause of a sub-
set of hitherto undiagnosed human DSD patients.O6-2
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Beijing Children's Hospital affiliated to Capital Medical University,
Endocrine Department
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):O6-2
Aims: Retrospectively reviewed the etiology, clinical features and dif-
ferential diagnosis of 88 46,XYDSD.
Methods: Collect from September 2008 to December 2015 in Beijing
Children's Hospital and gene detection of 300 cases, selecting thediagnosed of 46, XYDSD of 88 cases except CHH that compared their
clinical symptoms and check and laboratory examination.
Result: The social gender of the 88 case was that male: 38, female:
50 aged 4 months to 17 years old, average 3.71 years. Clinical diag-
nosis were androgen insensitivity syndrome (AIS) in 33 cases (37.5%),
5 alpha reductase deficiency (5 alpha RD) in 31 cases (35.2%), 17
alpha hydroxylase deficiency in 11 cases (12.5%); relatively rare in
turn Nr5a1 gene mutation in 7 cases (8.0%), 17 beta hydroxysteroid
dehydrogenase deficiency in 2 cases (2.3%), 3 beta hydroxysteroid
dehydrogenase deficiency in 2 cases (2.3%), Fraiser syndrome (FS)
and Denys Drash syndrome (DDS) in 1 case (1.1%). The main clinical
manifestations of abnormal vulva: The external Prader classification
of AIS, 5 alpha RD and 17 alpha hydroxylase in children showed no
significant difference; and the rest of the rare case of Prader classifi-
cation for 0-3. There was no significant difference in the distribution
of testicular position in various diseases. In accordance with the hCG
classification experiments between Leydig cell function in normal
and interstitial function is not normal statistical grouping: interstitial
cells of AIS and 5 alpha RD is normal, normal T/DHT, and between
the two kinds of diseases were no difference; and 17 alpha hydroxy-
lase deficiency, Nr5a1 gene mutation, 17 beta hydroxysteroid de-
hydrogenase deficiency, 3 beta hydroxysteroid dehydrogenase
deficiency disease,'s and DDS showed interstitial cells are not normal
after hCG stimulation.
Conclusion: There are many overlapping clinical manifestations, the
differential diagnosis of 46, XYDSD was difficultiesThere were no dif-
ferences between the Prader grading and testicular position of the
body in different cause, but significant differences in the distribution
of the different causes. Other rare disorders as 17 beta - hydroxy
steroid dehydrogenase deficiency, 3 beta - hydroxy steroid dehydro-
genase deficiency,'s and DDS require individual specific analysis. In-
ternal genital organs in various diseases had no significant
difference, pure sex hormone detection in diagnosis is unreliable
.HCG stimulation test can divid into testicular Leydig cells normal
and abnormal group, but specific disease is not easy to identify. T/
DHT have disorders identification, for the above, when there is
doubt, should take gene detection for further confirmed.
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Background: While previous studies have shown that 20–30% of
Caucasian male hypogonadotropic hypogonadism (MHH) patients har-
bored causative gene mutations, genetic backgrounds of Japanese MHH
patients have not been fully elucidated. Moreover, we do not know mu-
tation frequency in MHH patients applicable to clinical practice.
Aim: To estimate mutation frequency in Japanese male patients with
severe form of HH.
Methods: In this study, we defined MHH as male patients meeting all
of the following criteria: (i) 18 years of age or older, (ii) no spontan-
eous testicular enlargement (volume ≥ 4 mL), (iii) low luteinizing hor-
mone levels regardless of history of treatment for puberty induction
and acquisition of fertility. We enrolled Japanese MHH probands, ex-
cluding CHARGE syndrome, combined pituitary hormone deficiency,
and chromosomal abnormalities. We sequenced 32 genes implicated
in HH using the MiSeq instrument. We defined mutations as variants
Table 1 (abstract O6-5). Characteristics of 8 girls with isolated
autonomous ovarian cyst
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genic, (ii) nonsense, frameshift, or splice site variants not observed in
dbSNP, and Human genetic variation database, (iii) missense variants
not observed in databases, conserved across species, and predicted
as damaging by in silico analyses with Polyphen-2 and SIFT.
Results: Twenty male patients were included, ranging in age from 18 to
37 years, with a median age of 24 years. Nine out of 20 patients (45.0%,
95% confidence interval: 23.2–66.8%) harbored gene mutations; 4 FGFR1
, 4 KAL1 , and 1 SOX2. Oligogenic mutations were not identified.
Discussion: The proportion of detecting gene mutations in Japanese
MHH patients was relatively high compared to Caucasian MHH pa-
tients, possibly due to our strict inclusion criteria. FGFR1 and KAL1
mutations were the two leading causes in Japanese MHH patients,
which was consistent with the previous studies on Caucasian.
Conclusion: Mutation frequency in Japanese male patients with se-
vere form of HH is 45.0%.
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Backgroud: Intracranial pathology has been reported in 8% of girls and
40% of boys with central precocious puberty. So the current guidelines
recommend that all boys with central precocious puberty and girls with
central precocious puberty at under 6 years of age should have a brain
MRI. And it is controversial whether all girls who develop central preco-
cious puberty between 6 and 8 years of age require brain MRI.
Objectives: We evaluated the intracranial lesions in Korean girls and
boys with central precocious puberty.
Methods: Total 369 patients (257 girls and 112 boys) diagnosed for
central precocious puberty since 2003 at Ajou university Hospital
underwent brain MRI. The patients were categorized into group A (nor-
mal findings) and group B (the other findings). We evaluated clinical
and biochemical factors associated with precocious puberty and stud-
ied relationship between the factors and the outcome of their MRI.
Results: Group A included 238 among 257 girls (92.6%) and 105
among 112 boys (93.8%). Group B were detected in 19 among 257 girls
(7.4%) and 7 among 112 boys (6.2%). Group B consisted of pituitary
gland hyperplasia, Rathke’s cleft cyst , and pineal cyst ; 11 of 19 (4.3%),
5 of 19 (1.9%) and 4 of 19 (1.1%) in girls and 4 of 7 (4.3%), 2 of 7 (1.9%)
and 1 of 7 (0.9%) in boys. None of group B had a pathological brain le-
sion associated with central precocious puberty. Girls in group B had
higher mean basal LH levels (p 0.031) and stimulated LH levels (p
0.009) than girls in group A, and the statistical difference was particu-
larly significant in pituitary gland hyperplasia. However, there was no
statistically significant difference between two groups of boys.
Conclusions: Intracranial lesions were rare in girls and boys with central
precocious puberty unlike the previously known incidence. So brain MRI
should not be regarded as routine screening tools for evaluation of cen-
tral precocious puberty. So we think that it is necessary to discuss again
for the incidence of intracranial lesion in central precocious puberty.
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activating GNAS mutations is characterized clinically by the classic
triad of fibrous dysplasia (FD), café-au-lait skin spots, and GnRH-
independent precocious puberty (PP) due to autonomous ovarian
cyst. In a previous report, somatic activating GNAS mutations were
found in 13 (33.3%) of 39 ovarian samples from girls with isolated au-
tonomous ovarian cyst (J Clin Enocrinol Metab 2004; 89: 2107). In the
same report, a series of nested PCR and restriction enzyme digestion
detected somatic activating GNAS mutations in only 3 (7.7%) in 39
peripheral blood leucocytes (PBL) samples. We reported that next
generation sequencing (NGS) detected somatic activating GNAS mu-
tations sensitively from PBL samples in MAS (PLoS One 2013; 8:
e60525).
Objective: To determine if we could detect somatic activating GNAS
mutations in girls with isolated autonomous ovarian cyst by NGS
using PBL samples.
Method: The study included 8 girls with GnRH-independent PP due
to isolated autonomous ovarian cyst. We excluded cases with fibrous
dysplasia (FD) and/or café-au-lait skin spots, the other classic triad of
MAS. We performed both NGS and combinatory method of peptide
nucleic acids (PNA) probe with NGS (PNA-NGS) using PBL samples
from all patients.
Results: We detected somatic activating GNAS mutat ions in one
(12.5%) by NGS and 5 (62.5%) by PNA-NGS of PBL samples (Table.1).
Conclusion: The combinatory method of PNA-NGS can detect som-
atic activating GNAS mutations sensitively from PBL samples in girls
with isolated autonomous ovarian cyst. Our data suggest that som-
atic activating GNAS mutations is the major cause of isolated autono-
mous ovarian cyst.O6-6
Effects of cryptorchidism on testicular function in Chinese boys
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Objective: To investigate the effects of different types of cryptorchid-
ism on testicular Leydig-cells and Sertoli-cells function in different
ages of Chinese boys.
Methods: Included were 101 Chinese prepubertal cryptorchid boys
and 136 controls (0.5-13 years). Those who have been operated were
also included in case group(Orchiopexy is performed in 1-3yr). Each
group was divided into five subgroups: 0.5-1year (yr), 1-3yr, 3-8yr, 8-
11yr, 11-13yr. The patients were analyzed by age subgroups, unilat-
eral vs bilateral and high-position vs low-position. LHRH & hCG
stimulation tests, serum-Anti-Müllerian-Hormone(AMH) and inhibin-
B(InhB) were examined.
Results: Effects of different ages on testicular function: Compared with
other age subgroups in case group, testosterone-values after hCG
stimulation tests was significantly higher in patients 0.5-1yr(p < 0.01);
Compared with the control group, serum-AMH and InhB were signifi-
cantly lower in the cryptorchid boys (p< 0.01). Especially, AMH-values in
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significantly lower (p < 0.01). Effects of high-position vs Low-
position on testicular function: Compared with low-position
group, testosterone-values after hCG stimulation tests in high-
position group were significantly lower(p=0.007). Moreover, AMH-
values and InhB values in high-position group were respectively
significantly lower(p=0.001, p=0.012). Effects of unilateral vs bilat-
eral on testicular function: Testosterone-values after hCG stimula-
tion tests, AMH-values and InhB-values between unilateral and
bilateral groups all have no significant difference (p>0.05).
Conclusion: 1. The Sertoli-cells function is firstly affected in crypt-
orchid boys before puberty, no matter orchiopexy has been per-
formed or not, and InhB decreased earlier than AMH which occurs
during 0.5-1yr, while AMH decreased more obviously after 1yr. How-
ever, the Leydig- cells function isn't severely affected in 1yr. 2.The ef-
fects of cryptorchidism on Leydig-cells and Sertoli-cells function are
related to the issue of high or low-position, but not of unilateral or
bilateral cryptorchidism.O7-1
Excessive gestational weight gain is associated with adverse health
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Background: Excessive gestational weight gain (GWtG) has been rec-
ognized as an important early-life risk factor for childhood obesity.
We aimed to examine whether excessive GWtG was associated with
alterations in body composition and metabolism in the offspring of
primiparous mothers who participated in a randomised controlled
trial of exercise regimen during pregnancy.
Methods: Of the initial 84 women and their offspring who partici-
pated in the trial, follow-up data were available on 52 mothers with
GWtG information and their children. 35 mothers (67%) were deter-
mined to have excessive GWtG as per IOM guidelines, with the
remaining 17 mothers having GWtG in the normal range. Note that
the proportion of participants in each group that exercised during
pregnancy was similar (60% and 54%, respectively). Children under-
went clinical assessments at approximately 7.6 years, including body
composition by DXA and fasting blood tests. All statistical analyses
were adjusted for important confounders, in particular maternal BMI
at trial recruitment (approximately 20 weeks of pregnancy).
Results: Birth weight SDS was not significantly different in the off-
spring of mothers with excessive or normal GWtG, when adjusted for
maternal BMI (0.01 vs -0.23 SDS, respectively; p=0.34). Children born
to mothers with excessive GWtG had a less favourable lipid profile
with lower HDL (1.57 vs 1.75 mmol/L; p=0.038), higher triglycerides
(0.87 vs 0.63 mmol/L; p=0.003), and higher total cholesterol to HDL
ratio (3.06 vs 2.53 mmol/L; p=0.018), as well as increased abdominal
adiposity (0.64 vs 0.55 android to gynoid fat ratio; p=0.043), even
though macronutrient intake was similar in both groups. Boys born
to mothers with excessive GWtG (n=19) were heavier (weight SDS
0.82 vs -0.01; p=0.010), had higher BMI SDS (0.35 vs -0.41 SDS;
p=0.012) and greater abdominal adiposity (0.62 vs 0.45 android to
gynoid fat ratio; p=0.010) than those born to mothers with normal
GWtG (n=9). There was a small number of girls with metabolic data,
but girls born to mothers with excessive GWtG (n=9) had higher fast-
ing insulin concentrations (8.0 vs 5.4 mU/L; p=0.033) and were more
insulin resistant (HOMA-IR 1.72 vs 1.16; p=0.048) than those born to
mothers with normal GWtG (n=5), despite adjustment for body fat.
Conclusions: Independently of maternal BMI early in pregnancy, ex-
cessive gestational weight gain is associated with adverse health out-
comes in the offspring at approximately 7.6 years of age, with some
indication of sex-dependent effects.O7-2
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Background: Healthy weight children tend to increase their weight
during winter and decrease weight gain during summer. In contrast,
accelerated summer weight gain has been observed among elemen-
tary overweight children. It is of great concern whether this seasonal
variation occurs during preschool childhood. However, few studies
examined growth seasonality during preschool childhood, and stud-
ies using longitudinal data are scarce.
Methods: The study population was derived from the nationwide
retrospective cohort of nursery school children born from April 2,
2004, to April 1, 2005. We could gather ten consecutive longitudinal
data of 15,259 children on height and weight measured in April and
October from 2006 to 2010. With these data, we calculated six-
month growth of these children in height, weight, and body mass
index (BMI). Growth from April to October was defined as the sum-
mer period growth, while that from October to next April as the win-
ter period growth. We analyzed longitudinal seasonal variation of
nursery school children by classifying children into six groups accord-
ing to the standard deviation score (SDS) of the last measurement
just before they entered an elementary school (i.e. <-2SD, -2SD~
-1SD, -1SD~ 0SD, 0SD ~ +1SD, +1SD ~ +2SD, +2SD).
Results: Distinctive seasonal growth variation in weight and BMI was
detected in the two groups of children with one or more than one
BMI SDS (figure). They had accelerated summer weight and BMI
gains and they could be detected from 2007 (p<0.0001). Notably,
they had begun since less than three years of age in children with
two or more than two BMI SDS. On the other hand, such growth sea-
sonality was not observed in height.
Conclusions: Seasonal growth variation in weight and BMI was de-
tected in relatively overweight preschool children during infancy.
These findings suggested that we should be careful of summer time
weight gain even in infancy for preventing the future obesity.
O7-3
Oleate protects INS1 cells from palmitate-induced apoptosis by
down-regulating ER stress and GSK3βthrought Stearoyl- CoA
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Backgroud: The loss of functional β -cell mass, at least in part sec-
ondary to increased β -cell apoptosis, is increasingly recognized as
one of the main contributing factors to the pathogenesis of type 2
diabetes. Our previous study have identified that endoplasmic
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-cell apoptosis (lipotoxicity). However, the effect of oleate on β -cell
is still controversial.
Objective: The present study investigated whether oleate protected β
-cell from palmitate-induced apoptosis and its molecular mechanisms.
Methods: INS1 cells were cultured with varying concentrations of
palmitate, oleate, TO-901317 or co-treatment of palmitate with either
oleate or TO-901317. Cell viability and apoptosis were measured by
CCK-8 assay, Hoechst 33342 / PI, flow cytometric assay and electron
microscopy; ER stress and GSK3 β activity were assessed by RT-PCR
and western blot. We also estimated intracellular triglyceride accu-
mulation through nile red staining and electron microscopy.
Results: Contrary to lipotoxicity of palmitate, 0.25~0.5 mM oleate in-
creased INS1 cells viability (p <0.05). Interesting, we identified that
oleate rather than palmitate induced a significant intracellular trigly-
ceride accumulation (p <0.05). Furthermore, co-treatment of oleate
with palmitate apparently decreased palmitate-induced apoptosis by
down-regulating ER stress and GSK3 β activity (p <0.05), Besides, we
also found that the mRNA level of Stearoyl-CoA Desaturase 1 (SCD1)
was up-regulated (p <0.05). Finally, co-treatment of Palmitate with
LXR- agonist TO-901317, which directly up-regulated SCD1, also
leaded to intracellular triglyceride accumulation and the reduction of
ER stress and GSK3 β activity.
Conclusion: Oleate protected INS1 cells from palmitate-induced
apoptosis by down-regulating ER stress and GSK3 β activity throught
promotion of appropriate triglyceride accumulation , which related
to the up-regulation of SCD1.
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Introduction: Childhood obesity is routinely described as a major
problem in developed and developing countries. Obesity in child-
hood is causative for many chronic diseases, including type 2 dia-
betes, cardiovascular disease and hypertension. Once obesity is
present, it is challenging to treat because of multiple physiological,
behavioral, and cultural feedback loops. Prevention is the key to suc-
cess in obesity control, but there is no effective method for screening
for high risk cases. Therefore, this study was performed to develop a
method for detection of a high risk of childhood obesity.
Methods: A total of 298 children in a birth cohort (town F, Tochigi,
Japan) were enrolled in the study. The population of this town is
18,000, with half of the people working as farmers and half commut-
ing to nearby large cities. Children in the study were followed up in
infant health checks at a health center during the preschool period,
and data were stored at a regional health center. At 12 years of age,
measurement of height and weight were performed at school.
Children at this age with body mass index (BMI) ≥ 95th percentile
and ≥ 85th percentile according to national reference data for height
and weight were diagnosed as obese and overweight, respectively.
Several screening methods focusing on relationships with BMI at 1.5
and 3 years old were examined by computing the odds ratio for each
method in multivariate analysis. The study was approved by the eth-
ics committee of Dokkyo Medical University.
Results: Data were available for 215 children. The odds ratios for
obesity and an overweight status at 12 years old were 18.9 (95%
confidence interval 5.9-60.8, predictive accuracy 0.92) and 16.9 (5.1-
55.9, 0.84), respectively, for a BMI increase 0.5 from 1.5 to 3 years
and BMI 16.8 at 3 years; 3.1 (1.2-8.2, 0.70) and 2.4 (1.2-4.9, 0.68), re-
spectively, for a BMI increase from 1.5 to 3 years; and 5.8 (2.1-16.0,
0.84) and 3.6 (1.6-8.2, 0.78) for a BMI increase 0.5 from 1.5 to 3 years.Discussion: The current study is the first to show that children with
both an increase of BMI 0.5 from 1.5 to 3 years old and BMI 16.8 at 3
years old are at high risk of later childhood obesity or an overweight
status. Identification of individuals at 3 years old who are at high risk
for obesity later in life may provide opportunities for early
interventions.
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Background: Cardiovascular disease as a result of atherosclerosis is
the major complication among children with type 1 diabetes mellitus
(T1DM). The aim of this prospective study was toexamining the pres-
ence of cardiovascular risk factors in children with T1DM.
Methods: We evaluated several cardiovascular risk factorsincluding
atherosclerosis, artery intima-media thickness(IMT) and metabolic
responsesin 122 (66 female) diabetic children (age median 12.6 ± 2.7
years, mean HbA1c of 7.9 ± 1.1%) with T1DM, and 105 non-diabetic
children (age median 12.5 ± 2.8 years) were enrolled as normal
controls.
Results: The diabetic children had significantly higher carotid intima-
media thickness (cIMT) and aorticIMT (aIMT) than the controls, mean-
while, the diabetic patientsalso had significantly higher values than
the controls for diastolic wall stress (DWS), incremental elastic modu-
lus (IEM) and for flow mediated dilatation (FMD). Tumor necrosis fac-
tor- α (TNF- α), Interleukin -4 (IL-4), high-sensitivity C-reactive protein
(hs-CRP) and leptin were all significantly greater as compared to
T1DM and controls. The difference was not significant between pa-
tients and controls for othercardiovascular risk factors.In children
with T1DM, cIMTandaIMTwere both correlated with several risk fac-
tors includingage, weight, body mass index (BMI), duration of diabe-
tes,waist/hip ratio, total cholesterol, triglyceridesand apolipoprotein
B, in addition to common risk factors, cIMTwas also associated with
systolic blood pressure (BP). Inflammatory factor TNF- α was just de-
pendently associated with weight, duration of diabetes, total choles-
terol, triglycerides and apolipoprotein B. Other risk factors such as
height, diastolic BP, LDL/HDL-cholesterol, apolipoproteinA TandS-
creatinine level were all not independent risk factors ofcardiovascular
diseasein T1DMchildren.
Conclusions: Our results suggested that children patients with T1DM
are associated with early impairment of the common carotid and
aortic artery structure and function and that diabetic state may be
the main risk factor for artery wall stiffening and thickening, which
are of considerable concern as possible early events in the genesis of
atheroma.
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Objective: FTo explore if the the change of the expression of FTO
regulate the PI3K and MAPK pathways, and finally destroy the endo-
thelial function.
Methods: Using RNA interference technology to build FTO-shRNA
lentivirus vector, infect HUVEC cells to silence the FTO gene and to
up-regulate the expression of FTO, then use Western Blot to prove
the effect. To detect the phosphorylation levels of ERK1/2, Akt CS6K1
and eNOS, NO level was detected by nitrate reductase method.
Results: Recombinant plasmid was constructed successfully. Silence of
the FTO gene leads to the phosphorylation level decreasing of Akt,
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results to PI3K and MAPK pathway activated, Akt and eNOS, ERK1/2,
S6K1 phosphorylation levels increased and NO synthesis more.
Conclusion: FTO expression can regulate PI3K and MAPK pathway,
suggesting that PI3K-Akt-eNOS pathway and ERK/MAPK pathway play
an important role in endothelial injury leadsby obesity, providing
new direction for research on Mechanism of cardiovascular function
destroy results by obesity.Fig. 1 (abstract O8-2). See text for descriptionO8-1
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Background: Hypophosphatasia (HPP) is a rare skeletal disease
caused by mutations in the gene coding the tissue-nonspecific
alkaline phosphatase (TNSALP). The most severe type of HPP is
often associated with respiratory failure due to the defect of
calcification. Other types of HPP also have many complications
including failure-to-thrive, hypercalcemia, premature loss of teeth
and bone deformity. Recently, an enzyme replacement therapy
using Asfotase Alfa (AA), a bone-targeted recombinant human
TNSALP, has been developed to ameliorate the complications of
HPP.
Methods: In an open-label, single-arm, multi-centered clinical
study, we evaluated the safety and efficacy of treatment with AA
in patients with HPP. We assessed the safety of repeated sub-
cutaneous injections of AA as primary outcome measures along
with the number of adverse events (AEs) including injection reac-
tions. Efficacy assessments as secondary outcome measures in-
cluded overall survival, respiratory status, rickets severity, physical
growth, and gross motor development.
Results: Thirteen patients, 9 females and 4 males, were enrolled
in this study; they ranged in age at baseline from day 0 to 34
years. Six patients had perinatal form, five had infantile form, one
had childhood form, and one had adult form. Total 195 AEs
reported, and the most frequent were injection site reactions
(45%). Serious AEs that possibly related to the treatment were
convulsion and hypocalcemia observed in the patients of prenatal
type. In contrast, hypercalcemia and/or hyperphosphatemia were
also observed in 3 patients of infantile form, and low calcium
and/or low phosphorus formula started to these patients. As the
efficacy of the treatment, all the patients survived. While total 8
patients required some forms of respiratory support at the base-
line, 5 of them were free from respiratory support including oxy-
gen supply at the end of the study. Baseline radiographs in all the
patients except 2 patients with closed growth plate showed undermi-
neralized metaphyses observed as hypophosphatasia-associated skel-
etal lesions. Mineralization was gradually improving with all thepatients. Gross motor milestone was evaluated in 10 infants. Develop-
mental milestones were also improved after the treatment.
Conclusions: The clinical trial revealed the improvement of skel-
etal, respiratory, and physical symptoms in patients with HPP by
AA. Careful monitoring of serum calcium and phosphate levels is
necessary because hypocalcemia, hypercalcemia, and hyperpho-
sphatemia may occur. (ClinicalTrials.gov number, NCT02456038;
UMIN CTR number, UMIN000014816).O8-2
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Spondyloepimetaphyseal dysplasias (SEMDs) comprise a heteroge-
neous group of autosomal-dominant and autosomal-recessive dis-
orders. An apparent X-linked recessive (XLR) form of SEMD in a
single Italian family was previously reported.We have been able
to restudy this family together with a second family from Korea
by segregating a severe SEMD in an X-linked pattern. Exome
sequencing showed missense mutations in BGN c.439A>G
(p.Lys147Glu) in the Korean family and c.776G>T (p.Gly259Val) in
the Italian family; the c.439A>G (p.Lys147Glu) mutation was also
identified in a further simplex SEMD case from India. Biglycan is
an extracellular matrix proteoglycan that can bind transforming
growth factor beta (TGF-b) and thus regulate its free concentra-
tion. In 3-dimensional simulation, both altered residues localized
to the concave arc of leucine-rich repeat domains of biglycan
that interact with TGF-b. The observation of recurrent BGN muta-
tions in XLR SEMD individuals from different ethnic backgrounds
allows us to define “XLR SEMD, BGN type” as a nosologic entity.
Table 1 (abstract O8-2). Clinical Findings of the Affected Individuals
with XLR SEMD BGN Type
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Many countries recommend daily infant vitamin D supplementation
during breast feeding, but compliance is often poor. A monthly, high
dose maternal regimen may offer an alternative strategy for dual ma-
ternal and infant supplementation, but its efficacy is unknown.
In a New Zealand population not offered routine vitamin D supple-
mentation, we aimed to determine the effect of two different
monthly maternal doses of cholecalciferol (D3) on both maternal and
infant 25-hydroxyvitamin D (25[OH]D) status during the first 5
months of breastfeeding.
Using a randomized, double blind, placebo-controlled design, breast-
feeding women (n=90, mean age 32.1 years) were assigned to re-
ceive either placebo, 50,000 IU, or 100,000 IU of D3 /mo from Week
4 to Week 20 postpartum. Change in maternal and infant serum
25(OH)D from baseline to week 20 was calculated for each group
and analysed using ANCOVA.
At 20 weeks, changes in maternal serum 25(OH)D were signifi-
cantly greater in those assigned to D3 versus placebo (P<0.05),
mean ± SD 17.3 ± 32.7, 30.2 ± 25.9, and 40 ± 29.3 nmol/L in the
placebo, 50,000 IU, and 100,000 IU groups, respectively. Mean
changes in infant serum 25(OH)D were 37.4 ± 51.9, 44.7 ± 44.7,
and 52.8 ± 46.4 nmol/L in the placebo, 50,000 IU, and 100,000 IU
groups respectively; however, these were not significantly differ-
ent between groups (p>0.1). After adjustment for season of birth,
vitamin D-fortified formula intake, and infant skin colour, the ef-
fect size for the 100,000 IU group was 19.1 nmol/L (95% CI 2.5
to 35.6; p=0.025) higher compared to placebo. For infants, mater-
nal D3 supplementation at a dose of 100,000 IU /mo during the
first 5 months of breastfeeding potentially benefits vitamin D sta-
tus. While attractive from a compliance perspective, further stud-
ies are required to determine optimum dose and dosing
frequency before this type of strategy is recommended as an al-
ternative to daily infant supplementation.
O8-4
Establishment of a human growth plate model with iPS
cell-derived cartilage
Takeshi Kimura1,2, Kie Yasuda1, Yoko Miyoshi1, Akihiro Yamashita2,
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):O8-4Background: Endochondral ossification in the growth plate cartilage
(GPC) determines the future length and shape of long bones. Several
skeletal dysplasias cause growth plate dysfunction and result in se-
vere short stature. There have been many studies on mice GPC func-
tion and development, but little is known about human GPC. We
have already reported that human iPS cell-derived cartilage (hiPSC-
Cart), when implanted into the subcutaneous spaces of the SCID
mice for one year, formed skeleton composed of epiphyseal cartil-
age- and diaphyseal bone-like structure.
Aim: The aim of this study is to establish a practical hiPSC-GPC
model for investigation about human growth and disease modeling.
Method: We used four hiPSC lines derived from healthy control and
patients with skeletal dysplasias (thanatopholic dysplasia, achondro-
plasia and hypochondroplasia). hiPSC-Carts were transplanted into
the subcutaneous space of SCID mice at various ages. Their ossifica-
tion was observed with X-ray images over time and evaluated
histologically.
Result: Histological analysis showed that transplanted hiPSC-Carts
have a zonal arrangement similar to GPC, and type X collagen, a spe-
cific marker of hypertrophic chondrocytes, is positive in the transition
between cartilage and bone. Furthermore, the ossification of hiPSC-
Carts is promoted in younger mice. For example, GPC-like structures
are formed 4 weeks after transplantation into 4 weeks-old mice. Epi-
physeal cartilage-like structures express human vimentin, but other
skeletal components do not. These results collectively suggest that
endochondral ossification of hiPSC-Carts depends on regulation in-
side the host. Interestingly, we observed abnormal GPC-like struc-
tures in the patient- specific iPSC-Carts. The hypertrophic zones of
these disease models showed irregular structures and cell sizes that
were smaller than healthy control samples. These changes reflected
the severity of the original diseases.
Conclusion: We have established an in vivo hiPSC-GPC model. The
model likely contributes to further investigation for human growth.O8-5
Vitamin D Deficiency and its Relationship with Cardiac Iron and
Function in Patients with Transfusion-Dependent Thalassemia at
Chiang Mai University Hospital
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Background: Vitamin D deficiency (VDD) is common in patients with
thalassemia. There were conflicting findings on relationship between
VDD and cardiac iron. Previous study reported that VDD may be as-
sociated with iron-related cardiomyopathy plausible linking L-type
calcium channel activity to cardiac iron loading in these patients.
Chronic heart failure was also well described in VDD. Parathyroid hor-
mone (PTH) was positively correlated to cardiac iron in patients with
thalassemia. However, a recent study was unable to identify the asso-
ciation between vitamin D and cardiac iron.
Objectives: We aim to determine the prevalence of VDD and to ex-
plore the impact of VDD on cardiac iron and cardiac function in pa-
tients with transfusion-dependent thalassemia (TDT).
Method: A prospective cohort study in patients with TDT (>12 trans-
fusions/year), aged 8-25 years, who were followed at Chiang Mai Uni-
versity Hospital during Sep 2013-March 2015 was conducted.
Patients with liver disease, renal disease, type 1 diabetes, malabsorp-
tion, hypercortisolism, malignancy, and contraindication for magnetic
resonance imaging (MRI), were excluded. Calcium, phosphate, alka-
line phosphatase (ALP), parathyroid hormone (PTH), 25-hydroxy vita-
min D (25(OH)D) were measured. The mean hemoglobin level in the
year preceding the study was calculated. Additionally, cardiac iron
(cardiac T2*) was determined by MRI, and left ventricular ejection
fraction (LVEF) was evaluated by echocardiography.
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prevalence of VDD was 50.8% (31/61). The mean hemoglobin in the
last 12 months and the mean ferritin during the past 5 years were
significantly correlated with 25(OH)D level (p=0.026 and p=0.026, re-
spectively). Patients with severe cardiac iron deposition (T2* ≤ 20 ms)
had tendency lower 25(OH)D than those with cardiac T2*>20 ms
(15.5 ± 4.7 vs 20.7 ± 7.0; p=0.065). The medians (ranges) of 25(OH)D
level were 15.4 (7.9-19.8) and 21.9 (20.2-48.6) ng/mL in VDD and
non- VDD group, respectively. Sex, age, serum calcium, phosphate,
ALP, PTH, liver iron concentration, cardiac T2*, and LVEF were not
statistically different between the groups with or without VDD. Pa-
tients with VDD had significantly lower hemoglobin levels as com-
pared to those without VDD (7.6 ± 0.9 vs 8.1 ± 0.9; p=0.043).
Conclusion: VDD is prevalent in patients with TDT and is correlated
with hemoglobin level. The correlations of VDD to cardiac iron up-
take and function are warranted in the large population with TDT.
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Background: Heterozygous loss-of-function mutations of FGFR1 are
known to cause multiple disorders including congenital hypogonado-
tropic hypogonadism (CHH), CHH with anosmia/hyposmia (Kallmann
syndrome, KS), and CHH with split-hand/foot malformation (CHH-
SHFM), with variable expressivity and penetrance.
Objective: The objective of this study was to examine FGFR1 in four
Japanese patients with CHH-SHFM.
Patients: This study consisted of four Japanese patients (cases 1–4) with
CHH-SHFM. Case 1 was a 3-month-old boy with micropenis, undetectable
serum LH and testosterone at mini-puberty, and right split hand. Case 2
was a 17-year-old boy with no pubertal development, undetectable serum
LH and testosterone, and bilateral split hands and feet. Case 3 was a 34-
year-old female with primary amenorrhea, low serum LH (0.4 mIU/mL)
and undetectable serum E2, and left split hand. Case 4 was a 2-month-old
boy with micropenis, undetectable serum LH and testosterone at mini-
puberty, bilateral split hands and feet, and cleft lip and palate.
Results: Direct sequencing identified two heterozygous missense mu-
tations (p.G97S in case 1 and p.R744T in case 2) and a heterozygous
splice donor site mutation (IVS12+1G>T in case 3). The two missense
mutations had drastically reduced luciferase activities, without a
dominant negative effect. The splice donor site mutation yielded a
small amount of mRNA skipping exon 12; in addition, it was pre-
dicted to produce two different types of aberrant mRNAs satifying
the condition for nonsense-mediated mRNA decay by in silico ana-
lysis. In case 4, although no mutation wasfound on the coding exons
2-18, a microdeletion around non-coding exon 1 was revealed by
MLPA analysis. This microdeletion was localized to a roughly 7.2-12.7
kb region by array CGH analysis, and was determined to be 8,312 bp
long by direct sequencing for a PCR product obtained with primers
flanking the microdeletion. Quantitative real time PCR analysis using
primers for exons 8 and 9 indcated roughly halved FGFR1 expression
in immortalized lymphoblastoid cells. In silico analysis indicated the
presence of promoter-compatible H3K4Me3 marks and CpG sites
around exon 1, and luciferase assays using various genomic frag-
ments around exon 1 showed high transactivation function for a 470bp segment encompassing the 5’ part and the just upstream region
of exon 1.
Conclusion: The results are consistent with heterozygous loss-of-
function mutations of FGFR1 being relevant to the development of
CHH- SHFM, and indicates the presence of the FGFR1 promoter
around non-coding exon 1.
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Background: Along with the improvement of cancer treatments, the
number of childhood cancer survivors (CCSs) is increasing. Together
with this, long-term endocrine complications such as gonadal dys-
function are gathering more attention. Anti-Mullerian hormone
(AMH) implies ovarian function in female. However, the clinical utility
of AMH on evaluation of gonadal function in children and adolescent
of CCSs is not well established.
Objective: To investigate the relationship between AMH concentra-
tion and gonadotropin (Gn) level in female CCSs and to investigate
its usefulness in evaluation of gonadal function.
Subjects & Method: Thirty-nine samples of 30 female CCSs (aged 0-
18) were involved in this study. We retrospectively analyzed the data
of AMH and baseline Gns and/or Gn levels after LHRH stimulation
test, obtained from June 2012 to June 2016 in our center. AMH was
measured by ELISA and Gns were measured by CLIA.
Result: Mean age at diagnosis for primary cancer was 6.6 ± 5.2 years
old and mean age at measurement of AMH was 8.9 ± 5.5 years old. All
the samples were obtained after treatments for cancer were conducted,
16 samples were within 1 year and 23 samples were beyond 1 year
from the treatment. Primary cancers were 3 brain tumors, 14 solid tu-
mors other than brain and 13 hematologic cancers. Data measured
under hormone replacement therapy was excluded. Mean AMH levels
of 13 samples in 12 cases with age < 6 years old was 0.7 ± 2.2ng/ ml, 8
samples in 4 cases with age >6 years old and prepuberty was < 0.1ng/
ml, and 18 samples in 14 cases with puberty was 1.8 ± 3.4ng/ ml. There
was no statistically significant association between AMH concentration
and gonadotropin levels throughout all age group. However, Gn levels
in pubertal cases with undetectable AMH level (< 0.10 ng/ml) were re-
markably high when compared with pubertal cases with detectable
AMH ( ≥ 0.10 ng/ml). Mean baseline LH level (n=9) was 30.4 ± 34.7
mIU/ml, mean peak LH level (n=5) was 86.9 ± 61.4 mIU/ml, mean base-
line'sH level (n=9) was 52.7 ± 42.5 mIU/ml and mean peak'sH level
(n=5) was 401.1 ± 708.2 mIU/ml in cases with undetectable AMH. In
contrast, mean baseline LH level (n=9) was 1.8 ± 1.7 mIU/ml, mean
peak LH level (n=3) was 1.1 ± 1.3 mIU/ml, mean baseline'sH level (n=9)
was 3.1 ± 1.7 mIU/ml and mean peak'sH level (n=3) was 6.6 ± 5.7 mIU/
ml in cases with detectable AMH.
Conclusion: Undetectably low AMH in pubertal female CCSs is associ-
ated high Gn levels and may indicate primary hypogonadism.
O9-3
Genetic diagnosis of 8 lipoatrophy patients in one single center via
whole exome sequencing
Jia-tong Hou, Shi-yao Wang, Lin-jie Wang, Hong-bo Yang,
Hua-bing Zhang, Feng-ying Gong, Hui Pan, Hui-juan Zhu
Department of Endocrinology, Key Laboratory of Endocrinology of
Ministry of Health CPeking Union Medical College Hospital, Chinese
Academy of Medical Sciences & Peking Union Medical College
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):O9-3
Background: Lipoatrophy is a group of rare diseases characterized by
lacking subcutaneous adipose tissue. It is agreed that lipoatrophy is
closely associated with various genetic variations. Despite lots of
genes had been defined as causal genes in many types of genetic
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patients with distinctive phenotypes remain unclear.
Methods: Eight patients with adolescent-onset lipoatrophy features
were recruited from Department of Endocrinology, Peking Union
Medical College Hospital. Clinical and biochemical parameters of the
patients are collected in details. Whole exome sequencing was per-
formed in all 8 patients, aiming to identify the potential gene muta-
tions linked with their lipoatrophy manifestations.
Results: All the patients had generalized fat loss and thin mottled
skin from the adolescent period. Two of them had progeroid fea-
tures. Clinical features of the patients were as follows: fasting insulin
(43.93 ± 7.66) μIU/ml, fasting glucose (5.7 ± 2.9) mmol/l, glycosylated
hemoglobin (6.1 ± 0.8)%; triglycerides (3.57 ± 1.40) mmol/l, total
cholesterol (4.31 ± 0.99) mmol/l, low-density lipoprotein cholesterol
(2.52 ± 0.60) mmol/l, high density lipoprotein cholesterol (0.87 ±
0.25) mmol/l, body fat rate (28.6 ± 9.0)%. With whole-exome sequen-
cing, we identified one POLD1 mutation (c.1812_1814delCTC,
p.Ser605del) in two patients, one WRN mutation (c.3020delG,
p.Gly1007Alafs*16) in one patient, one CIDEC mutation(c.686C>T,
p.Thr229Met) in one patient, two INSR mutations(c.4028G>A,
p.Arg1343Gln and c.1534A>G, p.Ile512Val) in two patients, and two
LMNA mutations(c.898G>C, p.Asp300His and c.29C>T, p.Thr10Ile) in
two patients. While one patient showed no genetic variations.
Conclusions: Through whole-exome sequencing, eight gene muta-
tions probably linked with lipoatrophy were detected. All gene muta-
tions detected could cause different subtypes of lipodystrophy.
When patients reveal lipoatrophy and progeroid features from the
adolescent period, the diagnosis of lipoatrophy should be taken into
consideration. Our study expanded the spectrum of clinical manifes-
tations and genetic variations of lipodystrophy. Like all previously re-
ported patients, these cases were diagnosed with whole exome
sequencing, highlighting the clinical utility of next generation se-
quencing in the diagnosis of rare, complex disorders.
Key words: Lipodystrophy, whole exome sequencing, genetics, diagnosis
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Background: Congenital adrenal hyperplasia (CAH), mostly caused by
21-hydroxylase deficiency, is autosomal recessive disorder character-
ized by impaired cortisol synthesis. It can be presented with a com-
bination of aldosterone and cortisol deficiency and androgen excess.
Therefore, excess production of androgen and glucocorticoid re-
placement can result to early bone maturation and ultimately dimin-
ished adult height (AH).
Objectives: The purpose of this study was to obtain objective data
on AH with classic CAH patients and analyze the affecting factors on
AH. Also we evaluated growth pattern during age increase.
Study design: We retrospectively reviewed the longitudinal medical re-
cords of 40 children with classic CAH (male [n=19]: 9 salt-wasting (SW),
10 simple-virilizing (SV); female [n=21]: 8 SW, 13 SV) who reached AH at
Pediatric endocrinology clinic of Severance hospital from 1977 to 2015.
We also analyzed the affecting factors on AH, and assessed growth pat-
terns with serial height standard deviation score (SDS) dividing into fol-
lowing stages of growth: early childhood (0-4.99 years), mid-childhood
(5-9.99 years), and adolescence (10-15 years).
Results: AH (162.7 ± 9.72 cm) was significantly shorter than the mid-
parental height (MPH) (172.5 ± 3.40 cm) in male patients (P <0.001),
and similarly, AH (154.5 ± 6.45 cm) was significantly shorter than the
MPH (158.7 ± 2.96) in female patients (P =0.002). Accordingly, the AH
SDS was meaningfully lower than the MPH SDS in both sex
(males: P <0.001, females: P =0.002). Considering subtypes, SVhad tendency to attain shorter AH than SW. In addition, the af-
fecting factors on AH were analyzed that they were not signifi-
cantly associated with subtype, age at diagnosis, dose of steroid,
except MPH. Height SDS for chronologic age showed gradual
decrement during childhood to adolescence (males: 0.5 ± 2.51 at
early childhood, 0.8 ± 2.26 at mid-childhood, 0.2 ± 1.62 at ado-
lescence; females: -0.4 ± 1.40, -0.2 ± 2.01, -0.3 ± 1.42 at those
same periods). The final AH SDS was -1.6 ± 1.98 in males and
-0.81 ± 1.45 in females.
Conclusion: Reduced AH was observed in children with classic CAH
compared with their given parental height, regardless of sex and
subtype. Furthermore, the height SDS tended to decrease in accord-
ance with age increase, so this finding suggests that proper interven-
tion about growth assessment is needed in children with CAH.
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Background: The relationship between long-term growth response
in GHD and pre-treatment whole genome gene expression (GE) as
an integrated biomarker of the consequences of being GHD has
never been explored. Prediction of long-term response to r-hGH ther-
apy would allow better decision making about start and mainten-
ance doses and hence cost:benefit.
Objective and hypotheses: To assess the relationship of pre-
treatment GE to growth response on r-hGH in GHD children over five
years of therapy.
Method: Pre-pubertal children with GHD (n=50) were enrolled from
the PREDICT studies (NCT00256126 and NCT00699855). Affymetrix
U133 plus 2.0 microarrays, analysed using Gene Expression Barcode
3.01, were used to determine whole blood GE prior to treatment.
Growth response to r-hGH treatment was determined using Height
velocity (HV) over the five years of therapy. Two groups of patients
were defined by assessing growth response over the five years of
treatment, (G1) always above and (G2) always below the median. The
effect of gender, age and distance to target height (DTH) on GE were
accounted for as covariates. Network models of gene expression and
random forest analysis, a machine learning analytical technique, were
used to relate GE to growth response using area under the curve
(AUC) of the receiver operating characteristic. The robustness of GE
markers was assessed using permutation testing (n=1000).
Results: There was no difference in gender, age and DTH (p>0.05)
between the HV groups (G1 and G2) at the start of treatment. Base-
line GE could predict growth response consistently above and below
the median over five years with an AUC of 0.86 and 0.89 respectively.
These observations were confirmed by permutation analysis. Genes
were identified (p<1x10-5) unique to G1 patients (n=69) or to G2 pa-
tients (n=72). Network models of GE prioritised 94 of these 141
genes. PIK3R1 gene expression (p=1.2x10-9), associated with cell pro-
liferation and known to be activated by GH, was related to G1.
DDX58 gene expression (p=2.2x10-10), associated with RNA second-
ary structure, was related to G2.
Conclusion: In pre-treatment GHD we have identified gene expres-
sion associated with growth response over five years of therapy. Fur-
ther assessment to determine predictive value and functional
significance of gene subsets is required.
Reference
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We have revealed that ESR1 encoding estrogen receptor a carries a ~ 50
kb linkage disequilibrium (LD) block in its 5’ region, and that a specific
“AGATA” haplotype markedly raises the susceptibility to the development
of male genital abnormalities by estrogenic endocrine disruptors (EEDs) in
Japanese population. Here, we report further evidence for the involvement
of the specific “AGATA” haplotype in the susceptibility to EEDs.
Identification of a 2,244 bp microdeletion in an absolute linkage dis-
equilibrium with the specific “AGATA” haplotype We sequenced the
region encompassing the LD block in two homozygotes for the spe-
cific haplotype and two subjects without this haplotype, and found a
2,244 bp microdeletion within intron 6 of the ESR1 gene in the ho-
mozygotes only. Subsequent analysis in Japanese subjects including
35 homozygotes and 151 heterozygotes for the “AGATA” haplotype
and 188 subjects lacking this haplotype demonstrated an “absolute
LD” between this microdeletion and the “AGATA” haplotype.
Examination of the ESR1 haplotype and the microdeletion in Italian popu-
lation Next, we studied Italian boys with hypospadias (n=13) and crypt-
orchidism (n=80), and Italian control boys (n=150). The same LD block and
the same four major haplotypes as in Japanese population were identified,
and the “AGATA” haplotype was significantly associated with the external
genital abnormalities as well. Furthermore, a nearly complete absolute LD
was identified between the microdeletion and the specific haplotype, ex-
cept for two subjects. This argues that in Italian population, the same gen-
etic susceptibility factor is also involved in the development of male
external genital abnormalities.
Comparison of the frequency of the mictodeletion between affected
subjects and normal controls The frequency of the microdeletion al-
lele was significantly higher in all groups of affected subjects. Conse-
quent genotype analysis indicated that the frequency of the
miclodeletion homozygotes was significantly higher in the Japanese
HS (17.94%) than in the control boys (3.26%) as well as in Italian
population (HS+CO; 3.23%, control boys; 0.67%). Comparison of the
frequency of the susceptibility factor between different generations
We compared the frequency of the normal homozygotes or hetero-
zygotes for the susceptibility factors between the two generations.
The frequency of the homozygotes/heterozygotes of the microdele-
tion was significantly lower in the normal child (39/98) than in the
normal adult (167/311). This implies of that male subjects carrying
the microdeletion are more susceptible to have genital abnormalities
under the elevated levels of the EEDs.
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(T1DM) has been greatly changing by common use of insulin analog
and continuous subcutaneous insulin infusion (CSII). We investigated
current status and trends in use of insulin analog for Japanese
children and adolescents with T1DM and its association with
glycemic control.
Subjects: The study subjects consisted of 1090 patients, 449 males
and 641 females (79 patients; 0-5 years of age, 280 ; 6-10 years of
age, 731 : 11-19 years of age) enrolled in 4th cohort of JSGIT (from
1st to 3rd period: March 2013 to February 2014).
Results and Discussion: Almost all patients were being treated with
multiple daily injections (MDI) or CSII. The proportion of CSII in-
creased (MDI vs CSII; 71.8% vs 23.4%, respectively at 1st period to
69.8% vs 25.8%, respectively at 3rd period), especially in 0-5 years of
age. Within patients with MDI, use of frequent injections with more
than 5 times a day increased. On the other hand, use of twice basal
injections decreased, suggesting that use of frequent bolus injections
adapted to lifestyle were increasing. The most frequently used basal
insulin was Glargine (G), followed by Detemir (D) and Degludec (T).
However, G and D decreased (G: 529 patients at 1st period to 424 at
3rd period, D: 217 to 163), whereas T increased (34 to 123). The most
frequently used bolus insulin was Aspart (A), followed by Lispro (L)
and Glulisine (AP). The most frequently used insulin in CSII was A,
followed by L and AP. In terms of bolus and CSII, trends are similar
during this period. The most frequently used basal-bolus combin-
ation was G-A, followed by D-A. However, both combinations de-
creased (G-A: 397 to 312, D-A: 201 to 150), whereas T-A increased (25
to 96). The median hemoglobin A1c (HbA1c) in patients using each
insulin analog and combination were 8.0%(G), 8.0%(D), 8.2%(T),
8.0%(A), 8.0%(L), 8.2%(AP), 7.9%(CSII-A), 8.2%(CSII-L), 7.6%(CSII-AP),
8.0 %( G-A), 7.8 %( G-L), 8.1 %( G-AP), 8.0%( D-A), 7.7 %( D-L), 7.6 %(
D-AP), 8.2 %( T-A), 8.6 %( T-L), 8.4 %( T-AP). Among patients using
any insulin analog for basal and CSII, patients using T and CSII-L had
significantly higher levels of HbA1c. On the other hand, there was no
difference among any bolus, CSII, and basal- bolus combinations.
These findings are the result from database of 1st year in this cohort.
Continuous investigation is needed under longer- term use.P1-1-2
Next-generation sequencing-based screening of monogenic
mutations in 43 Japanese children clinically diagnosed with type
1B diabetes
Kikumi Ushijima1, Maki Fukami1, Tadayuki Ayabe1, Misako Okuno1,2,
Satoshi Narumi1, Tsutomu Ogata3, Nobuyuki Kikuchi4,
Tomoyuki Kawamura5, Tatsuhiko Urakami2, Ichiro Yokota6,
Shin Amemiya7, Shigetaka Sugihara8
1Department of Molecular Endocrinology, National Research Institute for
Child Health and Development; 2Department of Pediatrics and Child
Health, Nihon University School of Medicine; 3Department of Pediatric,
Hamamatsu University School of Medicine; 4Department of Pediatric,
Yokohama City Minato Red Cross Hospital; 5Department of Pediatric,
Osaka City University School of Medicine; 6Division of Pediatric
Endocrinology and Metabolism, Shikoku Medical Center for Children and
Adults, Department of Pediatric; 7Department of Pediatric, Saitama
Medical University Faculty of Medicine; 8Department of Pediatric, Tokyo
Women's Medical University Medical Center East
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-1-2
Background: Diabetes mellitus is classified into type 1 (T1D), type 2,
other specific types, and gestational diabetes. T1D lacking diabetes-
associated autoantibodies are termed as type 1B (T1BD). The group
of “other specific types of diabetes mellitus” includes monogenic dia-
betes such as neonatal diabetes and maturity-onset diabetes of the
young caused by genetic defects in the insulin secretion pathway.
Because clinical characteristics of those monogenic forms and T1BD
are partially overlapping, children with monogenic diabetes could be
clinically diagnosed with T1BD, especially during childhood.
Objectives: The objectives of this study was to clarify the prevalence
and clinical consequences of monogenic mutations in Japanese chil-
dren clinically diagnosed with T1BD.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 39 of 144Methods: We studied 43 Japanese children from 42 families diag-
nosed with T1D at age between 0.5 and 16.0 years and had no dia-
betes- associated autoantibodies. The participants were recruited
from 30 hospitals during the fourth cohort study of the Japanese
Study Group of Insulin Therapy for Children and Adolescent Diabetes.
We performed genetic analysis using the HaloPlex target enrichment
system (Agilent) and a next-generation sequencer HiSeq (Illumina) to
screen mutations in 30 genes known to cause monogenic diabetes.
Results: Four of the 43 participants had heterozygous missense mu-
tations in the insulin gene (INS ). No mutations were observed in the
remaining 29 genes. The INS mutations (p.G75C, p.C96F and p.V42A)
were hitherto unreported. The p.C96F mutation-carrying children
were siblings, whose mother was also affected by T1D. No significant
differences were observed in body mass index-Z score between the
INS mutation carriers and non-carriers (-0.4 vs -0.9, p = 0.26). Age at
diagnosis was significantly younger in the INS mutations carriers than
that of non-carriers (2.7 vs 9.4 years, p = 0.025).
Conclusions: The results indicate that small proportion of children
clinically diagnosed with T1BD children with onset age >0.5 years
had monogenic mutations. Mutation screening of those children is
helpful not only to understand the molecular pathogenesis but also
to provide individualize management, including genetic counseling.P1-1-3
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Miswar Fattah4
1Pediatric Endocrinology Division, Child Health Department, Medical
School, University of Sumatera; 2Pediatric Endocrinology Division,
Medical School, University of Indonesia; 3Department of Nutritional
Sciences, Medical School, University of Sumatera; 4Department of
Molecular Biology, Prodia Widyahusada Laboratory
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-1-3
Introduction: In recent years, obesity is becoming an epidemic
health problem. Leptin is known to play an important role in the
pathogenesis of obesity. Levels of soluble leptin receptor (sOB-R) can
provide an indication of free leptin, are postulated to play an import-
ant role in the pathophysiology of energy homeostasis. The free lep-
tin index (FLI), which may be a more accurate determinant of leptin
function.
Objective: To evaluate the association between leptin, sOB-R, and FLI
with body mass index (BMI) in elementary school children in Medan,
Indonesia.
Methods: We conducted a case control study in ten elementary
schools in Medan, Leptin and sOB-R were measured by enzyme link
immunosorbent assay (ELISA). The ratio of serum leptin to sOB-R pro-
vides a measure of the free leptin index (FLI).
Results: A total of 202 children between 6 and 12 years old were re-
cruited in this study. We found significantly association between
body mass index with leptin, sOB-R, and FLI (p <0.05). Soluble OB-R
levels were lower in children with obesity than normal weight chil-
dren (28.1 ± 8.1, 37.7 ± 9.3 ng/mL, respectively), but, leptin and FLI
levels were higher than control (756.9 ± 493.4, 160,7 ± 284.7 ng/mL,
respectively).
Conclusions: This study showed a decrease in levels of sOB-R and in-
crease levels of leptin and FLI in children with obesity, and there
were significantly associations between Leptin, sOB-R, and FLI with
BMI.
Keywords: Leptin, free leptin index, soluble leptin receptor, body
mass index, obesityP1-1-4
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Background, Aims and Objectives: We hypothesized that classical
brown adipose tissue (cBAT) could play a crucial role in the anti-
obesity effects of erythropoietin (Epo). Our study highlights the
mechanism in which Epo treatment could upregulate energy ex-
penditure and improve glucose homeostasis through cBAT in obese
mice fed with a high-fat diet (HFD).
Methods: C57BL/6J mice had been fed with HFD since the age of 4
weeks (HFD mice). We administered recombinant human Epo (200IU/
kg) to some HFD mice intraperitoneally, 3 times per week for 4
weeks (HFD+Epo mice). Blood glucose, serum insulin and FGF21
were monitored and an intraperitoneal glucose tolerance test (IPGTT)
was performed on the two groups. We analyzed the interscapular
BAT (iBAT) and the liver harvested from both groups using molecular
biology and physiological methods.
Results: Body weight, blood glucose and serum insulin were de-
creased in HFD+Epo mice compared with HFD mice. Serum level of
FGF21, interscapular surface temperature and oxygen consumption
were higher in HFD+Epo mice in comparison with HFD mice. The
IPGTT showed that the levels of blood glucose were lower in HFD
+Epo mice than in HFD mice. The weight of iBAT was larger in HFD
+Epo mice than in HFD mice, whereas that of white adipose tissue
was decreased in HFD+Epo mice than in HFD mice. The mRNA and
protein levels of UCP1, beta3ADR, PRDM16, PPAR α and FGF21 in the
iBAT were higher in HFD+Epo than in HFD mice. However, the mRNA
and protein level of FGF21 in the liver was similar between the two
groups. In addition, the mRNA levels of PEPCK and G6Pase in the
liver were lower in HFD+Epo mice compared with HFD mice. Epo
treatment significantly stimulated phosphorylation of Epo receptor
(EpoR) /STAT3 in the iBAT in a HFD condition.
Conclusions: The activation of EpoR/STAT3 pathway in the cBAT by
extrinsic Epo could contribute to the upregulation of energy expend-
iture and the improvement of glucose homeostasis by increasing the
secretion of FGF21 on the cBAT in HFD mice.
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Introduction: Previous s tudies have demonstrated total basal insulin
dose (TBD)/ total daily insulin dose (TDD) as about 40-50% and TDD
as about 0.8-1.2U/kg/day in children with type 1 diabetes on CSII.
Since Feb, 2015 sensor augmented pump (SAP) is available in Japan,
and we expected the improvement of HbA1c level and the adjust-
ment of the bolus basal ratio. Therefore, we investigated the changes
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 40 of 144in HbA1c level, TDD (U/kg/day) and TBD/ TDD (%) among children
under 18 years old with type 1 diabetes after starting SAP therapy in
our hospital.
Subjects and methods: Subjects included 11 children with type1 dia-
betes (M/F= T/ U, 9.0 ± 8.7 years old). They were classified into good
glycemic control group (HbA1c<7.5 n=4, 9.9 ± 8.8 years old) and the
poor glycemic control group (HBA1c>8.5 n=4, 10.3 ± 5.0 years old)
based on HbA1c level after starting SAP therapy. TBD/TDD and TDD
also investigated between the two groups.
We compared HbA1c level, TBD/TDD and TDD after and before SAP
treatment in all subjects, and also compared TBD/TDD and TDD be-
tween the good and poor glycemic control groups.
Results: HbA1c level were significantly lowered by using 0.8% after
using SAP (from 8.6% to 7.8%, p=0.036). In 7 out of 11 patients,
HbA1c levels were lowered by 0.5%, however, TBD/TDD and TDD
didn’t change significantly after using SAP (p=0.846 vs p=0.76). BD/
TDD showed significant difference between the good and poor gly-
cemic control groups (median 28% vs 43%, P=0.03). Whereas, TDD
between the two groups didn’t change significantly (median 0.855U/
kg/day vs 0.875U/kg/day, p=1.0).
Discussion: SAP therapy effectively lowered HbA1c level in children
with type 1 diabetes. Overall, TBD/TDD and TDD didn’t change, but
TBD/TDD in the good glycemic control group was significantly lower
than in the poor glycemic control group. These results suggested
that good glycemic control was achieved by increasing the bolus
based on the sensor glucose levels.
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Purpose: We investigated the prevalence rate of metabolic syndrome
(MetS) among Korean children and aolescents, and the distribution
of indirect index of insulin resistance (IR) using homeostasis model of
insulin resistance (HOMA-IR) and triglyceride and glucose (TyG) index.
Also we suggested the cutoff values of HOMA-IR and TyG index to
screen high risk group of MetS.
Methods: Data from 3,3313 Korean subjects (1,756 male and 1,556
female, aged 10-18 years) were included from the Korean National
Health and Nutrition Examination Survey (K-NHANES) conducted dur-
ing 2007-2010. We used three different criteria of MetS by de Ferranti
et al., Cook et al., and International Diabets Federation (IDF). The cut-
off values of HOMA-IR and TyG indx were obtained from the re-
ceiver- operation characterisitics curves.
Results: According to the criteria of MetS in the order of de Ferranti
et al., and Cook et al., and IDF, the prevalence rates of MetS in male
and female were 13.9% and 12.3%, 4.6% and 3.6%, and 1.4% and
1.8%, respectively. The cutoff values of HOMA-IR and TyG index were
2.94 and 8.41, 3.29 and 8.48, and 3.54 and 8.66, respectively. Each cutoff
values from the three criteria approximately corresponds to 50th, 75th, and
75th to 90th percentiles of normal distribution of HOMA-IR and TyG index.
Conclusion: We presented the prevalence rate of MetS, the distribu-
tion of indirect index of IR, and the cutoff values to screen high risk
group of MetS in Korean children and adolescents. The usefulness of
these criteria needs to be verified by further evaluatin.
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among transfusion-dependent thalassemia (TDT) patients. Recently,
studies have shown that endocrinopathies such as adrenal insuffi-
ciency, vitamin D deficiency, low bone mass and glucose intolerance
are also quite common among non-transfusion dependent thalas-
semia (NTDT) patients.
Although HbH is the most common NTDT in Southeast Asia, little is
known regarding the glucose metabolism among these patients. The
purpose of our study was to evaluate the glucose tolerance among
young HbH patients.
Methods: We investigated β -cell function (HOMA- β ) and insulin
sensitivity (HOMA–IR) by performing OGTT among 32 children and
adolescents with HbH disease, mean aged 15.5 (range; 10.7-24.9)
years. Patients were divided into two groups based on the types of
HbH which were deletional (–/ α -, n = 16) and non-deletional HbH
(–/ αα T, n = 16). We compared demographic, hematological data,
HOMA-β and HOMA–IR between deletional vs. non-deletional groups.
We also compared demographic and hematological data between
normal vs. abnormal HOMA- β and normal vs. abnormal HOMA–IR
groups. Statistical analyses were performed using the unpaired t-test,
the Mann-Whitney U-test and the chi-squared test as appropriate.
Statistical significance was considered at P value of < 0.05.
Results: All patients had normal glucose tolerance. However, 40.6%
and 21.9% of patients had abnormal HOMA- β (decreased β -cell in-
sulin secretion) and abnormal HOMA–IR (insulin resistance), respect-
ively. Non-deletional patients had significantly lower height Z-score
and functional hemoglobin levels [7.4 ± 1.2 vs. 8.5 ± 1.3 g/dL,
P=0.018 ] but higher serum ferritin levels [237.9 (range 60.5 to
1881.8) vs. 87.9 (range 38.2 to 414.0) ng/mL, P=0.012 ] than dele-
tional HbH patients. Interestingly, patients with abnormal HOMA- β
had significant lower weight Z-score and functional hemoglobin
levels [7.6 ± 1.5 vs.8.3 ± 1.1 g/dL, P=0.039 ] than those with normal
HOMA- β . Meanwhile, patients with abnormal HOMA–IR had signifi-
cant higher weight Z-score and higher percentage of overweight
and obesity than those with normal HOMA-IR. The types of HbH dis-
ease were not significantly different between normal vs. abnormal
HOMA- β groups and normal vs. abnormal HOMA–IR groups.
Conclusion: A high prevalence of decreased β -cell insulin secretion
was shown for the first time among young HbH patients in this study.
The severity of anemia as determined by the levels of functional
hemoglobin seemed to be related with decreased β -cell insulin secre-
tion independent of the types of HbH disease. Prospective studies to
evaluate glucose metabolism among children and adolescents with
HbH disease who have impaired β -cell insulin secretion are needed.
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Background: Type 1 diabetes (T1D) is frequently associated with
other autoimmune disease, including autoimmune thyroid disease
(AITD). There is a paucity of understandings of AITD in children and
young adults with T1D. Here we investigated the clinical features of
T1D patients with AITD.
Subjects and methods: Data were analyzed from 446 patients with
T1D (2.2-51.7 years old; the mean age, 20.3 ± 9.1 years; 57.7% fe-
male), who visited our department during April 2014-March 2016, by
using the medical records.
Results: Among 446 patients with T1D, total 30 patients (76.7% fe-
male) were diagnosed with any of autoimmune diseases; 29 AITD, 1
SLE, 1 celiac disease, 1 ITP. There were 2 patients with three auto-
immune diseases, one was T1D with Hashimoto’s thyroiditis (HT) and
ITP, and the other was T1D with HT and celiac disease. Out of the 29
T1D patients with AITD, 18 patients were diagnosed with Graves’ dis-
ease (GD) (84.2% female) and the rest of 11 patients (60% female)
were diagnosed with clinical HT requiring treatments. Antithyroid
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 41 of 144antibodies (thyroglobulin and thyroid peroxidase) were examined in
271 T1D patients. 77 (28.4%) out of the 271 patients were positive
for any of the antibodies. Mean ages of T1D onset were not signifi-
cantly different among T1D patients with or without AITD. The mean
age at diagnosis of GD and HT was 18.0 and 8.2 years old, respect-
ively. Out of 19 patients who developed GD, 15 patients developed
GD after T1D was diagnosed. Mean interval was 12.8 years. While out
of 10 patients who developed HT, 6 patients developed HT after T1D
was diagnosed. Mean interval was 7.1 years. All of T1D patients with
GD were controlled by antithyroid drug therapy, and none of them
needed surgery or radiotherapy. Relapse of GD after remission oc-
curred in 2 patients.
Conclusions: Prevalence of AITD in T1D patients was higher com-
pared with general population. Especially female patients with T1D
have higher risk of AITD than male patients with T1D. GD tends to
develop several years after the onset of T1D and careful monitoring
should be considered. Antithyroid antibodies’ positivity was high in
T1D patients but most of the cases did not develop clinical HT. In
conclusion, this study supports the recommendation for regular
examination of thyroid antibodies and thyroid function in children
and young adults with T1D.
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Diabetic ketoacidosis (DKA) is a major life-threatening complication
of type 1 diabetes (T1DM). The aim of this study was to identify the
risk factors for the presence and severity of DKA at onset of T1DM in
Korean children and adolescents.
A retrospective chart review of children and adolescents newly
diagnosed as T1DM from January 2000 to May 2015 was done in
7 secondary and tertiary centers in South Korea. Eligible subjects were
< under age of 20 years and had records on the presence or absence
of DKA at T1DM diagnosis. The severity of DKA was categorized as mild
(venous blood pH<7.3), moderate (venous blood pH<7.2) and severe
(venous blood pH<7.1). Data was collected on age, height, body weight
at diagnosis, body weight after stabilization, pubertal status, family his-
tory of diabetes, delayed diagnosis of T1DM, preceding infection, health
insurance status, and parental education.
A total of 361 children and adolescents diagnosed with T1DM were
included. The mean age was 8.8 ± 4.0 years and 37 patients were
younger than 3 years of age and 91 patients were older than 12
years of age. 53.7% (n=194) of the patients were female. Overall
48.9% (n=177) of the patients presented with DKA at T1DM diagno-
sis. Thirty six percent of all patients (n=137) was not diagnosed as
T1DM at the first medical consultation and in 13% (n=47), a preced-
ing infection was present. The risk for DKA at diagnosis was 2.8 times
(P=0.022) higher in patients younger than 3 years of age, and was
1.8 times (P=0.007) higher in patients older than 12 compared to pa-
tients between 3 and 12 years old. Lower serum c-peptide levels
(P<0001), presence of preceding infection (P=0.001), and delayeddiagnosis (P=0.02) significantly increased the risk of DKA at T1DM
diagnosis. Multivariate analysis revealed that age greater than 12
(OR=2.8, PDelayed diagnosis, being too young to express symptoms
or being old enough to be relatively free from parental care, and pre-
ceding infection increased the risk of DKA at T1DM diagnosis. Insur-
ance status, parental educational level and preceding infection
affected the severity of DKA. These results imply that alertness of the
physician and public awareness of the symptoms of diabetes are
needed to decrease the incidence and the severity of DKA at diagno-
sis of T1DM.
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Introduction: Growth differentiation factor 15 (GDF15) is a member
of the BMP family of TGF-beta superfamily proteins, has been re-
ported to increase in a various disorders including diabetes mellitus,
cardiac/renal insufficiency or cancers. Several reports described that
the elevation of GDF15 is the useful biomarker for diabetic nephrop-
athy, or diabetic cardiomyopathy in adult. However, there are no re-
ports about serum GDF15 in relation with the diagnostic purpose of
type 1 diabetes mellitus (T1DM) in children. In this study, we investi-
gated whether GDF15 is the good biomarker for diagnostic purpose
of T1DM in children.
Methods: We collected serum samples in pediatric patients with
T1DM and type 2 diabetes mellitus (T2DM), who were enrolled at
Kurume University Hospital from April 2012 to June 2016. We also
collected serum samples of pediatric voluntary healthy controls from
July 2013 to August 2013. We measured serum GDF15 level. We also
checked age, body weight, and height. Anti-GAD antibody, anti-
insulin antibody, and anti-IA2 antibody were measured in all T1DM
and T2DM patients at diagnosis. The study protocol was approved by
the institutional review boards of all centers (coordinator: Kurume
University Hospital, #13099). Written informed consent was obtained
from all subjects before enrollment.
Results: Thirty-two (female; 16) pediatric T1DM, 8 (female; 4) pediatric
T2DM and 60 (female; 23) controls were collected. The mean (SD) of
age in T1DM, T2DM and controls was 9.80 (4.38), 9.54 (4.32), and 13.4
(2.05) years of age, respectively. The median of GDF15 in T1DM, T2DM
and controls was 291.0, 414.0, and 453.5 ng/mL, respectively. No pa-
tients had diabetic retinopathy nor diabetic nephropathy. GDF15 was
lower in T1DM compared to controls (p<0.0001), and T2DM (p=0.0243).
GDF15 in T2DM was not significantly different compared to controls
(p=0.42). GDF15 in T1DM was no significant difference from autoanti-
bodies, respectively. (Anti-GAD antibody; p=0.66, anti-insulin antibody;
p=0.57, anti-IA2 antibody; p=0.51).
Discussion: GDF15 in pediatric T1DM was significantly decreased
than those seen in the controls and T2DM. Our results implied that
the GDF15 may be a useful biomarker to distinguish T2DM in the pa-
tient autoantibodies were negative. GDF15 has been reported to be
increased in T2DM in adult, our data did not show increase in T2DM
in children. Those discrepancies may remain to be solved in future.
Conclusions: GDF15 was lower in T1DM in children than those in
controls and T2DM, suggested that GDF15 may be a useful bio-
marker for T1DM in children.P1-1-11
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 42 of 144Background: Adipose tissue has been proven to be not merely a site
for energy storage but also the largest endocrine organ that secretes
various adipocytocine. Plasma visfatin is predominantly secreted
from visceral adipose tissue, has insulin-mimetic effects and the level
closely linked to insulin resistance.
Objective: The aim of this study was to investigate the differences
plasma visfatin level between obese and non obese adolescents and
also between obese adolecent with insulin resistance and without in-
sulin resistance.
Methods: This was a cross-sectional study and conducted in three
Senior High School in Padang. Twenty eight obese adolescents and
28 control were enrolled in the study. The age of the subjects ranged
from 14-18 years. Obesity criteria was measure based on body mass
index (BMI). Fasting serum glucose level measured by glucose
hexokinase fotometrik method and serum insulin was measured by
chemiluminessence immunoassay method. Plasma visfatin was
measured with enzyme-linked immunosorbent assay (ELISA). The
insulin resistance index was estimated from fasting serum insulin
and glucose level using the formula. Differences in the variables were
tested using independent t-test and Mann-Whitney depending on
the distribution of the variables.
Result: The plasma visfatin level was higher in the obese than in the
control group 2,55 (SD 1,54) ng/ml vs 1,61 (SD 0,64) ng/ml, p: 0,005,
and the insulin resistance group had higher plasma visfatin level
than non resistance group 3,61 (SD 1,59) vs 1,96 (SD 1,18), p: 0,004
Conclusion: There were increasing level plasma visfatin toward in-
crease of HOMA-IR in obese adolescents.
Key word: obese adolescents, insulin resistance, plasma visfatin.
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Introduction: Carbohydrate Counting (CC) has been going to be
popular for type 1 diabetes (T1D) in these days in Japan. It has
passed ten years since we published the first Japanese text about CC
of Japanese foods in 2006, and have started to educate our patients
CC first in Japan. For educating CC to the childhood T1D, their age
and development should be considered. We developed the original
education method of CC. It is comprised with two parts of, the esti-
mation carbohydrate amount and the calculation of insulin dose. The
“Carb” as a unit which is equal to 10 g of carbohydrate is used. For
the training of the estimation, the “Carb-flashcards” are applied. For
the training of calculation, the simplified calculation sheets are used.
There is few reports about the CC education for the childhood and
adolescent T1D so far.
Objectives: To elucidate the educative status of CC among T1D pa-
tients in our clinic.
Methods: The questionnaire was carried out to T1D patients in our
clinic.
Results: Data were obtained from 108 patients or 64 parents. The
age of patients was 3-45 years old (Median 17 years old), The disease
duration was 0-20 years (Median 8 years). The ratio of MDI/Pump
was 46%/56%. The first education of CC was provided, 27% was only
for the parents, 41% was for both the patients and parents, and 26%
was only for the patients. In the cases of infant and toddler (below 6
years old), the CC education was usually provided only for the par-
ents. More than 60% of patients above 9 years old can use CC by
themselves. Some patients at 7 years old can estimate the amount of
carbohydrate in food and calculate the insulin dose by CC by them-
selves. Seventy-one percent of patients use the “Carb”. The others
use “gram”. Among the patients using Pump therapy, 60 % of them
use the bolus calculator function of the pump. Many patients havemastered CC with 1 years. The duration to master CC, has become
shorted significantly in the recent onset patients. That was not re-
lated to the therapies of MDI or pump.
Conclusion: The CC education should be begun at 6-7 years old of
patients. Our recent education method of CC has become efficient.
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Trends in the prevalence of extreme obesity among Korean
children and adolescents from 1998 to 2014
Hyo-Kyoung Nam, Hye Ryun Kim, Young Jun Rhie, Kee-Hyoung Lee
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Objectives: Although recent studies reported that prevalence of
childhood obesity stabilized around early 2000s, national trends of
extreme obesity in Korea have not been studied. We aimed to assess
the prevalence of obesity and extreme obesity for Korean children
and adolescents and the impact of extreme obesity on metabolic
syndrome.
Subjects and Methods: Data for 21,402 children and adolescents
aged 2 to 19 years (11,188 boys and 10,214 girls), were obtained
from the Korean National Health and Nutrition Examination Surveys
during 1998-2014. We used age- and sex-specific body mass index
(BMI) percentiles and examined the trends in the prevalence of obes-
ity and extreme obesity based on criteria suggested by the Korean
national reference standard (KCDC) and an US Centers for Disease
Control and Prevention (CDC). We used the definition of metabolic
syndrome from the modified the National Cholesterol Education Pro-
gram Adult Treatment Panel III (NCEP ATP III).
Results: The prevalence of extreme obesity using the KCDC criteria
was higher than using the CDC criteria. No significant increases in
the prevalence of both overweight and obesity were found among
boys and girls aged 2-19 between 1998 and 2014. Significant in-
creases in the prevalence of extreme obesity were detected among
adolescents aged 10-19, especially in boys. The rates of the meta-
bolic syndrome combined with extreme obesity were 51.6% and
34.4% in teenage boys and girls, respectively. The odds ratios of ex-
treme obesity on metabolic syndrome compared with normal BMI
were 60.7 and 34.7 in teenage boys and girls, respectively.
Conclusions: Despite the prevalence of childhood overweight and
obesity in South Korea stabilized since the early 2000s, the preva-
lence of extreme obesity is increasing especially in teenage boys.
Given the greater morbidity risks for the extreme obesity, monitoring
and preventing progression to extreme obesity become more
important.
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Objective: The Japanese Study Group of Insulin Therapy for Child-
hood and Adolescent Diabetes (JSGIT) showed that glycemic control
in Japanese children with type 1 diabetes had improved through
changes in insulin regimens and using a combination of insulin ana-
logues since 1995. Fluctuation of HbA1c values, well-known seasonal
variations, are composed of high HbA1c values in winter and low
Fig. 1 (abstract P1-1-16). Predictor of metabolic complications in
obese Indian children (N = 205)
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various reports of improved glycemic controls in diabetic patients, lit-
tle is known about whether the seasonal variation has changed with
times. This study was driven by the question of how the seasonal
variation of glycemic control in patients with type 1 diabetes had
changed from 1995 to 2012, using the data of 1995, 2000 and 2008
cohorts of JSGIT.
Methods: Participants included 662 patients in the 1995 cohort, 791
patients in the 2000 cohort and 859 subjects in the 2008 cohort. We
conducted longitudinal analyses on changes in seasonal variations of
HbA1c. Seasonal variation per year, HbA1c, was calculated as HbA1c
value in winter minus HbA1c value in summer. Statically analysis
were performed by linear regression or Mann–Whitney U test.
Results: Average HbA1c values have decreased year by year (average
HbA1c (%) = -0.0672*year +143.1543, P<0.0001). HbA1c values in
winter were higher than those in summer, with statistically signifi-
cance in following periods except 2003 and 2007 (P<0.05). HbA1c
had become smaller year by year (average HbA1c (%) = - 0.0032*year
+ 6.7736, P=0.0440).
Conclusions: HbA1c values in Japanese children with type 1 diabetes
had significantly improved with seasonal variation; almost 0.22%. The
seasonal variations of HbA1c were chronologically improved, but
there were obvious seasonal variations in 2012. Further study is war-
ranted whether advanced treatment and support for type 1 diabetes
may ameliorate seasonal variation of glycemic control.
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Background: Obesity has become a global problem and continues to
be a major problem in many poor and developing countries and has
reached the alarm. Obesity leads to insulin resistance in childhood.
Retinol binding protein (RBP4), secreted primarily from the liver and
adipose tissues, was recently proposed as a link between obesity and
insulin resistance. The role of RBP4 in pediatric obesity and its rela-
tionship with insulin resistance are not elucidated.
Objective: The objective of the study was to determine the status of
RBP4 levels in obese and lean adolescent and the relationship be-
tween RBP4 levels and insulin resistance based on Index of Homeo-
stasis Model Assessment Insulin Resistance (HOMA - IR ).
Method: This was a cross-sectional study and conducted in three Se-
nior High School in Padang. Samples included 14-18 years old obes-
ity and normal weight adolescent (n=56). We measured body mass
index (BMI) and serum RBP4. Insulin resistance was assessed using
HOMA-IR index.
Result: Similar RBP4 levels were found in the obese vs. non- obese
group group (p > 0,05). Higher RBP4 levels were found in the insulin
resistance vs. non-insulin resistance group but the differences was
not significant (p > 0,05)
Conclusion: There were no significant differences in mean levels of
RBP4 in the group of obese adolescents compared with non- obese
adolescents . So also in the group of obese adolescents with insulin
resistance compared with those without insulin resistance
Keywords: Obesity, Retinol binding protein 4 (RBP4), insulin
resistance
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Fat or Fit- Search for predictors of metabolic complications in
obese Indian children?
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in obese children. Body mass index (BMI) alone is however not a reli-
able predictor of these complications as they are not observed in
many children with very high BMI. This heterogenity in the preva-
lence of metabolic complications for the same level of BMI makes
identification of their pointers a desirable goal.
Aim: To identify predictors of metabolic complications in Indian chil-
dren with obesity.
Design: Ongoing prospective observational study (April 1 2015 on-
wards). 205 children (120 boys, 5.1-18 years) with obesity underwent
clinical assessment, complication screening (oral glucose tolerance
test, lipid profile, fasting insulin and SGPT) and dual enhanced X Ray
absorpimetery (DEXA) scan for body composition (body fat percent-
age and android to gynoid fat ratio). Predictors for metabolic compli-
cations were assessed using a step wise linear regression model.
Results: Metabolic complications observed in study included low
HDL in 103 children (50.2%), high triglyceride levels in 51 (24.9%),
pre diabetes in 44 (21.4%) and type 2 DM in 12 (5.9%). Children with
metabolic complications had higher waist circumference standard
deviation score (SDS, p =0.01), DEXA assessed total body fat percent-
age (p = 0.01) and android to gynoid ratio (p = 0.02) but similar body
mass index (BMI) SDS (p = 0.1) compared to those without metabolic
complications. HOMA IR levels correlated significantly with body fat,
android to gynoid ratio and waist circumference SDS but not with
body mass index SDS.
Conclusions: Metabolic complications are common in Indian children
with obesity. High waist circumference SDS, AG ratio and total body
fat are predictors to these complications. Their assessment would
help target preventive and therapeutic interventions in obese
children.P1-1-17
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type of diabetes mellitus and its clinical application
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Objectives: To explore the clinical value of common pathogenic
gene detection in the diagnosis and treatment in hyperglycemia in-
fants and children.
Subjects and Methods: Subjects were in-patients with hypergly-
cemia, age of onset before 1 year-old Cor insulin antibody negative
and with family history of diabetes. Gene sequencing for ABCC8 ,
KCNJ11 , INS and GCK were performed and potential mutations were
analyzed. The patients with ABCC8 and KCNJ11 gene mutations were
treated with sulfonylurea, patients with GCK mutations were given
the lifestyle intervention and others with insulin.
Results: Total 21 patients were enrolled, 15 patients were found with
pathogenic gene mutations, 52.4% in ABCC8 gene and KCNJ11 gene
(11/21). The patients with KCNJ11 or ABCC8 gene mutation are with
average age 2.01 ± 1.62 months or 2.52 ± 2.60 months, respectively.
GCK gene mutations were detected in children with age of onset
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 44 of 144more than or equal to 12 months, at 58.33 ± 43.02 months of age.
There existed significant statistical difference among the onset ages
of the three genetic variants, P = 0.001. The onset random blood glu-
cose levels were significantly higher in the patients with INS gene
mutation (66.70 mmol/L) than those of GCK gene mutation patients
(9.73 + 1.97mmol/ L, P=0.003). 11 patients with ABCC8 or KCNJ11
gene mutation were treated with sulfonylurea and 9 patients
reached euglycemia.
Conclusions: Mutations in potassium channel related genes (KCNJ11
and ABCC8) were the most common cause of neonatal diabetes in
Chinese. Sulfonylurea therapy was effective and euglycemia were
reached in most of the patients with the mutations in KCNJ11 and
ABCC8 . Patients who were diagnosed hyperglycemia before 1 year-
old Cor with negative antibody testing and family history of diabetes
were referred for gene testing, even by targeted next-generation se-
quencing of all known related genes. The target therapy based on
gene diagnosis is more effective and improvement of life quality.Table 1 (abstract P1-1-19). Mean micronutrient intake and proportion
with intake less than RDAP1-1-18
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Objectives: To investigate the period prevalence, clinical presenta-
tion, and molecular genetics of patients diagnosed MODY in the
Chinese pediatric population of Hong Kong.
Methods: A retrospective study of Chinese patients with genetically con-
firmed MODY aged from birth to 18 years under the care of the 2 major
pediatric departments of the Hong Kong New Territories East Cluster
(NTEC) of Hospital Authority from 1st January 2010 to 31st December
2015. Non-Chinese patient was excluded. For the calculation of the esti-
mated period prevalence, only patients aged below15 years were included
as government population statistics stratified age at below 15 years.
The Electronic Patient Record System was employed to retrieve the clin-
ical and genetic data. Descriptive statistics employed for data analysis.
Results: The period prevalence of Chinese patients with MODY, aged
below 15 years, was 58.5 cases per 1,000,000 populations from 1st
January 2010 to 31st December 2015 in the NTEC catchment areas.
For those aged 18 years or below, there were 9 Chinese MODY pa-
tients, of whom 2 were related siblings. Two patients diagnosed
MODY 3, the rest MODY 2. The F:M was 2:1 and mean age 10-year-5-
month. All patients were non-obese. The presenting HbA1c was 5.3%
- 6.7% in MODY 2, 7.5-7.7% in MODY 3. Family history was positive in
8/9, and 6/8 involved 2 generations (not counting the index patient).
Anti-islet antibodies were tested and negative in 4 patients. A novel
frame-shift mutation, heterozygous GCK c.1239delinsAA, p.(Tyr413*),
was detected in the 2 related siblings, whereas the rest had been
reported in non- Chinese studies.
Conclusion: Our study reported the first period prevalence of MODY
2 and 3 in Chinese pediatric patients in Hong Kong. This showed
MODY was not uncommon in Chinese, as compared to the estimated
prevalence of 68-108 cases per million (aged <= 25years) from 1996
to 2009 in UK (Shields et al. Diabetologia. 2010 Dec;53(12):2504-8).
The limitation of our estimation included: (1) The case identification
was based on clinical suspicion rather than protocol, (2) Due to limi-
tation of age stratification of population statistics, only prevalence for
those under 15 years was calculated. The clinical features were simi-
lar to reported in Caucasian studies. A larger sample is required to
delineate any founder mutations for Chinese patients with MODY.P1-1-19
Micronutrient deficiency in overweight / obese adolescents: Dual
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Introduction: Several micronutrients deficiencies affect functional
and physical performance of the children. Frequent consumption of
junk food may be associated with micronutrient deficiency. This
study was conducted to assess macro- and micronutrient intake in
overweight/ obese adolescents aged 10-16 yrs.
Materials and Methods: 214 overweight adolescents (147 boys) aged
10 to 16 y were enrolled. Dietary assessment was done by one day 24
hr recall and quantitative food frequency questionnaire methods. The
intakes were compared with the Recommended Dietary Allowance
(RDA) for age and gender for each child. Data was presented as mean
± SD and as proportion (%) with intake above or below the RDA.
Results: Mean age was 11.9 ± 1.6 y and BMI SDS 2.3 ± 1.1. The mean
daily energy intake was 2922 ± 838 Kcal, with the mean contribution
from protein, carbohydrate and fat
being 11.3%, 59.8% and 29.3%, respectively. Mean daily fiber intake
was 8.6 ± 3.8 g. Energy and fat intake exceeded the RDA in 75% and
95% subjects, respectively, while fiber intake was less than the RDA
in 95%. The mean micronutrient intake of the subjects and the pro-
portion whose intake was less than the RDA is presented in Table 1.
Deficiency of Iron, Vitamin B12 and Zinc was seen in more than 60%
of the subjects, while Magnesium, Folic acid and Vitamin C intakes
were optimal in a majority.
Discussion: While energy and fat intake exceed the RDA in overweight
adolescents, they have lower intake of fiber and essential micronutri-
ents, s u c h a s i r o n , B 1 2 a n d z i n c . O v e r w e i g h t adoles-
cents have a dual burden of malnutrition and should be encouraged to
have more servings of fruits, vegetables and whole grains.P1-1-20
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Background: Diabetic ketoacidosis (DKA) associated with rhabdo-
myolysis has previously been reported and may significantly influ-
ence primary care.
Case: A 14-year-old female patient with a one-week history of fatigue
was admitted to our hospital with dyspnea and impaired conscious-
ness in December 2015. A urine examination performed at her school
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 45 of 144when she was 8 -years -old had been positive for sugar. On admis-
sion, a biochemical examination of the patient’s urine and blood re-
vealed the following: pH, 6.864, HCO3-, 4.7 mmol/L, serum glucose
level, 716 mg/dL (39.7mmol/L), glycated hemoglobin, 15.8%, serum
ketone level, 13,066 μmol/L, urinary C-peptide, 45 μg/d and positive
for urine ketones and negative for pancreas–related autoantibodies.
The patient was diagnosed with type 2 diabetes mellitus (T2DM) and
DKA. Metabolic acidosis was attenuated by intravenous infusion with
10 mL/kg saline and 0.1 U/kg/h insulin. Within 21 h of therapy initi-
ation, the levels of serum creatinine (Cre, 1.33 mg/dL, 117.6μmol/L),
serum creatine kinase (CK, 2359 IU/L) and urinary myoglobine
(20,000 ng/ mL) were increased, and the patient presented with
rhabdomyolysis and acute kidney injury. The patient’s blood pressure
and urine volume were maintained, and consciousness was gradually
restored. As the blood glucose levels had not decreased after admis-
sion, the dosage of insulin infusion was increased to 0.2 U/kg/h. Subse-
quently, the blood glucose level was normalized and urinary ketones
were undetectable. Serum Cre and CK levels were improved 32 h later.
However, the patient presented with oliguria and systemic edema 43 h
later, and was administered 0.2 g/kg albumin and 10 mg furosemide.
Systemic edema and urine volume were improved from the 4th day
following hospitalization, and serum Cre and CK levels were normalized
on the 7th day. The patient was discharged on the 19th day.
Conclusion: In cases of severe DKA, the complication of rhabdo-
myolysis should be considered and the serum CK level and renal
function should be carefully observed.
Consent for publication: The authors declare that written informed
consent was obtained for publication.P1-1-21
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Background: Early identification of HNF4A mutations in neonates
with HH can facilitate the management of both the child and family.
Aims: To identify HNF4A mutations in neonates with prolonged hyper-
insulinaemic hypoglycemia (HH) and parental history of diabetes.
Methods: Neonates delivered at our institution requiring glucose infu-
sion rate (GIR) >10mg/kg/min after 48h of life from April 2015 to March
2016 were identified. We collected demographic data and determined
if there was history of diabetes in the baby’s parents. We analyzed the
HNF4A status of those with positive parental history of diabetes.
Results: There were 4 babies whose parents had pre-existing dia-
betes. Of these 4 neonates with parental history (2 male, all of Malay
ethnicity), 1 had paternal and 3 had maternal history of pre-existing
diabetes. Patient 1 (dad with diabetes from age 15y) was diagnosed
with a heterozygous novel HNF4A missense mutation p.345Y, which
was paternally inherited as a de novo mutation. Patient 2 (mum with
diabetes from 18y) did not consent for genetic study. Patient 3
(mum with diabetes from 13y) and Patient 4 (mum with diabetes
from 18y) were tested negative for HNF4A. These neonates were
among twenty-five (56% male) neonates who satisfied the criteria for
HH at 48h. These 25 HH neonates were out of 11923 babies born at
KK Hospital over 1 year (incidence 2.1/1000). There were 10 Chinese
(40%), 10 Malay (40%) and 5 babies of other races.
Conclusion: The presence of pre-existing diabetes in parents of neo-
nates with HH may suggest a genetic etiology. Our preliminary data
indicates that HNF4A gene testing should be performed in a larger
number of neonates with HH and positive parental history of pre-
existing diabetes before a definitive recommendation can be made.P1-1-22
Insulin pump therapy in type 1 diabetes: The Indian experience
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Background: Insulin pumps have been used for the management of
type 1 diabetes for over 15 years in the west. However similar experi-
ence is lacking in India where multi dose insulin injections still form
the mainstay of management of type 1 diabetes. In a first study of its
kind from India, we attempt to highlight the effectiveness, safety and
superiority of insulin pump use in type 1 diabetes.
Objective and hypotheses: To determine the impact of insulin pump
therapy on short and long term glycaemic control, body mass index
(BMI), rate of severe hypoglycaemia and diabetic ketoacidosis (DKA)
in children, adolescents and young adults.
Method: Retrospective analysis of data from case records of patients
at our clinic. Out of the 64 patients on insulin pump, 52 were in-
cluded in the study. Age of the patients at initiation of insulin pump
ranged from 3 years to 26 years. Reckoning age-wise categorisation
at 5 year intervals, patients were stratified into 5 groups (0-5, 6-10,
11-15, 16-20, 21-25 yrs). Data regarding pre-pump HbA1C (average
HbA1C in the 6 months before starting insulin pump), pre-pump BMI
(BMI at last visit before pump), pre-pump episodes of hypoglycaemia
and DKA and post pump HbA1C (at 6months and one year after
pump initiation), post pump BMI (BMI at 6 months after pump) and
post-pump episodes of hypoglycaemia and DKA (in the one year
after pump) in each patient was recorded and compared.
Results: Of the 52 patients included, only 27 followed up for one year
or more after initiation of pump and 25 had visits only upto 6 months.
There was a drop in HbA1C and increase in BMI across all age groups
with the maximum difference seen in the oldest age group after start-
ing pump therapy. Only 3 episodes of DKA were recorded after pump
therapy against 10 episodes in the pre pump period. However there
were 3 episodes of severe hypoglycaemia in the post pump period as
compared to 2 episodes in the pre pump period.
Conclusion: This study suggests that insulin pump therapy is effect-
ive, safe and superior in children, adolescents and young adults with
type 1 diabetes.
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Lower adiponectin, higher ALT level, lower AST/ALT ratio, and
higher VAT value may suggest a risk for the onset of type 2
diabetes in obese children
Yuki Yasuda, Hisafumi Matsuoka, Shigetaka Sugihara
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Objective: An association between type 2 diabetes mellitus and
metabolic syndrome (MS) has been suggested in obese children. We
compared the characteristics of fat accumulation, blood chemistry,
and adipokine levels among obese children with type 2 diabetes or
MS without type 2 diabetes. We then analyzed the threshold value of
the risk factor for type 2 diabetes.
Methods: One hundred and seven obese children visiting our out-
patient clinic were enrolled in this study. The subjects were divided
into 3 groups: Group A, obese children with type 2 diabetes (n = 19);
Group B, obese children with metabolic syndrome but without type
2 diabetes (n = 19); and Group C, obese children without type 2 dia-
betes or metabolic syndrome (n = 69). Biochemical examinations and
the measurement of serum adiponectin and leptin levels were
performed for each patient. The visceral adipose tissue (VAT) and
subcutaneous adipose tissue (SAT) levels were measured using cross-
sectional computed tomography (CT) images obtained at the
umbilical level. An ROC analysis was performed according to the
presence of MS or diabetes mellitus. The statistical analysis was per-
formed using JMP pro 12. This study was approved by the ethics
committee of Tokyo Women’s Medical University.
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and lower leptin and adiponectin levels, compared with Groups B and
C. In Group A, the serum ALT levels were significantly higher and the
AST/ALT ratio was significantly lower than those in Group C. In Group
B, the VAT and SAT values were higher than those in Group C. An ROC
analysis for the onset of type 2 diabetes showed that the optimal cut-
off point for adiponectin was 6.4 μ g/mL (AUC = 0.859), while those for
ALT, the AST/ALT ratio, and VAT were 35 IU/L (AUC = 0.821), 0.85
(AUC= 0.794), and 78 cm2 (AUC = 0.713), respectively. No significant
correlation between the HbA1c and adiponectin levels was seen in
obese children without diabetes. Group A had a significantly higher fre-
quency of a family history of type 2 diabetes than Group B.
Conclusion: These results suggest that an adiponectin level of less
than 6.4 μ g/mL, an ALT level of more than 35 IU/L, an AST/ALT ratio
of less than 0.85, and a VAT value of more than 78 cm2 may indicate
a risk for type 2 diabetes in obese Japanese children.
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Background: Studies from developed countries have exposed an
elevated risk for obesity and type 2 diabetes mellitus in individuals
exposed to gestational diabetes mellitus(GDM) during fetal life.
Maternal obesity and pregnancy weight gain are risk factors for de-
velopment of GDM. Risk for GDM is seen rarely in non-obese
mothers. GDM affects up to 17.8% of pregnancies in urban south
India, 13.8% in semi-urban areas and 9.9% in rural regions. Children
born to GDM mothers have disproportionate growth and are prone
to complications in the newborn period and later life.
Aim: Analyse the growth of neonates born to GDM mothers in
south-India using Ponderal index and other anthropometry.
Methodology: Birth weight, gestational age, head, chest & mid-arm
circumference and length of neonates born at GKNM Hospital, Coim-
batore from April 2014-March 2015 were recorded 0-48 hours after
birth. History of maternal diabetes, antenatal illnesses, pre-pregnancy
weight, weight before delivery and mother’s height were recorded
from clinical records. Ponderal index was calculated as weight(grams)
x 100/ length3(cm) and body mass index(BMI) was calculated as
weight(kilograms)/ length2(metres).
Results: 745 babies were analysed (GDM: non-GDM = 192:553). Pon-
deral index was elevated in GDM offspring (mean difference=0.06;
p=0.008). Mid-arm circumference (mean difference=0.28cms;p=0.001)
and chest circumference(mean difference=0.44cms;p=0.01) were
higher in neonates of GDM mothers. Head circumference (p=0.25),
length (p=0.06) and birth weight (p=0.17) were similar in both
groups. Proportion of boys: girls (p=0.99), duration of gestation
(p=0.25), socio-economic status (p=0.66) and birth order (p=0.78)
were similar too. Caesarean and instrumental deliveries were high
amongst GDM mothers (79% in GDM and 68% in non-GDM;p=0.01).
Pre-pregnancy BMI of GDM mothers (mean=24.94): non-GDM
(mean=23.56) were within normal range, though mean difference
was 1.38(p=0). GDM mothers were heavier in the pre-pregnancy
period (mean difference = 2.283kgs; p=0.008). But, pregnancy weight
gain was higher in non-GDM (11.96kgs) than GDM mothers
(10.97kgs; p=0.019). No difference was noted in Ponderal index with
respect to treatment modalities for GDM (p=0.95).
Discussion: Babies born to GDM south Indian mothers have dispropor-
tionate body composition including elevated Ponderal index, mid-arm
& chest circumference suggestive of neonatal adiposity even for minorvariations in BMI(difference between groups=1.38) within the normal
range and lower pregnancy weight gain. Normal Indian neonates have
intrauterine origin of adiposity, central adiposity and hyperinsulinemia.
As observed in the Pima Indians, GDM increases the risk for later obes-
ity in the offspring irrespective of maternal obesity.
Conclusion: Risk for later diabetes, obesity and other metabolic disor-
ders in the unique non-obese Indian GDM scenario could be eluci-
dated only in larger longitudinal studies.P1-2-3
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Background: Wolfram syndrome (WS) is a disorder characterized by
the association of early-onset, insulin-dependent diabetes mellitus,
diabetes insipidus, deafness, and progressive optic atrophy. The dis-
ease is caused by mutations of WFS1 gene located on 4p16 encoding
protein that is called WFS1. This protein composes the tetramer
which is expressed especially in pancreatic islet β -cells and the resi-
dent component of the endoplasmic reticulum (ER) membrane. Dur-
ing the protein synthesizing process in ER, the accumulation of
misfolded and unfolded protein occurs in a certain frequency (known
as “ER stress”). This ER stress is attenuated by the activation of the
unfolded protein response (UPR), which recovers and maintains the
ER function. Since WFS1 is known as the component of UPR, the mu-
tant WFS1 results in unresolvable ER stress conditions and cell apop-
tosis. This is the major cause underlying the development of
symptoms in WS.
Case report: We report a Japanese female WS patient with novel het-
erozygous mutation in WFS1 gene. She was admitted to our hospital
for poor weight gain and DM. Her growth failure was evident at 3
months old and congenital cataract was noticed at 7 months old.
Her auditory brainstem response (ABR) test revealed severe bilateral
hearing loss. Her WFS1 gene showed a heterozygous twelve bases
deletion in exon 8, resulting in 4 amino acid in-frame deletion
(p.N325_I328del). Methods: We analyzed the functional consequence
of the patient WFS1 using luciferase assay, western blotting and
fluoresence analysis in vitro .
Results: (1) The patient mutant WFS1 (p.N325_I328del) raises the ER
stress, ATF6 reporter activity and NFAT reporter activity in the ab-
sence of thapsigargin, indicating that this mutation induces a consti-
tutive ER stress and elevation of the cytoplasmic Ca2+ concentration.
(2) p.N325_I328del monomer has a dominant negative effect over
the wild type monomer. (3) Induced constitutive ER stress is canceled
by the chemical chaperone (4-phenylbutyric acid). (4) p.N325_I328del
reduces the mRNA expression levels of SERCA2b (sarcoplasmic/endo-
plasmic reticulum Ca2+ transport ATPase 2b).
Since SERCA2b is required for ER and cytoplasmic Ca2+ homeostasis,
these results raise the possibility that p.N325_I328del causes consti-
tutive ER stress and cell apoptosis through ER Ca2+ depletion.
Conclusion: We report a severe WS patient caused by novel hetero-
zygous mutation of WFS1 gene. The patient mutant WFS1 induces
constitutive ER stress and cell apoptosis through Ca2+ efflux from ER.
These results provide new insights into the roles of WFS1 in UPR
mechanism.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 47 of 144P1-2-4
Sodium pyruvate treatment improved endogenous insulin
secretion in a patient with mitochondrial diabetes
Tadayuki Ayabe1, Takeshi Inoue2, Yuji Oto2, Nobuyuki Murakami2,
Yasutoshi Koga3, Ryoichi Sakuta2
1Department of Molecular Endocrinology, National Research Institute for
Child Health and Development; 2Department of Pediatrics, Dokkyo
Medical University Koshigaya Hospital; 3Department of Pediatrics and
Child Health, Kurume University Graduate School of Medicine
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-2-4
Background: Mitochondrial diabetes is a rare form of diabetes melli-
tus, and reveals progressive decline in endogenous insulin secretion.
Sodium pyruvate treatment has been reported to be a potential
therapeutic choice for fatigability in patients with mitochondrial dis-
eases. However, the effect of sodium pyruvate treatment for glucose
intolerance in patients with mitochondrial diabetes remains to be
clarified.
Case presentation: Water-based sodium pyruvate solutions (0.5 g/kg/
day) were administrated orally to a Japanese man with mitochondrial
diabetes and myopathy caused by the m.14709T-C mutation. He was
already diagnosed with diabetes mellitus and started insulin self- injec-
tion. He did not have any kind of islet autoantibodies. To evaluate
therapeutic effects, we measured urinary C-peptide, HbA1c and total
daily insulin dose (TDD) 6 months later. His urinary C-peptide level im-
proved from 4.3 to 17.2 mcg/day after 1 day and to 30.2 mcg/day after
6 months of sodium pyruvate treatment. He experienced no adverse
event such as diarrhea resulting from sodium pyruvate treatment, ex-
cept episodes of mild hypoglycemia. To avoid hypoglycemia, his TDD
could be reduced from 33 Units/day to 20 Units/day. Despite reduction
of TDD, his HbA1c declined from 6.5% to 5.9%.
Conclusions: Sodium pyruvate treatment improved endogenous in-
sulin secretion and resulted in reduced TDD in a patient with mito-
chondrial diabetes. Sodium pyruvate treatment may be a potential
therapeutic choice for patients with mitochondrial diabetes.P1-2-5
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Background: Childhood obesity has been suggested to be a risk fac-
tor for bronchial asthma. However, the pathological association be-
tween body fat accumulation and eosinophilic inflammation in the
airway is not well known.
Objective: We examined the relationship between clinical factors of
obesity and eosinophilic inflammation based on fractional exhaled nitric
oxide (FeNO) measurements and peripheral blood eosinophil counts.
Methods: Thirty-two obese children (age: 6-15 years, mean age: 10.5
years) attending our outpatient clinic were enrolled in this study.
Cases with diabetes mellitus, any endocrine disease, or bronchial
asthma were excluded. We measured the height, weight, waist cir-
cumference, blood pressure, and FeNO of each subject. Blood sam-
ples were taken to examine the blood eosinophil count, IgE, AST,
ALT, γ -GTP, TG, HDL- Chol, MDA-LDL, uric acid, insulin, hs-CRP, leptin,
adiponectin and PAI-1 level in the morning after an overnight fast.
The correlations between these values and FeNO or the peripheral
blood eosinophil counts were then analyzed. A multivariable analysis
was performed using FeNO and the peripheral blood eosinophil
counts as objective variables. The statistical analysis was performed
using JMP pro 12. This study was approved by the ethics committee
of Tokyo Women’s Medical University.Results: The mean BMI-z score of the 32 obese children in this study
was 1.8. No single correlation between either FeNO or the eosinophil
counts and the BMI-z score was found. A significant single correlation
between FeNO and MDA-LDL was found (r = 0.38, P = 0.034). A
multiple regression analysis revealed that leptin/adiponectin , leptin,
adiponectin, the eosinophil counts, and γ GTP were selected for the
FeNO model (R2: 0.70, P < 0.0001), while AST/ALT, ALT, MDA-LDL,
and IgE were selected for the eosinophil count model (R2: 0.64, P <
0.0001). Discussion: FeNO reflects eosinophil inflammation of the air-
way. On the other hand, the peripheral eosinophil counts reflect sys-
temic inflammation. Our data demonstrated that the increased
visceral fat accumulation associated with adipokine changes, such as
the leptin/ adiponectin level, and oxidative stress markers, such as
MDA-LDL, were strongly correlated with eosinophilic inflammation in
the airway and whole body.
Conclusion: Increased visceral fat accumulation during childhood
obesity may induce eosinophilic inflammation in both the airway
and the whole body through adipokine changes and oxidative stress.
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Cardiac autonomic neuropathy (CAN) is an often overlooked chronic
and serious complication of diabetes. Reduced heart rate variability
(HRV) with parasympathetic loss is the earliest subclinical marker of
CAN. The purpose of this study was to investigate predictors for re-
duced overall HRV and parasympathetic loss in youth with
childhood-onset type 1 diabetes mellitus (T1DM) without microvascu-
lar complications.
A total of 113 patients with T1DM (19.7 ± 4.4 years, 55 males), who
were followed up ≥ 5 years, were enrolled between January, 2014
and June, 2015 at Seoul National University Children’s Hospital. To
evaluate overall HRV and parasympathetic activity, time domain
[standard deviation of mean NN intervals (SDNN) and root mean
squared difference of successive NN intervals (RMSSD)] and fre-
quency domain [total power (TP), high frequency (HF)] indices were
measured using 5-min ECG recording using SA-2000E (Medicore Co.
Korea). Multivariate regression model was constructed using possible
covariates (age, sex, diabetes duration, mean HbA1c, diastolic blood
pressure [BP], non-HDL cholesterol, smoking, drinking). The mean
age at T1DM diagnosis were 7.9 ± 4.0 years and diabetes duration
was 11.7 ± 4.4 years (mean HbA1c 8.3 ± 1.1%). The mean HbA1c and
diastolic BP were inversely related to SDNN (P= 0.013 and P= 0.035,
respectively) and TP (P= 0.012, and P= 0.007, respectively) after
adjusting for covariates, indicating that both poor glycemic control
and high BP were significant predictors for reduced HRV in patients
with T1DM. The mean HbA1c and diastolic BP were also inversely
associated with RMSSD (P= 0.012 and P= 0.002, respectively), HF (P=
0.014 and P= 0.007, respectively) after adjusting for covariates, sug-
gesting that both poor glycemic control and high BP were significant
predictors for parasympathetic denervation in patients with T1DM.
Both poor glycemic control and hypertension (especially diastolic)
were independent predictors for reduced overall HRV and parasym-
pathetic denervation in youth with T1DM. Optimizing glycemic and
BP control are important to maintain HRV and prevent CAN.
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Backgrounds: Severe obesity in adolescents has become an import-
ant global public health issue. However, little information is available
for analyzing the associations between abnormal metabolic risk fac-
tors and severe obesity in Korean adolescents.
Methods: This is a cross-sectional study. Among 7197 subjects aged
10–18 years who participated in the 2007-2014 K-NHANES and
checked anthropometric data, 1326 adolescents (male = 744, female
= 582) with age and sex specific BMI ≥ 85th percentile were in-
cluded. These obese adolescents were classified by increasing levels
of BMI percentile according to the following categories: overweight
(85th ≤ BMI 95th percentile), obesity (95th ≤ BMI 120% of 95th BMI),
severe obesity ( ≥ 120% of 95th BMI or BMI 35, whichever was
lower), and extreme severe obesity ( ≥ 140% of 95th BMI or BMI 40,
whichever was lower).
Results: The prevalence of overweight, obesity, severe obesity and
extreme severe obesity were 5.6%, 6.2%, 5.9% and 0.9% in 10-18-
year- old Korean adolescents, respectively. Among the obese adoles-
cents, the proportions of overweight, obesity, severe obesity and ex-
treme severe obesity were 30%, 33.4%, 32%, and 4.7%, respectively.
With increasing level of obese categoty, the mean levels of total
cholesterol (TC, P for trend < 0.001), triglyceride (TG, P for trend
<0.001), low density lipoprotein (LDL, P for trend <0.001), HbA1C (P
for trend < 0.036), systolic blood pressure (SBP, P for trend < 0.001)
were increased and high density lipoprotein (HDL, P for trend <
0.001) was decreased. With increasing level of obese categoty, the in-
cidence of TC ≥ 200 mg/dL (P < 0.007), HDL 40 mg/dL or 50 mg/dL
in girls older than 16 years-old (P <0.001), LDL ≥ 130 mg/dL (P <
0.004), TG ≥ 150 mg/dL (P < 0.003), HbA1C ≥ 5.8% (P < 0.006), SBP ≥
130 mmHg (P < 0.003) increased, respectively.
Conclusions: Adolescents with severe obesity have more metabolic
risk factors than less severe obese form adolescents. Early recogni-
tion of severe obesity is important for assessing and management of
current morbidity in adolescents.
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Background and Objective: Vitamin D (VD) is known to modify pan-
creatic β cell function and affects glucose homeostasis. VD deficiency
can be a risk factor for insulin resistance and diabetes. In the previ-
ous studies, the associations between VD and glucose homeostasis
were reported in late childhood and puberty. On the other hand,
there were a few reports in early childhood about this relationship.
The objective of this study was to examine the associations among
serum concentrations of VD, glucose metabolism and its association
factors in early childhood.
Subjects and methods: 653 infants (male = 341, 52.2%) at 3-years of
age, participating in the NCCHD birth cohort were included in this
study. Random blood samples were obtained during morning hours.
Serum 25-hydroxyvitamin D (25(OH)D) was measured by LC-MS/MS.
Serum insulin (IRI) was measured by CLIA, and plasma glucose levelwas measured by commonly used enzyme method. HOMA-IR and
BMI were calculated from the biochemical and physical data.
Statistical analysis was performed using linear regression analysis and
t-test.
Results: Serum 25(OH)D levels were 23.8 ± 6.1 ng/ml imean ± SD
Arange 9.0 `42.6 ng/ml ). There were no significant difference of
25(OH) D levels between male and female (23.9 ± 6.1 ng/ml vs 23.6
± 6.1 ng/ml) . Significant negative correlation between 25(OH)D and
serum glucose (r |0.22 Ap 0.01) was observed. The number of sub-
jects with VD deficiency ( 20 ng/ml) and VD sufficiency (>20 mg/ml)
were 28.2% (n=184) and 71.8 % (n=469), respectively. VD deficient
group had significantly higher glucose level (73.7 ± 15.2 mg/dl vs
69.2 ± 15.8 mg/dl, p<0.01) and higher HOMA-IR (1.22 ± 1.25 vs 1.01
± 0.82, p<0.02) than in VD sufficient group. Although there were
nosignificant difference, VD deficient group tended to have higher
insulin levels (6.3 ± 5.1 vs 5.7 ± 4.0, p 0.14) and BMI (15.8 ± 1.2 vs
15.6 ± 1.1, p 0.15) compared to VD sufficient group.
Conclusion: Although there is a limitation of interpretation since this
study was conducted in the non-complete fast condition, our data
suggested that Vitamin D deficiency may affect glucose homeostasis
from infancy.
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Objectives: While HbA1c (A1C) has been used as the gold standard
of glycemic control, it is difficult to estimate glycemic control within
a month in case of the measurement every 3 or 4 months. We aimed
to clarify whether the change in the ratio of glycated albumin (GA)
to A1C could estimate the recent past glycemic control based on the
difference in these half-lives.
Methods: We examined individual long-term consistency of GA/A1C
ratio in 306 childhood-onset type 1 diabetes patients whose GA and
A1C were measured simultaneously more than 10 times in the obser-
vational study every 4 months as a period. A concordance between a
change of A1C during previous one month ( Δ A1C) and GA/A1C ra-
tio at test was examined, where A1C value was expressed by both
NGSP (National Glycohemoglobin Standardization Program) and IFCC
(International Federation of Clinical Chemistry) numbers.
Results: We confirmed individual consistency of GA/A1C ratio by the
significant correlation of quadric curve between the products of GA/
A1C ratio at different period over time. The concordance rates of Δ
A1C with the difference between GA/A1C ratio at test and the intrin-
sic value as the individual mean of GA/A1C ratios were higher than
those with SD score of GA/A1C ratio at test as a whole cohort. When
Δ A1C improved ≤ -0.3% (NGSP) or ≤ -2.0mmol/mol (IFCC) and wors-
ened ≥ +0.3% or ≥ +2.0mmol/mol, the concordance rate of Δ A1C
using NGSP number was more accurate to estimate the deterioration
of glycemic control. However, the concordance rate of improved re-
cent past glycemic control was not significant in using either NGSP
number or IFCC number. In addition, a statistically significant positive
correlation was observed between GA/A1C ratio and A1C in NGSP
number.
Conclusions: A change of GA/A1C ratio from the intrinsic value was
useful to estimate the deterioration in the glycemic control within a
month. The discrepancy of estimation was considered to depend on
the difference of A1C expressed by IFCC or NGSP number, due to what
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 49 of 144is measured as A1C in each standardized system. Since A1C in NGSP
number contains non-glycated hemoglobin, GA/A1C ratio may show a
positive relation as A1C gets increased in the NGSP standardization.
Thus estimation using NGSP number of deteriorated glycemic control
was apparently higher than that using IFCC number.P1-2-10
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Background: The mechanism of IUGR resulting in metabolic syn-
drome continues poorly understood and controversial. Normal devel-
opment of pancreas is crucial for the normal structure and function
maintenance. Some studies suggest that autophagy plays an import-
ant role in the development and maintenance of individual cell func-
tion. The aims of this work were: (1) to compare the differences in
autophagy, between β -cells in normal rats and IUGR rats; (2) to
study the regulation mechanism of autophagy in rats with IUGR.
Methodology/Principal Findings: Compared with normal rats, rats
with IUGR had higher levels of autophagy-related proteins LC3B-II,
beclin-1. Furthermore, cytotrophoblasts cultured under hypoxia (2%
oxygen) in the presence or absence of nutlin-3 (a p53 activity stimu-
lator) had higher levels of LC3B-II. Protein expression in IUGR group
compared with the normal group. mTOR and P70S6K (Thr389) ex-
pression were decreased (P <0.05), P-ULK1 (Ser757) was up-regulated
(P <0.05). High fat diet could activate mTOR and P70S6K (Thr389),
and P-ULK1 (Ser757) expression was down regulated (P <0.05).
Conclusion: Elevated levels of autophagy were in pancreas of rats
with IUGR in the middle-late develpment period, as well as that in
adult rats, which might lead to poor development of pancreas. De-
creased mTOR sinaling in IUGR rats could lead to the increase of au-
tophagy. Autophagic activity of β cells of islet of IUGR rats may be
normal in early adulthood.P1-2-11
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Objectives: Immune dysregulation, polyendocrinopathy, enteropathy,
X-linked syndrome (IPEX syndrome) is a rare recessive X-linked her-
editary disease, which is characterized by different clinical manifesta-
tions including autoimmune endocrinopathies, refractory diarrhea
and eczema. It is caused by FOXP3 gene mutation, which results in
abnormality of regulatory T cell, leading to destruction of auto-
immune stability, causing multiple symptoms, and therefore has poor
prognosis. We would like to discuss the current research of the dis-
ease by studying the diagnose and treatment of a 6-year-old boy
with IPEX syndrome, in order to avoid misdiagnosing.
Methods: The initial finding of the patient was insulin-dependent
diabetes mellitus iIDDM ) when he was 2 years old. Repeated respira-
tory tract infections during the treatment suggested the immune
dysregulation with a markedly increase IgE level. Diabetes nephropa-
thy was diagnosed when he had proteinuria at the age of 4, with
concomitant repeated intestinal infection, with eczema around the
mouth, electrolyte disorders and malnutrition. Therefore, he was clin-
ically diagnosed as IPEX syndrome and took a genetic analysis.Results: We identified a missense mutation in his FOXP3 gene
(c.1010G>A Cp.Arg337Gln). His mother was an asymptomatic female
gene carrier (heterozygous) while his father had no mutation in this
gene loci. Hence this child was diagnosed with IPEX syndrome and
treated with methylprednisolone.
Conclusions: We’ve diagnosed the IPEX syndrome through the clin-
ical features and gene analysis. Children with early-onset IDDM, re-
fractory diarrhea and eczema should be considered the possibility of
IPEX syndrome and FOXP3 gene analysis will provide a guiding sug-
gestion in diagnosing. During the acute stage, supporting therapy in-
cluding infection control, glucose regulation and parenteral nutrition
should be taken to improve symptoms, while immunosuppressant
agents or hematopoietic stem cell transplantation (HSCT) will play an
important role in the further treatment.
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Background: Diabetes education is essential in diabetes care. Inter-
net can be a tool to provide educational intervention in children with
T1DM.
Aim: The objective is to develop a web-based education programme
to assist in diabetes management and to provide support for chil-
dren with T1DM in Malaysia.
Methods: Data was collected in three phases using a mix-method ap-
proach. There were 91 participants; 64 children with T1DM, 12 par-
ents and 3 clinicians from Malaysia. An additional 12 Malaysian
children who were living in Newcastle were invited to participate in
the study.
In phase one, the data was collected using both qualitative and
quantitative method to understand the challenges of children with
T1DM (n=52). They were asked to identify regularly consumed
carbohydrate-rich foods. In phase two, a semi-structured interview
and an open- ended questionnaire given to healthy children in New-
castle (n=12). This is to analyse views and general usability of the
website. In the final phase, children with T1DM and their families
(n=12) were recruited and introduced to the website. They were
guided on how to use it at home for six months. Semi-structured in-
terviews were conducted on these children, their parents and clini-
cians (n=27). An additional set of questionnaires were given to the
children only (n=12) to analyse participants’ views, experiences and
acceptance of the website.
Results: All children reported that the website is useful to obtain in-
formation on carbohydrate content of foods and drinks. They used it
to adjust insulin accordingly. They reported that they have made
changes in their food choices based on the information obtained
from the website. Most of them did not record their blood glucose
(BG) regularly into the BG meter diary in the website. The majority
n=10 (83%) felt more confident in managing their diet, insulin, and
monitoring BG. Seventeen percent (n=2) reported that the website
did not help to improve confidence level or manage their diabetes
better. The clinicians indicated that the website was helpful in the
clinic setting to teach and review children’s BG and dietary intake.
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the children to use for self-education and self-management system.
Conclusion: This study suggested that the website provides add-
itional benefit to the children and their parents in terms of improving
knowledge on carbohydrate content, diet choices, insulin adjustment
and confidence level. The website is useful for the clinicians to help
educate children with T1DM during clinic visits.
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Study Objective: To investigate whether sleep deprivation is a risk
factor for obesity in adolescents.
Design: Cross-sectional study.
Setting: Korean National Health and Nutrition Examination Survey.
Participants: Subjects were 4,126 adolescents, aged 12-18 years old,
who participated in the Korean National Health and Nutrition Exam-
ination Survey IV and V, conducted between 2007 and 2012.
Measurements and Results: Subjective sleep duration was evaluated
as a risk factor for obesity. Hours of sleep were self-reported. An-
thropometric measurements, a questionnaire about medical history
and lifestyle, and biochemical laboratory measurements were con-
ducted. Body mass index (BMI) z-scores were decreased with longer
sleep duration. Subjects were classified according to sleep duration
as those who slept ≥ 9 h/night, those who slept 7 to 9 h/night, and
those who slept < 7 h/night. Odds of obesity were assessed accord-
ing to sleep duration. Adolescents who slept < 7 h/night had higher
odds of being obese (OR = 1.39, 95% CI 1.04-1.87) than adolescents
who slept ≥ 7 h/night. One additional hour of sleep duration reduced
obesity risk 11% (OR = 0.89 95% CI 0.81-0.98) and decreased BMI z-
scores at the rate of 0.08. These finding were more significant in boys
than in girls. Physical activity, energy intake, and stress (as index
scores) did not increase the risk for obesity.
Conclusions: Sleep deprivation increases the risk for obesity in ado-
lescents, while the degree of physical activity and energy intake may
be not associated with obesity.
P1-2-14
Fulminant Type 1 Diabetes Mellitus in Japanese Children and
Adolescents
Kentaro Shiga1,7, Tatsuhiko Urakami2,7, Junichi Suzuki2,7, Yasuhiko Igarashi3,7,
Hanako Tajima4,7, Shin Amemiya5,7, Shigetaka Sugihara6,7
1Yokohama City University Medical Center, Children's Medical Center;
2Department of Pediatrics, Nihon University Hospital; 3Department of
Pediatrics, Igarashi Children's Clinic; 4Nippon Medical School;
5Department of Pediatrics, Saitama Medical University; 6Department of
Pediatrics, Tokyo Women's Medical University Medical Center East; 7The
Japanese Study Group of Insulin Therapy for Childhood and Adolescent
Diabetes (JSGIT)
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-2-14
Objective: Fulminant type 1 diabetes mellitus (FT1DM) is a subtype
of T1DM characterized by remarkably abrupt onset. Reportedly, the
frequency of FT1DM is approximately 20% of adult onset-T1DM in
Japan. On the contrary, few reports have described FT1DM in
pediatric patients. The purpose of this study is to determine the fre-
quency and clinical characteristics of FT1DM in Japanese children
and adolescents.
Method: A 2-phase questionnaire survey was sent to the members of
the Japanese Study Group of Insulin Therapy for Childhood and Ado-
lescent Diabetes (JSGIT) regarding their clinical experience with
FT1DM with the age at onset below 16 years. This group is consisted
of pediatric diabetologists from 79 hospitals and is the largest study
group for pediatric T1DM in Japan.Results: Responses to the questionnaires were obtained from 54 of
79 hospitals (collection rate, 68.4%). Overall, 9 hospitals had treated
17 pediatric patients with FT1DM (5 patients, 4 patients and 2 pa-
tients in 1 hospital each, and 1 patient each in 6 hospitals). The distri-
bution of patient age was biphasic, including young children aged
below 5 years and children above 8 years of age. The clinical charac-
teristics of the disease in this population, such as severity of the
symptoms at onset and precursor symptoms, did not differ from
those of adult-onset FT1DM.
Conclusion: Among children and adolescents, the frequency of
FT1DM is rather rare compared to those of adult. Since FT1DM is a
life- threatening metabolic state, early as possible and accurate diag-
nosis and an appropriate therapy are crucial. Pediatricians should
take enough notice of the diagnosis of FT1DM.
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Combined therapy with pump and long acting insulin for type 1
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Kosuke Imai1, Kenichi Kashimada1, Tatsuhiko Urakami2, Tomohiro Morio1
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Background: STAT 1 gain-of-function (GOF) is the most common
genetic cause of autosomal dominant chronic mucocutaneous can-
didiasis (AD-CMC) and underlies a variety of infectious and auto-
immune features. AD-CMC is a rare condition, and type1 diabetes
mellitus (T1DM) is one of the concerning complications of GOF
STAT1 mutation. However, clinical details of T1DM with AD-CMC have
not been clarified. Here we report a clinical course of a case with
STAT 1 GOF who developed T1DM at the age of three months.
Case report: Since developing T1DM, she received insulin therapy
with continuous subcutaneous insulin infusion (CSII), and the control
was acceptable for her age with 8.2% of HbA1c. Since the age of 3
years, she repeated to candidiasis at scalp, genitalia and oral cavity.
She was referred to our hospital for closer examination for immuno-
deficiency, and heterozygous missense mutation (Met202Glu) in
STAT1 was identified, diagnosing her with AD-CMC. Simultaneously,
the control of her blood glucose became worse with more than 10%
of HbA1c, and the control was not improved by introducing sensor
augmented pump (SAP) at the age of 7 years. Her blood glucose
fluctuated violently due to unstable effect of insulin therapy. By close
monitoring, we learned that instability of insulin effect was more
prominent on the second day after changing an infusion set and res-
ervoir, requiring changing the set every 2 days. She frequently devel-
oped a subcutaneous nodule at infusion site, and we suspected that
unexpected inflammation due to AD-CMC has occurred in site, result-
ing in unstable effects of the insulin therapy by blocking the tube or
by affecting insulin absorption in site. For the sake of stable supply
of insulin, we introduced injection of long acting insulin together
with SAP, and her blood glucose level was remarkably improved
from 11.3% to 8.7% of HbA1c.
Discussion: STAT 1 is involved in various signaling inflammatory
pathways of IFN- γ , IFN- α / β , IL-27, IL-6 and IL-21. We assume that
GOF mutation of STAT1 may activate those pathways, subsequently
causing unexpected inflammatory reaction to insulin or to stimula-
tion by catheter.
Conclusion: Insulin pump therapy accompanied with long acting insulin
would be a useful option for the therapy of T1DM with STAT1 mutation.P1-2-16
Permanent neonatal diabetes mellitus due to a G32S heterozygous
mutation in the insulin gene
Xiao-Qin Xu, Ke Huang, Fang Hong
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Background/ Objective: Non-alcoholic fatty liver disease (NAFLD) has
emerged as a significant complication of childhood obesity affecting
30-50% of all obese children in various studies. Ultrasonography
(USG) is typically used as the screening tool. The present study was
undertaken to determine the sensitivity and specificity of USG for
diagnosis of NAFLD in overweight adolescents as compared to meas-
urement of hepatic fat fraction by MRI.
Methodology: The study was conducted at Departments of Radi-
ology and Pediatrics, All India Institute of Medical Sciences, New
Delhi after ethical approval and voluntary informed consent. Thirty-
four overweight adolescents (mean BMI SDS 2.3 +/- 1.1), aged be-
tween 10 – 15 years were included in the study. They underwent
grey scale sonography in a single state of the art ultrasound scanner
by a single observer. NAFLD grading was done as 0 (absent), 1 (mild),
2 (moderate) and 3 (severe) on USG. Chemical shift MR imaging with
dual echo Dixon method was performed. Fat fraction (FF) was calcu-
lated from the in phase and opposed phase images as FF= signal in
in-phase (IP)- signal in opposed phase (OP)/ 2 x IP.
NAFLD grading in MRI was done as present (0) and absent (1); taking
a cut off of 5% FF for the presence of fatty liver.
Results: Fatty liver was present in 22 (22/34; 64.7%) cases on USG,
and 16 (16/34; 47.1%) on MRI. In 22 cases the MRI and USG findings
were congruent. In three cases, MRI detected fatty liver with a fat
fraction of 7.5, 9 and 11.9 but USG failed to detect fatty liver. In 9
cases, USG detected NAFLD but on MRI it was not designated as fatty
liver as the fat fraction was < 5% (0.85- 4.9). In 8 of these 9 cases, the
USG diagnosis was mild NAFLD. Considering MRI as the gold stand-
ard, the sensitivity and specificity of USG were 0.81 and 0.50,
respectively.
Conclusion: USG is more susceptible to subjectivity and inter and
intra-observer variability, which may miss mild NAFLD, as well as
overdiagnose it. The sensitivity is acceptable but specificity is low.
Hence USG can be used as a screening test for NAFLD, but the diag-
nosis should ideally be confirmed by estimation of hepatic fat frac-
tion by MRI.
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Think beyond type 1 and 2 diabetes
Antony Fu
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A teenage girl initially presented to our department for short stature.
She was a product of non-consanguinous parents with Chinese back-
ground. She has also been followed up by opthalmology and surgery
for retinopathy and sensorineural hearing loss respectively.
Almost a year after presentation, she started to developed nocturia,
polyuria and polydipsia. Investigations showed hyperglycemia, keto-
sis without acidosis, HbA1c 14.1 %, borderline low C-peptide and
negative anti-islet cell antibody. She has been put on multi-dose in-
sulin for presumably type 1 diabetes since then.
Another year after insulin treatment, she complained of anorexia and
frequent abdominal pain. Subsequent workup revealed primary
hypoparathyroidism. Therefore she was put on calcium supplement
and caltriol with satisfactory response.
Putting diabetes, primary hypoparathyroidism, hearing loss and retin-
opathy together, we kickstarted the genetic study which confirmed
the diagnosis of Kearns-Sayre syndrome. Her lactate and creatine kin-
ase levels were normal, recent echocardiogram and electrocardio-
gram were both unremarkable. She was treated with Riboflavin and
Coenzyme Q10 thereafter.
This case outlines the importance of thinking outside the box - espe-
cially when we encounter co-morbidities beyond the scope oftraditional type 1 and 2 diabetes. Earlier recognition and treatment
could make a difference.
Consent for publication: The author declares that informed consent
was obtained for publication.
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Introduction: Type 1 diabetes mellitus (T1D) is a non-curable disease
which requires continuous patient self-management for maintaining
blood glucose control hence preventing related complications. Many
studies have found associated incidences of psychiatric disorders in
children and adolescents with T1D for example depression, anxiety
or eating problems. Furthermore the pediatric patient’s parents have
also suffered from conflicts over patient management of T1D and, in
general, a lower quality of life resulting from the burden of taking
care their children and taking time off work.
Objectives: Our study aims to determine the prevalence of mental
health issues and to analyze several factors affecting patient’s mental
health including gender, parental marital status, primary care givers,
family income, duration of diabetes, insulin regimen and frequency
of self-monitoring of blood glucose (SMBG) and the association be-
tween mental health issues and glycemic control.
Methods: A cross-sectional descriptive study had been done with
T1D patients and parents who attended the pediatric diabetes clinic
during 1 August 2015 to 31 January 2016 using standardized
screening questionnaires. For the children, both the Children’s
Depression Inventory (CDI) Thai version and the Eating Attitudes
Test-26 (EAT-26) Thai version were used. For the parents, the Thai
Youth Checklist (TYC) for analyzing behavioral and emotional prob-
lems was used.
Results: Seventy-nine T1D (50 females, 29 males) patients and sixty-
eight care-givers were enrolled. Mean patients age was 12.3 ± 2.8
years, mean diabetes duration was 4.9 ± 2.7 years. The screening re-
sults found that T1D patients had positive behavioral/emotional
problems, depression, and eating problems at 16.2% (11/68), 22.7%
(17/75) and 33.3% (7/21), respectively. No positive screening results
were found in patients with good glycemic control as noted by
HbA1c of less than 7.5%. In addition, there were no associated fac-
tors between all mental health issues and glycemic control among
patients with HbA1c <7.5%, 7.5–9% and >9% (p >0.05). The same
could be said for the gender, primary care giver, family income, dur-
ation of diabetes, insulin regimen and number of SMBG per day fac-
tors. Nevertheless a divorced family status was significant indicator
related to a patients’ eating problems (p = 0.024).
Conclusions: Childhood and adolescents with T1D have an increased
risk of developing eating disorders, depression and behavioral/emo-
tional problems, leading to deterioration of glycemic control, thus in-
creased awareness as well as early detection in diabetic children and
adolescents is required.
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Adiponectin, Interleukin-6 and high-sensitivity CRP levels in
overweight/ obese Indian children
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Background/ objectives: Interleukin (IL)- 6 and high-sensitivity CRP
(hsCRP) are markers of inflammation associated with risk of
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 52 of 144cardiovascular disease and diabetes. Low Adiponectin levels are asso-
ciated with insulin resistance. The aim of this study was to assess
serum IL-6, hsCRP and Adiponectin and their correlation with con-
ventional risk factors for cardiovascular disease and diabetes in over-
weight/obese Indian children.
Methodology: Children between 7-15 years, with BMI > 85th centile
were enrolled from Pediatric outpatient at AIIMS, New Delhi. Weight,
height, waist circumference (WC) and BP were measured. Fasting
blood sample was drawn for glucose (BG), total cholesterol (TC), HDL
cholesterol (HDL), triglycerides ( TG), adiponectin, IL-6 and
hsCRP. The following cut-offs were taken to define abnormality:
BG > 100mg/dl, TC ≥ 200mg/dl, LDL ≥ 130mg/dl, HDL 150mg/dl,
Adiponectin 3 mg/L and IL-6 > 10 pg/ ml. Data was expressed
as mean/ median and proportion with abnormal values. Correla-
tions were checked between adiponectin, IL-6 and hsCRP and
BMI, WC and BG.
Results: Eighty-four subjects (48 boys) with mean age 10.2 ± 1.9 yrs,
and mean BMI z-score 2.7 ± 0.8 were enrolled. Two-thirds were pre-
pubertal and 67.3% had abdominal obesity. Mean systolic and dia-
stolic BP was 113 ± 10 and 74 ± 10 mm Hg, with hypertension in
15.5%. The biochemical parameters are summarized in Table 1. Low
HDL was noted in 35.1%, impaired fasting glucose in 10.7% and low
Adiponectin in 16.5%. High inflammatory mediators, IL-6 in 54.4%
and hsCRP in 49.4% constituted the commonest abnormality. Adipo-
nectin was inversely correlated with WC (r= -0.28, p=0.047). IL-6 was
positively correlated with BMI (r=0.23, p= 0.09), and BG (r=0.24,
p=0.08). IL-6 was higher in children with impaired BG as compared
to those with normal BG (107 (IQR 22.5 – 197.5) vs. 8.5 (5-116) pg/ml,
p=0.06).
Conclusions: Inflammatory mediators hsCRP and IL-6 were elevated
in half of the subjects. Inverse correlation between Adiponectin and
waist circumference and positive correlation between IL-6 with BMI
and fasting glucose indicated the usefulness of these markers in
pediatric population.Table 1 (Abstract 1-2-20) See text for descriptionP1-2-21
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Objective: The oral hygiene level in obes with Type 1 Diabetes
Mellitus needs to be elucidated. The purpose of this study was to
evaluate the oral hygiene status in obese with Type 1 Diabetes melli-
tus and normal weight adolescents.Methods: A cross-sectional survey of 13-15-year-old adolescents was
conducted on a sample of totaly 36 who were admitted to pediatric
endocrinology clinic in 2014 and 2015. The sample was divided into
equal two groups: ODM (obese with Type-1 Diabetes Mellitus; n = 18; 11
boys and 7 girls, mean age 13.21) and N (normal weight; n = 18; 9 boys
and 9 girls, mean age 14.01). The subjects were asked to complete a
questionnaire concerning medical history and dietary/oral hygiene habits.
For anthropometric evaluation, the body mass index (BMI)-for-age was
used. In oral examinations, the study used Oral Hygiene Index (OHI) and
Gingival Bleeding Index (GBI) for the evaluation the oral hygiene status.
Statistical differences were evaluated Chi-square, odds ratio (OR), Wil-
coxon and Pearson correlation tests were used (P < 0.05).
Results: In both groups, the participants displayed similar oral hy-
giene habits According to the total sample, 2/18 ODM (11.1 %) and
8/18N (44.4 %) had good OHI, while 7/18 ODM (38.9 %) and 2/18 N
(5.5%) were classified in a low level of OHI, with a significance be-
tween the groups (p < 0.001), even after sorting by age. According
to the classification of GBI, 18/18 ODM (100.0%) and 13/18 N (72.2%)
had GBI 1 (bleeding gingiva), and 0/18 ODM and 5/18 N (27.7%)
were classified as GBI 0 (healthy gingiva), with a significance between
the groups (p <0.001), even after sorting by age.
Conclusions: This study indicated that oral hygiene level were signifi-
cantly lower in the ODM group.P1-2-22
Construction of remote monitoring system of the elementary
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Background: A school nurse and a school physician do screening of
short stature and overweight by height and weight measured in the
school health examination. Furthermore, in the municipality, practi-
tioners are doing medical examination to preventing for children’s
unhealthy lifestyle to applicants. However the pediatric endocrinolo-
gists of the ward sometimes examine the first visit patients with
short stature, highly obese or type 2 diabete patients who have
passed a few years from the onset.
Objective: To reveal how many children who have the extent phys-
ique problems from height and weight data obtained from school
health check of the ward there are. To build a regional cooperation
system not to miss the patients who hospital consultation from the
onset becomes too late. This study shows the change of the fre-
quency the elementary school upper grades child with problems in
physique of 2 years.<br />
Methods: We analyzed the height and weight data which had been
input to the academic affairs system and which were the total of 14
times in the school medical examination from April 2011 to Septem-
ber 2015. Sharing the results with the Medical.
Result: We were able to obtain the data of 10,022/10031 children (in
fiscal 2014/2015) to sixth graders from fourth graders who belonged
to the public elementary school of the ward. 254/320 students with
tall stature (Total 2.67%/3.19%: 4th Grade 2.55%/3.05%, 5th 2.79%/
3.08%, 6th 2.36%/3.44%), 147/108 students with short stature (Total
1.55%/1.08%: 1.27%/1.01%, 1.58%/0.92%, 1.59%/1.31%), 740/1054
obese students (Total 7.52%/10.51%: 7.50%/11.18%, 7.58%/11.22%
7.54%/9.14%), 560/825 slimming students (Total 5.69%/8.22%: 4.47%/
10.73%, 5.88%/7.79%, 7.07%/6.23%).
Conclusion: Unlike propotion of the tall stature, that of short stature
was about 1.0-1.6% not follow Gauss distribution. According to the
school year it goes up, because the students that have problems in
physique poor weight gain, obesity, short stature was observed tends
to increase, there is a need for early intervention.
Table 1 (abstract P1-3-2). See text for description
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Background: Azoospermia and oligozoospermia are multifactorial
conditions that affect more than 1% of adult men. To date, 26 genes
have been implicated in the development of non-obstructive azo/
oligozoospermia. However, there is no single report of systematic
mutation screening of these genes in patient cohorts. Thus, the signifi-
cance of monogenic mutations in the etiology of azo/oligozoospermia
remains unknown.
Objective: To clarify the frequency of mutations in known probable
pathogenic genes in Japanese patients with non-obstructive azo/
oligozoospermia.
Materials and Methods: The study group consisted of 48 Japanese pa-
tients with non-obstructive azo/oligozoospermia. Next generation se-
quencing was performed for coding regions of ART3 , BPY2 , DBY,
DNMT3L , FKBP6, FKBPL , KLHL10, MEI1 , MSH4 , PARP2 , PLK4, PRDM9 ,
PYGO2 , RBMY , SEPTIN12 , SOHLH1 , SPATA17 , STRA8 , SYCP3 , TAF4B ,
TAF7L , TEX11 , UBR2, USP9Y, ZMYND15 and ZNF230. In this study,
we focused on nucleotide alterations that affect protein sequences
or splice sites. Nucleotide changes whose frequency in the general
population is more than 1.0% were excluded as common polymor-
phisms. Functional consequences of missence variants were pre-
dicted by two in silico assays.
Results: A total of 19 nucleotide alterations were identified in 16 of
48 patients. These variants consisted of 4 hitherto unreported substi-
tutions and 15 rare polymorphisms. Of the 19 nucleotide alterations,
9 were assessed as “possibly/probably damaging” or “deleterious” by
in silico assays. In addition, 3 substitutions affected splice sites. Of
these, c.346-1G>A in SOHLH1 and c.A511G in TEX11 have been
reported as the cause of azoospermia.
Conclusions: This study indicates that nucleotide alterations in
known probable pathogenic genes account for a certain fraction of
cases with non-obstructive azo/oligozoospermia. These results need
to be validated in future studies.
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Background: Familial lipoprotein lipase(LPL) deficiency is an ex-
tremely rare autosomal recessive disorder of lipoprotein metabolism
occurring in 1 per million population. LPL is responsible for the clear-
ance of chylomicrons(large lipoprotein molecules) from circulation.
LPL is produced by myocytes and adipocytes, transported to the vas-
cular endothelium for lipolysis of triacylglycerols in chylomicrons. LPL
deficiency could happen due to mutations of LPLgenes/apoCII/
apoA5/GPIHBP1/LMF1.Clinical features associated with LPL deficiency include recurrent ab-
dominal pain, poor growth, xanthomatosis, hepatosplenomegaly, lipe-
mic plasma. Severe complications such as recurrent pancreatitis and
lipid encephalopathy could happen. Treatment options include dietary
fat restriction, use of medium chain triglycerides, fibrates, plasmapher-
esis and alipogene tiparvovec gene therapy. Acquired hypertriglyceri-
demia(HTGL) observed in patients with diabetes mellitus improve with
insulin, dietary fat restriction, fibrates or niacin. Acquired LPL deficiency
is observed during insulin deficiency and could be improved with insu-
lin therapy. Hence, we tried the option of glucose- insulin infusion in a
2 month old boy with recurrent pancreatitis.
Case Scenario: Third born 2 month old boy of 3rd degree consanguin-
eous parents had developed fever and vomiting at 10 days of life.
Laboratory investigations revealed lipemic serum. He had suffered four
episodes of acute pancreatitis by 2 months. Lipid profile is available in
Table 1. A homozygous novel mutation was detected in exon 6 of the
LPL gene c.904T>C/ p.Cys302Arg which created a missense mutation in
the coding region. Other investigations were normal.
Treatment: Baby was treated with pancreatitis protocol. Extremely low
dose of insulin was infused simultaneously with glucose along-with
hourly glucose monitoring. Baby did not have any episodes of pancrea-
titis after the glucose-insulin intravenous infusion. He is currently on
fat-restricted diet with medium chain triglycerides(MCT) and growing
normally. Another schedule of IV glucose-insulin infusion helped reduce
the triglycerides back to near normalcy at 9 months of age while oral
fibrates and sub-cutaneous insulin were ineffective.
Future: Subcutaneous insulin needs to be tried on a few more occa-
sions with regular glucose monitoring to enable effective manage-
ment at home. Glucose-insulin therapy should be replicated in more
patients and could be a cheaper option for familial LPL deficiency.P1-3-3
Glycemic Levels in Normal Newborn-Preliminary Results
Raphael DR Liberatore Junior, Nathalia Azevedo, Daniela Daltoso,
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The definition of glycemic normal variation in the newborn period is
one of the most difficult patterns in neonatology. Different values
are proposed based mainly in data from blood glucose samples ob-
tained in the 60’s from the last century.
We proposed to check glycemic interstitial levels in the first 24 hs in a
group of normal newborns using a glycemic sensor (Medtronic IproII)
Fig. 1 (abstract P1-3-4). See text for description
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were born with more than 38 weeks of gestational age, with no med-
ical problem, and Apgar Score of more than 8 in the first minute. The
mothers were not in use of any medication and have no know medical
condition. All babies received only breast milk from their own mother
and nothing else, including water. The study was approved by ethical
committee and the sensor was installed only after write permission
from the mother and the father. The results were achieved and showed
minimum, maximum, median and standard deviation.
30 normal babies with gestational age between 38 and 41 weeks were
studied. The weight ate the born range between 2610 and 3825 grams.
The minimum value ranged between 40 and 67 mg/dl, median 47,5
mg/dl. The maximum value ranged between 53 and 99 mg/dl, median
59,5 mg/dl. Normal curve for minute after born will be showed.
The results show that interstitial glycemic levels in normal babies are
very close to normal levels in older children. Those results would be
very important to define normality of glycaemia.
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Background: Generalised pseudohypoaldosteronism type1(PHA1) is an
extremely rare salt wasting disorder with hyponatremia, hyperkalemia
and metabolic acidosis with elevated levels of aldosterone. Homozy-
gous or compound heterozygous inactivating mutations of the alpha,
beta or gamma sub-units of amiloride-sensitive epithelial sodium chan-
nel(ENaC) could result in PHA1(OMIM #264350). While severe salt wast-
ing happens from kidneys, colon, sweat, salivary glands in autosomal
recessive generalised PHA1(arPHA1), the autosomal dominant PHA1 is
a mild disease. The child reported here is the first SCNN1B mutation
arPHA1 from India with a novel mutation too.
Case Scenario: Term boy born by caesarean section to non-
consanguineous parents developed purulent conjunctivitis and acute
otitis media on Day 3 of life which was unresponsive to standard
management. Baby was admitted on Day7 with normal activity, 16%
weight loss and dehydration.
Investigations revealed severe hyperkalemia (10.2mEq/L), hyponatre-
mia (127mEq/L) and acidosis (pH=7.2). Serum creatinine, calcium,
phosphorus and creatine kinase were normal. Child was treated with
anti-hyperkalemic measures (parenteral calcium gluconate, glucose-
insulin infusion, salbutamol nebulisation, bicarbonate, per-rectal po-
tassium binders), parenteral antibiotics, oral hydrocortisone and
fludrocortisone with a provisional diagnosis of congenital adrenal
hyperplasia. Synacthen stimulation test revealed normal 17OH pro-
gesterone, DHEAS and cortisol peak. Serum aldosterone (>150ng/dL;
normal=1-16) and plasma renin activity (12.44ng/ml/hour;nor-
mal=0.15-2.33) were elevated with persistently elevated serum potas-
sium (K+) and reduced urinary potassium. PHA1 was diagnosed and
oral salt was added after stopping hydrocortisone. Electrocardiogram
revealed severe hyperkalemia. Since K+ continued to be high, peri-
toneal dialysis was undertaken after a difficult catheter insertion. K+
dropped to normal levels (4.5mEq/L) and baby was discharged home
on oral salt and per-rectal potassium binders. Child returned within a
week with severe hyperkalemia and succumbed inspite of all treat-
ment measures.
Genetics: Modified NGS panel with custom bioinformatic pipeline
run revealed homozygous novel variant in exon 8 of the SCNN1B
gene c.1212C>A /p.Tyr404Ter (Y404X) which resulted in premature
termination of the amino acid chain. Not previously reported in data-
bases, but pathogenic as per all prediction algorithms.
Conclusion: Clinical suspicion, prompt diagnosis and management of
electrolyte abnormalities would probably help children with less se-
vere phenotype. Initiation of routine mutation analysis in suspected
PHA1 Indian children would help in research into successful treat-
ment measures.Consent for publication: The authors declare that written informed
consent was obtained for publication.P1-3-5
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treatment of hyponatremia in a pediatric patient with chronic
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Background: Tolvaptan is a vasopressin V2 receptor antagonist for
the treatment of euvolemic and hypervolemic hyponatremia. Tolvap-
tan has demonstrated eficacy in adult patients with syndrome of
inappropriate antidiuretic hormone secretion (SIADH); however, there
are only a few reports of SIADH in children. Moreover, use of
tolvaptan for the treatment of SIADH is not covered by the medical
insurance in Japan. SIADH is usually transient and self-limited and
can be controlled by short-term water restriction and sodium supple-
mentation. However, the management of chronic SIADH is more diffi-
cult, especially in children.
Patient report: The patient was a 4-year-old Japanese boy. A delayed
language development was noted at a medical check-up for children,
at 3 years of age. A brain magnetic resonance imaging (MRI) revealed
midbrain tumor and ventricular enlargement. He had undergone an
endoscopic third ventriculostomy and tumor biopsy at 3 years and 4
months of age; finally, he was diagnosed as having pilocytic astrocy-
toma. Since then, his serum sodium concentration fluctuated in the
range of 120~130 mEq/L denoting asymptomatic hyponatremia. He
had generalized tonic-clonic seizure with fever at the age of 4. We
diagnosed chronic SIADH based on his clinical data. In spite of water
restriction (800 mL/day) and oral sodium supplementation, his hypo-
natremia did not improve. Then, on anticonvulsant treatment, he de-
veloped afebrile convulsions several times. He was administered oral
tolvaptan at 15 mg daily (0.5 mg/kg/day) together with mild water
restriction (1000 mL/day). A serum sodium concentration of 130 -135
mEq/L was achieved, and the drug was well tolerated without any
side effects. Therefore, the dose of tolvaptan was increased to 22.5
mg daily (0.8 mg/kg/day). After tolvaptan treatment, no seizures
were reported.
Conclusion: In this patient with chronic SIADH after the surgical
treatment for pilocytic astrocytoma, tolvaptan was effective and safe
in maintaining the serum sodium concentrations at 130 mEq/L or
above. Further clinical studies are necessary for understanding the ef-
fect and safety of the long-term use of tolvaptan in children.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Objective: To provide for the basis of pathological change for the ef-
fect of Letrozole on the reproductive function and linear growth in
the early puberty rats.
Method: At 3 weeks (20-22 days) of age, 14 of 20 SD rats were ran-
domly divided into experimental group (male and female half ),
treated with letrozole solution 1 mg/kg/d, 6 of control group (male
and female half ), treated with 0.1 ml distilled water, both groups
take for 30 days. Every 3 to 4 days weighing, measuring length (nose
long anal), the left tibia weight, after 30 days, anesthesia to death
and take bilateral ovaries rats (female), testis (male) and left tibial tis-
sue section, using HE staining to observe each group rats ovary (fe-
male), testis (males) and the left tibia pathological changes of
organizations.
Results: 1.The testicular tissue of sperm cells development, mature
sperm counts, sertoli cell development and interstitial cells of experi-
mental group had no significant change compared with control
group. 2.The experimental group had ovarian cystic structure and
atresia follicles significantly increased than control group, appeared
the polycystic ovary (PCOS) change, and significantly reduce the
granular cell layer. 3.Letrozole had a tendency to increase on the
growth plate in the early puberty rats (male, female), which is more
obvious in the male rat.
Conclusion: 1.30 days use of letrozole in the early puberty male rats
had no obvious influence on testicular tissue, its sperm cells develop-
ment, mature sperm counts, sertoli cell development and interstitial
cells had no significant change compared with control group. 2.30
days use of letrozole can cause polycystic ovary change in the early
pubertal female rat. 3.30 days ues of letrozole had a tendency to in-
crease on the growth plate in the early puberty rats (male, female),
which is more obvious in the male rat.P1-3-7
Endocrine dysfunctions in Mandibular Hypoplasia, Deafness,
Progeroid Features (MDP) Syndrome: A Case Report and Review of
the Literature
Ting Chen, Linqi Chen, Haiying Wu, Fengyun Wang, Xiuli Chen,
Rongrong Xie
Children's Hospital of Soochow University, Endocrinology and
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Objective: Mandibular hypoplasia, deafness, and progeroid features
and lipodystrophy (MDPL) syndrome is an autosomal dominant dis-
order characterized mainly by mandibular hypoplasia, sensorineural
deafness, progressive lipodystrophy, and hypogonadism in male. This
syndrome is caused by heterozygous mutations in POLD1 gene.
Short stature was described in half of the reported cases.
Subjects and methods: We report here the clinical description of a
10-year-old boy first presented with short stature and hypogonadism.
After GH treatment, his fat loss gradually became obvious. We clari-
fied his genetic bases through whole-exome sequencing analysis,
and verified the results via sanger sequencing. We also carefully ex-
amined the GH/IGF-1 axis, hypothalamic-pituitary-testicular axis, and
islet function in the MDPL patient.
Results: This article reports the 13th MDPL patient with de novo p.
S605del mutation in POLD1 , and the first MDPL patient in Eastern
Asia. We found that GH levels after GH stimulation tests were normal,
while baseline IGF-1 level was extremely low. The rhGH therapy was
effective in accelerating growth velocity, but it would accelerate fat
loss and should be contradicted. We also found that the patient had
extremely low baseline AMH and testosterone after HCG stimulation.
Glucose and insulin levels were normal during OGTT in the patient.Conclusions: Our findings suggested that MDPL syndrome was a
possible diagnosis in boys with both short stature and hypogonad-
ism, and rhGH therapy should be started only when this syndrome
was excluded. Our study provided better understandings of the
endocrine disorders in MDPL syndrome.P1-3-8
Mutation analysis of BSCL2 gene in two patients with type 2
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Context: Type 2 congenital generalized lipodystrophy (CGL2, OMIM
269700) is a rare autosomal recessive disease, characterized by the
generalized absence of adipose tissue at birth or in early infancy. Mu-
tations in BSCL2 gene have been reported to be responsible for
CGL2. Objective To analyze the clinical characteristics of two patients
with CGL2, and to investigate the BSCL2 gene in two pedigrees.
Methods: Medical history, clinical manifestations, physical examin-
ation, laboratory data, and ultrasonography findings were analyzed
from two patients with CGL2. Blood samples from both families were
obtained for genome DNA extraction. And then the 2742 genes of
inherited diseases were amplified by PCR and sequenced.
Results: Two patients mainly showed generalized lack of body fat
with extreme muscularity from birth, hirsutism, skin pigmentation es-
pecially necks and armpits; abnormal faces with empty cheeks,
growth acceleration, advanced bone age; hepatomegaly, one of the
patients presented with macropenis, renal hypertrophy, and mental
retardation; laboratory data showed hypertriglyceridemia, hyperchol-
esterolemia, and low high-density lipoprotein cholesterol. During the
follow-up, they appeared bad temper, irritability, with aggressive be-
havior, abdominal ultrasound of patient 1 prompted fatty liver. They
were treated with low-fat, high-carbohydrate diet, blood lipids were
controlled to some degree. BSCL2 gene of patient 1 showed a homo-
zygous mutation of c.728dupG, p.Ile262Hisfs * 12, whose parents
were carriers of the
heterozygous mutation; BSCL2 gene of patient 2 showed a com-
pound heterozygous mutation: missense mutation c. 713G> A,
p.Gly238Asp from paternal; nucleotide repeat c.728dupG, p.Ile262-
Hisfs * 12 from maternal.
Conclusion: We describe two patients with classic clinical manifesta-
tions of CGL2 confirmed by genetic sequence analysis. Of them, the
c.713G>A, p.Gly238Asp is a novel mutation in BSCL2 gene, previously
unreported.P1-3-9
X chromosomal deletion due to microhomology-mediated
break-induced replication in a boy with Xp22.3 contiguous gene
deletion syndrome: Implications for novel genomic defects leading
to Kallmann Syndrome
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Background: KAL1 is one of the causative genes for Kallmann
syndrome (KS), a rare genetic disorder characterized by hypogonado-
tropic hypogonadism and anosmia. KS is frequently associated with
various complications including renal aplasia. Submicroscopic X
chromosomal rearrangements involving KAL1 underlie KS either as
an isolated anomaly or as a component of contiguous gene
deletion syndromes. The genomic basis of these rearrangements
remains largely unknown, although non-allelic homologous
Fig. 1 (abstract P1-3-10). See text for description
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plicated in a few cases.
Objective: To report molecular findings of a patient with KS due to a
contiguous gene deletion syndrome.
Case report: A 6 month-old boy presented with bilateral cryptorchid-
ism, micropenis, and ichthyosis at his trunk and limbs. His height was
67.4 cm (-0.17 SD), stretched penile length was 2.0 cm (-3.6 SD) and
testicular diameters were 8-9 mm bilaterally. His mental development
was age-appropriate. GnRH stimulation test at 6 months of age
showed normal LH response (< 0.07 to 2.51 mIU/mL) and increased's
H response (0.68 to 24.71 mIU/mL). Brain magnetic resonance im-
aging detected olfactory sulcus and bulbs but no olfactory tracts nor
tubercles. Abdominal ultrasonograms and renal scintigrams showed
left renal aplasia.
Molecular analysis: Array-based comparative genomic hybridization
detected a 2.7-Mb deletion at Xp22.3. Breakpoint characterization re-
vealed that the deletion was 2,735,696 bp in physical length and
contained NLGN4X, VCX3A, HDHD1, STS, VCX, PNPLA4, VCX2, and
VCX3B , in addition to exons 8-14 of KAL1 . The breakpoints shared
no long homology but had microhomology of 2-bp. Both break-
points resided at the margin of Alu repeats. Nucleotide stretches
were absent at the fusion junction.
Discussion: We characterized a microdeletion in a boy with KS. KS
and ichthyosis of the boy can be ascribed to the deletion of KAL1
and STS , respectively. Since the patient lacked NLGN4X and VCX
genes involved in the brain function, his mental development should
be re-evaluated in future studies. Breakpoint structure indicates that
the deletion arose from a break-induced replication mediated by 2-
bp microhomology. Notably, the two breakpoints resided at the mar-
gin of Alu repeats. Since a high concentration of repetitive elements
is known to predispose replication-based errors, the deletion in our
patient could have been facilitated by Alu repeats.
Conclusion: The results indicate that microhomology-mediated
break-induced replication can underlie Xp22.3 contiguous gene dele-
tion syndromes including KS. Alu repeats may be involved in the de-
velopment of replication errors involving KAL1.
Consent for publication: The authors declare that written informed
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Context: Patients with polycystic ovary syndrome (PCOS) frequently
develop hyperandrogenemia. So far, blood androgens in PCOS pa-
tients have been measured primarily by immunoassays. However, ac-
cumulating evidence suggests that liquid chromatography-tandem
mass spectrometry (LC-MS/MS) is more accurate in steroid qualifica-
tion than immunoassays.
Objective: To compare the results of immunoassays and LC-MS/MS
in androgen measurement in PCOS patients and eumenorrheic
women. Materials and Methods: Blood samples were obtained from
31 PCOS patients and 28 eumenorrheic women. Serum levels of tes-
tosterone and androstenedione were analyzed by chemiluminescent
enzyme immunoassay (CLEIA) and radioimmunoassay (RIA) respect-
ively, and by LC- MS/MS. The results of the patients were comparedto normal ranges (the mean ± 2.0 standard deviation of the control
individuals).
Results: Testosterone values of each individual were closely matched
between CLEIA and LC-MS/MS (correlation coefficient in patients,
0.852; in controls, 0.898). The correlation coefficients were compar-
able between the patient and control groups (p = 0.470). Andro-
stenedione values in each individual determined by LC-MS/MS and
RIA were closely matched in controls (correlation coefficient, 0.908),
but less correlated in patients (correlation coefficient, 0.717; p =
0.026). Testosterone measurement by CLEIA yielded false positive
and negative results in one and three cases respectively, and andro-
stenedione measurement by RIA provided false positive and negative
results in six and four cases respectively.
Discussion: The results are consistent with the previously proposed
notion that the results of immunoassays are affected by cross-
reacting steroids. The effects of cross- reaction seem to be more
prominent in androstenedione measurement than in testosterone
measurement, and in PCOS patients than in eumenorrheic women.
Notably, androstenedione measurement by RIA yielded false positive
(indicated by gray boxes in the figure)/negative (indicated by black
boxes in the figure) results in 10 of 31 PCOS patients. Since increased
blood levels of testosterone and androstenedione is associated with
the risk of metabolic diseases in PCOS patients, precise androgen
measurement using LC-MS/MS would serve to improve the long-
term prognosis of these patients.
Conclusions: In PCOS pat ients, bloo d levels of androgens, particu-
larly those of androstenedione, should be measured by LC-MS/MS.P1-3-11
Clinical and Genetic Study of One Case with Complex Glycerol
Kinase Deficiency
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Background: Complex glycerol kinase deficiency (CGKD), also called
Xp21 contiguous gene deletion syndrome, is a rare X linked recessive
disorder which may including congenital adrenal cortical dysfunction
(AHC), glycerol kinase deficiency (GKD), Duchenne muscular dys-
trophy (DMD), chronic granulomatous disease (CGD), retinitis pig-
mentosa (RP), Xpter - Alan islands eye disease (AIED), etc.
Objective: To analyze the clinical and genetic features of CGKD, to
provide a more accurate diagnosis in children, while improving
clinician awareness of the disease.
Methods: Summarize the clinical characters of a patient diagnosed
with CGKD. And analyzing his gene mutation by using EDTA anti-
coagulant for the specimens with single-gene disorders whole exon
sequencing, and verifying the result by PCR electrophoresis.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 57 of 144Results: A 52-day-old boy characterized with progressive deepening
skin pigmentation and slow weight gain. Auxiliary examinations
showed electrolyte disorders (hyponatremia, hyperkalemia), low
serum cortisol, high adrenocorticotropic hormone (ACTH), damaged
liver function, significantly increased creatine kinase, elevated blood
triglycerides, normal blood sugar and cholesterol. Results of single
gene disorders whole exon sequencing indicated the child has
NR0B1 Exon1-2, IL1RAPL1 Exon2-11, TAB3 Exon5-11, GK Exon1-21,
DMD Exon48-79 gene deletions, which were homozygous mutation.
Conclusion: The clinical manifestations of the patient and results
from the single gene disorders whole exon sequencing once again
proved CGKD relate to the X chromosome gene deletion near Xp21.
It has been revealed that NR0B1, IL1RAPL1, GK, DMD gene are
respectively related to adrenal cortical dysfunction, X-linked mental
retardation 21, glycerol kinase deficiency, Duchenne muscular dys-
trophy. However, the association between TAB3 gene deletion and
CGKD has not reported in the literature, which may be a new
discovery of the CGKD-related mutations, and further broaden the
CGKD gene mutation spectrum.
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Autosomal dominant familial neurohypophyseal diabetes insipidus
(adFNDI) is an inherited disorder of free water conservation charac-
terized by childhood onset polyuria, polydipsia and dehydration
caused by arginine vasopressin deficiency. A variety of disease-
causing mutations of the arginine vasopressin neurophysin II gene
(AVP) on chromosome 20p13 have been described. A four year old
body with polyuria and polydipsia was shown to have central dia-
betes insipidus using the water deprivation test and a vasopressin
challenge test. His family history was consistent with autosomal
transmission of the polyuric syndrome, with affected family members
in three generations, including several females. Direct sequencing of
the AVP gene showed a heterozygous missense mutation in exon 2
of the AVP gene (Cys98Gly). This mutation was predicted to yield an
abnormal AVP precursor in its neurophysin II moiety and the function
of neurophysin as a carrier protein for AVP would be impaired. The
proband's mother and additional three family members have the
same mutation. Presence of this mutation suggests that the portion
of the neurophysin peptide encoded by this sequence is important
for the appropriate expression of vasopressin. We present a mutation
of AVP in a Korean family suffering with adFNDI over three
generations.
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children with different causes of short stature
Feng Xiong, Xueshuang Zhang
Department of Endocrinology, Chongqing Medical University Affiliated
Children's Hospital
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-3-13
Introduction: To investigate differences in clinical efficacy and safety
of using recombinant human growth hormone (rhGH) in Chinese
children with different causes of short stature.
Methods: From August 2005 to October 2015, 73 children (43 males
and 30 females, aged 9.5 ± 3.3 years) with growth hormone defi-
ciency (GHD), 56 children i22 males and 34 females, aged 8.9 ± 2.7
years ) with Idiopathic Short Stature (ISS), 50 children(aged 9.9 ± 2.9
years) with Turner syndrome (TS) and 21 children(8 males and 13females, aged 9.9 ± 2.9 years) with small for gestational age (SGA)
were enrolled from the endocrine clinic of Chongqing Medical Uni-
versity Affiliated Children's Hospital. Height(Ht), growth velocity(GV),
height standard deviation score (HtSDS), body mass index(BMI), body
mass index standard deviation score(BMI SDS), bone age(BA), final
adult height(FAH) and side effects were observed during 2-4 years of
rhGH treatment.
Results: 1, The GVs of the enrolled children were significantly in-
creased in the first year treatment, respectively (11.23 ± 2.63) cm/
year, (9.91 ± 1.67) cm/year, (8.45 ± 1.83) cm/year and (9.78 ± 1.72)
cm/year, then decreased progressively during each succeeding treat-
ment year. 2, The HtSDSs of the enrolled children were improved
year by year, and the change of HtSDS ( Δ HtSDS) in children with
GHD(2.12 ± 1.12) was greater as compared to children with ISS(1.51
± 0.82), TS(1.23 ± 0.73), and SGA(2.07 ± 1.04). 3, The FAH in some of
the enrolled children was documentedand found to be close to their
target height. 4, After 2-4 years of rhGH treatment, the BMI and BMI
SDS of the enrolled children were slowly increased. 5, During 2 `4
years of rhGH treatment, the bone age and puberty of the enrolled
children didn’t advance, and adverse reactions were rare.
Conclusion: There was a great effect of rhGH treatment on growth in
children with GHD, ISS, TS and SGA, However Cthe efficacy of rhGH
differed greatly in children with different causes of short stature, and
children with GHD had the most obvious effect, followed by children
with SGA, ISS and TS.P1-3-14
Exercise capacity and left ventricular function in adolescents born
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Background: Children born post-term ( ≥ 42 weeks gestation) may
be at risk of adverse health outcomes in adulthood. Recent studies
showed that metabolic abnormalities, including reduced insulin sen-
sitivity, dyslipidaemia, and alterations in blood pressure are already
present in childhood. These abnormalities are similar to those re-
ported in small-for-gestational-age and preterm children and
adolescents, who also have reductions on exercise capacity and car-
diovascular alterations during adolescence. It is not known whether
adolescents born post-term have similar cardiovascular impairments.
Therefore, we investigated aerobic capacity and cardiovascular func-
tion in adolescents born post-term in comparison to peers born at
term (37-41 weeks of gestation).
Methods: 51 participants were recruited: 25 born post-term and 26
controls aged 14.3 years (range 12–20 years). Body composition
(DXA), exercise capacity (VO2max), 24-hour ambulatory blood pres-
sure monitoring, and fasting blood tests were performed in all partic-
ipants. Left ventricular structure and function were assessed by MRI
scans at rest and during submaximal exercise, using a compatible
cycle ergometer.
Results: There no observed differences in weight, height, body com-
position, blood parameters, or 24-h blood pressure between groups.
Exercise capacity was lower in the post-term vs control group, with
more marked differences seen when NZ Europeans were examined
separately (46.3 vs 51.4 ml/kgffm/min; p=0.041). Diastolic blood pres-
sure was higher at peak exercise in those born post-term (62 vs 57
mmHg; p=0.03). There were no differences in left ventricular volumes
and mass between groups at rest and during submaximal exercise.
Conclusion: Adolescents born post-term have reduced exercise
capacity when compared to match term-born controls. However,
measurements of central cardiac function showed no differences be-
tween the two groups. Hence, we hypothesize that the reduction in
exercise capacity in adolescents born post-term could be associated
with changes in the peripheral vascular system.
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Objective: The purpose of this study was to investigate the clinical
and genetic characteristics of autosomal dominant hypocalcemia
type 1.
Method: Targeted sequencing was used on a children who was
accurately diagnosed as autosomal dominant hypocalcemia type 1 in
Children’ s Hospital Affiliated to Soochow University to analyze the
major clinical manifestations of the disease. An analysis of the CaSR
genes was made on the patient.
Result: The patient was a girl, 1 months 11 days old, and had
recurrent seizures for more than three weeks, aggravating for three
days. Laboratory work-up revealed hypocalcemia, hypomagnesemia,
hyperphosphatemia, suppressed PTH, increased urinary calcium-to-
creatinine. The child was clinically highly suspected of autosomal
dominant hypocalcemia type 1. Targeted sequencing showed a mu-
tation in exon 3 Gene, c.392G>A, p.cys131Tyr, and both parents did
not harbor the child’s mutation, indicating that her mutation had
arisen de novo.
Conclusion: Autosomal dominant hypocalcemia type 1 is caused by
gain-of-function mutations in the CaSR gene, manifests familial or
sporadic hypercalciuric hypocalcemia. One pathogenic mutations
(c.392G>A, p.cys131Tyr) in CaSR gene was found.
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Introduction: Congenital hyperinsulinism (CHI) is the most common
cause of intractable hypoglycemia during newborn and infantile
period which resulting from inappropriate insulin secretion by pan-
creatic β -cell . The incidence is approximately 1: 50,000 live births.
Mutation in ABCC8 and KCNJ11, encoding subunit of ATP- sensitive K
+ (KATP) channel in pancreatic β cell, are found in more than 50% of
patients with CHI. These 2 mutation causing severe CHI and unre-
sponsiveness to K ATP channel agonist, diazoxide. Here, we report 2
cases of diazoxide-unresponsive CHI due to ABCC8 mutation.
Case1: A 36 weeks male infant, BW 3,490 g was born from non-
consanguineous parents. He presented with hypoglycemia at birth
and was given IV concentrated glucose up to 10 mg/kg/min. Investi-
gations revealed blood sugar 1.16 mmol/L, insulin 7.9 μIU/L, cortisol
3.5 μg/dL and negative serum ketone. ACTH stimulation was normal.
He was diagnosed hyperinsulinemic hypoglycemia of infancy. After
treated with diazoxide 20 mg/kg/day, hypoglycemia still persisted.
Nifedipine use for decreased insulin secretion was given at starting
dose of 0.3 mg/ kg/day then titrated up to 1 mg/kg/day, but
frequently hypoglycemia persisted. Genetic study showed ABCC8
missense mutations. He was referred for near total (about 98 %) pan-
createctomy. After pancreatectomy, diazoxide and nifedipine werediscontinue and rate of iv glucose gradually decreased until 4 mg/
kg/min. Few days later, his blood sugar was < 2.8 mmol/L again then
diazoxide was restarted. At present, the patient is 1 year and 7
months old. The treatment are diazoxide 17 mg/kg/day, octreotide
12 μg/kg/day and corn starch. His weight and height below 3rd per-
centile and delay language.
Case2: A 6 weeks old female infant presented with 4 episodes of
hypoglycemia seizure. Her blood sugar was 1.61 mmol/L while insulin
level was 6.9 μIU/L. Other hormone test were normal. She was diag-
nosed hyperinsulinemic hypoglycemia of infancy. Diazoxide was
given up to 17mg/kg/day but she still frequently hypoglycemia. Gen-
etic study showed ABCC8 nonsense mutations. The patient was re-
ferred for 18-F DOPA PET scan and focal pancreatectomy was done.
After pancreatectomy, she still needed diazoxide 4.5 mg/kg/day for
normalize blood sugar.
Conclusion: although rare, CHI should be evaluated in newborn and
infant who had persistent hypoglycemia and need glucose concen-
tration > 8 mg/kg/min. Genetic study should be done as a guide for
prognosis and treatment strategy. Hypoglycemia must be promptly
treated with high concentration glucose, diazoxide, octreotide to pre-
vent brain damage. When medical are failure, surgical treatment is
required.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Clinical and genetic findings in Chinese patients with
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Objective: To analyze the heterogeneity of in frequent symptoms
among Chinese children with methylmalonic aciduria (MMA) origi-
nated from a mixed geneti background.
Subjects and Methods: We investigated 26 Chinese patients (17
males and 9 females) diagnosed by elevated urinary MMA, elevated
serum C3, C3/C2 ratio and decreased serum free carnitine. Genetic
diagnoses of these children were made by sequencing of MUT ,
MMAA , MMAB , MMACHC , MMADHC , LMBRD1 , MCEE , SUCLG1 ,
SUCLG2 and ABCD4 gene. The clinical and biochemical features were
analyzed.
Results: We identified a considerable variation between clinical mani-
festations of these children. Symptoms of MMA varied from mild
vomiting to severe encephalopathy and the age onset from 3 days
to 13 years. Less frequent symptoms (<10%) such as hydrocephalus,
isolated pulmonary hypertension, peripheral neuropathy and diabetic
ketoacidosis were found as the first signs in MMA patients. Mutatios
in MUT , MMACHC and MMADHC gene were identified in 22 patients.
Among these mutations, two novel missense mutations in MUT gene
(c.1540C>A and c.505G>T) were identified. In 2 patients with isolated
pulmonary hypertension, we found the same mutation sites and so
that in 2 patients with hydrocephalus (Table 3).
Conclusions: The heterogeneous clinical manifestation identified
among our Chinese patients with MMA indicated that the genetic
profiles of MMA patients vary from ethnics and there were
phenotype-genotype correlations according to our genetic sequen-
cing results.P1-3-19
New mutation in pseudohypoparathyroidism type Ia
Zerrin Orbak
Department of Pediatric Endocrinolpgy, Ataturk University Medical
Faculty
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-3-19
The GNAS gene encodes the alpha-subunit of the stimulatory G pro-
teins, which play a crucial role in intracellular signal transduction of
peptide and neurotransmitter receptors. Heterozygous inactivating
maternally inherited mutations of GNAS lead to a phenotype in
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hypoparathyroidism type Ia.
The GNAS gene of a 5-year-old boy with brachydactily, mental re-
tardation, obesity, pseudohypoparathyroidism and congenital
hypothyroidism was investigated. We found a heterozygous mutation
of exon 6 (p.Gln171*(c.511C>T)).
This report demonstrates the new mutation at the GNAS gene in a pa-
tient who was thought to have pseudohypoparathyroidism type Ia.P1-4-1
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GH replacement as daily s.c. injections for patients with AGHD can be
cumbersome. Somapacitan (Novo Nordisk), a once-weekly reversible
albumin-binding GH derivative, has been shown in short-term trials to
be well tolerated in healthy adults and in patients with AGHD. This trial
was a multinational, multicentre, randomised (2:1), open-label, active-
controlled trial (NCT02382939; REAL 2) investigating the safety, toler-
ability and treatment satisfaction of once-weekly somapacitan versus
once-daily GH (somatropin) in patients with AGHD.
Ninety-two patients (diagnosed with AGHD, previously treated with
somatropin for ≥ 6 months, male or female, aged 18–79 years) were
randomised to once-weekly somapacitan or once-daily somatropin.
During the first 8 weeks, somapacitan and somatropin doses were ti-
trated according to serum insulin-like growth factor-I (IGF-I) standard
deviation score (SDS) levels in order to achieve IGF-I levels within the
normal range and preferably between 0 and 2 SDS; a fixed dose was
received for the remaining 18-week period. Treatment satisfaction
was assessed using the Treatment Satisfaction Questionnaire for
Medication-9 (TSQM-9), with an increase in scores signifying an in-
crease in treatment satisfaction. A similar pattern and rate of adverse
events (AEs) and serious AEs was observed with the two treatments.
The most frequently occurring AEs for somapacitan and somatropin
were nasopharyngitis, headache and fatigue. Mild and transient in-
jection site reactions were observed only in the somapacitan group.
After dose titration, the IGF-I levels were maintained in both treat-
ment groups. No anti-somapacitan or anti-GH antibodies were de-
tected. Using a mixed model for repeated measurements with
treatment, GHD onset type, gender, and region as factors and base-
line as a covariate, all nested within week as a factor, a statistically
significant difference in change from baseline to end of treatment
period in convenience score was observed with once-weekly soma-
pacitan being more convenient than once-daily somatropin. Using
the same analysis model, no statistically significant difference in
change from baseline to end of treatment period between once-
weekly somapacitan and once-daily somatropin was shown for the
effectiveness and global satisfactions scores.In conclusion, somapacitan was well tolerated and no safety issues
were identified. These data indicate that somapacitan may serve as a
well-tolerated, once-weekly treatment for AGHD and may be more
convenient for patients than once-daily treatment.
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Background: The safety of growth hormone (GH) treatment in chil-
dren with short stature has generally been demonstrated, with no
significant adverse events reported in association with GH treatment
after more than 20 years of postmarketing use. The safety record of
GH remains good, which is supported by evidence from the follow-
up of tens of thousands of children. However, the potential risk of
GH therapy leading to diabetes mellitus and certain tumoral diseases
remains a concern because GH acts as an insulin counterregulatory
hormone and promotes cell proliferation. Accordingly, there is a high
demand for results of large scale observational studies.
Objective: The primary objective of the Genetics and Neuroendocri-
nology of Short Stature International Study (GeNeSIS) was to assess
the safety and efficacy of HUMATROPE®, a GH preparation manufac-
tured by Eli Lilly and Company, in the treatment of pediatric patients
with short stature (NCT01088412). We report our findings in the GH-
treated Japanese pediatric population focusing on the incidence of
type 2 diabetes mellitus and occurrence of neoplasms.
Methods and Results: A total of 2,356 patients were registered for
enrollment in the study between 2000 and 2013. Of these 2,308 had
≥1 follow-up visit allowing for assessment of safety. During a mean
study observation period of 3.3 years, type 2 diabetes mellitus oc-
curred in 3 patients (0.13%) and SPIDDM related to MELAS in 1 pa-
tient (0.04%). Neoplasms were reported in 12 patients (0.52%),
including 1 patient with de novo germinoma, and 5 with craniophar-
yngiomas (4 were recurrences and 1 was newly assessed by the in-
vestigator), the remainder were benign, typically dermatological,
neoplasms.
Discussion: In the present study, pre-existing craniopharyngioma was
found in 25 of the 57 patients with growth hormone deficiency
(GHD) due to intracranial tumors, recurring in 4 of the 25 patients
(16%). The global KIGS data published in the Acta Paediatrica (2006)
and Lancet (2000) revealed a recurrence-free survival rate of 63% for
craniopharyngioma patients and an incidence rate of 0.12% for dia-
betes mellitus during a GH treatment, neither of which was different
from our results.
Conclusion: The incidence of diabetes mellitus determined in the
present study did not differ from previous reports of GH-treated
pediatric patients with short stature, and there was no apparent in-
crease in the risk of new neoplastic lesions or malignant tumors.
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Background: Short stature patients with mutations in known genes
of the GH-IGF-1 axis are usually diagnosed by specific physical or
endocrinological findings. Although recent studies have identified
genetic defects in GHR and IGF-1 in a few patients clinically diag-
nosed with idiopathic short stature (ISS), it remains unknown
whether mutations in genes of the GH-IGF-1 axis are common in
children with ISS. Objective: To elucidate the frequency of sequence
variations in genes of the GH-IGF-1 axis in children clinically diag-
nosed with ISS.
Subjects and Methods: The study group consisted of 96 Japanese
children (63 males and 33 females) with height below − 2.0 stadard
deviation score based on the Japanese growth reference. Patients
with syndromic short stature, apparent GH deficiency, thyroid disor-
ders, and other chronic diseases were excluded from this study. We
also excluded individuals with SHOX haploinsufficiency and those
born small for gestational age. We analyzed the coding exons of GH1
, GHRHR , GHSR , GHR , IGF1 , and IGF1R by next generation sequen-
cing. In this study, we focused on nonsynonymous variants and nu-
cleotide changes at splice sites. We excluded common variants
whose allele frequency in the general population was more than
1.0%. The functional consequences of nucleotide alterations were
assessed by in silico analyses.
Results: Seven nucleotide changes were identified in 10 children. Of
these, three were hitherto unreported, while remaining four have
been submitted to the Single Nucleotide Polymorphism Database.
Four missense substitutions (one in GHR , two in GHRHR , and one in
IGF1R ) of four individuals were predicted as “damaging”.
Discussion: Possibly damaging variations affecting the GH-IGF-1 axis
were identified in four of 96 children with ISS. Clinical significance of
these variations needs to be validated in future studies. The results
of this study indicate that sequence variations in genes of the GH-
IGF-1 axis play a minor role in the etiology of ISS.
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Background/Aims: Normal growth in childhood depends on multiple
hormones, secreted molecules, and intracellular factors that regulate
the activity of growth plate and bones. Recently, in vivo functional
analyses of genes in mice revealed numerous epigenetic regulators
controlling chondrogenesis and osteogenesis. For instance, phylo-
genically conserved Polycomb group (PcG) proteins play indispens-
able epigenetic role in development and growth. So far, wegenerated mice nullizygous for Cbx2, one of the members of Poly-
comb repressive complex 1 (PRC1), and reported the bone growth
defects in ESPE 2013 and JSPE 2014. Yet, it remains unclear whether
Cbx2 in bones contributes to their own growth, because of the ubi-
quitous expression of Cbx2 in the developing embryo. To elucidate
functions of Cbx2 in the skeletal lineage, we generated conditional
Cbx2 knockout mouse (Cbx2 mscKO), in which Cbx2 was deleted in
skeletal lineage progenitor.
Results: Ossification delay was observed in the prenatal Cbx2 mscKO
(Cbx2flox/flox:Prrx1-Cre+ ). For Cbx2 mscKO generation, a cross
breading of Prrx1-Cre skeletal lineage specific deleter line (Jackson
Laboratory, USA) and Cbx2flox/flox line was carried out. We
generated Cbx2flox/flo line by intercrossing Cbx2tm1a/Wtsi (MRC,
the Wellcome Trust Sanger Institute, UK) and Actb-flp knock-in mice
(Established by Dr. Sakimura, Niigata University, Japan). All mouse
line utilized in this study was established and maintained in C57Bl/6
genetic background.
Discussion: In the skeletal lineage, one of the members of PRC1 com-
ponent, Cbx2, has an essential role for the bone growth. PcG proteins
configure two major multimeric protein complexes; PRC1 and PRC2.
PRC1 and PRC2 are tethering around the large number of develop-
mental key regulator genes and cooperate to regulate their expres-
sion. Recently, PRC2 member Ezh2 was deleted in the skeletal
lineage using Prrx1- Cre+ (Ezh2 mscKO) (Dudakovic et al., 2015). In
the report, defects in the bone formation in newborn mscEzh2 KO
were demonstrated. Similar functions of Ezh2 and Cbx2 in bone for-
mation are consistent with the proposed model of cooperative func-
tions of PRC1 and PRC2.
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Background: Noonan syndrome (NS) is a clinically and genetically
heterogeneous syndrome characterized by distinctive facial features,
short stature, congenital heart diseases, and other comorbidities. NS-
specific growth charts are essential for NS care, but currently no such
charts are available for Asian populations. Therefore, we have re-
cently established growth references of height, weight, and body
mass index (BMI) for Japanese individuals with Noonan syndrome.
The purpose of this study is to draw practical growth charts of
height, weight, and BMI, and newly construct those of weight for
height (WFH). In addition, we compare these charts to those of
Turner syndrome (TS) or normal population.
Methods: The population for this study was the same as the previous
study. Briefly, we conducted a nationwide survey by collaborating
with three academic societies in Japan. We obtained the data of 356
clinically diagnosed NS subjects from 20 hospitals. The LMS method
was used for establishing growth charts.
Results: A total of 308 subjects (boy: 159, girl: 149) were analyzed after
excluding 48 subjects because of missing auxological data, presence of
complications affecting growth, and extreme longitudinal growth aber-
rations which lay more or less than three standard deviation scores
(SDS) from the mean. The practical charts were constructed with 3,249
mixed longitudinal and cross-sectional measurements. According to
the charts, the adult height is 157.3 ± 7.4 cm for boys (-2.3 ± 1.3 SDS)
and 146.8 ± 6.9 cm for girls (-2.1 ± 1.3 SDS), respectively, when it is de-
fined as the mean height at the age of 20 years. Growth pattern of
height in girls with NS is similar to that of TS below age five but there
are gradual increase and pubertal spurt resulting in 1.2SD taller adult
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populations and TS girls until approximately five years of age, but grad-
ual increase after BMI rebound age is milder. As for the WFH reference,
WFH in NS is almost the same as normal populations. In contrast, WFH
in NS girls is almost the same as those in TS girls below the height of
100 cm, but above 120 cm there is a lack of more rapid increase of the
WFH evident in TS girls.
Conclusion: Practical growth charts for Japanese individuals with NS
were established. These charts are expected to be adopted and used
in various clinical settings.
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Background: Short stature is the key to diagnosis for Turner syn-
drome (TS) in childhood and adolescence. We often encountered
some girls with TS already had growth retardation from their infantile
period but growth patterns during this period have not been well
described. Objective: To characterize growth patterns for TS during
their infantile period and relations to clinical diagnosis.
Subjects and methods: A retrospective review of medical records
was performed on Japanese girls with TS in our hospital who were
not on GH therapy until 3 years old.
Results: Growth records of twenty four girls with TS were subjected to
analysis. Mean changes in height SDS from birth to 1 month, 3months,
18 months and 3 years were +0.4, 0.0, -0.9 and -1.1 respectively, indicat-
ing catch-up growth was observed only during the first few months and
the growth was retarded thereafter. No correlation between karyotypes
and growth patterns was observed. Next we divided into two groups: A)
height SDS decreased below -2SD by 3 years of age (n=11), B) height
SDS remained above -2SD at age 3 (n=13). Height at birth was signifi-
cantly lower in group A (-1.58 ± 1.54SD) than B (-0.36 ± 0.79SD). There
was no significant difference between two groups regarding with the
growth patterns from birth to 3 years old. Median age at diagnosis was
4 years old in group A but it was 9 years old in group B.
Discussion and Conclusion: In Japan, the 3 year checkup is the last
regular checkup before the preschool checkup and short stature is
important health problem which prompts physicians to refer children
to pediatric endocrinologists. Therefore we observed that girls who
didn’t have apparent short stature at the checkup tended to be diag-
nosed with TS later. Early diagnosis is anticipated before problems at
school occur. Since growth retardation in girls with TS was observed
as early as 3 months old, it is important to pay attention to the
change in infantile growth rate as well as height-for-age.
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Objective: We conduct a multicenter, open-label, study to evaluate
safety and efficacy of long-term treatment of Genotropin® in short
children born SGA without epiphyseal closure. This represents the
unique clinical trial in Japanese subjects treated with continuously
high dose of rhGH (0.067 mg/kg/day) until near adult height (NAH).
Method: Sixty-seven short children born SGA were included from 20
sites in the one-year treatment, Study 002 (Tanaka, et al. 2008), and
were randomized to receive two different doses (0.033 or 0.067 mg/kg/day). After completing one-year of treatment in Study 002, out of
62 subjects who were entered in this study, 61 were treated with the
dose of 0.067 mg/kg/day and continued until pre-specified treatment
termination criteria were fulfilled. This study was continued after the
approval of the indication as a post-marketing clinical trial (Clinical-
trials. gov: NCT01859949). Descriptive statistics for each endpoint
were summarized by treatment group based on assignment in Study
002. NAH was defined in this study as an “annual height velocity < 2
cm after achieving peak velocity at puberty” or “reaching an epiphys-
eal closure (centrally measured by the TW2-RUS method or investiga-
tor’s evaluation)”; these are the treatment termination criteria.
Result and Conclusion: Treatment-related adverse events were 54
events in 22 (36.1%) of the 61 subjects throughout the treatment
period. Most of the observed adverse events were mild to moderate
in severity. Two subjects experienced adverse event leading to per-
manently discontinuation and two subjects had treatment-related
serious adverse event, although which outcomes to have resolved.
No clinically significant changes were observed for HbA1c levels and
bone maturation throughout the study. Neither new safety informa-
tion nor safety concern was identified in this long-term study.
Twenty subjects (11 boys and 9 girls) reached NAH (mean age (year);
mean cm [height SDS]), 16.0; 159.1 [-1.56] in boys and 14.3; 146.9
[-1.61] in girls, at the end of treatment. We have confirmed the safety
and efficacy of high dose rhGH treatment in the more than a decade
long-term clinical trial in Japan.P1-4-8
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Context: Hypoglycemia in neonate is caused by hyperinsulinism, in-
adequate glycogen stores and impaired glycogenolysis or gluconeo-
genesis. However the pathophysiological condition still remains
unknown, and the contribution of the insulin/insulin-like growth fac-
tor I (IGF-I) signaling pathway including insulin receptor substrate
(IRS) to neonatal hypoglycemia are not clearly known.
Objective: To elucidate relationship between glucose level and insu-
lin/IGF-I signaling in appropriate for gestational age (AGA) and small
for gestational age (SGA) neonates.
Patients and Methods: Neonates born in the Perinatal Medical
Center of Tottori University Hospital were enrolled. We measured glu-
cose level, serum levels of insulin and IGF-I of samples collected from
umbilical cord or venous blood at birth. Using same samples, we evalu-
ated the expression of IGF-1 receptor (IGF1R ), insulin receptor (INSR ),
insulin receptor substrate-1 (IRS-1 ), IRS-2 , glucose transporter 2
(SLC2A2 ) and SLC2A4 mRNA by quantitative real-time PCR.
Results: Forty three neonates (38 AGA neonates and 5 SGA neonates)
were enrolled. Mean gestational age was 38.5 weeks (range 37-41
weeks). Mean birth weight in AGA was 3,006g (mean ± SD: 0.19 ±
0.92) and in SGA; 1,832g (-2.6 ± 0.82). Blood glucose level of SGA
was significantly lower than that in AGA [SGA, 40.8 ± 12.3 mg/dL vs.
AGA, 85.8 ± 33.7 mg/dL]. Serum insulin and IGF-1 levels of AGA were
slightly higher than those of SGA. As both groups did not show any
increase of insulin to glucose ratio, they did not have hyperinsulin-
ism. IRS-2 and SLC2A4 mRNA expression were significantly higher in
SGA group. There was no difference in the expression of IGF1R, INSR,
IRS-1 and SLC2A2 mRNA in between SGA and AGA.
Discussion and Conclusions: The expression of IRS-2 protein is in-
creased by undernutrition, and reduced by insulin. It was suggested
that the increased expression of IRS-2 mRNA on SGA was caused by
fetal undernutrition, and hyperinsulinism was not occurred in fetal
period on SGA in our study. These findings reveal that intrauterine
growth restriction induce the change of insulin/IGF axis, and provide
the important information of neonatal hypoglycemia.
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Background: Prader-Willi syndrome(PWS) is a neuro-developmental
genetic disoeder caused by lack of expression of genes on the pater-
nally inherited chromosome 15q11.2-q13 region.Short stature is one
of the most prominent feature of them. In Japan, growth hormone
(GH) treatment was approved in January 2002 for the indication of
short stature ( below -2SD of normal people) and growth failure due
to PWS.Adult heights of untreated Japanese PWS patients are re-
ported 147.7 ± 7.7cm i-4.0 ± 1.3SD ) for male and 141.2 ± 4.8cm i-3.2
± 0.9SD ) for female.
Objective: To search for effectiveness of GH, we determined the the
final height and body mass index (BMI) of PWS patients.
Patients and methods: Final height and BMI was reviewed in the
medical records of 26 PWS patients, treated with and without
Growth hormone at Nagoyaka Children’s Clinic. Nine patients were
male and
14 patients were female.Three patients who treated with GH for less
than 5 years were excluded. Height was expressed as standard devi-
ation scores (SDSs) of normal Japanese people.
Results: Table
Discussions: Final mean height in Japanese PWS patients without GH
is -4.0 ± 1.3SD for male and -3.2 ± 0.9SD for female. It can be said
short stature is more prominent in male. Final height after GH is
-0.2SD ± 1.1 for male and -1.0SD ± 0.5 for female. The effect of GH
for final height is greater for male than female. Mean BMI is 21.5 ±
4.1 for male and 20.3 ± 3.8 for female. Considering BMI is higher in
female than male by nature, the improvement of BMI is more re-
markable in female.
Conclusion: Our data clearly show administration of GH to PWS pa-
tients improved final height and BMI. It is suggested the effect is
more prominent for male than female. It is not sure the change will
continue for life and contribute to better quality of life. Further stud-
ies will be required to determine the long term effect.Table 1 (abstract P1-4-9). See text for descriptionP1-4-10
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Background: Appropriate L-thyroxine (L-T4) substitution is necessary for
the optimal effect of growth hormone (GH) administration on growth
rate. A decrease in free thyroxine (FT4) levels at recombinant human GH
(rhGH) therapy onset has been reported by several studies. However,
their results are conflicting. The aim of the present study was to evaluate
the effects of thyroid hormone supplementation on growth rate in chil-
dren with ISS and low normal FT4 who are receiving GH therapy.
Methods: We selected 64 prepubertal children with FT4 levels in the
lowest third of the normal range (FT4:11.5-15.2 pmol/L) as Lower FT4
groupand they were divided randomly into two subgroups: L-T4
treated subgroup included 29 ISS children with L-T4 (0.5 to 3.0 mg/
kg/d) from the beginning of rhGH therapy, non-L-T4 treated sub-
group included 33 ISS children received placebo during the same
period. We also selected 39 ISS children with FT4 in the upper two-
thirds of the normal range (FT4:18.9-22.7 pmol/L) as Higher FT4
group(control group). In all children, height velocity (HV) were
assessed before and after 1 year of rhGH therapy, whereas thyroid
stimulating hormone (TSH), FT4, FT3 and insulin-like growth factor-I
(IGF-I) were assessed before treatment and after 3 to 6 months and 1
year of treatment.
Results: During 1st year of rhGH administration, Lower FT4 grouphad
lower FT3, FT4, TSH, IGF-I SDS compared with higher FT4 group and
their HV was significantly lower(9.64 ± 0.75 vs 11.09 ± 0.63/12 months).
However, in Lower FT4 group, after L-T4 supplementation, L-T4 treated
subgroup had higher FT4, FT3, TSH and IGF-I SDS concentrations com-
pared with those non-L-T4 treated subgroup and their HV was signifi-
cantly higher( 12.03 ± 0.70 vs 9.64 ± 0.75/12 months).
Conclusions: In children with ISS, the negative effect of thyroid hor-
mone deficiency on growth rate should be considered when the FT4
level is in the low-normal range prior to rhGH treatment.
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Background: Growth failure and abnormal plasma glucose level are
common in patients with thalassemia major (TM), which are usually
due to iron overload after repeated blood transfusion. Patients after
successful bone marrow transplantation (BMT) will be free from fur-
ther blood transfusion and thus spared from complications of iron
overload. This study aimed at determining the incidence of abnormal
glucose level in TM patients and studying the height difference be-
tween the TM patients who underwent BMT and who did not.
Objective and hypotheses: The “BMT group” consisted of 19 patients
with TM who had undergone BMT and were followed up for at least
two years. 57 TM patients of similar age who did not undergo BMT
were recruited as the “non-BMT group”.
Method: The age at BMT and present age, weight, height, height
standard deviation score (SDS) and weight SDS values, serum ferritin
(SF), the fast blood glucose and insulin level were evaluated.
Results: The mean age was 10.3 ± 3.6 years and transplantation age
was 6.29 ± 3.4 years. The SF of the BTM was lower than the non-BTM
group (P =0.002). The height SDS score in BTM was found better
than the non-BTM (P = 0.039). There were no statistical differences in
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of BTM patients had insulin resistance, while it was 14.81%(8/54) in non-
BTM group iP =1 ). None of the BTM had impaired fast glucose (IFG) or
diabetes mellitus (DM). While in non-BTM group, the prevalence was
18.5% i10/54 ) and 3.7% i2/54 ) respectively ip =0.029 ).
Conclusion: Allogeneic BTM may improve short stature of TM pa-
tients. Although BMT didn’t alter the abnormal glucose status of TM
completely, it prevented this disease from exacerbating. The patients
should be followed up regularly after transplantation.P1-4-12
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Background: Gain-of-function mutations in the v-akt murine thym-
oma viral oncogene homolog 3 (AKT3 ) have been reported to cause
megalencephaly-related syndromes. To date, three gain-of -function
germline AKT3 mutations have been reported in 6 MCAP/MPPH pa-
tients. Here, we describe a novel germline mutation, p.Glu40Lys, in
AKT3 causing megalencephaly with growth hormone (GH) deficiency.
Case report: The patient, a 5-year-old Japanese boy, is the first child
of non-consanguineous healthy parents. He was vaginally delivered
at 40 weeks of gestation. His birth weight was 4.2 kg (+ 2.9 SD),
length was 54.0 cm (+ 2.5 SD), and head circumference (HC) was
39.0 cm (+ 4.4 SD). He was referred to us at the age of 7 months be-
cause of poor body weight gain and hypotonia. He had frontal bos-
sing, and was unable to hold his head steady. Brain magnetic
resonance imaging (MRI) showed neither polymicrogyria nor ven-
tricular dilation. At 15 months of age, he was admitted to our hos-
pital by hypoglycemia. Hyperinsulinism and central adrenal
insufficiency were excluded based on the analysis of critical samples.
Low serum GH level (de novo novel heterozygous c.118G>A transi-
tion (p.Glu40Lys) in AKT3 . The phosphorylation in CHO cell level of
the E40K AKT3 variant was upregulated relative to control, indicating
that E40K ATK3 was a gain-of-function mutation.
Discussion: In this case, it is indicated that hypoglycemia is induced
by GH deficiency. The severity of the meurogical changes in our pa-
tient was milder than in patients with other gain-of-function germ-
line AKT3 mutations. To our knowledge, this is the first case of
megalencephaly and GH deficiency, harboring a germline de novo
mutation in AKT3. The association between AKT3 mutations and GH
deficiencies remains to be elucidated. Therefore, further studies are
necessary to determine the independent contribution of AKT3 muta-
tions to the development of GH deficiency
Consent for publication: The authors declare that written informed
consent was obtained for publication.P1-4-14
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Background: The effects of growth hormone (GH) treatment have
not been sufficiently evaluated in extremely low birth weight (ELBW)
children born small for gestational age (SGA). One of the objectives
of GH treatment for SGA short stature is to achieve normal adult
height. Because the height at the onset of puberty is critical to deter-
mine the adult height, we evaluated the effects of GH treatment in
SGA short stature with ELBW on the onset of puberty.
Subjects and Methods: Fifteen children (10 boys and 5 girls), who
were born with ELBW and received GH treatment for SGA short stat-
ure in our hospital, were recruited in this study. GH treatment was
initiated before the onset of puberty, and the height and the age of
pubertal onset was analyzed retrospectively based on the medical
records.
Result: The median gestational age was 29.1 weeks (range; 26.3 `33.1
weeks), and the median birth weight was 680g (range; 356 `978g). At
the initiation of GH treatment, the mean age was 5.0 years (range;
3.2 `8.4 years), and the mean height SD score was |3.0. The median
age at onset of puberty was 11.4 years in boys and 10.4 years in girls.
The mean height at onset of puberty was 135.3 cm in boys and
130.1 cm in girls. The mean change in height SD score from the initi-
ation of GH treatment to pubertal onset was {1.6.
Discussion and Conclusion: The current study revealed that the tim-
ing of pubertal onset was not accelerated by GH treatment in SGA
children with ELBW. Moreover, GH treatment resulted in an increase
in height SD score at the pubertal onset. These findings indicate that
GH treatment is an effective approach to normalize the adult height
without affecting the timing of puberty in SGA children with ELBW;
however, the effects of GH treatment on the adult height in these
children are not fully understood. Further studies are clearly required
to reveal the effects of GH treatment in SGA children with ELBW.
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Nipbl deletion in pyramidal neurons results in postnatal growth
retardation and early lethality
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Cornelia de Lange syndrome (CdLS) is a genetically and clinically het-
erogeneous disorder characterized by growth and mental retard-
ation. It is caused by mutations in core cohesin subunits SMC1A,
SMC3 and RAD21, or their regulators NIPBL and HDAC8. Nipbl ac-
counts for most cases of CdLS. It has been implied NIPBL has a “dual
role” in loading cohesin and in cohesin-independent gene regulation.
Yet, its role in the maintenance of balance of neural function remains
unknown. To address these questions, selective deletion of Nipbl was
achieved in late postnatal (CaMKII aNipblcKO) developmental stages.
Although born healthy with expected Mendelian frequencies, CaMKII
aNipblcKO exhibited severe growth retardation and pre-weaning le-
thality. As demonstrated by ISH or real-time PCR, the mRNA level of
nipbl at P3 in CaMKII-Cre; nipbl flox/flox was comparable to that in
the littermate heterozygous CaMKII-Cre; nipblflox/+ and CaMKII-Cre;
nipbl+/+, but was largely diminished at P15 Cand the absence of
NIPBL in hippocampus and cortex was dramatic, but also reduction
of NIPBL mRNA was shown in olfactory bulb and hypothalamus, con-
sistent with the expression pattern of iCre in previous report. At birth,
the appearance and size of the CaMKII aNipblcKO pups were similar
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aNipblcKO mice failed to thrive and displayed severe growth retard-
ation. Closer examination revealed that CaMKII aNipblcKO failed to
suckle effectively and had stomachs devoid of milk. Suckling reflex is
thought to be processed by neural networks involving the olfactory
bulb and the hippocampus. The brain size of the homozygous pups
and control group was significantly comparable. Detailed histological
examination revealed the cerebral cortex of CaMKII aNipblcKO was
remarkbly thinner than the controls. Together, these data suggest
that nipbl in neurons controll the suckling response at this stage.
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Background: The common symptoms of trisomy 14 mosaicism are
growth retardation, developmental delay, facial dysmorphic features,
abnormal ears, cardiac anomalies and genitourinary abnormalities.
Approximately 40 cases of trisomy 14 mosaicism with a wide range
of symptoms have been reported. Maternal uniparental disomy of
chromosome 14 (upd(14)mat) is also a rare chromosomal disease.
The main clinical symptoms of upd(14)mat are prenatal and postna-
tal growth retardation, hypotonia, and early-onset puberty. We
present a severely short statured 3-year-old girl, who had trisomy 14
mosaicism with upd(14)mat.
Case report: A 3-year-old girl was referred to our hospital due to
short stature, failure to thrive (height: 78.8cm (-5.08 SD), weight:
8.77kg (-3.31 SD)) and developmental delay. She was born at term,
but her height and weight were lower than 10th percentile at birth.
She had mild facial dysmorphic features, ear malformation, deafness,
coloboma and closed ventricular septal defect. Endocrine tests in-
cluding thyroid function and growth hormone measurements
showed normal findings. Methylation analysis using genomic DNA
extracted from her leukocytes was performed, and we identified mild
hypomethylation at the MEG3-DMR at the 14q32.2 imprinted region.
Genome wide comparative genomic hybridization array revealed no
specific copy-number change, but fluorescence in situ hybridization
analysis revealed trisomy 14 mosaicism in blood (proportion of tri-
somy 14 cells was 46.8%). Microsatellites analysis of chromosome 14
resulted in the diagnosis of trisomy 14 mosaicism and upd(14)mat.
Discussion: We report the second and youngest case of trisomy 14
mosaicism with upd(14)mat. Previous cases of trisomy 14 mosaicism
had mild to moderate short stature, moreover, upd(14)mat patients
also exhibited short stature. Considering the severe short stature in
our case, we believe that the combination of trisomy 14 mosaicism
and upd(14)mat severely affects stature growth.
Conclusion: We report severe short stature associated with trisomy
14 mosaicism and upd(14)mat. Detailed genetic analysis is required
for patients with severe short stature. Follow up studies of our pa-
tient will clarify whether she develops other symptoms of
upd(14)mat such as early-onset puberty.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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sia characterized by short stature, short hands and feet, mild fa-
cial dysmorphism, normal intelligence, and characteristic
radiographic findings of the hands. AD is caused by a mutation
in the fibrillin 1 (FBN1 ) gene. Here, we describe the clinical
findings and an experience of growth hormone (GH) treatment
in a child with AD caused by a novel heterozygous mutation,
c.5282C>T (p.Thr1761Ile), in FBN1 (NM_000138.4). The patient
showed growth retardation, short and stubby hands and feet,
mild facial dysmorphism, and normal intelligence. A skeletal sur-
vey at the age of 11 years showed delayed bone age, brachy-
metacarpy, and acetabular dysplasia. He has been diagnosed as
partial GH deficiency and treated with GH for 3.5 years with
good response. Similar to the previous reports, the mutation in
our patient was located in the TB5 domain, which suggests that
this domain of FBN1 is responsible for the pathogenesis of AD.P1-4-18
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Children with Idiopathic Short Stature (ISS): a Randomised
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Background: Idiopathic short stature (ISS) is the commonest cause of
referral to paediatric endocrinology clinics and is also a frequent
cause of referral to general paediatricians and primary care health
workers. For the children affected, there is an unmet need to im-
prove height prognosis and growth rates.
Aim: The aim of the current study was to evaluate the effects of re-
combinant human growth hormone (GH, Saizen®, Merck) treatment
on height velocity (HV) in Korean pre-pubertal children ( ≥ 5 years of
age) with ISS.
Methods: A 12-month, open-label, randomized, two-arm, parallel-
group, Phase III study conducted in nine centres throughout South
Korea. Patients were randomised 2:1 to receive either 0.067mg/kg/
day GH for 12 months (treatment group, n=60, 31 males) or 6
months of no treatment then 6 months 0.067 mg/kg/day GH (control
group, n=30, 17 males); assessments were at screening, baseline
(Month 0) and at Months 3, 6, 9, and 12. The primary efficacy end-
point was change in ( Δ ) HV from baseline to 6 months of study.
Secondary endpoints included Δ HV over 12 months, Δ Height (cm)
and Δ Height SDS over 6 and 12 months, Δ IGF-I and Δ IGFBP-3
levels (Siemens Immulite 2000 immunoassay system), adherence and
safety.
Results: At 6 months, the mean Δ HV from baseline was signifi-
cantly greater (p<0.0001) in the treatment group ( Δ HV = 4.45 ±
2.70 cm/year, LS mean = 4.47, SE = 0.35; n=59) than in the
control group ( Δ HV = 1.01 ± 3.15 cm/year, LS mean = 0.99, SE
= 0.54; n=29). In the GH treatment group (n=59), the increase in
HV of 4.45 ± 2.70 cm/year observed after 6 months, compared to
the baseline value, was also clinically relevant. Patients treated
with GH for 12 months (n=52) continuously demonstrated a sig-
nificant increase in Δ Height SDS compared to the control group
(n=27), both at 6 months (difference between LS means 0.51
[95% CI 0.42, 0.60]; p<0.0001) and at 12 months (difference be-
tween LS means 0.33 [95% CI 0.21, 0.45]; p<0.0001), respectively.
Serum IGF-I levels at 6 months were significantly increased
(p<0.0001) in the treatment group (122.57 ± 96.9 μ g/L) versus
the control group (8.30 ± 41.57 μ g/L). No treatment-related SAEs
were reported and there were no treatment discontinuations due
to adverse events.
Conclusions: Korean children with ISS receiving Saizen® GH showed
a significantly increased HV and change in height after 6 months of
treatment and the increased growth was maintained over 12
months. Saizen® GH was well tolerated.
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Background: Recombinant Growth Hormone(rhGH) therapy has been
into use for the last three decades but it became more accessible for
use in Indian children in the last decade . The authors were fortunate
to use it and are sharing their clinical experience.
Aim: To study the outcome of recombinant Growth Hormone on chil-
dren with Idiopathic Growth Hormone deficiency.
Method: A prospective cohort of 138 short statured children attend-
ing Pediatrics OPD during period from May 2005 to December 2013
who received recombinant Growth Hormone therapy .
Results: During the study period 138 children were labeled as “Short
Stature” based on clinical , auxological and biochemical criteria. How-
ever 58 children (37 boys & 21girls) were identified as having Short
Stature due to Idiopathic Growth Hormone Deficiency and received
minimum two years of rhGH therapy. 14 children were less than 8
years and 44 children were more than 8 years at the time of diagno-
sis. All these children were Growth Hormone deficient (Average peak
GH levels on provocative testing was 3.90 +/- 4.05 ng/ml). Average
initial height at beginning of therapy was 124.06 cm (minimum 80
cm and maximum 146 cm). Average height SDS at start of treatment
was – 2.73 (minimum -4.8 and maximum -2.1). 26 children completed
rhGH treatment during the study period and 24 reached their pre-
dicted height in their target range. Average final height at end of
therapy was 156.99 cm (maximum 167.8 cm and minimum 133.8
cm). Average Height SDS at end of therapy was -0.98(minimum -3.38
and maximum 0.1). Average height gain in first year of treatment
was 9.0 cm (maximum 11.5 cm and minimum was 8.0 cm) and in the
second year of treatment was 7.5 cm(maximum 9.0 cm and mini-
mum 6.5 cm). Of the children who took treatment for extended
period, they gained on average 6.4 cm during third year, 5.9 cm dur-
ing fourth year and 5.4 cm during fifth year of rhGH therapy. There
were no reported adverse effects of the therapy.
Conclusion: Indian Idiopathic Growth Hormone deficient children re-
spond well to rhGH therapy and the usage of rhGH is relatively safe.
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Objective: To study the outcomes of GnRHa on final adult height in
Chinese ICPP girls.
Methods: In this study, we retrospect our 10 years data from 3 clin-
ical hospitals between 2004 to 2014, and 101 girls with ICPP received
GnRHa therapy more than 6 months reached their adult height were
enrolled. These patients were treated by Leuprorelin or Triprorelin
without recombined human growth hormone. Height, bone age,
midparent height, HtSDS, sexual development, therapy duration and
PAH at the start of GnRHa and end of GnRHa, and final adult height
were calculated. We compared not only PAH at start of GnRHa and
end of GnRHa, and final adult height, but also the percentage of
short stature according to their midparent height and normal Chin-
ese girls’ height distribution. At the same time, we evaluated the cor-
relation between adult height and other factors.
Results: 101 girls with ICPP were enrolled in this study. Their average
age at the start of puberty was 7.1 ± 0.75 years, and they started totherapy with GnRHa at 8.4 ± 0.84 years, bone age were 10.6 ± 0.53
years. Their PAH at end of GnRHa (153.1 ± 5.37 cm) increased signifi-
cantly compared to that at start of GnRHa (158.4 ± 6.00cm), P<0.001,
and their final adult height (157.0 ± 4.82) increased significantly com-
pared to PAH at the start of GnRHa(P<0.001), but there was no differ-
ence between PAH at end of GnRHa and FAH(p>0.05). After GnRHa
therapy, most of ICPP girls reached their midparent height compared
to that at start of GnRHa(P<0.01). FAH was positively correlated with
height at start of GnRHa, height at end of GnRHa, PAH at start and
end of GnRHa, and also midparent height (R2=0.43, 0.61, 0.82, 0.89
and 0.75, P<0.001), while FAH was not correlated with duration of
treatment, BA at start of GnRHa(R2=-0.08, 0.1, p>0.05). The percent-
age of adult short stature and reached midparent height increased
significantly after GnRHa therapy compared to that at start of
GnRHa(60.6% vs 30.4% and 67.85% vs 94.64%, P<0.05, respectively).
Conclusions: GnRHa therapy to ICPP girls can achieve the final height
effectively, and after GnRHa therapy, most of patients reach their
midparent height and less of patients become adult short stature.
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Introduction: Continued growth monitoring is a quick, easy, inexpen-
sive and non-invasive method of assuring the general wellbeing of
the children. Children in rural areas have high prevalence of anaemia,
underweight and stunting.
Evaluation of growth necessitates the use of growth charts. We tried
to evaluate the growth parameters of school children on the Indian
1992, Indian 2015 and CDC 2000 references to assess the growth
performance of rural school children in India.
Aim: To assess the growth parameters of height, weight and BMI of
rural children and adolescents of Pune, India on the various growth
references.To assess the suitability of the charts for the present In-
dian rural population
Material and Methods: This was an Observational, Cross sectional
field study across socioeconomic class conducted for around 22
months on 2162 children, (1151) boys ( 5-15 years) from rural Pune.
Z scores according to the Indian 1992; Indian 2015 and CDC 2000
references for height, weight and BMI were calculated for
comparison.
Observation and Results: Each of these categories were further di-
vided into 3 more sub categories depending on the type of school
the children attended to see if there was a significant difference. In-
dian 1992 charts consistently gave the least prevalence for under-
nourished categories like stunting, wasting and underweight. It
misses out on picking many undernourished children as its lower cut
offs are very low and for the same reason it classified more children
as taller or overweight.CDC estimated far too many children as
underweight, stunted and wasted as it has very high cut off values.
Indian 2015 charts are the most appropriate for the rural children of
Pune. It showed prevalence of stunting among the children is 10.9
%, and tall children are only 0.6%. The prevalence of wasting is 12.7
%, Underweight children account for 6.9%, overweight for 6.4% and
obese for 2.0%. According to Indian 2015 charts, Z score analysis of
weight shows that the prevalence severely underweight and under-
weight , severe wasting and wasting, severe stunting and stunting is
more in girls as compared to boys. School wise categorisation
showed that the among the children of the fully paid schools, the
prevalence of undernourished states like stunting, wasting and
underweight were least, while the prevalence of overweight and
obesity were the highest.
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Purpose: It is wildly noted that spermarche begins at SMR 3 in boys
and menarche begins at SMR 3-4 in girls. While previous studies have
demonstrated that the mean age of menarche has been declining
constantly, little is known about the secular trend in mean age at
spermarche. Furthermore, it is rare that a study reports the secular
trend in mean ages of both menarche and spermache in Korean
population. The objective of this study is to reveal the pubertal trend
in age at menarche and spermarche in Korean adolescents over the
past decade since 2006.
Methods: Data collected from the KYRBS between 2006 and 2015
were used for the analysis. KYRBS is a cross-sectional, nationwide
school- based web survey with a stratified multistage probability
sampling design. It has a national representative sample of Korean
students in Grades 7-12 and is conducted annually. Participants are
Korean adolescents randomly assigned from 400 middle and 400
high schools. We conducted a cross-sectional analysis of self-
reported age at menarche and spermarche. Reponses from those
who have not experienced menarche/spermarche at the time of the
survey were not included for the analysis. Descriptive statistics were
calculated to demonstrate the general characteristics of the study
population.
Results: The sample size of a survey varies from 68,043 to 75,643, of
which approximately 52-3% are boys and 46-47% are girls. Through
years, the minimum average age of the study population is 14.94
(SD=0.02) in 2006, and the maximum is 15.15 (SD=0.02) in 2010. Tim-
ing of menarche and spermarche tends to shift downward; while in-
creases of 5.43% and 0.16% in experiencing menarche and
spermarche, respectively, were observed in Grade 7, decreases of
3.57% and 5.43% in experiencing menarche and spermarche, re-
spectively, were observed in Grade 9. In addition, the mean age at
menarche in 2015 was 12.241 years, which showed a decrease from
12.457 years in the 2005. The mean age at spermache in 2015 was
12.997 years, which showed a notable decrease from 13.148 years in
the 2005.
Conclusion: We have found that ages at menarche and spermarche
have been falling in the Korean adolescents for the last 10 years. Fur-
ther analysis including potential risk factors of early menarche and
spermarche needs to be performed to identify underlying causes of
these secular trends in the Korean adolescents.
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Introduction: The school age is nutritionally significant because this
is the time to built-up body stores of nutrients in preparation for
rapid growtg of adolescence.
Objective: The purpose of the study is to observe nutritional status
and anaemia among the school aged children and to compare the
urban and rural children as well as to see the correlation between
malnutrition and anaemia .
Methods: It is a descriptive cross sectional study. data were collected
from 600 primary school children of mymensingh district for a period
of one year.Results: Among the primary school children in mymensingh 15.1%
were wasted, 22.1% were stunted, 2.3%were both stunted and
wasted, 60.4% children were within normal limit. Malnutrition were
more in rural areas in comparison with urban area. In rural areas
severly underweight, moderately underweight children 72.4%, 73.6%
and corresponding result in urban areas were 27.6%,26.4% respect-
ively. In rural area severly stunted, moderately stunted children were
100%,58.6% and in urban area they were 0%,41.4% respectively.
Again severly wasted and moderately wasted children were 62.5%,
59.5% rural areas and 37.5%, 40.5% in urban areas respectively. Mal-
nutrition among girls were more then the boys.71% of our primary
school children were anaemic. Again rural children are more sufferer.
Anaemia was more in low income group and illiterate mother's child.
Some anaemic children are malnourished and some were not but there
were significant relationship between anaemia and malnutrition.
Conclusion: A large portion of our primary school children suffered
from malnutrition and anaemia and both the conditions were more
prevalent in rural areas. an endocrinological survey could be done to
asertain any endocrinological cause realted behind this growth
deficiency.P1-4-24
Efficacy and safety of recombinant human growth hormone
treatment in six Chinese patients with Noonan syndrome
Zhi-Hui Liu, Shi-yao Wang, Hui Pan, Hong-Bo Yang, Lin-jie Wang,
Feng-Ying Gong, Zi-meng Jin, Hui-juan Zhu
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Background: Noonan syndrome (NS) is an autosomal dominant
inherited disorder, characterized by short stature, special face fea-
tures, and congenital heart disease. Previous studies showed that re-
combinant human growth hormone(rhGH) can significantly improve
the patient's adult height. But there are no reports about clinical
manifestations or rhGH treatment responses in Chinese NS patients.
Methods: 1. Six NS patients were collected from May 2009 to August
2015 in Department of Endocrinology, Peking Union Medical College
Hospital with series of physical examination, laboratory tests, and
genetic screening results. 2. Five patients were prescribed with rhGH
with the daily dose of 0.04-0.06 mg/kg subcutaneously in the even-
ing and made the regular follow-up. 3. Ten age/gender matched
Turner syndrome (TS) patients and 10 growth hormone deficiency
(GHD) patients were also collected in the study, aiming to analyze
the efficacy differences of rhGH treatment in NS, TS, and GHD
patients.
Results: 1. Clinical manifestations: all patients manifested short sta-
ture(average height -3.6 ± 0.9 SDS) and typical facial features. Five of
them had congenital heart disease, four of them showed skeletal sys-
tem abnormalities. 2. Genetic test results: PTPN11 is the most com-
mon affected gene in NS patients (4/6). The other gene mutations
including KRAS (1/6) and SOS1 (1/6). 3. Five of six patients were
treated with rhGH. The annual growth rate of the patients was sig-
nificantly increased than before (P <0.01). One patient entered 3-
10th percentile of the normal range of height in the 1-year follow-
up, while the remaining four patients’ height was still less than 3rd.
4. The age-matched NS and TS patients had the similar efficacy of
rhGH treatment in every follow-up. However, compared with age/
gender matched GHD patients, NS patients revealed less treatment
benefit. 5. Adverse events: two NS patients emerged subclinical
hypothyroidism during the follow-up, levothyroxine was adminis-
tered to correct their thyroid function.
Conclusion: NS patients had relatively common symptoms and
clinical features. Gene screening is the definite way to confirm the
diagnosis. rhGH showed the significant efficacy and safety in the
Fig. 1 (abstract P1-5-1). See text for description
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needed in the follow-up.
Key words: Noonan syndrome; Turner syndrome, Growth hormone
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Mucopolysaccharidosis type II patients
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Background: Mucopolysaccharidosis type II (MPSII) is X-linked lyso-
somal storage disorder due to deficiency of iduronate-2-sulfatase,
which leads to variable symptoms by the accumulation of heparan
sulfate and dermatan sulfate in various tissues and organs. Patients
with MPSII generally show overgrowth until the age 3. However their
growth is gradually impaired, and eventually patients show short
statue. We investigated the effectiveness of enzyme replacement
therapy (ERT) to the growth.
Method/Patients: We analyzed 10 patients ages at initiation of ERT
were 1 to 28 yrs. We divided patients into two groups by the age of
the beginning of ERT. 6 patients were before the age of 3yrs (early
ERT group), and 3 patients were after 9yrs (late/no ERT group). We
compare their growth among these groups by height (HT) and body
weight (BW). The length of metacarpal bone (LMB) was measured
only in early ERT group. Patients with growth hormone deficiency
were excluded.
Result: Average HT SDs were in early ERT group; +1.7 at 3yrs, +1.2 at
5yrs and +0.8 at 8yrs, and in late/no ERT group; +0.4 at 3yrs, -0.47 at
5yrs and -3.0 at 8yrs. Average BW SDs were in early ERT group; +3.0
at 3yrs, +1.2 at 5yrs and +1.5 at 8yrs, and in late/no ERT group; +3.6
at 3yrs, +1.9 at 5yrs and -0.4 at 8yrs. Average LMB was -0.6SD at 3yrs
and -1.0SD at 8yrs in the early ERT group.
Discussion: The effectiveness of ERT was observed with HT, but less
for LMB, suggesting that improved joint contracture by ERT contrib-
uted more to HT improvement. Earlier diagnosis and treatment are
very important to normal growth.
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Background: Congenital hypothyroidism is insufficient production of
thyroid hormone which is necessary for normal metabolism, growth
and brain development, and its incidence is estimated 1 for
2000~3000 birth in Japan. LT4 supplementation is given priority to
precise diagnosis of hypothyroidism, therefore, in order to confirm
the diagnosis and to identify the pathophysiology of the condition,
the patients are recommended to be re-evaluated at the age of 3
y.o. or after. However, there are few reports to show the details of
the re-evaluation to date.
Objects and Methods: We retrospectively analyzed the 50 patients
(29 males and 21 females) who were diagnosed with congenital
hypothyroidism during their neonatal or early infantile period and re-
examined during from 2009 to 2015.
Result: The diagram of the results was indicated below. The re-
examination was performed from 3 to 12y.o.. Out of fifty cases, thirty
seven cases (74%) were identified by newborn- screening (NBS), and
twenty one patients (42%) revealed positive results on TRH test. Thy-
roid dysgenesis accounted for 61% (13/21) in permanent CH that
was lower than previously reports. Dyshormogenesis that showed el-
evated level of 123I uptake or perchlorate discharge, were observedin 28% and 44% of permanent and transient CH, respectively. Our
data suggested that there are substantial numbers of transient CH
pat ients w ith subclinical dyshormogenesis. There were statistically
significant difference of the l-T4 dosage between permanent and
transient CH, 3.14 ± 1.01 μ g/kg/day and 2.00 ± 0.72 μ g/kg/day
(p<0.001), respectively.
Conclusion: Our present study gave an overview of the clinical details
of congenital hypothyroidism, and suggested that substantial number
of patients classified transient CH would have mild dyshromogenesis,
requiring careful follow–up is necessary even after re-examination.P1-5-2
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Context: Thyroid peroxidase (TPO) is a thyroid-specific membrane-
bound enzyme that plays a crucial role in iodination of the thyro-
globulin (Tg) protein. The TPO defect, which is caused by biallelic
mutations of TPO , is a well-established genetic form of congenital
hypothyroidism (CH). More than 100 mutation-proven cases have
been published, but only four had a negative result in newborn
screening for CH. Here, we report three TPO mutation-carrying
hypothyroidism patients that were missed by newborn screening,
and had relatively mild thyroid phenotypes.
Patients: Three patients were born at term after uneventful preg-
nancy and delivery, and had a negative result in newborn screening
for CH. They were treated with levothyroxine after the diagnosis of
hypothyroidism. Patient 1 developed goiter at age 8 years. Blood test
showed mild hypothyroidism (TSH 6.47 mU/L, FT4 0.99 ng/dL, FT3
4.10 pg/mL) with an elevated serum Tg level (1,057 ng/mL; reference
<30). 123I uptake was high (65% at 4 h; reference 5-15), and the per-
chlorate discharge test was positive (35.4%; reference <10). Patient 2
had mild developmental delay and was followed up by primary care
physician. At age 1 year, she developed goiter, and received her first
thyroid function tests, revealing a high serum TSH level (41.5 mU/L),
a low FT4 (0.59 ng/dL) level and a high FT3 level (5.85 pg/mL). The
serum Tg level was high (3,640 ng/mL). 123I scintigraphy was not
performed. Patient 3 had mild developmental delay but the growth
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test showed a slightly high serum TSH level (5.9 mU/L), a low total
T4 level (3.5 μ g/dL; reference 6.0-13.8), and a high total T3 level
(2.20 ng/mL; reference 0.60-1.81). 123I uptake was elevated (72% at 4
h). Perchlorate discharge test was not performed. His goiter was not
resolved by levothyroxine treatment, and he finally received thyroid-
ectomy at age 17 years.
Genetic analysis: Sequencing of TPO revealed compound heterozy-
gous mutations in Patient 1 (p.Asp224del / c.820-2A>G), seemingly
compound heterozygous mutations in Patient 2 (p.Arg540* /
p.Ile657Thr), and a homozygous mutation (p.Trp527Cys) in Patient 3.
Conclusions: The TPO defect can be missed by newborn screening.
Considering preserved thyroid hormone-producing capacity in Pa-
tients 1 and 3, the negative results were possibly associated with re-
sidual TPO activity. All three patients had high T3/T4 ratio, indicating
elevated type 2 deiodinase activity in their thyroids.
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Context: Congenital central hypothyroidism(C-CH) is rare disease in
which thyroid hormone deficiency is caused by sufficient thyrotro-
pin(TSH) stimulation of a normally-located thyroid gland. Recently,
deficiency of immunoglobulin super family member 1(IGSF1) has
been demonstrated to cause C-CH.We report Japanese brothers with
C-CH caused by a novel mutation of the IGSF1 gene.
Patient finding: As an elder brother showed developmental delay
and constipation at one age, he was referred to our hospital. Serum
FT4 and TSH were 0.57 ng/dL and 0.67 μIU/mL, respectively. There-
fore he was diagnosed as having C-CH. A younger brother showed
symptoms of CH, such as poor feeding, hypothermia and prolonged
jaundice at 6 days of age. Based on clinical and biochemical evalu-
ation the diagnosis of C-CH was done. Serum FT4 and TSH were 0.38
ng/dL and 1.10 μIU/mL, respectively. In addition, these patients had
several characteristic features of IGSF1 deficiency such as heavy birth
weight, obesity and hypoprolactinemia.
Result: The genetic analysis revealed a novel IGSF1 mutation
(c.3607del s, p.W1159G’sx8) in the both patients.
Conclusion: We report Japanese siblings with C-CH caused by IGSF1
deficiency. As IGSF1 deficiency shows neurological developmental
delay in some patients, it is important for diagnosis of C-CH and
prompt initiation of L-T4.
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Background and objectives: Atrioventricular regurgitation, such as
tricuspid regurgitation (TR), mitral regurgitation (MR) and mitral valve
prolapse (MVP) has high incidence in hyperthyroidism, but only few
studies have been conducted in children. Therefore, in the current
study, we investigated the incidence and clinical importance of car-
diovascular abnormalities in children with Graves’ disease which is
the most common cause of pediatric hyperthyroidism. We also evalu-
ated the association between thyroid hormone levels and cardiac
abnormalities.
Methods: Fifty-one pediatric patients (42 girls/9 boys, 12.29 ± 2.89
years of age) with newly diagnosed thyrotoxicosis due to Graves’ dis-
ease were recruited by retrospective medical record review from May
2010 through April 2016 at the Department of Pediatrics in AjouUniversity Hospital. Medical history, laboratory determinations,
complete physical examination results, electrocardiographic findings
and echocardiographic findings were recorded for all patients.
Results: Major laboratory finding was free T4 3.70 ± 0.88 ng/dL, T3
403.6 ± 165.89 ng/dL, TSH 0.17 ± 0.44 μ IU/mL, TSH receptor- stimu-
lating antibody 36.45 ± 45.15 U/ml. Sinus tachycardia was present in
all patients (n=51, 100%), while atrial fibrillation was none. MVP was
present in six patients (6 girls, 11.8%). All of them had MR (14 girls,
27.5%). TR observed in nine patients (8 girls/1 boy, 17.6%). TR with
MR observed in four patients (3 girls/1 boy, 7.8%). One patient had
TR with MVP (1 girl, 2%), two patients had aortic regurgitation (AR, 2
girls, 3.9%) and three patients has left ventricular hypertrophy (LVH,
1 girl/2 boys, 5.9%). There were no differences between group of ab-
normal echocardiographic findings (n=24, 47.1%) and the normal
finding group (n=27, 52.9%) in laboratory findings, symptoms and
signs. Likewise, MVP with MR, MR, TR with MVP, AR and LVH were no
differences in laboratory finding, symptoms and signs. TR (pressure
gradient, mean 38.4mmHg, range 32~54, SD 6.47) was significant
correlation with T3 (p 0.031).
Conclusions: We observed high T3 level correlated with TR incidence.
So we should be concerned with cardiovascular complication, be-
cause TR is a pre-state of right heart failure. Furthermore, based on
our echocardiographic research, we found that cardiac abnormalities
(47.1%) are more likely to happen to children who have a Graves’
thyrotoxicosis. Thus, we suggest that echocardiography should be
regarded as routine screening tool to detect cardiac abnormalities in
pediatric Graves’ thyrotoxicosis.
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Purposes: The aim of this study was to recognize difference between
transient congenital hypothyroidism (TCH) from permanent congeni-
tal hypothyroidism (PCH) by determining clinical characteristics, la-
boratory tests and imaging studies.
Methods: We performed retrospective study using database of the
patients with congenital hypothyroidism treated with or without
Levo- Thyroxine at Bundang Jesaeng General Hospital, from January
1998 to February 2016. Their ages, birth weights, gestational ages,
symptoms, ages at diagnosis and treatment were recorded. We mea-
sured TSH, free thyroxine(FT4), triiodothyronine(TT3) levels at diagno-
sis and treatment, and those levels at one, two and three months
after treatment. Thyroid scan(Tc99m scintigraphy) and thyroid ultra-
sonography reports were described.
Results: Among the 282 neonates included in this analysis, 51 were
diagnosed with congenital hypothyroidism. The sex distribution was
male 51% (26/51) vs. female 49% (25/51). Their initial postnatal ages
of starting Levo-thyroxine treatment were 26.97 ± 15.4 days. 27 pa-
tients out of 51 were identified as TCH and 24 were revealed PCH. In
the TCH patients group, male patients were 66.7% (18/27) and fe-
male patients were 33.3% (9/27). Ages of initial treatment of TCH
were 31.15 ± 13.78 days. The sex distribution of PCH was male 33.3%
(8/24) vs. female 66.7% (16/24). Ages of initial treatment of PCH pa-
tients were 27.93 ± 31.07 days. The mean duration of treatment in
TCH group were 28.94 ± 13.89 months. Serum TSH levels were mea-
sured at diagnosis of PCH group (mean 150.49 , median 77.70 , 25-
75% 43.8-185 IU/mL) were significantly higher than those of TCH
group (mean 30.29 , median 21.40 , 25-75% 17.1-291 IU/mL)
(p<0.001). FT4 levels (PCH;0.73 ± 0.50ng/dL vs. TCH;1.17 ± 0.53ng/dL,
p<0.02) and TT3 levels (PCH;1.36 ± 0.68ng/mL, vs. TCH;1.90 ± 0.35ng/
mL, p<0.019) measured at start of treatment also showed significant
differences. FT4 level measured at two months later from start of
treatment in PCH group were significantly higher than TCH group
(p<0.034). Required treatment doses were significantly different only
that of 2-years of therapy. Thyroid USG were normal in 53.3% of
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were normal. We found another difference in Tc99m scintigraphy re-
ports of both group. The sizes of thyroids in patients of PCH group
were bigger than TCH group (p<0.033).
Conclusion: According to these data, we might consider initial mea-
surements of serum TSH, FT4, T3 and size of thyroid as predictive fac-
tors in categorizing TCH from PCH.
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Introduction: MCT8 gene mutations produce thyroid hormone (TH)
deficiency in human brain, causing severe neuropsychomotor abnor-
malities not correctable with TH. Mice have two TH transporters,
Mct8 and Oatp1c1, although human have only MCT8. Mct8 single
knockout (KO) mouse did not show neuropsychomotor abnormal-
ities. Therefore, the ideal animal model for Mct8 deficiency is Mct8
/Oatp1c1 double KO mouse. In this study, we generated Oatp1c1 KO
mice by CRISPR/Cas9, the new powerful genome editing tool, to ob-
tain Mct8 / Oatp1c1 double KO mice.
Method: To produce mutant mice, guide RNAs were designed by
CRSPR direct program. The gRNAs used in this study were: Oatp1c1
gRNA1 5’–attcagcgcaacctgccggaggg-3’, gRNA2 5’-ggacggatatccgactg-
taaagg-3’. Template DNAs for in vitro transcription were generated
by PCR amplification of the ORFs of hCas9 and gRNAs from each
plasmid using Prime STAR (TaKaRa). The PCR products were purified
and used for the in vitro RNA synthesis using mMessage mMachine
T7 kit. Mouse zygotes were obtained by mating superovulated wild
type BDF1 females and wild type BDF1 males. RNAs of hCas9 and
gRNA were mixed just before microinjection into the cytoplasm of
zygotes and the injected embryos were incubated at 37 degree until
they were transfeered into pseudopregnant females at the two-cell
stage. Genomic DNA was extracted from the tail or ear tips of pups,
and the genomic sequences around the gRNA target sites were PCR
amplified and sequenced directly, or were cloned into the plasmid
and sequenced. The electropherograms of each sequence were clas-
sified into four caegories: wild type (no mutation and no overlapping
peaks), hetero-like mutation (double peaks, which started from the
gRNA target site), minor mosaic-like mutation (one of the double
peaks is dominant to the other) and Indels (Both alleles have the
same insertion and/or deletion).
Result: We obtained 28 pups from surrogate mothers. One mouse
died at day 33. Of 27 mice, 24 were males and 3 were females; 15
mice were classified into hetero-like mutation, 3 were minor mosaic-
like mutation, 9 were Indels. One mouse was hard to be classified.
No mouse was wild type. The mutation rate was 26/27 (96.3%). We
will report the phenotype of Mct8 /Oatp1c1 double knokckout mice
at the meeting.
Conclusion: CRISPR/Cas9 system can provide high efficient and rapid
generation of KO mice.
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Thyrotoxicosis longer than 5 weeks after 22 weeks of gestation is
required for the development of central hypothyroidism due to
maternal Graves’ disease
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Introduction: Central hypothyroidism (CH) in neonates born to
mothers with poorly-controlled Graves’ disease (GD) was first re-
ported in 1988. For the development of this type of CH (mGD-CH),
the following factors must be present: (1) passage of maternal thy-
roid antibodies through the placenta; (2) negative feedback in the
fetal pituitary-thyroid axis; (3) requisite duration of thyrotoxicosis in
both the mother and the fetus.
Objective: To elucidate the minimum duration of maternal and fetal
GD for the development of this disorder.
Materials and Methods: “Pubmed” was searched for clinical informa-
tion on 20 cases of mGD-CH from 8 papers published between 1988
and 2010. All diagnoses were re-confirmed. Maternal thyrotoxicosis
had been found either before pregnancy or during pregnancy except
in 1 mother who was diagnosed on postpartum day 7. The diagnosis
of mGD-CH (serum free T4 1.0 microgram/dL and TSH 7.5 mU/L) was
made between postpartum day 7 and 425. Finally, the duration of
maternal and fetal thyrotoxicosis was calculated on the assumption
that conditions (1) and (2) were established by the gestational age of
22 weeks.
Results: The timing of the diagnosis of maternal GD during preg-
nancy ranged from the gestational age of 14 to 31 weeks. In the pa-
tient with the latest diagnosis of maternal GD during pregnancy at
GW 31, the timing of the delivery was GW 37, suggesting that the
duration of thyrotoxicosis for both the mother and fetus was 6 at
least weeks. The timing of delivery varied from 27 to 41 weeks. In
the most premature case at 27 weeks, the period of maternal and
fetal thyrotoxicosis was 5 weeks, as calculated by subtracting 22
weeks from 27 weeks. The minimum period of thyrotoxicosis was
thus estimated to be more than 5 weeks.
Discussion: Our assumption that factors (1) and (2) were established
at GW 22 stemmed from the following facts: transplacental passage
of TRAb has been reported at GW 21 (Mckenzie, et al. 1992); fetal GD
presenting an undetectable TSH level and markedly elevated thyrox-
ine has been documented at GW 20 (Racover, et al. 1999); intra-
amniotic thyroxine therapy for fetal hypothyroidism was effective at
GW 22. (Hanono, et al. 2009). In conclusion, thyrotoxicosis in both
the mother and fetus after GW 22 for a duration of more than 5
weeks was required for the development of mGD-CH.
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Background: The standard pharmacological treatment strategy of
thyroid storm has just been published in 2016 Japan Society of
Pediatric Endocrinology Guideline. Although thiamazole (MMI) is rec-
ommended to be used as the first choice in Graves’ disease, the ef-
fect of propylthiouracil (PTU) to block the conversion from T4 to T3
in peripheral tissues encourages clinicians to use against thyroid
storm in very early phase, and switch to MMI later. Nevertheless, the
optimal timing of the switch has not been established to date and
recently, pediatric cases with thyroid storm are quite rare in devel-
oped countries.
Case: The patient was initially diagnosed as having Graves’ disease at
age 8 years in a rural area of Philippines and prescribed with MMI.
She quit hospital visiting soon after the diagnosis. At age 12 years,
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family moved to Japan. On the day of onset, she had a strong dys-
pnea and was unable to lie flat. She was brought to the tertiary care
center to be diagnosed as thyroid storm and transferred to PICU in
our hospital. The patient was fully conscious and orthopneic. Bilateral
exophthalmos and diffuse goiter were noted. Both the fT3 and fT4
were beyond the measurable range. The patient was treated with
dexamethasone 8mg, PTU 1,200mg and iodine 200mg. Four days
after the treatment, fT3 was decreased to the measurable range
(8.0pg/mL). We immediately switched PTU to MMI 80mg. On 6th day,
we reduced the dose of MMI into 60mg, switched dexamethasone to
hydrocortisone. On 11th day, the symptoms and test results further
improved and we reduced MMI into 30mg along with introduction
of levothyroxine to prevent hypothyroidism and suspended iodine.
On day 16, the patient was discharged from the hospital.
Discussions: In this case, high dose PTU rapidly suppressed fT3 w
ithin 4 days. Free T3 drop to measurable range can be a good indica-
tor of optimal timing of switching PTU to MMI. Relatively higher dose
of MMI as 80mg might be required to keep suppressing the thyroid
just after the switch.
Consent for publication: The authors declare that written informed
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Background: The thyroid dysfunction is one of the frequently seen
complications after bone marrow transplantation (BMT). Althoughhypothyroidism is the most common thyroid disease after BMT,
hyperthyroidism is a rare condition. Herein, we report a series of 2
patients who were euthyroid before BMT but developed hyperthy-
roidism after transplantation.
Objective: Case reports and the frequency of hyperthyroidism after
BMT in our institute.
Case 1: A 10-year-old boy was diagnosed with adrenoleukodystrophy
and underwent transplantation twice from his HLA-unmatched sister
when 10 years of age. Conditioning regimens consisted of thora-
coabdominal irradiation + Busulfan (Bu) + Cyclophosphamide (CY) +
Antithymocyte globulin (ATG) for the first BMT and Bu + CY + ATG
for the second BMT due to a rejection of the first BMT. At the time of
both BMTs, his thyroid function tests were normal, respectively, and
his donor had no history of thyroid disease. Prophylaxis against
graft-versus- host disease (GVHD) was used short-term methotrexate
(sMTX) and cyclosporine (CyA). He had acute GVHD presenting with
nodular rash and prednisolone was initiated. Although subclinical
compensated hypothyroidism was demonstrated after the first BMT,
hyperthyroidism occurred 3 years after the first BMT. He was treated
with methimazole.
Case 2: A 15-year-old boy was diagnosed with severe aplastic anemia
and underwent transplantation from his HLA-matched sister when 15
years of age. Conditioning regimens consisted of CY + ATG. Prophy-
laxis against GVHD was used sMTX and CyA. He had no acute and
chronic GVHD. Hyperthyroidism occurred 3 years after BMT. After he
was followed without treatment for 9 months, we started to treat
with methimazole.
Results: Systematic evaluation of thyroid function tests in 156 who
underwent BMT and are follow-up at our institute gave a rate of
hyperthyroidism at 1.3% in this study.
Conclusion: The clinician should be alert to hyperthyroidism as a
possible complication after BMT.
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Introduction: Maternal hyperthyroidism can lead to variable thyroid
abnormalities found in the babies, with potential detrimental out-
comes. Central hypothyroidism (CH) is one of the rarer form of thy-
roid dysfunction described in this entity.
Aim: To describe a case series of central hypothyroidism found in ba-
bies born to mothers with hyperthyroidism from a Children’s Hospital.
Method: All cases of CH resulted from maternal hyperthyroidism be-
ing followed up in a paediatric endocrine clinic from 1 January 2014
to 31 May 2016 were retrieved. Their clinical features and progress of
illness were summarised. Diagnosis is based on low free thyroxine
(fT4) concentration associated with inappropriately normal or low
Thyroid Stimulating Hormone (TSH) level.
Results: There are total eight cases identified, including a pair of
twins. The twins were born small and prematurely, another two ba-
bies were born prematurely with appropriate size, the rest were born
at term with appropriate weight. For maternal diagnoses, there were
four cases of hyperthyroidism, presumptively Graves’ disease, and
the rest are toxic thyroid nodule, multinodular goiter and subclinical
hyperthyroidism. Evidence of CH developed immediately after birth
in two cases, two to six weeks later after a transient period of euthyr-
oidism in five cases, and after 3 months of hyperthyroidism which
required Carbimazole treatment in the last case. Poorer control of
maternal hyperthyroidism was found in the three babies who devel-
oped immediate CH and initial hyperthyroidism. The mean duration
of follow-ups was 10.6 ± 8.3 months. All were still dependent on thy-
roxine, with a mean dosage of 4.2 ± 1.4 mcg/kg/day. Nevertheless,
two cases had shown partial recovery of TSH from 13 and 19 months
respectively. Developmental milestones were normal for all cases, ex-
cept slight gross motor delay for the case with initial hyperthyroid-
ism. Thyrotropin releasing hormone stimulation test to confirm the
CH was not done due to limited resource.
Fig. 1 (abstract P1-5-14). The effect of levothyroxine on thyroid
volume SDS in euthyroid children with autoimmune thyroiditis
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centre warrants a further evaluation of the real prevalence of CH sec-
ondary to maternal hyperthyroidism. Careful monitoring of neonatal
thyroid function born to these mothers is important, as CH will not
be detected by TSH-based screening method and may developed
after a period of euthyroidism.
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Aim: To evaluation of thyroid function in neonates born from
mothers affected by thyroid disease in order to define follow-up thy-
roid function test is needed for these children.
Methods: Records were reviewed for all newborn with thyroid dys-
function of mothers who were born in Cheill General Hospital, from
May, 2012 to May, 2015. All neonates were tested for thyroid func-
tion by measurement of thyroxine (T4) and thyroid stimulating hor-
mone (TSH) in 3rd or 4th day. Babies whose first results was
abnormal or who were born from mothers affected by thyroid dis-
ease were tested for thyroid function repeatedly by measurement of
free thyroxine (fT4) and TSH at about 2weeks and at one month of
life. Data concerning etiology of maternal thyroid disease during
pregnancy were retrospectively collected. Neonates who were born
from women with thyroid disease and having anti-thyroglobulin
(ATG) or anti-microsomal (AMA) antibodies were assigned as group I,
women with hypothyroidism who did not have autoantibodies were
assigned as group II, and women without thyroid problems were
assigned as group III.
Results: In group I, 12(6.1%) infants were diagnosed with compen-
sated hypothyroidism and started levothyroxine therapy. The median
age of diagnosis of hypothyroidism was 37.4 days. 20(10.2%) infants
had hyperthyrotropinemia at 1st test. 24(12.2%) infants had transient
hyperthyrotropinemia. The median period of normalization of TSH
was 112.7 days. Especially, 5 neonates were diagnosed with
hypothyroidism, despite of normal results of 1st screening test. 35 in-
fants (9.7%) in group II had hyperthyrotropinemia at 1st test. 9 (2.5%)
of them were diagnosed with compensated hypothyroidism and
started levothyroxine therapy. The median age of diagnosis of
hypothyroidism was 70.4 days. 64 (17.7%) infants had transient
hyperthyrotropinemia. The median period of normalization of TSH
was 117.5 days. Especially, 3 neonates were diagnosed with
hypothyroidism, despite of normal results of 1st screening test. In
group III, 468 infants had hyperthyrotropinemia at the 1st test and a
spontaneous completely normalization of TSH value was observed.
47 of them were diagnosed with compensated hypothyroidism and
started levothyroxine therapy.
Conclusion: Persistent hyperthyrotropinemia requiring replacement
therapy is observed in 6.1% of group I, 2.5 % of group II. According
to our experience, follow-up is recommended in these newborns-
Newborn infants born from women with thyroid disorders should be
followed closely for thyroid dysfunction.
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overt hypothyroidism, subclinical hypothyroidism, euthyroid or
hyperthyroidism. Although there is no consensus on treating euthyr-
oid condition in thyroiditis autoimmune children, some studies
showed efficacy of levothyroxine in decreasing thyroid volume, im-
proving thyroid function, and stabilizing immunological process.
Objectives: to determine the effect of levothyroxine on thyroid vol-
ume changes, thyroid functions and thyroid antibodies in euthyroid
children with autoimmune thyroiditis.
Methods: Systematic review was performed in euthyroid children with
autoimmune thyroiditis. Electronic databases search (the Cochrane
Library, MEDLINE, EBSCO, Proquest, clinicaltrials.gov and other sources)
and non-electronic search (handsearch of journals, conference proceed-
ing) were done. Randomised and quasi-randomised controlled trials
comparing levothyroxine to control in all euthyroid children with auto-
immune thyroiditis were selected. Two person independently extracted
data, assessed the risk of bias, analyzed pooled data from included
study by random effect model and performed sensitivity analysis.
Results: Two studies (80 participants) were included from 48 studies
identified from searching methods. Only thyroid volume SDS data
could be aggregated. Mean difference of thyroid volume change was
-1,18 (95%CI; -1,65; -0,70) SDS between levothyroxine and control.
Mean difference of TSH, fT4, TPOAb and TgAb change between
levothyroxine and control were -0,24 mU/liter (IK95% -1,96; 1,12);
-0,76 pmol/liter (95%CI -4,77; 3,25); 135,2 U/ml (95%CI -319,8; 590,2);
and -75,53 U/mililiter (95%CI -255,32; 104,26). Risk of goiter was de-
creasing with levothyroxine treatment (OR 0,06; IK95% 0,01-0,28).
Conclusion: Levothyroxine treatment for euthyroid children with
autoimmune thyroid might reduce thyroid volume (SDS) and risk of
goiter.
Treatment of levothyroxine do not conclusively improve changes of
TSH, fT4, TPOAb and TgAb.
Keyword: autoimmune thyroiditis, euthyroid, levothyroxine, thyroid
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Introduction: Thyroid cancer is one of the most common causes of
malignancy in childhood, accounting for 0.5%-3% of all childhood
malignancy. Radiation exposure has been established as one of the
risk factors to develop thyroid cancer; but there are also several
genes associated with development of thyroid cancer such as RET/
TRK, BRAF, RET/PTC, PTEN tumor suppressor gene, and GNAS-1 gene
mutation.
Case: A-14 years old male adolescents referred to our clinic due to
left thyroid enlargement since a year prior with no signs and symp-
toms of hypothyroidism or hyperthyroidism. No weight reduction
was found. The first thyroid ultrasound revealed diffuse enlargement
of the left thyroid lobe and the hormonal assay showed normal FT4
and TSHs level. He received L-thyroxin treatment for one year with
no reduction in goiter size. They were high incidence of malignancy
running through his family .i.e. thyroid malignancy, breast
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 72 of 144malignancy, and lymphoma. His second US examination revealed left
lobe enlargement with the size of 7.3 x 6.4 x 4.9 cm with multiple
hyperechoic and hypoechoic nodules. Anti-TPO and anti thyroglobu-
lin were negative. His thyroid scan showed multiple cold nodules. He
then underwent FNAB which appropriate with benign adenomatous
goiter. He continued to received L-thyroxin treatment for the next 6
months, but loss to follow up for 5 months and returned with further
enlarge thyroid. CT-Scan of the thyroid revealed diffuse enlargement
of left lobe with the size of 8.8 x 5.9 x 6.3 cm with necrotic spots. No
lymph nodes enlargement found. Right thyroid lobe was normal. He
underwent the second FNAB with the result of atypical cell of un-
determined significance and was advised to do FNAB within in the
next three months. The third FNAB revealed carcinoma thyroid. He
then underwent total thyroidectomy and result of thyroid biopsy was
appropriate with papillary thyroid carcinoma with solid and follicular
variant.
Conclusions: This patient showed an evolution from benign thyroid
nodule to thyroid carcinoma in an adolescence with time span of
one and half years. High incidence of malignancy in his family raise
suspicion of the possibility of genetic predispotition. PTEN gene is
one of the gene that should be consider in this patients considering
the occurrence of thyroid, breast and lymph node malignancy in his
family. Further studies and collaborations with other centers are
needed to support this hypothesis.
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Background: The transplacental passage of maternal thyrotropin re-
ceptor (TSHR) antibodies in the case of maternal autoimmune thyroid
disease influences the function of fetal and neonatal thyroid gland.
The clinical picture depends on the functional activity of TSHR
antibodies
their ability to inhibit (typically in maternal autoimmune atrophic thy-
roiditis) or activate (in maternal Graves-Basedow thyrotoxicosis) TSH
receptor.
Objective: It has been described previously that maternal autoanti-
bodies binding to TSHR can cause fetal and neonatal hyperthyroid-
ism or congenital hypothyroidism. The remission of this condition
can be expected in 3-6 months with disappearing of antibodies.
Case reports: We have followed three girls with congenital
hypothyroidism and two patients with neonatal hyperthyroidism
with high levels of TSHR antibodies at diagnosis. The cases of con-
genital hypothyroidism were diagnosed in nation-wide neonatal
screening based on high levels of TSH. Their mothers were treated
for chronic lymphocytic thyroiditis. Two neonatates with severe neo-
natal thyrotoxicosis were diagnosed based on clinical symptoms in
neonatal period. One mother had undiagnosed Graves-Basedow
thyrotoxicosis, the second underwent thyroidectomy for the same
condition prior to pregnancy.
Conclusions: It is recommended to follow levels of TSHR antibodies
in pregnant women with active Graves-Basedow disease but also in
those who underwent thyroidectomy or radioiodine therapy for this
condition previously as antibodies may persist. Depending on mater-
nal TSHR antibodies levels, the close follow up of the fetus and neo-
nate can be required. Even if transplacental passage of TSHR
antibodies is not a frequent cause of congenital hypothyroidism, we
perform TSHR antibodies testing in all newborns with congenital
hypothyroidism and also in their mothers.P1-6-1
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The genetic basis of SRY -negative 46,XX testicular/ovotesticular dis-
orders of sex development (DSD) remains largely unknown. Although
mutations in NR5A1 are known to cause 46,XY gonadal dysgenesis
and 46,XX ovarian insufficiency, this gene has not been implicated in
testicular development of 46,XX gonads.
We performed sequence analysis of 28 genes known to be involved
in gonadal development in 8 patients with SRY -negative 46,XX tes-
ticular/ ovotesticular DSD. Nucleotide alterations were screened by
next generation sequencing and confirmed by Sanger sequencing.
As a result, we detected identical NR5A1 mutations (p.R92W) in two
unrelated patients. These patients carried no additional mutations in
tested genes. The patients had testicular or ovotesticular tissues in
the gonads and lacked uterus or vagina. The NR5A1 mutation was
absent in the clinically normal mothers of the patients. The mutation
was not found in exome databases or in 200 unaffected control indi-
viduals. In silico analyses suggested that the p.R92W is probably
pathogenic and induces conformational changes at the DNA-binding
site. In vitro assays demonstrated that, compared with wildtype
NR5A1, the mutant protein was less sensitive to NR0B1 induced sup-
pression on the SOX9 enhancer sequence core element. Our findings
provide the first indication that NR5A1 is a causative gene for 46,XX
testicular/ ovotesticular DSD.P1-6-2
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Introduction: MAMLD1 on chromosome Xq28 is known as a
causative gene for 46,XY disorders of sex development; however,
clinical information is virtually limited in patients of infancy to early
childhood. Here, we report long-term genital and hormonal findings
in three previously described Japanese patients with MAMLD1
mutations.
Subjects: We report 3 parients; patients 1 and 2 with p.E197X and
patient 3 with p.R726X. Patients 1–3 exhibited penoscrotal hypospa-
dias with chordee, microphallus, bifid/hypoplastic scrotum, and/or bi-
lateral cryptorchidism/retractile testes.
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showed sufficiently high serum basal or hCG-stimulated testosterone
values. Subsequently, patient 1 had low serum hCG-stimulated tes-
tosterone value (126 ng/dL) at 13 11/12 years of age, and manifested
microphallus (4.5 cm), relatively small testes (left 8 mL and right 10
mL), Tanner stage 3 genitalia and pubic hair development at 18 3/12
years of age. Similarly, patients 2 and 3 showed mild hypergonado-
tropic hypogonadism at 7 0/12 and 9 9/12 years of age, respectively,
with serum GnRH-stimulated LH values of 5.5 and 7.2 mIU/mL and'sH
values of 10.3 and 19.8 mIU/mL and hCG-stimulated testosterone
values of 70 and 80 ng/dL, respectively. Testis ultrasound studies de-
lineated microlithiasis in patients 1 and 3.
Conclusion: These results imply for the first time deterioration of testicu-
lar function with age in patients with pathologic MAMLD1 mutations.
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Context: In male fetuses, androgens could be produced in three tis-
sues: (1) the fetal testis that would produce the frontdoor-derived tes-
tosterone (T) (which is further converted to dihydrotestosterone (DHT)
in the external genital tissues) and the backdoor-derived DHT; (2) the
placenta that produces T from DHEA, and (3) the fetal adrenal that
could produce the backdoor-derived DHT in co-operation with perman-
ent adrenal. In this regard, previous studies in genetic males with P450
oxidoreductase (POR) deficiency (PORD) have suggested that testicular
T and DHT production is compromised, whereas placental T production
and the fetal adrenal-related DHT production may be exaggerated in
PORD. To examine this notion, we studied the androgen production
properties in a genetic male infant with prenatally diagnosed PORD.
Patient: This Japanese genetic male infant was prenatally diagnosed
as having PORD, on the basis of severely undermasculinized external
genitalia (he was initially regarded as a female), radio-humeral synos-
tosis on computed tomography, and maternal virilization. Shortly
after birth, chromosome analysis showed a 46,XY karyotype, and dir-
ect sequencing revealed compound heterozygous mutations of POR
(c.601C>T, p.Q201X in exon 6 and c.1370G>A, p.R457H in exon 12).
Methods: Steroid metabolites were measured by LC-MS/MS, using
longitudinal blood samples of this patient and umbilical blood
samples from control males (n=5) and females (n=5).
Results: 17-hydroxyprogesterone (17-OHP4), androstenedione (A-
dione), T, and DHT values showed transient marked elevation around
birth (at birth and one day of age) in this patient as compared with
controls. However, the A-dione/T and T/DHT ratios were comparable
between the patient and controls at that time, and the backdoor-
derived 5 α -androstane,3α,17 β -diol (5α,3α-A-diol) value was compar-
able between the patient and the controls. In addition, T and DHT were
higher in control males than in control females, and other steroid me-
tabolites including those on the backdoor pathway were comparable
between male and female controls.
Discussion: These results imply that elevated T and DHT around birth
of this patient is primarily derived from the placenta, and that the
relevance of the backdoor pathway to the elevated DHT remains
minor, if any. In addition, the backdoor pathway is unlikely to be op-
erating in the fetal testis around the birth.
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hypospadias and mutations of MAMLD1.
Methods: Seventy-two patients were diagnosed to be hypospadias in
department of endocrinology and department of urinary surgery in
our hospital. Among all the patients, 69 were with normal karyotype
and enrolled as the studied group. Fifty healthy boys were employed
as the controls. Peripheral Blood were collected for DNA extraction.
For the studied group, PCR primer was designed and direct sequen-
cing was performed for screening for MAMLD1 mutations in six
coding exons and the flanking region. Those mutated exons were ex-
amined for the control group.
Results: Thirty-five of all the 72 patients (48.6 %) were isolated hypo-
spadias. The other 37 cases (51.4%) were complicated by other geni-
tourinary system malformations, including 12 cases with micropenis
and/or underdeveloped testicles. Abnormal karyotype was identified
in 3 patients, and all were karyotype as 46, XX (SRY+ in 1 case and
SRY- in 2 cases). Six types of MAMLD1 mutations were detected in
exon 2, 3, 5, 7 in studied group, including c.5A G (p.D2G), IVS4-364C/
A, c.1910A G ip.N637S), c.2208T C, c.2227 G A (p.E742K) and IVS8-
144C/T. All were single nucleotide polymorphism except c.5A G
(p.D2G), a newly discovered point mutation. The frequency of IVS4-
364C/A was significantly different between patients and controls,
and it was also significantly different between patients with and
without micropenis and/or underdeveloped testicles.
Conclusion: Chromosome abnormality is not the leading cause of
other genitourinary system malformations complicated with hypo-
spadias. Mutations of MAMLD1 maybe closely related to hypospadias
in Chinese. c.5A G ip.D2G ) is the newly discovered point mutation in
this work. IVS4-364C/A is associated with underdeveloped testicles
and/or micropenis in hypospadias patients.P1-6-5
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Background: Mastermind-like domain containing 1 (MAMLD1 ) on
the human X chromosome is a causative gene for 46,XY disorders of
sex development. Recently, progressive deterioration of testicular
function was documented in three boys with loss-of-function
MAMLD1 mutations. However, the function of MAMLD1 in adult
males has not been investigated.
Objective: To clarify the role of MAMLD1 in the reproductive function
of adult male mice.
Materials and Methods: We analyzed phenotypic characteristics of
adult male mice lacking Mamld1 (KO). Testes were obtained from 8
week-old wild-type (WT) and KO mice, and subjected to histological
and histochemical analyses. Sperm were analyzed using computer-
assisted semen analysis system and microscope. Serum steroid me-
tabolites were measured by liquid chromatography-tandem mass
spectrometry. WT and KO male mice were mated with WT female
mice and the number of pups was counted on the day of delivery.
Results: At 8 weeks of age, Mamld1 KO male mice exhibited no dis-
cernible abnormalities, except for reduced testicular size. Testes of
KO mice showed reduced diameter of seminiferous tubules and
decreased number of mitotic cells stained by anti-proliferating cell
nuclear antigen antibody. Daily sperm production was impaired in
KO mice, although epididymal sperm count was comparable
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of KO mice showed normal morphology, motility, and in-vitro-
fertilizing ability. Furthermore, blood testosterone levels and the
number of pups were comparable between WT and KO male mice.
Conclusions: These results indicate that MAMLD1 is involved in post-
natal testicular development and sperm production, however is dis-
pensable to maintain male fertility in mice.
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Background: Inactivating mutations in NR0B1 , a gene encoding
DAX1, cause X-linked adrenal hypoplasia congenita. While most
NR0B1 mutations lead to adrenal crisis during infancy of early
childhood, p.Gln37*, p.Trp39*, and certain other mutations result in
late-onset or latent adrenal insufficiency. A small fraction of boys
with NR0B1 mutations develop precocious puberty in addition to
adrenal insufficiency. Objective: To report a boy with an NR0B1
mutation who exhibited central precocious puberty without adrenal
insufficiency.
Case report: At 4 years of age, the patient showed signs of puberty:
pubic hair of Tanner stage 3, external genitalia of Tanner stage 4,
and testes of 6 mL in size. He was tall (117 cm, +3.2 SD) and had
advanced bone age (8.5 years). Laboratory examination detected
elevated serum levels of testosterone and gonadotropins and hyper-
responses of gonadotropins to GnRH stimulation. Blood electrolyte
and adrenal hormone levels were within normal ranges. Brain
magnetic resonance imaging detected no abnormalities. The patient
was diagnosed with idiopathic central precocious puberty. Treatment
with a GnRH analog partially ameliorated the hormonal abnormal-
ities, but did not improve the physical symptoms. On his latest visit
at 7 years and 6 months of age, the patient showed no clinical signs
of adrenal insufficiency. Blood levels of ACTH and cortisol were
normal.
Molecular analysis: The patient was subjected to mutation screening
of 32 genes known to control the hypothalamic-pituitary-gonadal
axis. The analysis identified a maternally inherited hemizygous 1-bp
deletion in exon 1 (p.Glu3fsAla*16) of NR0B1 . The mutation was pre-
dicted to generate an N-terminally truncated hypomorphic protein,
similar to that produced by p.Gln37*and p.Trp39*. No pathogenic
mutations were found in other tested genes.
Conclusions: We identified an NR0B1 frameshift mutation in a boy
clinically diagnosed with idiopathic central precocious puberty. The
results expand the clinical manifestations of NR0B1 mutations to in-
clude male central precocious puberty without adrenal insufficiency.
NR0B1 mutations likely underlie testosterone overproduction through
both GnRH-dependent and -independent mechanisms.
Consent for publication: The authors declare that written informed
consent for study enrollment including publication was obtained
from the parents of the patient.
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-6-7Background: Micropenis is a heterogeneous condition defined as sig-
nificantly small penis (stretched penile length [SPL] below − 2.5 SD
of the mean in age-matched control boys) which is free from associ-
ated external genital ambiguity such as hypospadias. Intramuscular
testosterone enanthate (TE) has widely been utilized in boys with
micropenis, to increase the penile length.
Objective: The purpose of this study was to examine the effect of TE
treatment on SPL in Japanese patients with micropenis.
Methods: We retrospectively examined 48 Japanese patients with
micropenis aged 3–65 months (median 10 months) who were seen
at our University Hospital between the years 2012–2015. The SD
score was calculated using the reference values for SPL in Japanese
boys (Ishii, 2014). All cases were treated with TE (25 mg injection) for
1–5 times (median 2 times; mean 2.13 times).
Results: The first treatment increased the SPL by 0.05–2.00 cm
(median 0.50 cm) in the 48 patients, with the Δ SDS of 0.05–11.77
(median 1.49). After entire course of treatments the SPLs increased
from 1.00–3.30 cm (median 2.5 cm) to 3.00–4.00 cm (median 3.5 cm).
A single patient with an extremely small penis who had defective
testosterone production because of severely hypoplastic testes
showed a marked response to TE (SPL, from 1.00 cm to 3.50 cm; SPL-
SDS; from − 13.19 to − 0.27). After excluding this particular patient,
the 47 patients were divided into two groups on the basis of the SPL
responses to the first TE treatment; (1) good responders whose SPLs
were increased by 0.5 cm (n = 29), and (2) poor responders whose
SPLs increased by < 0.5 cm (n = 18). Subsequent TE treatment was
performed more frequently in poor responders than in good re-
sponders (1–5 times, median 2 times, mean 2.7 vs. 1–4 times, median
2 times, mean 1.8 times). After such treatment, the SPLs became 3.54
cm ( − 0.78 SDS) in good responders and 3.45 cm ( − 0.95 SDS) in
poor responders (P = 0.47).
Discussion: The effect of the first injection on SPL is compatible with
previous reports. In all cases, SPLs after treatments reached above 3
cm that is a satisfying length for standing urination. No apparent ad-
verse effects were observed.
Conclusion: TE therapy is favorable and well-tolerated treatment for
micropenis.
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A novel mutation of KISS1R causing a normosmic isolated
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Background: Kisspeptin receptor, which is also called as GPR54 and
encoded by KISS1R, is a G-protein-coupled receptor expressed in
GnRH neurons. Its ligand kisspeptin is known as strong regulator of
GnRH secretion. Loss of function mutations in KISS1R have been re-
ported in very few patients with normosmic isolated hypogonadotro-
pic hypogonadism (nIHH). Objective: To describe the phenotype of
the nIHH female patient with a novel homozygous KISS1R mutation
and to characterize functionally this mutation. The patient was a 28
year-old Senegalese woman with primary amenorrhea. She was the
second child born to consanguineous parents. Her height was 182
cm, her weight 55 kg. Breast development was scored Tanner stage
2, pubic and axillary hair growth could not be evaluated because of
depilation. She had no evidence with hyposmia. Hormone assays re-
vealed low levels of estradiol and inappropriate normal levels of go-
nadotropins. Brain MRI showed normal pituitary and olfactory bulbs.
Pelvic ultrasonography showed a small uterus and right small ovary
with follicles. The left ovary was not visualized. Her karyotype was
46,XX.
Method: Exon and exon-intron boundaries of nIHH candidate genes
(KISS1 , KISS1R , TAC3 TACR3 , GNRH1 , GNRHR ) were sequenced.
Functional analysis of the mutated receptor was performed by intra-
cellular inositol phosphate measurement, western blot and immuno-
fluorescence staining in heterologous cells.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 75 of 144Results: A novel homozygous mutation c.953T>C was identified in
the proband, leading to the amino acid substitution of leucine 318
by proline (p.L318P). Functional analysis showed impaired inositol
phosphate generation under kisspeptin stimulation. The mutated re-
ceptor was not detected at the cell surface in transfected HEK 293
cells. Western blot analysis showed the absence of mature glycosyl-
ated receptor but the presence of an immature form.
Conclusion: The nIHH observed in this patient is due to a novel loss-
of-function mutation in KISS1R . The L318P substitution impedes the
intracellular trafficking of KiSSR. This patient is a novel candidate to a
treatment by a chemical chaperone to rescue expression of the mu-
tated receptor at the cell surface.
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Metformin attenuated lipid metabolism and glycometabolism,
insulin resistance and aromatase in rats with sexual precosity
Shanshan Zhang
General Hospital, Tianjin Medical UniversityDepartment of Pediatrics
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-6-9
Objective: To investigate the effects of metformin on the glycometa-
bolism, lipid metabolism, and insulin resistance, as well as estrogen
level and aromatase expression in the adipose tissues.
Methods: Rats were fed on a high fat diet to induce insulin resist-
ance and sexual precosity. The animals were randomly divided into
the following groups, including normal control (n=8), high fat group
(n=8), low dose of metformin group (n=8), and high dose of metfor-
min group (n=8). Fasting insulin (FINS) in serum was determined
using commercial radioimmunoassay kit. The serum estradiol (E2),
total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL)
and high density lipoprotein (HDL) were determined using the
Glamour 1600 automatic biochemistry analyzer (Metrolab, Argentina).
Real-Time PCR was carried out to determine the expression of
Cyp19a1 mRNA in the kidney and ovary tissues. Western blotting
analysis was performed to determine the aromatase expression.
Results: At week 6, the levels of FINS, FPG, HOMA-IR, E2, TC, TG, and
LDL were remarkably elevated in the high fat group compared with
the normal control, while the level of HDL in the model group was
obviously lower than that of the normal control. The expression of
aromatase in the high fat group was about 1.5-fold increase com-
pared with that of the control group (P<0.05). Compared with the
high fat group, metformin could remarkably down-regulated the ex-
pression of aromatase, especially the animals subjected to high dose
of aromatase. Compared with normal control, the expression of
Cyp19a1 was remarkably elevated in the high fat group, which was
nearly 2.0-fold higher than the normal control. However, such
phenomenon was completely reversed after metformin group, espe-
cially the high dose group.
Conclusions: High fat diet could induce sex precosity and insulin re-
sistance in female rats. Metformin could decrease the insulin resist-
ance, and the E2, and aromatase protein and mRNA expression in a
dose dependent manner.
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-6-10Background: McCune–Albright syndrome (MAS) is a rare disease and
defined by the triad of fibrous dysplasia (FD), cafe’-au-lait spots, and
peripheral precocious puberty (PP). Because of the rarity of this dis-
ease, only a few individuals with MAS have been reported in Korea.
We describe the various clinical, endocrine manifestations, and gen-
etic analysis of fourteen patients with MAS in Korea.
Methods: Patient's clinical data including peripheral PP, FD, and
other endocrine problems were reviewed retrospectively. In addition,
treatment experiences of letrozole on five patients with peripheral
PP were described. Mutant enrichment with 3’-modified oligonucleo-
tides - polymerase chain reaction (MEMO-PCR) was performed on
eight patients to detect mutation in GNAS using blood. MEMO-PCR is
a simple and practical method that enables nondestructive selection
and enrichment of minor mutant allele in blood.
Results: The median age at diagnosis was 5 years 2 months (range
from 18 months to 16 years). Eleven patients were female and three
male. Thirteen patients showed FD. All female patients showed per-
ipheral PP at onset, and three patients subsequently developed cen-
tral PP. There was a significant decrease in estradiol level after two
years of letrozole treatment. However, bone age was advanced in four
patients. Two patients had clinical hyperthyroidism and two patients
had growth hormone excess with pituitary microadenoma. c.602G>A
(p.Arg201His) in GNAS was detected in two patients in blood (by
MEMO-PCR) and c.601C>T (p.Arg201Cys) in GNAS was detected in one
patient in pituitary adenoma tissue (by Sanger sequencing).
Conclusions: This study described various clinical manifestations of
fourteen patients with MAS in single center in Korea. This study first ap-
plied MEMO-PCR on MAS patients to detect GNAS mutation. Because a
broad spectrum of endocrine manifestations could be found in MAS,
multiple endocrinopathies should be monitored in MAS patients. Better
treatment options for peripheral PP with MAS are needed.P1-6-11
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Background: Mutations in the ATRX gene cause X-linked alpha-
thalassemia/mental retardation (ATR-X) syndrome. Typically ATR-X
syndrome is characterized by severe mental retardation (>95%),
alpha thalassemia (90%), facial abnormalities during infant (>90%),
genital abnormalities (80%), microcephaly (75%) and short stature
(65%). These genital abnormalities extend from hypospadias with
microphallus to ambiguous female external genitalia. ATRX mutations
cluster mainly in the ATRX-DNMT3-DNMT3L (ADD) domain ( `50%)
and helicase domain ( `20%). The patient of ATRX mutation who has
micropenis without other features such as mental retardation and fa-
cial abnormality was unreported previously.
Cases: Two of three brothers having micropenis visited our hospital.
The characteristic data of three brothers were described in Table. We
sequenced 26 genes implicated in 46XY disorders of sex develop-
ment using MiSeq instrument. We found an ATRX sequence variation
(c.3063G>C, p.Glu1021Asp), which is located outside ADD and heli-
case domains in all three brothers, confirmed by PCR-direct sequen-
cing. This variation was not registered on the databases of SNPs.
Glu1021 was conserved in rhesus, mouse, dog, elephant, chicken and
Xenopus tropicalis. The sequence-based mutation prediction for
c.3063G>C was damaging by Polyphen-2, and tolerated by SIFT. The
brilliant cresyl blue stain for red blood cells is underway, being the
most sensitive for detection of alpha thalassemia.
Discussion: A c.3063G>C (p.Glu1021Asp) must be a novel mutation,
because of no registration of databases of SNPs, conservation of
Glu1021 evolutionarily, and in silico analyses. Two of three brothers
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 76 of 144had micropenis while another didn’t. The phenotypic variation may
be caused by other genetic and/or environmental factors. Intri-
guingly two brothers who had micropenis didn’t have other feature
of ATR-X syndrome. ATRX gene analysis for patients with micropenis
is warranted to find similar cases.
Conclusion: We identified a novel mutation of ATRX gene, c.3063G>C
(p.Glu1021Asp), in two brothers who had only micropenis.Table 1 (abstract P1-6-11) Characteristic data of 3 brothers having
c.3063G>C, p.Glu1021AspP1-6-12
The change in body mass index and insulin resistance after
one-year treatment of gonadotropin-releasing hormone agonists
in girls with central precocious puberty
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Aims: Gonadotropin-releasing hormone agonist (GnRHa) has been
used as a therapeutic agent of central precocious puberty. There has
been a concern of increased obesity after the GnRHa treatment. The
purpose of this study is to compare the body mass index (BMI) and
insulin resistance during the first year of GnRHa treatment in girls
with CPP.
Methods: A total of 83 girls aged between 7.0-8.9 years with breast
development and a peak LH of ≥ 5 IU/L after GnRH stimulation test
was included as the patient group. The control group was 48 pre-
pubertal girls. BMI and Indices related to insulin resistance, such as
homeostasis model assessment of insulin resistance (HOMA-IR) and
quantitative insulin sensitivity check index (QUICKI), were used to
compared between two groups before the treatment and among the
patient group before and after 1 year of GnRHa treatment.
Results: There was no statistical difference in BMI z-score between the
control group and the patient group before the treatment. Fasting insu-
lin and HOMA-IR were higher in the patient group, whereas FGIR and
QUICKI were higher in the control group. (all P<0.001). In normal
weight subjects in the patient group, BMI z-score was significantly in-
creased during a year of GnRHa treatment (-0.1 ± 0.7 vs. 0.1 ± 0.8;
P<0.001), whereas HOMA-IR and QUICKI showed no difference. In over-
weight subjects of the patient group, BMI z-score and HOMA-IR were
not significantly different, whereas QUICKI was significantly decreased
during GnRHa treatment (0.35 ± 0.03 vs. 0.33 ± 0.02; P=0.044).
Conclusion: The girls with precocious puberty showed increased in-
sulin resistance compared to the control group. During the GnRHa
treatment, the normal weight group showed increased BMI z-scorewithout increase of insulin resistance, whereas the overweight group
seemed to show increased insulin resistance without significant change
in BMI z-score. Long-term follow up for the change of BMI and insulin
resistance in patients with precocious puberty was needed.
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Background: Although variations in key genes controlling gonadal
development have been identified, the majority of 46,XY disorders of
sex development (46,XY DSD) are unexplained after karyotyping and/
or sequencing of known causal genes. We assessed a patient with
unexplained 46,XY DSD using array comparative genomic
hybridization (aCGH), and identified a 2.2Mb deletion in 9q33.3 in-
cluding the NR5A1 gene, encoding SF-1/Ad4BP.
A report of case: The patient of 46, XY female is now 1 year and 5
months old. Left renal agenesis, bilateral cleft lip and palate were
pointed out by prenatal ultrasound. She was delivered normally at
39 weeks of gestation with a birth weight of 2962g with normal fe-
male genitalia, minor dysmorphisms of ptosis, curled hair and rib
hump. When an abdominal MRI scan was performed at 8 months of
age, bilateral inguinal masses were identified, but female internal
genitalia was not. Karyotype was 46,XY. Further endocrinological
evaluation showed that serum testosterone was 163 ng/dL(normal
range 12 `21 ng/dL) and AMH 82.6ng/mL (normal range 14 `466ng/
mL), respectively. Serum LH and'sH showed normal response to
GnRH stimulation. After hCG stimulation serum testosterone in-
creased from 347.2ng/dL to 932.1ng/ dL and T/DHT ratio was normal.
As she showed marked increase of testosterone after hCG stimula-
tion, she was suspected to have androgen resistance. Molecular ana-
lysis of the AR gene did not show any mutation, however aCGH
identified a heterozygous 2.2Mb deletion in 9q33.3. Her developmen-
tal milestones are almost normal so far.
Discussion: Testosterone levels elevated in our patient similar to an-
drogen resistance, however there is no genetic defect of the AR
gene. Instead a 2.2 Mb microdeletion in 9q33.3 including the NR5A1
gene was identified. Facial dysmorphism, cleft palate, and renal
agenesis may be related to other genes in the 2.2 Mb deleted region.
Similar to our case, it has been reported that some patients with
NR5A1 mutations had ambiguous genitalia despite high serum tes-
tosterone levels. The exact reason for why androgen resistance oc-
curred is not clear. Further investigation is necessary. In conclusion,
our case further expands on the range of mutations associated with
NR5A1 and aCGH studies in patients presenting with unusual or syn-
dromic DSD is useful.
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The enzyme 17 β -hydroxysteroid dehydrogenase type 3 (17 β
-HSD3) belonging to the short-chain dehydrogenase reductase (SDR)
protein superfamily, catalyzes the conversion of androstenedione
(AD) to testosterone (T) in the testes. And its deficiency is a rare dis-
order of sex development in 46,XY individuals. Mutations in the
HSD17B3 gene confer a spectrum of 46,XY disorders of sexual organ
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 77 of 144development ranging from completely undervirilized external female
genitalia, predominantly female, ambiguous, to predominantly male
with micropenis and hypospadias. We report two chinese preschool
girls with the 46,XY karyotype and 17 β -HSD3 deficiency, showing
different degrees of genital ambiguity, increased androstenedione
and decreased testosterone levels, and testosterone to androstene-
dione ratio < 0.8 after human corionic gonadotropin (hCG) stimula-
tion. Both patients had been raised as females, and female gender
identity was maintained in case 1, while case 2 chose the male gen-
der. Molecular analysis revealed a previously unreported compound
heterozygosis for c.242C>T Ac.172G>T Cof the HSD17B3 gene in case
1. In addition, compound heterozygosis for c.645A>C Ac.239G>A of
the HSD17B3 gene which had reported, were identified in case 2.
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Background: Recently, we first clarified that spermatocytes expressed
mRNAs and proteins of anti-Müllerian hormone (AMH) and AMH type
II receptor (AMHR2) in rats aged 21 days (21d) by immunohistochem-
ical staining and in situ hybridization. However, the physiological role
of AMH on mature testis is not entirely clear, although AMH is abun-
dant in seminiferous tubules. In this study, therefore, we planned to
clarify the expression pattern of AMH and AMHR2 in germ cells of
mature rat testis during spermatogenic cycle.
Subjects: SD rat testes and isolated germ cells of 49d testes.
Methods: Quantitative RT-PCR, in situ hybridization (ISH) and immu-
nohistochemical staining (IHCS) of AMH and AMHR2 in 49d testes.
Results: In quantitative RT-PCR, germ cells isolated from 49d testes
expressed Amh and Amhr2 .In ISH, signals of Amh and Amhr2 in
spermatocytes were detected at all stages of spermatogenic cycle,
especially intense signals were detected at stage VIII. Amh and
Amhr2 signals in round and elongated spermatids were negative at
all stages, those in spermatogonia were unclear, and in Sertoli cells
were faint.In IHCS, expression of AMH in spermatocytes was negative
or weak at stage I-IV, but that was strongly observed at stage VII-XIV.
The strongest expression of AMH was observed at stage VIII. Expres-
sion of AMH in round spermatids was clearly observed at stage I-IV,
but that was decreased at stage VII, and diminished in elongated
spermatids at stage VIII-XIV. Expression of AMHR2 in spermatocytes
was negative or weak at stage I-IV, but that was strongly observed at
stage VII-XIV. Unlike expression of AMH in spermatids, the expression
of AMHR2 was found in round and elongated spermatids of all
stages, especially clearly observed in cell membranes of round sper-
matids at stage VII-VIII.
Discussion: In this study, we first clarified that spermatocytes and
spermatids coexpressed AMH and AMHR2 stage-specifically during
spermatogenic cycle in 49d rat testes. When spermatocytes differen-
tiated to round spermatids, AMH and AMHR2 were transferred from
spermatocytes to round spermatids. The pattern of expressions of
AMH and AMHR2 indicate that AMH mainly produced by spermato-
cytes acts round and elongated spermatids through AMHR2 in para-
crine fashion during all stages. It appears likely that AMH involves onmorphological change in spermatids from round form into elongated
form at stage VIII to IX, and the change in elongated form during
stage IX to XIV and I to VIII.P1-6-17
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Background: CHARGE syndrome is a clinically heterogeneous syn-
drome named by specific features such as coloboma of the eye
Cheart defects Catresia of the choanae Cretardation of growth and/
or development Cgenital and/or urinary abnormalities and ear abnor-
malities. Loss of function mutations in CHD7 are found in most cases.
Microphthalamia syndrome caused by SOX2 mutations sometimes
associated with hypogonadism. Case presentation FA boy was re-
ferred to us at 5 months of age because of micropenis. He was
pointed out a right cupped ear Cright facial palsy and bilateral sen-
sorineural hearing loss in the neonatal period. He had a small penis
with length of 1.1cm and bilateral cryptorchidism. He also had a
square face DThere were no congenital heart defects on cardiac
ultrasonography, but an ophthalmologic examination revealed bilat-
eral optic nerve hypoplasia. He grew well and his karyotype was nor-
mal (46, XY). Dilatation of the right lateral semicircular canal and
vestibule and absence of the right anterior semicircular canal and
the right stapes were revealed by computed tomography. Brain MRI
analysis revealed a normal pituitary. He was diagnosed clinically as
CHARGE syndrome according to the criteria by Blake, but since optic
nerve hypoplasia was not seen frequently in CHARGE syndrome, we
underwent gene analysis for 29 genes that related to hypogonado-
tropic hypogonadism by next generation sequencing. In addition to
a novel missense mutation p.Arg1940Cys in exon 29 of CHD7, we
identified a novel nonsense mutation p.Tyr110X in exon 1 of SOX2.
Discussion: Most of the features of this patient would be caused by
the mutation in CHD7 because he was compatible with CHARGE syn-
drome clinically, except for optic nerve hypoplasia which might be
caused by the mutation in SOX2. As SOX2 is also related to the de-
velopment of inner ear and male genitalia, his genital abnormalities
and hearing loss could be caused by the both mutations in CHD7
and SOX2 . Since SOX2 is reported to interact with CHD7, it is pos-
sible that mutations in both genes modify the phenotype of the
patient.
Consent for publication: The authors declare that written informed
consent was obtained for publication.P1-6-18
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Purpose: The prevalence of obesity is at high rate in girls with central
precocious puberty (CPP). There has been no reports about the ef-
fects after gonadotropin-releasing hormone agonist (GnRHa) treat-
ment in obese patients with CPP. We aimed to compare the clinical
course and the effect of GnRHa treatment in obese girls with normal
weight girls.
Methods: We reviewed the medical records of 192 girls with CPP
who had been treated with GnRHa. The patients were classified as
normal weight (n=110) and obese group (n=82). We compared
chronological age (CA), bone age (BA), the standard deviation score
(SDS) of height, body mass index (BMI), predicted adult height (PAH)
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 78 of 144and laboratory findings at baseline, 1 year and the end of GnRHa
treatment.
Results: Mean BMI at baseline were 16.87 ± 1.30 kg/m2 in normal
weight group and 20.86 ± 1.35 kg/m2 in obese group. At the begin-
ning of GnRHa treatment, the CA, BA and PAH was similar between
the two groups. The difference between BA and CA was significantly
higher in obese group than normal weight group at baseline and
end of treatment. The difference between BA and CA in both groups
significantly decreased compared with baseline during treatment re-
spectively (P =0.000). The height-SDS for BA at 1 year and the end of
treatment significantly showed increase in both groups. The height-
SDS for BA between groups was similar during treatment. The PAH
increased significantly in both groups after treatment compared with
baseline (P =0.000). At the end of therapy, the PAH in obese group
(159.99 ± 3.34 cm) was similar to that of the normal weight group
(159.19 ± 3.22 cm). Factors influencing end PAH in obese group were
initial height, baseline height-SDS for BA, height increment during
1st year, duration of treatment and basal'sH.
Conclusion: The GnRHa treatment in obese girls with CPP improved
height outcome similar to that in the normal weight girls. Obesity
may not affect the treatment efficacy in CPP.P1-6-19
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Background: The nourishing “Yin”-removing “Fire” (NYRF) Chinese
herbal mixture can effectively delay the onset of puberty in children
with precocious (early) puberty. In our current study, female rats
undergoing puberty were used as experimental models to explore
the effects of NYRF herbal mixture on puberty onset and expression
of hypothalamic mTOR gene and protein levels in these rats. We fur-
ther investigated the neurobiological mechanism by which this Chin-
ese medicine delays the puberty onset.
Methods: Forty female 20-day-old (d20) SD rats were randomly di-
vided into Chinese herbal mixture (CHM) and normal saline (NS)
groups (20 rats in each group). Rats in CHM and NS groups were
treated with the NYRF mixture and an equal volume of normal saline,
respectively, from d22. Five rats in each group were sacrificed on
d28 and d31 (before onset of puberty). On d34, the rest 10 rats from
each group were sacrificed to obtain samples. Serum luteinizing hor-
mone (LH), follicle stimulating hormone (FSH) and estradiol iE2 )
levels were analyzed by ELISA. Hypothalamic mTOR mRNA expression
levels were determined by RT-PCR and hypothalamic p-mTOR protein
levels were assayed by western blot.
Results: The vaginal opening time in the CHM group was signifi-
cantly delayed (P < 0.05). On d31, serum LH and E2 levels were sig-
nificantly lower in the CHM group (P < 0.05), in comparison with
those in the NS group, and the expression levels of hypothalamic
mTOR mRNA and p-mTOR protein were significantly lower (P < 0.05).
Conclusion: Nourishing “Yin”- removing “Fire” Chinese herbal mixture
can delay puberty onset in rats, and down-regulate the expression
levels of mTOR mRNA and p-mTOR protein within the hypothalamus.
Therefore, the mechanism by which this Chinese herbal mixture de-
lays puberty onset may be associated with the inhibition of the
hypothalamic mTOR signaling pathway.Keywords: nourishing “Yin”-removing “Fire” Chinese herbal mixture;
mTOR signal; puberty onset.
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Objective: To provide clinical data for the effect of letrozole on the
reproductive function and linear growth in the early and middle
period of puberty boy.
Method: 43 early and middle pubertal boy with seriously damaged
predict adult height, treated with letrozole 1.5 mg/m2/d Po( ≯ 2.5mg/
d) were enrolled as treatment group. 48 cases of healthy puberty boy
(include boy with idiopathic short stature) were enrolled as control. Ac-
cording to the letrozole treatment time, divide into short time group,
mid-long time group, long time group, the control group as the match.
Results: After letrozole treatment, testicular volume and Genital stage
of treatment group with short time and mid-long time group were sig-
nificantly increased compared with the corresponding control group.
The testicular volume and T in control group had a good positive cor-
relation, as well in treatment group (r = 0.803, P < 0.001 and r = 0.835,
P < 0.001).The testosterone levels in each group of treatment group
were significantly higher than accordingly control group, as well as ser-
um'sH, LH, LH/FSH level. While E2 level with long time group of treat-
ment group significantly reduced than the control group. 17 cases of
control group, 13 cases of treatment group had serum AMH, INHB level
tested before and after intervention. The control group of serum AMH
level had decreasing trend in puberty, blood testosterone values ele-
vated gradually, and serum AMH and T show a significantly negative
correlation (r = -0.466, p=0.059). While the treatment group of serum
AMH and T show significant positive correlation (r=0.586.p=0.035), dif-
fer from normal AMH change trend. Serum INHB level in two groups
after intervention all had different level rise, and INHB in control group
increase more than the treatment group, but there was no statistically
significant difference.Children in long time group of treatment group
had more evident bone age inhibition than control group.
Conclusion: The testicular volume change and testosterone levels
changes had high consistency, suggesting it may clinical preliminary
judge serum testosterone levels according to the size of testis. Letro-
zole treatment can obviously promote the secondary sex characters
development in adolescent boys. The AMH change trend with letro-
zole treatment group differ from normal trend, prompt that it may
have inhibitory effect on testis maturity. Letrozole treatment group
with its serum INHB level had a little different with control group, it
can not deny that testis sertoli cells function had unaffected com-
pletely, further study needed. Children with long-term letrozole treat-
ment had bone age delayed.P1-6-21
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Table 1 (abstract P1-6-23). See text for description
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Premature puberty and thelarche are frequent conditions for female
children, but the etiologic reasons have not been obviously demon-
strated yet. Many underlying causes are known and endocrinologic
disruptors are one of them. Among endocrinologic ones, PCBs may
cause this kind of conditions due to their high toxicity and long-term
effects. Intracellular estrogen metabolism comprising the step starts
with the synthesis of pregnenolone from cholesterol. In these
metabolic pathways where many intermediate compounds were
synthesized and destroyed by CYP family of enzymes in this
metabolic pathway, many enzymes including CYP enzyme family
(CYP11 A, CYP17, CYP19, CYP3A4, CYP1A1 / 2 and CYP1B1), catechol
O-methyltransferase (COMT) enzyme and 17-beta-hydroxysteroid de-
hydrogenase 1-2 enzymes, are involved. Aroclor 1254 and 1260 had
a general inhibitory effect on enzymes of intracellular mechanisms
and decreased estrogen mRNA expression levels in varied degrees.
We studied Aroclor 1254 and 1260, the CYP11, CYP17, CYP19, COMT
and 17beta-hidroksteroiddehidrogenaz (17ß-HSD) 1-2 enzyme mRNA
expressions in OVCAR3 and HGF-1 cells series. We detected that Aro-
clor 1254 and Aroclor 1260 are lowering enzyme mRNA expression
levels in various amounts by inhibiting the attendant enzymes in es-
trogen metabolism in OVCAR3 and HGF-1 cell series. Since this inhib-
ition is blocked totally or partially in the presence of fulvestrant, we
determined that Aroclor 1254 and Aroclor 1260 are made their ef-
fects through the estrogen receptors.P1-6-23
Premature ovarian insufficiency in 5 patients with leukemia post
hematopoietic stem cell transplantation
Wenjing Li1, Chunxiu Gong1, Maoquan Qin2, Huyong Zheng2
1Department of Endocrinology, Genetics and Metabolism, Beijing
Children's Hospital, Capital Medical University; 2Beijing Children's
Hospital, Capital Medical University, Hematology Oncology Center
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-6-23
Objective: To assess the relationship between premature ovarian in-
sufficiency iPOI ) and hematopoietic stem cell transplantation (HSCT)
through the investigation of the clinical characteristics of POI post
HSCT in 5 patients with leukemia.
Methods: Follow-up the gonadal functions of the patients post HSCT
after 7 years to diagnose POI, and collected and analyzed the clinical
characteristics through the clinical data.
Result: POI is defined as a primary ovarian defect characterized by
absent menarche (primary amenorrhea) or premature depletion of
ovarian follicles before the age of 40 (secondary amenorrhea) with
hypergonadotropism (follicle-stimulating hormone,'sH > 40IU/l) and
hypoestrogenism. The patients were diagnosed with leukemia aged
from 6.5 to 10.2, and underwent HSCT at the age from 7.4 to 10.9.
POI was diagnosed about 0.2 to 4 years later post HSCT in 5 girls,
clinical data shown in table 1.
The first visit of one patient’s visiting at endocrinal clinic was 4 year
post HSCT. She had breast developed spontaneously, but she didn’ t
have menstruation spontaneously 3 years later. Only one patient
complained of amenorrhea. The other 4 patients diagnosed by in-
terim sexual hormone screening with elevated gonadotropin levels.
The sex and gonadotropin hormone levels were normal in 3 patients
post chemotherapy and before HSCT. 2 patients took pelvic ultrason-
ography post HSCT and before POI onset, with size over 0.3cm of fol-
licle detected. All the POI patients showed that the levels of LH
and'sH were elevated; meanwhile the serum estradiol levels weredecreased. The levels of AMH and inhibin B were decreased also.
There were no detectable follicles in 4 patients by pelvic
ultrasonography.
Conclusion: POI post HSCT was happened at pre-adolescent or early
adolescent stage. POI clinical symptoms were occult that only one
patient complained of primary amenorrhea. Most of the patients
were identified through screening. Pediatric POI is more likely hap-
pened at 0.5 to 1 year post HSCT. To early diagnosis of POI, or pre-
vent POI onset is our new research direction. Recommend regular
inspection and evaluation of gonadal function before and post HSCT.P1-6-24
Determination of serum and urinary levels of polychlorinated
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Premature puberty and thelarche are frequent conditions for female
children, but the ethiologic reasons have not been obviously demon-
strated yet. Many underlying causes are known and endocrinologic
disruptors are one of them. Among endodocrinologic ones, PCBs
may cause this kind of conditions due to their high toxicity and long-
term effects. The aim of this study is to investigate potential relation-
ship between PCBs and premature puberty and thelarche. Serum
and urine PCB levels of female children with premature puberty and
thelarche were compared with same-age-group healthy female chil-
dren. Serum and urine PCB levels were measured with GC-EDC de-
vice and mRNA expressions in cell cultures were evaluated with RT-
PCR. In overall interpretations of serum samples, PCB 138, PCB 151
and PCB 101 were most frequently detected. In control group, mostly
PCB 151 was detected, but in premature puberty and thelarche
group, most commonly PCB 138 was detected. In overall interpreta-
tions of urine samples, PCB 151, PCB 18 and PCB 66 were most fre-
quently detected. In control group, mostly PCB 151 was detected,
but in premature puberty and thelarche group, yet again, most com-
monly PCB 52 was detected.
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Background: 5-alpha reductase 2 deficiency is an autosomal reces-
sive disorder characterized by lack of virilization in male infants due
to failure to convert testosterone to dihydrotestosterone. Use of di-
hydrotestosterone (DHT) cream has been successfully promoting
phallic growth in infants with this condition. We reported the effects
of use of DHT cream in our patients.
Case Studies: Patient 1 was born at 36 weeks by vaginal delivery
with birth weight 2415gram. Antenatal scan showed bilateral prom-
inent labioscrotal folds and suspicious testes inside but genital tuber-
cle not enlarged. Parents were non-consanguineous. There was no
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 80 of 144family history of note. Examination at birth revealed no dysmorphism
nor midline defect. There was penoscrotal hypospadias with chordee.
Phallic length measured 2.0cm and width 0.8cm. Both gonads were
palpable in bifid scrotum. At day 1 of life, his luteinizing hormone
(LH) was 4.4IU/ L, follicle-stimulating hormone (FSH) 1.9IU/L and tes-
tosterone 8.4nmol/L. Karyotype was 46,XY. Ultrasound showed both
testes in scrotum and no Mullerian structure. Mutational analysis of
SRD5A2 gene confirmed compound heterozygous mutations. Spot
urine steroid profiling at 5 months of age suggested 5-alpha reduc-
tase 2 deficiency. At 12 months of age, stretched penile measured
2.3cm and width 0.8cm. Hence, hypospadias surgery was deferred.
DHT cream was started at 0.27mg/kg/day. At 17 months of age,
stretched penile length measured 3.5cm and width1.5cm. Hypospa-
dias surgery became feasible.
Patient 2 was born full term in mainland China. Antenatal course was
uneventful. Parents were non-consanguineous. There was no family
history of note. Karyotype was 46,XY. Blood tests at 3 months of age
showed LH 1.30IU/L,'sH 0.94IU/L, testosterone 8.84nmol/L and di-
hydrotestosterone 13ng/dL (reference range 16-79ng/dL). Ultrasound
was unremarkable. Examination at 11 months of age revealed no
dysmorphism nor midline defect. There was scrotal hypospadias with
chordee. Phallic length measured 1.5cm and width 0.7cm. Both go-
nads were palpable in prepenile bifid scrotum. Hypospadias surgery
was deferred until favourable penile size. Spot urine steroid profiling
at 23 months of age suggested 5-alpha reductase 2 deficiency. Muta-
tional analysis of SRD5A2 gene confirmed compound heterozygous
mutations. At 29 months of age, stretched penile length measured
2.0cm and width 0.8cm. DHT cream was started at 0.17mg/kg/day. At
36 months of age, stretched penile length measured 3.0cm and
width 1.0cm. Hypospadias surgery became feasible.
Conclusion: Use of DHT cream at 0.17-0.27mg/kg/day for a period of
4-7 months was effective in promoting penile growth prior to hypo-
spadias surgery in our patients. No adverse effect had been reported.
Consent for publication: The author declare that written informed
consent was obtained for publication.
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-7-1Background: Congenital adrenal hyperplasia is a potentially lethal
condition and was assumed to be associated with excess mortality
due to adrenal crisis. In Japan, a nationwide newborn screening pro-
gram for congenital adrenal hyperplasia due to 21-hydroxylase defi-
ciency (21- OHD) has been carried out since 1989, and it has
detected one case in approximately every 18,000-22,000 births. Our
committee reported 12 cases of death during 12 years after the
introduction of the newborn screening (1989-2001), suggesting that
mortality is estimated to be one in 25-80 21-OHD patients in
childhood.
Objective: To review mortality and causes of death in 21-OHD pa-
tients since 2001 and to clarify incidence of misidentification of sex
assignment in 21-OHD patients
Design: We performed a questionnaire survey for all councilors of the
Japanese Society for Pediatric Endocrinology. Clinical information of
cases of death or misidentification of sex assignment was collected
from each attending physician in a secondary survey.
Results: Eighty five out of 178 questionnaires were available for the
analysis (response rate: 48%). Only two deaths including one 2-years-
old case with influenza-associated adrenal crisis and another adult
case were reported. The mortality was estimated to be one in 400
21-OHD patients in childhood and improved from that before 2001.
Furthermore, we detected two cases required changing sex status on
the family register in infant. Both cases had salt-wasting type of 21-
OHD and Prader stage V of ambiguous genitalia. After changing sex
status, both cases did not reveal treatment noncompliance or gender
confusion.
Conclusion: Our report suggested that enlightenment and dissemin-
ation of knowledge on 21-OHD throughout the newborn screening
might contribute to improvement of mortality in 21-OHD patients.
Furthermore, call for further attention to the aspect of disorders of
sex development in 21-OHD might be required.
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Background: Growth suppression becomes evident by 1 year of age
in patients with classical 21-hydroxylase deficiency (21OHD), and
may result in reduced adult height.
Objective: To clarify the relationship between body weight gain in
early infancy and height at 1 year of age in the classical 21-
hydroxylase deficient population.
Subjects and Methods: 92 patients from 3 medical institutions in
Japan were enrolled. The inclusion criteria were the diagnosis of clas-
sical 21OHD and the availability of height and body weight records
for at least 6 different time points between birth and 1 year of age.
Height and body weight on days 0, 30, 60, 90, 180, 270, and 360
were calculated by a linear fit between their pre- and post-
measurements. The SD (standard deviation) of these auxological pa-
rameters was calculated, and the sequential changes were examined.
The degree of change in the SD from day 0 was calculated on each
designated date.
Results: Mean height SD decreased significantly from 0.45 on day 0
to -1.34 on day 180 but showed no significant change afterwards.
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on day 60. Significant correlation was observed between Δ body weight
SD (day 0-60) and Δ height SD (day 0-360) (see Figure below).
Conclusion: Growth suppression in patients with classical 21OHD
was discussed in relation to high dose glucocorticoid supplementa-
tion. Our results suggested that poor body weight gain in early in-
fancy may be another factor affecting prognosis in terms of height.Fig. 1 (abstract P1-7-2). See text for descriptionP1-7-3
Steroid Hormone Profiles of 6- to 14-Year-Old Normal Male
Children by LC-MS Method
Bingyan Cao, Chunxiu Gong, Di Wu, Xuejue Liang, Wenjing Li, Min Liu,
Chang Su, Miao Qin, Xi Meng
Division of Endocrinology and Metabolism, Beijing Children’s Hospital,
Capital Medical University
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-7-3
Objectives: To establish reference intervals for steroid hormones of
6- to 14-year-old normal male children using the LC-MS method and
study the variation pattern of steroid hormones in terms of age and
sexual maturation.
Subjects and Methods: A total of 820 male children with normal
weight aged 6 to 14 years from Shunyi District, Beijing, participated
in this research study. The puberty status was assessed by trained
pediatricians according to the Tanner method (Tanner genital sta-
ging: stage G1, prepuberty; stage G5, postpuberty). Pregnenolone, 17
α hydroxyprogesterone, corticosterone, dehydroepiandrosterone
(DHEA), and androstenedione were measured by the Liquid
Chromatography-Mass Spectrometry method (LC-MS). Free testoster-
one was measured by the chemiluminescence immunoassay method
(CLIA). Statistics were analyzed with SPSS 17.0. An abnormal distribu-
tion was described by the median and inter-quartile ranges. The ref-
erence range used 2.5 percentile as the lower limit and 97.5
percentile as the upper limit. Interclass variance was analyzed with
the Kruskal-Wallis test.
Results: Median pregnenolone and 17áhydroxyprogesterone concen-
trations of normal male children did not exhibit significant variance
at the adrenarche ages, from approximately 6-8 years old (before pu-
berty initiation) to 9 years old. After the age of 10-11 years, the con-
centrations increased with age. The level of corticosterone did not
change significantly with age. Median levels of DHEA, androstene-
dione, and free testosterone increased with age. Pregnenolone dis-
played a significant increase from stage G1 to G2 and remainedsteady from stage G3 onward. 17 α -hydroxyprogesterone rose evi-
dently with the progression of puberty from stage G1 to G3 and slo-
wed from stage G4. Corticosterone did not change with the
progression of puberty. DHEA and androstenedione exhibited signifi-
cant increases from stage G1 to G2 with no evident intersection and
increased at a lower rate after stage G3. Free testosterone levels rose
sharply during puberty from stage G1 to G3 without evident intersec-
tion and rose slowly after stage G4.
Conclusion: The concentration of the precursor of mineralocorticoids
in the zona glomerulosa (ZG) of male children from the age of 6 to
14 years does not relate to age or the progression of puberty; how-
ever, the concentrations of glucocorticoids and their precursors in
the zona fasciculate are associated with pubertal progression. The
levels of androgens increase with age and sexual maturation.P1-7-4
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Introduction: Primary Adrenal Insufficiency(PAI) in children is rare,
potentially lethal but treatable. The etiology of PAI in children differs
substantially from that in adult population, diagnostic investigation is
quite challenging.
Objective: To investigate the etiology and clinical features of children
with PAI
Method: Retrospective study between Sept 1989 and Mar 2016
Result: 427cases were included (228males, 199females). Median age at
diagnosis was 1.66(10th-90th C0.06~8.73 ) y respectively.An identified
diagnosis (clinical or genetic) was obtained in 93.4% children with PAI
(399/427). In the other twenty cases (6.6%, 28/427), though the etiology
unidentifiable, congenital adrenal hyperplasia(CAH) had been excluded.
Of which 399 cases of known etiology, i1 )351 cases (88.0%) were CAH,
which 21 hydroxylase deficiency(21OHD) were the most common eti-
ology (341cases,97.2%). The other CAH formed were 17 hydroxylase
deficiency(17OHD) (5cases,1.4%), 11 hydroxylase deficiency(11OHD)
(3cases,0.9%), congenital lipoid adrenal hyperplasia(CLAH) (2 cases,
0.6%). i2 )48 cases (12.0%) were non-CAH etiology. The etiology of this
group were Adrenoleuokodystrophy(ALD) (22cases,45.8%), DAX1 muta-
tion(19cases,39.6%), Autoimmune Polyglandular Syndrome(APS)(3-
cases,6.8%), Triple A Syndrome(AS)(2cases,4.2%), Steroidogenic factor
(SF1) mutation (1case,2.1%), Adrenalectomy (1case,2.1%). Comparison
based on sexual phenotype of 58 cases non-CAH 21OHD. Male pheno-
type patients were predominantly in this study (49/58, 84.5%). ALD was
the most common etiology of male phenotype PAI (49%, 22/49). The
other were DAX1 mutation 38.8%(19/ 49) CAPS 6.1%(3/49). The 11OHD,
CLAH, AS and adrenalectomy only accounted for 2.0% (1/49) of cases.
Female phenotype patients were fewer than male(15.5%, 9 cases).
17OHD was the most common in female, accounted for 44.4% (4/9) of
cases. The other etiology: 11OHD, LCAH, SF1, AS were rarer, which
accounted for 22.2% (2/9), 11.1% (1/9), 11.1% (1/9), 11.1% (1/9) of cases
respectively. PAI Clinical features: genital ambiguity was the common
manifestation, accounted for 42.4%. The other features include gastro-
intestinal symptoms35.4% Cgrowth failure26.7%, gonadal related symp-
tom(premature pubarche, sexual infantilism, amenorrhea) 21.1%,
hyperpigmentation9.8%, demyelination of central nervous system3.3%,
prolonged jaundice2.3%, fatigue2.3%, convulsion2.3%. 62.3% patients
presented 2 or more onset of symptoms, 4.2% patients with adrenal cri-
sis onset. Physical examination showed that only 57.6% patients were
exhibiting hyperpigmentation.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 82 of 144Conclusion: 1) PAI in pediatric population is commonly in congenital
forms, with CAH being the most frequent etiology. 2) Children with
PAI have wide range symptoms, lack specificity. 3) Diagnosis of the
underlying cause of PAI in children is recommended. Identification of
a genetic etiology can provide information about prognosis and
treatment.
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Purpose: Steroid 21-hydroxylase deficiency is the most common en-
zymatic defect of congenital adrenal hyperplasia (CAH) caused by in-
activating mutations in the CYP21A2 gene. This study investigated
mutation spectrum of CYP21A2 and clinical outcome in patients with
21-hydroxylase deficiency.
Patients and methods: This study included 157 patients with 21-
hydroxylase deficiency from 143 independent pedigrees. The diagno-
sis was confirmed by by biochemical or molecular analysis of
CYP21A2 using differential PCR amplification of CYP21A2 and
CYP21A1P , followed by entire CYP21A2 gene sequencing and multi-
plex ligation dependent probe amplification analysis.
Results: Of a total of 157 patients, 115 patients (73.2%) were salt-
wasting form, 41 patients (26.1%) were simple-virilizing form, and 1
patient (0.6%) had non-classical form. One hundred and two patients
of salt-losing 21-OHD (102/115, 88.7%) were diagnosed in the neo-
natal period. Five genetic female patients (46,XX) with simple-
virilizing form of 21-OHD were assigned as male sex because of de-
layed diagnosis. Molecular analysis of CYP21A2 was performed in
134 pedigrees (99 with salt-wasting form and 35 with simple-
virilizing form). The c.293- 13A>G was the most common mutation in
patients with salt-wasting form (63/198 alleles, 31.8%), whereas
p.I172N was the most frequent in simple-virilizing form (27/70 alleles,
38.6%). Forty patients (29.9%) had homozygous mutation for large
gene deletion (9/134, 6.7%), c.293- 13A>G (19/134, 14.2%), p.I172N
(4/134, 3.0%), p.R356W (4/134, 3.0%), c.1451_1452delinsC (2/134,
1.5%), p.S371G (1/134, 0.7%), and c.923_924insC (1/134, 0.7%),
whereas 94 patients (71.2%) were compound heterozygotes.
Conclusions: There was a broad spectrum of the clinical and hormo-
nal phenotypes of 21-hydroxylase deficiency depending on the
genotype. Further research is needed to identify modifier genes in
21-hydroxylase deficiency, which could explain the phenotypic vari-
ability of androgen effects.
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Introduction: In 21-hydroxylase deficiency (21OHD), prenatal dexa-
methasone treatment has been performed in order to prevent
virilization of affected girls by suppressing excessive fetal adrenalandrogen, and consequently to avoid reconstructive surgery. Effective-
ness of this therapy has been widely reported whereas animal studies
and epidemiological data have indicated adverse effects including psy-
chosocial developmental delay and possible late metabolic effects.
Objective: To determine physical and developmental outcome of
children treated with dexamethasone in utero.
Subjects and Treatment: The prenatal dexamethasone treatment
was approved by the ethics committee of our institution. 14 mothers
of patients with 21OHD orally administered dexamethasone at a
dose of 20 μ g/kgBW/day (max 1mg/day) from 6-11 weeks of gesta-
tion, after obtaining informed consents. At 11-13 weeks of gestation,
chorionic villi sampling was performed, sex chromosome and genetic
analysis were undertaken; the treatment was discontinued when the
fetus was a boy or an unaffected girl. Only the mothers with affected
female fetuses continue oral dexamethasone until delivery.
Results: Four out of 15 fetuses (one twins) were affected girls. One of
these four was lost by elective abortion. Three affected girls were
born with completely normal female genitalia. One of them had mild
skin defect on forehead. Another one had partial permanent teeth
defect. In 11 others, one was an affected boy, 6 were unaffected girls
and 4 were unaffected boy. They showed no deformities. All 14 cases
have been followed for their physical and mental outcome. One un-
affected girl whose mother developed pregnancy induced hyperten-
sion at mid-gestation was born prematurely at 29 weeks, has shown
normal motor development but had mild developmental delay
with'sIQ 77 by WISC- IV at 6 years old. Other 13 have passed normal
developmental milestone. In 3 cases, we conducted further develop-
mental evaluations; 3-year- old affected girl showed total IQ 94 with
PM (posture-motor) 105 and LS (lingual-social) 87 by new K-type de-
velopmental test; 4-year-old affected boy showed total IQ 91 with LS
94 and CA (cognition-adaptation) 89 by new K-type developmental
test; 6 − year-old unaffected boy showed'sIQ 114 with PRI 124 and
VCI 99 by WISC-IV.
Conclusion: Prenatal dexamethasone treatment with current regimen
perfectly prevents virilizaion in affected female fetuses. However, its
safety and long term developmental and metabolic/physical effects
should be carefully further monitored.1-7-7
The level of LH and'sH would be a monitoring marker for adult
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Background: Infertility is one of the major problems of male adult
patients with 21-hydroxylase deficiency (21-OHD) because substitu-
tion therapy of glucocorticoid for preventing adrenal crisis is often in-
sufficient to reduce androgen synthesis from adrenal cortex. The
clinical details of male adult 21-OHD patients are not clarified, and
there is no consensus of the treatment for preserving fertility in male
adult 21- OHD patients.
Patients and methods: We carried out retrospective analysis of nine
male 21-OHD patients (1: non-classical form, 2: simple virilizing form,
6: salt wasting form) who were followed up continuously from neo-
natal period to adulthood when they reached their final height. All
patients were treated with glucocorticoid according to the guideline.
Fig. 1 (abstract P1-7-8). See text for description
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 83 of 144It is reported that the patients with oligozoospermia had a mean tes-
ticular volume (TV).
Result: Three and six patients were categorized in group A and B, re-
spectively. LH and'sH of group A were significantly lower than those
of group B (p =0.02). LH/FSH and TV were positively correlated (r
=0.45) with the formula of, LH(mIU/ml) = 0.1445 × TV (ml)+ 0.093
and'sH (mIU/ml)= 0.3035 × TV (ml)+ 0.1532. The mean level of LH
and'sH of all patients was 1.9mIU/mL[0-2.6] and 3.0mIU/mL [0-4.6],
respectively. The level of 17-OHP was correlated with TV (r =-0.45),
but it was no difference between group A and B (p =0.3). Urinary
pregnanetriol was not correlated with TV (r =-0.086) nor different be-
tween group A and B (p =0.2). Interestingly, TV and BMI was nega-
tively correlated (r =-0.69, p =0.041).
Discussion: Our data suggested that basal gonadotropin is correlated
with TV and would be a good marker to predict TV. Based on the for-
mula mentioned above, in order to maintain TV 10ml or more, LH
1.5mIU/mL or'sH 3.0mIU/mL would be sufficient. The sensitivity and
specificity of the cut-off level was 83% and 100%, respectively. The
negative correlation between BMI and TV suggested that in some pa-
tients, it is difficult to preserve fertility without overtreatment of
glucocorticoid.
Conclusion: LH>1.5mIU/mL or'sH>3.0mIU/mL would be sufficient to
preserving fertility in 21-OHD adult male patients, but careful moni-
toring for iatrogenic Cushing’s syndrome is essential.
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Background: In many patients with 21-hydroxylase deficiency
(21OHD) adult height is not optimal. Height SD scores (Ht-SDS) of
infancy are already compromised, which was speculated to be
due to glucocorticoid overtreatment. Objective FTo show Ht-SDS
during the first 1 year of life in 21OHD patients and their rela-
tionship with the doses of glucocorticoid.
Subjects and Methods: The subjects were 84 children with 21OHD
who were treated with hydrocortisone (HC) and fludrocortisone
at 3 institutions in Japan. Ht SDS at birth, 180 and 360 days were
analyzed. The integrated dose of HC at each interval was calcu-
lated. The study population was divided into “good prognosis
group (GPG; N=12)” and “poor prognosis group (PPG; N=72)”,
where the difference in height SD score (SDS) between at birth
and at 360 days of age was ≥ -0.5 SD and < -0.5 SD,
respectively.
Results: Ht SDS were similarly decreased from birth to 180 days.
Ht SDS from 180 to 360 days in GPG was increased significantly
whereas those in PPG was not. GPG received significantly higher
integrated HC dose between 180 and 360 days (“HC 180-360d”)
(p<0.05). When the threshold of HC (180-360d) was set at 21.5
mg/m2/day, the sensitivity and specificity for GPC or PPG was
65% and 83%, respectively.
Conclusion: We may predict PPG with good specificity by using
HC(180-360d) with cut-off value at 21.5 mg/m2/day.P1-7-9
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Introduction: X-linked adrenal hypoplasia congenita (AHC) is caused
by mutations of the NR0B1 (DAX1) gene. Clinical characteristics in-
clude primary adrenal insufficiency in infancy and hypogonadotropic
hypogonadism in later life. Although pubertal failure is a key feature,
GnRH- independent precocious puberty (GIPP) was established as an
atypical presentation of this disease which may complicate the
diagnosis.
Case report: A 1-month-old boy presented with salt wasting adrenal
crisis. An ACTH stimulation test exhibited poor cortisol response (rose
from 8.4 to 10.9 μ g/dL at 60 min) and moderately elevated 17-
hydroxyprogesterone (17OHP) levels (baseline 480 and stimulated
7160 ng/dL). After initial bolus, hydrocortisone (HC) was replaced at
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 84 of 144the dose of 12.5 mg/m2/day with a provisional diagnosis of 21-
hydroxylase deficiency (21-OHD) and later was gradually decreased
to 5 mg/m2/day due to rapid weight gain and suppressed 17OHP
levels. At the age of 10 months, he developed acne, rapid growth
with penile enlargement (SPL 8.5 cm, testes 3 mL bilaterally). Testos-
terone levels were elevated (3.2 ng/mL) with low DHEAS and 17OHP
levels. LHRH stimulation test demonstrated a GIPP (stimulated LH 7.5
IU/L (NR <15),'sH 3.9 IU/L). Brain and adrenal glands imaging were
unremarkable. After increment of hydrocortisone dose, acne and
genital development were ceased and testosterone was normalized
(0.3 ng/mL). During follow up period, acne, rapid height gain with
advanced bone age and elevated testosterone levels recurred when
the hydrocortisone dose was inadequate. A repeated ACTH stimula-
tion test (after 5 days HC suspension) at 11 years of age showed low
stimulated cortisol and steroidogenic precursors suggesting AHC.
Thus NR0B1 gene was sequenced and c.363delG, p.Gly122Valfs*142
novel mutation was found.
Discussion: Our patient presented with adrenal insufficiency with
GIPP which was controlled with higher dose of hydrocortisone re-
placement. The low steroidogenic precursors with persistently low
17OHP during treatment led us to perform a genetic testing for AHC.
The association between AHC and GIPP had been rarely described.
Although the exact mechanism of premature sexual development in
this condition is still unclear, there are some postulated hypotheses
include high ACTH stimulated testicular steroidogenesis via melano-
cortin receptor type 1(MCR1) and autonomous Leydig cell hyperpla-
sia in testes. Further studies are needed to confirm these hypotheses.
Conclusion: Our study extends the phenotypic and mutational
spectrum of DAX-1 mutation to include peripheral precocious pu-
berty and novel mutation. Primary adrenal insufficiency in male with
low steroidogenic precursors are important diagnostic clues of AHC.
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Aims: To detect the genomic aberration in a child with disorder sex-
ual development using the new technique of array Comparative Gen-
omic Hybridization (aCGH) and fluorescence in situ hybridization.
Methods: Clinical characteristics and venous blood samples of this
child were collected. Related examinations such as endocrine func-
tions are conducted. Genome DNA was extracted and underwent
fluorescence in situ hybridization and aCGH analysis.
Results: This child was 15 years old, with phenotype of male. His
main complain was short stature and external genital dysplasia. He
got penis growth and growth acceleration at 13 years old but the
growth significantly slowed down at 15 years old. His voice change
and pubic hair appeared at 14 years old. Physical examination
showed poor scrotum development, pubic hair sparse and male dis-
tribution of PH3. Sex hormones showed'sH 44.05mIU/mL CLH
24.51mIU/mL CT 318.28ng/dl, T has no response after HCG stimula-
tion. Testicular ultrasound showed the volume of testis was small,
normal morphology and homogeneous internal echo. Karyotype ana-
lysis showed 46, XX and SRY positive. aCGH analysis showed CNV
was (1) ChrXp22.33 missing, (2) ChrYp11.31 - p11.2; ChrYp11.2 repeti-
tion. Copy number of ChrYp11.2 increased with the long arm of Y
chromosome missing.
Conclusion: This 46XX sex reversal child had copy number missing at
Xp22.33 where contains ARSE gene. ARSE gene missing resulted in
cartilage dysplasia and short stature. The copy number of SRY-
containing ChrYp11.2 increase and the long arm of Y chromosome
missing determined the social gender for this child is male. aCGH
analysis confirmed that part of the sperm Y chromosome of this
child’s father translocated to the end of the short arm of X chromo-
some during meiosis (X/SRY). FISH detection illustrated that the SRY
gene translocated at the end of the short arm of X chromosome,confirming that the gender of male was determined by Yp - Xp
translocation. The gene missing in the long arm of Y chromosome
confirmed that this child failed to got Y gene from his father.
Consent for publication: The authors declare that written informed
consent was obtained for publication.P1-7-12
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We recently worked with three patients, who presented with All-
grove Syndrome. Since only a few such cases have been reported
thus far, it’s relevant to describe presentations of this rare autosomal
recessive disorder, characterised by Alacrimia, Achalasia, & insensivity
to ACTH.
The patients included an 8-year old boy (Case 1), an 18 month old
girl (Case 2), and a 3.5 year old boy (Case 3). The primary complaint
in each case was progressive darkening of complexion, while two of
the three presented with hypoglycaemic seizures and easy
fatigability. When queried, all the patients admitted to an absence of
tears since birth. Case 2 had a history of frequent vomiting at onset.
Family history for Case 1 was positive for absent tears & Achalasia in
respect of an elder sibling, for which he was operated. This however
was without symptoms of adrenal insufficiency. Case 2 & 3 were pro-
geny of second-degree consanguinity. Predictably, on clinical exam-
ination, all patients were noted to have hyper-pigmentation &
hypotension, two had hypoglycaemia (Case 1 & 3) & one had hypo-
natremia (Case 2). Lab reports likewise indicated low cortisol and
high ACTH values across cases. All three patients responded
favourably to hydrocortisone therapy, showing improvement in
hyper-pigmentation and growth. Subsequently during follow-up,
Case 1 was incidentally diagnosed at 14 years of age with Achalasia,
though asymptomatic. Case 2 was diagnosed with Achalasia within a
year of presentation, only when incidence of vomiting became more
frequent, while in respect of Case 3, no such symptoms have pre-
sented thus far. Genetic testing was abjured due to cost constraints
in each case.
Key insights from case experiences are: Adrenal insufficiency must be
suspected in children presenting with hyoglycemic seizures, espe-
cially when accompanied with hyperpigmentation. History of absent
tears should be ascertained in all cases of adrenal insufficiency. Save
absence of tears which usually presents since birth, progression of
other symptoms – Achalasia, Adrenal insufficiency maybe in any
order in cases of Allgrove Syndrome.
Consent for publication: The authors declare that written informed
consent was obtained for publication.P1-7-14
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Introduction: Most of CAH cases in Indonesia is salt losing type,
resulting in a low level of cortisol and aldosterone. Cortisol is
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 85 of 144replaced by synthetic steroid treatment called hydrocortisone. How-
ever, hydrocortisone is not available in Indonesia.
Objective: To explain how hospital, pediatricians, and related parties
resolve the unavailability of CAH medicine in Indonesia.
Method: This research is using a qualitative approach that is con-
ducted on June 2016 by interviewing the head of Cipto Mangunku-
sumo Hospital (RSCM), pharmacy installation, Medicine distributor
(Indofarma & Kimia farma), KAHAKI (the CAH club Indonesia), self
hydrocortisone provider pediatrician in Malang and Semarang. The
technique of data analysis is content analysis from the interview in
verbatim form.
Result: This study shows that CAH medicine procurement in
Indonesia is purchased independently because of medicine produc-
tion by Indofarma is just approved by National Agency of Drugs and
Foods Controls Indonesia but it will take long time to be distributed,
while medicine procurement that has been done by special access
Scheme (SAS) of Indonesian Ministry of Health is only available on
2014-2015. CAH medicine procurement done in several different
ways. RSCM has been cooperating with medical distributors such as
Indofarma (2007- 2014) and Kimia farma (2014–present). But the
complex system and poor communication have made the medicine
is unavailable for the last three months that has forced the patients
to buy the medicine to KAHAKI themselves or they can get methyl-
prednisolone with suited dose as an alternative. Pediatricians in Ma-
lang and Semarang buy the medicine from Australia and Amsterdam
by asking help to Indonesian citizen who will return to Indonesia as
a courier, or asking to the other pediatricians who have the medi-
cine. On 2006 –2011, KAHAKI cooperate with CLAN (Carrying & Living
as Neighbors) to get the hydrocortisone tablet donation but today
they buy the medicine from Singapore once in three weeks. Self pro-
curement medicine also meets some difficulties such as limited num-
ber of medicine, customs issues, also high cost.
Conclusion: Indonesia has difficulties to access hydrocortisone. CAH
procurement in Indonesia has been done independently but not well-
organized that cause limited access to this medicine. Furthermore, it is
needed to produce the medicine by local pharmacy industry and the
complex bureaucracy must be solved, so that CAH medicine will be
available through Jaminan Kesehatan Nasional systems.
Key words: Congenital adrenal hyperplasia, hydrocortisone, Indonesia
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Adrenocortical tumor is a rare tumor in children. The most common
presentation is androgen excess with or without cortisol excess and
vast majority of them had unilateral tumor. However, contralateral
tumor has been occasionally found. Here we report a 12-year-old girl
who developed contralateral virilizing adrenocortical adenoma 10
years after resection of first tumor. The proposita is now 12 years old
girl. She was first seen at age of 1.5 years with history of acne and
pubic hair that had been notices 9 months before. On physical exam-
ination, she had deep voice, acnes, pubic hair, and enlarged clitoris
measuring 2 cm. Breast tanner was stage 1, no growth spurt and her
bone age was 24 months. Laboratory analysis showed DHEAs >
1,000 mcg/dL, testosterone 786 ng/dL, ACTH 7.2 pg/mL with loss of
diurnal variation of cortisol; 8 am and midnight cortisol were 20.39
and 18.4 mcg/dL, respectively. Chromosome study was normal 46,XX.
MRI showed heterogeneous enhanced right adrenal mass size 7 x 7 x
7.5 cm with internal bleeding. No evidence of liver, lung and bone
metastasis were found. A right total adrenalectomy was performed
and histological examination revealed an adrenocortical adenoma.
Postoperatively, her clinical of androgen excess was improved. She
was follow-up at regular intervals. Ten year later on 2016, she devel-
oped sign of androgen excess again, including deep voice and pubic
hair tanner stage 4. Investigations reveal a markedly increase DHEAs
level of 1,230 mcg/dL and testosterone level of 302 ng/dL. Otherhormonal profiles were normal. A well-defined border left suprarenal
mass size 3.6 x 4.7 x 4.2 cm was demonstrated by CT abdomen. No
evidence of distance metastasis in liver, lung and bone. The patient
underwent left total adrenalectomy and intra-operative finding
showed a round mass diameter of 8 cm with no evidence of capsule
invasion. Histological diagnosis of adrenocortical adenoma was made
according to the modified Weiss criteria score of 2 from 7. Tissue im-
munohistochemistry study was positive for TP53 staining. The result
of TP53 germline testing of patient and parent is pending. No post-
operative complication and her DHEAs level decreased to 46 mcg/dL.
She was discharge home with steroid replacement therapy. Bilateral
virilizing adrenocortical adenoma is a rare condition and metachro-
nous tumor can occur after long duration of first diagnosis. Under-
lying genetic cause especially TP53 mutation should be concerned
and follow up of subsequent tumor is necessary.
Consent for publication: The authors declare that written informed
consent was obtained for publication.P1-7-16
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To analyze the clinical features and CYP11B1 gene mutations of a
family with 11 β -hydroxylase deficiency (11 β -OHD). Physical exam-
ination and laboratory tests were done on a 4 years old girl and gene
mutation screening was conducted in her and her parents. The adre-
nocorticotropic hormone (ACTH), 17-hydroxyprogesterone(17-OHP)
were normal and testosterone, DHEA, estradiol, serum sodium levels
increased while potassium and renin levels decreased. Bilateral ad-
renal enlarged according to CT scan. A novel compound heterozy-
gous mutation R453Q/R374W was found in the patient and the
mother was found to carry R374W allele and the father was found to
carry R453Q allele. R453Q was a missense mutation previously re-
ported to cause the disease. R374W was a novel missense mutation
that was predicted to lead to decreased 11 β -hydroxylase activity.
The indicators of the patient recovered and keep normal under
hydrocortisone.P1-8-1
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Background: 25-hydroxyvitamin D (25(OH)D), which is the major cir-
culating form of vitamin D, is usually measured by immunoassay or
competitive protein binding assay. However, recent studies have
shown discrepancy among assays mainly due to cross reactivity with
vitamin D metabolites. Liquid chromatography tandem mass spec-
trometry (LC-MS/MS) is the gold standard for the measurement of
serum 25(OH)D levels characterized by (1) separating 25(OH)D3 and
25(OH)D2, and (2) separating 25(OH)D3 and other vitamin D3 metab-
olites. In this study, we evaluated serum 25(OH)D3 levels of term in-
fants using LC-MS/MS.
Subjects and methods: 192 term infants born in Tokyo (latitude 35
degrees-north), from June, 2014 to April, 2016 were enrolled, who
were originally assessed for jaundice at the age of one month. We
measured serum concentration of 25(OH)D3 and 25(OH)D2 by LC-
MS/MS. Serum calcium, phosphorus, alkaline phosphatase, intact
PTH, 1, 25-dihydroxy- vitamin D, and total bilirubin were measured
concurrently. We compared serum 25(OH)D3 level between exclu-
sively breast-fed infants and mixed- fed by Mann-Whitney U test. We
also analyzed serum 25(OH)D3 levels in each month for possible sea-
sonal variation by Steel-Dwass test.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 86 of 144Results: 102 infants out of 192 (53.1%: 95%CI, 45.8-60.3%) had serum
25(OH)D3 levels below the lower limit of detection (4 ng/mL). None
of the infants had detectable 25(OH)D2. All infants were asymptom-
atic and did not have hypocalcemia (ie, calcium level 3 levels com-
pared to mixed- fed (p<0.01) (Figure). No statistical difference was
observed depending on month.
Discussion and Conclusions: We measured serum 25(OH)D3 levels of
one-month-old term infants using LC-MS/MS for the first time in
Japan. Our data indicate that about half of healthy infants at one
month of age in Tokyo have serum 25(OH)D3 level of less than 4ng/
mL. We think that significantly lower serum 25(OH)D3 level of exclu-
sively breast-fed is due to lower content of vitamin D3 in breast milk
than formula milk. We could not find any seasonal variation of serum
25(OH)D3 levels in Tokyo.Fig. 1 (abstract P1-8-1). Serum 25(OH)D3 levels between exclusively
breast-fed and mixed-fedP1-8-2
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Introduction: Luminal Ca2+ depletion from the endoplasmic
reticulum (ER) triggers activation of Ca2+ release-activated Ca2+
(CRAC) channels in the plasma membrane to slowly replenish the
level of Ca2+ in ER. Dominant mutations in ORAI1 , encoding a pro-
tein composed of CRAC channels, were recently identified in several
families with combined hypocalcemia and myopathy. Here we de-
scribe a boy and his mother with familial hypoparathyroidism and
equinus foot deformity due to this rare genetic disorder.
Case report: The proband is a 14-year-old boy born to non-
consanguineous Japanese parents. He developed severe hypocalce-
mia (serum Ca 1.37 mmol/L) shortly after birth which was treated
with alfacalcidol. Hypoparathyroidism was diagnosed by serum low
level of intact PTH (16 pg/mL) despite hypocalcemia (Ca 1.77mmol/L)
and hyperphosphatemia (IP 2.94 mmol/L). No mutation was found in
the CASR gene. His motor development had been normal until 2-3
years of age when equinus gait appeared. He was referred to our
hospital at 8 years of age for elevated serum creatine kinase (CK) of
more than 2000 IU/L. Brain and spinal MRI were not remarkable, but
brain CT revealed ectopic calcification in the subcortical whitematter. His gait abnormality has been slowly progressive. At age 13
years, he is still ambulatory with mild mental retardation. His mother
also had a clinical history of hypoparathyroidism, diabetes, muscle
weakness and equinus contractures on both feet. She was diagnosed
with tubular aggregate myopathy at 45 year of age. Whole exome
sequencing of the family members revealed a heterozygous
c.292G>A (G98S) mutation in the ORAI1 gene.
Discussion: Endo et al. reported that the CRAC channel is
constitutively activated by the heterozygous ORAI1 gain-of-function
mutations so that Ca2+ influx from the extracellular space to the
cytoplasm persists irrespective of Ca2+ stores in ER. Hypoparathyr-
oidism was present in all patients with a heterozygous c.292G>A mu-
tation in ORAI1 identified to date. Although further elucidation of
pathogenic mechanisms about disease phenotypes associated with
mutations in ORAI1 is needed, we should take ORAI1 genetic testing
into consideration in patients who displayed hypocalcemia and
muscle weakness accompanied by increased serum CK levels and/or
joint contractures.
Acknowledgement: We thank Dr. Satoru Noguchi (National Center of
Neurology and Psychiatry) for assistance in DNA sequencing.
P1-8-3
Beckwith-Wiedemann syndrome and pseudohypoparathyroidism
type Ib in a patient with multilocus imprinting disturbance
Shinichiro Sano1,2,3, Keiko Matsubara2, Keisuke Nagasaki4, Toru Kikuchi5,
Kazuhiko Nakabayashi6, Kenichiro Hata6, Maki Fukami2, Masayo Kagami2,
Tsutomu Ogata2,3
1Department of Pediatrics, Hamamatsu Medical Center; 2Department of
Molecular Endocrinology, National Research Institute for Child Health
and Development; 3Department of Pediatrics, Hamamatsu University
School of Medicine; 4Department of Homeostatic Regulation and
Development, Niigata University Graduate School of Medical and Dental
Sciences, Division of Pediatrics; 5Department of Pediatrics, Saitama
Medical University; 6Department of Maternal-Fetal Biology, National
Research Institute for Child Health and Development
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-8-3
Recent studies have identified multilocus imprinting disturbance
(MLID) with hypo- or hyper-methylated at differentially methylated
regions (DMRs) in a subset of patients with imprinting disorders (IDs).
However, most patients exhibit clinical features of the original ID
only. Here, we report a 14-year-old Japanese female patient diag-
nosed as having Beckwith-Wiedemann syndrome (macroglossia, um-
bilical hernia, overgrowth, and transient neonatal hypoglycemia) and
pseudohypoparathyroidism type Ib (PTH resistance without Albright’s
hereditary osteodystrophy). Molecular studies revealed marked hypo-
methylation at the Kv -DMR, A/B -DMR, XLas -DMR, AS -DMR and
hypermethylation at the NESP55 -DMR, and variable methylation de-
fects at four additional DMRs, in the absence of copy number alter-
ation and uniparental disomy of the chromosomes harboring such
DMRs. No mutation was found in CDKN1C and GNAS , as well as in
genes known to be associated with MLID such as ZFP57 , NLRP2 ,
NLRP7 , KHDC3L , and NLRP5 . It is likely that the methylation defects
at the Kv -DMR and the GNAS -DMRs (A/B -DMR, XLas-DMR, AS
-DMR, and NESP55 -DMR) were sufficient to cause clinically
recognizable IDs, whereas the remaining methylation defects were
insufficient to result in clinical consequences or took place at DMRs
with no disease-causing imprinted gene(s). The development of MLID
and the two IDs of this patient may be due to a mutation in a hith-
erto unknown gene for MLID, or to a reduced amount of DNA
methyltransferase-1 (DNMT1) available for the methylation mainten-
ance of DMRs because of the consumption of DNMT1 by the
maintenance of X-inactivation. In support of the latter notion,
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 87 of 144co-existence of two IDs has primarily been identified in female
patients, and MLID has predominantly been identified as loss of
methylations.
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Introduction: Hypophosphatasia (HPP) is an inherited metabolic dis-
ease characterized by impaired bone mineralization due to de-
creased tissue nonspecific alkaline phosphatase (TNSALP) activity.
HPP is caused by loss-of-function mutations in the ALPL encoding
TNSALP. Enzyme replacement therapy (ERT) for HPP was approved
recently, and severe patients can be saved. We present manifesta-
tions and genetic backgrounds of 6 HPP cases.
Case 1: A neonate with no family history of bone disease was
pointed out lower limb shortening in utero. He showed a mild dys-
pnea and tonic convulsions soon after birth. His serum ALP was ex-
tremely low (16 IU/l) and radiograph of cranium and long bones
showed hypomineralization. Sequence analysis of ALPL revealed
homozygous mutation of c.1559delT. Initiating ERT has significantly
improved skeletal mineralization.
Case 2: A 2-year-old girl was suspected for osteogenesis imperfecta
due to shortening and flexura of limbs in utero. She had no breath-
ing problems after birth, and skeletal mineralization defect and low
serum ALP (27 IU/l) were recognized. She was a compound heterozy-
gote of c.1559delT and p.E191G. On 5 months ERT was started and
the improvement of bowing of long bones were remarkable.
Case 3: An 8-year-old boy was a brother of case 2. He lost 6 decidu-
ous teeth by 3-4 years of age. ALP was 136 IU/l. He was a compound
heterozygote of c.1559delT and p.E191G as his sister, though he ex-
perienced no deformity or fracture.
Case 4: A 3 year-old girl lost seven deciduous teeth by 3 years of age
with no other symptoms. ALP was 255 IU/l, bone mineral density was
low. She was a compound heterozygote of c.1559delT and p.F310L.
Case 5: A 1-month- old boy was hospitalized for convulsion. ALP was
low (140 IU/l) and his limbs showed a slight ossification defect radio-
graphycally. He was a heterozygote of p.M62I, and his father shared
the same mutation.
Case 6: A 6-year-old girl was a triplet and was diagnosed as HPP by
low serum ALP (150 IU/l) and high urinary phosphoethanolamine
levels during NICU hospitalization. Her metaphysis was slightly ir-
regular radiographycally and bone mineral density was low.
Discussion: The symptoms of HPP are various including those who
carry homozygous c.1559delT mutation, and even in siblings who
have the same mutations. Since severity of HPP is wide-ranging, it is
important to accumulate experience of ERT and to consider indica-
tion of ERT for HPP patients.
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Background: Adolescents with musculoskeletal disability have de-
creased mobility resulting in reduced bone and muscle mass. There
is a paucity of non-invasive therapeutic interventions aimed at in-
creasing muscle mass and muscle function, as well as bone health inthis population. We aimed to evaluate the effect of 20 weeks of
whole-body vibration therapy (WBVT) on muscle function and bone
health of adolescents with musculoskeletal disability.
Methods: 24 adolescents (50% females) aged 16.4 ± 2.3 years with
mild to moderate musculoskeletal disability (Gross Motor Function
Classification System II and III) underwent WBVT 9 minutes per day,
4x per week, for 20 weeks on a Galileo platform. Clinical assessments
were performed at baseline and after 20 weeks, including 6-minute
walk test, whole-body dual-energy X-ray absorptiometry, peripheral
quantitative computed tomography of the non-dominant tibia, as
well as muscle force and power using a ground reaction force plate.
Results: WBVT increased lean mass overall (+991 g; p=0.004). There
were also consistent improvements in bone mass, with bone mineral
content increasing in whole body (+43 g; p=0.019) and spine L1-L4
(+2 g; p=0.001). Similarly, bone mineral density also increased in
spine L1-L4 (+0.023 g/cm2; p=0.030). Participants reduced the time
taken to perform the chair test (-1.2 seconds; p<0.001), improved the
distance covered in the 6-minute walk test (+40 m; p<0.001), and im-
proved balance on standing position (-1.7 cm2 in standing ellipse
area; p=0.004).
Conclusion: 20 weeks of whole-body vibration therapy led to in-
creases in muscle and bone mass, while also improving mobility, hav-
ing therefore a positive effect on the health and well-being of
children with musculoskeletal disability.
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Objective: Bartter syndrome (BS) and Gitelman syndrome (GS) have
similar clinical manifestations. It’s hard to be distinguished by the
symptoms and laboratory, even though the genetic analysis. The
study was based on the analysis of clinical data of 72 patients of BS
and GS, and tries to find some useful parameters to help to differen-
tiate diagnose.
Methods: To summarize the clinical data, and to analyze the correl-
ation between urinary calcium, blood magnesium and clinical symp-
toms. Result: 72 cases patients aged from 2 months to 15.5 years
(median 1.75years), sex ratio of boy: girl is 52:20. All patients had
hypokalemia, metabolic alkalosis, normal blood pressure and the
levels of plasma rennin, angiontension and aldosterone elevated. The
ratio of urine calcium/creatinine over 0.2 was considered as a mark of
hypercalciuria. The age of hypercalciuria group was 2.64 ± 2.95 yrs old,
and that of ratio < 0.2 was 8.26 ± 4.49 yrs (P = 0.00). The SDS of weight
was -2.58 ± 1.11 and -1.59 ± 1.26 respectively (P < 0.005). The age of
patients with hypomagnesemia( serum magnesium < 0.8mmol/l ) was
7.88 ± 4.47 yrs Cand the age of normal serum magnesium was 3.78 ±
4.14 yrs (P = 0.001), the SDS of weight were -2.42 ± 1.60 and -1.42 ±
1.13 (P = 0.005). There was no significant difference between the two
groups with the ratio of urine calcium/creatinine. Correlation analysis
showed that urinary calcium/creatinine ratio positive correlated with
serum magnesium (R =0.355, P= 0.008)
Conclusion: The patients with hypercalciuria were younger than that
of normal urine calcium, and coincidently with poor nourished and
growth. The GS patients with hypomagnesemia usually had mild
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 88 of 144symptoms. The clinical types and genotypes of BS and GS were often
overlapped. The parameters of hypercalciuria and hypomagnesemia
were useful in the differential diagnosis of BS and GS.P1-8-8
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Introduction: Fat has a complex interaction with bone though adipo-
kines and inflammatory mediators. This study was conducted to evalu-
ate the relation between obesity and bone health in adolescents.
Methods: This cross sectional study was conducted at All India Institute
of Medical Sciences, Delhi. Healthy adolescents between 10 and 16 years
of age with BMI above 85th percentile on Indian charts were recruited
as cases (overweight/obese group, n=48), and those with BMI between
10th-75th percentile were recruited as controls (n=29). Bone mineral
density (BMD) and concentration (BMC), and body fat was measured by
whole body dual energy X-ray absorptiometry (DEXA, Discovery, Hologic
Inc, USA). Bone speed of sound (SOS, a measure of structural quality as
well as BMD) of distal radius and mid tibia was measured by quantitative
ultrasonography (Sunlight Omnisense, Beam Med Ltd, Israel). Serum
25OHD, leptin, adiponectin and osteoprotegerin were measured.
Results: Comparison of age, BMI SDS, biochemical parameters, SOS
and DXA of the overweight/obese group and normal group is pre-
sented in Table 1. While bone SOS was significantly higher in the
normal weight group, BMC and BMD were higher in the overweight/
obese group for subtotal body (total minus head), thoracic spine and
limbs. In overweight/obese group, total body fat was negatively
correlated with lumbar spine (r -0.38, p 0.02) and pelvis BMC (r -0.34,
p 0.04); osteoprotegerin was negatively correlated with subtotal BMD
(r -0.35, p 0.03); leptin was positively correlated with whole body
BMD (rho 0.37, p 0.02) and radius SOS(rho 0.3, p 0.03) and adiponec-
tin was negatively correlated with tibia SOS z-score(rho-0.33, p 0.02).
In normal weight group, BMI SDS was positively correlated with total
body (r 0.52, p <0.01) as well as regional BMC and BMD.
Conclusion: Bone ultrasound and DXA showed contrasting results, with
overweight/obese group having lower SOS but higher BMD, suggesting
that the bone may be structurally of poorer quality in the overweight/
obese. Some degree of adiposity may benefit, while excessive fat my
adversely affect bone health. Bone health parameters correlated posi-
tively with leptin and negatively with osteoprotegerin and adiponectin.Table 1 (abstract P1-8-8). Comparison of bone health parameters in
overweight/obese and normal weight adolescentsP1-8-9
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Background: There is high prevalence of Vitamin D deficiency (VDD)
in Hashimoto’s thyroiditis (HT) as reported in literature. However, it is
uncertain whether VDD is a cause or effect of HT. The effect L- thy-
roxine replacement on vitamin D levels in children with HT has not
been studied.
Objective and hypotheses: To study vitamin D level of newly diag-
nosed children with HT and to observe the change in vitamin D level
after L-thyroxine therapy.
Method: A prospective observational study was conducted on 35
consecutive children (less than 12years old) who were newly diag-
nosed with HT, and not yet started on L-thyroxine, over a one year
study period. Children with concomitant chronic kidney/liver disease,
Celiac disease, on anti-tubercular therapy/antiepileptics or glucocorti-
coids and who received vitamin D supplements in last 6 months
were excluded. Serum 25 (OH) D levels was estimated before starting
L-thyroxine and on follow-up. Vitamin D levels were compared with
historical controls (from a study from same centre on healthy chil-
dren of similar age and epidemiological profile).
Results: The mean vitamin D level in cases at diagnosis was signifi-
cantly low as compared to controls (33.34 ± 16.93 nmol/L Vs 65.13 ±
30.57 nmol/L; p value<0.0001). Out of 22 Vitamin D deficient children
with HT, who received vitamin D therapy, 7 (31.8%) remained defi-
cient even at follow-up. Thirteen patients (with sufficient/insufficient
vitamin D levels) who were not supplemented with vitamin D had a
fall in vitamin D levels in follow-up. However, degree of fall in Vita-
min D was not statistically significant.
Conclusion: Children with HT were observed to have low vitamin D
levels at diagnosis and L-thyroxine therapy lead to further comprom-
ise in vitamin D levels.P1-8-11
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Background: Osteogenesis imperfecta (OI) is a heritable skeletal dis-
ease mostly caused by mutations in either COL1A1 or COL1A2 that
encode type I collagen. Treatment with bisphosphonate (BP) for OI
patients has been successfully performed worldwide. Of these BPs,
pamidronate infusion is commonly used, and administration of zole-
dronic acid biannually has been reported recently. But there are
some concerns about using a potent BP with a longer treatment
interval for children or a BP with large infusion volume for infants.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 89 of 144Method: Nine patients with OI (5 type I, 3 type III, 1 type IV; ages
from 0 to 12 years, average 5 years) were treated with monthly alen-
dronate (ALN) infusion with a dose of 18μg/kg (2ml/kg) over 1 hour.
Four of the patients received previous therapy. Oral calcium was sup-
plemented for a week after ALN infusion. Lumbar bone mineral dens-
ity (BMD) was measured by DXA every 6 months.
Results: Six months of ALN treatment increased BMD by 15.5 % from
baseline in average. During that period, 4 fractures were reported.
Febrile episode was seen in two patients after the initial infusion of
ALN. Respiratory distress occurred in a type IIb/III infant after the
third ALN infusion. Symptoms related hypocalcemia such as seizure
were not reported during the treatment.
Discussion: ALN infusion is used for adult osteoporosis patients with
a dose of 900μg. In this study, the initial dose of 18μg (2ml)/kg was
selected with assumption of adult BW was 50 kg. The dose 2 mls per
kg body weight of ALN would be safe and well tolerated, and could
be enough to increase BMD in OI patients. But in severe patients, in-
crease of the dose may be necessary.
Conclusion: Monthly ALN infusion may be safe and efficacious for OI
even in younger age.
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Vitamin D-dependent rickets type I (VDDR1) is a rare autosomal re-
cessive disorder caused by mutations in the 25-hydroxyvitamin D 1-
α-hydroxylase gene (CYP27B1). Mutations in CYP27B1 disrupt or lead
to a loss of the 1- α -hydroxylase activity. 1a-OHase deficiency im-
pedes the activation of vitamin D. We present a case of 20 months-
old boy presented with failure to thrive (9.5kg, <3percentile), 76.5cm,
<3percentile), and inability to walk. Frontal bossing, delay in closure
of anterior fontanelle, rachitic rosary and widening of wrists were
noted on physical examination. Laboratory findings are hypocalcae-
mia (calcium: 5.8 mg/dL), elevated serum levels of alkaline phosphat-
ase (2509 U/L) and intact-parathyroid hormone (238 pg/mL) with low
level of 1,25(OH)2 D3 (11.2 pg/mL) despite normal concentrations of
25(OH)D3 (38.6 ng/mL). Radiograph of the wrist and hand showed
classic sign of rickets with widening, cupping, and fraying of the dis-
tal radius and ulna metaphyses with an associated increase in the
thickness of the growth plate. CYP27B1 was analyzed by sequencing
of the entire coding region, and 2 novel mutations in exon 1 were
found. Both parents are heterozygous carriers of the mutation. A het-
erozygous c.57_69del (p.Glu20Profs*2) mutation led to the substitu-
tion of a glutamic acid by a proline on amino acid position 20 and a
second heterozygous c.171dupG (p.Leu58Alafs*275) duplication mu-
tation led to the substitution of a leucine by a alanine on amino acid
position 58. Both mutations result in a frameshift and the creation of
premature stop codons. After treatment with calcitriol and supple-
mental calcium, his biochemical and clinical improvement and catch
up growth were observed.
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Primary hyperparathyroidism in children is very rare. We report a
pediatric case of an ectopic parathyroid adenoma. The patient was a
13-year-old boy who developed abdominal pain and hematuria inJune 2014. Ultrasonography at another hospital revealed hydrone-
phrosis, and computed tomography (CT) revealed a ureteral calculus.
Blood tests showed elevated levels of serum calcium (12.1mg/dL)
and intact parathyroid hormone (PTH) (102 pg/mL). 99mTc-MIBI sin-
gle photon emission computed tomography and 3-dimensional
contrast-enhanced CT revealed a small tumor in the superior anterior
mediastinum. We diagnosed ectopic primary hyperparathyroidism.
Cinacalcet was administered, after which, serum calcium levels de-
creased, and abdominal pain and hematuria remitted. However, the
patient had persistent nausea, a side effect of cinacalcet. Antiemetic
drugs were needed for treating the nausea until surgery. In March
2015, thoracoscopic resection was successfully performed for an ec-
topic parathyroid tumor (adenoma), which was intraoperatively de-
tected in the thymus by using a gamma-ray detection probe. We
also monitored serum intact PTH levels before and after resection to
ensure adequate tumor resection; the level decreased from 154 pg/
mL to 22 pg/mL. Serum calcium and intact PTH levels have remained
within the normal ranges, with no apparent recurrence. When an ec-
topic parathyroid adenoma associated with hypercalcemia is de-
tected, tumor resection is the first choice for treatment. Cinacalcet
effectively decreased the serum levels of calcium and intact PTH and
prevented the manifestations of hypercalcemia in our case. This drug
is useful as a bridge treatment during preparation for surgery of an
ectopic parathyroid adenoma.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Background: FOSTEO (Forum Osteogenesis Imperfecta) was estab-
lished on November 18th 2013 replacing PERKOI (Perkumpulan
Keluarga (penderita) Osteogenesis Imperfecta) and cooperates with
CLAN, as a community for osteogenesis imperfecta (OI) family in
Indonesia to share each other. Since establishment until now, FOS-
TEO had given large impact to the members and Indonesian people.
This study aims to evaluate the performance of FOSTEO.
Methods: A Study was conducted in May-June 2016 involving 126
members of FOSTEO and OI patients in Indonesia. Data for cross-
sectional study were based on FOSTEO evaluation online
questionnaire, patient/guardian interviews as members of FOSTEO,
doctors, and other parties who involved in management of OI in
Indonesia. FOSTEO members who did not fill questionnaire com-
pletely or were unreachable via WhatsApp group and phone call
would be dropped out.
Results: From 126 OI patients in registry data, 49 patients (38.89%)
filled the quetionnaire, 48 patients (38.09%) were lost contact, 12 pa-
tients (9.52%) did not answer phone calls, 8 patients (6.35%) died
and 9 patients (7.14%) were not members of FOSTEO. Among 49 pa-
tients’ guardians who filled the questionnaire and were interviewed,
found that most of patients were children 2-4 years old (32.65%).
Most of respondents said that FOSTEO was helpful for them (85.71%)
and for Indonesia (79.59%). The advantages mentioned such as they
found a new family, not feel alone anymore, shared information, ar-
ranged treatment schedule, able to do drugs sharing, and available
wards searching. Fifty one percent members of FOSTEO could not at-
tend FOSTEO regular events or programs because of the distance,
and 36.73% respondents said that the events were not held on
schedule. Some provinces/areas such as Central Java, Makassar and
Papua, provincial community do not have formal representatives,
thus routine events and information delivery were not done equally.
This study also found that most respondents agree that treatment
management was easy, medications and wards were available,
distance between home to hospital was not an obstacle, health
insurance was helpful, and doctors were competent. However, 19
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 90 of 144respondents said government had not showed any concern to OI patients,
and 32 respondents stated that primary health care physicians could not
detect OI, although FOSTEO already held wishbone day every year.
Conclusion: FOSTEO gave huge benefits to its members and
Indonesian people. Hopefully, FOSTEO could be better in giving in-
formation about osteogenesis imperfecta to increase awareness of
Indonesian people about this non-communicable disease.
Keyword: FOSTEO evaluation, osteogenesis impefecta, Indonesia,
wishbone day
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Background: Metaphyseal chondrodysplasia Schmid type (MCDS) is
an autosomal dominant inherited disorder caused by mutations in
COL10A1 gene. MCDS is characterized by bow-legs, short stature,
coxa vara, and normal facial appearance. The symptoms and the
radiographic findings are similar to those of rickets. The increasing
incidence of vitamin D-deficient rickets sometimes leads us to over-
look the possibility of MCDS among children with bow-legs.
Case: This 3-year-old boy was born at 38 weeks to non-consanguineous
healthy parents. His birth weight and length were 2808g and 50.0cm, re-
spectively. At 16 months of age, he was referred to the previous institu-
tion because of bow-legs with short stature (-2.0SD). He was breastfed
but spent outdoors naturally. Radiography revealed irregular metaphysis
consistent with rickets. Blood tests showed slightly elevated ALP (1,366
U/mL) and low 25(OH)D levels (19.9 ng/mL), and normal levels of Ca
(10.6 mg/dL), IP (4.8 mg/dL), intact PTH (33 pg/ mL), FGF23 (29 pg/mL)
and 1,25(OH)2D (66 pg/mL). Since vitamin D-deficiency could not be
ruled out, he was treated with oral vitamin D supplement. His ALP level
decreased to 845 U/mL, but his radiographic abnormalities and bow-
legs were not improved. He was referred to our institution for further in-
vestigation. At age 3 years, his height SD level decreased to -2.6SD
(88.2cm). Bow-legs, wide gait, and enlargement of the joints were ob-
served. Laboratory tests showed normal ALP, Ca, IP, PTH levels, and
25(OH)D level of 16 ng/mL. From those data and the treatment course,
we suspected of MCDS.
Genetic analysis: The genetic analysis of COL10A1 gene was performed
with informed consent and the approval of the Ethics Committee. It re-
vealed a novel heterozygous mutation, c.2015T>C(p.F672S). This muta-
tion was not found in his parents, indicating a de novo mutation. It was
not found in dbSNP. The amino acid is well conserved among various
species. In Silico analyses predicted this mutation as disease causing.
Discussion: We found a novel de novo COL10A1 mutation in a boy who
had been treated as rickets with atypical clinical course. The mutated
amino acid was located in the C-terminal non-collagenous (NC1) domain
that is required for collagen trimer assembly. The reported COL10A1 mu-
tations in MCDS are predominantly clustered in the NC1 domain. Consid-
ering together with the in Silico analyses, p.F672S might be the causative
mutation for MCDS in this patient. In case of atypical clinical or thera-
peutic course rickets, COL10A1 gene analysis would be useful to
distinguish MCDS from vitamin D-deficient rickets.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-8-16Aims of study: Osteogenesis imperfecta (OI) is an inherited disorder
of connective tissue characterized by bones fragility. Bisphosphonate
therapy and surgical interventions are two main treatment options.
For surgical intervention intramedullary rods are accepted mode of
treatment. The standard implant cost is more than 2000 US dollars
including the shipment cost also which is out of reach of patients
from developing world. We are using locally manufactured implant
made of medical grade steel in OI. The purpose of this study was to
find out implant safety and quality of life in terms of ambulation and
socialization.
Methodology: This descriptive case series was conducted at Paediat-
ric Surgical department of National Institute of Child Health Karachi,
Pakistan over a period of two years from 2013 to 2015. Material used
was locally manufactured telescopic rods made of internationally
specified medical grade steel. Standard technique as described by
Sofield-Miller was used. All patients were also receiving biphospho-
nates. Patients were kept in hospital overnight and then followed up
in Outpatient at regular intervals. Clinical and radiological evaluation
was done. Ambulatory status were also analyzed. Minimum follow up
was of three months and maximum of twelve months. Descriptive
statistics were used like frequencies and numbers to present data.
Results: Total number of patients operated was twelve. A total of 19
long bones were operated in these patients. All patients had moder-
ate and severe form of OI with history of multiple fractures. There
were 7 males and five females. The age ranged from 4 year to 14
year with mean age of + 8.5 year. This included eight femora and
eleven tibia. Number of femora operated was 08 and tibia in 11 pa-
tients. There was no early complication in all the patients and hos-
pital stay was 24 to 48 hours. Pain was the only complaint in early
period. Other complications found were migration of rod in three pa-
tients, fracture post trauma in one patient and bending of rod in one
patient. All of these complication were already been described inter-
nationally .The cost of the locally manufactures rod is approximately
90 US dollars.
Conclusion: The ambulatory status improved after the telescopic rods
surgeries, especially when it was associated with intravenous adminis-
tration of biphosphonates. Locally manufactured rods are as effective
as international rods. There is a huge cost saving. The use of locally
manufactured rods allowing many affected children to be benefit.
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Background: Bartter syndrome is a disorder characterized by hypo-
kalemic metabolic alkalosis with hypercalciuria and salt wasting. Bart-
ter syndrome and cholelithiasis are respectively very rare diseases in
infants. However, a few studies have reported an association be-
tween these two conditions. We report a case of Bartter syndrome
associated with cholelithiasis in an infant.
Patient case: A 3-month-old girl with a genetic diagnosis of Bartter
syndrome type 3 was receiving high-volume electrolyte supplemen-
tation in addition to indomethacin and spironolactone. An ultra-
sound examination performed to screen for the cause of failure to
thrive unexpectedly revealed asymptomatic gallstones, which were
followed up with no treatment. At the age of 11 months, the patient
was admitted because of vomiting and electrolyte abnormalities. She
had poor growth for her age (length: 62.6 cm; -3.93 SD, weight: 5.2
kg; BMI- SDS -2.46 SD). Serum laboratory values were as follows: WBC
13,120/μL, CRP 0.35 mg/dL, Na 134 mEq/L, K 2.4 mEq/L, urinary Na
60 mEq/L, urinary K 154.3 mEq/L, AST 300 IU/L, ALT 154 IU/L, T-Bil
0.9 mg/dL, pH 7.431, HCO3- 33.8 mmol/L, and BE 8.1 mmol/L. Intra-
venous rehydration and electrolyte supplementation improved the
electrolyte abnormalities, while vomiting persisted. On the 12th
hospital day, she had discolored stool, and an abdominal ultrasound
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Gallstone dissolution therapy with ursodeoxycholic acid was begun and
led to spontaneous evacuation of the gallstones after 11 days of treat-
ment. Calculus analysis showed that she had a calcium phosphate stone,
not a bilirubin stone, which is more common in infants.
Conclusion: The predisposing factors for the formation of gallstones
in neonates and infants include prematurity, necrotizing enterocolitis,
total parenteral nutrition, starvation, dehydration, and treatment with
ceftriaxone or furosemide. Bartter syndrome typically presents with
dehydration and urinary electrolyte loss similar to that produced by
furosemide. Therefore, patients with Bartter syndrome might be at
risk for cholelithiasis. Abdominal ultrasound screening for cholelithia-
sis should be performed in patients with Bartter syndrome who
present with repeated vomiting without an obvious cause.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Aims: To describe the clinical profile of children with Osteogenesis
Imperfecta (OI)
Methods: Retrospective chart review of children with OI who were
treated by the Paediatric Endocrine division of Christian Medical
College, Vellore between 2009-2016.
Treatment protocol: Pamidronate is the only bisphosphonate used.
Children receive 8-9 mg/kg/year during the first year and 4-5 mg/kg/
year during the subsequent years of treatment. Infants are com-
menced on Pamidronate at 4 weeks of age when diagnosed ante-
natally. During infancy, Pamidronate injections are given every 2
months till 6 months and thereafter every 3 months. Older children
are given injections every 3-4 months. After the infusion calcium and
calcitriol are supplemented for 7 days. Treatment outcomes observed
are reduction in fracture frequency and bone pain as well as im-
provement in ambulation. Improvement in DEXA BMD z scores are
compared annually with the each child’s baseline BMD Z scores.
Results: Data of 27 (15 males) children aged 0-16 years were in-
cluded. Of the 10 infants in the group, 3 were neonates who were di-
agnosed antenatally. Almost half the children had OI type-3 (severe),
24% had OI type-4, and 20% had OI type-1. Blue sclera was seen in
78% of children, and 28% had dentinogenesis imperfecta. Baseline
mean LS spine BMD z score was -4.31. The mean follow up duration
was 34.8 (0-103) months. Antenatally diagnosed infants received 8.2
mg/kg in the first year. Older children received a mean of 4.98+2.74
mg/kg of pamidronate, and 2.54 cycles in the first year. The main
reasons for delay in the injection cycles were due to fractures and
osteotomies. Bone pain, ambulation, motor development and frac-
ture frequency improved. Sixteen (57%) children were fracture free in
the 1st year of treatment. Flu-like symptoms was seen only in 2, and
hypocalcemia was seen in 3 of all the pamidronate infusions.
Conclusion: Pamidronate is a safe and effective therapy for children with
OI and improves clinical symptoms and morbidity. Neonates with severe OI
should be started early on Pamidronate. Optimum doses of Pamidronate
could not be achieved in many due to fractures and surgical procedures.
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P1-8-19Myhre syndrome (MS) is a malformation syndrome that mainly af-
fects connective tissues. The clinical hallmarks include mental and
growth deficiency, generalized muscular hypertrophy, joint restric-
tion, mixed hearing loss, and unusual facies including midface
hypoplasia with prognathism, belephalophimosis, and short philtrum.
MS also shows mild, but distinctive, skeletal alterations, such as thick
calvaria, large pedicles, abbreviated long bones, and brachydactyly.
MS was firstly reported in 1981, and SMAD4 was found to be the
disease-causing gene in 2012. To date, more than 50 affected
individuals have been known. It is intriguing that most cases were
diagnosed in the school age, and the youngest affected individual
was a 4-year-old girl. This fact raises a suspicion that MS is a late-
onset disorder that is postnatally progressive.
We report here on an affected Japanese boy, whose clinical features
become fully manifest over a period of mid-childhood. He was born
at 38 weeks of gestation. Birth length and weight were normal. At
age 3.5 years, he was referred to us due to short stature and mild
mental retardation. Height was 88cm (-2.40 SD) and weight 13.4kg
(-0.74 SD). He showed mild brachydactyly and thick skin. Cardiac as-
sessment revealed mild pulmonary hypertension with complete right
bundle branch block (CRBBB). Radiological examination demon-
strated thick calvarium, brachymetacarpia, and fusion of C2-C3 verte-
brae. No specific diagnosis was made. At age 8 years, he showed
progressive joint contracture and skin thickness. Short philtrum, thin
upper lip, prognathism and obesity were evident. Repeated skeletal
survey revealed large pedicles, hypoplastic ilia, and deterioration of
brachydactyly. The latter was ascertained based on the metacarpo-
phalangeal (MCPP) pattern profile analysis (Z-score: -2.0 SD at age 3.5
years and -3.5SD at 8 years). These clinical and radiological findings
led us to a Sanger analysis for SMAD4 , which showed a heterozy-
gous mutation (c.1498A > G). In conclusion, our experience recapitu-
lated what were previously reported in MS patients, and suggested
the postnatal progressive nature of the disorder.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Introduction: Nutritional rickets remains the single most common
cause of rickets in many parts of the world. As Sri Lanka is a tropical
country with adequate sun exposure throughout the year, Vitamin D
deficiency is not considered as a diagnostic possibility.
Objective: Describe the aetiological classification of Rickets in Sri
Lanka.
Methodology: Children who presented to the Endocrinology unit of
Lady Ridgeway Hospital from September 2014 to May 2016 with
radiological evidence of Rickets were included. Patients with chronic
renal insufficiency and chronic liver disease were excluded. Duration
of exposure to sun light and exclusive breast feeding, maternal vita-
min D intake during lactation were obtained apart from socio-
demographic data. Vitamin D level and bone profile was done.
Results: A total number of 61 children were included in our study.
The mean age of presentation among the study group was 23
months while the age ranged from 3 months to 46 months. There
was no statistically significant sex predisposition among the study
group. 90% of children presented with bowing of legs.6.5% pre-
sented with hypocalcaemic seizures and 3.2% with delay in walking.
82% of children were exclusively breast fed for 6 months and were
continued to breast feed up to the presentation and only 31% of
mothers had vitamin D supplementation during lactation. 57.3% of
children had no sun exposure at all. Among the cohort of 61 patients
10 patients( 16.4.4% ) had vitamin D levels below 30nmol/L and 33
patients ( 54% ) had levels between 30-50nmol/L. 2 (3.2%) patients
were diagnosed with vitamin D dependant rickets.
Discussion: This preliminary study supports that continuing breast
feeding beyond 6 months of age predispose children to nutritional
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 92 of 144rickets and the suboptimal maternal vitamin D supplementation dur-
ing lactation may indicate maternal vitamin D deficiency on top of
childhood vitamin D deficiency. Though we have adequate sun ex-
posure still majority of our children did not get adequate sun expos-
ure predisposing them to vitamin D deficiency. As majority of our
patients had insufficient levels of vitamin D it points out the possibil-
ity of co existing calcium deficiency among this cohort.
Conclusion: This preliminary study further stresses the need of large
scale community based studies in identifying the aetiology of rickets
in Sri Lanka, Vitamin D supplementation during infancy, place of
introducing fortification of food with vitamin D, importance of sun
exposure.
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Aims: There are no published clinical guidelines on the training and
education for paediatric and adolescent patients commencing insulin
pump therapy. The study aims were to:
Describe current clinical practice regarding initiation of insulin pump
therapy in children and adolescents with type 1 diabetes in hospitals
in Australia and New Zealand.Identify differences in clinical practice
both within and between these two countries.
Methods: Paediatric Diabetes Nurse Specialists from all New Zealand
diabetes teams (n =16), and tertiary centres in Australia (n =9) were
identified and approached by email and/or phone. For those con-
senting to participate, structured oral interviews were conducted.
The questions covered basic hospital demographics, and various as-
pects of insulin pump initiation, including pump start planning, edu-
cation and follow-up monitoring.
Results: Response rate was 16/16 for New Zealand, and 6/9 for
Australia. Diabetes centres varied in size from 50 – 1154 patients;
and frequency of pump use from 20% - 40%. Clinical practice dif-
fered both within and between each country, with differences seen
relating to: the structure and duration of pump starts varying from 6
to 21 hours; access to funding; polarised views on use of advanced
features, varying from immediate to delayed use; and the use of the
continuous glucose monitoring (13/22). Location of pump starts also
varied, with both in- (2/22) and outpatient (13/22) approaches seen,
as well as a mixture of the two (7/22). The motivations and beliefs re-
lating to these various pump start approaches also varied.
Conclusion: This is the first study to investigate current paediatric
clinical practice in relation to insulin pump initiation. The lack of
consistency seen between centres reflects a lack of consensus/guid-
ance from the medical literature. Lessons may be learnt, and further
rationalisation and improvement in education remains possible by
combining and adopting strengths from different centres.
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Introduction: Excess body fat (adiposity) is an important independ-
ent risk factor for development of insulin resistance in adults andchildren. Some obese children do not develop metabolic comorbidi-
ties of obesity, whereas some children are more metabolically sensi-
tive to adiposity. The mechanism underlying this phenotype is not
explained by adiposity levels, although metabolic sensitivity to adi-
posity may differ between ethnic groups. To interpret this mechan-
ism, we hypothesized that an increase in body mass index (BMI)
from about 1.5 to 3 years old, a period normally characterized by a
decreased or stable BMI, may augment insulin resistance correspond-
ing to BMI at adolescent age.
Method: All 192 children (101 boys and 91 girls) in a birth cohort (F
town) in Tochigi prefecture in Japan were enrolled in the study. All of
the children in the study were followed up in infant health checks at a
health center during the preschool period, and data were stored at a
regional health center. At 12 years of age, fasting blood sampling and
measurement of blood pressure were performed at school. Fasting
blood samples were collected for determination of plasma glucose and
insulin. The participants were divided into groups by gender and based
on an increase or no increase in BMI from age 1.5 to 3 years. In statis-
tical analysis, regression coefficients between log-transformed BMI and
log-transformed HOMA-IR were computed in regression analysis strati-
fied by gender and change of BMI from 1.5 to 3 years.
Result: The augmented degree of log-transformed HOMA-IR per log-
transformed BMI was significantly higher in girls who had a BMI in-
crease from 1.5 to 3 years compared to those who did not have this
increase. A similar tendency was observed in boys, but without a sig-
nificant difference.
Discussion: This suggests that children who show an increase of BMI
from 1.5 to 3 years, a period normally characterized by a decreased
or stable BMI, are more prone to developing insulin resistance at 12
years of age. From a practical standpoint, identification of individuals
with a higher cardiometabolic health risks may allow more aggres-
sive intervention for these persons than for their lower-risk peers.
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Objectives: Genome wide association studies have identified more
than 50 susceptibility genes for type 1 diabetes mellitus. However,
low frequency risk variants could remain unrecognized. The present
study aimed to identify novel type 1 diabetes mellitus susceptibility
genes by newly established methods.
Methods: We performed whole-exome sequencing and genome-
wide copy-number analysis for a Japanese family consisting of two
patients with type 1 diabetes mellitus and three unaffected relatives.
Further mutation screening was carried out for 127 individuals with
sporadic type 1 diabetes mellitus. The functional consequences of
identified substitutions were evaluated by in silico analyses and fluor-
escence- activated cell sorting of blood samples.
Results: Familial molecular analysis revealed co-segregation of the
p.V863L substitution in CD101, the human homolog of an auto-
immune diabetes gene in the non-obese diabetic mouse, with type 1
diabetes mellitus. Mutation screening of CD101 in 127 sporadic cases
Fig. 1 (abstract P2-1-4). See text for description
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p.V863L, p.V678L, and p.T944R substitutions were absent or ex-
tremely rare in the general population and were assessed as “prob-
ably/possibly damaging” by in silico analyses. CD101 expression on
monocytes, granulocytes, and myeloid dendritic cells of mutation-
positive patients was weaker than that of control individuals.
Conclusions: These results raise the possibility that CD101 is a sus-
ceptibility gene for type 1 diabetes mellitus.
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Introduction: Defects of the insulin receptor gene (INSR ) cause clinic-
ally wide spectrums of congenital insulin resistance. Monoallelic defects
develop milder type, insulin-resistant diabetes mellitus with acanthusis
nigricans (IRAN, type A) with autosomal dominant inheritance. On the
other hand, leprechaunism (Donohue syndrome), which is caused by
biallelic defects of INSR with autosomal recessive inheritance, is an ex-
tremely rare and the severest condition with lethal phenotype during
infantile period. We detected two missense mutations in our cases of
primary insulin-receptor (INSR) defects, leprechaunism and IRAN, type
A, and reduced mRNA expression in the former case.
Methods: [Case1] 11 year-old male was referred to our hospital be-
cause of acanthosis nigricans in the axilla and insulin resistance
(HOMA- IR:16.9). [Case2] 8 day-old female born with a birth weight of
1234g at 36 weeks of gestation was referred to us for an elfin-like
face, acanthosis nigricans, and severe insulin resistance (plasma glu-
cose level:>11.0 mmol/L and IRI:7430-46400 pmol/L). Direct sequen-
cing of INSR gene revealed a missense mutation for each case. We
performed in vitro analysis including INSR phosphorylation assay, in-
sulin binding assay and qRT-PCR for mRNA of INSR to confirm the
two mutations are responsible for the phenotype.
Results: The heterozygote mutations c.3436G>A (p.Gly1146Arg) and
c.294C>A (p.Ser98Arg) were identified in Case1 and Case2, respect-
ively. Gly1146Arg is previously reported in a diabetic case without
precise functional analyses, and Ser98Arg is a novel mutation.
Gly1146 is located on tyrosine kinase domain and Gly1146Arg re-
sulted in impairment of INSR phosphorylation, while Ser98 is located
on the ligand- binding domain of INSR and assay for insulin binding
revealed disruption of INSR by Ser98Arg. Three dimensional model
analyses supported these results. In addition to the missense muta-
tion Ser98Arg, mRNA expression of INSR in her lymphocytes was re-
duced at qRT-PCR assay in the leprechaunism case.
Discussion: We concluded two missense mutations are responsible for
primary insulin resistance. In case2, reduced expression level of mRNA,
together with defect of INSR by Ser98Arg, resulted in severest pheno-
type. Further, our present study suggested that reduced expression of
INSR should be considered as a possible cause for insulin resistance.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-1-5Aim: To prevent obesity in middle age, early precautions and inter-
ventions are required during childhood. Therefore, it is important to
find an indicator that can accurately predict the degree of both adi-
posity and metabolic complications in children. In 2011, a new an-
thropometric indicator, body adiposity index (BAI; hip/height1.5 –
18), was proposed as a good marker for adiposity in adults. The aim
of this study was to investigate whether BAI and other hip/heightPratios are useful in obese children.
Method: Ninety obese Japanese children, 55 boys and 35 girls, who
visited our University Clinic, were enrolled. The age was 9.92 ± 2.6
(mean ± SD) years. In Japan, a child was considered to be obese
when the percentage overweight (POW) exceeded 20%. POW = 20%
means that one’s body weight is 120% of standard body weight in
2000. The mean POW and BMI-for-age percentile value were 51.6 ±
18.8 (%) and 97.8 ± 2.5 (percentile), respectively. We set the power
value of the hip/heightP 0, 0.5, 1, 1.5, and 2 and studied the associ-
ation with overweight indices, biochemical data, and fat area mea-
sured by computed tomography. Waist circumference, waist/height
ratio, and waist/hip ratio were also evaluated.
Results: Hip/height was more closely correlated with POW, BMI-
percentile, and percentage body fat than hip/height1.5 (BAI). The cor-
relation coefficient of hip/height with POW (r = 0.855) was the high-
est among the studied hip/heightP indices. The waist/height was
also highly correlated with POW (r = 0.879). The approximate line to
predict POW was 411 × hip/height – 207 and 308 × waist/height –
131, respectively. If one’s hip/height is >0.63 or waist/height is >0.59,
he or she is considered to be severely obesity, POW > 50%. Hip and
hip/height0.5 were more closely correlated with visceral fat area than
hip/height and hip/height1.5. Hip and hip/height0.5 were signifi-
cantly correlated with serum insulin level. Only hip was also signifi-
cantly associated with dyslipidemia. All hip/heightP indices were not
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was significantly correlated with serum lipids, ALT, and insulin.
Conclusion: Hip/height is a better marker for overweight (adiposity)
in obese children than BAI. However, hip/height and BAI are not
useful to predict metabolic complications. Waist/height is also a
marker for overweight, but not for visceral adiposity. Waist circumfer-
ence itself is considered to be the best index for obese children
overall at this time because waist significantly reflects the metabolic
complications.
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Objective: Donohue syndrome or leprechaunism (OMIM: 246200)
and Rabson-Mendenhall syndrome (OMIM: 262190) are two rare
autosomal recessive conditions caused by mutations in the INSR
gene. We reported an infant with Rabson-Mendenhall syndrome and
premature thelarche who has a novel mutation of INSR gene.
Case: A 7-month-old girl visited our hospital due to fasting
hypoglycemia. Not only fasting hypoglycaemia, but also postprandial
hyperglycemia with severe hyperinsulinemia were found. This subject
showed hirsutism, anteverted nostrils, dry and loose skin, and bra-
chydactyly. Typical acanthosis nigricans was observed on the neck,
axillae, and inguinal area. The girl was born at 39 weeks of gesta-
tional age with 2.17 kg of birth weight. The height and weight at visit
were 3rd percentile, respectively and the breast were in Tanner stage
II. Pelvic unltrasound showed multiple cysts in the bilateral ovaries
and estradiol, and DHEA-S were also elevated. The serum glucose, in-
sulin, and C-peptide during fasting were 48 mg/dL, >300 μIU/mL,
and 28.6 ng/mL, respectively. The HbA1c was 6.8%. Direct
sequencing of INSR revealed compound heterozygous mutations of
c.356C>T (p.Ala119Val) in exon 2 and c.2978C>A (p.Ala993Asp) in
exon 16. A novel nonsynonymous variant, p.Ala993Asp, within a
highly conserved regionwas considered as a pathogenic mutation by
in silico tools (SIFT and polyphen-2). Each mutation was inherited
from the parents, respectively. Metformin was administrated and
glucose was controlled within 70 to 250 mg/dL.
Conclusions: This study describes the clinical course of an infant
patient with Rabson-Mendenhall syndrome and the molecular char-
acteristics of compound heterozygous INSR mutations including a
novel missense mutation.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Genetic diagnosis is crucial in neonatal diabetes mellitus (NDM) for
therapy and prognostication. We present unique genetic and clinical
features in 4 patients with NDM.
Patient 1 has Wolcott- Rallison syndrome (WRS) with two novel mis-
sense compound heterozygous mutations in exons 12 and 13 of the
EIF2AK3 gene (c.1975 G>A/c.2809 C>T). Presentation was at 2
months of age, with diabetic ketoacidosis, anemia and liver failure.
At last follow up visit at 3 years of age, she had normal development,
no further episode of hepatic failure, renal failure and anemia. Re-
markably, she does not have any skeletal dysplasia till now.Patient 2 has a homozygous missense mutation in exon 5 of the
ABCC8 gene which is known to cause transient NDM (TNDM) in het-
erozygous but not in homozygous form. The child presented at the
age of 36 days with diabetic ketoacidosis. He was initially started on
insulin but after getting the genetic report, was successfully switched
over to glibenclamide. By 14 months of age, the drug was tapered
and stopped. At 36 months of age, he is still euglycemic. Both par-
ents have normal glucose tolerance so far.
Patient 3, diagnosed at 2.5 years of age, has a homozygous glucoki-
nase (GCK) missense mutation (p.Gly44Ala). She was symptomatic
since 8 months of age, had intrauterine growth retardation, motor
delay, seizures and hemiparesis. She also has some dysmorphic fea-
tures like depressed nasal bridge, bilateral epicanthic fold, short 4th
and 5th metacarpals. These neurological and dysmorphic features
are unusual in GCK PNDM. Her younger male sibling (homozygous
for the same mutation) is a known case of NDM since 22 days of life.
Both the parents have been newly diagnosed with diabetes and are
heterozygous for the mutation. They belong to an endogamous com-
munity, but have a non- consanguineous marriage. Mother has a 2
generation family history of diabetes with onset in young adulthood.
Conclusion: Genetic diagnosis plays an important role in the man-
agement algorithm of neonatal diabetes. WRS has highly variable
phenotype. Some homozygous activating ABCCD8 mutations may be
associated with TNDM. GCK mutation can have varied presentation
within a family. Acknowledgement: We are grateful to Royal Devon
and Exeter NHS Foundation Trust and Prof. Hattersley for carrying
out the genetic studies for all the babies.
Consent for publication: The authors declare that written informed
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Aims: Type 1 diabetes mellitus (T1DM) is an autoimmune disease
characterized by destruction of the beta-cells of the pancreas. Mono-
cytes play important roles in antigen presentation and cytokine pro-
duction for the proper immune response in the development and
progression of T1DM. This study aimed to analyze different mono-
cyte subsets in the peripheral blood of recent-onset T1DM children
in respect to the proportion change and likely relevance to the re-
sidual islet beta cells function.
Methods: To determine if monocytes were abnormally changed in
T1DM, 4-color flow cytometry analysis was performed in a cross- sec-
tional study of 31 T1DM children and 22 healthy controls. In our hos-
pital HbA1c was tested by the method of High Performance Liquid
Chromatography (HPLC), and insulin and C-peptide was measured by
a Roche cobase 601 analyser. All statistical analyses were performed
using SPSS.
Results: Our demonstration that the percentage and absolute num-
ber of intermediate monocytes in peripheral blood were expanded
in patients with T1DM inumber Fpatients 3.73 ± 2.60 × 104, control
2.43 ± 1.14 × 104 Ct =2.07 CP<0.05; percentage: patients 13.47 ±
1.50, control 10.60 ± 1.48 Ct =6.55, P <0.05 ). The increase of the
intermediate monocytes in patients was positively associated with
HbA1c (r=0.45, P<0.05), but negatively associated with serum insulin
(r=-0.62, P<0.05) and C-peptide (r=-0.57, P<0.05). In addition, the fre-
quency of CD45RO+CD3+ memory T cells were found increase in
Fig. 1 (abstract P2-1-9). See text for description
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 95 of 144patients, which exhibits a significant positive correlation with in-
creased intermediate monocytes (r=0.44, P<0.05).
Conclusions: As the intermediate monocytes were shown to have
proinflammatory activity, they are likely to implicate in the impaired
function of b cells, which have deleterious consequences for the de-
velopment of T1DM. Further characterization of the function of inter-
mediate monocytes could pave the road for understanding the
relationship between these pro-inflammatory cells and the destruc-
tion of b cells in T1DM children.
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Background: Dipeptidyl peptidase 4(DPP4) is an enzyme well known with
its action in inactivating GLP-1 and its inhibitor has been already used for
adult type 2 diabetes. Recent reports elucidated increased expression of
DPP4 in visceral adipocytes of obese adults and hepatocytes of adults with
non-alcoholic fatty liver disease. These findings support the hypothesis
that DPP4 plays a role in pro-inflammatory pathways in adipose tissues to
enhance local insulin resistance. The relationship between DPP4 and insu-
lin resistance is well studied among adults but not in children.
Aim: The aim of this study was to elucidate the relationship between
DPP4 and insulin resistance in type 1 diabetes mellitus (T1DM) by
measuring serum DPP4 activity and evaluating metabolic markers re-
lated to insulin resistance.
Subjects: Forty-three Japanese children with T1DM (17 boys and 26
girls, mean age 9.3 yr) and 26 age- and gender-matched control chil-
dren (14 boys and 12 girls, mean age 9.7 yr) were enrolled. Methods:
Blood samples were obtained from each child in the fasting state.
Serum DPP4 activities were measured by fluorometric assay. Blood
glucose, HbA1c, glutamic acid decarboxylase antibodies (GADA), C-
peptides and adiponectin levels were measured in the T1DM chil-
dren. In the control children, serum DPP4 activities, blood glucose
and adiponectin levels were measured.
Results: Serum DPP4 activities were significantly higher in the T1DM
children than in the controls (3.57 ± 0.99 vs.2.67 ± 0.77U/mL,
p<0.001). In the T1DM children, DPP4 activities were not correlated
with HbA1c, blood glucose, or duration of diabetes. A significant
negative correlation was found between DPP4 activities and serum
adiponectin levels in the T1DM group (r=-0.35, p<0.05).
Conclusions: Serum DPP4 activity was increased in T1DM children,
whereas it was not associated with glycemic control. This study indi-
cates the possibility that DPP4 in T1DM children plays a significant
role in enhancing insulin resistance when it was measured by de-
creased adiponectin level as surrogate marker. Further mechanisms
are to be elucidated specially when harboring clinical application of
DPP4 inhibitor to T1DM children.
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The aim was to evaluate the associations of Sfrp5 and Wnt5a with
blood pressure (BP), and to examine whether BP can be influenced by
changes in adipocytokines, such as Sfrp5, adiponectin, chemerin, and
hsCRP, in obese children after lifestyle intervention. A cross-sectional
study was conducted in 263 obese children. In addition, a 6-month life-
style intervention was performed in a subgroup of 89 obese children
with hypertension. Anthropometric parameters, clinical data, adiponec-
tin, chemerin, Sfrp5, and Wnt5a were measured at baseline and after
lifestyle intervention. Sfrp5 and adiponectin levels were significantly
lower in obese children with hypertension, but Wnt5a, hsCRP, andchemerin levels were elevated in obese children with hypertension. In
multivariable linear regression analysis, Sfrp5, Wnt5a, adiponectin,
chemerin, and hsCRP were associated with both standard deviation
score-systolic blood pressure (SDS-SBP) and -diastolic blood pressure
(SDS-DBP). Lifestyle intervention resulted in a significant improvement
in BP and weight loss. These were accompanied by significant de-
creases in hsCRP and chemerin, and significant increases in Sfrp5 and
adiponectin, whereas Wnt5a was not changed. Furthermore, the
changes in Sfrp5, adiponectin, chemerin, and hsCRP act as partial medi-
ators of the relationship between weight loss and BP reduction. Al-
though Sfrp5 and Wnt5a levels correlated with BP at baseline, after
lifestyle intervention, Sfrp5 is more sensitive to reduction in BMI and BP
compared to Wnt5a, and the relationship between weight loss and BP
reduction were partially mediated by changes in Sfrp5. So we speculate
if Sfrp5 and Wnt5a each play a role in regulating BP, it must be differ-
ent roles.
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Background: It is said that the effect of new long acting insulin glar-
gine U300 and degludec continue over 24 hours from injection. It is
unclear that which is more useful and effective.
Subject and method: We conducted a crossover study to compare
the effect of new long-acting insulin in patients with type 1 diabetes.
9 young type 1 diabetes patients participated in this study with in-
formed consent. All patients were treated by multiple daily injection
therapy, and they were randomly assigned to change insulin deglu-
dec or glargine 300. After 2 months use, they switched to another
long-acting insulin. On the last day of each phase, they skip their
long acting insulin injection until next morning. We compared about
blood glucose (BG) differences from bedtime BG to fasting BG be-
tween degludec and glargine U300.
Results: Mean age and diabetes duration was 15.9 ± 6.0 years old,
and 8.5 ± 7.3 years respectively. Before registration of this study,
their mean HbA1c was 7.8 ± 1.0%, and mean total daily dose was
63.5 ± 24.8 units (1.01U/kg/day). Mean long acting insulin dose was
24.4 ± 11.1 Unit/day. Mean HbA1c in degludec phase (7.6 ± 0.8%; 1M
and 7.5 ± 0.6; 2M) was lower than glargine U 300 phase (7.9 ± 1.0%;
1M and 8.0 ± 0.9%; 2M). However, there was not significant
difference between two groups (p = 0.604). Insulin requirement of
glargine U300 phase (28.8 ± 18.9 U; 1M and 27.7 ± 20.2 U; 2M) was
more than that of degludec phase (24.1 ± 11.3 U; 1M and 24.4 ± 12.9
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(p = 0.378). One patient required approximately 1.5 times glargine
U300 dose (75U) than degludec (52U). After skipping injection, the
BG change was from 174.1 ± 61.3 mg/dl to 233.6 ± 103.6 mg/dl in
glargine U300 phase. In degludec phase, the BG change was from
169.3 ± 81.5 mg/dl to 269.1 ± 71.3 mg/dl. There was not significant
difference between two groups (p = 0.386).
Conclusion: There was not a significant difference between insulin
glargine U300 and insulin degludec about approximately 1.5 day
effect. Young patients with type 1 diabetes tend to require more
glargine U300 dose than insulin degludec.P2-1-12
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with overweight and nonalcoholic fatty liver disease in Indian
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Background/Objectives: Non alcoholic fatty liver disease (NAFLD) is
a complex metabolic condition leading to chronic liver disease.
Tumor necrosis factor (TNF)- α is an inflammatory mediator that may
have a role in pathogenesis of NAFLD. The aim of the study was to
investigate the association of polymorphisms in the promoter region
of TNF- α gene with overweight and NAFLD in Indian adolescents.
Methods: Overweight adolescents were enrolled from Pediatric OPD,
AIIMS, Delhi. NAFLD was diagnosed by ultrasonography. Healthy lean
adults aged 40-60 years were recruited as controls after excluding
diabetes and NAFLD. Polymerase chain reaction and restriction frag-
ment length polymorphism (PCR-RFLP) were undertaken to detect
SNPs: -238 (rs 361525), -863 (rs 1800630) and -1031 (rs 1799964) in
promoter region of TNF- α gene. Genotype frequencies were com-
pared with Asian HapMap- HCB population. The genotype distribu-
tion for all 3SNPs was in Hardy-Weinberg equilibrium.
Results: 208 overweight adolescents (130 (62.5%) with NAFLD) and
88 lean adult controls without NAFLD were enrolled. The comparison
of frequency of wild type, heterozygous and homozygous mutants
for TNF- α genes is presented in Table 1. We found that the over-
weight subjects with NAFLD as well as those without NAFLD had sig-
nificantly higher frequency of homo mutant and hetero mutant
alleles of -863 and -1031 SNPs of TNF- α in comparison to controls.
Genotype frequency distribution of -238 SNP of TNF- α was similar
between subjects and controls.
Conclusion: Our results indicate that -863 and -1031 promoter gene
polymorphisms of TNF- α may be associated with increased risk of
overweight in adolescents. However, they do not confer additional
risk of NAFLD in overweight adolescents.Table 1 (abstract P2-1-12). Comparison of frequency of wild type,
heterozygous and homosygous mutants for the TNF- α SNPs between
overweight subjects (with and without NAFLD) and lean healthy
adult controlsP2-1-13
The analyses of the influence of iron overload in glucose
metabolism in thalassemia major patients and the related
mechanism
Wenqin Lao1, Liyang Liang2, Hui Ou2, Zhe Meng2, Lina Zhang2
1Department of Pediatrics, The Second Affiliated Hospital of Guangzhou
Medical University; 2Department of Pediatrics, Sun Yat-sen Memorial
Hospital
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-1-13
Objective: This study aimed at determining the characteristics of the
glucose homeostasis and the status of the β -cell function of the pa-
tients with β -thalassemia major ( β -TM) in our hospital and studying
the potential factors responsible for secondary abnormal glucose of
TM patients, in order to provide the clinical evidences for early diag-
nosis and treatment of abnormal glucose induced by iron overload.
Method: A total of 57 (36 males) transfusion-dependent β -TM pa-
tients were in the “TM group ”; 25 age-and gender- matched healthy
teenagers were recruited as the “control group”. The height, weight,
fast blood glucose(FBG) and insulin level, serum ferritin (SF), super-
oxide dismutase (SOD ) and ultrasensitive C-reactive protein(hs-CRP)
were evaluated in all subjects. Insulin resistance index (IRI), insulin
sensitivity index and β -cell function index (BFI) were also estima-
ted.There were 36 patients estimating cardiac T2* and liver T2*.
Result: 1 The TM group had significantly higher levels of FBG, FINS
and HOMA-IRI than the control group. But HOMA-ISI and HOMA- β FI
were lower with no statistic sense in HOMA- β FI. None of the control
group had IFG or DM. In TM group, the prevalence was 24.56%
and7.02% respectively. There were 43.33% of patients with cardiac
T2* < 20 ms and 96.27% of patients with liver T2* < 6.3ms. 2 The in-
cidences of abnormal glucose among different ages, the levels of SF
and the severity of cardiac iron overload were different. And the inci-
dence increased with them.3 The levels of SOD and hs-CRP were
higher in the TM group than in the control group.4 The result of lo-
gistic regression analysis indicated that the cardiac T2* was a signifi-
cant predictor for the incidence of abnormal glucose in TM patients.
Conclusion: 1 In our center the prevalence of IFG and DM was
24.56% and7.02% respectively. 2 Iron overload was the main cause
of abnormal glucose even the secondary diabetes mellitus in β -TM
patients.Factors like age over 5, the level of SF over 2000ng/ml and
moderate degree of cardiac iron increased the incidences of abnor-
mal glucose in β -TM patients. The cardiac T2* was an independent
risk for the incidence of abnormal glucose in TM patients. 3 The
pathophysiological procedure of secondary of DM in TM was periph-
eral insulin resistance happened first; then insulin secretion decline
as it exacerbated; finally the function of β cell became failure, which
was similar to the type 2 diabetes.P2-1-14
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Background: Vitamin D has hormonal activities in humans. Its most
widely known function is its role in bone metabolism and calcium
homeostasis. Studies have outlined clinical evidence on the non-
classical role of vitamin D in many autoimmune diseases, type 1 dia-
betes mellitus (T1DM), included. Studies have suggested a link be-
tween vitamin D deficiency in early life and the development of
T1DM later in life. Locally, a significant proportion of T1DM patients
have Vitamin D inadequacy.
Objective: This study aims to study the effect of Vitamin D supple-
mentation on the Vitamin D status and HbA1c levels of T1DM
pediatric patients with vitamin D inadequacy.
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34 subjects with T1DM ( 21 females, 13 males ) with mean age of 14.5 (
SD 5.23, 11.07-18.49 ), and mean duration of 5.74 years. All subjects
had (1) a diagnosis of diabetes following the International Society of
Pediatric and Adolescent Diabetes (ISPAD) diagnostic criteria, (2) had
baseline measurements of 25(OH)D, HbA1c, ALT, Creatinine, and Sun
Exposure Score, (3) received Vitamin D supplementation, thereafter, in
addition to routine T1DM management, and (4) had post supplementa-
tion measurements of 25(OH)D, HbA1c and Sun Exposure Score.
Results: At baseline, Vitamin D deficiency was noted in 100% of the
subjects, with an average 25(OH)D level of 6.93 ng/ml ( SD 6.3; 1.4-15.1).
Further, 64.71% of the subjects had poor glycemic control, with an aver-
age HbA1c of 9.42% ( SD 5.67, 5.3 - 17 ). Post-supplementation, Vitamin
D levels improved, with 11.76% of subjects having sufficient levels and
58.82% having insufficient levels. The mean 25(OH)D post- supplementa-
tion was 23.21 ng/ ml ( SD 9.77, 13.6 - 37.7 ). Post-supplementation,
61.76% of subjects still had poor glycemic control, with an average
HbA1c level of 9.82% ( SD 4.2, 5.4 - 14.7 ). There was a statistically
significant increase in 25(OH)D level post-supplementation ( p < 0.01 ).
However, there was no statistically significant change in HbA1c
levels ( p = 0.32 ).
Conclusion: Vitamin D deficiency is prevalent in patients with T1DM.
Vitamin D supplementation in these patients was associated with a
statistically significant increase in 25(OH)D levels. Despite this, there
was no statistically significant change noted in the HbA1c levels of
the subjects. There is a need to look into other factors contributing
to the glycemic control in these subjects.Table 1 (abstract P2-1-16). Summary of clinical, demographic and
genetic mutation profile of the casesP2-1-15
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Background: Type 1 Diabetes Mellitus (T1DM) prevalence in Indones-
ian children is increasing. Ketoacidosis is the leading cause of mortal-
ity in children with T1DM. Ketoacidosis is life-threatening acute
complication that could be preventable. This study aimed to identify
risk factors that are responsible for recurrence to reduce mortality
from that and increase quality of life of children with T1DM.
Method: A sequential mixed method study was conducted among
nineteen T1DM children who had ketoacidosis between 2010 and
2014 at Department of Child Health in Dr. Hasan Sadikin General
Hospital, Bandung. We reviewed the medical records to identify the
risk factors followed by interviewed parents after got the consent for
qualitative analysis through phenomenology approach.
Results: Nine patient from 19 children included had recurrent
ketoacidosis. Twelve of patients are female which seven of them
had recurrence. All patients showed poor glycemic control. Type
of insulin therapy was not implicated to recurrence state. Insulin
therapy compliance contributed to ketoacidosis recurrence.
Control compliance was involved to insulin therapy compliance.
Patients and parents knowledge and understanding toward
T1DM, and geographical and economical access to medical care
influences the control compliance.
Conclusion: Main risk factor of recurrent ketoacidosis is insulin
therapy compliance. In the context of new scheme health insurance
implementation, insulin therapy compliance was related to hospital
control compliance. Counselling was needed to enhance knowledge
and understanding of patients and parents toward T1DM.Government and society role were expected to overcome the oppor-
tunity cost.
Keywords: Diabetic ketoacidosis, recurrence, risk factors, type 1 dia-
betes mellitusP2-1-16
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Objective: To study the genetic mutations and clinical profile in chil-
dren with neonatal diabetes mellitus (NDM)
Methods: Genetic evaluation and clinical follow- up of children with
a diagnosis of NDM at Department of Pediatrics, AIIMS, Delhi in last 7
years
Results: Out of 12 infants with NDM, 8 had permanent type. Patho-
genic genetic mutations were identified in 8 (66.7%) children. Three
infants with mutations in KCNJ11 gene and 1 with mutations in
ABCC8 gene were switched to oral sulfonylurea. Mutations in INS
gene were identified in 3 infants and ZFP57 mutation in differentially
methylated region of chromosome 6q24 in 1. The median age at ini-
tial presentation was 8 weeks, mean birth weight was 2.4 ± 0.5 kg
and presentation with diabetic ketoacidosis was seen in 6 infants
(50%). The current median age is 2 yrs (range 5.5 months to 7 yrs)
and mean HbA1c is 7.0 ± 0.9% (Table 1).
Conclusion: NDM is a heterogeneous disorder. Identification of the
genetic cause guides clinical management. With concerted team effort,
optimal glycemic control, growth and development are achievable in
the children on sulfonylureas as well as those requiring insulin.
Table 1 (abstract P2-1-19). Glycemic control and glibenclamide
dosage before and after swithching to sulfonylurea
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Background: Pancreatic iron deposition in regularly blood-transfused
thalassemic patients causes β -cell dysfunction and diabetes. Insulin
resistance is the other mechanism contributed to the development
of diabetes. However, the acute effects of blood transfusion in pre-
existing iron-overload thalassemic patients on insulin sensitivity and
β -cell function are unknown.
Methods: Fifty children, aged 5-20 years with β -thalassemia/HbE dis-
ease were enrolled. Oral glucose tolerance tests (OGTT) were per-
formed twice, before and at 1 week after blood transfusion. Insulin
sensitivity and β -cell function indices [homeostatic model assess-
ment (HOMA) of insulin resistance (HOMA-IR), HOMA of β -cell func-
tion (HOMA- β ), insulinogenic index (IGI), whole body insulin
sensitivity index (WBISI) and disposition index (DI)] were calculated
from glucose and insulin levels obtained during the OGTT.
Hemoglobin (Hb) and serum ferritin were measured from the base-
line blood samples obtained at each OGTT.
Results: Median Hb and serum ferritin were significantly increased at
1 week following transfusion from 8.6 to 10.1 g/dL (p <0.001) and
1764 to 2160 ng/mL (p < 0.001), respectively. β -Cell function indices
were significantly increased following the transfusion [median IGI:
0.48 vs. 0.61 (p=0.03) and median HOMA- β: 74.3 vs. 82.0 (p=0.045)].
However, insulin resistance tended to increase following the transfu-
sion as demonstrated by decreasing median WBISI (11.9 vs. 10.1,
p=0.196) and increasing median HOMA-IR (0.76 vs. 0.85, p=0.113),
however, the statistical significance was not reached. Median DI also
tended to increase (5.26 vs. 6.26, p=0.094). Only posttranfused IGI
was correlated with posttransfused Hb (r=0.34, p=0.017).
Conclusions: Acute iron loading following blood transfusion poten-
tially aggravated insulin resistance in β -thalassemia/HbE patients
and might result in a compensatory increase in insulin secretion.
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Objective: More frequent self-monitoring of blood glucose testing
(SMBG) has been founded to be associated with lower HbA1c levels
in studies of youth with type 1 diabetes (T1DM). We evaluated the
relationship between the daily number of SMBG measurements and
HbA1c level in T1DM adolescents. For optimal glycemic control of
T1DM adolescents, the factors in related to frequency of SMBG were
assessed.
Method : This study was administered among youth with type 1 dia-
betes (n=61, 13-19yr) at an outpatient clinic or diabetic camp with
single structured self report questionnaires.
Results: Mean daily number of SMBG measurement was 3.6 ± 2.2
times and mean HbA1c level was 8.5 ± 1.4%. A higher daily number
of SMBG measurement were associated with a lower HbA1c (p <
0.001). Odds ratio of the group with frequent testing ≥ 5 times a day
for predicting HbA1c < 8% was 3.69 (95% CI 1.093-12.477). Fre-
quency of daily SMBG in school was strong positively correlated with
a higher number of daily SMBG measurement (p < 0.001).
Conclusion: For performing adequate diabetic care in youth with
T1DM, frequency of daily SMBG is important. The support for SMBGmeasurement in school might help the optimal glucose control in
T1DM adolescents.P2-1-19
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Background: Permanent neonatal diabetes mellitus (PNDM) is a rare
form of diabetes, characterized by the onset of diabetes before age of
6 months. 50% of cases are caused by an activating mutation in
KCNJ11, encoding the Kir6.2 subunit of ATP-sensitive potassium (KATP)
channel. 20% have associated neurologic features like DEND (Develop-
mental Delay, Epilepsy, Neonatal Diabetes) or intermediate DEND
(iDEND) syndrome. Now it is known that the majority of PNDM patients
with KATP mutations respond to oral therapy which is sulfonylurea.
Case presentations: A 4-week old male baby, presented to the hos-
pital for high grade fever, during the work up was found to have per-
sistent hyperglycemia so the diagnosis of neonatal diabetes was
made. His past medical history was significant for intrauterine growth
restriction (birth weight 1850 g:< 3rd percentile. He was started with
conventional insulin regimen until 8 yr old. We first saw him when
he was 9 yr old, then switched him to basal bolus regimen. He had
markedly developmental delayed, functioning as 1 yr 6 mo old. EEG
was normal. Anti-insulin and anti-GAD autoantibodies were negative.
Genetic study for neonatal diabetes was done at 9 yr and 5 mo old,
showed a heterozygous missense mutation of KCNJ11, encoding
Kir6.2, c.175G>A (p.Val59Met).
Transition of treatment to oral sulfonylurea (glibenclamide) was
attempted at 10 yr old. Glibenclamide was initiated at 0.2 mg/kg/day
divided to 2 equal doses. Dose was gradually increased to 2.8 mg/
kg/day over 3 weeks and then insulin was stopped. Blood glucose
was well controlled without episodes of hypoglycemia. HbA1c has
been lower than when the patient was on insulin injection regimen,
as shown on table 1. No other side effects of sulfonylurea have been
noticed, such as leukopenia and elevated liver enzymes.
Conclusion: W e report the PNDM case due to KCNJ11 mutation with
intermediate DEND syndrome w ith successfully switching from insu-
lin injection to sulfonylurea at 10 years of age. An early genetic diag-
nosis provides clinicians w ith valuable information for the patient’s
clinical management, suggesting the possibility of treatment changeand awareness of development of neurological features.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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DKA with Severe Acute Kidney Injury in an Adolescent Boy: a case
report
Kansuda Ariyawatkul
Department of Pediatrics, Panyananthaphikkhu Chonprathan Medical
Center Srinakharinwirot University
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Fig. 1 (abstract P2-1-20). See text for description
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betic ketoacidosis (DKA) in children and adolescent. Reported mortal-
ity in AKI complicating DKA was 40%.
Objective: To describe our experience of treating acute kidney injury
in an adolescent boy with severe DKA as first manifestation of
diabetes.
Results: A 13-year-old boy was presented at our pediatric emergency
with decreased level of consciousness and Kussmaul breathing. We
reviewed there was a history of abdominal pain, polyuria, polydipsia
and significant weight loss. When he arrived at hospital, he was
stupor and severe dehydration. Vital signs revealed tachycardia and
high blood pressure. On admission, our patient was found to have
severe DKA. Laboratory investigation revealed serum urea of 27 mg/
dL and creatinine of 1.11 mg/dL. Intravenous fluid resuscitation was
administered immediately, followed by continuous insulin infusion
and potassium chloride. On the next day, his renal function deterio-
rated with serum urea of 40 mg/dL, creatinine 3.7 mg/dL. His urinaly-
sis showed 3+ glucose, 2+ protein and 3+ ketone without RBC and
WBC. Fractional excretion of sodium and urea were calculated and
equivalent to 22.3% and 56.3%, respectively. Potassium phosphate
was initiated along with intravenous fluid. Although his DKA and
level of consciousness improved and he had good urine flow, his
serum creatinine progressively increased within the first five days
with maximum serum creatinine of 7.77 mg/dl. Ultrasonography of
both kidneys showed prominent in size with slightly increased paren-
chymal echogenicity of both kidneys. Potassium phosphate and bi-
carbonate were given to correct electrolyte disturbance. Amlodipine
was started to reduce blood pressure and nephrotoxic drug was
avoided. Then his serum creatinine gradually declined to normal
range within 16 days without renal replacement therapy, in conjunc-
tion with amlodipine and bicarbonate were discontinued. He was dis-
charged home with basal-bolus insulin regimen and follow up 1
month later. His blood pressure was 106/61 mmHg and serum cre-
atinine was 0.6 mg/dL.
Conclusion: The acute kidney injury in DKA possibly result from de-
creased intravascular volume due to osmotic polyuria and gastrointestinal
loss. Early recognition of AKI along with appropriate fluid and electrolyte
management is important to prevent deterioration in renal function.
P2-1-21
2 Cases Suffered from Type 1 Diabetes Mellitus with Ketotic
Acidosis and Henoch-Schöenlein Purpura
Jia Jia Chen
Division of Endocrinology and Metabolism, Beijing Children's Hospital
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Type 1 Diabetes Mellitus (T1DM) and Henoch-Schonlein purpura
(HSP) are autoimmune diseases. Here we presented two boys with
diabetic ketosis and HSP. The two boys with past medical history of
T1DM more than 3 years were admitted for the main symptoms of
abdominal pain, vomiting. The colicky abdominal pain associated
with diffuse was acute and the parts changing and was not fixed,
however, slight abdominal signs with only mild tenderness and
muscle tension. The rash occurred after abdominal pain. And in the
course of the disease, gastrointestinal bleeding happened. Serum
IgEs in the two cases were significantly elevated, while 1 case of IgA
increased. Complement and CD series of the two cases were normal.
Parenteral nutrition support was used for the two boys with severe
gastrointestinal symptoms. After the symptoms remissioned, we gave
them gradually sugar-free rice soup, rice porridge, free of animal pro-
tein diets without sugar residue. Glucocorticoid 1-2 mg/ (kg. d) intra-
venous used actively could prohibit the inflammatory response. At
the same time, the two boys with T1DM, intravenous insulin was
used to control blood sugar. Until the gastrointestinal symptoms and
signs disappeared respectively on the 37th day and the 20th day in
hospital, with the intravenous nutrition stopping, insulinsubcutaneous injection 4 times/day insteaded. The amount of insulin
were 0.72 IU/kg. (d) and 1.18 U/kg. (d) with dietary calorie equivalent
to 50% of the normal. So, when the T1DM patient with complaints
such as abdominal pain, vomiting, we need to pay attention to the
possibility of precipitated by HSP. Patient with severe intestinal mu-
cosa involvement, the treatment with glucocorticoid actively is
needed with parenteral nutrition, while controlling blood sugar has
more difficulty.
P2-2-1
Greater maternal BMI early in pregnancy is associated with
increased adiposity in 7-year-old offspring, but without adverse
effects on metabolism
Valentina Chiavaroli, Jose’ G B Derraik, Sarah A Hopkins, Raquel O
Rodrigues, Wayne S Cutfield, Paul L Hofman
University of Auckland, Liggins Institute
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-2-1
Background: There is growing evidence that maternal overweight or
obesity during pregnancy is associated with an increased risk of obesity
in their children. However, gestational weight gain is a confounding
factor, and it is unclear whether there are associated metabolic effects
on the offspring. Thus, we aimed to examine whether maternal BMI at
20 weeks of gestation was associated with alterations in body compos-
ition and metabolism in the offspring of primiparous mothers who par-
ticipated in a randomised controlled trial of exercise regimen during
pregnancy.
Methods: Of the initial 84 women and their offspring who partici-
pated in the trial, follow-up data were available on 56 mothers and
their children. 28 mothers were overweight/obese early in pregnancy
(approximately 20 weeks of gestation) and 28 were of normal weight,
with a similar proportion of participants in each group who exercised
during pregnancy (61% and 57%, respectively). Children underwent
clinical assessments at approximately 7.6 years, including body com-
position by DXA and fasting blood tests (i.e. glucose, insulin, and
lipid profile), while their nutritional intake was estimated from food
diaries. All statistical analyses were adjusted for important con-
founders, in particular gestational weight gain.
Results: Greater maternal BMI was associated with increased weight
SDS ( β =0.107; p=0.0004), BMI SDS ( β =0.093; p=0.002), percentage
body fat ( β =0.546; p=0.006), and android fat ( β =0.528; p=0.040),
but lower percentage lean mass ( β ;=-0.486; p=0.007) in the off-
spring in childhood. Children born to overweight/obese mothers
were heavier (weight SDS 0.71 vs 0.06; p=0.002) and had greater BMI
SDS (0.41 vs -0.21; p=0.003). There were no differences in fasting
metabolic parameters in children born to normal weight or
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children of overweight/obese mothers had a lower daily intake of
dietary fibre (18 vs 23 g; p=0.009) and a greater proportion of their
energy intake was derived from fats (32% vs 26%; p=0.008), including
saturated fats (15% vs 12%; p=0.027).
Conclusions: Greater maternal BMI early in pregnancy is associated
with increased adiposity in the offspring at age 7.6 years independ-
ently of gestational weight gain, but without observed adverse ef-
fects on fasting metabolic parameters. However, the increased
adiposity in the children of overweight/obese mothers in our cohort
may be in part explained by poorer dietary habits.
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Left ventricular mass in offspring of diabetic mothers: at 5-7 years
old
Rista Lestari, Noormanto, Madarina Julia
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Mada/ Dr. Sardjito Hospital
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Background: Newborns of diabetic mothers have increased risk for
cardiac left ventricular (LV) hypertrophy. Diabetic pregnancy is also
associated with increased risk for obesity and hypertension, as well
as for later cardiovascular morbidity and mortality.
Objectives: This study aimed to see the interaction between being
the offspring of a diabetic pregnancy, hypertension and obesity to
the risk to have increased left ventricular mass (LVM) and altered LV
geometry in childhood.
Methods: We conducted a retrospective cohort study on 23 offspring
of diabetic mothers and 23 sex and age matched control children at
the age of 5-7 years old. LVM and LV geometry were assessed using
M-mode echocardiography and indexed for height2.7. Data analyses
were adjusted for birth weight, current overweight/ obesity status
and blood pressure.
Results: Prevalence of increased LVM/height2.7 was higher in children
of diabetic mothers, i.e 43.5% vs. 8.7% in the control group, RR (95%CI)
5.0 (1.2-20.4), p < 0.007. The association between maternal diabetes
and increased LVM persisted after adjustment for age, sex, birth weight,
current overweight/ obesity status and blood pressure, regression coef-
ficient (95%CI): 5.7 (1.4-10.1), p=0.01. Together, maternal diabetes, over-
weight/ obesity status and blood pressure contributed 50% to the
increase. Children of diabetic mothers were more likely to have altered
LV geometry, RR (95%CI) 6.0 (1.5-23.9), p < 0.001.
Conclusion: Maternal diabetes is a risk factor for increased LVM and
altered LV geometry in childhood.
P2-2-3
Clinical characteristics in schoolchildren with renal glucosuria
detected by a urine glucose screening program at schools in
Tokyo metropolitan area during 2000-2016
Tatsuhiko Urakami, Yusuke Mine, Masako Aoki, Misako Okuno,
Junichi Suzuki
Department of Pediatrics, Nihon University School of Medicine
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Renal glucosuriais is considered a rare condition with decreased renal
tubular resorption of glucose in the absence of hyperglycemia. On
the other hand, we have conducted an annual urine glusoce screen-
ing program at schools, and detected children with diabetes at the
early stage. We also have identified some cases with renal glucosuria
based on a positive result for glucosuria with normal glucose metab-
olism. We hereby report clinical characteristics in schoolchildren diag-
nosed with renal glucosuria detected by the screening program from2000 to 2015. During the study period, 3,309,631 children, 6-15 years
old, participated in the screening program, and 350 showed positive
results for glucosuria. We performed an OGTT to evaluate glucose in-
tolerance. As a result, 102 children were diagnosed as diabetes, and
246 (70.3%) were finally identifies as renal glucosuria. Frequency of
male was 50.3%, and the mean age at diagnosis was 11.0 ± 2.4 years.
Forty (11.4%) children had overweight (BMI SDS>+2.0), whereas only
5 (1.3%) had underweight (BMI SDS<-2.0). 251 (71.7%) had family
members suspecting to have this disorder in the first- and second-
degree relatives. All cases showed normal glucose tolerance in the
absence of insulin resistance and impaired insulin secretion. In con-
clusion, renal glucosuria is revealed not a rare condition among
schoolchildren with glucosuria. This disorder seems to be strongly
inherited and to show less commonly body weight loss despite con-
tinually excretion of glucose in urine.P2-2-4
Strikingly high prevalence of non-alcoholic fatty liver disease in
overweight Indian adolescents: Clinical and biochemical correlates
Vandana Jain1, Manisha Jana2, Babita Upadhyaya1, Nayeem Ahmad1,
Oshima Jain1, Ashish Upadhyaya3
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Objectives: We aimed to assess the prevalence of non-alcoholic fatty
liver disease (NAFLD) among overweight adolescents, and to study
its association with clinical and biochemical parameters.
Methods: 218 overweight adolescents (151 boys) aged 10 to 16 y
were recruited. BMI, waist circumference, BP and body fat (FM%)
were measured. Standard deviation scores (SDS) were calculated
for BMI and WC using Indian reference data. NAFLD was diag-
nosed and graded by ultrasonography. Fasting blood sample was
drawn for glucose, ALT, AST, insulin, triglyceride, apolipoprotein
C3 (ApoC3), tumor necrosis factor α (TNF α ), adiponectin, total
and high- density lipoprotein (HDL) cholesterol. Homeostatic
model assessment of insulin resistance (HOMA-IR) was calculated.
Parents’ BMI was checked and USG for NAFLD done. Biochemical
and clinical variables were compared between the two groups.
ROC analysis and logistic regression was done to find out param-
eters associated with NAFLD.
Results: Mean age was 11.9 ± 1.6 y and BMI SDS 2.3 ± 1.1. NAFLD
was seen in 62.5% adolescents (95% C.I. 56.2 – 69.4%); being mild in
40.4%, moderate in 18.8% and severe in 3.3%. Among the other
complications of overweight, low HDL (3.5) in 43.5%, hypertension in
22.9%, impaired fasting glucose in 9.3%, and metabolic syndrome
(by IDF criteria) in 26%. Comparison of clinical and biochemical pa-
rameters in adolescents with and without NAFLD are presented in
Table 1. ROC analysis showed that WC SDS > 1.4, ALT > 33U/L, BMI
SDS >2.2, body fat% >37.7, Insulin >15 and HOMA-IR >3.2 were asso-
ciated with NAFLD with AUC of 0.73, 0.70, 0.69, 0.63 and 0.68, re-
spectively. On multiple logistic regression, BMI SDS, ALT and insulin
were independently associated with NAFLD with odds ratios (95% CI)
of 2.92 (1.53-5.59), 2.72(1.42-5.21) and 1.97(1.02-3.80), respectively.
Conclusions: Strikingly high prevalence of NAFLD was noted among
overweight Indian adolescents. BMI and waist circumference SDS,
FM%, BP, acanthosis nigricans, ALT, AST, HOMA-IR and insulin were
higher among adolescents with NAFLD while age, gender distribu-
tion, pubertal status, lipid profile, adiponectin, TNF- α and parents/
BMI and fatty liver status were similar. NAFLD was independently as-
sociated with BMI, serum ALT and insulin.
Fig. 1 (abstract P2-2-5). Study flow diagram
Table 1 (abstract P2-2-4). Comparison of clinical and biochemical
parameters between subjects with and without NAFLD (USG done in
n=208 adolescents)
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 101 of 144P2-2-5
Use of Professional Continuous Glucose Monitoring in Children with
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Background: Frequent self monitoring of blood glucose (SMBG) is
the only accurate method available for insulin dose titration T1DM
patients. Professional continuous glucose monitoring (p-CGM) is
blinded recording of glucose trends over 5-7 days and helps physi-
cians to guide insulin titration to patient.
Objective: To assess efficacy of insulin dose adjustments, based p-CGM
plus SMBG in improving glycemic control compared to SMBG alone.
Methods: Trial design: Open label, randomized control trial (CTRI Ref.
No 2015/04/008867)
Participants: Children (2 - 10 years) with T1DM for at least 6 months,
on basal-bolus insulin regimen and SMBG for at least 3 times a day.
Children having DKA within 2 months were excluded.
Intervention: Subjects in the Intervention group were placed on p-
CGM (iPro®2 Professional CGM, Medtronic, USA) for 3-5 days along
with regular SMBG. Data from p-CGM was analyzed by physician and
used to guide insulin titration along with SMBG over following 3
months. Control group had only SMBG for titrating insulin doses.
Outcome: Change in HbA1c 3 months after p-CGM.
Randomization: Done using computer generated random number
list. Group allocation was concealed from investigator and partici-
pants using opaque sealed envelopes.
Results: Numbers randomized : Out of 310 patients screened, 68 eli-
gible patients were randomized, 34 each to either arms (Figure 1).
Recruitment: closed
Numbers analyzed : Thirty children in intervention group and 33 in
control group. Intention to treat analysis was also performed. Out-
come: There was more decreased unit change in HbA1c, percentage
of low sugar records and total insulin requirement per day, after 3
months follow-up, in intervention group. However, difference wasnot significant except for total insulin Units/kg/day (p=0.014). In sub-
group analysis of children with baseline HbA1c > 7.5%, there was a
significant mean fall of HbA1c by 1.27%.
Harms: Accidental removal of p-CGM in 2 patients and for
hospitalization in one. P-CGM caused local redness (10/34) and local
irritation (12/34).
Conclusions: Addition of p-CGM along with SMBG may help in
adjusting insulin dose more effectively especially in children with
higher baseline HbA1c.P2-2-6
Diabetic screening system for school children in Atsugi city
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Background: In Japan, diabetic screening for school children using
urinalysis has been performed to detect diabetes mellitus during
childhood throughout the country. However, inadequate follow-up
system after urinary screening caused several problems. The rate of
participation in workup examination still remains less than 30%. Also,
accurate annual incidences of children with type 1 diabetes mellitus
(T1DM) and type 2 diabetes mellitus (T2DM) detected by screening
of urine glucose have not been determined.
Objective: Under the cooperation with Atsugi city (population:
around 224,000), the present study was performed to achieve full
participation of children with positive urine glucose in workup exam-
ination, and to clarify accurate annual incidences of children with
T1DM and T2DM in this city.
Subjects and Method: Subjects were school children with positive
urine glucose for the past eight years from 2009 through 2016 in
Atsugi city. Workup examination of diabetes mellitus, including
HbA1c and anti-GAD antibody, was carried out for them at our hos-
pital. And then we retrospectively analyzed clinical diagnosis and
management of them. The results of first screening tests by urinalysis
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Results: A total of 146,866 school children were tested by diabetic
screening system. The average participation rate for eight years was
85%. 41 of these children showed positive response of urine glucose.
Continuously, all of them could receive secondary workup examination
at our hospital by active support of Atsugi city. Through this screening
system, four children were finally diagnosed as having T2DM. The over-
all incidence of T2DM was 2.70 per 100,000 per year. On the other
hand, three children were diagnosed as having T1DM. The overall inci-
dence of T1DM was 2.09 per 100,000 per year. Furthermore, one child
was diagnosed as having insulin receptor abnormality (Rabson- Men-
denhall syndrome), and another one was found before onset of T1DM.
Conclusion: We could achieve improvement of diabetic screening
system for school children by close cooperation with a local govern-
ment of Atsugi city, and then found eight patients with various types
of DM. Our study demonstrated that the annual incidence of children
with T2DM in Atsugi city was comparable with those in other munici-
palities (2.65-3.57 per 100,000 per year), but interestingly, the annual
incidence of children with T1DM was almost 4 times higher than that
in Tokyo (0.51 per 100,000 per year). The reason for this difference is
unclear, and therefore further study is necessary.P2-2-7
Glycemic Control Indicators Levels at Diagnosis of Neonatal
Diabetes Mellitus: Comparison with Other Types of
Insulin- Dependent Diabetes Mellitus
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Background: Neonatal diabetes mellitus (NDM) is a monogenic dia-
betes whose onset is within 6 months of age. The HbA1c and glycated
albumin (GA) levels in NDM are falsely low because of high hemoglobin
F levels and high albumin metabolism, respectively in early infancy. In-
stead, we reported that the Age-adjusted GA (Aa-GA) accurately
reflected glycemic control in NDM. Glycemic control indicators (HbA1c
or GA) reflect both plasma glucose and the duration of hyperglycemia
in the manner of the weighted mean of the plasma glucose level.
Therefore, glycemic control indicators levels at diagnosis of diabetes in-
dicate what extent or how long hyperglycemia continues until diagno-
sis. However, the time course of glycemia until diagnosis of NDM,
which is one of the insulin dependent diabetes, are unclear.
Objective: To compare glycemic control indicators levels at diagnosis
between NDM and other types of insulin-dependent diabetes melli-
tus (fulminant type 1 diabetes [FT1D] and acute-onset autoimmune
type 1 diabetes [T1AD]).
Subjects and Methods: The subjects consisted of eight NDM pa-
tients, eight FT1D patients, and 24 T1AD patients. Plasma glucose,
HbA1c, GA and Aa-GA, which was calculated as previously reported
(Aa-GA = GA x 14.0 / [1.77 x log-age (days) + 6.65].), were compared.
Results: Plasma glucose levels in the FT1D were significantly higher
than in the T1AD, while there were no significant differences be-
tween the plasma glucose levels in the NDM and those in the FT1D
or the T1AD. HbA1c and GA levels in the NDM were not significantly
different from those in the FT1D, respectively, and both indicators
were lower than those in the T1AD. On the other hand, Aa-GA levels
in the NDM were not significantly different from those in the T1AD,
and were higher than those in the FT1D.
Conclusions: These findings suggested that the time-course of the
elevation of plasma glucose in NDM at diagnosis was close to that of
T1AD. In addition, the high Aa-GA value in NDM at diagnosis for
NDM indicated that it is useful for assessing the chronic hypergly-
cemic conditions in NDM.P2-2-8
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Background: Early detection and prevention of diabetic retinopathy
(DR) is crucial to reduce the risk of severe visual disturbance. Early
stage of DR is characterized by pathological changes in macula. Op-
tical coherence tomography angiography (OCTA) is a newly devel-
oped instrument which can precisely assess the area around macula.
It does not require intravenous administration of a contrast medium
and takes only 5-10 minutes for inspection, implying that less-
invasive and faster than Fluorescein angiography. Even though there
are increasing reports on OCTA in ophthalmology, clinical experience
is still lacking in pediatric field. Thereby, we present our experience
of OCTA for DR screening in patients with childhood-onset diabetes.
Subjects and Methods: OCTA data was collected from 1st January
2016 to 30st July 2016. 47 patients with diabetes who had been di-
agnosed under 15-year-old were recruited. They consisted of 36 pa-
tients with type 1 diabetes, 7 with type 2 diabetes, and 4 with
maturity-onset diabetes of the young (MODY). There were 15 males
and 32 females, diabetic durations were 10.3 ± 11.0years, average
HbA1c (among 1-year) was 8.2 ± 1.6%. The patients underwent oph-
thalmoscope prior to OCTA. Data on diabetes duration, urine exami-
nations and HbA1c levels were collected from hospital records.
Results: DR was detected in 12 patients. Simple DR (SDR) was ob-
served in 50% (6/12), pre-proliferative DR (PPDR) was observed in
17% (2/12), proliferative DR (PDR) was observed in 33% (4/12) of the
cases. 4 out of 6 SDR were detected using OCTA for the first time in
this study period. The prevalence of DR was higher in patients who
were older and had longer diabetes durations, but we found SDR in
16-year- old patient with poor glycemic control in 4-year duration of
diabetes. The youngest patient who were performed OCTA was 4
years old. There were no adverse symptoms related to OCTA.
Discussion: Overall, in our cohort, OCTA was safe and non-invasive.
Furthermore, it can easily detect early-stage DR lesions in macular
area. OCTA in combination with ophthalmoscopy seems to be effect-
ive for evaluating DR. We detected SDR in an adolescent patient with
poor glycemic control. OCTA seems to be effective as the additional
DR screening for young patients with poor glycemic control.
Conclusion: OCTA is enforceable with young patients. It seems to be
useful to use OCTA in combination with ophthalmoscopy as a precise
and non-invasive screening for DR.
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cholesterol ratio : surrogate markers for metabolic syndrome in
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Background: Reference values of triglycerides (TG) to high density
lipoprotein cholesterol (HDL-C) ratio, total cholesterol (TC) to HDL-C
ratio, and non-HDL-C concentrations, and their clinical utility have
not been fully examined in adolescents.
Objectives: We aimed to examine the distribution of TG/HDL-C ratio, TC/
HDL-C ratio, and non-HDL-C concentrations in Korean adolescents, and to
explore their significance as surrogate markers for metabolic syndrome.
Methods: We analyzed data for 2,721 adolescents aged 10-18 years
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 103 of 144(1,436 boys and 1,285 girls) who participated in the Korean National
Health and Nutrition Examination Surveys from 2008 to 2010.
Metabolic syndrome was defined using the International Diabetes
Federation criteria.
Results: The mean values of TG/HDL-C, TC/HDL, and non-HDL-C were
1.9, 3.3 and 108.6 mg/dL, respectively. TG, TG/HDL-C, and TC/HDL-C
were not significantly different by gender, but non-HDL-C levels sig-
nificantly higher in girls than in boys. TC/HDL-C ratio did not change
with age in both genders. Non-HDL-C significantly decreased with
age in boys, while age-related difference was not found in girls. TG
and TG/ HDL-C increased with age in boys, not in girls. Compared
with the other lipid parameters, correlation coefficient with waist cir-
cumference (WC) was highest for TC/HDL-C, while correlation coeffi-
cients with the homeostatic model assessment–insulin resistance
(HOMA-IR) were highest for TG and TG/HDL-C. The areas of under
the receiver operating characteristic (ROC) curve for predicting meta-
bolic syndrome of TG (0.923), TG/HDL-C (0.947), and TC/HDL-C
(0.924) were higher than HOMA-IR (0.822). Optimal cutoffs (sensitiv-
ity, specificity) of TG, TG/HDL-C, and TC/HDL-C for identifying adoles-
cents with metabolic syndrome were 145 (82.5% 90.5%), 3.4 (85.0%,
91.0%), and 4.0 (85%, 85.6%), respectively.
Conclusions: TG/HDL-C and TC/HDL-C ratio might be useful surro-
gate markers for metabolic syndrome in Korean adolescents.P2-2-10
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Background: In October 2014, we started to introduce the sensor
augmented pump (SAP: Minimed 620G with Enlite®) for patients with
type 1 diabetes for the first time in Japan. SAP which is available in
Japan is only Minimed 620G with Enlite®. So far about 100 patients
in our hospital had started to use SAP by April 2016, whereas over
30 patients stopped using them.
Methods: We retrospectively analyzed the clinical features of patients
who started SAP. The reasons why some patients stopped SAP were
examined. Then we identified 35 patients who had used SAP for
more than one year (aged 2 to 75, HbA1c 7.63 ± 1.14 %). We retro-
spectively examined whether their HbA1c had improved or not. The
factors which might affected on the blood glucose control were ana-
lyzed. Then we asked them how they felt about SAP by the
questionnaire.
The major reasons for stopping SAP were the itching and the bother-
ing by wearing the sensors. The level of HbA1c in 35 patients who
continued SAP for 1 year, had not changed (7.63 ± 1.14 % to 7.65 ±
1.03 %). Their average blood glucose level and standard deviation
had not changed (192.4 ± 81.3 to 180.7 ± 70.3). Some patients,
whose HbA1c were high level before using SAP, improved signifi-
cantly. The using time of the sensors per week, age, nor sex were
not related to the improvement of HbA1c.
Their satisfaction about 620 G with Enlite was high (7-8 points at ten
points of perfect scores), even though HbA1c in many patients was
not improved. Almost all of them answered that they felt that it was
comfortable and convenient to use SAP, because of showing glucose
level and its trend.
Thirty % of patients stopped using 620 G with Enlite system because
of the sensor troubles. Thirty-five patients so far continued using it
for more than 1 year. SAP had not changed blood glucose control
significantly in one year. However, many patients felt highly satisfac-
tion to use the SAP system.P2-2-11
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Background: Insulin pumps are commonly used in the management
of type 1 diabetes mellitus (T1DM). While there have been many
outcome-focussed studies, only a few focused on potential adverse
events (AEs), with none examining the relationship between AEs and
pump/infusion set type, ethnicity nor socioeconomic status. In
addition, current data on the incidence and characteristics of pump-
associated AEs are confined to one paediatric centre.
Subjects and Methods: We approached adults, and families of chil-
dren with T1DM on insulin pumps in four main New Zealand centres.
Participants completed a questionnaire examining pump-related is-
sues they had experienced in the preceding 12 months.
Results: Response rate was 64% with 174 of 270 eligible people par-
ticipating in the study. 84% of subjects reported one or more AEs,
with an overall AE incidence of 3.42 per person/year (95% CI 3.14,
3.73). An event serious enough to require a hospital presentation oc-
curred in 9.8%, all but one reporting high ketones or diabetic ketoa-
cidosis (DKA). Set/site problems were the AE most commonly
reported (by 53% of respondents), followed by cutaneous complica-
tions (43%) and pump malfunction (38%). Few predictors of AEs (of
any type) were found, however a negative binomial regression model
found that a longer duration of pumping (p=0.018) and age
Conclusions: Insulin pump-associated AEs are very common. How-
ever, few variables are predictive of them with no relationships seen
with glycaemic control, socioeconomic status, pump manufacturer
nor infusion set type. Based on these findings, AEs should be antici-
pated in both adults and children, with anticipatory patient educa-
tion and training recommended for their successful and safe use.
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Background: In the setting of insulin resistance, progressive islet β
-cell dysfunction is especially important in the onset and progression
of metabolic syndrome (MS) and diabetes. However, data of β -cell
function in youth with MS or cMD icomponent metabolic disorders )
are very limited.
Objective and hypotheses: To evaluate islet β - cell function in
obese children and adolescents with clinical diagnosis of MS, cMD or
iOB to provide a reference for clinical interventions and early
prevention.
Method: We prospectively designed three groups of participants for
study: MS, cMD and iOB, clinically data from obese children and ado-
lescents (50 iOB, 72 cMD, and 59 MS) between May, 2013, and May,
2015 were obtained. All of the participants underwent MMTT ithe li-
quid mixed-meal test ) and OGTT, indices of insulin secretory func-
tion and insulin sensitivity were calculated for study.
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at 120 minutes (P=.007 ) and peak CP (P=.007 ) derived from MMTT
were significantly higher in the MS group compared with the iOB
group both before and after adjusting for BMI. The MS group had
higher HOMA- β - % compared with the cMD and iOB groups after
adjusting for BMI (P=.036 P=.008 ). However, there was no difference
between the cMD and iOB groups in AUC CP120, peak CP, and
HOMA- β - %. The Δ I30/ Δ G30 and oDI derived from OGTT were
not different among the three groups.
Conclusion: Obese children and adolescents with MS and cMD still
had a commendable pancreatic β - cell function in response to their
severe insulin resistance, offering a window in time for intervention
before development of diabetes.
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Background: Childhood obesity associated with an increased risk for
metabolic syndrome, such as insulin resistance. Homeostasis Model
Assesment Insulin Resistance (HOMA-IR) is a chemical marker widely
used for insulin resistance. Chemerin is a 18 kDa protein produced by
adipose tissue, function as chemoatractant plays an important role con-
tributing to the development of inflammation and insulin resistance.
Objective: To determine assosiation chemerin level and HOMA-IR in
obese adolescent.
Methods: This was a cross-sectional study and conducted in three
Senior High School in Padang. Twenty eight obese adolescents and
28 control were enrolled in the study. The age of the subjects ranged
from 14-18 years. Obesity criteria was measure based on body mass
index (BMI). Fasting serum glucose level measured by glucose hexo-
kinase fotometrik method and serum insulin was measured by che-
miluminessence immunoassay method. Plasma chemerin was
measured with enzyme-linked immunosorbent assay (ELISA). The in-
sulin resistance index was estimated from fasting serum insulin and
glucose level using the formula.Data was analyzed using correlation
test and t-test, P<0,05 was significant.
Result: The plasma chemerin level was higher in the obese than in
the control group 121,52 (SD 2,09) ng/ml vs 97,23 (SD 2,41) ng/ml, p:
0,001, and the insulin resistance group had higher plasma chemerin
level than non resistance group 133,1(SD 19,24) vs 115,09 (SD 19,52),
p: 0,027. There is a weak correlation with the value chemerin levels
HOMA-IR in obesity (r = 0.382; p = 0.045) and weak correlation with
value chemerin levels HOMA-IR in obese insulin resistance (r = 0.297;
p = 0.405).
Conclusion: There is a weak correlation with the value chemerin
levels HOMA-IR in obesity and insulin resistance.
Key Words: Obese adolescents, insulin resistance, plasma chemerin.
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Insulin resistance is a common feature of childhood obesity and is
considered to have a significant relationship with Type 2 diabetes
mellitus and cardiovascular disease. On the other hand, the high fre-
quency of insulin resistance was found in malnutrition, too. Changes
of antioxidant vitamins levels have been reported in children with
obesity and malnutrition due to lack of food intake and chronicoxidative stres in several studies. The aim of this study is to investi-
gate the relationship between HOMA-IR (homeostasis model assess-
ment for insulin resistance) and serum antioxidant vitamins (retinol,
α -tocopherol, ascorbic acid) levels in preschool children.
76 children in our study were classified as underweight (n=15), nor-
mal weight (n=31), and overweight-obese (n=30) using parameter of
body mass index. A HOMA-IR was used for the diagnosis of insulin
resistance. Insulin resistance was found in 20% of underweight chil-
dren and 26,7% of overweight and obese children whereas there
was no child with insulin resistance in normal weight children.
The serum vitamin E ( α -tocopherol) and vitamin A (retinol) levels
weren’t found statistically different in all three groups (p>0,05). The
serum vitamin C levels in normal weight group is higher than those
in overweight and obese. Just in overweight-obese group HOMA-IR
was negatively associated with vitamin E. Low concentration of vita-
min E but not vitamin A and C in children who were underweight
and overweight-obese were associated with insulin resistance.
As a result, underweight children have the risk of insulin resistance
so they should be investigated for insulin resistance like obese chil-
dren. Also, vitamin E may have a part in insulin resistance.
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Introduction: Diabetes self-management education (DSME) is a
process that evaluates the patient’s self-care management to confirm
that they can take care themselves at home and have good glycemic
control. Although DSME was provided in most newly-diagnosed dia-
betic patients, some of them still have poor glycemic control. Besides
the education, other factors may affect glycemic control including
the timing of DSME as one of the factors. Recommendations suggest
starting DSME as soon as possible after diagnosis. However, parental
anxiety and depression can be found in newly-diagnosed with type 1
diabetes (T1D) within several weeks may affect the perception of
DSME if it is provided too soon.
Objective: To evaluate relationship between timing of DSME after
diagnosis and glycemic control, and to determine factors affecting
glycemic control in T1D patients.
Materials and Methods: One hundred and ten T1D patients and their
parents who received DSME in the period of 2005-2014 were inter-
viewed at time of enrollment, data collection from medical records
and HbA1c was evaluated for 2 years after DSME. Their average
HbA1c in 1st and 2nd year after DSME were analyzed by divided into
three groups according to timing of DSME after diagnosis: less than
1 month (N=58), 1-6 months (N=30), and over 6 months (N=22).
Results: The mean age at diagnosis was 8.03 ± 3.36 years and mean
age at receiving DSME was 8.63 ± 3.38 years. Mean HbA1c at receiv-
ing DSME, 1st and 2nd year after DSME were 11.15 ± 2.72%, 8.65 ±
1.36% and 9.07 ± 1.40%, respectively. Comparison among timing of
DSME groups, less than 1 month, 1-6 months and over 6 months
after diagnosis groups were demonstrated statistic significantly bet-
ter glycemic control in the 1st year (HbA1c <7.5% was 22.4%, 10.0%
and 4.5%, respectively, p=0.035). In multivariate analyses of potential
factors for good HbA1c in 1st year, patients who received DSME
within 1 month after diagnosis were likely to have better glycemic
control (adjusted OR: 10.572 [95% CI: 1.184-94.433]). Other factors as-
sociated with good glycemic control were found including high par-
ental education (p=0.022), high family income (p=0.034), more family
member received DSME (p=0.025), multiple daily injections
(p=0.014).
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family supports were associated with glycemic control during 1st
year after DSME in T1D. Early and continuous intensive education is
recommended for all T1D patients and their family members.
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Background: During the last three decades, the incidence of type 2
diabetes mellitus (T2DM) in children and adolescents has increased
in Japan, which is related to the increasing prevalence of obesity and
various related health problems. T2DM symptoms progress more
slowly, compared to those of type 1 diabetes mellitus, and most pa-
tients with T2DM are identified incidentally during urine glucose
screening. Nevertheless, it is difficult to motivate patients with T2DM
in children and adolescents to comply with their treatment, as they
are often asymptomatic.
Objectives and methods: This study aimed to determine the clinical
and glycemic control characteristics of T2DM in children and adoles-
cents. This study included 43 patients (20 male patients and 23 fe-
male patients) who were
Results: The mean age at the diagnosis was 13.1 years, the mean
duration of diabetes was 3.3 years, and 88.3% of the patients were
identified using urine glucose screening. The HbA1c levels at the
diagnosis and most recent visit were 8.51 ± 2.7% and 7.1 ± 1.8%, re-
spectively. Approximately 80% of the patients (95% of the male pa-
tients and 65% of the female patients) were obese (percent ideal
body weight over 120%), and the frequency of a family history of
T2DM was 60.5%. 65.1% of the patients were receiving oral
hypoglycemic agents or insulin, and 55.9% of the patients had expe-
rienced complications (e.g., hepatic dysfunction, hyperlipidemia, hy-
peruricemia, and hypertension).
Discussion: Among patients who were treated at our center, the on-
set of T2DM in children and adolescents was related to the progres-
sion of obesity and genetic factors, which agrees with previously
reported findings. Moreover, most of our patients with T2DM are
identified incidentally using urine glucose screening performed in
Yokohama City. As these patients are often asymptomatic, they may
not be motivated to continue their treatment. However, most of our
patients ultimately achieved glycemic control using lifestyle interven-
tions and medication. Nevertheless, we did not consider patients
who discontinued their treatment, which indicates that there may be
higher incidences of poorly controlled glycemia and the progression
of diabetic complications. Therefore, initial and on-going education
regarding T2DM may help highlight the importance of behavioral,
dietary, and physical activity changes to patients with T2DM in chil-
dren and adolescents.
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Background: As the human genome is further explored, multiple gen-
etic anomalies at different loci are being found that confer varying de-
grees of predisposition to diabetes. MODY is the most common form
of monogenic diabetes, accounting 2 to 5 percent of diabetes. Recently,
we have found and reported three noble gene variants relating to
MODY in Korean children (Shim et al, Horm Res Pediatr, 2015). Object-
ive and hypotheses: This study was done to see the frequency of pos-
sible monogenic diabetes in Korean children with diabetes mellitus and
their clinical and laboratory characteristics.Method: Study patients consisted of 126 children with diabete melli-
tus (DM) who visited our institute between 2008 and 2015. Their
medical records were reviewed retrospectively. They classified into
three groups; type I (T1DM), type II (T2DM) and monogenic diabetes
mellitus (MDM) including MODY by the ADA classification of DM.
Various clinical and laboratory data was analyzed.
Results: The frequencies were 48 (38%) in T1DM, 42 (33%) in T2DM,
and 36 (29%) in possible MDM. Majority of possible MDM was MODY
(22 out of 36, 61%). Ages (yrs) at diagnosis were 9.2 ± 4.1 in T1DM,
13.4 ± 2.4 in T2DM, and 12.3 ± 3.1 in MDM. The age at diagnosis was
significantly older in T2DM compared to T1DM (p=0.000). BMI (kg/
m2) was significantly higher in T2DM compared to T1DM or MDM,
25.9 ± 4.7 vs 16.9 ± 5.1 vs 19.7 ± 5.1, respectively (p=0.001). Initial
fasting insulin levels (IU/mL) were significantly higher in T2DM than
T1DM or MDM, 13.01 ± 9.45 vs 2.10 ± 2.68 vs 4.85 ± 5.25, respect-
ively (p=0.000). C-peptide levels (ng/mL) were significantly higher in
T2DM compared to T1DM or MDM, 3.19 ± 1.40 vs 0.29 ± 0.15 vs 1.17 ±
0.39, respectively (p=0.000). HbA1c levels (%) were significantly higher
in T1DM compared to T2DM, 13.31 ± 3.09 vs 11.22 ± 2.40, respectively
(p=0.001).
Conclusions: It appears that possible monogenic diabetes including
MODY in Korean children with DM is more prevalent than expected.
Further large scaled studies including genes related to monogenic
DM are necessary.
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There is no consensus on the optimal insulin treatment for children
newly diagnosed with type 1 diabetes (T1DM). The aims of this study
were (1) to describe the prevalence of various insulin regimen use by
age, country (AU vs. NZ), and region; (2) to describe other aspects of
management and education relevant to new onset T1DM by coun-
try/region.
An online survey of medical professionals caring for children with
T1DM in AU and NZ was undertaken (n= 110), with questions per-
taining to clinic demographics; insulin regimen/dosing choices, and
education.
Response rate was 91%. Differences in regimen choice and practice
were seen between countries/centres. The majority of endocrinolo-
gists and centres in Australia (69%, p<0.05) favour intensive insulin
therapy (MDI/CSII) at all ages. In contrast, for NZ, and Victoria, AU, for
ages. This is the first study to examine individual practice with regard
to treatment choices at diagnosis of T1DM. Practice varies across
Australasia by clinician and location. This lack of consensus is likely
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 106 of 144driven by ongoing debate and gaps in the current paediatric dia-
betes evidence base, as well as by differences in clinician/centre pref-
erence, and their interpretations of the influence of various patient
factors.
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Objective: Neonatal diabetes secondary to mutations in potassium-
channel subunits is a rare disease. To study the clinical features, gen-
etic etiology and effects of glimepiride in 6 Chinese patients.
Methods: We reviewed the medical records of 6 NDM patients along
with their follow-up details. We recorded the HbA1c, C peptide and
insulin levels, and tried to find the correlation between the genetic
pothogeny and glimepiride effects.
Results: Among 6 NDM cases, 1case was transient, recovered at 4
months old after transient therapy of intravenous insulin. One case
got treated with subcutaneous insulin. The other four were tried for
glimepiride transition.All were successful with decreased HbA1c
levels, increased C peptide and insulin.In which, three patients had
genetic examination, one had KCNJ11 mutation, one heterozygous
mutations with ABCC8 and INSR, one known mutation of E1F2AK3.
KCNJ11 or ABCC8gene, encoding the ATP-sensitive potassium chan-
nel (KATP channel). The significant effect time of SU was longer,
HbA1c level was higher in the E1F2AK3 mutation case than in the
KATP channel mutation cases.
Conclusion: Oral sulfonylurea is beneficial for NDM, especially for pa-
tients with KATP channel mutations. Gene detection could give indi-
cation for precise treatment.
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Objectives: Obesity frequency has been increased in the world espe-
cially in children. It is suggested that obesity influences sleep quality.
Sleep disorder has negative impact on children health. In this study it is
aimed to determine association between obesity and sleep disorder.
Methods: Reliability and validity confirmed Turkish version of
Pediatric Sleep Questionnaire (PSQ) was conducted 132 children
(65 females, 67 males), diagnosed obesity by Body Mass Index,
aged 9-14 in Gulhane Military Medical Faculty.
Results: Concerning the demographics, both groups consist of
healthy and obese children at different ages (p=0.03). Addition-
ally, each group has also evaluated considering gender difference
separately in the following tests (p=0.5). Sleeping scores deter-
mined for obese and healthy children are 21.51 ± 10.62 and15.53 ± 8.97 respectively. The sleep scores showed statistical dif-
ference between each group. As a result, that is reached that
sleep quality for obese children is higher than control groups. Be-
sides, that is resulted that gender difference has no effects on
this study.
Conclusion: Sleep has a vital impact on healthy life and school
performance. Although there is no difference between healthy and
obese group for sleep disorder, it is believed that obesity has and
impact on sleep quality. Chronic conditions such as obesity
should be investigated as objective criteria to elaborate sleep dis-
order problems.P2-2-22
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Background
Neonatal Diabetes Mellitus (NDM) is a rare condition occurring
in 1:300,000 -1:400,000 live births. All patients are diagnosed
with diabetes in the first 6 months of life. Two main groups
have been recognized: transient NDM (TNDM) and permanent
NDM (PNDM). TNDM usually remits within a few weeks or
months.
All patients were diagnosed with diabetes under 6 months should
undergo genetic testing for monogenic NDM.
Case report
He was born prematurely. His gestational age was 31+ weeks on
October 4th, 2015. His birth weight was 1,540 grams. He is the
first child of his family. His blood glucose has been high since
birth. He received insulin therapy infusion for 32 days, then he
was given insulin subcutaneously once daily. Insulin therapy
lasted for a total of 60 days.
The physical examination showed that he had macroglossia and um-
bilical hernia.
Methylation specific analysis showed that he has a loss of maternal
methylation at chromosome 6q24, confirming a diagnosis of transi-
ent neonatal diabetes (TND). TND is a rare subtype of diabetes, af-
fecting only ~1 in 400,000 babies.
Progression
Now he is 13 months old (corrected age 11 months). His weight is
10.5 kg (P50-P75), height is 76 cm (P50-P75). Currently, he does not
have macroglossia and umbilical hernia. His growth and develop-
ment is normal. His blood glucose is 68-95 mg/dL. His last HbA1C (10
Nov 2016) is 4.9%.
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70% of TND have abnormalities at the 6q24 locus which disturb ex-
pression of the imprinted genes PLAGL1 and HYMAI. Diabetes re-
lapses in at least 50–60% of patients, usually around puberty.
Prolonged follow-up is imperative.Fig. 1 (abstract P2-2-23). Pedigree of this patient
Fig. 2 (abstract P2-2-23). See text for description
Fig. 3 (abstract P2-2-23). MS MLPA result showing loss of
methylation for the PLAG1 ProbesConsent for publication: The authors declare that the written in-
formed consent was obtained for publication.
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Background: The incidence of Turner syndrome has been reported as
1:2500 female livebirths. It’s diagnosis requires the presence of charac-
teristic features in phenotypic females with complete or partial absence
of the second sex chromosome, with or without cell line mosaicism.
Recognising these phenotypic characteristics will aid in early diagnosis
and improvement in management. We aimed to describe thephenotypic characteristics of Turner syndrome patients and assess the
correlation of genotype with phenotype and clinical outcome.
Methods: This is a cross sectional study over 1 year period whereby
all female patients with karyotype proven Turner syndrome who are
on paediatric endocrine clinic follow up in Universiti Kebangsaan
Malaysia Medical Centre from year 1995 till year 2016 were examined
for physical features of Turner syndrome. Other physiologic features
such as cardiac, ENT and ophthalmologic abnormalities were ob-
tained from medical records. Patients were classified based upon
karyotype into females with monosomy 45,X (Group A) and females
with other X chromosomal abnormalities ie X mosaicism, Y mosai-
cism, ring X, isochromosome Xq and Xp (Group B). Clinical features
of the two groups were analysed.
Results: Of the 34 patients included in the study, 16 (47.1%) were di-
agnosed with monosomy 45,X and the rest with other X chromo-
somal abnormalities. Short stature was universal in Group A versus
94.4% in group B. Short, webbed neck and edema of hands/feet
were significantly more common in Group A than Group B ( 43.8-
93.8% vs 16.7-38.9%). Cubitus valgus, short 4th and 5th metacarpals/
metatarsals and nail dysplasia were common in both groups
occurring in 83.3-94.4% of patients. All patients in Group A had no
spontaneous puberty compared with 71.4% in Group B. Cardiac and
ear abnormalities were more common in Group A than Group B
(50-56.3% vs 11-27.8%) . Hypertension, hypothyroidism, impaired
carbohydrate metabolism and learning disabilities were however
more common in Group B than Group A ( 11.1-33.3% vs 0-6.3%).
Conclusion: Phenotypic characteristics may be subtle in Turner pa-
tients with other X chromosomal abnormalities, suggesting the im-
portance of karyotyping as part of the work up for short stature in
girls. This study also suggests that chromosomal variations may affect
the phenotype and clinical outcome of Turner patients. This alludes
to the importance of good cell numbers in karyotyping and the use
of FISH study to enable detection of low level mosaicism which can
carry clinical significance to the patient’s presentation.
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Background: CNSGCTs account for over 10% of primary paediatric
brain tumours in Asian countries. CNSGCTs are characterized with dif-
ferent spectrums of endocrine problems as they are commonly located
near the hypothalamic-pituitary axis. In this study, we aim to review the
endocrine manifestations of the local paediatrics CNSGCT tumors at
presentation and after treatment.
Methods: We carried a retrospective review for paediatrics CNSGCT pa-
tients who were diagnosed at less or equal to 18 years and received
treatment protocols in Prince of Wales Hospital Children’s Cancer
Centre during the 18-year period January 1996-June 2014. Exclusion cri-
teria included congenital germ cell tumour and oncological treatment
or endocrinological surveillance provided in other hospitals.
Results: Total 28 patients were included in our study. 18 (64%) were
male and 10 (36%) were female. Mean age was 12.5 ± 3.8 years old.
The mean follow up period was 7.1 years. 19 patients (68%) had pure
germinoma and 9 patients (32%) had non-germinomatous germi-
noma. The most common location of CNSGCT was suprasella region
(46%) including 4 with bifocal tumours and 1 patient with multifocal
disease. All of the patients included had received any kinds of sur-
gery including biopsy or subsequent gross tumour resection. 82% pa-
tients had received chemotherapy, 93% had radiotherapy. Thirteen
patients (41%) presented with either endocrine manifestations alone
or together with neurological symptoms. Twelve of these patients
have their tumours located either along hypothalamic-pituitary axis
or at suprasella region. The endocrine manifestation and tumour lo-
cation correlated with statistical significance (p=0.045 ). Pathology
and size of germ cell tumour did not correlate with the types of
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pidus was most commonly presented (39%) before diagnosis of
CNSGCTs. 46% of the patients had pan-hypopituitarism defining as 3 or
more pituitary hormonal dysfunctions on follow up. The body height
SD showed statistical significant drop from mean SD -0.339 on presen-
tation to SD -1.13 at the final visit after completion of treatment (
p=0.004 ). Total 4 patients (14%) and 7 patients (25%) belonged to ei-
ther overweight or obese groups on diagnosis and at the last follow up
respectively. The change of BMI z-score from presentation to the final
follow up did not show statistical significance (p=0.059).
Conclusions: Endocrine manifestations and complications are com-
mon in paediatrics CNSGCT. By early involvement of paediatrics
endocrine subspecialty and a systematic endocrine care approach
after the diagnosis and treatment of CNSGCT can provide patients a
more holistic care.
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Background: Pediatric sellar and parasellar tumors include a diverse
group of tumors that form a separate entity, as far as incidence, histology
and responsiveness to therapy is concerned. These tumors are not un-
common, and mainly present with neuro-ophthalmic signs and symp-
toms. Endocrinologic dysfunction is a common abnormality seen in these
patients, even in the pre-operative period, the most common of which
are secondary/ central hypothyroidism and/ or hypocortisolism.
Objective: The study aims to determine the prevalence of central/
secondary hypothyroidism and hypocortisolism among pediatric pa-
tients diagnosed with a sellar-parasellar mass, and to describe their
clinical and radiologic characteristics and to determine the presence
of any association.
Study Design: This is a 5-year retrospective chart review.
Material and Methods: Fifty-six children and adolescents, 1.07-18.49
years old, median 11.34, treated in our centre in the years 2009-2014,
with a diagnosis of a “sellar-parasellar” mass, were included in the
study. In the analysis, clinical symptoms at the time of diagnosis, as well
as, data from medical histories, physical examination, auxological data,
biochemical, hormonal and radiologic parameters were analyzed.
Results: Among 56 patients, central/ secondary hypothyroidism was
noted in 55%, while hypocortisolism was seen in 39%. Hypocortiso-
lism in patients with sellar-parasellar mass was positively associated
with the male sex (OR 5.7) and with a tissue diagnosis of craniophar-
yngioma (OR 6.5). Hypothyroidism was also positively associated with
craniopharyngioma (OR 10.71). Further, the presence of hydroceph-
alus also had an association with the development of both
hypothyroidism ( OR 2.33 ) and hypocortisolism ( OR 4.2).
Conclusion/ Recommendations: Sellar-parasellar masses are associated
with significant co-existing endocrinopathies. Close attention to the his-
tory, physical examination, auxological, biochemical and radiologic pa-
rameters would facilitate early appropriate intervention and support.
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tumor that located in hypothalamic and pituitary region, both of
which are important in endocrine function. Tumor itself and their
treatment can lead to significant long-term pituitary dysfunction im-
paired quality of life due to their proximity to vital structures. We de-
scribe the experience of single institute on the endocrinological
issues of CP in children and adolescent for 20 years.
Methods: The medical records of pediatric patients who got a neuro-
surgical operation and diagnosed with CP in single institute between
1994 and 2014 were identified. 49 patients diagnosed with CP in that
period, and their medical records of endocrinological issues are ana-
lyzed retrospectively.
Results: Among 49 patients, the female-to-male ratio was 24:25, and
the mean age of patients was 8.9 years (range 5 months - 18 years).
Based on the results of cocktail test after operation, thyroid stimulating
hormone (TSH) deficiency, adrenocorticotropic hormone (ACTH) defi-
ciency, growth hormone deficiency and gonadotropin deficiency were
35 (71%), 35 (71%), 42 (85%), and 12 (24%) respectively. However, most
patients practically took adrenocorticosteroid (n=47, 95%), levothyrox-
ine (n=44, 89%), and desmopressin (n=47, 95%). 29 and 24 patients
were administrated growth hormone and sex hormone respectively.
The mean height, weight and BMI SDS were increased from -0.8, 0.1
and 1.1 at diagnosis to 0.6, 1.6 and 1.9 at 5 years after operation. 6 and
3 patients were dyslipidemia and type II diabetes mellitus.
Conclusion: Pediatric patient with CP has many endocrinological
problems at diagnosis and most of problems need to take medica-
tion for long time. And they are getting obese and at risk of meta-
bolic syndrome, dyslipidemia and type II diabetes mellitus. A better
understanding and frequent surveillance of the determinants of
obesity would provide preventive interventions for improving health
outcomes in adulthood.
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Introduction: Combined pituitary hormone deficiency (CPHD) is a con-
dition that causes a shortage of several hormones produced by the pi-
tuitary grand. Since some neonates with severe congenital CPHD show
severe hypoglycemia and respiratory failure, early recognition and
prompt treatment is required. In addition, some neonates with CPHD
develop cholestasis. Here, we present two brothers with CPHD.
A report of cases: The elder brother showed growth failure at 1 year
of age. Endocrine examination showed GH and TSH deficiency. The
brain MRI showed small anterior pituitary. He was diagnosed with
CPHD and GH and L-T4 supplementation was started. The younger
brother presented with respiratory distress and shock shortly after
birth.Mechanical ventilation and catecholamine therapy were re-
quired. As he showed micropenis and cryptorchidism and family his-
tory, the diagnosis of CPHD was suspected. At 1 day of age,
hydrocortisone replacement was initiated, and thereafter his circula-
tory dynamics improved. Endocrine studies confirmed that he had
ACTH, GH, TSH, PRL and gonadotropins deficiency. The brain MRI ex-
hibited hypoplasia of anterior pituitary and ectopic posterior pituit-
ary. The patient developed cholestasis and sludge in the common
bile duct and the gallbladder at 18 days of age. Recombinant human
GH therapy was started at 19 days of age. After GH supplementation,
cholestasis was gradually improved and sludge disappeared at 3
months of age. Now, he is 9 months old. His height is 69.4 cm
(-0.9SD) and body weight is 8470g (-0.4SD). His head control was ob-
tained at 4 months of age, but he could not sit on his own. His
motor development is slightly delayed.
Conclusion: We report siblings with congenital CPHD. This report in-
dicates that shock is rare, but one of clinical features of severe CPHD.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 109 of 144In addition, development of biliary sludge should be carefully
checked in severe CPHD. The etiology of CPHD in siblings is now
investigating.
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consent was obtained for publication.
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Background: Germ cell tumors accounts for about 20% of pediatric
brain tumors. Neurohypophysial germinomas are associated with a
high incidence of hormonal and metabolic abnormalities attribute to
the hypothalamus and pituitary dysfunction. Few detailed assess-
ment of endocrine functions in children with neurohypophysial ger-
minoma have been reported.
Objective: This study investigated the pre and post treatment endo-
crine status of 13 children with neurohypophysial germinomas.
Methods: According to a retrospective review of medical records, we
assessed the profile, clinical course and endocrinological function of
the patients. Thirteen children (7 males and 6 females, median age
was 11y) were diagnosed with a histological confirmation at Torano-
mon hospital during 2002 to 2012.
Results: All patients were diagnosed neurohypophysial germinoma,
with a histological confirmation, although HCG or AFP levels were
high only in two patients. The treatment regimens of the patients in-
cluded 13 chemo-radiation therapy, one underwent HSCT (autolo-
gous sources). Three patients have received radiation therapy more
than 30 Gy. One patient had local recurrence 18 months after initial
treatment. Polyuria was the most frequent initial symptom and all of
the 13 patients had impaired ADH secretion. More than one anterior
pituitary hormones were impaired at diagnosis in all patients. Im-
paired GH, TSH, ACTH and ADH secretion persisted after treatment.
There was some improvement in gonadotropin levels in 5 of 11
patients.
Conclusion: It is important to evaluate endocrine functions and care-
fully follow up growth and pubertal development in children with
neurohypophysial germinomas.
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Pituitary Cushing’s syndrome or Cushing’s disease in childhood and
adolescence is very rare. Hormonal assay and special tests should be
done for diagnosis. This report showed a 12-year old girl presenting
with Cushing appearance. She had a history of 16 kilograms weightgain within 6 months. Her mother noticed that she looked round
face, and increased dark skin around her neck. She had no history of
exogenous glucocorticoid used. On examination, BP was 140/100
mmHg. She had moon face, buffalo hump and acne. Her height and
weight were 154 cm (P50-75) and 51 kg (P90), respectively. Weight
for height was 116%. Laboratory tests showed loss of diurnal variation
of serum cortisol, high serum ACTH, can’t be suppressed by low dose
dexamethasone suppression test but can be suppressed by high dose
dexamethasone suppression test. Pituitary MRI showed an inhomogen-
eous enhancing sellar mass, 1x1 cm in size. It was compatible with pitu-
itary Cushing’ s disease. Tumor removal was done by transsphenoidal
surgery. Pathology showed pituitary tumor, corticotroph adenoma. Six
months after operation, tumor recurrence was found and hypophysec-
tomy was done again. Post-operative complications were found such
as diabetes insipidus, central hypothyroidism, adrenal insufficiency and
were treated by hormonal replacement. She has normal growth param-
eters and needs continuous long term follow-up.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Introduction: Septo-optic dysplasia (SOD), known as de Morsier syn-
drome, is a rare congenital malformation syndrome, which is charac-
terized by underdevelopment of the optic nerve, pituitary gland
dysfunction, and absence of the septum pellucidum (a midline part
of the brain). The clinical diagnosis of SOD is made when two or
more characteristics of the classic triad are present. The degree of pi-
tuitary deficiency and visual impairment can vary in the severity of
clinical presentation and phenotype. The brain effects are variable as
well. SOD has been associated with young maternal age, while muta-
tions in HESX1, OTX2, SOX2 and PAX6 have been implicated in cases
of SOD and congenital hypopituitarism. However, in most cases SOD
is a sporadic birth defect of unknown cause and does not recur with
subsequent pregnancies.
Case presentation: A 6 year old girl was referred to our Pediatric
Endocrinology Department for investigation of short stature, im-
paired growth velocity, polyuria and polydipsia as well as visual dis-
orders, such as nystagmus and decreased visual acuity. On physical
examination, her height was 104 cm (< 3rd percentile) and her
weight was 19 kg (50th percentile). She had no dysmorphic features.
She had bilateral nystagmus. The rest of the PE was normal and she
was prepubertal. Investigation of the pituitary function revealed
growth hormone deficiency and partial diabetes insipidus. MRI of the
brain and pituitary revealed an intact septum pellucidum with bilat-
eral optic nerve hypoplasia, hypoplasia of the sella turcica and thin-
ning of the pituitary gland, suggestive of SOD. Treatment with
recombinant human GH and desmopressin was initiated. During
follow-up, central hypothyroidism was recognized and L-thyroxine
substitution therapy was initiated. She was followed regularly, having
a very good response in therapy with growth acceleration and
normalization of height SDS. She entered puberty spontaneously.
Molecular genetic analysis is anticipated.
Conclusion: The presence of optic nerve hypoplasia should raise the
suspicion of hypopituitarism, in terms of SOD. Moreover, as the
degree of visual impairment and pituitary dysfunction are highly
variable, a high level of suspicion regarding the associated endocri-
nopathies and prompt investigation is very important.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Objective: The objective is to know the dynamic changes of AMH and
INHB of prepubertal ALL girls at the stage of initial chemotherapy and
to discuss the influence of CCCG-ALL-2015 on ovarian function.
Methods: We chooseed 21 girls who received chemotherapy in the
department of hematology in our hospital for the first onset
standard-risk acute lymphoblastic leukemia.They were prepubertal
girls.They all received the chemotherapy regimens. During the course
of chemotherapy, determined the levels of AMH and INHB at the
stages of pre-chemotherapy, after three months and six months of
chemotherapy by ELISA. Then we compared the dynamic changes of
AMH with the paired samples T test. We compared the dynamic
changes of INHB with the Wilcoxon Matched-Pairs Signed-Ranks Test.
Results: We tested the AMH and INHB level in all these samples. The
paired samples T test was adopted to evaluate the level of AMH. The re-
sults showed that the level of AMH after three months of chemotherapy
were statistically significant lower than prechemotherapy ip=0.023<0.05
). The level of AMH after six months of chemotherapy were statistically
significant lower than pre-chemotherapy ip=0.045<0.05 ). The AMH level
was no significant difference between after three months group and six
months group of chemotherapy (p=0.39>0.05). The level of INHB of 12
patients were beyond the detection limit before and after Chemothera-
py.we compared the changes of INHB level between pre-chemotherapy
and chemotherapy for 3 months; the changes of INHB level between
pre-therapy and chemotherapy for 6 months, The statistics show there is
no statistical difference between any two groups.
Conclusion: At the initial Stage of CCCG-ALL-2015, the AMH of the
girls show significant decrease and the ovarian function is disturbed.
For prepubertal ALL girls who receive chemotherapy, INHB may not
be suitable to choose as an indicator to evaluate the effect of the ini-
tial chemotherapy to ovarian function.
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Purpose: Rathke’s cleft cysts (RCCs) are nonneoplastic, sellar or supra-
sellar epithelium-lined cysts originated from Rathke's pouch in the pi-
tuitary gland. Patients with RCCs are usually asymptomatic, but some
were identified when turned symptomatic in the middle age. The
charecteristics of the patients during childhood or adolescence re-
mains unknown.
Methods: We describe an 18-year-old girl who sometimes suffered
from malicious fatigue in the morning since her early teens and brain
MRI exhibited T1 hyperintense/T2 hypointense signals between the
anterior and posterior pituitary glands indicating the presence of
RCC. Based on the authentic endocrinological evaluation, her adrenal
function was supposed to be normal, whereas serum cortisol level
was strangely dropped around noon suggesting the presence of
hypothalamic adrenal dysfunction. Next, we reviewed and summa-
rized the 8 cases reported from 2002 to 2014.
Results: There was no case with isolated adrenal dysfunction, and 4
of 8 cases (50%) were associated with hypogonadism, 2 of 8 (25%)
with growth hormone deficiency, 2 of 8 (25%) with central diabetes
insipidus, and 1 case (12.5%) with hypothyroidism.
Conclusions: The present girl and the previously reported cases sug-
gested that dysfunction of the hypothalamic pituitary system mightprogress slowly from their teens, resulting in the multisystem dys-
function of hypothalamus and pituitary gland in their later life. We
speculate that hypothalamic hypoadrenalism may be subsumed in
the adolescent girls with prolonged and indefinite complaints. Brain
MRI and endocrinological evaluation including daily blood cortisol
profiling would be the key to get to the diagnosis of impaired central
adrenal function by RCC.
Consent for publication: The authors declare that the written in-
formed consent was obtained for publication.
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Purpose: To evaluate the clinical features of Rathke cleft cysts (RCCs)
in children.
Methods: A retrospective analysis was conducted in 24 patients with
RCCs diagnosed by magnetic resonance(MR) between July 2010 and
August 2015. Their clinical, hormonal, and imaging findings were
reviewed.
Results: 24 patients got 1~6 years follow-up. 6 cases (25.0%) were di-
agnosed precocious puberty and half of them were central preco-
cious puberty. 3 cases (12.5%) were obesity. 7 patients (29.2%) had
idiopathic short stature, 8 (37.5%) had growth hormone deficiency
(GHD). In all GHD cases, 1 patient combined with central diabetes
insipdus, another onecombined with central hypothyroidism. Till Feb-
ruary 2016, all of the patients were re-examined pituitary MR. Rathke
cysts in 3 patients were disappeared. 2 patients got transsphenoidal
pituitary cyst excision and theirs Rathke cysts were not recurrenced
after 3-4 years follow-up.
Conclusion: Pituitary dysfunction is most common in pediatric RCCs
patients. Most of Rathke’s cleft cysts pediatric patients don't need
surgery therapy, some cases are self-healing.P2-3-13
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Background: Little is known about the potential programming effect
of maternal chrononutrition during pregnancy on offspring's cardio-
vascular outcomes. We examined the association between day-time
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 111 of 144and night-time fasting intervals during pregnancy with offspring
early childhood blood pressures.
Methods: Mother-offspring pairs (n=247) from a prospective cohort
in Singapore were studied. At 26-28 weeks’ gestation, maternal lon-
gest day-time (0700 to 1859h) and night-time (1900 to 0659h) fasting
intervals were determined from 3-day food diaries. Offspring systolic
blood pressure (SBP) and diastolic blood pressure (DBP) were mea-
sured at 3-year-old. Offspring SBP and DBP were categorised into
normal (<90th percentile) or risk of hypertension ( ≥ 90th percentile)
by sex and height. Multiple logistic regressions with confounders ad-
justment were used to examine the association between maternal
fasting intervals and offspring blood pressures.
Results: Means (standard deviations, SD) maternal fasting intervals
were 4.7 (1.1) hours during the day-time and 10.0 (1.3) hours during
the night-time. Means (SD) offspring SBP and DBP were 96.4 (8.5)
mmHg and 57.3 (5.0) mmHg respectively. Each hourly increase in ma-
ternal night-time fasting interval was associated with decreased
risk of hypertension in offspring (SBP: adjusted OR=0.57, 95% CI
0.33, p =0.043) and DBP (DBP: adjusted OR=0.45, 95% CI 0.26,
0.79, p =0.005). The association between day-time fasting interval
and offspring blood pressures was not significant.
Conclusion: Longer maternal night-fasting intervals during preg-
nancy are associated with lower offspring risk of hypertension at 3
years of age. Studies are needed to further evaluate the effects of
maternal fasting intervals during pregnancy and long-term cardiovas-
cular health in the offspring.Table 1 (abstract P2-3-13). The association of maternal pregnancy
fasting duration with offspring’s risk of hypertensionP2-3-14
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Background: Symptomatic hyperprolactinemia is a rare condition in
children, and may affect pubertal development by inhibiting
hypothalamic-pituitary-gonadal (HPG) axis. The main causes of hyper-
prolactinemia are pituitary tumors and drugs, such as dopamine
antagonists. Recently, dopamine antagonists have been widely used for
school-age children with psychotic disorders, arising concerns for in-
creasing the number of children with drug induced hyperprolactinemia.
However, few cases have been reported to develop hyperprolactinemia
during pubertal period, and the details of clinical courses of pubertal
development with hyperprolactinemia have not been documented.
Object: We report a case of drug induced hyperprolactinemia with
atypical development of puberty, and clarify the details of clinical
features of drug induced hyperprolactinamia during pubertal period.
Case: An eight-and-a-half-year-old girl was referred to our hospital
because of developing pubic hair without other obvious pubertal
signs. Although she had sparse curly hairs on the labia majora
(Tanner III), other pubertal signs, such as breast development and
growth spurt were not observed. Despite prepubertal levels of
gonadotropins and estradiol (LH: 0.2 mIU/ml,'sH: 2.7 mIU/ml, E2: 5
pg/ml), the serum level of DHEA-S, 385 ng/ml, suggested that the pa-
tient developed adrenarche. By repeated assay for PRL, we identified
hyperprolactinemia (PRL: 22.5~75.1 ng/ml) that would suppress LHand'sH secretion. She had been prescribed a selective antagonist at
dopamine receptors, sulpiride, for a psychosomatic problem for six
months, and we suspected that hyperprolactinemia was caused by
sulpiride, resulting in atypical pubertal development by suppressing
HPG axis. Indeed, one month after careful cessation of sulpiride, her
HPG axis was recovered to pubertal level, LH: 1.9 mIU/ml,'sH: 4.8
mIU/ml with reduced serum level of PRL, 1 ng/ml. Subsequently, she
developed other pubertal signs, including growth spurt (8 cm/year)
and breast development.
Discussion: Generally, development of pubic hair depends on adre-
narche, and is independent from other pubertal sings that are
caused by estradiol belonging to HPG axis, and atypical pubertal de-
velopment could be caused by isolated gonadotropin deficiency
such as Prader-Willi syndrome. In this case, we presume that atypical
pubertal development would be the characteristics of hyperprolacti-
nemia during pubertal period because prolactin excess does not in-
hibit the adrenal androgen.
Conclusion: One of the adverse effects of dopamine antagonist,
atypical pubertal progress, developing pubic hair without other obvi-
ous pubertal signs, should be considered.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Background: Suprasellar tumors account for 15%–20% of all pediatric
brain tumors, neurologic or ophthalmic symptoms prompting most
such diagnoses. However, endocrine-related symptoms such as
growth retardation, obesity, polydipsia, and polyuria and endocrino-
logical deficits such as growth hormone deficiency, central
hypothyroidism, central hypoadrenalism and central diabetes insipi-
dus frequently precede onset of neuro-ophthalmic symptoms. Most
patients with suprasellar tumors have permanent residual endocrino-
logical deficits after treatment of their tumors by surgical excision,
chemotherapy, or radiation therapy and therefore require endocrine
replacement therapy to maintain optimal health and normal growth.
Nevertheless, endocrine-related symptoms are not always easily iden-
tifiable and accurate evaluation of these patients’ endocrinological
status is difficult. Our objective was to clarify the relationship be-
tween presenting symptoms and results of accurate endocrinological
evaluation before treatment of suprasellar tumors.
Methods: This was a single center retrospective study of data ob-
tained from our hospital’s medical records on patients with suprasel-
lar tumors treated by our institution.
Results: Data of 12 patients who had undergone treatment of supra-
sellar tumors (craniopharyngioma, n=7; germ cell tumor, n=4; xantho-
granuloma, n=1) were assessed. The chief symptoms leading to
tumor diagnosis were neurologic-ophthalmic (n=7, 58%) and endo-
crinological (n=3, 25%). In addition to these three patients, another
seven (58%) had unrecognized endocrinological symptoms prior to
diagnosis; thus, endocrinological symptoms preceded diagnosis in
10/12 study patients (83%). The main unidentified endocrinological
symptoms were growth retardation and polydipsia. Six of seven
patients (86%) who had undergone accurate endocrinological
evaluation had endocrinological deficits before tumor treatment;
namely, growth hormone deficiency (n=6, 86%), central hypoadrenal-
ism (n=4, 33%), central diabetes insipidus (n=4, 33%), and central
hypothyroidism (n=2, 29%).
Discussion: Most patients with suprasellar tumors reportedly have
some endocrinological abnormalities long before diagnosis of their
tumors, only a minority of these patients being aware of endocrine-
related symptoms or having endocrinological deficits identified at diag-
nosis. Although a few studies included suprasellar tumors that we
excluded (i.e., hamartoma, optic pathway glioma, suprasellar archanoid
cyst, hypothalamic-pituitary astrocytoma) and are therefore not strictly
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 112 of 144comparable, endocrine-related symptoms and deficits were more fre-
quently present in our cohort than has previously been reported.
Conclusion: Patients with suprasellar tumors more often have endo-
crinological abnormalities at diagnosis than previously reported.P2-3-16
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Background: Neonatal central diabetes insipidus (CDI) is rare as
compared to nephrogenic diabetes insipidus (NDI) and it has been
associated with meningitis, central nervous system malformations, in-
traventricular haemorrhage and hypoxic ischaemic encephalopathy.
Case Report: A 25 week premature male neonate with a birth weight
of 804 grams had a stormy perinatal clinical course complicated by se-
vere respiratory distress syndrome and grade III bilateral intraventricular
hemorrhage. On day 69 of life, he developed polyuria with a serum so-
dium level of 157 mmol/L, serum osmolality of 352 mmol/kg and a de-
creased urine osmolality of 181 mmol/kg, which was diagnostic of
diabetes insipidus. Intravenous (IV) pitressin was commenced at 0.1
mU/kg/hr and titrated upwards so as to achieve clinical and biochem-
ical effect (Table 1). He showed a gradual response over the next 72
hours with a decrease in serum sodium to 133 mmol/L and serum
osmolality to 269 mmol/kg and an increase in urine osmolality to 291
mmol/kg. Subsequently, his serum sodium remained stable within the
range of 140-148 mmol/kg while on a dose of IV pitressin of 1.4 mU/
kg/hr, He was then converted to oral desmopressin, the dose of which
was titrated to 3 micrograms/kg/dose 12 hourly with good effect.
Discussion: In neonates, NDI is more common than CDI. Hence it
was important to differentiate the two, especially in our patient who
was a premature baby neonate. To our knowledge, this is the first re-
port of IV vasopressin in the diagnosis of CDI. Other studies have
used intranasal desmopressin which has been associated with large
swings in serum sodium. The advantage with the initial use of an IV
vasopressin infusion lies in the titration of the dose in a controlled
and safe manner to establish response, and allows a clear differenti-
ation of CDI from NDI. The use of vasopressin in neonates is technic-
ally challenging with regard to both the 4,000 fold dilution and
administration. However when done accurately, using IV vasopressin
can allow for very close and safe titration of dose to response.
Consent for publication: The authors declare that written informed
consent was obtained for publication.Table 1 (abstract P2-3-16). See text for descriptionP2-3-17
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Background: Cholestasis in the neonatal and early infancy period is
rare, but one of presenting features in patients with combined pituit-
ary hormone deficiency (CPHD). Here, we report two cases where
both the patients presented with prolonged cholestasis as a charac-
teristic manifestation of CPHD.
Case 1: A 4-month-old boy who was born by cesarean section with
birth weight of 1638 g (at 36 weeks’ gestation) with asphyxia pre-
sented failure to thrive. At 10 d of age, he discharged clay-colored
stools. At 40 d of age, he was diagnosed with hypothyroidism (TSH
6.68 μ U/ mL, fT4 0.75 ng/dL) and started to take L-thyroxine. At 46 d
of age, he showed liver dysfunction with cholestasis, accompanied
by apparent hypoglycemia. Brain magnetic resonance imaging (MRI)
at 4 months of age revealed hypoplastic anterior pituitary, attenu-
ated pituitary stalk, and ectopic posterior lobe. GHRP-2 stimulation
test showed extremely low GH, ACTH, and cortisol (F) responses
(each peak level: 5.09 ng/mL, 7.9 pg/mL, 0.3 μg/dL, respectively). He
was diagnosed with CPHD, and therefore GH and hydrocortisone re-
placement therapy was immediately initiated. The hormone replace-
ment therapy (HRT) for 4 months normalized his liver function.
Case 2: A 3-month-old boy who was born at term by breech delivery
with asphyxia, hypoglycemia, and microphallus presented persistent
jaundice. At 26 d of age he was diagnosed with hypothyroidism (TSH
8.5 μ U/mL, fT4 0.5 ng/dL), and L-thyroxine replacement therapy was
started. From 70 d of age, his liver function was deteriorating with
an increased conjugated bilirubin concentration, and abdominal
ultrasonography revealed some gallstones. Brain MRI indicated atten-
uated pituitary stalk and ectopic posterior lobe. GHRP-2 and LHRH
stimulation tests demonstrated low responses of GH, F, LH, and'sH
(each peak level: 10.06 ng/mL, 3.2 μg/dL, 0.87 mIU/mL, 0.57 mIU/mL,
respectively). GH and hydrocortisone replacement was introduced
subsequently. By the two months after starting the HRT, his liver
function had been recovered.
Discussion: In both cases, the antecedent administration of L-
thyroxine prior to that of GH and hydrocortisone could delay the pa-
tients’ recovery from cholestatic liver dysfunction, and could also
lead to the extended time of failure to thrive. That is why early insti-
tution of proper HRT is necessary for CPHD patients.
Conclusion: Brain MRI and examination of multiple pituitary hor-
mones should be properly conducted for infants who present such
features of CPHD as prolonged cholestatic jaundice, apparent
hypoglycemia, and microphallus in the males.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Objective: FUnderstand the research progress of dopa-responsive
dystonia by reporting two cases of this rare disease.
Methods: FAnalysed the clinical manifestations Aclinical laboratory
examination and gene sequencing of two cases of dopa-responsive
dystonia patient and reviewed the related literatures.
Results: FClinical and Laboratory diagnosis two cases of dopa-
responsive dystonia.
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characteristics include FAchildhood-onset dystonia with marked diur-
nal fluctuation and female predominance, for the not enough sup-
plement of BH4 during the day Aa dramatic and sustained response
to relatively low doses of levodopa, but Little effectiveness of treat-
ment of BH4A mutations of GCH-I gene and TH gene A increased
prolactin by regulation of dopamine D2 receptor clinical diagnosis of
DRD remains difficult. The children who suspected the disease
should be taken genetic test once diagnosed C the Comprehensive
Treatment C low doses of levodopa therapy Cs hould be taken to im-
prove the quality of life as soon as possible.P2-4-1
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Objective: To identify determinants of height for age z-score (HAZ)
and stunting at 2 years of age
Methodology: This cohort study was conducted at AIIMS, New Delhi.
Healthy term neonates were enrolled and followed till 2 years. Weight
and length were measured at birth, 1 and 2 years using electronic
weighing scale and infantometer. Caloric intake was assessed by 24 hrs
recall at 1 and 2 yrs. Fasting blood samples for vitamin D (25OHD) and
insulin were drawn for a subset. HAZ at 2 years was calculated by WHO
Anthro, and its correlation checked with weight and length at birth and
1 yr, parents’ height and BMI, socio-economic status (SES), gestational
diabetes (GDM), caloric intake, 25OHD and insulin at 1 and 2 years.
Results: We studied 186 children (110 boys). Median (IQR) of HAZ at
2 years was -0.87 (-1.49 to -0.07) with 17 (9.1%) children being
stunted (HAZ<-2). Median 25OHD at 1 yr (n=93) was 4.0 (3.0-9.1)
ng/ml, and at 2 yrs (n=78), 10.8 (6.5-17.5) ng/ml. Median (IQR) of Insulin
at 1 yr (n=117) μU/ml was 3.1 (1.3-6.2) and at 2 yrs (n=101), 3.1 (1.8-4.6)
μU/ml. Thirty-four (18.3%) were born to mothers with GDM. The mean
± SD of various parameters and their correlation with HAZ at 2 years
are presented in Table 1. The correlation was strongest for weight and
length at 1 yr. The odds ratios of stunting in the presence of various
categorical variables are summarized in Table 1. Fathers’ height < 160
cm, and length at 1 yr < 71.5 cm had the highest odds for stunting at 2
yrs. Maternal BMI, GDM, SES, 25OHD and Insulin levels at 1 and 2 yrs
were not correlated with HAZ at 2 years.
Conclusion: Height at 2 years was correlated with size at birth and 1
yr and caloric intakes at 1 and 2 years. Higher odds for stunting were
seen if parents were short, length at birth or 1 yr was short, and
weight and caloric intake at 1 yr were low. Serum 25OHD and Insulin
levels were not correlated with HAZ.Table 1 (abstract P2-4-1). Summary of various parameters, their
correlation with height z-score (HAZ) at 2 years, and association with
stunting (HAZ<-2)P2-4-2
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Purpose: Noonan syndrome (NS) is characterized by short stature,
heart anomalies, developmental delay, dysmorphic features, crypt-
orchidism, and coagulation defects. Several studies reported the
short-term effects of recombinant human growth hormone (rhGH)
treatment on the improvement of height. This study was performed
to evaluate the long-term efficacy of rhGH in patients with NS in
Korea.
Methods: This study included 15 prepubertal children with NS who
received rhGH subcutaneously at a dose of 50–75 μ g/kg/day for 6
days a week for at least >3 years. Pre- and post-treatment data, such
as height, weight, bone age, IGF-1, and IGFBP-3 levels, were collected
every 6 months.
Results: Chronologic age and bone age at the start of treatment
were 7.97 ± 1.81 and 5.09 ± 2.12 years, respectively. Height standard
deviation score (SDS) was increased from -2.64 ± 0.64 to -1.54 ± 1.24
years after 3 years (P < 0.001). Serum IGF-1 SDS levels were elevated
from -1.28 ± 1.03 to -0.10 ± 0.94 (P < 0.001). Height SDS was more in-
creased in subjects without PTPN11 mutations compared to those
with mutations after 3 years (P = 0.012). However, the other parame-
ters, including bone age, IGF-1 SDS, and IGFBP-3 SDS, were not
significantly different between patients with and without PTPN11
mutations.
Conclusions: Although this study included a relatively small number
of patients, long-term rhGH therapy in NS patients was safe and ef-
fective at improving height, growth velocity, and serum IGF-1 levels,
in accordance with previous studies. However, the meticulous moni-
toring of potential adverse events is still needed because of high
dose of hGH and preexisting hyperactivity of RAS-MAPK pathway.
Patients with PTPN11 mutations demonstrated a decreased response
to rhGH therapy compared to those without mutations.
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Objective: A study has reported increased body mass index (BMI) of
preschool children after the great east Japan earthquake (BMJ Open
2016:e010978). The results were limited to preschool children, and evi-
dence of infant growth after the earthquake is necessary. The present
study aimed to determine how the earthquake changed the growth of
infants who were residing on the Pacific Ocean side of northeast Japan.
Methods: We collected health examination data of infants at 3, 6, 18
and 42 months of age in Fukushima, Miyagi and Iwate prefectures in
Japan. For primary comparison, we defined three infant groups.
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earthquake between 3- and 6-month examinations. (2) ‘Toddler
group’ included the infants who had experienced the earthquake at
the age of 21–30 months. (3) ‘Unaffected group’ included the infants
who had undergone the 42-month examination before the earth-
quake and therefore whose anthropometric data were not affected.
In the strata of the prefectures and sexes, we graphically plotted the
changes in BMI from 3 through 42 months of age, adjusting for ges-
tational age, infant age in month and time points of health examina-
tions in general linear model. Thereafter, we compared the changes
in BMI between each affected vs. referent-unaffected groups.
Results: The analyses included 8,479 boys and 8,218 girls. In the
milk-fed group at the age of 6 months, the girls in Fukushima, the
boys (p<0.001) and girls in Miyagi and the boys and girls in Iwate
represented slight to statistically significant decreases in change in
BMI, compared to those in the unaffected group. In the milk-fed
group in Fukushima, there were also statistically significant increases
in the boys at 18 (p<0.01) and 42 months (p<0.001) and the girls at
42 months (p<0.01).
Conclusions: The data indicate that immediately aftermath of the
earthquake, the growth of the affected suckling infants were slightly
disturbed. The affected suckling infants in Fukushima also represent
increased BMI at the age of 42 months and may have potential to
show early adiposity rebound. The results highlight the need of med-
ical follow-up to the infants in Fukushima.Fig. 1 (abstract P2-4-3). See text for descriptionP2-4-4
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Background: Children born small for gestational age (SGA) are at
high risk of developing metabolic syndrome in adulthood. Growth
hormone (GH) treatment for children born SGA has been reported to
have favorable effects on lipid metabolism through the activating of
signal transduction on metabolism, and probably, on immunity.
Objective: We aimed to elucidate the metabolic and immunological char-
acteristics for SGA children and to assess their alteration by GH treatment.
Subjects: Twenty-six prepubertal short children (mean age 4.4 yr)
born SGA were included for the study, and 26 healthy children
(mean age 4.7 yr) had participated as controls.
Methods: All of 26 SGA patients were treated with GH. Anthropom-
etry and measurement of hematologic, biochemical, immunological
and endocrinological parameters were performed before and 1, 3, 6,
9 and 12 months after the start of GH treatment. At baseline, we
compared these parameters between the SGA and control groups.We also examined the change of these parameters at each point of
time from the baseline levels.
Results: After 12-month GH treatment, mean height SDS of SGA chil-
dren changed from -3.29 SD to -2.73 SD. HbA1c level did not change
significantly during the GH treatment. Total cholesterol, LDL-C and
HDL-C levels were similar in both groups, and these parameters did
not show significant changes during the GH treatment. SGA children
had higher baseline levels of ApoA1 than controls, and the levels in-
creased by 12-month GH treatment. The ApoB level and ApoB/
ApoA1 ratio decreased by 12-month GH treatment. Among immuno-
logical parameters, monocyte counts were lower in patients than
controls at base line, and increased by GH treatment. Neutrophil
counts tended to be lower in patients than controls, and significantly
rose after GH treatment. Flow cytometric analyses showed the NK
cell ratio in peripheral leukocytes was higher in SGA patients, and de-
creased after GH treatment. Leptin and resistin levels were lower in
patients than controls, which showed no significant change during
GH treatment.
Discussion: Our study demonstrated the GH treatment changed apo-
protein profiles toward improvement of lipid metabolism and pre-
vention of cardiovascular disease for SGA children. The unique
immunological profiles of lower neutrophils and monocytes and
higher NK cell ratio in peripheral blood might affect the predispos-
ition to metabolic syndrome for SGA children. GH treatment could
significantly modify the immunological profiles.
Conclusion: GH treatment for SGA children potentially has favorable
effects not only on the growth, but also on the lipid metabolism and
immune system.
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Objective: It is as yet unclear whether the WHO 2006 Child Growth
Standards (WS) are applicable to East Asian populations in general.
We studied the applicability of WS as standard may be appropriate
in Japanese children.
Methods: We used the 2007-2013 Tokyo public child care center sur-
vey data (Tokyo 2007-2013 survey cohort: 3430 boys, 3025 girls, 0-60
months of age, semi-longitudinal data). For each child, z-scores for
length/height and weight were calculated by comparison with both
WS and the Japanese 2000 reference (JR). We adopted Cohen’s
criteria (differences of 0.20 SD units, small; 0.50 SD, medium; 0.80 SD,
large), in the assessment of differences in length/height and weight.
The prevalence of children below and above certain thresholds for
length/height and weight were obtained according to WS and JR in
Japanese children (Tokyo 2007-2013 survey cohort): short stature,
length/height < 3rd centile; tall stature, length/height > 97th centile;
underweight, weight < 3rd centile; overweight, weight > 97th centile.
Results: Japanese children had significantly low mean z-scores for
length/height: the mean z-score was close to -1.0 (medium-large
difference for the most part) while mean z-scores for weight ranged
from -0.01 to -0.62 compared with WS (small difference for the most
part). (Table) Percentages of children classified as short stature, tall
stature, underweight and overweight were as follows.
Short stature: 6.8-13.7% (WS), 0.3-8.0% (JR), in boys; 3.7-10.8% (WS),
0.6-7.2% (JR), in girls.
Tall stature: 0.0-1.6% (WS), 0.0-3.1% (JR), in boys; 0.0-1.8% (WS), 0.1-
4.4% (JR), in girls.
Underweight: 2.4-6.8% (WS), 1.5-5.7% (JR), in boys; 0.8-6.9% (WS), 1.4-
5.3% (JR), in girls.
Overweight: 0.0-1.0% (WS), 1.5-4.6% (JR), in boys; 0.0-1.6% (WS), 1.8-
5.8% (JR), in girls.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 115 of 144Discussion: Compared with WS, our subjects were shorter and lighter,
and substantially altered the prevalence of short stature, tall stature,
underweight and overweight, overestimating short stature and under-
estimating overweight. These findings advocate that the WS is not ap-
propriate for clinical use in Japanese children age 0-60 months.Table 1 (abstract P2-4-5). Mean z-scores for lenght/height and weight
from birth to 60 months according to WS or JR in Tokyo 2007-2013
survey cohortP2-4-6
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Introduction: Activating mutations in the phosphatidylinositol 3-
kinase (PI3K) gene PI3KCA cause the macrocephaly–capillary malfor-
mation (MCAP) overgrowth syndrome. We detected a novel germline
frameshift mutation in the PI3KCA gene in a patient with MCAP pre-
viously reported in JSPE2013 . We investigated the phenotype–geno-
type relationship and the pathophysiology of the PI3KCA activating
mutation in this patient.
Patient and Methods: A male infant was born at 30 weeks gestation
weighing 2998 g (+6.63 S.D), with a body length of 47.0 cm (+4.01 S.D)
and head circumference of 36.5 cm (+6.23 S.D ). Physical examination re-
vealed a peculiar face with hypertelorism, anteverted nares, thick lips, and
frontal bossing and capillary malformation with a broad, prominent fore-
head. He also presented with hydrocephalus requiring a VP shunt. He was
diagnosed with MCAP based on his clinical characteristics. At 10 months
of age, the patient presented with convulsions with hypoglycemia (27
mg/dl ) and low growth hormone reaction (3.37 ng/ml). He was treated
with growth and thyroid hormone replacements and assisted ventilation.
An oral glucose tolerance test at 3 years old showed a massive increase in
glucose to 280 mg/dl with an insufficient insulin reaction, falling to 24 mg/
dl after the test. He showed severe growth retardation, and his insulin-like
growth factor-1 (IGF-1) levels were extremely low or undetectable after
growth hormone replacement. The patient died suddenly of unknown
causes at 7 years 9 months old. Sequence analysis revealed that the pa-
tient had a previously unreported de novo heterozygous
c.1658_1659delGTinsC mutation in exon 10 of the PIK3CA gene, which
could have caused a p.Ser552ThrfsX6 frameshift mutation.
Discussion: MCAP has recently been included in the PIK3CA-related
overgrowth spectrum related to PI3K hyperactivation. PI3K is distrib-
uted in multiple organs and its activity is related to growth, metabol-
ism, and inflammation. The current patient showed characteristic in
utero overgrowth and postnatal growth retardation, as well asabnormal blood glucose fluctuation and undetectable IGF-1 produc-
tion. To the best of our knowledge, this patient represents the first
reported case of a p.Ser552ThrfsX6 frameshift mutation in the PI3KCA
gene, with an undetermined effect on PI3K activity. This is also the
first report of an MCAP patient with PI3K hyperactivity, undetectable
IGF-1, and insufficient insulin reaction after growth hormone replace-
ment. Further studies are needed to clarify the effects of PI3KCA
mutations on glucose and IGF-1 metabolism.
P2-4-7
Ocular changes during growth hormone therapy in children with
isolated growth hormone deficiency
Ersoy Betül1, Alp Şenay2, Kizilay Özalp Deniz3, Taneli Fatma4, Başer Esin5
1Division of Pediatric Endocrinology and Metabolism, Celal Bayar
University, Faculty of Medicine; 2Department of Ophtalmology, Celal
Bayar University, Faculty of Medicine; 3Division of Pediatric
Endocrinology, Celal Bayar University, Faculty of Medicine; 4Department
of Clinical Biochemistry, Celal Bayar University, Faculty of Medicine;
5Department of Ophtalmology, Celal Bayar University, Faculty of
Medicine
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-4-7
Introduction: Growth Hormone (GH) and Insulin like Growth Factor-1
(IGF-1) are known to be involved in ocular development. However know-
ledge about ocular effects of GH treatment is very insufficient. The aims
of this study were to evaluate ocular changes in children with isolated
Growth Hormone Deficiency (IGHD) after 6 months of GH therapy and to
determine the relationship between ocular and growth parameters.
Patients and Methods: Sixty two pubertal children with isolated
GHD (32 male, 30 female) were included this study. Mean age of the
patients was 11.8 ± 2.1 years. Ocular parameters comprised of deter-
mination of best corrected visual activity (BCVA) and spherical
equivalent (SE) of refraction, mesaurements of intraocular pressure
(IOP), central corneal thickness (CCT), Goldmann correlated IOP
(IOPG), corneal hysteresis (CH), corneal resistance factor (CRF), kerato-
metry, axial length (AL), lens thickness (LT), and retinal nerve fiber
layer (RNFL) thickness. These ocular examinations were performed at
baseline and repeated at 6 months. IGF-1 levels were also evaluated
before and at 6 months of GH therapy.
Results: Significant differences in AL and spherical equivalent were found
between baseline and after 6 months of GH therapy (p<0.001). AL in
GHD children increased significantly compared to baseline after 6 months
of GH treatment (22.81 ± 0.09 and 22.83 ± 0.09 mm, respectively), with a
corresponding decrease of SE value (1.0 ± 1.0 and 0.89 ± 1.0 diopters, re-
spectively, (p<0.001). There were no correlations between IGF levels and
SE values (p>0.05). Positive correlations were found between AL and IGF-
1 levels (r=0.427, p=0.022). All other ocular parameters were found to be
stable during the study period (p>0.05 for all).
Conclusion: GH treatment in children with isolated GHD seems to
affect growth of the eye ball as displayed by an increase in mean AL
and a decrease in mean SE, which were related with increased IGF-1
levels. More precise conclusions about the effects of GH on eye tis-
sues can be deduced after further follow up our patients.
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 116 of 144Background: The ECOS observational study in Spain (NCT01376921)
was designed to evaluate adherence to r-hGH therapy prescribed via
the easypod™ electromechanical auto-injector device and to analyse
factors that may influence adherence in paediatric patients. Easy-
pod™ administers pre-set doses of Saizen® r-hGH and stores accurate
records of each dose and injection taken, which can then be shared
with the HCP for evaluation of the patient’s adherence.
Objectives: To assess the use and acceptability of easypod™ and ad-
herence to r-hGH therapy, to assess individual patients’ dosing pat-
terns and growth outcomes, and to assess the socioeconomic
background of the parents and care givers of these patients.
Methodology: Adherence was determined categorically and also as
%adherence over time, defined as the number of days with injections
received, divided by the number of days with injections planned. Ac-
curate individual adherence data were transcribed directly from the pa-
tients’ easypod™, while socioeconomic, demographic, auxological and
diagnostic data were obtained from medical notes.
Results: The Spanish cohort consisted of 280 children, of whom 240
were included in the final analysis set (52% male). The majority were
Caucasian (93.8%), with a diagnosis of growth hormone deficiency
(GHD, 60.0%), small for gestational age (SGA, 35.8%), Turner Syn-
drome (TS, 3.3%) or chronic renal failure (CRF, 0.83%). Despite high
overall adherence (median 98.8%, mean 94.5% [95% CI 92.8, 96.3]),
growth responses varied. Patterns of missed doses proved highly in-
dividual and, in some cases, fluctuated over time, possibly reflecting
changes in caregiver or other life circumstances. The different pat-
terns of adherence may be reflected in the growth outcomes for in-
dividual cases, although different causes of GHD (idiopathic; organic,
history of chemotherapy and/or radiation), with varying histories of r-
hGH use and at differing stages of development and puberty can
complicate interpretation of growth outcomes. Adherence often falls
on entry into adolescence but use of easypod™ enabled physicians
to rapidly identify patients with inadequate adherence and to help
them to achieve the benefits of r-hGH treatment. At baseline, 79.6%
of parents were married or cohabiting, 4.6% divorced, 0.8% single,
2.1% widowed, while 12.2% were unknown or missing. Almost 80%
of injection-giving carers were employed, while 31.5% had degree
level education, 35.0% had only had school level education, 9.5%
had ‘other’ education and 22% had not had this recorded.
Conclusions: The majority of children adhere extremely well to their
treatment regimen using the easypod™ device. Individual cases show
distinctive patterns of adherence and growth outcomes.
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Influences of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on
1 year follow-up outcome of growth hormone treatment in Korean
children with growth hormone deficiency
Joon Woo Baek, Yeon Joung Oh, Min Jae Kang, Young Suk Shim,
Il Tae Hwang, Seung Yang
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Background: The GHR-exon3 and the -202 A/C IGFBP3 polymor-
phisms have been suggested to affect responses to recombinant
human growth hormone (rhGH) therapy in some individuals with
short stature. This study aimed to assess the influences of the two
polymorphisms on treatment outcomes in patients with growth hor-
mone deficiency (GHD).
Methods: In 72 (32 girls and 40 boys) children with confirmed diag-
nosis of GHD, genotyping and serial measurements of auxological
and endocrinological parameters were performed. Forty-nine patients
who remained in the prepubertal state after 1 year of GH treatment
were analyzed.
Results: Distribution of the GHR-exon3 genotypes was as follows: d3/
d3 genotype 2.8%; d3/fl genotype 15.3%; and fl/fl genotype 81.9%.
Frequencies of the -202 A/C IGFBP3 genotypes were as follow: A/A
genotype 55.5%; A/C genotype 38.9%; and C/C genotype 5.6%. In
comparing the d3/d3 and d3/fl group with the fl/fl group, there was
no significant difference in first-year height velocity (9.4 ± 2.2 cm vs.
8.1 ± 1.7 cm, P = 0.08). Likewise, comparing the A/A group with the
A/C and C/C group, no significant difference was observed in heightvelocity (8.3 ± 2.0 cm, 8.3 ± 1.7 cm, P = 0.97). Combined analysis of
the two polymorphisms showed no significant interaction on the first
year height velocity.
Conclusions: Our results suggest that the two polymorphisms are
not major factors in the modulation of interindividual growth re-
sponse to GH therapy in Korean children with GHD.
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Secondary pseudohypoaldosteronism (PHA) in infancy is a transient
condition that is characterized by lack of response to aldosterone in
the distal tubule and associated with various uropathy; obstructive
uropathy, vesicoureteral reflux, urinary tract infection. PHA causes
hyponatremia, hyperkalemia, and metabolic asidosis. Osmotic de-
myelination syndorome (ODS), which includes both central pontine
myelinolysis (CPM) and extrapontine myelinolysis (EPM), is serious
neurological complication resulting from rapid correction of serum
sodium and associated changes in serum osmolality. Recently we ex-
perienced a rare case with secondary PHA presenting with ODS.
A six-month-old Japanese boy was referred to our hospital because
of failure to thrive and hyponatremia. He was delivered at 41wk ges-
tation with birth weight 3594 g. He was healthy until the age of
three months, when his body weight was 6435 g. However, when he
was six-month- old, he began to vomit once a day, was admitted to
our hospital because of failure to thrive and hyponatremia. On ad-
mission, he had severely dehydration, and his body weight was 5852
g. Laboratory examination indicated severe hyponatremia (109 mEq/
L) and hyperkalemia (6.3 mEq/L) and metabolic asidosis. His urinalysis
revealed pyuria, and the renal sonography showed grade 2 uretero-
hydronephrosis of left kidney. As plasma aldosterone and renin activ-
ity were markedly elevated, 22,800 pg/mL and 61 ng/ml/hr, he was
diagnosed as secondary PHA. His serum sodium was normalized after
five days of intravenous sodium replacement and antibiotics, but
generalised edema with pleural and peritoneal effusions developed.
Through diuretics administration improved his edema, he was pre-
sented with hypernatremia (153 mEq/L) on hospital day 10. Two days
later, his serum sodium was normalized (143 mEq/L), but he devel-
oped generalized seizures. Diffusion– weighted (DW) magnetic reson-
ance imaging (MRI) showed high signal intensity changes in the
central pons and bilateral thalami, and he was diagnosed having
CPM and EPM. With steroid pulse therapy and fosphenytoin, his
neurological status improved gradually. Thereafter his serum electro-
cyte levels remained normal and serum aldosterone level was de-
creased. Six months later, both weight gain and developement were
normal, MRI showed disappearance of CPM/EPM signs. It is important
to consider secondary PHA associated with uropathy in infants with
hyponatremia and hyperkalemia. In our case, ODS occurred despite
of standardized correction of hyponatremia. Hence chronic hypona-
tremia might be corrected as slow as possible to prevent ODS.
Consent for publication: The authors declare that written informed
consent was obtained for publication
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Diagnostic value of growth hormone stimulation test in short
children
Jeesuk Yu, Seung Yeon Jung
Department of Pediatrics, Dankook University Hospital
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-4-11
Background: It is important to find the cause of short stature in chil-
dren. Growth hormone (GH) stimulation test is considered as a ‘gold
standard’ for the diagnosis of GH deficiency. Several pharmacologic
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 117 of 144agents including insulin, glucagon, L-dopa, or clonidine are used for
GH stimulation test. This study was designed to compare the diag-
nostic value of GH stimulation test.
Method: Subjects who visited the pediatric endocrine clinic from Sep-
tember 2001 to February 2016 for the evaluation of short stature and
underwent GH stimulation test were included in the study. Two or 3
pharmacologic agents were used for GH stimulation test. Growth hor-
mone deficiency was defined when serum peak GH concentration was
less than 10 ng/mL in at least two provocation tests. Clinical data were
collected retrospectively based on medical records. We compared each
test by calculating their sensitivity, specificity, positive predictive value,
and negative predictive values, and by ROC curves.
Result: A total of 67 short children were included. Forty five (67.2%)
were diagnosed with GH deficiency. Average age was 9.05 ± 3.36
years, and 55 subjects were in pre-puberty. Mean height z score was
-2.40. Insulin, glucagon, L-dopa, and clonidine test were done in 67,
56, 56, and 10 subjects, and sensitivity for GH deficiency was 95.6%,
61.8%, 71%, and 90%, respectively. Specificity was 50% in insulin,
86.4% in glucagon, and 94.5% in L-dopa test. Positive predictive
value for GH deficiency was highest in clonidine test (100%) followed
by L-dopa test (96.4%). Negative predictive value was highest in insu-
lin test (84.6%). In ROC curve, areas under the curve of insulin, gluca-
gon, L-dopa tests were 0.742, 0.832, 0.839, respectively. There was no
serious adverse event during GHST, except for mild hypoglycemic
symptoms or transient vomiting.
Conclusion: Any GH stimulation test was relatively safe to perform in
short children. Many patients showed different results on different
growth hormone stimulation test, therefore it is reasonable to test by
using 2 or more agents for the diagnosis. Insulin test showed the
highest sensitivity, whereas L-dopa test showed the highest specifi-
city. L-dopa test was the most useful test in diagnosing GH defi-
ciency based on ROC curve.
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Recuperation of height by the age of 3 for small-for-gestational
age (SGA) infants who received care at Neonatal Intensibe Care
Unit (NICU)
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Background: By age 2, approximately 90% of small-for-gestational
age (SGA) infants catch up to a normal height range. However, it is
known that only approximately 70% of SGA infants with less than 32
weeks gestation are able to catch up to a normal height range,
which is relatively lower than that for full term infants.
Purpose: This study was conducted to delineate the recuperation of
height in 3-year-old SGA infants who had been hospitalized and
cared for at the Neonatal Intensive Care Unit (NICU).
Subject and Method: A total of 299 infants were admitted to NICU
from January to December 2012. There were 37 cases of SGAs.
Among which 22 infants with height and weight that meet the cri-
teria of eligibility for GH treatment, excluding chromosomal abnor-
malities, etc., were enrolled in this study.
Result: Of the 22 cases, 11 (50%) did not catch up to normal height by
age 2. Of these 11 cases, 4 (18%) caught up to normal height between
ages 2 and 3, all of which were extremely low birth weight infants under
1500g at birth. Of the 7 cases (32%) eligible for GH treatment after being
diagnosed as having short stature as a result of SGA, 5 cases had begun
GH treatment between the ages of 3 and 4. Five cases out of 8 infants
born with less than 32 weeks gestation were short statured as a result of
SGA by age 2, and 3 cases had a height SD score under -2.5 at age 3.
Discussion: Many SGA infants in our hospital were extremely low
birth weight infants that could not catch up to normal height, and
approximately half of them were diagnosed as having short stature
as a result of SGA at age 2. However, there were cases of infantsunder 1500g at birth catching up to normal height between ages 2
and 3, indicating a need for careful observation of changes in height
and weight of the infant. Many SGA infants under care at our hos-
pital begin GH treatment at age 3, suggesting a high recognition of
SGA treatments among guardians and medical professionals.P2-4-13
Growth Hormone Therapy in Turner Syndrome
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Turner syndrome (TS) is associated with short stature and primary
ovarian failure. Owing to association with hypogonadism, patients
with Turner Syndrome fail to experience a pubertal growth spurt but
continue to grow at a slow rate for several more years. The final
height deficit is approximately 20 cm. Growth hormone deficiency is
not implicated in Turner short stature. However Recombinant human
Growth Hormone (rhGH) has been shown to improve the height po-
tential of girls with TS. Final height in treated girls depends upon
height at start of the treatment, GH dose, duration of treatment and
age of induction of puberty.
A retrospective study was carried out at Sir Ganga Ram Hospital,
New Delhi, a tertiary care hospital in northern India. 27 girls were di-
agnosed to have Turner Syndrome from January 2008 to December
2015. History alongwith complete clinical details including screening
results for other associated abnormalities and laboratory findings
were noted. All patients were given daily injections of recombinant
growth hormone 0.05mg/kg/day and response was measured in
terms of height gain per year. Treatment was continued till height
velocity (HV) dropped to 2cm/year. Final heights and near final
heights (for patients with ongoing treatment) were recorded and
height gain was compared in relation to the duration of therapy.
Fifteen patients who had received rhGH for a duration of more than
12 months were included in the study. Mean age of starting GHT
was 11years with minimum age of 8y and maximum being 14.91yr.
Mean height gain was 21.64cm. Height gain showed positive correl-
ation with duration of rhGh therapy with a p value of 0.00001. Mean
height velocity in the first year of treatment was 9.7cm/year which
was significantly higher than the mean height velocity of 3.75cm/
year prior to GH therapy (p <0.001). However, HV in second year of
treatment 6.42cm/yr was significantly less than HV in first year of
treatment (p<0.005). HRT was added at a mean age of 15.25yr at a
mean bone age of 13.1yr. Final height was known in six patients.
Average final height was 148.2cm + 5.06 with the maximum height
being 153.2cm.
To conclude, Growth hormone is an effective treatment for improv-
ing final height in patients with Turner syndrome with best outcome
if treatment is started at an early age.
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stanozolol on growth velocity of girls with Turner Syndrome
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Objective: To compare the different efficacies of recombinant human
growth hormone (rhGH) alone and rhGH combined with low dose sta-
nozolol on growth velocity (GV) of girls with Turner syndrome (TS).
Methods: Fifty-one girls with TS were divided into two groups: Group
1 (n=23) were treated with rhGH alone and group 2 (n=28) with
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 118 of 144rhGH combined with low dose stanozolol both for more than six
months. The two groups were compared in terms of GV, height
standard deviation score for chronological age (HtSDSca), height
standard deviation score for bone age (HtSDSba), and the change of
bone age during treatment periods.
Results: In the first year, the GV was i6.29 ± 1.44 ) and i8.13 ± 1.87 ) /
in group 1 and group 2 respectively DHtSDSca changed from i-3.51
± 0.99 ) to i-3.19 ± 1.09 ) and i-4.21 ± 1.19 ) to i-3.42 ± 1.06 ) Cand
changes in ratio of BA and CA ( Δ a` ^ Δ b`) was (0.60 ± 0.39) and
i0.77 ± 0.56 ) group 1 and group 2 respectively. The f u and changes
of HtSDSca i group 2 were significantly better than group 1 (p<0.05)
Dthe G u was negatively correlated with the age.
Conclusions: Compared with the therapy of rhGH alone, the one with
rhGH combined with low dosage stanazolol is more effective in improv-
ing GV without accelerating bone maturation among the girls with TS.P2-4-15
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Introduction: Imprinted genes are expressed in parent-of-origin specific
manner and play an important role in growth and development. In
humans, aberrant expression of some imprinted genes causes imprint-
ing disorders. Insulin and Insulin-like Growth Factor 1 (IGF1) are crucial in
maintaining the whole organism's homeostasis. These effects are medi-
ated through ligand activation of the tyrosine kinase activity of their re-
ceptors, Insulin receptors (IRs) and IGF1 receptors (IGF1Rs). Boucher
reported that loss of IRs and IGF1R in adipose cells of mice induced the
change of expression of some imprinted genes through changes of
DNA methylation status at imprinted differentially methylated regions
(iDMRs) independently of ligand activation (Boucher, 2014). However, it
is not known whether IRs or IGF1Rs had such effects in humans. Here,
we studied the methylation status at iDMRs using gDNA of the patients
with hypomorphic mutations in INSR or IGF1R gene.
Methods: We performed DNA methylation analysis using gDNA ex-
tracted from peripheral blood lymphocytes of two patients with
Donohue syndrome due to compound heterozygous mutations in
INSR gene (patient 1: T910M/E1047K, 2: C280T/R863X) and three with
short stature due to heterozygous mutations in IGF1R gene (patient
3: D1135E, 4: Q1250X, 5: W1249X) by Illumina HumanMethylation450
BeadChip. We compared the methylation status at known 51 iDMRs
of these patients with those of 36 normal controls.
Results: We inquired into the data of known 51 iDMRs. Overall, there
was no difference in the methylation status of gDNA between the
patients with mutations in INSR or IGF1R gene and the normal con-
trol, indicating that methylation defects at iDMRs were not observed
in the patients.
Discussion: In this study, we analyzed methylation status at iDMRs
using the blood of five patients with hypomorphic mutations in INSR or
IGF1R gene, and found no methylation defect. This result is not consist-
ent with that of the experiment in which preadipocytes and adiposetissue of mice lacking IRs with or without IGF1Rs exhibited the change
of DNA methylation at some iDMRs. The reason for this discrepancy
would be the difference of somatic tissues examined and species-
specific differences between humans and mice. Besides, the mecha-
nisms causing IRs and IGF1Rs dysfunction were different between pre-
vious experiment and our study. For understanding the effect of IRs
and IGF1Rs on the change of epigenome in humans, different somatic
tissues other than blood, or more patients with other genetic back-
ground causing IRs or IGF1R dysfunction need to be examined.P2-4-16
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Background: Short stature is a major problem in both transfusion
dependent and non-transfusion dependent thalassemia (NTDT) pa-
tients. Defects in growth hormone (GH) secretion have been reported
as a cause of short stature in thalassemia major patients while being
an infrequently mentioned cause in NTDT patients. The objectives of
this study were to evaluate the percentage of growth hormone defi-
ciency (GHD) present in NTDT patients presenting with short stature
(SS) using two GH provocative tests (Insulin tolerance test (ITT) and
Clonidine test), and to define associated factors with GHD.
Methods: A cross-sectional study was conducted in patients who
were diagnosed as NTDT with short stature. Demographic data: gen-
der, age, weight, height, history of blood transfusions, medications,
hemoglobin, serum ferritin, growth hormone provocative test results,
insulin-like growth factor-1 (IGF-1) and insulin-like growth factor
binding protein-3 (IGFBP-3) levels were collected. Two different GH
provocative tests were performed in NTDT cases and the percentage
of GH deficiency was calculated. The predictive factors of GH defi-
ciency in NTDT patients were analyzed.
Results: Five out of thirteen patients (38%) who were diagnosed as
NTDT with short stature had growth hormone deficiency confirmed by
using two different GH provocative tests. Four of them (30%) were di-
agnosed with growth hormone deficiency by decreased height velocity
and GH provocative tests. There was no factors predicting growth hor-
mone deficiency in NTDT patients with short stature found.
Conclusions: Growth hormone deficiency is not uncommon in
patients with NTDT and short stature. This study found no factors
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 119 of 144that predicted growth hormone deficiency, possibly due to its small
sample size.
Key words: non-transfusion dependent thalassemia (NTDT), growth
hormone deficiency (GHD), Insulin tolerance test (ITT), Clonidine testTable 1 (abstract P2-4-17). Clinical and biochemical and radiographic
characteristics of 13 NTDT patients with cohort statureP2-4-18
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Background: Short stature (SS) is defined as height or length below
the third percentile for age and sex. Although short stature is a com-
mon healthcare issue with diverse etiologies, delayed diagnosis is ex-
tremely common worldwide. The practice of population height
measurement to identify short stature varies widely across countries.
In Taiwan, elementary or high school nurses are required to measure
children’ s heights every semester and to refer children with short
stature to their pediatrician. Because school nurses are the first line
contacts for children and parents, they need to have adequate com-
petencies and knowledge regarding diagnosis and treatment of short
stature. However, although there is a high proportion of referrals,
nurses in Taiwan are not specialized in different disease areas. School
nurses might not be familiar with the post-referral processes for
growth problems, such as the evaluation criteria and investigations
that are required for this endocrinological disorder.
Methods: In July 2015, the Child Growth Association of Taiwan held
two disease awareness programs among school nurses. The objective
of the programs was to educate nurses on the disease and its psy-
chological aspects and on the referral processes and methods of in-
vestigation. This, it was believed, would help lead to earlier diagnosis
and would also enable the nurses to provide psychological and med-
ical support for short stature patients and their families.
Our group of physicians developed the training programs which
were attended by 850 school nurses. Two experienced pediatric en-
docrinologists provided insights into the diagnosis, management and
care of short stature patients.
Results: These sessions triggered many questions and an interactive
exchange between the physicians and nurses during a subsequent
Q&A session. Questions included “When to refer?”, “What are the
indications for GH?” and “How can parents or patients approach
hospital healthcare professionals?”. A post-program survey was
conducted and the majority of participants (93.3%) gave positive
feedback. Many (83.3%) mentioned that they felt had betterunderstanding of disease and treatment for short stature and felt
more confident about counselling the patients and their parents.
Conclusions: The disease awareness programs were very successful
and were well received. This initiative has emphasized that care of
short stature patients resided not only with doctors but also with
school nurses, who can play a vital role in identifying, counselling
and following up patients with short stature.
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Background: Growth pattern of children and adolescents of certain
race or ethnic may differ from other races or ethnics. Likewise, secu-
lar trend may change the pattern of growth across time.
Aims: To assess the secular trends in growth of children and adoles-
cents in Indonesia using data collected between 1998 to 2014.
Methods: Data of urban pre-pubertal children, i.e. between 5 to 8
years for girls and 5 to 9 years for boys, were collected in 1998 and
2003. Data for urban adolescents were collected in 2003 and 2012
for junior high school adolescent and in 2003 and 2014 for senior
high school adolescents. Data of age, sex and height were converted
into height standard deviation scores (SDS) based on WHO Growth
Reference 2007.
Results: Data of 1708 pre-pubertal children of year 1998 were com-
pared to 2276 pre-pubertal children of 2005. Like wise, data of 4765
urban junior high school adolescents of year 2003 were compared to
1890 urban junior high school adolescents of year 2012, while data of
775 urban senior high school adolescents of year 2003 were compared
to data of 3968 urban senior high school adolescents of year 2014.
Overall, there were improvements of around 0.1 to 0.3 SDS in height-
for-age SDS between the two measurements. The best improvement
was attained at pre-pubertal age, i.e. from mean (SD) height SDS of
-0.99(0.9) to -0.63(1.3). Improvement in adolescents was less.
Conclusion: Secular trend in growth of Indonesian children is better
before puberty.
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Objective: We reported on a 10 years old girl with Schimke immuno-
osseous dysplasia (SIOD) and literature review to provide clinical and
genetic materials of this rare disease.
Methods: Retrospective analysis of a patient who admitted because
of short stature, she had normal intellectual and neurological devel-
opment. Growth in early childhood and psychomotor development
were normal. Growth retardation was first noticed at 5years; after
that, her growth velocity was 3~4 cm/year. Her weight was 36 kg
(p50-75; average for 11 years) and her stature was 123 cm (p<3; aver-
age for 7 years), with a short upper segment (upper/lower segment
measurements: 59/64cm), and slightly lumbar lordosis. She had short
neck and triangular face. She was found to have special facial fea-
tures Cshe had multiple small café-au-lait spots Cosseous dysplasia.
The blood smear as follows: hemoglobin 14.5g/dl ;lymphopenia 1.13
× 109( lymphocytes/l, normal 1.5 × 109–6.5 × 109) and platelets: 345
× 109 /l(normal 150 × 109–400 × 109). Clinical chemistry demon-
strated triglyceride 0.52mmol/L(0-1.69) and hypertryglyceridemia2.13
mmol/L(0.86-1.87), albumin 44.7 g/dl(normal 35–55) and total protein
in serum 68.9g/L ( normal 60–80), while glucose, electrolytes and cre-
atinine were normal. The 24-h urine specimen demonstrated features
of proteinuria. She was suspected as SIOD. After informed consent
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 120 of 144Cshe and her parents’s DNA were extracted from blood for detect
gene SMARCALl. Results:The patient was a milder case. A novel Non-
sense c.445C>T ip.Q149X ) was found. One reported missense muta-
tions c.1933C>T ip.R645C ) was detected.
Conclusions: c.445C>T ip.Q149X ) was a novel nonsense mutation
which cause polypeptide chain synthesis stopped. Compared with re-
ported 3 SIOD cases in China, we found that main features of SIOD
were short stature, cell immune deficiency, osseous dysplasia, café-au-
lait spots and proteinuria. The genetype of SIOD was variable. The rela-
tionship between genetype and phenotype of SIOD remained elusive.
Key words: Schimke immuno-osseous dysplasia; short stature;
SMARCALl;mutation
P2-4-21
Efficacy of GH treatment in 6 cases of SGA short stature born with
extremely low birth weight
Seiko Hirose, Tae Kimura, Maki Saitoh, Ayako Ozawa, Erina Ono,
Yukitoshi Tanabe, Masahisa Kobayashi, Ichiro Miyata
Department of Pediatrics, The Jikei University School of Medicine
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-4-21
Background: The efficacy of growth hormone (GH) treatment for
short children born small for gestational age (SGA) has been
reported. However, its effect for SGA short children born with
extremely low birth weight remains unclear. In the present study, we
investigated the efficacy of medium- to long-term GH treatment for
those children.
Subjects and Methods: Subjects were 6 cases that were born with
extremely low birth weight at our hospital and diagnosed as having
SGA short stature at the age of 3 years. Their gestational age was
ranged from 24 weeks and 3 days to 29 weeks and 6 days, and their
birth weight was 417 g to 802 g. For all cases, 0.23 mg/kg/week of
GH was started from 3 years old. Then, we determined the dosage of
GH based on growth rate (cm/yr), Δheight SDS andΔIGF- T SDS for
every one year, and examined the efficacy of treatment for 3~7
years. Furthermore, we also assessed bone age/chronological age
(BA/CA) ratio longitudinally.
Results: The averages of growth rate,Δheight SDS andΔIGF- T SDS
after one year were 8.32 cm/yr, 0.66 and 1.72, respectively. In regard
to the dosage of GH from the second year, the same dose (0.23 mg/
kg/week) was continued in 3 cases (Δheight SDS > 0.75). Addition-
ally, the dose was increased to 0.35 mg/kg/week in 2 cases
(0.5Δheight SDS < 0.75), and increased to 0.47 mg/kg/week in one
case (Δheight SDS < 0.5). Growth rate in all cases showed each max-
imum value in one year from the start of treatment or the increase
of GH dosage, but decreasing trend was observed subsequently.
Maximum Δheight SDS in each case was 0.6 to 0.9. Δ IGF- T SDS in
all cases was also reached each peak value in the first or second year,
and then was decreased. Moreover, BA/CA ratio of each case was 0.6
to 1.0 before the start of this study, but it never exceeded 1.2 during
the treatment period.
Discussion: GH treatment was effective in growth promoting for SGA
short children born with extremely low birth weight. Especially, the
response of growth was higher in early phase of treatment course or
just after increase of the dosage. It’s important to assess the individ-
ual response and to adjust the dosage in early phase.
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Background: Maternal uniparental disomy of chromosome 14
[matUPD(14)] is a genetic condition of inherited both homologue of
a maternal chromosome 14. Its clinical appearance is very similar toPrader-Willi syndrome (PWS) and the differential diagnosis is import-
ant. Recently, the efficacy of GH treatment on short stature and
hypotonia has been reported in matUPD(14). Here we report a
matUPD(14) patient and the effect of GH treatment.
Patient: The patient is a three years old boy, born at 36 weeks of
gestation to nonconsanguineous parents, with a birthweight of 1436
g (-2.8 SD) and a body length of 40.5 cm (- 3.0 SD) shown to be small
for gestational age (SGA). The pregnancy was established by intracy-
toplasmic sperm injection and frozen embryo transfer. Oligohy-
droamnios and fetal growth restriction had been observed since 30
weeks of gestation. After birth, he showed hypotonia, poor feeding,
small hands and feet, cryptorchidism and peculiar face, however, his
methylation testing for PWS was negative. At 2 years of age, further
genetic analysis of MEG3 methylation testing and chromosome 14
polymorphism analysis were demonstrated and he had matUPD(14).
His growth failure had not improved by the age of three, and his
height was 80.4 cm (-3.6 SD) and weight was 9.8 kg (-2.5 SD) at 3 years
of age. Endocrinological evaluation showed that the serum IGF-1 level
was 77 ng/ml and GH secretion after arginine tolerance test (ATT) was
within normal range. GH treatment was started as short stature for SGA
at this time. Three months after GH treatment, his growth velocity has
been improved and GH treatment is now going on.
Discussion: Since the efficacy of GH treatment for matUPD(14) has
been reported in only a few cases, its benefit could not be deter-
mined yet. Therefore, careful follow-up of each case is required. Fur-
ther accumulation of matUPD(14) cases treated with GH is important
to determine the effect of GH treatment.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Laron syndrome-a rare cause of short stature
Sreejith Mullassery, Hammadur Rahman, Rajesh Khadgawat
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Primary growth hormone (GH) resistance or GH insensitivity syn-
drome, a very rare cause of short stature, is characterized by a clinical
appearance of severe growth hormone deficiency with high levels of
circulating GH and low serum insulin-like growth factor 1(IGF 1)
values. It is caused by deletions or mutations in the growth hormone
receptor gene or by post-receptor defects.These patients are refrac-
tory to GH therapy and respond only to recombinant IGF 1.
A 12 year old girl, born of a second degree consanguineous marriage
presented with failure to gain height since one year of age. She was
born of a full term normal vaginal delivery without any significant
antenatal or postnatal complications. Her birth weight was 1.8 kg
while birth length was unknown. There was no history suggestive of
any chronic medical illness.No history suggestive of hypoglycemia in
the past. The child had an average scholastic performance.There was
no family history of short stature.
Examination revealed subtle facial dysmorphism (prominent fore-
head, depressed nasal bridge, sparse hair, blue sclera). Tanner sta-
ging was A1B1P1. Her height was 99.5cm (<5th centile; Ht SDS -8.12,
Indian standards) while weight was 14.7kg (BMI - 14.84kg/m2). The
mean parental height was 149 cm. There were no stigmata of turner
syndrome. External genitalia was normal. Clinical systemic examin-
ation was unremarkable. Investigations revealed a normal hemo-
gram, renal and liver function tests. Thyroid function tests and serum
cortisol were also normal. Skeletal survey ruled out skeletal dysplasia.
Bone age was 9 years. Pituitary gland was normal on neuroimaging.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 121 of 144Karyotyping was 46XX. Basal serum GH level (31.18 ng/ml) and peak
level on provocation with clonidine (93.56ng/ml) were high while
serum IGF1 (11.3ng/ml) and IGFBP3 (411.25 ng/dl) were low, confirm-
ing diagnosis of GH insensitivity. She was started on recombinant
IGF1 therapy (Inj Mecasermin, IPSEN Limited; 40ug/kg twice daily).
On six months follow-up, she gained 5cm in height suggesting a sat-
isfactory response to therapy.
Consent for publication: The authors declare that written informed
consent was obtained for publication.P2-4-25
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Introduction: One of the complications of recombinant human
growth hormone (rhGH) therapy is lipoatrophy, although rare, the
prevalence increases in female adults compared to men. In children,
lipoatrophy is still more rarely reported. The mechanism of lipoatro-
phy is unknown, however, lipoatrophy for rhGH injection is said to
be caused by insufficient rotation sites. The present case developed
lipoatrophy in rhGH injection, and recovered after rotation of the in-
jection sites.
Case: A 2.7 year old boy was born at 40 weeks and 5 days gestation;
height was 49 cm and weight was 3480 g. He was referred to our
hospital for short stature. Additional complications were mild devel-
opmental delay and mild autistic disorder. His height was 81.1 cm
(-2.94 SD) and his weight was 11.7 kg on consultation. Screening
tests were performed for short stature. Thyroid function was within
normal range, bone age was delayed by 1.5 years, and IGF-I was low
level at 24 ng/mL. We performed GH stimulating tests, using arginine
and clonidine. The peak levels of GH were 1.59 ng/mL and 2.70 ng/mL,
respectively, resulting in the diagnosis of severe GHD. Pituitary
was normal size by enhanced MRI. RnGH therapy (0.20 mg/kg/
week) was started. Administration was performed at the same
site, subsequently, lipoatrophy gradually developed during the
next 4 months. Injection of rhGH was discontinued, and after 1
month, injection of rhGH (0.19 mg/kg/week) was resumed, taking
into care to administer at several sites. No lipoatrophy reoccurred
using rhGH, and currently his height is 90.6 cm (-2.62 SD), and
his weight is 12.6 kg (-1.6 SD) at 4.1 years old.
Discussion: Lipoatrophy is a very rare yet debilitating complication of
rhGH injection in children. Past reports conclude that lipoatrophy de-
velops in severe GHD due to immune tolerance deficiency. On the
other hand, lipoatrophy may be induced since rhGH directly reacts to
adipose tissue.
Conclusions: Caution is warranted for daily subcutaneous rhGH injec-
tion without injection site rotation, which may induce localized lipoa-
trophy for especially severe GHD patients.
Consent for publication: The authors declare that written informed
consent was obtained for publication.P2-5-1
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Background: The effectiveness of Methimazole (MMI) + inorganic iod-
ine combination therapy in rapid improvement of hyperthyroidism foradult with Graves’ disease (GD) has been reported, while there is little
information for child and adolescent patients.
Object: To study effectiveness of MMI + potassium iodine (KI) com-
bination as an initial treatment by comparing MMI alone and to re-
veal drawbacks of MMI+KI therapy in child and adolescent patients
with severe hyperthyroidism due to GD.
Methods: We retrospectively studied 235 patients aged 18 years or
younger who were newly diagnosed with GD between January 2005
and June 2015 (Median age 16 (7-18) yr, 207 females). Serum FT4 level
at diagnosis was more than 7.0 ng/dl and observation period after ATD
initiation was more than 6 months (Median period 56.2 months
(6.2-621.6)). Patients were initially treated with MMI15mg+KI50mg
daily (MK group, n=150) or MMI30mg daily (M group, n=85).
Results: The prevalence of all adverse events induced by MMI was
6.7 % in MK group and 17.6 % in M group (P<0.01). FT4 level was
more rapidly normalized in MK group (Median 26 days (13-218)) than
in M group (Median 49 days (14-168)) (p<0.01) in 182 patients ex-
cluding 53 patients who switched to other treatments or increased
MMI dose before FT4 normalization. One drawback of MK therapy
was that the rate of patients who required increase of MMI dose to
normalize FT4 was significantly higher in MK group (39 patients (26.0
%)) than in M group (7 patients (7.1%)) (p<0.01). Thyroid volume at
diagnosis was significantly larger in MMI dose increase group.
(p<0.01) The other drawback was that FT4 rebound after KI with-
drawal was found in 41 of 132 patients (31.1 %) whose data around
KI withdrawal was available. KI treatment duration was significantly
shorter and FT4 level at KI withdrawal was significantly higher in the
rebound group (median 55 days (14-397) and 1.1 ng/dl (0.17-2.63),
respectively) than in the no rebound group (median 90 days
(14-1061) and 0.81 ng/dl (0.18-1.60), respectively) (P<0.01).
Conclusion: Combination of MMI and KI is an effective initial treat-
ment for rapid improvement of hyperthyroidism and reducing ad-
verse events in child and adolescent patients with severe GD.
However, considerations in combined use of KI; Necessity of MMI
dose increase to normalize FT4 and possibility of FT4 rebound after
KI withdrawal in some patients, should be recognized.
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Background/Aims: Congenital hypothyroidism (CH), occurring in ap-
proximately 1:2000 to 1:4000 newborns, is the most frequent con-
genital endocrine disorder. Several causative genes for CH have been
reported. This study aimed to examine the phenotype-genotype rela-
tionship in CH with identified genetic abnormality.
Methods: Fifteen patients with CH, including two family cases with
identified genetic abnormalities, who were treated in the Nagoya
City University Hospital, were enrolled in this study. The genetic ab-
normalities causing CH were identified by targeted next-generation
sequencing. The relationship between the genetic abnormalities and
phenotypes was determined based on the medical records.
Results: Of these 15 patients, nine had mutation in DUOX2; four, in
TSHR; and two, in TPO, All mutations were biallelic mutations. Three
patients of TSHR mutation harbored the homozygous R450H muta-
tion. The nine patients with DUOX2 mutations and four with TSHR
mutation showed mean serum TSH values of 174.1 μ U/mL (from 7.1
to 743.8 μ U/mL) and 24.9 μ U/mL (from 19.8 to 33.3 μ U/mL) and
mean serum fT4 levels of 0.6 ng/dL (from 0.3 to 0.7 ng/dL) and 1.4
ng/dL (from 1.3 to 1.5 ng/dL) respectively, at the first visit to the hos-
pital. Of the patients with DUOX2 mutation, three were suspected of
excessive iodine intake because of the elevated urine iodine concen-
trations or episode of hysterosalpingography. These patients had
higher TSH levels than did patients without suspicion of excessive
iodine intake did. The size of the distal femur bone nucleus at CH
diagnosis was normal in all patients, except the one with TPO muta-
tion. The mean thyroglobulin levels before treatment in four patients
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mutation were 1248.6 ng/mL, 85.9 ng/mL, and 4610.0 ng/mL, re-
spectively. The patients were treated with l-thyroxine, based on the
identified mutation, at the following average doses: DUOX2 mutation
except two patients who had stopped taking l-thyroxine 1.8μ g/kg/day
(age range, 1-10years); TSHR mutation, 3.9μg/kg/day (age range,
1-11years); and TPO mutation, 2.5μg/kg/day (patient age, 3 years and
15 years).
Conclusion: Patients with biallelic TSHR mutation did not stop taking
l-thyroxine. In contrast, patients with biallelic DUOX2 mutation would
stop taking l-thyroxine or only take a very little amount. Thus, gen-
etic analysis is beneficial for predicting the clinical course of CH.P2-5-3
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Ouyporn Panamonta1, Songpon Getsuwan1, Pattara Wiromrat1,
Manat Panamonta1, Sunphat Paireepinas2
1Faculty of Medicine, Division of Endocrinology, Department of
Pediatrics, Khon Kaen University; 2Faculty of Medicine, Division of
Nuclear Radiology, Department of Radiology, Khon Kaen University
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-5-3
Background: Graves’ disease (GD) is the most common cause of
hyperthyroidism in children and adolescents. Treatments consist of
medication, radioactive iodine (RAI) therapy and surgery. Currently,
RAI therapy is the first line treatment in many medical centers.
Objective: To evaluate the effectiveness and safety of RAI therapy in
childhood Graves’ disease.
Methods: A retrospective study was performed in 46 GD patients,
aged at onset ≤ 15 years, who had undergone RAI therapy at the
aged ≥ 10 years. Goiter grading, evidence of hypothyroidism, severity
of ophthalmopathy, RAI dosage and side effects of RAI therapy were
evaluated.
Results: The cure rate was 95.6%. All participating patients had goiter
reduction (p=0.005). Hypothyroidism was induced in 33 (71.7%) and
11 (23.9%) patients after the first and second RAI therapy. The freeT4
level and the total RAI dosage were significantly higher in the pa-
tients with failure response (p=0.001). The average time to induce
hypothyroidism after the first RAI therapy was 127.5 (IQR:94.5-123.0)
days. All of the patients had improvement of ophthalmopathy and
none had thyroid carcinoma during the follw-up period of 42.5 (IQR:
17-52) months.
Conclusion: Radioactive iodine therapy is effective and safe in the
treatment of children and adolescents with Graves’ disease.P2-5-4
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Purpose: To clarify the maximum tolerable level of iodine intake in
Japanese neonates.
Subjects and methods: This study included a prospective observa-
tional study performed at Kitakyushu Municipal Medical Center from
September 2013 through November 2014 (Group A), and a
retrospective observational study performed at National Hospital
Organization Kokura medical center from September 2015 through
June 2016 (Group B). Subjects of Group A were born to mothers with
a family history of thyroid disease (within third-degree close rela-
tives). Subjects of Group B tested positive at the screening or had
symptoms of hypothyroidism. Both groups comprised term or
near-term newborns without severe complications. Serum thyroid-
stimulating hormone (TSH) and free thyroxine (FT4) levels were mea-
sured in the first 5 days of life (DOL) and/or at 1 month of life (MOL).Thyroid autoantibodies, thyroglobulin, and urinary iodine (UI) were
measured within 1 month after birth.
Results: In Group A, 13 newborns of 840 pregnant women met the
selection criteria and were enrolled in this study. Three of the 13
newborns negative for thyroid autoantibodies showed slightly ele-
vated serum TSH levels and high UI levels, but normal FT4 levels.
There was a positive correlation between serum TSH and UI levels.
When UI >1,500 μ g/L or >8,000 μ g/gram of creatinine was used as
a cut-off, elevation of serum TSH levels exceeding the standard was
predicted with 100% sensitivity and specificity. In Group B, two new-
borns negative for thyroid autoantibodies showed slightly elevated
serum TSH and high UI levels. One tested positive and the other
negative on the mass- screening test. These newborns had pro-
longed jaundice, poor weight gain, and/or umbilical hernias.
Conclusion: Prenatal exposure to excessive amounts of iodine can
cause elevation of serum TSH levels and show a tendency to demon-
strate excessive and prolonged TSH responses compared to older
children and adults. In our study, serum TSH levels were within
standard limits or slightly high (MS-negative) at 5 DOL, but gradually
increased from 5 DOL to 1 MOL. These findings suggest the possibil-
ity of delayed- onset hypothyroidism. In group A, iodine-induced thy-
roid dysfunction was subclinical, and no cases required treatment
with levothyroxine. However, in Group B, 2 neonates had clinical
hypothyroidism symptoms and required levothyroxine therapy. There
are many reports of iodine-induced overt thyroid dysfunction and/or
goiter, suggesting that not only iodine dosing but also factors such
as heredity or environment are involved, whether or not symptoms
of overt hypothyroidism are present.
P2-5-5
The management of the children born from mothers with
hypothyroidism/subclinical hypothyroidism
Yasuko Ogiwara, Tomoko Yoshida, Kanako Nakao, Yumiko Terada, Yuta Chiba,
Kazuko Mizutani, Yusuke Fujisawa, Yasuhiro Naiki, Reiko Horikawa
Division of Endocrinology and Metabolism / Department of Pediatrics,
National Center for Child Health and Development
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-5-5
Background: Hypothyroidism during pregnancy can lead to pre-
eclampsia, anemia, and miscarriage. Maternal hypothyroidism also af-
fects their children by causing intrauterine growth retardation and/or
developmental delay; previous report showed even modest maternal
hypothyroidism relates to the lower IQ of their children when com-
pared to the euthyroid controls.
Objectives: To evaluate thyroid function after birth in children of
hypothyroid mothers
Subjects and methods: 201 pregnant women, who have diagnosed as
having hypothyroidism and been followed at our institute, and their
children were involved in this study. The diagnosis of mothers were 95
cases with Hashimoto’s disease (29 inactive, without l-T4)(47.3%), 48
with hypothyroidism after hysterosalpingography (23.9%), 46 with sub-
clinical hypothyroidism (TSH 5μU/mL with thyroid antibodies, 16 with-
out l-T4) (22.9%), 5 with iodine excess (2.5%), 5 with subacute
thyroiditis (2.5%), and 2 with drug-induced hypothyroidism (1.0%).
Hypothyroidism after thyroidectomy in Graves’ disease was excluded
from this study. Thyroid function in their children were checked at day
1 and 5, 1 months, 3 months, 6 months, 1 yr, 2yrs, 3yrs, and 6yrs.
Results: In mothers with hypothyroidism/subclinical hypothyroidism
during pregnancy, 156 (77.6%) were treated with thyroid hormone
replacement and kept euthyroid condition. 15 children were born
prematurely (25-36w) and excluded from the following analysis. In
186 children, 165 children were followed up at 1months, 92 at 1 year,
28 at 3 years, 9 at 6 years, respectively. In children, TSH 5μU/mL were
observed in 20 (10.8%) at day 5, 17(10.3%) at one month, 7 at 3
months ( 5.2%). Four children (2.2%) were diagnosed as transient
hypothyroidism and thyroid hormone replacement was needed.
These children were born from Hashimoto mothers, one with thyroid
blocking antibody transferred through placenta. One baby born from
Hashimoto mother had normal TSH levels at day 5 but follow-up at 1
month revealed elevated TSH level at 79.2 μU/ml and had ectopic
thyroid. One with family history of congenital hypothyroidism, and
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on hormone replacement.
Conclusion: 2.2% of children born from Hashimoto mothers needed
thyroid hormone replacement and about 10 % of children showed
TSH levels higher than 5 μ U/ml at 5 days and 1 month of age,
suggesting maternal hypothyroidism has moderate effect on thyroid
function in their babies. Close follow-up is necessary, at least until
one month, for babies from maternal hypothyroidism.
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Introduction: Mutations in the ligand binding domain of the thyroid
hormone receptor alpha 1 (TR α 1) cause resistance to thyroid hormone
alpha (RTH α ). The typical phenotypes include growth retardation, de-
layed development, macrocephaly, constipation, anemia and abnormal
thyroid functions (low/low-normal FT4, high/high-normal FT3, low T4/
T3 ratio and normal TSH). However, the phenotypes are various and do
not necessarily correlate with the defect in T3 binding. TRs initiate gene
transcription by binding to thyroid hormone response elements (TREs),
which usually consist of two half site sequences arranged in either dir-
ect (DR) or inverted (IR) or everted (ER) repeat configurations. Studies of
TR β mutants in RTH β indicate that the orientation of TREs can influ-
ence the functional properties of mutant receptors. Because of the high
degree of homology between TR α 1 and TR β 1, we hypothesized that
the transcriptional activity of TR α 1 mutants could also vary depending
on TRE configuration. This may, in part, contribute to phenotypic vari-
ability in RTH α patients.
Methods: JEG3 cells were transfected with 20 ng of FLAG-tagged
wild-type TR α 1 (WT α 1) or mutant TR α 1 expression vectors, 120
ng of luciferase reporter constructs containing either DR (MAL), IR
(PAL) or ER (F2) TRE, and 60 ng of pMaxGFP control reporter. After 24
hours, cells were incubated for 24 hours with 0-10,000 nM T3. Lucif-
erase and GFP activities were measured, and half maximal effective
T3 concentration (EC50) and maximum responses were determined.
Cellular receptor expression was verified by immunoblotting of nu-
clear extracts with FLAG antibodies.
Results: WT and mutant receptors were expressed at similar levels.
All mutants showed a clear increase in EC50, which varied between
TREs. Overall, the fold increase in EC50 was highest on ER (~80 fold),
intermediate on DR (~20 fold) and lowest on IR (~10 fold). The EC50s
of L287V α 1 and D211G α 1 were significantly higher compared with
WT on all TREs. In contrast, P398H α 1 showed a significantly in-
creased EC50 only on DR and ER, and A263S α 1 only on ER. The
maximum response was modestly decreased for most mutants, but
reached significance only for T223A α 1 (~60%WT) and P398H α 1
(~40%WT) on all TREs, except for P398H α 1 on ER.
Conclusions: The degree of defective transcriptional function of TR α
1 mutants does vary depending on configuration of TRE. This likely
contributes to the variable tissue resistance and phenotypes seen in
RTH α patients with different TR α mutations.
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-5-7Fetal thyroid goiter suspicious of fetal hypothyroidism is a rare
phenomenon. Large fetal goiters can obstruct the trachea and
esophagus and may cause polyhydramniosis, thus complicating labor
and causing neonatal respiratory distress. We present a case of fetal
goitrous hypothyroidism treated by administration of levothyroxine
(L-T4) into the maternal amniotic fluid. A 32-year-old woman was re-
ferred to our hospital because of polyhydramniosis with fetal thyroid
goiter at 32 weeks of gestation. She was diagnosed with Graves’
disease and treated with propylthiouracil 150 mg/day during preg-
nancy. The fetal trachea and esophagus were compressed by the goi-
ter. Cordocentesis was performed at 34 weeks of gestation and
thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), and
free thyroxine (fT4) levels in the fetal blood were 97.8 μ IU/mL, 2.52
pg/mL, and 0.47 ng/dL, respectively. Maternal propylthiouracil was
discontinued and LT-4 300 μ g was administered into the amniotic
fluid at 35 and 36 weeks of gestation, respectively. The fetal goiter
reduced in size, the trachea and esophagus lumens increased, and
the amniotic fluid index decreased. A female infant weighing 3224 g
was delivered by elective cesarean section at 37 weeks of gestation.
The infant displayed no respiratory distress at birth and her thyroid
gland was not palpable. Her thyroid function at birth was 42.45μIU/mL
TSH, 1.45 pg/mL fT3, and 1.39 ng/dL fT4, and her TSH level had
decreased to within the normal range by 10 days after birth. We pre-
dicted that transplacental TSAb could have damaged the infant’s thy-
roid function, but she remained asymptomatic and was discharged at
17 days postpartum. Her growth and development were normal at last
follow-up at 2 years old. We considered that this fetal goitrous
hypothyroidism could have been caused by the following: (1) excessive
fetal thyroglobulin production as a result of transplacental TSAb; (2)
excessive fetal thyroid function caused by maternal thyroid hormone
deficiency and (3) transplacental passage of maternal PTU; or (4) other
reasons, e.g., iodide overload, iodide deficiency, and congenitally
abnormal synthesis of thyroid hormone. Abnormalities of fetal thyroid
function have been reported to cause mental retardation, and fetal
goiters and thyroid function should thus be assessed and treated
appropriately.
Consent for publication: The authors declare that written informed
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Background: Endocrinopathies are common in patients with DiGeorge
syndrome. While hypocalcemia is one of the cardinal features of
DiGeorge syndrome, autoimmune thyroid problem such as Graves’ dis-
ease has been sporadically reported. However, co-existing pathology of
hyperthyroidism and hypoparathyroidism in the patient can sometimes
obscure the problem of hypocalcemia, and may delay the diagnosis of
DiGeorge syndrome.
Case presentation: A 14-year-old girl was first referred for manage-
ment of hyperthyroidism. She presented with palpitation and weight
loss for few months. The girl was noted to have diffuse goitre with
physical signs of thyrotoxicosis including sinus tachycardia and hand
tremor. She also had prominent forehead and hypertelorism, which
were overlooked at the first visit. Biochemically, she had elevated
FT4 (>100 pmol/L; reference 12-22 pmol/L) and undetectable TSH.
Anti-thyroglobulin titre and anti-thyroid microsomal titre were ele-
vated. Her serum calcium (2.23 mmol/L; reference 2.15-2.55 mmol/L)
was normal at that time. The girl was diagnosed to have Graves’ dis-
ease and was started on carbimazole. After medical treatment for a
few months, her symptoms of thyrotoxicosis were gradually resolved
and her FT4 was normalized (17.3 pmol/L). However, concomitantly,
the girl was found to have asymptomatic hypocalcemia. Her serum
calcium dropped significantly when her thyroid problem underwent
good control by carbimazole. While she had normal thyroid function,
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calcium. Further investigations for hypocalcemia showed normal
25OH vitamin D level, normal magnesium and low urinary calcium to
creatinine ratio. Parathyroid hormone level (4.0 pmol/L; reference
1.6-6.9 pmol/L) was inappropriate normal in the presence of hypocal-
cemia. A diagnosis of hypoparathyroidism was established. In view of
her hypoparathyroidism and subtle facial dysmorphism, the possibil-
ity of DiGeorge syndrome was highly suspected. Fluorescent in situ
hybridization was performed and showed a microdeletion on one of
the homologs 22q11.2. She was treated with calcitriol and calcium
supplement with good response.
Conclusion: Autoimmune disease such as Graves’ disease is reported
at an increased incidence in DiGeorge syndrome. This case report illus-
trated that early diagnosis of DiGeorge syndrome could be challenging
in the presence of co-existing hyperthyroidism. In this patient, her
underlying hypoparathyroidism was undetected by the possible hyper-
calcemic effect of hyperthyroidism. Treatment of the Graves’ disease
allowed the problem of hypocalcemia to be identified, followed by con-
firmation of the diagnosis of DiGeorge syndrome.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Introduction: Prompt intervention can prevent permanent adverse
neurological effects caused by neonatal hypothyroidism. Thyroid
function changes rapidly in the first few days of life but age-related
reference intervals (RIs) for TSH, FT4 and FT3 are not available to aid
interpretation. This is further complicated by the imprecision of how
the days of life are classified, e.g., a neonate who was born just be-
fore midnight would be classified as day-1 a few minutes after mid-
night rather than day-0. We have developed hour-based RIs using
data mining.
Methods: All TSH, FT4 and FT3 results (Beckman) with date and time
of collection from neonates aged
Results: Of the 728 neonates qualifying, 569 had time of birth avail-
able. All 569 had TSH, 415 had FT4 and 146 had FT3 results. For age
≤24h, 24.1-48.0h, 48.1-72.0h, 72.1-120.0h and 120.0-168.0h of life, the
TSH RIs (2.5th-97.5th) (mIU/L) were 4.1-40.2, 3.2-29.6, 2.6-17.3, 1.0-
10.3 and 1.0-8.2 respectively; the FT4 RIs (mean ± 2SD) (pmol/L) were
15.3-43.6, 14.7-53.2, 16.5-45.5, 17.8-39.4, 15.3-32.1, 14.5-32.6, 13.9-30.9
and 14.4-28.6 respectively; and the FT3 RIs (mean ± 2SD) (pmol/L)
were 5.0-9.4, 4.1-9.0, 2.8-7.8, 3.5-7.2, 3.4-8.0, 3.8-7.9 and 3.8-7.2
respectively.
Conclusion: In most babies, there is a substantial surge in TSH and
FT4 shortly after birth followed by a rapid decline over the subse-
quent 168 hours. The upper limits are manyfold higher than the
values for adults. Use of method- and hour-based RIs in newborns al-
lows for correct identification of neonates who are at risk of
hypothyroidism. Due to current lack of analytical harmonisation,
these RIs must necessarily be method-specific.
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Introduction: The prevalence of congenital hypothyroidism in India
is 1:500 to 1:1221. Ectopic thyroid(ET) accounts for 49-61% of thyroid
dysgenesis. Prevalence of ET in the population is 1 per 1,00,000 -3,00,000. As there is minimal information on the spectrum of ET in
South-Indian children, we analysed the clinical characteristics
amongst children presenting at a tertiary care hospital.
Setting: Outpatient department of Pediatric Endocrinology, GKNM
Hospital, Coimbatore, India.
Methodology: Retrospective record review of all patients diagnosed
with ectopic thyroid between January 2005 & March 2016 has been
done. Details extracted are clinical presentation, age at diagnosis, thy-
roid hormonal profile, visibility of the gland at ectopic position, nuclear
imaging findings and management. Aetiological diagnosis is done by
scintigraphy before initiation of thyroxine. A four week period of
hormone withdrawal at 3 years of age is followed by radionuclide scan
in children treated with thyroxine without etiological diagnosis in early
infancy. Ultrasonography has not been used due to poor sensitivity and
specificity in the diagnosis of ET as compared to scintigraphy.
Results and discussion: Amongst 52 children with ectopic thyroid,
27 were girls. Mean age at presentation is 3.3 years (range 2 days to
12.5 years). 11.5% are diagnosed after 10 years of age while 23% are
identified in the neonatal period. Radionuclide scan revealed tracer
uptake in the lingual region in 44 of 52 (85%) children and in the
upper part of the neck in others (15%). Two children have dual ec-
topic thyroid gland. Rare combinations include lingual thyroid+gen-
eralized resistance to thyroid hormone and lingual thyroid+Turner
syndrome. Predominant symptom at presentation is developmental
delay in 14 of 52 children. Oyher symptoms include short stature,
neck swelling and prolonged neonatal jaundice in 7, 6 and 8 children
respectively. Physician’s examination revealed lingual thyroid as a
posterior-tongue mass in two patients. The average age at diagnosis
is 7.3 years for children who presented with short stature which is
later than any other symptom of presentation. 24 of 52 children
(46%) had TSH above 60 miu/L at diagnosis. 10 out of 14 (71%) chil-
dren with developmental delay have an initial TSH above 60 miu/L.
The neck masses and externally visible lingual thyroids regressed
with oral thyroxine replacement.
Conclusions: Ectopic thyroid gland should be considered while
evaluating any asymptomatic child with a posterior tongue mass or
midline mass in the neck. Prompt thyroxine replacement prevents
surgical excision.
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Background and aims: Congenital hypothyroism (CH) is the most
common cause of preventable mental retardation. Recently, detec-
tion of CH with eutopic thyroid gland has increased through
neonatal screening program. In this study, we aimed to evaluate the
predicting factors to distinguish between permanent and transient
CH in patients with a eutopic thyroid gland.
Methods: We retrospectively reviewed 121 children who were
diagnosed with CH and eutopic thyroid gland. All subjects were
treated with L-thyroxine and underwent re-evaluation after 3 years
old of age.
Results: Of the 121 CH patients, 24 (19.8%) children were evaluated
as having permanent CH (PCH) and 97 (80.2%) children showed tran-
sient CH (TCH). Initial free T4 and TSH level were significantly higher
in TCH than in PCH subjects. Also, the mean doses of L-thyroxine
(ug/kg/day) at 24 months and 36 months were significantly lower in
TCH than in PCH subjects with a eutopic thyroid gland during a 3-
year treatment period. Based on the receiver operating characteristic
(ROC) curve, the optimal cut point of L-thyroxine dose at 2 and 3
years were 3.2 and 2.7 ug/kg day in predicting TCH, which was
associated with an 83.5% sensitivity and 69.6% specificity at 2 years
and 92.8% sensitivity and 58.3% specificity at 3 years, respectively.
Conclusion: The L-thyroxine requirements during treatment period
have a predictive role for differentiate TCH from PCH in the patients
with eutopic thyroid gland.
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Background: Graves disease is one of the most common causes of
thyrotoxicosis in children that is characterized by hyperthyroidism,
diffuse goiter, ophthalmopathy and rarely dermopathy.
Objectives: This study presented the clinical profile of patients
diagnosed with Graves disease seen at the out-patient department
of a tertiary pediatric hospital from 2003-2013. It described the
demographic data of the patients, the signs and symptoms at initial
consult, the thyroid function tests at initial and final consult, the
treatment options taken: medical with antithyroid drugs, surgical or
radioactive iodine ablation and determined the remission rate of
patients after medical therapy.
Study Design: Retrospective study of forty two patients with Graves
disease diagnosed from 2003-2013. Data from patient charts were
extracted from the out-patient department of a tertiary pediatric
institution.
Results: Forty two patients with Graves disease from 2003-2013 were
included, thirty five females and seven males. A positive family
history for thyroid disease was seen in twenty six percent. Initial pres-
entation included goiter, neck mass, weakness, increased sweating,
and palpitations. Medical treatment with Methimazole was the initial
treatment in twenty eight patients (67%). Only nine patients went
into remission (21.42%).
Conclusion: Hyperthyroidism is more common in females. Signs and
symptoms were comparable with local and international data. Remis-
sion rate of twenty one percent approximates that of published
reports.
Recommendations: A large scale multicenter study should be done
to compare remission rates of different institutions managing
patients with Graves disease. A study on factors affecting remission
is recommended.
Keywords: Graves disease, Methimazole, Propylthiouracil, Radioactive
Iodine Ablation, Remission
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Slipped capital femoral epiphysis (SCFE) is a rare disease. However, it is a
very important complication of hypothyroidism occurring in childhood.
The patient was an 8-year-old boy with a pain in the hip joint. Hip
joint radiography and MRI scans diagnosed him with chronic bilateral
SCFE. He was short stature and his growth had slowed down for 4
years from around age 4. Hirsutism, dry skin and bradycardia were
noted. Decreased thyroid function was observed (FT4 0.10 ng/dl, TSH
1,789 μ IU/ml) and thyroid autoantibodies were positive (TPOAb
>600 IU/ ml, TgAb 1,720 IU/ml). Thyroid ultrasonography showed
marked atrophy of the thyroid. Thus, a diagnosis of atrophic thyroid-
itis was made. For the treatment of SCFE, the patient was admitted
and kept at rest with traction of the lower limbs. Atrophic thyroiditis
was treated with oral levothyroxine therapy beginning at a low dose
followed by gradual dose increase. The FT4 level was improved
within the normal range about 2 months later. Surgery was per-
formed for bilateral SCFE.We review the literature reporting the patients with SCFE associated
with hypothyroidism. SCFE associated with hypothyroidism is rare; 41
cases were found from 24 reports according to our search of litera-
ture published from 1980 to present. We analyzed the clinical fea-
tures in 42 cases comprising these reported cases and our case. Our
present study that compared general SCFE and SCFE associated with
hypothyroidism revealed the following characteristic features of the
latter: 1) the age at onset is mostly early teens, the same as in cases
of general SCFE, but the onset is occasionally seen before or after pu-
berty and in adulthood, 2) non-obese patients are relatively frequent,
and 3) short stature is frequent. In particular, the occurrence of SCFE
in patients aged 16 years or older, who normally have closed epiphy-
sis, cannot be explained by the mechanisms of general SCFE and
suggests the presence of hypothyroidism. Moreover, as in our
present case, the presence of hypothyroidism should also be sus-
pected in cases of SCFE occurring in prepubertal patients aged 8
years or younger. Close examination of thyroid function should be
conducted aggressively in patients with SCFE who are not in their
early teens, are non-obese, or have short stature or decreased
growth rate.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Background: Over one-hundred and thirty years ago a link between
Down’s syndrome and thyroid disease had been proposed. The addi-
tive effects of this co-morbid condition leads to further amplification
of the clinical problems in these children with Down’s syndrome.
While several international studies have shown association of thyroid
dysfunction with Down’s syndrome, there is paucity of data available
from Bangladesh.
Objective: The purpose of this study was to know the prevalence of
thyroid dysfunction in Down’s syndrome children in our setting and
to correlate the features of Down’s syndrome with those of thyroid
dysfunction.
Methods: A cross-sectional study was carried out with 40 patients of
Down’s syndrome admitted at Dhaka Shishu Hospital from January
2014 to March 2015. Diagnosis of Down’s syndrome was considered
clinically with or without support of karyotyping. Thyroid function
was assessed by serum FT4 and TSH.
Results: All 40 patients enrolled were below 5 years and most of them
(72.5%) were within 12 months of age. Twenty-one cases were male
and 19 female. Hypothyroidism was found in 6cases (15.0%), of which
4 (10%) had compensated hypothyroidism. Hyperthyroidism was not
observed in any of the cases. There was no significant sex difference.
Conclusion: Hypothyroidism in children with Down’s syndrome is
prevalent in our setting. It thus seems necessary to screen all Down’s
syndrome children for thyroid dysfunction.
Key words: Down’s syndrome, hypothyroidism.
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Introduction: Although Hashimoto’s thyroiditis is the most common
cause of acquired hypothyroidism, many patients are asymptomatically
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often used as a contrast agent in imaging studies. Exposure to transient
excess iodine does not usually induce hypothyroidism, because it is
generally tolerated well. We report a patient with asymptomatic
Hashimoto’s thyroiditis, who developed symptomatically hypothyroidism
after exposure to ICM.
Case report: Seventeen-year-old girl was diagnosed as having pul-
monary arteriovenous fistulas at 8 years old. She has received many
cardiac catheterization procedures at the age of 8 to 14 years old,
using ICM, and has been no symptoms until the age of 17 years.
Since she showed low oxygen saturation at 17 years old, she re-
ceived cardiac catheterization and coil embolization again. General
fatigue and headache were immediately appeared at the same day
of last cardiac catheterization. After discharge, she complained severe
general fatigue and headache, and finally she could not walk alone.
She showed 39 bpm in heart, and 67/37 mmHg in blood pressure.
Free T4 (fT4) level was 0.59 ng/dL, and TSH level was 1.39 μIU/mL.
Anti-thyroglobulin antibody (TgAb), 122.3U/mL (>28U/mL) and anti-
thyroid peroxidase antibody (TPOAb), 20.9U/mL (>16U/mL) were
both positive. She was diagnosed with Hashimoto’s thyroiditis. To
rule out brain abscess and/or tumor, she received enhanced CT with
ICM and had negative findings. She was referred to our hospital for
treatment of Hashimoto’s thyroiditis. She was continued for goitor,
hair loss and general fatigue. In our hospital, fT4 level was 0.89 ng/dL
(lower limit of the normal range), TSH level was 0.87 μIU/mL. TgAb
and TPOAb were continuously positive. FT4 level was still slightly
low, then, we treated low dose of levothyroxine for the therapeutic
purpose of hypothyroidism. Her symptoms were improved after the
levothyroxine treatment. To date, no symptoms of hypothyroidism
exist with low dose of levothyroxine treatment.
Discussion: Production of thyroid hormone depends on adequate
iodine intake. Wolff-Chaikoff effect is known that ultra-excessive iod-
ine reduces production of thyroid . Individuals with underlying thy-
roid disease sometime develop hyper- or hypothyroidism after
excess iodine exposure. She may be oligosymptomatic carrier of
Hashimoto’s thyroiditis around 17 years old, however her thyroid sta-
tus changed to be symptomatic hypothyroidism after exposure to
ICM. Mechanism of iodine-induced thyroid dysfunction is uncertain.
Conclusions: Individuals who have an antibodies associated with
Hashimoto’s thyroiditis may be at risk for hypothyroidism after expos-
ure to ICM.
Consent for publication: The authors declare that written informed
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Objective: To explore the Polymorphisms of estrogen receptor-
β(ERβ) gene RasI and AluI sites in the girls with idiopathic central
precocious puberty(ICPP).
Methods: F RasI and AluI sites in ERβ gene were detected by direct
DNA sequencing in 100 girls with ICPP and 100 healthy girls, And the
frequency distribution of genotypes and alleles of RasI and AluI were
statistically analyzed between the ICPP group and the control.
Results: (1) There was statistically significant difference in the genoty-
pe(RR, Rr, rr) frequency of RasI site between ICPP group and control
group iχ2 = 5.960, P =0.045 ), And the risk of ICPP in girls with allele
R was 1.579 fold of that with allele r i95%CI F1.047 `2.382, P <0.05 ).
(2) There was no statistically significant difference in the genoty-
pe(AA, Aa, aa) frequency of AluI site between ICPP group and the
control iχ2 =2.889, P =0.236), the risk of ICPP in girls with allele A
was 1.589 fold of that with allele a i95%CI F0.916 `2.755 CP >0.05 ).
Conclusions: The polymorphisms of RasI site but AluI site in ERβ-
gene may be related to ICPP, And Allele R may be a risk factor
of ICPP for girls.P2-6-2
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Background: Idiopathic central precocious puberty (ICPP) is a com-
mon endocrine disorder. Gonadotropin releasing hormone agonist
(GnRHa) is the standard treatment to preserve adult height and men-
strual cessation. However, the height outcomes varied across studies.
Objective: To evaluate the final adult height of Thai girls with ICPP
who received GnRHa treatment.
Methods: In this longitudinal retrospective study, medical records of
45 girls who were diagnosed as ICPP and treated with GnRHa during
2000-2016 were reviewed. All girls received a fixed 3.75 mg dose of
GnRHa subcutaneously every 4 weeks. Predicted adult height (PAH)
was calculated according to Bayley and Pinneau method from initial
bone age (BA). Their heights, weights and Tanner stages were
followed every 3 months until they reached final adult height (FAH).
Results: Mean age of thelarche was 6.9 ± 0.6 years. Twenty-seven
girls presented with menstrual bleeding at mean age of 8.4 ± 0.8
years. GnRHa was started at 8.5 ± 0.8 years with mean duration of
3.3 ± 1 years. Thirty-one and fourteen patients received leuprolide
acetate and triptorelin depot respectively. Leuprolide was switched
to triptorelin in two patients due to pubertal progression. Mean FAH
was 157.4 ± 5.7cm which significantly increased from PAH (153.4 ±
6.8 cm, p<0.01) and target height (TH) (155.3 ± 4.4 cm, p<0.01). Sub-
group analysis showed the PAH in girls who presented with and
without menstruation were not different at baseline (153.3 ± 6.8 vs
153.3 ± 7.1 cm, p=0.9) although girls with menstruation had more
advanced BA (12.5 ± 0.6 vs 11 ± 0.6 years, p<0.01). But after treat-
ment, girls presented with menstruation had significantly decreased
FAH compared with those who had not (156 ± 5.7 vs 160 ± 4.9 cm,
p=0.01). However, FAH was increased significantly from PAH in girls
presented with menstruation.
Conclusion: GnRHa treatment at the usual dose of 3.75 mg subcuta-
neously every 4 weeks could effectively improve final adult height in
Thai girls with ICPP. Modest benefit could also be observed even in
girls presented with menstruation.
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PCOS, the most common female endocrine disorder of unknown eti-
ology is characterized by reproductive abnormalities and associated
metabolic conditions. PCOS has also been associated with an in-
crease in atherosclerotic disease and endothelial dysfunction and an
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hypertension. We have shown that transgenic overexpression of
NGF, a marker of sympathetic hyperactivity, directed to the ovary by
the mouse 17 α-hydroxylase promoter (17NF mice), resulted in ovar-
ian abnormalities and associated metabolic perturbations including
insulin resistance and hyperinsulinemia similar to those seen in
women with PCOS. 17NF mice also display an increase in body
weight and abnormal body fat distribution. Importantly, overproduc-
tion of NGF leads to systemic sympathetic hyperactivity in these
mice. Here, we sought to determine whether 17NF mice exhibit asso-
ciated cardiovascular alterations. We evaluated left ventricular (LV)
structure and function through the use of echocardiography. Several
structural and functional cardiac alterations were observed in 17NF
mice compared to WT mice including decreased LV mass to body
weight ratio as a result of a thinner LV posterior wall and shorter lon-
gitudinal heart axis. Additionally, likely due to LV wall thinning, LV
area and volume was enlarged in 17NF mice. Moreover, despite in-
creased left ventricular volume, stroke volume was similar in both
groups of mice suggesting compromised cardiac function. In support
of this, ejection fraction was also found to be slightly decreased in
17NF mice. Furthermore, decreased systolic-diastolic changes in the
area of the left ventricle and LV posterior wall dimensions in 17NF
mice suggest compromised LV contractility. To determine whether
cardiac remodeling observed in 17NF mice was associated with alter-
ations in myocardial collagen content, LV interstitial myocardial colla-
gen fraction was assessed by analysis of picrosirus red stained LV
sections. Interstitial myocardial collagen fraction was found to be ap-
proximately 30% lower in 17NF mice compared to WT mice at 10
weeks of age and 20 weeks of age. We also measured blood pressure
by tail cuff recording in body weight-matched mice. A significant in-
crease in Systolic BP (p<0.05) was detected across the 10-week time
period, in 17NF mice compared to WT mice and at the time points
17 and 17.5 weeks of age. Altogether, these results suggest an over-
expression of NGF in the ovary is sufficient to cause reproductive,
metabolic and cardiovascular alterations of PCOS and are in support
of the hypothesis that sympathetic hyperactivity may play a patho-
logical role in the development and/or progression of PCOS.
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Background: Thyroid disorders affect the timing of puberty, such as
precocious puberty or delayed puberty. Although the cross-talk be-
tween the hypothalamic-pituitary-gonadal (HPG) and hypothalamic-
pituitary-thyroid (HPT) axes has been suggested in the reproductive
regulation by thyroid hormones, the mechanisms involved in the ab-
normal puberty by thyroid disorders have not been fully elucidated.
Gonadotropin- inhibitory hormone (GnIH) is a hypothalamic neuro-
peptide inhibiting gonadotropin secretion by decreasing the activity
of gonadotropin- releasing hormone (GnRH) neurons as well as dir-
ectly acting on gonadotropes, indicating that GnIH is a key factor of
the HPG axis. Therefore, we investigated the possible role of GnIH as
a mediator between the HPG and HPT axes involved in the regula-
tion of puberty onset by thyroid status.
Methods: First, we investigated the effect of thyroid status on pu-
berty onset and GnIH expression. Hypothyroidism and hyperthyroid-
ism were induced in female mice at postnatal days 20 by 2-weeks
administration of propylthiouracil (PTU) and thyroxine (T4),respectively. Second, we examined the effect of thyroid hormone (tri-
iodothyronine, T3) on GnIH mRNA expression in hypothalamic ex-
plants. Finally, we investigated the expression of thyroid hormone
receptors (TRs) in GnIH neurons by immunohistochemistry combined
with in situ hybridization.
Results: Female mice treated with PTU were induced to become
hypothyroidism evidenced by the lower T3 and elevated TSH levels,
and loss of weight. Hypothyroidism mice showed delayed pubertal
onset and increased GnIH mRNA expression. These results imply that
increased GnIH expression may inhibit the HPG axis, thus puberty on-
set is delayed. In contrast, T4-treated hyperthyroidism mice, which
determined by elevated T3 and lower TSH levels, and gain of weight,
showed no significant difference in the puberty onset. Although ele-
vated T3 levels did not affect puberty onset in hyperthyroidism mice,
GnIH expression was reduced by less than 50%, indicating that thy-
roid status could regulate GnIH expression. Supporting our hypoth-
esis, T3 treatment decreased GnIH mRNA levels in hypothalamic
explants. Furthermore, we showed that GnIH neurons express both
TR α and TR β , indicating that thyroid hormone could directly act on
GnIH neurons via TRs.
Conclusions: We demonstrated that thyroid status alters GnIH mRNA
expression in vivo and in vitro , and GnIH neurons express TRs, indi-
cating that the effect of thyroid hormone on GnIH expression is me-
diated by TRs. Therefore, we suggest that GnIH is concerned in the
regulation of reproduction by thyroid hormone by mediating cross-
talk between the HPG and HPT axes.P2-6-6
rFSH monotherapy prior to hCG-rFSH combination therapy is an
effective new treatment to achieving future fertility in adolescent
patients with congenital male hypogonadotropic hypogonadism
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Background: Congenital male hypogonadotropic hypogonadism
(CMHH), a disorder associated with infertility, is treated with hCG-
rFSH combination therapy (hCG-rFSH) to achieve fertility. However,
approximately 60% of CMHH could not achieve sufficient spermato-
genesis with the current hCG-rFSH (Sato et al.). Dywer et al. reported
on the effectiveness of rFSH mono-therapy followed by hCG-rFSH to
improve spermatogenesis in adult patients with CMHH with small
testis. But there is no report of this treatment in adolescent patients
with CMHH (ADCMHH).
Objective: With the aim of improving spermatogenesis of ADCMHH,
new methods are to be proposed and effectiveness for spermatogen-
esis is discussed.
Proposal for new treatment: After rFSH (75IU) for two months, hCG-
rFSH is administered in appropriate therapeutic dose according to age.
Case 1: 18-year-old male: He was diagnosed as Kallmann syndrome
(KS) because of micropenis and hyposmia in infancy and identified
with KAL1 mutation. From the age of 12 years, low dose testosterone
was administered. At the age of 16, treatment was changed to rFSH
mono-therapy for 4 months. From the age of 17 to the present, hCG-
rFSH has been continued. After two months of switching to rFSH-
hCG, testosterone reached adult level and testicular volume was
increased to double. Sperm count was confirmed by semen test at
the age of 18.
Case 2: 21-year-old male: At the age of 18, He was diagnosed as KS
because of cryptorchidism, delayed puberty and hyposmia. rFSH
mono- therapy was administered daily for 60 days, then switched to
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 128 of 144hCG-rFSH. Testis volume was less than 1 ml when treatment began
and increased to 5 ml in two years. Testosterone reached adult level.
Nocturnal emission was confirmed.
Conclusion: rFSH mono-therapy prior to hCG-rFSH was used to treat
ADCMHH with small testis. Enlargement of testis and spermatogen-
esis were recognized. This result suggests the effectiveness of this
new method to achieve future fertility in ADCMHH.
Consent for publication: The authors declare that written informed
consent was obtained for publication.P2-6-7
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Background/Aims: CHARGE syndrome is an autosomal dominant
genetic condition characterized by various features such as colo-
boma, heart malformation, atresia of the choanae, retardation of
growth or development, genital anomalies, and ear malformation. In
2004, CHD7 was identified as the gene responsible for CHARGE syn-
drome. Although several diagnostic criteria and genotype-phenotype
studies have been reported for CHARGE syndrome, the complex
phenotypic spectrum associated with pathogenic CHD7 mutations
has not been well understood. The aim of this study was to gain a
greater understanding of various phenotypes of CHARGE syndrome
identified by pathogenic CHD7 mutation.
Methods: We enrolled 17 cases with clinically suspected CHARGE syn-
drome diagnoses. All coding exons of CHD7 of all the cases were se-
quenced using an Ion PGM system with the Ion Ampliseq Custom
Panel for hypogonadotropic hypogonadism (including CHD7 ). We
identified ten cases with pathogenic CHD7 mutations and extracted
phenotypes from medical records or clinical information collected from
the primary pediatrician. In cases harboring a previously reported muta-
tion, we compared our case with the published clinical information.
Results: We identified five nonsense, three frame-shift, and one mis-
sense mutation in ten CHARGE syndrome cases. The same nonsense
mutation was identified in two unrelated cases. Of the nine CHD7
mutations, six were novel. At the time of the study, the mean patient
age was 5.8 years (1 month to 12.6 years) and nine of the ten pa-
tients were male. Seven male patients had cryptorchidism and/or
micropenis but two male patients did not have either phenotype as
an endocrinological finding. A male patient harboring a CHD7 non-
sense mutation, who had double outlet right ventricle (DORV) and
esophageal atresia, died at the age of 1 year 9 months owing to sud-
den cardiorespiratory insufficiency of unknown cause. Another infant
with the same CHD7 mutation as the deceased had no congenital
heart disease and had several different phenotypes. The other cases
displayed some phenotypic differences from those previously re-
ported in cases with the same CHD7 mutation. We could not find a
clear phenotype trend by type of mutation.
Conclusion: This study shows that there is a range of phenotypes
within the diagnosis of CHARGE syndrome, even in individuals
with the same CHD7 mutation. Our results indicate that the type
and position of CHD7 mutation alone are not sufficient to deter-
mine CHARGE phenotype. Other elements, such as environmental
factors during the fetal period, might modify the CHARGE syn-
drome phenotype.P2-6-8
Physical assessment and reference growth curves for children with
46, XY disorders of sex development
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Objective: In addition to the abnormalities pertaining to sexual de-
velopment, impaired growth and development is another important
issue to be considered in disorders of sex development (DSD)
patients. This study is to profile the growth and development of
children with 46, XY DSD.
Methods: Cases of 46, XY DSD aged between 0-16 years were
sourced from the hospital registration database. Height differences
were compared between DSD and normal boys. Growth curves for
DSD were obtained by LMS method.
Results: 571 cases of non-CAH 46, XY DSD were included in the
study. The HtSDS of study subjects were -0.031 ± 1.202. 304 cases
showed good response with HCG standard test, with HtSDS of 0.082
± 1.212. 123 cases showed a poor response, with HtSDS of -0.240 ±
1.090. The HtSDS of poor response with HCG test group was gener-
ally lower than that of normal boys (P=0.017). In children aged 12
years or older in both groups, HtSDS were significantly lower than
normal boys. HtSDS of both groups were lower than average height
of normal boy among multiple age groups since early infancy. A
growth lag in study subjects was particularly discernible in the 12-16
years age group, which tended to be more pronounced in the poor
response group.
Conclusion: The growth retardation of children with non-CAH, 46, XY
DSD was observed in early childhood and puberty. The level of re-
tardation related with androgens, which suggests that the male hor-
mone has an effect on the physical development of these children.P2-6-9
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Background: WAGR (W ilms’ tumor, a niridia, g enitourinary
anomalies, and mental r etardation) syndrome is rare genetic dis-
order caused by contiguous gene deletion at 11p, including WT1 in-
volved in the development of Wilms’ tumor and urogenital
abnormality and PAX6 relevant to the development of arniridia and
mental retardation. Here, we report a patient with WAGR syndrome
and 46,XY,del(11)(p11.12p14.3) who was born to a mother with
46,XX,ins(13;11)(q21.2;p11.12p14.3).
Case report: A 5-month-old Japanese phenotypic female presented
with ambiguous genitalia, microphthalmia and cataract. Ultrasound
examination showed uterus-like structure and failed to delineate go-
nads. MRI revealed hypoplasia of the corpus callosum and cerebel-
lum. Cytogenetic analysis showed a 46,XY,del(11)(p11.12p14.3)
karyotype in the patient and a 46,XX,ins(13;11)(q21.2;p11.12p14.3)
karyotype in the phenotypically normal mother. Family history
showed multiple abortions by the maternal grandmother and a sin-
gle abortion by a maternal elder brother.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 129 of 144aCGH analysis: An approximately 27.2 Mb deletion on 11p including
WT1 and PAX6 was detected in the patient, and no apparent dele-
tion or duplication was found in the mother.
Discussion: The results indicates that the patient had WAGR pheno-
type because of the contiguous gene deletion at 11p. Notably, the
interstitial deletion at 11p of this girl was caused by the balanced in-
sertion of the mother, and the family history suggests that the inser-
tion was derived from the grandmother and inherited to the
maternal elder brother as well. Thus, careful genetic counseling is
recommended in this family, with regard to the risk of the develop-
ment of WAGR syndrome in the offsprings.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Object: Hypospadias is a common congenital malformation in males and
often observed in infants with intrauterine growth restriction (IUGR). Be-
cause placental insufficiency has been implicated in the pathogenesis of
IUGR, we investigated the association between placental histological find-
ings and clinical presentations in patients with hypospadias.
Subject and method: Thirty six boys born between January 2011
and September 2015 were retrospectively analyzed based on their
medical records.
Results: Hypospadias are classified into three types based on the lo-
cation of urethral meatus; glandular/graular and coronal/subcoronal
type (type 1), distal (penile) type (type 2), proximal (peroscrotal, scro-
tal, perineal) type (type 3), and 17 patients (47.2%) were categorized
into type 1, 4 patients (11.1%) in type 2 and 15 patients (41.7%) in
type 3. Thirteen out of 28 IUGR patients were classified into type 3
hypospadias, whereas 2 out of 8 non-IUGR patients had type 3 hypo-
spadias, suggesting that the percentage of severe hypospadias was
greater in IUGR patients compared to non-IUGR patients. Hypospa-
dias was observed more frequently in preterm-IUGR patients (94.1%)
than term-IUGR patients (63.4%). Nine patients (25%) exhibited geni-
tourinary complications including micropenis in 2, cryptorchidism in
5 and bifid scrotum in 2. Histological examinations revealed placental
abnormalities such as low placental weight, ischemic changes, calcifi-
cations, villitis and degenerative changes in most of IUGR patients.
Discussion: Hypospadias is caused by the abnormal fusion of urethral
folds during early fetal development, by the time of approximately 16-
week of gestation. Placenta plays important roles in the development
of external genitalia by stimulating the synthesis of fetal gonadal hor-
mones through the production of placental hCG; therefore, the im-
paired placental function in IUGR patients may be responsible for the
insufficient development of external genitalia and cause hypospadias.
Conclusion: Severe hypospadias are more frequently observed in
IUGR patients, especially in case of preterm birth.
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The effect of letrozole on the reproductive function and linear
growth in the early and middle period of puberty boy
Juan Lin, Mei Hua Ma
Department of Pediatrics, The Third Affiliated Hospital of Sun Yat-Sen
University
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-6-11Objective: To provide clinical data for the effect of letrozole on the
reproductive function and linear growth in the early and middle
period of puberty boy.
Method: 43 early and middle pubertal boy with seriously damaged
predict adult height, treated with letrozole 1.5 mg/m2/d Po( ≯
2.5mg/d) were enrolled as treatment group. 48 cases of healthy pu-
berty boy(include boy with idiopathic short stature) were enrolled as
control. According to letrozole treatment time, divide into short time
group, mid-long time group, long time group, the control group as
the match.
Results: After letrozole treatment, testicular volume and Genital stage
of treatment group with short time and mid-long time group were
significantly increased compared with the corresponding control
group. The testicular volume and T in control group had a good posi-
tive correlation, as well in treatment group (r = 0.803, P < 0.001 and
r = 0.835, P < 0.001).The testosterone levels in each group of treat-
ment group were significantly higher than accordingly control group,
as well as serum'sH, LH, LH/FSH level. While E2 level with long time
group of treatment group significantly reduced than the control
group. 17 cases of control group, 13 cases of treatment group had
serum AMH, INHB level tested before and after intervention. The con-
trol group of serum AMH level had decreasing trend in puberty,
blood testosterone values elevated gradually, and serum AMH and T
show a significantly negative correlation (r = -0.466, p=0.059). While
treatment group of serum AMH and T show significant positive cor-
relation (r=0.586.p=0.035), differ from normal AMH change trend.
Serum INHB level in two groups after intervention all had different
level rise, and INHB in control group increase more than the treat-
ment group, but there was no statistically significant difference. Chil-
dren in long time group of treatment group had more evident bone
age inhibition than control group.
Conclusion: The testicular volume change and testosterone levels
changes had high consistency, suggesting it may clinical preliminary
judge serum testosterone levels according to the size of testis. Letro-
zole treatment can obviously promote the secondary sex characters
development in adolescent boys. The AMH change trend with letro-
zole treatment group differ from normal trend, prompt that it may
have inhibitory effect on testis maturity. Letrozole treatment group
with its serum INHB level had a little different with control group, it
cannot deny that testis sertoli cells function had unaffected com-
pletely, further study needed. Children with long-term letrozole treat-
ment had bone age delayed.
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Aims: Disorders of puberty are diagnosed and monitored by meas-
urement of hormones of the hypothalamic-pituitary-gonadal (HPG)
axis. As growth and development can influence normal circulating
concentrations of these hormones, gender- and Tanner stage-specific
gonadotropin ranges are more meaningful than age-specific values.
In particular, given the pulsatile nature of gonadotropin release, are
baseline luteinising hormone (LH) and follicle-stimulating hormone
(FSH) levels using a sensitive assay able to distinguish between pre-
puberty and the onset of puberty?
Methods: LH and'sH results (measured on Beckman Coulter UniCel
DxI 800 analyser) betweeen March 2011 and October 2015 were ex-
tracted from Monash Pathology laboratory information system. Patients
were included where data on Tanner staging were available. Patients
with primary gonadal failure and on treatments influencing the HPG
axis were excluded. The remaining data were used to calculate gender-
and Tanner stage-specific LH and'sH ranges (mean +/- 2SD).
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 130 of 144Results: Of 724 records of paired LH and'sH measurements Tanner
staging for 185 was available. See table below for gender- and
Tanner stage-specific LH and'sH ranges (mean +/- 2SD).
Conclusion: Results from a cohort of healthy children and adoles-
cents are ideal for calculation of paediatric reference intervals for go-
nadotropins. Nevertheless, our data from hospital outpatients (after
exclusion of any intervention that might alter HPG axis) still provided
a useful picture of gonadotropin levels across Tanner stages. More
data points are required to establish reference ranges for routine
clinical use. There is significant overlap between gonadotropin results
between Tanner Stages I and II suggesting that diagnosing the onset
of puberty is difficult using baseline measurements, particularly in fe-
males, suggesting the need for gonadotropin-releasing hormone-
stimulated gonadotropins to assess maturity of the HPG axis.
P2-6-13
The efficacy of intramuscular testosterone enanthate therapy for
micropenis or microphalus is different among hypogonadotropic
hypogonadism, hypergonadotropic hypogonadism, and other
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Background: Micropenis or microphalus is defined as penile length
(PL)-SDS less than -2.5 with the absence or presence of anatomical
defects including hypospadias, respectively. We previously reported
that intramuscular testosterone enanthate (TE) therapy effectively in-
creased PL in boys with micropenis or microphalus. However, the ef-
fect of TE has never been compared among hypogonadotropic
hypogonadism, hypergonadotropic hypogonadism, and idiopathic
forms.
Methods: We retrospectively investigated the effect of TE in 60 Japa-
nese boys (age, median 2.4 years, range 0.3 to 6.8) with micropenis
(N=43) or microphalus (N=17) at Department of Pediatrics, Keio Uni-
versity Hospital. The inclusion criteria are as follows: (1) age AR and
SRD5A2 mutation (Group 3). Increment of PL-SDS at the first injection
of TE was primarily assessed between micropenis and microphalus or
among Groups 1, 2, and 3 by non-parametric analyses.
Results: All the boys showed significant improvement of PL-SDS with
up to four times TE injections (before TE, median -3.9, range -13.6 to
-2.6; after TE, median -1.8, range -5.3 to 0.6; p <0.0001) without se-
vere adverse events. Increment of PL-SDS at the first injection of TE
was significantly correlated inversely with age (r =-0.45 and p
=0.0003), not significantly correlated with PL-SDS before TE (r =-0.20
and p =0.13), not significantly different in boys between micropenis
(median 1.3, range 0.0 to 8.1) and microphalus (median 1.3, range
-0.1 to 4.3) (p =0.89), and significantly greater in group 1 (median
3.1, range 0.8 to 8.1) than in group 2 (median 0.9, range -0.1 to 5.9)
or in group 3 (median 1.3, range 0.0 to 4.9) (p =0.026; p p
Discussion: The response of PL to TE therapy was significantly
greater in boys with hypogonadotropic hypogonadism than those
with other etiologies. These results suggest that patients with hypo-
gonadotropic hypogonadism can relatively preserve PL potential,
consistent with the previous findings by Bin-Abbas B, et al. that an
adult PL in hypogonadotropic hypogonadism reached within 2 SD of
the mean by replacement therapy at puberty.
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Background: Central precocious puberty (CPP) is a characteristic de-
velopment of sexual puberty as a consequence of premature activity
of hypothalamic hypophyse gonadal (HHP) axis before 8 years oldfor girls or 9 years old for boys. Several studies have showed differ-
ent results in Leuprolide Acetate (LA) therapy for CPP in terms of ad-
ministration doses and time of treatment on suppression of
gonadotropine secretion. Objective: To determine effects of different
administration of LA therapy, monthly doses and every three month,
on suppression of LH secretion in CPP patients.
Method: Meta-analyses of systematic review on available literature
from Cochrane library, MEDLINE, EBSCO, PROQUEST and other regis-
tered reference about therapy to suppress LH secretion in CPP patients.
Three researches independently conducted reviews on abstract and
full- texts for inclusion criterion and data extraction, respectively.
Result: There are two studies fulfill inclusion criterion and included in
the meta-analyses. Meta-analyses showed that LH suppression varies
with different administration doses and time of LA. These studies
compare LA therapy using 11,25 mg/3 month with control 7,5 mg/
month, 22,5 mg/3 month with control 7,5 mg/month, and 22,5 mg/3
month with control 11,25 mg/3 month doses.
Conclusion: LA therapy 7,5 mg/month gives greater LH suppression
compared with 11,25 mg/3 month and 22,5 mg/3 month; while LA
therapy 22,5 mg/3 month provides greater suppression compared
with 11,25 mg/3 month. There are no differences in growth velocity
with different doses of LA therapy.
Key words: Central precocious puberty, LH suppression, leuprolide
acetateP2-6-15
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Objective: This study aimed to investigate the relationship between
the plasma level of Kisspeptin and premature thelarche (PT) in fe-
male infants and risk factors associated with PT in female infants.
Methods: Forty-two female infants with an onset of PT under 2 years
of age were selected from Children’s Hospital of Jiangxi Province during
Sep 2013 to Mar 2016.Out of the 42 PT patients,18 cases were observed
complete regression( CR group) of PT symptom, 11 were persistent or
reproduction(PR group),13 were developed ICPP(ICPP group).Thirty-five
healthy age-matched female infants were served as controls(control
group).Plasma level of Kisspeptin was examined by enzyme linked im-
munosorbent assay(ELISA). Risk factors associated with PT were ana-
lyzed using multivariable logistic regression analysis.
Results: 1.In the ICPP and PR group, kisspeptin levels were significantly
higher compared to control group (1.52 ± 0.14 ng/ml vs 0.45± 0.15ng/
ml, P<0.05; 0.73 ± 0.12ng/ml vs 0.45 ± 0.15ng/ml, P<0.05).2.There were
no significantly difference between CR and control group 3. There were
association between the prevalence of PT and inharmonious relation-
ship in parents, PT family history, mother’s menarche age, pollution of
living environment, exposure to light at night.
Conclusion: These results suggest that kisspeptin maybe closely re-
lated with PT in female infants which will develop to ICPP and the
kisspeptin levels could be a potential predict marker for these pa-
tients. Inharmonious relationship in parents, PT family history,
mother’s menarche age, pollution of living environment, exposure to
light at night were the risk factors to PT.P2-6-16
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Objective: Gynecomastia is defined as a benign enlargement of the
male mammary glands due to an imbalance of free estrogen and an-
drogen activity, resulting in palpable subareolar tissue. This condition
is frequently benign in origin but may have a serious underlying
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 131 of 144etiology. In this study we sought to investigate various etiology and
clinical course in patients with gynecomastia.
Methods: During 2009-2014, a total of 73 patients were diagnosed
with gynecomastia. Clinical courses and the causes of gynecomastia
were reviewed retrospectively.
Results: The number of patients showing gynecomastia based on
onset-age was 15(20.5%) between 5 and 9 years of age, 39(53.3%) be-
tween 10 and 14 years of age, and 19(26%) between 15 and 18 years
of age. The number of patients with gynecomastia based on age at visit
was 10(13.8%) between 5 and 9 years of age, 31(42.4%) between 10
and 14 years of age, and 32(43.8%) between 15 and 18 years of age.
The etiology of gynecomastia includes pubertal gynecomastia (75.3%),
simple obesity (12.3%), central precocious puberty (2.7%), Cushing’ s
syndrome (20.7%), Klinefelter syndrome (2.7%), idiopathic hyperprolac-
tinemia (2.7%), subclinical hypothyroidism (2.7%), aromatase excess
syndrome (2.7%), antiepileptic drug (2.7%), and ADHD drug (2.7%).
Among the 55 patients with pubertal gynecomastia, 69% were only ob-
served, 19% were treated with tamoxifen, and 12% underwent surgical
procedure. Mean (SD) age of treated patients with tamoxifen was 14.6
± 0.7 years with gynecomastia duration of 21.7 ± 4.8 months. Mean re-
duction in breast nodule diameter was 1.45 ± 0.69cm (p<0.0001) after
treatment of 3.2 ± 0.9 months with tamoxifen. No side effects were re-
ported in the treated subjects. Mean (SD) age of treated patients with
surgical procedure was 17.4 ± 0.5 years with gynecomastia duration of
47 ± 7.3 months in addition to satisfactory results.
Conclusions: Considering the diversity of possible etiologies a careful
history taking and physical examination or laboratory testing is im-
perative and treatment of the underlying cause is warranted after
gynecomastia has been diagnosed.P2-6-17
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Objective: To investigate the aromatase expression in the presence
of insulin resistance, or the conditions with metformin interference.
Methods: Insulin resistant 3T3-L1 preadipocytes were induced by glu-
cose (25 mmol/L) and insulin (10-6mol/L). Cells were divided into
three groups, including (i) blank control, (ii) preadipocytes with insu-
lin resistance, and (iii) preadipocytes with insulin resistance subject
to metformin with a concentration of 1.0mmol/L, 0.1 mmol/L and
0.01 mmol/L, respectively. Determination of aromatase (Cyp19a1)
mRNA and protein expression was performed using Real-time PCR
and Western blot analysis, respectively.
Results: After high glucose and insulin induction, the glucose con-
sumption showed remarkable decrease compared with the baseline
level (12.39 ± 2.14mmol/L vs. 5.74 ± 2.00mmol/L, P<0.05), while the
glucose consumption ratio also showed obvious decrease compared
with the baseline level (68.87 ± 11.91% vs. 31.91 ± 11.12%, P<0.05).
Compared with the insulin-resistant cells, cells subject to low dose of
metformin (10-5mol/L) induced no statistical difference, however,
when cells were subject to metformin of 10-3mol/L or 10-4mol/L, re-
markable decrease was noticed in the expression of Cyp19a1 compared
with the insulin-resistant adipocytes. Compared with the mature adipo-
cytes, the expression of aromatase in the insulin-resistant cells showed
remarkable up-regulation. However, after metformin interference with
a concentration of 10-3mol/L and 10-4mol/L, the expression of aroma-
tase was obviously down-regulated. Compared with the metformin
group, the expression of p-ERK showed obvious decrease in the cells
subject to metformin and PD98059. The p-ERK/t-ERK showed
remarkable decrease after PD98059 interference. Furthermore, the ex-
pression of Cyp19a1 gene expression after PD98059 showed remark-
able increase compared with the cells subject to metformin.
Conclusions: Metformin could down-regulate the expression of
Cyp19a1 mRNA and protein expression significantly, and the MEK/
ERK signaling pathway involved in such process.P2-6-18
Peripheral precocity due to hcg secreting pineal tumor: a rare cause
Sk H Rahaman
Department of Endocrinology, All India Institute of Medical Sciences
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A boy of three and half year old brought to our department with
complains of progressive phallic enlargement, noticed by the mother
at the age of two and half year. Family members also noticed change
of voice and appearance of pubic hair for 6 months. He had acceler-
ated growth and aggressive behaviour. However, there was no facial
hair. The child didn’t have headache, vomiting, visual impairment or
seizure. Neither there was bony pain, fracture or deformity. He was
born out of non-consanguineous marriage, full term. Mother’s preg-
nancy was uncomplicated. There was no birth asphyxia. His develop-
mental milestones were normal. There was no significant medical
history in the past. Family history was non-contributory.
He was alert, hyperactive, normotensive without having goiter, facial
asymmetry or bony deformity. There was no hyperpigmentation. An-
thropometrics revealed height 107cm, weight 22 kg (both >97th cen-
tiles, according to Indian chart), MPH 163cm (5th centile, according
to Indian chart). Testicular volume bilateral 6ml, SPL 8cm and pubic
hair Tanner stage 3. There was no hepato-splenomegally. Rest of the
general and systemic examination revealed no abnormality. Investi-
gations revealed normal hemogram, kidney and liver function. Bone
age was 5.5 years. He had elevated testosterone (509.62 ng/dl) and
suppressed gonadotropins (LH<0.21mIU/ml,'sH<0.66mIU/ml). hCG
stimulation test didn’t increase LH levels. A diagnosis of peripheral
precocity was made. On further evaluation, we found normal thyroid
function, 17 hydroxy-progesterone and DHEAS. However serum beta-
hCG level (31.49 mIU/L, normal level: To search for the source of
beta-hCG, CECT chest and abdomen was done and was normal. MR
sella and brain revealed a subtle abnormality in pineal gland but
without any definite lesion. USG scrotum revealed no testicular mass.
FDG PET scan and 68 Gallium DOTANOC PET CT scan also didn’t con-
tribute. In view of non-localisation, CSF analysis was done. CSF beta-
hCG level (49.21 mIU/L) came higher than peripheral blood and
alpha feto protein level was normal with normal CSF cytology. To
characterise the lesion of pineal gland, thin section MR brain was
done which picked a 8.0 x 6.0 x 5.0 mm cystic pineal gland with
blood fluid level within. A diagnosis of peripheral precocious puberty
caused by beta-hCG secreting pineal tumor was made. After discus-
sion with the parents and medical oncology opinion, cisplatin based
chemotherapy was planned.
Consent for publication: The author declares that written informed
consent was obtained for publication.
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Challeges in the evaluation of primary amenorrhea
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Evaluation of primary amenorrhea is a clinical challenge wherein one
often comes across atypical clinical scenarios. We report 5 cases of
primary amenorrhea to highlight the importance of a careful and in-
dividualized evaluation to arrive at a diagnosis.
Case 1 is a 16-year-old patient of primary amenorrhea with presence
of secondary sexual characteristics compatible with her chronological
age. On examination, a blind vaginal pouch was observed. Her pelvic
ultrasound and magnetic resonance imaging revealed hypoplastic
uterus without endometrial lining with atretic upper vagina. Bilateral
ovaries were normal for age with numerous follicles. Hormonal pro-
file was normal and karyotype was 46XX, thus leading to the diagno-
sis of Mayer-Rokitansky-Kuster-Hauser syndrome.
Case 2 is a 14 year old patient of primary amenorrhea and absent
secondary sexual characteristics. Evaluation revealed female external
genitalia, 46 XY karyotype, hypergonadotrophic hypogonadism, ab-
sent gonadal tissue and absent Mullerian structures. Laparoscopic
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 132 of 144examination is planned. The most probable diagnosis in this case is
rare embryonic testicular regression or partial gonadal dysgenesis.
Case 3 is a 15 year old patient of primary amenorrhea and absent
secondary sexual characteristics. Examination was suggestive of fe-
male external genitalia, 46 XX karyotype, hypergonadotrophic hypo-
gonadism, hypoplastic uterus with bilateral small ovaries devoid of
follicles. A diagnosis of primary ovarian insufficiency has been consid-
ered in this case.
Case 4 presented to us at 14 years of age with primary amenorrhea
and absent secondary sexual characteristics. Ambiguous genitals
were detected at birth; evaluation revealed 46 XY karyotype with hy-
poplastic mullerian structures and right sided gonad. At 7 months of
age, she was subjected to clitoral resection and gonadectomy which
revealed testicular tissue with ovarian stroma. Examination was sug-
gestive of female external genitalia with clitoral scarring and a blind
vaginal pouch, hypergonadotrophic hypogonadism, absent gonadal
tissue and absent Mullerian structures. A diagnosis of partial gonadal
dysgenesis versus ovotesticular DSD was considered.
Case 5 is a 15 year old patient of primary amenorrhea and absent
secondary sexual characteristics. Examination was suggestive of fe-
male external genitalia, blind vaginal pouch, 46 XY/45XO karyotype,
hypergonadotrophic hypogonadism, hypoplastic uterus with bilateral
small ovaries. Laparoscopic examination was suggestive of rudimen-
tary Mullerian structures and dysplastic gonads which were excised.
She was diagnosed as case of Mixed Gonadal dysgenesis.
The above cases demonstrate the atypical presentations and varied
constellation of clinical and laboratory features which can pose a
diagnostic dilemma to the treating physician unless a systematic
strategy for evaluation is employed.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Background: Leptin is mainly produced by adipocytes. In animal and
human, it is a potnet anorectic and increases in obesity. Some re-
ported that precocious puberty is prevelent in children with obesity.
Objective and hypotheses: This study was done to see the changes
of blood leptin levels in both obese and non-obese children with
early puberty or precocious puberty.
Method: Study patients consist of 325 children with early puberty or
precocious puberty showing abnormally high blood leptin levels
(>7.8 ng/mL) who visited our institute for GnRH stimulation tests be-
tween Jan 2014 and Feb 2015. Their medical records were reviewed
retrospectively. And their clinical and laboratory data was analyzed.
Results: They are 273 girls and 52 boys. Their mean ages are 9.2 ±
1.7 yrs. 254 out of 325 (78%) were non-obese, and 71 (22%) were
obese. Hyperleptinemia was more frequent in non-obese group than
obese group. Blood leptin levels (ng/mL) was significantly higher in
obese group compared to non-obese group, 17.0 ± 7.8 vs 12.6 ± 4.9, re-
spectively (p<0.001). In obese group, boy’s blood leptin levels (ng/ mL)
are significantly higher than girl’s, 23.2 ± 11.2 vs 16.1 ± 6.8, respectively
(p<0.05). Blood leptin levels does not show any significant difference
between GnRH (+) (peak LH >5 mIU/mL) and GnRH (-) groups. In GnRH
(+) group, their age was significantly older compared to the age of
GnRH(-) group in both girls and boys (p<0.05). Interestingly, obese
GnRH (+) girl’s age was younger than non-obese GnRH (+) girls
(p<0.05), this would be said that obesity may associates with earlier pu-
bertal onset in GnRH (+) girls with hyperleptinemia.
Conclusion: hyperleptinemia was more frequently found in non-
obese sexually precocious children than expected. Further study
regarding the mechanism of hyperleptinemia and its clinical signifi-
cance in non-obese children with early puberty or precocious
puberty is necessary.P2-6-21
Mood disorder in one of adolescent monozygotic twins with
late-onset combined methylmalonic aciduria and homocystinemia
due to MMACHC gene defect
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This study reported a school boy, one of the monozygotic twins, with
late-onset combined methylmalonic aciduria and homocystinemia
(Cblc type) characterized as mood disorder. The previously happy
boy presented with feeling sad, anxious, irritable, and lack of interest
at the age of 12 years and 5 months . The patient's diagnosis was de-
layed until a metabolic workup revealed hyper-ratio of plasma pro-
pionylcarnitine ^acetylcarnitine (0.37 vs. normal range 0.04 to 0.25),
hyperhomocysteinemia(>65umol/L vs. normal range 5-13.9umol^L),
low methionine(5.525umol ^L vs. normal range 8 - 35umol ^L), and
methylmalonic aciduria(197.88 mmol/mol creatinine vs normal range
0.2 to 3.6 mmol/mmol creatinine) . MRI showed cerebral atrophy. Mo-
lecular testing showed compound heterozygosity for mutations
(c.482G>A and c.609G>A) in the MMACHC gene. After a month’s
treatment with hydroxocobalamin, L-carnitine, betaine, and folate,
progressive improvement has been observed. Another of the twins
had no symptoms, and the MRI was normal, but similar changes
were found in his metabolic workup, and the same mutations were
found in his MMACHC gene, so we provided treatment for him too.
Based on this case, we recommend that all teenagers with psychi-
atric disorders should be considered in making a differential diagno-
sis of inborn errors of metabolism.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Aims: To evaluate the fat mass and body composition by dual-
energy x-ray absorptiometry (DEXA) in Chinese precocious puberty
girls, and to examine the association between body fat composition,
body mass index (BMI) and pubertal mutation in girls.
Method: CPP girls were diagnosed according to their clinical charac-
ters and the results of LHRH stimulating test. Total body fat mass
and percent body fat (BF) was assessed with DEXA.
Results: Altogether, 26 central precocious puberty (CPP) girls and 28
age-matched prepubertal girls (age, 7 to 9 years) were enrolled in
this study. The %BF of the CPP girls was significantly higher than
control group (30.53 VS 28.33, p<0.05); while the BMI of the two
groups was 16.84 and 15.78, respectively (p<0.05). In the CPP girls,
the peak LH level in the LHRH stimulating test was negative corre-
lated with the %BF and BMI.
Conclusion: Higher BMI and %BF were found in CPP girls. The use of
DEXA has been shown to be a reliable and accurate measurement of
fat mass. Because of its low cost and rapid administration, BMI is still
a useful measurement for screening obesity and puberty.
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Introduction: Primary amenorrhoea is defined as either absence of
menarche by age 14 if the girl has no secondary sexual characteris-
tics development, or by age 16 in the presence of normal growth
and secondary sexual characteristics. Secondary amenorrhoea is de-
fined as the absence of menses for three months in ladies with
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previous oligomenorrhoea. Numerous conditions could lead to
amenorrhoea. We would like to describe the clinical features and in-
vestigation findings of two girls who had amenorrhoea due to mül-
lerian agenesis.
Case 1: She was born with low-birth-weight (1.91kg). She had bilateral
inguinal hernia at 2 months old with herniotomy done. Karyotype re-
vealed 46XX. Ultrasound at 5-year-old could not identify uterus and
ovaries. Vagina was probably present. She defaulted follow-up since 6
years old. She was referred back to our hospital at age of 10 due to
short stature. She had mild thoracic scoliosis. She had gradual pubertal
development but did not have menarche. Investigations at 14 years old
showed normal serum LH,'sH and oestradiol levels. Repeat of ultra-
sound pelvis failed to identify normal ovaries and uterus. MRI pelvis
demonstrated normal ovaries but could not identify normal uterus and
vagina. Impression was uterine agenesis
Case 2: She presented at age 13 because of obesity. She had breast
development at 10 years old. She reported to have menarche at 13
years old, but she had no more menstruation afterward. She had pro-
gressive pubertal development thereafter. Medroxyprogesterone
acetate was prescribed but no withdrawal bleeding occurred. Investi-
gations showed normal serum LH,'sH and oestradiol levels. The
uterus and ovaries were not visualised in ultrasound pelvis. MRI pel-
vis revealed normal ovaries but uterus was not seen. Vagina was
probably rudimentary. The diagnosis was also müllerian agenesis.
Discussion: Müllerian agenesis, also known as Mayer-Rokitansky-
Kuster-Hauser (MRKH) syndrome, is reported to be the second com-
monest cause of primary amenorrhoea. Majority of cases are spor-
adic. The estimated incidence is 1 in 4000-5000 liveborn females.
About 15% of girls with primary amenorrhoea are caused by MRKH
syndrome. It could be associated with other anomalies involving
renal system, skeletal system and hearing. Paediatricians should con-
sider this entity in the differential diagnoses of primary amenorrhoea,
as counselling on fertility problem is needed. These girls should be
referred to gynaecologist for creation of neovagina when they start
to be sexually active.Fig. 1 (abstract P2-6-25). See text for descriptionP2-6-24
Precocious Puberty Secondary to Juvenile Granulosa Cell
Tumor - A Case Report
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-6-24
Precocious puberty is characterized by early pubertal changes before
the age of 8 years in girls and 9 years in boys. The etiologies for pre-
cocious puberty in young girls include central, peripheral, and some-
times idiopathic causes. In girls with peripheral precocious puberty, a
common etiology is the presence of an ovarian tumor. This is a case
of a 4-year old girl who developed prolonged vaginal bleeding,
breast budding and abdominal enlargement. Diagnostic evaluation
revealed elevated estradiol levels and presence of a left adnexal
mass. Surgical excision of the tumor led to cessation of the vaginal
bleeding and normalization of estradiol levels. Pathology reported a
juvenile granulosa tumor of the ovary.
Consent for publication: The authors declare that written informed
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Case Report: Sex Chromosome Disorder of Sexual Development:
45,X/46,XY Mosaicism
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A 45,X/46,XY mosaicism is associated with a broad spectrum of phe-
notypes ranging from apparently normal male development to indi-
viduals with incomplete sexual differentiation and accompanying
clinical signs of Turner syndrome in both males and females [1]. This
type of disorder of sexual development is associated with a numer-
ical sex chromosome abnormality leading to abnormal gonadal de-
velopment [2]. Among individuals with a 45,X/46,XY karyotype,
sexual ambiguity is the most common presentation, accounting for
approximately 60% [1]. This case report of an 11-year old male who
presented with ambiguous genitalia at birth, documents the medical
and genetic complexity of children with DSDs and the need for a
multi-disciplinary team approach. The patient was born, preterm, first
of twins, and was noted to have hypospadias with chordee and with
non-palpable gonads. The twin brother exhibited a normal male
genitalia. On physical examination, he has a short stature and exam-
ination of the external genitalia showed presence of a phallus, hypo-
spadias with chordee, perineal body with a urethral orifice and
hyperpigmented empty labio-scrotal folds, pubic hair tanner stage 2
and genitalia tanner stage 2. Diagnostic work-up revealed presence
of mullerian structures (uterus, fallopian tubes, and cervix) and non-
functioning gonads. Chromosomal analysis revealed 45,X/46,XY mo-
saicism. Total laparoscopic hysterectomy, bilateral gonadectomy and
first stage repair of hypospadias were the surgical management of
choice after the decision was made to continuously rear the patient
as a male and to prevent tumor development. Growth hormone and
testosterone were advised to the family as the most appropriate hor-
mone treatment for the patient.
Consent for publication: The authors declare that written informed
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Introduction: Aldosterone Synthase deficiency(ASD) is a rare auto-
somal recessive disease caused by CYP11B2 gene mutation, usually
presenting with severe salt-wasting in infancy or stress-induced
hyperkalaemia and postural hypotension in adulthood. ASD is unable
to be detected by Neonatal screening of 17-hydroxyprogesterone,
Table 1 (abstract P2-7-2). Summary of Cases
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 134 of 144hence patients would not be diagnosed until they suffer from salt-
wasting crisis.
Objective: to summarize the clinical features of ASD.
Method: By describing clinical features and outcomes.
Result: Two brothers (M1, M2) visited our unit for the first time at 2m
and 2.5y respectively; the other patient is a 5month-old girl (F). All of
three patients had repeated vomiting with poor feeding at newborn
period and failure to thrive. They all visited local hospitals and were
found to have hyperkalaemia, hyponatremia and metabolic acidosis.
Treatment of underlying condition was started at that time, followed
by giving sodium supplementary 2.0-4.5g/d. “F” has a healthy sister;-
and a brother who died 10 days after birth, was also suspected to be
affected. All of them have normal external genitalia. “M1” and “F” la-
boratory test showed: hyperkalaemia [K+ 7.64~7.69mmol/l], hypona-
tremia [Na+ 123~132mmol/l], patient F had metabolic acidosis.
Plasma ACTH, Cortisol, 17-hydroxyprogesterone, Androstenedione
were normal. Plasma renin was highly elevated, while plasma aldos-
terone was in normal. Sequencing of CYP11B2 gene showed that
“M1” and “M2” both carried same heterogenous pathogenic muta-
tion: c.1121G>A (p.Arg374Gln) and c.1486delC p.(Leu496fs) , inherited
from their parent. “F” homozygous for c.1303G>A p.(Gly435Ser)
inherited from her mother who has generalized weakness with un-
known newborn condition. “M2” had been given only sodium sup-
plementation treatment till 6 month old. He presented normal
growth and blood electrolyte till his last follow up at 4.33 years old.
“M1” and “F” received fludrocortisone therapy at dosages of 0.1 mg
Qd and 0.1 mg Bid, with sodium supplementation 2-3g/d and 3-6g/d
respectively. “M1” mother only gave him fludrocortisone at 0.1g Qd
and discontinued sodium therapy by herself when M1 started to re-
ceive his food supplements at 6 month old. He regularly followed up
till his last visit at 1 years old, showed normal blood electrolyte and
growth. “F” last visit was at 12m, still needed NaCl 3-6g/d supple-
mentation and fludrocortisone therapy 0.1 g Bid. Her blood electro-
lyte was normal but her growth is slower than others her age.
Conclusion: We reported 3 Chinese patients from two kindred that
have newborn salt-wasting clinical features. Adequate fludrocortisone
therapy and sodium treatment brings good prognosis for patients.
Consent for publication: The authors declare that written informed
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Background: Pheochromocytoma (PHEO) and paraganglioma (PGL) are
rare catecholamine producing neuroendocrine tumors in children.
Hypertension with headaches, sweating and palpitation are the com-
mon presenting symptoms of PHEO/PGL. Measurement of plasma free
metanephrines or urinary fractionated metanephrines is the gold stand-
ard for diagnosis of PHEO/PGL. Generally, the tumor can be located by
computed tomography (CT) scan, magnetic resonance imaging (MRI) or
metaiodo-benzylguanidine (MIBG) scintigraphy.
Case presentations: We reported 3 cases of PHEO/PGL who had un-
usual presentation or trouble localizing the lesion. They were man-
aged at the pediatric endocrine unit of King Chulalongkorn Memorial
Hospital between 2011 and 2015. Table 1 summarized their presenta-
tion, management and genetic testing in brief.
Cases 1: A 14-year-old Thai boy presented with hypertensive crisis,
congestive heart failure and chronic intestinal pseudo-obstruction.
Case 2 was an 8-year-old Thai boy who presented with head-
aches, sweating, palpitation and hypertension. His plasma freemetanephrines and urinary fractionated metanephrines were in
normal range, but plasma Chromogranin A was high. Case 3 was
a 10-year-old Thai boy presented with headache. He had high
level of plasma normetanephrine and chromogranin A levels. Al-
though there was no detectable lesion from CT scan of chest
and abdomen in case 3, but 18F-fluorodihydroxy-phenylalanine
(18-F-FDOPA) could detect the multiple lesions in pelvic cavity
and anterolateral to urinary bladder, size up to 3.4 x 2.4 x
4.3cm. All of them underwent exploratory laparotomy with suc-
cessful tumor removal and pathological examination revealed
composite pheochromocytoma for case 1 and paraganglioma
for case 2 and 3.
Conclusion: We report here the youngest case of pheochromocytoma
manifested with chronic intestinal pseudo obstruction, a very rare but
potentially life-threatening complication. Measurement of plasma chro-
mogranin A can improve diagnostic accuracy in patients with normal
levels of plasma or urinary fractionated metanephrines. The functional
imaging modality such as 18-F useful to localize the lesion.
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Background: X-linked adrenoleukodystrophy (X-ALD) is caused by
a defect in the gene ABCD1.This disease characterized by pro-
gressive neurologic dysfunction, occasionally associated with ad-
renal insufficiency.
Objective: To describe the clinical, laboratory, cerebral MRI character-
istics in Addison patients who have mutations of ABCD1.
Method: This is case series study. Clinical features, biochemical find-
ing and cerebral MRI lesions of 16 cases from 14 unrelated families
were studied.
Results: In this study, we had 12 cerebral adrenoleukodystrophy (CALD)
cases, 3 Addison only (AO) cases and one adrenomyeloneuropathy
(AMN) case. Approximately 50% of the CALD patients had adrenal in-
sufficiency preceded the onset of neurological symptoms. In 5 cases,
adrenal insufficiency symptoms were overlooked, the patients were
only admitted to hospital when they had progressive neurological
symptoms such as: hemiparesis or seizures. Endocrine inviestigations
(9/16 cases) showed: low serum cortisol levels, and increased plasma
ACTH. All of AO patients were followed up by cerebral MRI every 6
months. No patients had abnormal lesions in MRI. By sequencing of
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 135 of 144ABCD1 gene, 13 different mutations were identified, including 2 novel
mutations [c.1668G>C (p.Q556H); c.292_296delTCGGC (p.S98Rfs*95)].
The reported mutation c.1628C>T (p.Pro543Leu) was identified in two
cases (siblings: the elder was AO; the younger was CALD). The reported
mutation c.1552 C>T (p.Arg518Tryp) was identified in two cases (sib-
lings: the elder was AMN; the younger had slow progressive of CALD).
Among the patients diagnosed with AO, none had acute adrenal crisis
and no death was observed. All AO patients had normal plasma ACTH
and good physical development after receiving hormone replacement
therapy. By contrast, 5 deaths were observed among 12 CALD cases,
and one of these deaths was due to acute adrenal crisis. Most of them
had vegetative state for several years before death.
Conclusions: It is critical to perfom mutation analysis for X-ALD in boys
diagnosed with unexplained adrenal insufficiency. If the test reveals an
elevation in VLCFA consistent with X-ALD, additional assessments in-
cluding a brain MRI and neurological and neuropsychological evalua-
tions should be performed to examine cerebral involvement.
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Background: An Endocrine Society Clinical Practice Guideline of ster-
oid 21-hydroxylase deficiency (21OHD) recommend the dose of
hydrocortisone (HC) should be less than 20 mg/m2/day during first
year and less than 15 mg/m2/day during childhood. Height loss in
patients with 21OHD is mentioned to be associated with the dose of
HC in childhood, genotype, and compliance. However, it has not
been elucidated which factor closely associates with growth.
Objective: To evaluate the influence of HC and 5 α fludrocorticoster-
one (F) dosage and genotype on growth pattern and outcome.
METHODS: We analyzed 40 patients with 21OHD (17 had completed
growth, 3 had been predicted final height, 20 still growing). Final
height (FH) /predicted FH (pFH) and loss of height potential related
to target height (TH) were calculated. The patients were divided into
4 groups depending on the dose of HC and evaluated height out-
come (Group1: HC >20 mg/m2/day in first year, >15 mg/m2/day in
5-10 years old, Group2: HC 2/day in first year, >15 mg/m2/day in 5-
10 years old, Group3: HC >20 mg/m2/day in first year, 2/day in 5-10
years old, Group4: HC< 20 mg/m2/day in first year, 2/day in 5-10 years
old). Mean FH SD score (SDS) and pFH SDS were analyzed in accord-
ance to genotype and dosage of HC and F. As for 20 patients before
final height, we analyzed their growth pattern including bone mass age
at 3 and 5 years old in each treatment groups and genotype.
Results: Mean (FH SDS and pFH SDS) was -1.1+/-0.83 SD. Two from
20 patients with final height were short stature (<-2SD). Mean
(FH-TH) was -0.72+/-0.92 SD. Goup2 exhibited higher FH SDS, pFH SDS
and smaller height losses. Patients harboring genotype associate with
null enzymatic activity required higher dose of HC and F and exhibited
smaller body height during early childhood. On the other hand, pa-
tients with I172N allele were treated with lower dose of HC and F than
the others, but showed acceleration of bone age.
Conclusions: HC substitution in 21OHD patients should be kept at
the lowest efficient level, if possible 2/day during the first year. How-
ever, bone age progression associate with too small dosage of HC
should be prevented with the optimization of HC, especially under
10 years old. Genotype played only a minor role in growth outcome,
but provided a supportive information about growth pattern.P2-7-5
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Background: European studies estimated the incidence of adrenal
crisis (AC) among pediatric- and adult-onset patients with adrenal in-
sufficiency (AI) as 3.6-8.3 per 100 person-years (PY), and determined
risk factors for AC including younger age, female sex, coexistence of
central diabetes insipidus (DI), primary AI with concomitant non-
endocrine disease, and past history of AC. However, neither its inci-
dence nor risk factors among Japanese patients with AI were pub-
lished in the literature.
Objectives: To elucidate incidence and risk factors of AC among Jap-
anese patients with pediatric-onset AI.
Methods: We retrospectively reviewed the medical records of pa-
tients who had been treated with oral glucocorticoid at Department
of Pediatrics, Keio University Hospital, Tokyo, Japan, between Janu-
ary, 2012 and December, 2015. We selected patients with AI which
was diagnosed biochemically or genetically such as congenital ad-
renal hyperplasia, adrenal hypoplasia congenita, or congenital or ac-
quired combined anterior pituitary hormone deficiency. We excluded
patients who started glucocorticoid replacement at the age of 18
and older or who had been followed less than 6 months. In this
study, AC was defined as acute impairment of general health requir-
ing intravenous glucocorticoid administration without any other
causes. We collected data of age, sex, anthropometric data, duration
of treatment, reported number of infections (fever, diarrhea, or em-
esis), and coexistence of central DI. The incidence of AC, death, se-
vere neurologic sequelae was calculated as total number of each
event divided by a total follow-up time. Risk factors for AC were
assessed by multiple regression analysis with age, sex, types of AIs
(primary or central), and reported number of infections.
Results: Eighty-three patients with a total follow-up time of 306.5 PY
were included (33 males and 50 females; 51 with primary AI and 32
with central AI). The median age of the patients was 25.0 years
(range 2-49). The incidence of AC was 7.1 per 100 PY [95% confi-
dence interval (CI) 4.2-10.0]. Death was not observed, and severe
neurologic sequela was 0.3 per 100 PY (95%CI 0.0-1.0). The reported
number of infections was the only significant risk factor for develop-
ing AC (p<0.0001).
Conclusion: The incidence of AC among Japanese patients with
pediatric-onset AI is similar to that in the previous European
studies. The reported number of infection, which was not taken
into account in the previous studies, is a risk factor developing
AC in our cohort, irrespective of age, sex, type of AI, or coexist-
ence of central DI.
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Introduction: Congenital Adrenal Hyperplasia (CAH) is an autosomal
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 136 of 144recessive inheritance due to the defect in the pathway that converts
cholesterol into cortisol leading to decreased production of cortisol.
Patients with CAH need life long treatment of glucocorticoid and
sometimes mineralocorticoid. Early recognition and treatment of
CAH can prevent adrenal crises. However, in our cohort of the classic
type of CAH, the late-identified patients with CAH are more prevalent
than early-identified patients who are different with countries that
already have CAH newborn screening. Moreover, fatal adrenal crises
are seen in clinical practice. Reports on mortality in patients with
CAH in Indonesia are lacking. The aims of this present study were to
report and identify the mortality problems of CAH in Indonesia.
Methods: A retrospective study was done in the Center for
Biomedical Research (CEBIOR) Semarang, Central Java. Data related
to mortality was derived from research database from 2004-2016.
Result: Of 78 patients with CAH (74 females and four males) in our
cohort database, ten patients (12, 8%) were reported died due to
adrenal crises. Among these ten patients had died of adrenal crises,
six patients with CAH have already confirmed with hormonal and
mutation analysis and four patients confirmed base on clinical and
hormonal analysis. The mean age of diagnosis was 8.4 months
(ranged from 1 month to 5.5 years). The average age of death was
22.3 month (ranged from 2 months to 6 years).
Among 78 patients, only 5% are 46 XY CAH, which may indicate that
adrenal crises in male newborn might be under-diagnosed or un-
identified. Nine siblings of seven families had a history of siblings
who died because of a probable salt wasting condition before diag-
nosis confirmation. Thus the mortality rate of CAH in Indonesia is
probably higher than this rate.
Conclusion: There was a high mortality rate of CAH in Central Java,
Indonesia due adrenal crises. The high mortality rate can be antici-
pated or reduced if the Hydrocortisone and Fludrocortisone were
available and affordable for patients with CAH. Findings from this
study are strongly recommend for promoting early diagnosis and
treatment as well as improving compliance of young patients with
CAH. In addition, awareness of the medical community in the rural
area and endorsement to the policy maker for availability of medica-
tion are essential to decrease the mortality rate of patients with CAH
in Indonesia.P2-7-7
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Objective: Pheochromocytoma is catecholamine-producing adrenal
tumors arising from neural crest-derived cells and characterized by
triads of paroxysmal headache, palpitations, and diaphoresis.
Pheochromocytoma may be associated with underlying hereditary
conditions, such as von Hippel-Lindau disease, multiple endocrine
neoplasia 2A and 2B, neurofibromatosis or tuberous sclerosis. This
study investigated clinical presentation and outcome of pheochro-
mocytoma in children and adolescents.
Methods: Seven patients (6 males and 1 female) were included. Clin-
ical and radiological features, laboratory findings, perioperative man-
agement were reviewed retrospectively.
Results: The age at diagnosis was 11.4 ± 1.4years and follow-up dur-
ation was 5.9 ± 7.5 years (1 months – 17.5 years). All patients mani-
fested with headache and hypertension (systolic and diastolic blood
pressure 174.9 ± 14.1 and 123.7 ± 17.0 mmHg, respectively). Another
presenting symptoms include decreased visual acuity (n=4), hyperhi-
drosis (n=3), weight loss (n=2), and seizure (n=1). Initial height- and
weight-SDS were -0.1 ± 0.9 and -1.0 ± 0.6, respectively. A diagnosis
was made by elevated 24 hour urine total metanephrine (5.8 ± 3.7
mg/day) in 6 patients and by elevated 24 hour urine norepinephrine
(2968.7 ± 3295.3 μ g/day). Computerized tomography demonstrated
tumors in adrenal gland; 5 in right side, 1 in left side, and 1 in bilat-
eral. Hypertensive retinopathy (n=4) and left ventricular hypertrophy(n=4) were observed as complications of hypertension. VHL gene
mutations were identified in 2 patients; one patient had previously
diagnosed retinal hemangioma and the other developed contralat-
eral pheochromocytoma after 12 years later. The other 5 patients did
not reveal the features suggesting genetic syndromes. Phenoxyben-
zamine (n=4) was the most frequently used antihypertensive medica-
tion, and the duration of preoperative blood control was 20.6 ± 7.7
days. All patients had hypertensive episodes during the surgery,
which were controlled by intravenous nitroprusside. One patient ex-
perienced postoperative hypotension and required intravenous
phenylephrine. During follow up no tumor recurrence was observed.
Conclusions: Most patients initially presented symptoms associated
with uncontrolled hypertension. Because pheochromocytoma could
be the initial presentation of tumor-predisposing syndrome, regular
monitoring is necessary after tumor resection.
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Background: Pheochromocytoma and paraganglioma (PHEO/PGL)
are neuroendocrine tumors that arise from adrenal medulla, and
sympathetic and parasympathetic paraganglia due to various causes.
Pediatric patients with PHEO/PGL are not common but more highly
associated with genetic mutations than adults. We report three
pediatric patients with PHEO/PGL due to various causes.
Clinical Cases: Patient 1 had abdominal pain after external injury at
the age of 11. Abdominal computed tomography (CT) showed retro-
peritoneal masses. He had headache and hypertension. Urine norme-
tanephrine levels elevated, and abdominal magnetic resonance
imaging (MRI) revealed multiple abdominal PGLs. The PGLs were ex-
cised after the preoperative preparation ofα-blocker and saline infu-
sion. We detected a germline mutation in the SDHD gene. Patient 2
had marfanoid habitus, chronic diarrhea and mucosal neuromas of
the tongue at the age of 13. She was diagnosed as multiple endo-
crine neoplasia type 2B (MEN2B) due to a germline mutation in the
RET gene. She also suffered from medullary thyroid carcinoma. Urine
metanephrine levels elevated, and 123I-metaiodobenzylguanidine
scintigraphy demonstrated bilateral PHEOs. Bilateral adrenalectomy
after the preoperative preparation was performed before thyroidec-
tomy. She had replacement therapy with hydrocortisone, fludrocorti-
sone and thyroxine. Patient 3 had tricuspid atresia (cyanotic
congenital heart disease: CCHD) followed by the Fontan surgery. She
had experienced mild hypoxia since birth. She did not have any spe-
cific symptoms related to PHEO/PGL. During cardiac catheterization,
her blood pressure increased markedly, and anα-blocker was admin-
istered. Urine normetanephrine levels elevated, and abdominal CT
demonstrated a tumor in the right adrenal gland. Surgical treatment
was performed, and PHEO was pathologically confirmed. We did not
detect any germline mutations in the RET, VHL, SDHB, SDHD,
TMEM127 and, MAX genes. Every patient had no family history of
PHEO/PGL.
Conclusion: Approximately 70% of pediatric patients with PHEO/PGL
have a germline mutation. Clinical features suspecting hereditary
causes include a positive family history, syndromic features such as
neurofibromatos type 1, MEN2 and von Hippel-Lindau (VHL) syn-
drome, and multifocal, bilateral, or metastatic conditions. In our
study, the germline mutations were proven in the patients with mul-
tiple PGLs and MEN2B. Although the patient with PHEO accompan-
ied by CCHD had no germline mutation, several studies report that
hypoxia can increase a risk of PHEO/PGL. We conclude that genetic
tests should be performed in pediatric patients with PHEO/PGL with
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 137 of 144a positive family history, syndromic features, and multifocal, bilateral,
or metastatic condition and that continuous hypoxia can be a risk of
PHEO/PGL.
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Introduction: Measurement of 17 hydroxyprogesterone (17 OHP)
in dried blood spots has been widely used as a newborn
screening tool for congenital adrenal hyperplasia. Various mater-
nal and neonatal factors can result in falsely high values of
17OHP.
Aim: To determine the effect of gender, mode of delivery, gestational
age, birth weight, maternal and neonatal factors on the newborn
17OHP values.
Methods: Retrospective data related to newborn 17 OHP values
and clinical characteristics were collected for the period between
October 2013 and October 2015. The blood samples from total
2009 newborns were spotted on to filter paper between 48-72
hours of age and the 17 OHP concentration was measured using
competitive Enzyme Immuno Assay. A single model including the
following covariates was evaluated using analysis of variance
(ANOVA): mode of delivery(normal/ caesarean section), gender,
gestational age(term, preterm- 34 weeks), birth weight( 2.5 kg,
maternal factors like gestational diabetes mellitus, hypertension,
polyhydraminos, olighydraminos, antenatal steroid use and neo-
natal factors like fetal distress, respiratory distress syndrome, early
onset sepsis, necrotizing enterocolitis and neonatal seizures. It
was followed up with a post-hoc Tukey HSD test to determine
the levels of statistical significance.
Results: The mean 17OHP value in the study group was 5.15 ± 2.97
ng/ml. There was no significant difference in 17 OHP values among
males and females. The levels were significantly greater in preterm
babies(7.31 ± 5.07 ng/ml, p<0.0001) and babies born by Caesarean
section ( 5.32 ± 3.14 ng/ml, p<0.0001). Among the preterm babies,
the levels were higher in the
Conclusion: Factors like mode of delivery, gestational age, birth
weight and neonatal morbidities should be taken into account while
interpreting newborn 17 OHP values.P2-7-10
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Background: X-linked adrenoleukodystrophy (X-ALD) is caused by a
defect in the gene ABCD1 , which maps to Xq28 and codes for a per-
oxisomal membrane protein that is a member of the ATP-binding
cassette transporter superfamily. This disease characterized by pro-
gressive neurologic dysfunction, occasionally associated with adrenal
insufficiency.
Objective: To describe cerebral involvement in affected Vietnamese
patients who have mutations identified in ABCD1 .
Method: This is case series study. Clinical features, biochemical find-
ing and cerebral MRI lesions of 16 cases from 14 unrelated families
were studied.Results: We had 12 cereral adrenoleukodystrophy (CALD) cases and 1
adrenomyeloneuropathy (AMN) case. The patients admitted to hospital
because of cerebral symptoms such as inattention, visual disturbances,
seizure. Most of the CALD patients had late symptoms including cogni-
tive impairment (12/12), extrapyramidal signs, aphasia (6/12), blind (3/
12). Six of 12 patients had an IQ of < 70. Neuroimaging studies (cere-
bral MRI) showed classical patterns in all patients with neurological
symptom. Only 4 patients had Loes score < 8 points. By sequencing
the ABCD1 gene, 13 different mutations were identified, including 2 un-
reported mutations [c.1668G>C (p.Q556H); c.292_296delTCGGC
(p.S98Rfs*95)]. The reported mutation c.1628C>T (p.Pro543Leu) was
identified in two cases (siblings: the elder was AO; the younger was
CALD). The reported mutation c.1552 C>T (p.Arg518Tryp) was identified
in two cases (siblings: the elder was AMN; the younger had slow pro-
gressive of CALD). All of the CALD had an extremely rapid procession.
Five of the 12 patients died during the following time, of whom one
died from acute adrenal crisis, and the four patients had had vegetative
state for several years before death.
Conclusion: Pediatricians, endocrinologists, neurologists and psychia-
trists may encounter X-ALD in clinical practice. Recognition of X-ALD
is highly important, since treatments, such as allogeneic HCT in the
early stage of CCALD and endocrine replacement therapy for adreno-
cortical insufficiency, is available in some cases.
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Introduction: Lipoid congenital adrenal hyperplasia (lipoid CAH) is a
rare autosomal recessive disorder that severely inhibits the synthesis
of all adrenal and gonadal steroids. Lipoid CAH is ususally caused by
mutations in the gene for steroidogenic acute regulatory protein (
StAR) , which is required for the movement of cholesterol from the
outer to the inner mitochondrial membranes to synthesize pregnen-
olone. Turner syndrome is a condition involving total or partial ab-
sence of one X chromosome in all or part of the body’s cells,
reduced final height, absence of female sex hormones. We report 33-
year-old female with lipoid CAH due to StAR mutation and Turner
syndrome concomitantly.
Case: A one-day-old patient, the second child of nonconsanguineous
Japanese parents, was born at 42 weeks of gestation with a weight
of 2.5 kg. The patient admitted due to adrenal salt wasting crisis, and
hyperpigmention. She had the normal female external genitalia and
no adrenal hemorrhage on ultrasonography.
Results: Her karyotype was reported as 46, X,idic(X)(p11.2)[20]/ 45,
X[10] , based on which a diagnosis of mosaic Turner syndrome. In
the StAR gene analysis, a homozygote or heterozygote Q258X
mutation was detected. She was short stature, delayed puberty and
osteopenia. Her treatment was hormonal replacement therapy with
physiological doses of glucocorticoids and mineralocorticoids and
with estrogens.
Conclusions: The pathogenesis of lipoid CAH with Turner syndrome
has not been previously reported. However, an awareness of rare
combination is important because of another future reports.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 138 of 144Introduction: 11β-Hydroxylase deficiency(11β-OHD) is hypertensive
form of Congenital Adrenal Hyperplasia(CAH). This form of CAH is
rare and represents about 5% of the number of 21-hydroxylase defi-
ciency. Here we experienced the brain bleeding case with 11β-OHD.
Case: The patient was 31-year-old male with CAH; 11β-OHD. He and
his younger sister were diagnosed as 11β-OHD at Hamamatsu med-
ical school. Steroid replacement therapies were started with hydro-
cortisone. They transferred to Kitakyushu-city at age 8 and 7. At 16
year-old, his medicine was changed to dexamethasone(0.75mg/day).
His blood pressure were almost 150-130/ 90 mmHg. Recent data
before bleeding showed as follows; ACTH 202.8, PRA 0.9ng/ ml/ hr,
Aldosterone 124 pg/ml, Na 141, K 4.1, Cl 104, BG 72. His career is
care-helper. He worked hard and night duty was 5 times at 1-month.
Brain Bleeding: He had apraxia and conscious disturbance(E3, V4,
M6). He and his mother visited our emergency clinic. His blood pres-
sure was 153/ 106mmHg. Brain CT revealed brain bleeding at left
frontal lobe with ventricular perforation. Brain MRI didnot present
any vascular malformation. Conservative therapy(antihypertensive
drug and antiepileptic drug) and steroid replacement were per-
formed. His laboratory data were high ACTH(227.6 pg/ml) and
DOC(1.10 ng/ml) levels. Na 138 CK 4.0, Cl 102, BG 74 were within nor-
mal range. He recovered well in final.
Conclusion: Brain bleeding happened in CAH; 11 β-OHD. Stress and
poor compliance might lead to brain bleeding in this case. 11 β-OHD
patients should check their blood pressure and keep normo-pressure
with steroid supplement.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Background: Congenital adrenal hyperplasia (CAH) is a rare disease in
the world, and also in Indonesia As an autosomal recessive disoder, it
leads to enzyme deficiency involving hormones i.e cortisol, aldosteron,
or both. Some problems of CAH management occure in Indonesia, es-
pecially unavailability of hydrocortisone. Parents or guardians of CAH
patients utilize media social for daily communication.
Objective: To explore the role of social media group for solving CAH
problems in Indonesia.
Method: This research used qualitative approach that was conducted
on June 2016 by interviewing parents or guardians of CAH patients,
KAHAKI (the CAH club in Indonesia), and Indonesian pediatric endo-
crinologists. The technique of data analysis was content analysis per-
forming data analysis from the interview in verbatim form.
Results: There were 348 cases found but not all of the patients’ data
were completely filled. Most cases were obtained in Jakarta (38,8%),
Central Java (21,8%) and East Java (17,8%). All the informants con-
firmed that social media group was useful for CAH patients. Because of
the limited medication, this group became a helpful media to inform
the availability of hydrocortisone in Indonesia. Parents/guardians of
CAH patients could also ask directly to pediatric endocrinologist in the
group if something happened to their child. The group also build the
connection between CAH patients and endocrinologists in various cities
in Indonesia to share their problems and solve them together.Conclusions: Social media group was useful for CAH patients,
especially to inform availability of hydrocortisone in Indonesia.
Keywords: congenital adrenal hyperplasia, Indonesia, social media groupP2-7-15
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Introduction: Adrenal crisis (AC) is a life-threatening complication of
adrenal insufficiency (AI) and often induced by mild infection. In this
status, stress dose of hydrocortisone (HC) should be administered im-
mediately to save lives. We experienced two cases of AC with sys-
temic inflammatory response syndrome (SIRS). Sepsis is defined as
infection-induced SIRS and its first-line therapies are fluid resuscita-
tion, vasopressors and antibiotics. It is difficult to differentiate AC
from sepsis and it means a delay of administering HC for AI patient.
We report two severe AC cases recovered from SIRS by the immedi-
ate administration of HC.
Case 1: 21 years old female. She has had panhypopituritarism, cen-
tral diabetes insipidus (CDI) and hypothalamus disorder because of
post-surgery for recurrent craniopharyngioma. She began to feel
fatigue 5 days before admission and had fever 2 days before. But she
didn’t increase the dose of HC for sick days. On arrival, she became
unconscious and had developed shock status. The stress dose of HC
was administered immediately. She was managed with respirator
and vasopressors in ICU. Her symptoms and blood test on admission
indicated SIRS and multiple organ failure (MOF) (SOFA score: 16
points). Her circulation was stabilized at 5 hours later. She could
leave ICU at 9 days after admission, but mild cerebellar ataxia de-
rived from hypoxic encephalopathy remained.
Case 2: 17 years old male. He also has had panhypopituritarism and
CDI because of craniopharyngioma. He began to feel fatigue 2 days
before admission. On the next day, his fatigue became more severe
and had fever at night. He didn’t take any steroids because of low
medication compliance. He became shock status in the morning on
the day of admission. The stress dose of HC was administered imme-
diately. His symptoms and blood test on admission indicated SIRS
and MOF (SOFA score: 12 points). He needed vasopressor, but we
could stop it at the next day. He had stayed in ICU for 4 days, but no
complication remained.
Conclusion: Both cases indicate that immediate administration of HC
is critical to save lives of AI patients, because it is difficult to distin-
guish AC from sepsis.
Consent for publication: The authors declare that written informed
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Adrenocortical tumors are rare childhood neoplasms. More than
95% are functional and present with virilization, Cushing’s
syndrome, hypertension, or hyperestrogenism. We present a excep-
tionally rare case of a patient with androgen- and cortisol-co-
secreting adrenal adenoma.
A 4-year-old girl was referred to us for appearance of symptoms of
virilization: moustache, pubic hair, and gradual enlargement of clit-
oris for 1 years. Her voice gardually deepened and changed to male
pattern. On systemic examination, her weight was 26kg, height was
112cm, BMI 17.46. Pulse was 100 beats/min, blood pressure was 100/
60mmHg. She had no Cushingoid features. The laboratory showed
that she had elavated 24 hour urine free cortisol level: 362.7 μg/dl
(21-143 μg/dl) and serum testosteron: 286.5 ng/dl (14-76 ng/dl). The
serum ACTH was low: 1.58 pg/ml (7.2-63.3 pg/ml). Levels of DHEAS
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 139 of 144were normal: 0.914 μg/ml (0.5-3.5μg/ml). Levels of 17OH(P), LH,'sH,
Estrogen were normal range. The bone-age was 11 years.
Abdominal CT scan showed a left adrenal mass. It was decided to
manage her with surgery to remove the tumor. Subsequently adre-
nalectomy was performed and histopathology study revealed a 5.5x
5 x3.5 adrenal adenoma. Follow-up of the patient showed that signs
of virilization were suppressed. Serum testosterone levels dropped to
normal after surgery, and remained normal. Two to six months after
adrenalectomy, she was noticed to have significant symptoms of ad-
renal insufficiency and gradual enlargement of breast (Tanner B2).
Laboratory tests showed: AM cortisol levels and ACTH levels were
low on several occasions. The tests of diagnosis for precocious pu-
berty (PP) were performed. After confirming the diagnosis adrenal in-
sufficiency and PP the patient was given 5mg of hydrocortisone a
day and 3.75mg of Diphereline a month.
In summary, a diagnosis of adrenal cortical adenoma requires surgi-
cal removal as early as possible to prevent the untoward effects of
virilization or corticosteroid excess. Although the girl in the present
study seems to have been cured, long-term follow-up is warranted.
Consent for publication: The author declare that written informed
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Objective: To investigate the bone mineral density (BMD) for Chong-
qing children and adolescents from 6 to 18 years old; to evaluate the re-
lationships between BMD vs age, sex, weight, height and puberty stage;
furthermore to establish the reference database of BMD in children.
Methods: 1334 healthy and normal children aged 6 to 18 years (687
girls C647 boys) in Chongqing were sampled with stratified cluster
sampling. The investigation items included the measurement of
height, weight, breast development (girls) and testicular volume by
orchidometer (boys), which evaluated using the criteria of Tanner. DXA
scans were performed using Hologic bone densitometers (QDR 4500
Discovery Wi), the posterior-anterior spine and total hip were the se-
lected sites. SPSS 17.0 of statistical software was used for data analysis.
Results: 1) The BMD increased progressively with age. In girls, the
BMD grew obviously from 11 to 14 years, fastest from 12 to 13 years,
slowly after 15. In boys, what was said above were respective from
12 to 16 years, from 15 to 16 year and after 16. 2) Regions of BMD
grew gradually with the increase of pubertal stage. The BMD in-
creased significantly during U stage to V stage, whice slowed down
at Xstage. 3) Regions of BMD had no sexual difference aged 6 to 9
years, which were higher aged 12 to 13 years and lower aged 16 to
18 years in girls. 4) The BMD were correlated with height and weight
in most age groups. 5) The 2nd, 10th, 25th, 50th, 75th, 90th, 98th
smoothed percentiles curves of BMD-for-age and -2, -1, 0, +1, +2 Z-
scores curves of BMD-for-Tanner stage for girls and boys were made
out respectively.
Conclusion: We establish the normative curves of BMD-for-age and
BMD-for-Tanner stage for Chongqing children and adolescents aged
6 to 18 years. Application of the curves will promote child discover-
ing early growth disorder, and will be useful to diagnosis of diseases
and assessment of therapeutic effects.P2-8-3
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Introduction: 3-M syndrome is rare disorder with both prenatal and
postnatal severe growth retardation. Three genes involved in this dis-
order were reported, which were CUL-7, OBSL1, and CCDC genes.
This disorder is considered as important cause of SGA dwarfism who
do not show catch- up growth.
Case 1: 15years old female was referred for the investigation of the
cause of severe growth retardation. No consanguinity. Short stature
in brother (CASE2). She was born at 39w gestation. Her birth weight
and height were 1672g and 41cm, respectively. Psychomotor devel-
opment was normal during infancy. Growth retardation was promin-
ent and no catch-up growth was observed. She was diagnosed as
growth hormone (GH) deficiency and had been treated with GH for
2 years. GH therapy was discontinued because of judgement as in-
sufficient growth promoting effect (SDS -5.98 to -4.65). Spontaneous
menarche was observed at age 11. Micrognathia and long philtrum
were obvious. Radiologically, educed diameter of vertebral body and
slender tubular bones. Compound heterozygous mutations of CUL7
gene which were p.Gly569Lys's 4X and p.Arg1604Phe's 34X were
detected.
Case 2: 11y old male, younger brother of case 1. He was born at 39w
gestation with 45cm and 1798g of height and weight, respectively.
Psychomotor development was normal. No catch up growth and no
pubertal change was observed. His height and weight were 111.4cm
(-4.7SD) and 23.3kg(-1.65SD). Characteristic face with long philtrum and
micrognathia was pointed out. Endocriological test revealed pubertal
response of LH with undetectable level of testosterone and estradiol,
and attenuated growth hormone response to pharmacological stimuli.
Radiologically, reduced diameter of vertebral body and slender tubular
bones. Bone age was 11y4m. Compound heterozygous mutations of
CUL7 gene which were p.Gly569Lys's 4X and p.Arg1604Phe's 34X were
detected. Early response against GH substitution revealed elevated IGF-
I and PINP. On the other hand, responses of bone alkaline phosphata-
se(BAP) or telopeptide of N-terminal type I collagen (NTx) was not ap-
parent, which suggested that abonormal signal transduction of IRS-1
function might affect bone turn over.
Discussion: The patient may have no mature protein of Cullin-7, and lack
of Cullin-7 may disturb proper IRS-1 signal transduction. Bone turn over is
not stimulated dramatically by GH. However, Mild height SD change dur-
ing GH therapy in case1 apparent even this low turnover state.
Conclusion: In case of severe growth retardation, 3Msyndrome is
should be considered. If available, GH can be a candidate for the
treatment for the growth.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Background: Osteogenesis imperfecta (OI) is a heritable disorder of
connective tissue characterized by increased bone fragility, low bone
mass and bone deformity. The majority of patients with OI have a
heterozygous mutation in either COL1A1 or COL1A2 , the genes that
encode type 1 collagen. Recently, mutations in the PPIB encoding
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forms a complex with P3H1 and CRTAP that 3-hydroxylates a proline
residue on the α 1(I) chain (Pro986) and has cis/trans isomerase
(PPIase) activity essential for proper collagen folding.
Case presentation: The patient was born at 39 wk of gestation after
an uncomplicated pregnancy. She was the first child of non- consan-
guineous Japanese parents. She had a femur fracture seven days
after birth. She had suffered femur fracture five times until the refer-
ral to our hospital at 6 years of age. At that time, her height was
108cm, and she did not show any clear blue sclerae or tooth hypo-
plasia. She could not walk alone without help. Lumbar bone mineral
density (BMD) by DXA was extremely low (0.246 g/cm2, -5.81SD).
With a diagnosis of OI type W, pamidronate treatment was started.
Her BMD gradually increased, and she had not experienced any frac-
tures afterwards. Now at 9 years of age, her height is 116.3 cm, and
her BMD has been improved to 0.497 g/cm2 (-1.4SD). By whole ex-
ome sequencing, she was identified to have a homozygous mutation
(c.377A>G, p.E126G) in the PPIB and her parents were heterozygous
carriers. OI caused by the absence of cyclophilin B is much milder
compared to the severe or lethal OI caused by a deficiency of P3HI
or CRTAP. Our patient’s clinical phenotype was similar to those of pa-
tients described in the previous reports. The parents of the case were
not related, but they were from the same community.
Conclusions: We identified a homozygous PPIB mutation in an OI pa-
tient. To our knowledge, this is the first Japanese family with reces-
sive OI caused by PPIB mutation.
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Introduction: McCune-Albright syndrome (MAS) is caused by a som-
atic mosaic mutation of GNAS . It was often difficult to detect the
GNAS mutation using DNA from peripheral blood leukocyte because
of the low rate mosaicism. Recent droplet digital PCR (ddPCR) tech-
nology have made it possible to detect low rate mosaic mutations
using TaqMan probe of a target sequence. When FAM-labeled probe
is designed for mutant and HEX-labeled probe is designed for wild,
the mutant alleles will be distinguished from wild type alleles by
their specific probe amplitude. We here present the trial to detect
the GNAS mutations of in MAS using ddPCR.
Materials and Methods: Five MAS patients were participated in our
study. DNA was obtained from peripheral blood leukocyte. Droplets
were generated using Droplet Generator and the DNA was distrib-
uted to 20,000 droplets. The droplets were amplified and finally each
droplets were measured fluorescence intensity one by one by Drop-
let Reader. The droplets including a mutant allele or a wild allele indi-
cate strong amplitude of FAM or HEX respectively, and the mutant
allele rate is calculated dividing the number of FAM-positive droplets
(the copies of mutant allele) by the total amount of FAM-positive
and HEX-positive droplets (= the total copies of DNA).
Results: The R201H mutation of a patient was detected to 9.4% of
the mutant allele frequency by ddPCR. The detection limit of ddPCR
was calculated to 0.2% by diluting the patient’s DNA with a control’s
DNA. Three of the other four patient’s mutations were able to be de-
tected when pre-PCR with PNA inhibiting wild type allele amplifica-
tion was performed before the ddPCR. The detection limit of ddPCR
after the nested PCR with PNA was calculated to 0.005%.
Conclusion: ddPCR is an extremely sensitive detection method and
needs only about ten dollars per one reaction and several hours todetect the mutations. We here presented that detection limit of
ddPCR in GNAS analysis is 0.005%.
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Hypocalcemia is a rare cause of dilated cardiomyopathy (DCM). Hy-
pocalcemic DCM is usually reversible, however the prognosis de-
pends on the severity and time of diagnosis. The most common
cause of infantile hypocalcemic DCM is vitamin D deficiency. To our
knowledge, hypocalcemic DCM due to hereditary vitamin D-resistant
rickets has never been reported. We report a 5-month-old girl who
presented with generalized tonic clonic seizure secondary to hypo-
calcemia. She had typical features associated with rickets including
frontal bossing, rachitic rosary and widening of wrists and ankles. In
addition, she had anterior mitral valve prolapse, mitral regurgitation
and congestive heart failure secondary to DCM. Her investigations
were compatible with hereditary vitamin D-resistant rickets. She
responded well to high dose calcium and calcitriol supplementation.
She had rapid improvement of left ventricular function after the
treatment of hypocalcemia. Therefore, she was diagnosed as having
DCM secondary to hypocalcemia. Despite complete recovery of left
ventricular function, she still has mild anterior mitral valve prolapse
and mitral regurgitation after 1-year of follow-up. In spite of the fact
that DCM is usually idiopathic, hypocalcemia should be considered
as one of the reversible etiologies.
Consent for publication: The authors declare that written informed
consent was obtained for publication.
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Low plasma levels of vitamin D (25(OH)D) have been associated with
the development of metabolic syndrome (MS) in adult. However,
there was no report about the potential relationship of 25(OH)D with
various MS-related components in childhood obesity and MS. We in-
vestigated the relationship between plasma levels of 25(OH)D and
anthropometries or various MS-related components in Japanese
obese children and adolescents. Seventy-four obese Japanese chil-
dren and adolescents (37 boys and 37 girls) were enrolled, ages 4.4
to 16.9 years old. The relationship between plasma levels of 25(OH)D
and anthropometries (BMI, BMI z-score, waist circumference), MS-
related components (systolic / diastolic blood pressure, TG, HDL-C,
AST, ALT, FBS, Insulin, UA, apo A1, apo A2, apo B, HOMA- IR, HOMA-
β) were evaluated. We defined vitamin D levels equal to or less than
10 ng/mL as severe deficiency, 11- 19 ng/mL as mild deficiency and
20- 29 ng/mL as insufficient. Vitamin D levels equal to or more than
30 ng/mL were considered sufficient. Among 74 obese children, 25
were diagnosed as MS. Plasma levels of 25(OH)D were significantly
decreased in the MS group, compared with the non-MS group (23.1
± 2.05 ng/mL vs . 28.1 ± 1.28 ng/mL, p <0.05). The mean of body
weight, POW, waist circumference, BMI, BMI z-score, AST, ALT, FPG,
UA, HOMA-IR and HOMA- β were significantly higher in the lowest
serum 25(OH)D group. The proportion of MS was significantly greater
than the proportion of non-MS in the severe vitamin D deficiency
group. By univariate linear regression analysis, plasma levels of
25(OH)D were inversely correlated with body weight, POW, BMI,
waist circumference, systolic / diastolic blood pressure, HOMA-IR and
HOMA-β. HDL-C was positively correlated with plasma levels of
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 141 of 14425(OH)D. Plasma levels of 25(OH)D, which is decreased in Japanese
children and adolescents with MS, are associated with anthropome-
tries and MS-related components. Our results showed a trend similar
to adults or adolescents, suggesting that vitamin D may play import-
ant roles in the development of MS even in earlier aged children.
Vitamin D deficiency is a risk factor of MS in children and adoles-
cents, and the screening of serum vitamin D levels are required in
obese children and adolescents.
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Objective: To analyze the specific locations and quantities of con-
served non-coding elements iCNEs of short stature homeobox con-
taining gene (Shox), and to explore the romote-control mechanisms
of CNEs for Shox gene.
Methods: Screened all CNEs of Shox gene by the method of com-
parative genomics, then plasmid containing different CNEs interven-
tion in human embryonic kidney (HEK293T) cells, detecting Shox
expression by quantitative Real-time PCR.
Results: The control group which transfected empty plasmid of ex-
cluding CNEs, Shox gene expression were no statistical significance
compared with the blank load transfection group(p =0.9487) and in
groups of CNE-4(p =0.6986) ACNE2(p =0.9352) ACNE3(p =0.9997)
ACNE4(p =1) ACNE5(p =0.429) ACNE6(p =0.1066) ACNE7(p =0.4284)
ACNE8(p =0.8373) ACNE12(p =1) ACNE13(p =0.1052) ACNE14(p
=0.8651) and CNE15(p =0.9295)(P>0.05), while the differences of
Shox expression in groups of CNE-5i(p <0.0001) ACNE-3(p <0.0001)
ACNE- 2(p <0.0001) ACNE9(p <0.0001) ACNE10(p <0.0001) and
CNE11(p <0.0001) was highly significant (P<0.05).
Conclusion: We have found two new CNEs(CNE10 ACNE11);2.CNE-5,
CNE-3, CNE-2, CNE9, CNE10, CNE11 has being involved in the regula-
tion of Enhancement of Shox expression in HEK293T cells.
Key words: Conserved non-coding elements, Shox gene, gene ex-
pression Cregulatory mechanism
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The mother and father of a patient are not consanguineous. He was
born by vacuum extraction at 41weeks gestation without asphyxia.
His birth weight, length and head circumstance were 2246g
(-3.47SD), 47cm (-1.85SD) and 33.5cm (-0.34SD), respectively. He
showed hypocalcemia at 7days after delivery due to transient
neonatal hypoparathyroidism. The administration of alfacalcidol and
calcium lactate normalized his calcium level. Calcium lactate adminis-
tration and alfacalcidol administration were ceased at the age of 15
and 48 days, respectively. The three-year follow-up revealed normal
cognitive development and no catch-up growth. He showed propor-
tionated short stature without specific findings in radiographic exam-
inations. A blood test revealed normal IGF-1 level. Growth hormone
therapy for short stature born in small for gestational started at the
age of 3 years when his height was 78.2 cm (-4.64 SD). His growth
velocity showed mild increase in response to growth hormone. At
the age of 5 years, growth hormone stimulation test by insulin
showed normal growth hormone secretion. We performed a genetic
analysis using an Illumina TruSight One sequencing panel on a MiSeq
platform according to the manufacturer’s instructions (Illumina, San
Diego, CA, USA). The sequencing reads were analyzed with Base-
space VariantStudio ver. 2.2 (Illumina). Mutations were validated by
standard sanger sequencing. We found novel compound heterozy-
gous mutations (p.Trp68X and p.Gly1536Asp) in CUL7, which is
known as a causative gene of 3M syndrome (OMIM#273750), a rareautosomal recessive primordial growth disorder characterized by
intrauterine and postnatal growth disorder. His mother has a hetero-
zygous mutation (p.Gly1536Asp). Targeted next-generation sequen-
cing provided the definitive molecular diagnosis of 3M syndrome
that is sufficient information for both disease prognosis and appro-
priate genetic counseling. Our case supports the usefulness of the
clinical application of next-generation sequencing for undiagnosed
growth disorders.
Consent for publication: The authors declare that written informed
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Aim and Method: Achondroplasia (ACH, MIM#100800) is the most
common cause of short-limb dwarfism. This disorder is caused by
gain- of-function mutation of the fibroblast growth factor receptor-3
(FGFR3) gene on chromosome 4p16.3. More than 98% of patients
with ACH have an identical glycine-to-arginine substitution at residue
380 of FGFR3 (G380R). We have been reported a female infant with
p.Ser348Cys mutation in the FGFR3 which was not reported before.
The patient with p.Ser348Cys mutation demonstrated typical rhizo-
melic phenotype at 9 month old. In this study, to estimate that the
phenotype of the patient with p.Ser348Cys mutation was compatible
with ACH, we analyzed the radiological features in the patients with
p.Ser348Cys mutation in comparison with 10 infant ACH cases who
had typical G380R mutations in FGFR3. Reported radiological features
of ACH include caudal narrowing of the interpedicular distance,
squared iliac wings, rhizomelic shortening of the limbs. We selected
four radiological index, which included the ratio of the interpedicular
distances at the first (L1) and the fourth (L4) lumbar vertebrae (L1/L4
ratio), the ratio of the interteardrop distance(I) to the pelvic width(P)
(I/P), the ratio of the radial/humeral length (R/H), and the ratio of the
tibial/femoral length (T/F).
Results: In the patient of p.Ser348Cys, L1/L4 ratio were average
G380R range (1.0 and 1.1 in patient at 1 and 9 month, respectively.
G380R:1.10+-0.12, mean+-SD). I/P ratio were low (0.34) at 1 month
and higher (0.39) at 9 month (G380R 0.4+-0.018) , R/H ratio remained
average G380R range (0.89, G380R:0.87+-0.058), T/F ratio showed
average G380R range at 1month, but lower value at 9 month
(0.83,0.74 at 1 and 9 month, G380R 0.84+-0.049).
Discussion and Conclusion: The most diagnostic radiologic criteria of
ACH was considered as L1/L4 ratio. Including L1/L4 ratio, the patient
with p.Ser348Cys demonstrated radiologically typical G380R data at
one month. Lower T/F ratio at 9 month may reflect the sufficient
growth of femur in this patient. In conclusion, our patient with
p.Ser348Cys FGFR3 demonstrated typical ACH phenotype, however
the growth of each bone should be carefully monitored.
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 142 of 144P2-8-12
Hypocalcemic seizure in infants with TBX1 gene mutation:
importance of searching for thymic hypoplasia
Kosei Hasegawa1, Hiroyuki Tanaka2, Yousuke Higuchi1,
Hirokazu Tsukahara3
1Department of Pediatrics, Okayama University Hospital; 2Department of
Pediatrics, Saiseikai General Hospital; 3Department of Pediatrics, Okayama
University Graduate School of Medicine, Dentistry and Pharmaceutical
Sciences
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-8-12
22q11.2 deletion syndrome is characterized by characteristic facial
appearance, hypoparathyroidism, thymic hypoplasia, congenital heart
disease and so on. 22q11.2 legion included TBX1 and other 30 genes,
and TBX1 is thought to be the central gene that causes 22q11.2 dele-
tion syndrome. (Case) 2 months old boy is referred to child neuro-
logical department because of repetitive seizure attack. He was born
in vaginal delivery and was fed by breast milk. Physiological examin-
ation showed no abnormalities except for polydactyly of right fifth
finger of foot. Laboratory examination revealed severe hypocalcemia
(4.7mg/dl), hyperphosphataemia(12.2mg/dl) and normal parathyroid
hormone level (42pg/ml).25(OH) vitamin D level was 15 ng/
ml(37.5nmol/L). Continuous calcium infusion and oral active vitamin
D corrected hypocalcemia and hyperphosphataemia. Radiological
examination revealed thymic hypoplasia that reminded us 22q11.2
deletion syndrome in combination of hypocalcemia, while deletion
of 22q11.2 was not detected by choromosomal analysis and FISH
analysis. Genetic analysis identified 11 base duplication (c.968-
977dupAACCCCGTGGC) in exon 8 of TBX1. This mutation causes early
termination in three isoforms of TBX1 mRNA and is considered to re-
duce expression of TBX1 mRNA. Appropriate amount of TBX1 expres-
sion is essential for hypoparathyroid gland and this mutation might
causes hypoparathyroidism. His development and growth is normal
at 7 years old. (Conclusion) In case of infantile hypocalcemia without
typical physical symptom of 22q11.2 deletion, it is important to
search thymic hypoplasia to detect TBX1 gene mutation.
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Background: Vitamin D deficiency has been associated with chronic
diseases, such as diabetes mellitus, obesity and autoimmune disease.
However, There are only a few studies about the correlation between
Vitamin D levels and precocious puberty in girls.
Objective: In the previous study, vitamin D levels may be associated
with precocious puberty. we also aimed to re-evaluate the relation-
ship between serum 25-hydroxyvitamin D (25(OH)D) and precocious
puberty in girls.
Method: A total of 155 girls with central precocious puberty (CPP)
and 45 control girls were enrolled. Anthropometric measurement
and serum level of 25(OH)D were estimated for all subjects.
Results: Mean 25(OH)D level of CPP group was 17.3 ± 5.6ng/mL, which
was lower than the control group(19.0 ± 5.3ng/mL). there was signifi-
cant difference in the mean serum 25OHD concentration between the
precocious puberty group and the control group (P =0.042). After
25(OH)D levels be classified by month(season), Significant difference in
the mean serum 25(OH)D concentration between the two groups was
only winter (Dec~Feb). 113 of the 155 girls with CPP (72.9%) had
25(OH)D deficiency (defined as serum 25(OH)D 30 ng/mL). the preva-
lence of 25(OH)D was significantly higer odds ratio (OR, 2.35; 95% CI,
1.18-4.66, P =0.017) among CPP group than controls.
Conclusion: Our results showed that vitamin D level was significant
association with precocious puberty. We also recommend furtherstudies are required to identify the correlation vitamin D levels and
precocious puberty.P2-8-14
A case of Hecht syndrome having bilateral hypoplastic mandibular
condyles and shallow mandibular fossas
Chieko Kusano1, Tomoyuki Yaguchi1, Naoaki Hori1, Yoshitake Sato1,
Kazumi Izawa2, Rika Kosaki3, Kenjiro Kosaki4, Gen Nishimura5,
Tomonobu Hasegawa6
1Department of Pediatrics, Ota Memorial Hospital; 2Department of Oral
and Maxillofacial Surgery, Ota Memorial Hospital; 3Division of Medical
Genetics, National Center for Child Health and Development; 4Keio
University School of Medicine, Center for Medical Genetics; 5Division of
Radiology, Tokyo Metropolitan Children's Medical Center; 6Department
of Pediatrics, Keio University School of Medicine
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):P2-8-14
Hecht syndrome (OMIM#158300) also known as Trismus-
Pseudocamptodactyly syndrome (TPS) is a rare autosomal dominant
distal arthrogryposis clinically characterized by trismus, pseudocamp-
todactyly, feet deformities and short stature. Bilateral hyperplasia of
coronoid processes was reported to cause trismus. Veugelers et al.
(2004) identified MYH8 heterozygous mutation (c.2021G A;
p.Arg674Gln) in TPS families. To date, all 8 families with TPS had
Arg679Gln, who were molecularly studied and described.
A 10-year-old Japanese boy visited us because of short stature and
abnormal multiple muscles and tendons. He received surgical fixation
for bilateral vertical taluses at 4 years. Family history was unremark-
able. His physical examination revealed short stature (-2.8SD), bilat-
eral ptosis, abnormal multiple muscles and tendons; limited opening
of mouth (trismus), limited dorsiflexion of neck, pseudocamptodac-
tyly (partial flexion of the 3-5th fingers on dorsiflexed right hand)
and camptodactyly of left 4-5th fingers, bilateral pes planovalgus, bi-
lateral limited planter flexion of both ankle joints and bilateral down-
turning toes. According to these phenotypes, we clinically diagnosed
him as Hecht syndrome. Endocrinological survey was normal. Bone
X-rays showed multiple camptdactyly and feet deformities. 3-D CT
scan showed bilateral hypoplastic mandibular condyles and bilateral
flat mandibular fossas without hyperplasia of mandibular coronoid
process. Molecular analysis identified heterozygous MYH8 sequence
variation (c.2404G A; p.Val802lle). According to PolyPhen-2 analysis,
Val802lle is predicted to be benign with a score of 0.000. Val802Ile is
reported in the healthy people with MAF score T=0.000008/1.
We experienced a Japanese boy diagnosed as clinically definite Hecht
syndrome. His CT scan showed bilateral hypoplastic mandibular con-
dyles and shallow mandibular fossas, which were never reported. We
propose that trismus in Hecht syndrome can be caused by the hypo-
plastic mandibular condyle and shallow mandibular fossa. Pathogen-
icity of Val802Ile remains to be determined in this case.
Consent for publication: The authors declare that written informed
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Hypophosphatasia is a rare hereditary disorder characterized by defect-
ive bone and teeth mineralization and the deficiency of tissue non- spe-
cific alkaline phosphatase (TNAP) activity. We describe the clinical and
biochemical findings as well as the molecular analysis of a Korean boy
International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 Page 143 of 144with infantile hypophosphatasia. A 1-month-old boy visited the clinic be-
cause of poor feeding, frequent vomiting, hypotonia, and failure to
thrive from birth. Total calcium, phosphorous, alkaline phosphatase
(ALP), parathyroid hormone (PTH), and 25-hydroxyvitamin D were 18.5
mg/dL (Reference range, RR, 8.5–10.5), 3.4 mg/dL (RR, 3.5–5.5), 7 IU/L
(RR, 150–240), 0.9 pg/mL (RR, 12–95), and 32.7 ng/mL (RR, 10–60), re-
spectively. Intravenous hydration with normal saline was started, and
dietary calcium intake was restricted. Skeletal X-rays showed a markedly
increased distance of the anterior fontanelle, impaired mineralization,
and rachitic changes in the metaphyses. Based on clinical, biochemical,
and radiological findings, hypophosphatasia seemed to be the most
probable underlying etiology. By Sanger sequencing of the ALPL gene,
we identified two heterozygous variants, including a missense
(c.334G>A; p.Gly112Ser) and a nonsense (c.1039C>T; p.Gln347*) variant.
The father and mother of the patient were confirmed to be heterozy-
gous carriers of each variant. The c.334G>A (p.Gly112Ser) variant had
previously been reported in a patient with lethal type hypophosphatasia,
while the nonsense c.1039C>T (p.Gln347*) variant was novel. We con-
cluded that the prompt and accurate diagnosis of the disorder, together
with appropriate interventions including genetic counselling, is essential
for avoiding preventable morbidity and premature mortality.
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Background: Osteogenesis imperfecta (OI) is a genetic disorder of con-
netive tissue by mutations of COL1A1 and COL1A2 with frequent frac-
tures as the main symptom because of reduced bone density. Case
detection rate and treatment management of OI have become more fa-
vorable in Indonesia since Forum Osteogenesis Imperfecta (FOSTEO) was
established in 2013. This study aims to assess the correlation between
frequency of fracture after therapy and HRQOL in children with OI in
Indonesia since there were no previous similar studies in Indonesia.
Methods: A cross-sectional study was conducted with all OI patients
in Indonesian OI children registry and members of FOSTEO by using
Pediatric Quality of Life InventoryTM (PedsQLTM) 4.0 Generic Core
Scale. Other data were also collected i.e latest medication, and fre-
quency of fracture. The questionnaire was filled by parents foryounger age using online form, and parents who did not join What-
sApp group of FOSTEO were called and interviewed by phone.
Results: Among 126 patients in the registry data, 49 (38.8%) filled
the questionnaire, 48 (38.69%) inactive numbers, 12 (9.52%) un-
answered phone calls, 8 (6.35%) reported dead, 9 (7.14%) were not
FOSTEO members. From 44 patients, only 41 filled the questionnaire
with more than 50% items were completed, found that 51.2% girls,
and 39% age 2-4 years old. Latest medications included pamidronate
(14.6%) and zolendronic acid (85.4%). PedsQLTM showed HRQOL of
children age 2-4, 5-7, 8-12, and 13-18 years old (mean score
69.57, 67.08, 58.83, 53.99 respectively). Statistically, frequency of
fracture (median 1, min-max 0-10) had very weak correlation with
HRQOL (mean 65.48 ± SD 14.71) by using Spearman test (r=0.251
and P= 0.188).
Conclusion: Frequency of bone fracture had very weak correlation
with HRQOL of children with OI. Require more time to call all of the
patients. Indonesian OI children registry needs to be updated.
Keywords: children, osteogenesis imperfecta, quality of life, fre-
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Introduction: Vitamin D deficiency (VDD) causes rickets, osteomalacia
or hypocalcemia. Recently, reports of the rickets or hypocalcemia
with VDD in infants has been increased in Japan, because of insuffi-
cient intake of vitamin D or calcium and decrease of exposure to
sunlight. However, hypocalcemia resulting from VDD are extremely
rare in adolescents. We report a case of VDD in a 14-year-old boy
with no underlying diseases.
Case report: A 14-year-old Japanese boy was brought to our hospital
during winter season because of tetany. He had heavily trained
“judo” in the sport hall for 4 hours every day for 2 years, and had
lived in insufficient sunlight exposure. His height was 165.8cm
(-0.03SD), weight 55.0kg (-0.11SD) and BMI 20.0. He presented with
both Chvostek’s sign and Trousseau’s sign, but had no bowleg or
genu valgum. His laboratory studies showed decreased serum cal-
cium level (5.4 mg/dL). His serum level of phosphate and alkaline
phosphatase were 5.0 mg/dL and 1,941 U/L, respectively. His serum
intact parathyroid hormone level showed increased (148 pg/mL), and
serum level of 25-hydroxyvitamin D was extremely low (7 ng/mL). A
radiograph of the wrists did not show any changes. The nutritionist
in our hospital revealed that his intake of vitamin D and calcium
were insufficient, and his intake of phosphate was increased. Accord-
ing to these findings, we diagnosed him as having hypocalcemia due
to primary VDD. He was treated with calcium lactate (0.05 mg/kg/
day) and alfacalcidol (2 μ g/day). By dietary counseling, nutritional
balance of his diet was improved. His serum calcium normalized one
week after treatment and his serum 25-hydroxyvitamin D level was
also improved 1 month after treatment. He has never showed tetany
and hypocalcemia after treatment. Discussion: We speculate that his
lifestyle and dietary habit caused the VDD. Furthermore, the increased
vitamin D requirement at puberty might worsen his VDD. We should
consider VDD as the cause of hypocalcemia even in adolescent.
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Introduction: Vitamin D deficiency is characterized biochemically by re-
duced serum 25-hydroxyvitaminD (25OH) level, hypocalcaemia, hypopho-
sphatemia, increased alkaline phosphatase (ALP) and parathyroid
hormone (PTH).
Pseudohypoparathyrodism (PHP) is a rare inherited disorder with
end-organ resistance to PTH featuring hypocalcaemia, hyperpho-
sphatemia, high PTH and decreased urinary phosphate excretion.
They represented two important diagnoses of hypocalcaemia with
distinctive features. We report a young infant with transient but sig-
nificant vitamin D deficiency presented as symptomatic hypocalcae-
mia with seizures. The biochemical features mimicked PHP, and
responded to treatment with vitamin D and calcium.
Case report: KL was a full term male baby with good past health,
was feeding well on breast milk and formula with good weight gain.
He was admitted on day 29 of life for repeated seizure attacks for 2
days. He had no clinical features of rickets nor dysmorphism. Low
ionized calcium 0.72mmol/L, hyperphosphatemia 3.7 mmol/L, raised
ALP 353 IU/L and PTH 8.4 pmol/L were found. Magnesium level was
borderline low 0.64 mmol/L. The renal threshold phosphate concentra-
tion (TmPi/GFR) was high (>2mmol/L, ref 1.02-2mmol/L), and no hyper-
calciuria was found. Blood gas and albumin were normal. X-ray showed
no ricketic changes. Seizure was treated with phenobarbitone and sub-
sided after hypocalcaemia resolved. Intravenous calcium gluconate was
given, followed by continuous calcium infusion and then oral calcium.
Calcium level was normalized with no more seizure after 2 days.
Mother's blood for calcium and PTH were normal, vitamin D level was
not checked. Mother’s blood test during 2nd trimester showed lowish
phosphate (0.8mmol/L) and calcium (2.08 mmol/L). Patient’s total 25OH
vitamin D, 25OH D2 and 25OH D3 were all low (<10nmol/L) indicating
severe deficiency. Oral alphacalcidol was added with maximum dose of
0.25 mcg /kg/day. Calcium supplement was stopped on day 37 of ad-
mission. He was discharged after 6 weeks with alfacalcidol 0.25mcg/kg/
day, which was gradually weaned off at age of 4 months. He was on for-
mula milk after discharge. No mutation was found in GNAS gene for Al-
bright Osteodystrophy. His calcium, PTH and vitamin D level were
normal till last blood test at 27 months old.
Discussion: Vitamin D deficiency can mimic pseudohypoparathyroid-
ism in the biochemical picture possibly due to end-organ resistance
to PTH. It is possible that our patient was exposed to a low vitamin D
level in utero (suggested by the lowish phosphate and calcium levelof mother) and postnatally. As breast milk has low vitamin D level,
vitamin D deficiency can be exacerbated.
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Background: Parathyroid hormone (PTH) level is one of the import-
ant clinical markers to differentiate between primary hypoparathyr-
oidism and pseudohypoparathyroidism (PHP).
Objective: To report a clinical course and molecular analysis of a
hypoparathyroidism patient who presented hypocalcemia with ele-
vated PTH level, atypical for primary hypoparathyroidism.
Case: A 13-year-old boy was referred to our hospital due to transient
unconsciousness with hypocalcemia. He had been diagnosed as mild
mental retardation when he was a junior high school student. His fa-
cial appearance was unremarkable. Blood test showed Ca < 5 mg/dl,
P 7.7 mg/dl, ALP 1526 U/L, intact PTH (iPTH) 164 pg/ml, Mg 1.9 mg/
dl, urine test showed Ca/Cr < 0.01 mg/mg. Radiography of the left
hand showed neither brachydactyly nor rickets. Ultrasonography re-
vealed no malformation of heart or kidney. Head computed tomo-
graphic scanning showed bilateral calcification of the basal ganglia.
He was successfully treated by administration of intravenous calcium
gluconate and oral alfacarcidol. After his serum calcium level was
normalized (iPTH level was 24 pg/ml), urinary cAMP elevated in re-
sponse to the PTH injection. Neither of the copy number alteration
nor the methylation alteration was detected at the GNAS locus.
Discussion: Urinary cAMP response to the PTH injection and the
subsequent molecular analysis at the GNAS locus was not suggestive of
PHP1b. In primary hypoparathyroidism, 22q11.2 deletion syndrome
presents broad severity. However other syndromes and gene mutations
that cause primary hypoparathyroidism have rarely been reported to
show hypocalcemia with elevated PTH levels. Molecular analysis for pri-
mary hypoparathyroidism needs to be done in our case.
Conclusion: Our case suggests that PTH level may not be useful to
differentiate between primary hypoparathyroidism and PHP.
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